[{"id": 68001, "ingredient1": "Clarithromycin", "ingredient2": "Sulfamethoxazole", "severity": "Minor", "effect": "Limited data suggest that sulfamethoxazole-trimethoprim (SMX-TMP) may rarely prolong the QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. There have been isolated reports of QT prolongation and ventricular arrhythmias occurring in patients treated with SMX-TMP intravenously. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "source": "DDInter", "management_text": "-", "mechanism_text": "Synergism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68088/", "reference_text": "[1] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[2] Crouch MA, Limon L, Cassano AT \"Clinical relevance and management of drug-related QT interval prolongation.\" Pharmacotherapy 23 (2003): 881-908[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] Wiener I, Rubin D, Martinez E, et al \"QT prolongation and paroxysmal ventricular tachycardia occurring during fever following trimethoprim-sulfamethoxazole administration.\" Mt Sinai J Med 48 (1981): 53-5[5] Lopez JA, Harold JG, Rosenthal MC, Oseran DS, Schapira JN, Peter T \"QT prolongation and torsades de pointes after administration of trimethoprin-sulfamethoxazole.\" Am J Cardiol 59 (1987): 376-7[6] Darpo B \"Spectrum of drugs prolonging QT interval and the incidence of torsades de pointes.\" Eur Heart J Suppl 3(Suppl K) (2001): K70-80[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Capreomycin, Rifamycin, Cycloserine, Pyridoxine, Ethionamide, Pretomanid, Aminosalicylic acid, Sulfamethizole, Sulfisoxazole, Tinidazole, Ascorbic acid, More", "alternatives_b": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Cimetidine, Esomeprazole, More", "updated_at": 1767369485}, {"id": 68002, "ingredient1": "Clarithromycin", "ingredient2": "Sunitinib", "severity": "Moderate", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may increase the plasma concentrations of sunitinib and its pharmacologically active metabolite, both of which are substrates of the isoenzyme. Because sunitinib is associated with concentration-dependent prolongation of the QT interval, increased levels may potentiate the risk of ventricular arrhythmias such as torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Alternative agents with no or minimal CYP450 3A4-inhibiting activity are recommended in patients treated with sunitinib. Some authorities recommend avoiding concomitant use of sunitinib during and for 2 weeks after treatment with itraconazole. A dose reduction for sunitinib to a minimum of 37.5 mg daily for gastrointestinal stromal tumor (GIST) and metastatic renal cell carcinoma (mRCC) or 25 mg daily for pancreatic neuroendocrine tumors (pNET) should be considered if it must be coadministered with potent CYP450 3A4 inhibitors such as itraconazole, ketoconazole, voriconazole, nefazodone, delavirdine, protease inhibitors, and ketolide and certain macrolide antibiotics.", "mechanism_text": "Metabolism", "recommendation": "Alternative agents with no or minimal CYP450 3A4-inhibiting activity are recommended in patients treated with sunitinib.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68089/", "reference_text": "[1] \"Product Information. Sutent (sunitinib).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Sporanox (itraconazole).\" Janssen Pharmaceutica, Titusville, NJ.[4] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[5] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[6] \"Product Information. Sutent (sunitinib).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.", "alternatives_a": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Cimetidine, Esomeprazole, Ranitidine, More", "alternatives_b": "Alpelisib, Trametinib, Dacomitinib, Tivozanib, Alectinib", "updated_at": 1767369485}, {"id": 68003, "ingredient1": "Clarithromycin", "ingredient2": "Suvorexant", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of suvorexant, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Concomitant use of suvorexant with potent CYP450 3A4 inhibitors should generally be avoided.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of suvorexant with potent CYP450 3A4 inhibitors should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68090/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[3] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[4] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[5] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.", "alternatives_a": "Tinidazole, Pantoprazole, Levofloxacin, Dexlansoprazole, Rabeprazole, Sucralfate, Tetracycline, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Famotidine, More", "alternatives_b": "Methohexital, Methylphenobarbital, Pentobarbital, Dichloralphenazone, Valerian, Butabarbital, Secobarbital, Chloral hydrate, Paraldehyde, Ethchlorvynol, Amobarbital, More", "updated_at": 1767369485}, {"id": 68004, "ingredient1": "Clarithromycin", "ingredient2": "Tacrine", "severity": "Moderate", "effect": "Acetylcholinesterase inhibitors may have vagotonic effects on the sinoatrial and atrioventricular nodes, which occasionally manifest as bradycardia or heart block (<2%). Because bradycardia is a risk factor for torsade de pointes, a theoretical risk exists when combined with agents that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when acetylcholinesterase inhibitors are used with drugs that can prolong the QT interval. Patients should be monitored for bradycardia, atrioventricular block and syncope, and advised to seek medical attention if they experience dizziness, lightheadedness, fainting, shortness of breath, or slow or irregular heartbeat.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when acetylcholinesterase inhibitors are used with drugs that can prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68091/", "reference_text": "[1] \"Product Information. Razadyne (galantamine).\" Johnson and Johnson Medical Inc, Arlington, TX.[2] \"Product Information. Exelon (rivastigmine)\" Novartis Pharmaceuticals, East Hanover, NJ.[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Aricept (donepezil).\" Pfizer US Pharmaceuticals, New York, NY.[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"", "alternatives_a": "Memantine, Ginkgo biloba, Aducanumab", "alternatives_b": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Nizatidine, Esomeprazole, More", "updated_at": 1767369485}, {"id": 68005, "ingredient1": "Clarithromycin", "ingredient2": "Tacrolimus", "severity": "Major", "effect": "Tacrolimus can cause concentration-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval such as macrolide and ketolide antibiotics may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Coadministration with certain macrolide or ketolide antibiotics may significantly increase the oral bioavailability of tacrolimus. The proposed mechanism is inhibition of tacrolimus metabolism via intestinal CYP450 3A4. Inhibition of P-glycoprotein (P-gp) efflux transporter in gut wall may also contribute.", "source": "DDInter", "management_text": "Caution is advised when tacrolimus is used with macrolide or ketolide antibiotics that significantly inhibit CYP450 3A4 such as clarithromycin, erythromycin, josamycin, and telithromycin. A preemptive dosage reduction for tacrolimus may be appropriate in some cases. Frequent monitoring of tacrolimus whole blood levels should be performed during and after discontinuation of macrolide antibiotic therapy, and the tacrolimus dosage adjusted accordingly. In addition, patients should be closely monitored for development of serious adverse effects such as nephrotoxicity, lymphoma and other malignancies, infections, diabetes, neurotoxicity (tremor, paraesthesia, encephalopathy, delirium, coma), hyperkalemia, QT prolongation, myocardial hypertrophy, and hypertension. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Metabolism, Synergism", "recommendation": "Caution is advised when tacrolimus is used with macrolide or ketolide antibiotics that significantly inhibit CYP450 3A4 such as clarithromycin, erythromycin, josamycin, and telithromycin.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68092/", "reference_text": "[1] Katari SR, Magnone M, Shapiro R, et al \"Clinical features of acute reversible tacrolimus (FK 506) nephrotoxicity in kidney transplant recipients.\" Clin Transplant 11 (1997): 237-42[2] Jensen C, Jordan M, Shapiro R, et al. \"Interaction between tacrolimus and erythromycin.\" Lancet 344 (1994): 825[3] Furlan V, Perello L, Jacquemin E, Debray D, Taburet AM \"Interactions between FK506 and rifampin or erythromycin in pediatric liver recipients.\" Transplantation 59 (1995): 1217-8[4] Ibrahim RB, Abella EM, Chandrasekar PH \"Tacrolimus-clarithromycin interaction in a patient receiving bone marrow transplantation.\" Ann Pharmacother 36 (2002): 1971-1972[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Gomez G, Alvarez ML, Errasti P, Lavilla FJ, Garcia N, Ballester B, Garcia I, Purroy A \"Acute tacrolimus nephrotoxicity in renal transplant patients treated with clarithromycin.\" Transplant Proc 31 (1999): 2250-1[7] Shaeffer MS, Collier D, Sorrell MF \"Interaction between FK506 and erythromycin.\" Ann Pharmacother 28 (1994): 280-1[8] \"Product Information. Ketek (telithromycin).\" Aventis Pharmaceuticals, Bridgewater, NJ.[9] Cakaloglu Y, Tredger JM, Devlin J, Williams R \"Importance of cytochrome p-450IIIA activity in determining dosage and blood levels of FK 506 and cyclosporine in liver transplant recipients.\" Hepatology 20 (1994): 309-16[10] \"Product Information. Prograf (tacrolimus).\" Fujisawa, Deerfield, IL.[11] Kunicki PK, Sobieszczanska-Malek M \"Pharmacokinetic interaction between tacrolimus and clarithromycin in a heart transplant patient.\" Ther Drug Monit 27 (2005): 107-108[12] Moreno M, Latorre A, Manzanares C, et al \"Clinical management of tacrolimus drug interactions in renal transplant patients.\" Transplant Proc 31 (1999): 2252-3[13] Pea F, Furlanut M \"Pharmacokinetic aspects of treating infections in the intensive care unit: focus on drug interactions.\" Clin Pharmacokinet 40 (2001): 833-868[14] Homma S, Takahashi KI, Nihei S, Kato F, Sugihara S, Nunoda S \"The successful management of respiratory complications with long-term, low-dose macrolide administration in pediatric heart transplant recipients.\" Int Heart J (2014):[15] Parissis H, Gould K, Dark J \"Dangerous drug interactions leading to hemolytic uremic syndrome following lung transplantation.\" J Cardiothorac Surg 5 (2010): 70[16] Wolter K, Wagner K, Philipp T, Fritschka E \"Interaction between FK 506 and clarithromycin in a renal transplant patient.\" Eur J Clin Pharmacol 47 (1994): 207-8[17] \"Product Information. Biaxin (clarithromycin).\" Abbott Pharmaceutical, Abbott Park, IL.[18] Hooks MA \"Tacrolimus, a new immunosuppressant--a review of the literature.\" Ann Pharmacother 28 (1994): 501-11[19] \"Product Information. Prograf (tacrolimus).\" Fujisawa, Deerfield, IL.", "alternatives_a": "Minoxidil, Deoxycholic acid, Calcium gluconate, Magnesium sulfate, Glycopyrronium, Pimecrolimus, Aminobenzoic acid, Caffeine, Abrocitinib, Dupilumab, Tralokinumab, More", "alternatives_b": "Bismuth subcitrate potassium, Lincomycin, Dirithromycin", "updated_at": 1767369485}, {"id": 68006, "ingredient1": "Clarithromycin", "ingredient2": "Tadalafil", "severity": "Moderate", "effect": "Coadministration with drugs that are potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of tadalafil, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Concomitant use of tadalafil with potent 3A4 inhibitors is not recommended in patients being treated for pulmonary arterial hypertension. In addition, some authorities recommend avoiding concomitant use of tadalafil during and for 2 weeks after treatment with itraconazole in patients with pulmonary arterial hypertension. For erectile dysfunction, tadalafil labeling recommends that the dosage not exceed 10 mg once every 72 hours when taken on an as needed basis in patients treated concomitantly with a potent CYP450 3A4 inhibitor. When taken on a daily basis, the dose should not exceed 2.5 mg per day. Patients should be advised to promptly notify their physician if they experience pain or tightness in the chest or jaw, irregular heartbeat, nausea, shortness of breath, visual disturbances, syncope, or prolonged erection (greater than 4 hours).", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of tadalafil with potent 3A4 inhibitors is not recommended in patients being treated for pulmonary arterial hypertension.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68093/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] \"Product Information. Cialis (tadalafil).\" Lilly, Eli and Company, Indianapolis, IN.[3] \"Product Information. Sporanox (itraconazole).\" Janssen Pharmaceutica, Titusville, NJ.[4] \"Product Information. Adcirca (tadalafil).\" United Therapeutics Corporation, Silver Spring, MD.[5] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[6] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[7] \"Product Information. Cialis (tadalafil).\" Lilly, Eli and Company, Indianapolis, IN.[8] \"Product Information. Adcirca (tadalafil).\" United Therapeutics Corporation, Silver Spring, MD.", "alternatives_a": "Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Trospium, Acetohydroxamic acid, Yohimbine, Flavoxate, Phenyl salicylate, Ammonium chloride, Dimethyl sulfoxide, Metyrosine", "alternatives_b": "Tinidazole, Tetracycline, Dexlansoprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Nizatidine, Esomeprazole, Vonoprazan, Levofloxacin, Dirithromycin, More", "updated_at": 1767369485}, {"id": 68007, "ingredient1": "Clarithromycin", "ingredient2": "Talazoparib", "severity": "Major", "effect": "Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of talazoparib, which has been shown in vitro to be a substrate of the efflux transporter.", "source": "DDInter", "management_text": "Concomitant use of talazoparib with amiodarone, carvedilol, clarithromycin, itraconazole, or verapamil should preferably be avoided. If coadministration is required, talazoparib should be initiated at a reduced dosage of 0.75 mg once daily. Patients should be closely monitored for adverse effects such as myelosuppression and myelodysplastic syndrome/acute myeloid leukemia, and further dosage adjustments made or treatment withheld as needed in accordance with the product labeling. After 3 to 5 half-lives following discontinuation of the P-gp inhibitor, the talazoparib dosage may be increased to that used prior to initiation of the P-gp inhibitor.", "mechanism_text": "Absorption", "recommendation": "Concomitant use of talazoparib with amiodarone, carvedilol, clarithromycin, itraconazole, or verapamil should preferably be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68094/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Talzenna (talazoparib).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.[3] \"Product Information. Sporanox oral solution (itraconazole).\" Janssen Pharmaceutica, Titusville, NJ.[4] \"Product Information. Sporanox (itraconazole).\" Janssen Pharmaceutica, Titusville, NJ.[5] Van Peer A, Woestenborghs R, Heykants J, et al \"The effects of food and dose on the oral systemic availability of itraconazole in healthy subjects.\" Eur J Clin Pharmacol 36 (1989): 423-6[6] Penzak SR, Gubbins PO, Gurley BJ, Wang PL, Saccente M \"Grapefruit juice decreases the systemic availability of itraconazole capsules in healthy volunteers.\" Ther Drug Monit 21 (1999): 304-9[7] Katz HI \"Drug interactions of the newer oral antifungal agents.\" Br J Dermatol 141 (1999): 26-32[8] Kawakami M, Suzuki K, Ishizuka T, Hidaka T, Matsuki Y, Nakamura H \"Effect of grapefruit juice on pharmacokinetics of itraconazole in healthy subjects.\" Int J Clin Pharmacol Ther 36 (1998): 306-8[9] Barone JA, Koh JG, Bierman RH, Colaizzi JL, Swanson KA, Gaffar MC, Moskovitz BL, Mechlinski W, Van de Velde V \"Food interaction and steady-state pharmacokinetics of itraconazole capsules in healthy male volunteers.\" Antimicrob Agents Chemother 37 (1993): 778-84[10] Wishart JM \"The influence of food on the pharmacokinetics of itraconazole in patients with superficial fungal infection.\" J Am Acad Dermatol 17 (1987): 220-3[11] Zimmermann T, Yeates RA, Albrecht M, Laufen H, Wildfeuer A \"Influence of concomitant food intake on the gastrointestinal absorption of fluconazole and itraconazole in japanese subjects.\" Int J Clin Pharmacol Res 14 (1994): 87-93[12] Barone JA, Moskotitz BL, Guarnieri J, Hassell AE, Colaizzi JL, Bierman RH, Jessen L \"Food interaction and steady-state pharmacokinetics of itraconazole oral solution in healthy volunteers.\" Pharmacotherapy 18 (1998): 295-301", "alternatives_a": "Tinidazole, Dexlansoprazole, Rabeprazole, Metronidazole, Vonoprazan, Amoxicillin, Pantoprazole, Misoprostol, Esomeprazole, Ranitidine, Levofloxacin, More", "alternatives_b": "Pertuzumab, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Ixazomib, Enasidenib, Mitotane, Niraparib, Porfimer sodium, More", "updated_at": 1767369485}, {"id": 68008, "ingredient1": "Clarithromycin", "ingredient2": "Tamoxifen", "severity": "Moderate", "effect": "Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.", "source": "DDInter", "management_text": "Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution and clinical monitoring are recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68095/", "reference_text": "[1] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):[2] Witchel HJ, Hancox JC, Nutt DJ \"Psychotropic drugs, cardiac arrhythmia, and sudden death.\" J Clin Psychopharmacol 23 (2003): 58-77[3] Iannini PB \"Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval.\" Expert Opin Drug Saf 1 (2002): 121-8[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[6] Glassman AH, Bigger JT Jr \"Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death.\" Am J Psychiatry 158 (2001): 1774-82[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] Honig PK, Wortham DC, Zamani K, et al \"Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences.\" JAMA 269 (1993): 1513-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[10] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P \"Torsades de pointes after terfenadine-itraconazole interaction.\" BMJ 306 (1993): 186[11] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[12] Mathews DR, McNutt B, Okerholm R, et al \"Torsades de pointes occurring in association with terfenadine use.\" JAMA 266 (1991): 2375-6[13] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL \"Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram.\" Clin Pharmacol Ther 59 (1996): 383-8[14] Zechnich AD, Haxby DG \"Drug interactions associated with terfenadine and related nonsedating antihistamines.\" West J Med 164 (1996): 68-9[15] Hsieh MH, Chen SA, Chiang CE, et al. \"Drug-induced torsades de pointes in one patient with congenital long QT syndrome.\" Int J Cardiol 54 (1996): 85-8[16] Woosley RL \"Cardiac actions of antihistamines.\" Annu Rev Pharmacol Toxicol 36 (1996): 233-52[17] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP \"Torsades-de-pointes induced by erythromycin and terfenadine.\" Am J Emerg Med 12 (1994): 636-8[18] Zimmermann M, Duruz H, Guinand O, et al \"Torsades de Pointes after treatment with terfenadine and ketoconazole.\" Eur Heart J 13 (1992): 1002-3[19] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG \"Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance.\" Clin Pharmacol Ther 61 (1997): 401-9[20] Honig PK, Wortham DC, Lazarev A, Cantilena LR \"Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine.\" J Clin Pharmacol 36 (1996): 345-51[21] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr \"Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin.\" Clin Pharmacol Ther 52 (1992): 231-8[22] Monahan BP, Ferguson CL, Killeavy ES, et al \"Torsades de pointes occurring in association with terfenadine use.\" JAMA 264 (1990): 2788-90[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[24] Cortese LM, Bjornson DC \"Potential interaction between terfenadine and macrolide antibiotics.\" Clin Pharm 11 (1992): 675", "alternatives_a": "Anastrozole, Aminoglutethimide, Exemestane, Fulvestrant", "alternatives_b": "Tinidazole, Tetracycline, Dexlansoprazole, Bismuth subcitrate potassium, Nizatidine, Esomeprazole, Vonoprazan, Amoxicillin, Lincomycin, Troleandomycin, Dirithromycin", "updated_at": 1767369485}, {"id": 68009, "ingredient1": "Clarithromycin", "ingredient2": "Tamsulosin", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of tamsulosin, which is primarily metabolized by the hepatic microsomal isoenzymes CYP450 3A4 and 2D6. Severe hypotension and priapism may occur.", "source": "DDInter", "management_text": "Since CYP450 2D6 poor metabolizers cannot be readily identified, concomitant use of tamsulosin with potent CYP450 3A4 inhibitors should generally be avoided. Some authorities recommend avoiding concomitant use of tamsulosin during and for 2 weeks after treatment with itraconazole. If tamsulosin administration is discontinued for several days or more at either the 0.4 or 0.8 mg dose, therapy should be reinitiated with the 0.4 mg once-daily dose and titrated gradually as needed.", "mechanism_text": "Metabolism", "recommendation": "Since CYP450 2D6 poor metabolizers cannot be readily identified, concomitant use of tamsulosin with potent CYP450 3A4 inhibitors should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68096/", "reference_text": "[1] \"Product Information. Sporanox (itraconazole).\" Janssen Pharmaceutica, Titusville, NJ.[2] \"Product Information. Flomax (tamsulosin).\" Boehringer-Ingelheim, Ridgefield, CT.[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] Franco-Salinas G, de la Rosette JJ, Michel MC \"Pharmacokinetics and pharmacodynamics of tamsulosin in its modified-release and oral controlled absorption system formulations.\" Clin Pharmacokinet 49 (2010): 177-88[5] Kamimura H, Oishi S, Matsushima H, et al. \"Identification of cytochrome P450 isozymes involved in metabolism of the alpha1-adrenoceptor blocker tamsulosin in human liver microsomes.\" Xenobiotica 28 (1998): 909-22[6] \"Product Information. Duagen (dutasteride).\" GlaxoSmithKline Healthcare, Pittsburgh, PA.[7] \"Product Information. Flomax (tamsulosin).\" Boehringer-Ingelheim, Ridgefield, CT.[8] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[9] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Lactic acid, Methazolamide, Trichlormethiazide, Probenecid, Tioconazole, Brinzolamide, Furazolidone, More", "alternatives_b": "Tinidazole, Dexlansoprazole, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Esomeprazole, Vonoprazan, Levofloxacin, Lincomycin, Dirithromycin", "updated_at": 1767369485}, {"id": 68010, "ingredient1": "Clarithromycin", "ingredient2": "Tasimelteon", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 1A2 and/or 3A4 may increase the plasma concentrations of tasimelteon, which is primarily metabolized by these isoenzymes.", "source": "DDInter", "management_text": "Caution is advised if tasimelteon is prescribed in combination with inhibitors of CYP450 1A2 and/or 3A4. Patients should be monitored for excessive sedation and other side effects.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if tasimelteon is prescribed in combination with inhibitors of CYP450 1A2 and/or 3A4.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68097/", "reference_text": "[1] \"Product Information. Hetlioz (tasimelteon).\" Vanda Pharmaceuticals Inc, Rockville, MD.[2] \"Product Information. Hetlioz (tasimelteon).\" Vanda Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Tinidazole, Pantoprazole, Levofloxacin, Dexlansoprazole, Rabeprazole, Sucralfate, Tetracycline, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Famotidine, More", "alternatives_b": "Methohexital, Methylphenobarbital, Pentobarbital, Dichloralphenazone, Valerian, Butabarbital, Secobarbital, Chloral hydrate, Paraldehyde, Ethchlorvynol, Amobarbital, More", "updated_at": 1767369485}, {"id": 68011, "ingredient1": "Clarithromycin", "ingredient2": "Tazemetostat", "severity": "Major", "effect": "Coadministration with moderate or potent CYP450 3A4 inhibitors may significantly increase the plasma concentrations of tazemetostat, which is primarily metabolized by the isoenzyme. Clinically, this interaction may result in an increased risk of the frequency or severity of adverse reactions due to tazemetostat such as secondary malignancies, hemorrhage, pleural effusion, skin infection, dyspnea, pain, and respiratory distress.", "source": "DDInter", "management_text": "Concomitant use of tazemetostat with moderate or potent CYP450 3A4 inhibitors should generally be avoided. Alternative therapeutic agents with less inhibitory potential should be considered whenever possible. If coadministration with a moderate CYP450 3A4 inhibitor is required and no other alternatives are possible, the dose of tazemetostat should be reduced as per manufacturer recommendations. After the inhibitor has been discontinued for 3 elimination half-lives, the tazemetostat dose that was taken prior to initiating the inhibitor may be resumed. Patients should be advised to notify their health care professional if they experience signs or symptoms of possible tazemetostat-related adverse effects including secondary malignancies, hemorrhage, pleural effusion, skin infection, dyspnea, pain, and respiratory distress.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of tazemetostat with moderate or potent CYP450 3A4 inhibitors should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68098/", "reference_text": "[1] \"Product Information. Tazverik (tazemetostat).\" Epizyme, Inc, Cambridge, MA.[2] \"Product Information. Tazverik (tazemetostat).\" Epizyme, Inc, Cambridge, MA.", "alternatives_a": "Pantoprazole, Levofloxacin, Tetracycline, Rabeprazole, Dexlansoprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Famotidine, Nizatidine, More", "alternatives_b": "Pertuzumab, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Ixazomib, Enasidenib, Mitotane, Niraparib, Porfimer sodium, More", "updated_at": 1767369485}, {"id": 68012, "ingredient1": "Clarithromycin", "ingredient2": "Telaprevir", "severity": "Moderate", "effect": "Coadministration of a macrolide or ketolide antibiotic (clarithromycin, erythromycin, telithromycin) with a hepatitis C virus (HCV) NS3/4A protease inhibitor (boceprevir, telaprevir) is expected to increase the plasma concentrations of both drugs. The mechanism may involve both competitive and noncompetitive inhibition of CYP450 3A4, since these drugs are all substrates as well as inhibitors of the isoenzyme. No pharmacokinetic data are currently available. Clinically, high plasma levels of macrolide or ketolide antibiotics may increase the risk of QT interval prolongation and torsade de pointes arrhythmia.", "source": "DDInter", "management_text": "Caution and close clinical monitoring are recommended if clarithromycin, erythromycin, or telithromycin are used in combination with a HCV NS3/4A protease inhibitor. Patients should be advised to seek medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, palpitations, or syncope.", "mechanism_text": "Metabolism", "recommendation": "Caution and close clinical monitoring are recommended if clarithromycin, erythromycin, or telithromycin are used in combination with a HCV NS3/4A protease inhibitor.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68099/", "reference_text": "[1] \"Product Information. Victrelis (boceprevir).\" Schering-Plough Corporation, Kenilworth, NJ.[2] \"Product Information. Incivek (telaprevir).\" Vertex Pharmaceuticals, Cambridge, MA.[3] \"Product Information. Incivek (telaprevir).\" Vertex Pharmaceuticals, Cambridge, MA.", "alternatives_a": "Pantoprazole, Levofloxacin, Tetracycline, Rabeprazole, Dexlansoprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Famotidine, Cimetidine, More", "alternatives_b": "Glecaprevir, Tenofovir alafenamide, Cabotegravir, Lenacapavir, Velpatasvir, Voxilaprevir, Maribavir, Pibrentasvir, Rimantadine, Elvitegravir, Valganciclovir, More", "updated_at": 1767369485}, {"id": 68013, "ingredient1": "Clarithromycin", "ingredient2": "Telavancin", "severity": "Moderate", "effect": "Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.", "source": "DDInter", "management_text": "Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution and clinical monitoring are recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68100/", "reference_text": "[1] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):[2] Witchel HJ, Hancox JC, Nutt DJ \"Psychotropic drugs, cardiac arrhythmia, and sudden death.\" J Clin Psychopharmacol 23 (2003): 58-77[3] Iannini PB \"Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval.\" Expert Opin Drug Saf 1 (2002): 121-8[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[6] Glassman AH, Bigger JT Jr \"Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death.\" Am J Psychiatry 158 (2001): 1774-82[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] Honig PK, Wortham DC, Zamani K, et al \"Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences.\" JAMA 269 (1993): 1513-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[10] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P \"Torsades de pointes after terfenadine-itraconazole interaction.\" BMJ 306 (1993): 186[11] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[12] Mathews DR, McNutt B, Okerholm R, et al \"Torsades de pointes occurring in association with terfenadine use.\" JAMA 266 (1991): 2375-6[13] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL \"Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram.\" Clin Pharmacol Ther 59 (1996): 383-8[14] Zechnich AD, Haxby DG \"Drug interactions associated with terfenadine and related nonsedating antihistamines.\" West J Med 164 (1996): 68-9[15] Hsieh MH, Chen SA, Chiang CE, et al. \"Drug-induced torsades de pointes in one patient with congenital long QT syndrome.\" Int J Cardiol 54 (1996): 85-8[16] Woosley RL \"Cardiac actions of antihistamines.\" Annu Rev Pharmacol Toxicol 36 (1996): 233-52[17] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP \"Torsades-de-pointes induced by erythromycin and terfenadine.\" Am J Emerg Med 12 (1994): 636-8[18] Zimmermann M, Duruz H, Guinand O, et al \"Torsades de Pointes after treatment with terfenadine and ketoconazole.\" Eur Heart J 13 (1992): 1002-3[19] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG \"Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance.\" Clin Pharmacol Ther 61 (1997): 401-9[20] Honig PK, Wortham DC, Lazarev A, Cantilena LR \"Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine.\" J Clin Pharmacol 36 (1996): 345-51[21] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr \"Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin.\" Clin Pharmacol Ther 52 (1992): 231-8[22] Monahan BP, Ferguson CL, Killeavy ES, et al \"Torsades de pointes occurring in association with terfenadine use.\" JAMA 264 (1990): 2788-90[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[24] Cortese LM, Bjornson DC \"Potential interaction between terfenadine and macrolide antibiotics.\" Clin Pharm 11 (1992): 675", "alternatives_a": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Cimetidine, Esomeprazole, More", "alternatives_b": "Tinidazole, Bacitracin, Polymyxin B, Oritavancin, Daptomycin, Methenamine, Spectinomycin, Fosfomycin, Tedizolid, Dalbavancin", "updated_at": 1767369485}, {"id": 68014, "ingredient1": "Clarithromycin", "ingredient2": "Telithromycin", "severity": "Moderate", "effect": "Telithromycin has the potential to prolong the QT interval of the electrocardiogram in some patients. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Although the risk of a serious interaction is probably low, caution is recommended if telithromycin is used in combination with other drugs that can prolong the QT interval. Since the magnitude of QTc prolongation may increase with increasing plasma concentrations of telithromycin, the recommended dosage should not be exceeded, particularly in patients with renal or hepatic impairment. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Although the risk of a serious interaction is probably low, caution is recommended if telithromycin is used in combination with other drugs that can prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68101/", "reference_text": "[1] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[2] \"Product Information. Ketek (telithromycin).\" Aventis Pharmaceuticals, Bridgewater, NJ.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Demolis JL, Vacheron F, Cardus S, Funck-Brentano C \"Effect of single and repeated oral doses of telithromycin on cardiac QT interval in healthy subjects.\" Clin Pharmacol Ther 73 (2003): 242-52[5] European Agency for the Evaluation of Medicinal Products. Committee for Proprietary Medicinal Products \"European Public Assessment Report Ketek (telithromycin) (Rev. 2) Available from: URL: http:www.emea.eu.int/humandocs/Humans/EPAR/Ketek/Ketek.htm.\" ([2001]):[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[8] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Clarithromycin, Lincomycin, Troleandomycin, Dirithromycin", "alternatives_b": "Tinidazole, Dexlansoprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Cimetidine, Esomeprazole, Nizatidine, Vonoprazan, Telithromycin, Dirithromycin", "updated_at": 1767369485}, {"id": 68015, "ingredient1": "Clarithromycin", "ingredient2": "Telotristat ethyl", "severity": "Moderate", "effect": "Coadministration with telotristat ethyl may decrease the plasma concentrations of drugs that are substrates of CYP450 3A4 and/or 2B6 isoenzymes. The proposed mechanism is accelerated clearance due to induction of CYP450 3A4 and/or 2B6 (in vitro) isoenzymes by telotristat ethyl.", "source": "DDInter", "management_text": "When drugs that are known substrates of CYP450 3A4 and/or 2B6 are coadministered with telotristat ethyl, the possibility of a diminished therapeutic response to those drugs should be considered. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs, particularly those with a narrow therapeutic range, whenever telotristat ethyl is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "When drugs that are known substrates of CYP450 3A4 and/or 2B6 are coadministered with telotristat ethyl, the possibility of a diminished therapeutic response to those drugs should be considered.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68102/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Xermelo (telotristat ethyl).\" Lexicon Pharmaceuticals, Inc., The Woodlands, TX.[3] \"Product Information. Xermelo (telotristat ethyl).\" Lexicon Pharmaceuticals, Inc., The Woodlands, TX.", "alternatives_a": "Pantoprazole, Levofloxacin, Tetracycline, Rabeprazole, Dexlansoprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Famotidine, Cimetidine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68016, "ingredient1": "Clarithromycin", "ingredient2": "Temsirolimus", "severity": "Major", "effect": "Coadministration of temsirolimus with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of sirolimus, a major active metabolite of temsirolimus and known substrate of CYP450 3A4.", "source": "DDInter", "management_text": "Concomitant use of temsirolimus with potent CYP450 3A4 inhibitors should generally be avoided. Some authorities recommend avoiding concomitant use of intravenous temsirolimus during and for 2 weeks after treatment with itraconazole (US). If coadministration is required, the manufacturer recommends reducing the temsirolimus dosage to 12.5 mg once a week. Based on pharmacokinetic studies, this dosage is predicted to adjust the sirolimus systemic exposure (AUC) to the range observed without inhibitors. However, clinical data are lacking. Following discontinuation of the potent CYP450 3A4 inhibitor, a washout period of approximately one week should be allowed before the temsirolimus dosage is adjusted upward to the normally recommended dosage (i.e., 25 mg once a week) or the dosage used prior to initiation of the CYP450 3A4 inhibitor.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of temsirolimus with potent CYP450 3A4 inhibitors should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68103/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] \"Product Information. Torisel (temsirolimus).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[3] \"Product Information. Sporanox (itraconazole).\" Janssen Pharmaceutica, Titusville, NJ.[4] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[5] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[6] \"Product Information. Torisel (temsirolimus).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.", "alternatives_a": "Tinidazole, Pantoprazole, Levofloxacin, Dexlansoprazole, Rabeprazole, Sucralfate, Tetracycline, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Famotidine, More", "alternatives_b": "Alpelisib, Trametinib, Dacomitinib, Tivozanib, Alectinib", "updated_at": 1767369485}, {"id": 68017, "ingredient1": "Clarithromycin", "ingredient2": "Terbutaline", "severity": "Moderate", "effect": "Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.", "source": "DDInter", "management_text": "Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68104/", "reference_text": "[1] \"Product Information. Arcapta Neohaler (indacaterol).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] Whyte KF, Addis GJ, Whitesmith R, Reid JL \"The mechanism of salbutamol-induced hypokalaemia.\" Br J Clin Pharmacol 23 (1987): 65-71[3] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA \"Metabolic and cardiovascular effects of carbuterol and metaproterenol.\" J Allergy Clin Immunol 60 (1977): 174-9[4] Larsson S, Svedmyr N \"Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics.\" Am Rev Respir Dis 116 (1977): 861-9[5] Clifton GD, Hunt BA, Patel RC, Burki NK \"Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses.\" Am Rev Respir Dis 141 (1990): 575-9[6] \"Hypokalaemia due to salbutamol overdosage.\" Br Med J (Clin Res Ed) 283 (1981): 500-1[7] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C \"Cardiovascular Safety of Salmeterol in COPD.\" Chest 123 (2003): 1817-24[8] \"Product Information. Striverdi Respimat (olodaterol).\" Boehringer Ingelheim, Ridgefield, CT.[9] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R \"A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol.\" N Z Med J 103 (1990): 259-61[10] Rakhmanina NY, Kearns GL, Farrar HC \"Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler.\" Pediatr Emerg Care 14 (1998): 145-7[11] \"Product Information. Brovana (arformoterol).\" Sepracor Inc, Marlborough, MA.[12] Bengtsson B, Fagerstrom PO \"Extrapulmonary effects of terbutaline during prolonged administration.\" Clin Pharmacol Ther 31 (1982): 726-32[13] Hastwell G, Lambert BE \"The effect of oral salbutamol on serum potassium and blood sugar.\" Br J Obstet Gynaecol 85 (1978): 767-9[14] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD \"Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease.\" Pharmacotherapy 14 (1994): 729-33[15] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE \"Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma.\" Lancet 336 (1990): 1396-9[16] \"Product Information. Xopenex (levalbuterol).\" Sepracor, Marlborough, MA.[17] \"Product Information. Breo Ellipta (fluticasone-vilanterol).\" GlaxoSmithKline, Research Triangle Park, NC.[18] Milic M, Bao X, Rizos D, Liu F, Ziegler MG \"Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation.\" Clin Ther 28 (2006): 582-90[19] \"Product Information. Severent (salmeterol).\" Glaxo Wellcome, Research Triangle Park, NC.[20] \"Product Information. Proventil (albuterol).\" Schering Laboratories, Kenilworth, NJ.[21] \"Product Information. Foradil (formoterol)\" Novartis Pharmaceuticals, East Hanover, NJ.[22] Gross TL, Sokol RJ \"Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment.\" Am J Obstet Gynecol 138 (1980): 1225-6[23] Sun ZH, Swan H, Vitasalo M, Toivonen L \"Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome.\" J Am Coll Cardiol 31 (1998): 1400-5[24] Gelmont DM, Balmes JR, Yee A \"Hypokalemia induced by inhaled bronchodilators.\" Chest 94 (1988): 763-6[25] Lowe MD, Rowland E, Brown MJ, Grace AA \"Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium.\" Heart 86 (2001): 45-51[26] \"Product Information. Maxair (pirbuterol).\" 3M Pharmaceuticals, St. Paul, MN.[27] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL \"Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences.\" Kidney Int 51 (1997): 1867-75[28] Hurlbert BJ, Edelman JD, David K \"Serum potassium levels during and after terbutaline.\" Anesth Analg 60 (1981): 723-5[29] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K \"Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects.\" Chest 106 (1994): 1654-9[30] Kantola I, Tarssanen L \"Hypokalemia from usual salbutamol dosage .\" Chest 89 (1986): 619-20", "alternatives_a": "Ephedrine, Mometasone furoate, Umeclidinium, Aclidinium, Glycopyrronium, Ipratropium, Beclomethasone dipropionate", "alternatives_b": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Cimetidine, Esomeprazole, More", "updated_at": 1767369485}, {"id": 68018, "ingredient1": "Clarithromycin", "ingredient2": "Terfenadine", "severity": "Major", "effect": "Coadministration with the ketolide, telithromycin, as well as certain macrolide antibiotics may significantly increase the plasma concentrations of astemizole and terfenadine. The mechanism is inhibition of CYP450 3A4, the isoenzyme responsible for the metabolic clearance of astemizole and terfenadine. High plasma levels of these agents have been associated with prolongation of the QT interval on the ECG; ventricular arrhythmias including ventricular tachycardia, ventricular fibrillation, and torsade de pointes; cardiac arrest; and sudden death. Macrolides that may significantly inhibit CYP450 3A4 include clarithromycin, erythromycin, and troleandomycin. Azithromycin and dirithromycin are generally believed to have little, if any, effect on CYP450 3A4.", "source": "DDInter", "management_text": "Given the potential for serious and life-threatening adverse cardiac events associated with increased plasma levels of astemizole and terfenadine, the use of these agents with clarithromycin, erythromycin, troleandomycin, or telithromycin is considered contraindicated. Loratadine, cetirizine, or fexofenadine may be safer alternatives during therapy with telithromycin or macrolides. Depending on organism susceptibility, azithromycin and dirithromycin may be appropriate alternatives during therapy with astemizole or terfenadine.", "mechanism_text": "Metabolism", "recommendation": "Given the potential for serious and life-threatening adverse cardiac events associated with increased plasma levels of astemizole and terfenadine, the use of these agents with clarithromycin, erythromycin, troleandomycin, or telithromycin is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68105/", "reference_text": "[1] Ament PW, Paterson A \"Drug interactions with the nonsedating antihistamines.\" Am Fam Physician 56 (1997): 223[2] Brannan MD, Reidenberg P, Radwanski E, et al \"Loratadine administered concomitantly with erythromycin: pharmacokinetic and electrocardiographic evaluations.\" Clin Pharmacol Ther 58 (1995): 269-78[3] Jurima-Romet M, Crawford K, Cyr T, Inaba T \"Terfenadine metabolism in human liver. In vitro inhibition by macrolide antibiotics and azole antifungals.\" Drug Metab Dispos 22 (1994): 849-57[4] European Agency for the Evaluation of Medicinal Products. Committee for Proprietary Medicinal Products \"European Public Assessment Report Ketek (telithromycin) (Rev. 2) Available from: URL: http:www.emea.eu.int/humandocs/Humans/EPAR/Ketek/Ketek.htm.\" ([2001]):[5] Hsieh MH, Chen SA, Chiang CE, et al. \"Drug-induced torsades de pointes in one patient with congenital long QT syndrome.\" Int J Cardiol 54 (1996): 85-8[6] Cortese LM, Bjornson DC \"Potential interaction between terfenadine and macrolide antibiotics.\" Clin Pharm 11 (1992): 675[7] Biglin KE, Faraon MS, Constance TD, Lieh-Lai M \"Drug-induced torsades de pointes: a possible interaction of terfenadine and erythromycin.\" Ann Pharmacother 28 (1994): 282[8] Nahata M \"Drug interactions with azithromycin and the macrolides: an overview.\" J Antimicrob Chemother 37 ( Suppl (1996): 133-42[9] Amsden GW \"Macrolides versus azalides: a drug interaction update.\" Ann Pharmacother 29 (1995): 906-17[10] Harris S, Hilligoss DM, Colangelo PM, Eller M, Okerholm R \"Azithromycin and terfenadine: lack of drug interaction.\" Clin Pharmacol Ther 58 (1995): 310-5[11] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP \"Torsades-de-pointes induced by erythromycin and terfenadine.\" Am J Emerg Med 12 (1994): 636-8[12] Kemp JP \"Decreased antihistamine metabolism.\" Ann Allergy 69 (1992): 533[13] \"Product Information. Hismanal (astemizole).\" Janssen Pharmaceutica, Titusville, NJ.[14] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr \"Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin.\" Clin Pharmacol Ther 52 (1992): 231-8[15] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P \"Torsades de pointes after terfenadine-itraconazole interaction.\" BMJ 306 (1993): 186[16] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[17] Zimmermann M, Duruz H, Guinand O, et al \"Torsades de Pointes after treatment with terfenadine and ketoconazole.\" Eur Heart J 13 (1992): 1002-3[18] Honig PK, Wortham DC, Lazarev A, Cantilena LR \"Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine.\" J Clin Pharmacol 36 (1996): 345-51[19] Honig PK, Wortham DC, Zamani K, et al \"Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences.\" JAMA 269 (1993): 1513-8[20] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[21] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL \"Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram.\" Clin Pharmacol Ther 59 (1996): 383-8[22] Mathews DR, McNutt B, Okerholm R, et al \"Torsades de pointes occurring in association with terfenadine use.\" JAMA 266 (1991): 2375-6[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[24] Hsieh MH, Chen SA, Chiang CE, et al. \"Drug-induced torsades de pointes in one patient with congenital long QT syndrome.\" Int J Cardiol 54 (1996): 85-8[25] Woosley RL \"Cardiac actions of antihistamines.\" Annu Rev Pharmacol Toxicol 36 (1996): 233-52[26] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG \"Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance.\" Clin Pharmacol Ther 61 (1997): 401-9[27] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr \"Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin.\" Clin Pharmacol Ther 52 (1992): 231-8[28] Monahan BP, Ferguson CL, Killeavy ES, et al \"Torsades de pointes occurring in association with terfenadine use.\" JAMA 264 (1990): 2788-90[29] Cortese LM, Bjornson DC \"Potential interaction between terfenadine and macrolide antibiotics.\" Clin Pharm 11 (1992): 675[30] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP \"Torsades-de-pointes induced by erythromycin and terfenadine.\" Am J Emerg Med 12 (1994): 636-8[31] Zechnich AD, Haxby DG \"Drug interactions associated with terfenadine and related nonsedating antihistamines.\" West J Med 164 (1996): 68-9", "alternatives_a": "Mepyramine, Levocetirizine, Chlorcyclizine, Acrivastine, Triprolidine, Tripelennamine, Dexbrompheniramine, Clemastine, Doxylamine, Meclizine, Cyclizine, More", "alternatives_b": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Nizatidine, Esomeprazole, More", "updated_at": 1767369485}, {"id": 68019, "ingredient1": "Clarithromycin", "ingredient2": "Teriflunomide", "severity": "Major", "effect": "The recent, concomitant, or subsequent use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity may potentiate the risk of liver injury associated with leflunomide. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide.", "source": "DDInter", "management_text": "Caution is advised if leflunomide or teriflunomide must be used in patients who are currently receiving or have recently received treatment with other hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice), and vice versa. Liver enzymes and bilirubin should be measured prior to initiation of leflunomide/teriflunomide therapy and at least monthly for the first six months of treatment and every 6 to 8 weeks thereafter. Patients with preexisting liver disease or elevated baseline liver enzymes (i.e., ALT greater than two times ULN) should not receive leflunomide or teriflunomide. Patients who develop elevated serum ALT greater than three times ULN while receiving these medications should discontinue treatment and be given washout procedures with cholestyramine or activated charcoal to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years. Follow-up monitoring should be conducted at least weekly until the ALT value is within normal range, and washout procedures repeated as necessary. All patients treated with leflunomide or teriflunomide should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if leflunomide or teriflunomide must be used in patients who are currently receiving or have recently received treatment with other hepatotoxic agents (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68106/", "reference_text": "[1] EMEA \"EMEA public statement on leflunomide (ARAVA) - severe and serious hepatic reactions. Available from URL: http://www.eudra.org/emea.html.\" ([1999 Sept 2]):[2] \"Product Information. Arava (leflunomide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[3] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"", "alternatives_a": "Pantoprazole, Tetracycline, Rabeprazole, Dexlansoprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Famotidine, Rifabutin, Nizatidine, Esomeprazole, More", "alternatives_b": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Abatacept, Anakinra, More", "updated_at": 1767369485}, {"id": 68020, "ingredient1": "Clarithromycin", "ingredient2": "Tetrabenazine", "severity": "Moderate", "effect": "Tetrabenazine may cause modest prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of tetrabenazine with other drugs that can prolong the QT interval should generally be avoided. Caution and clinical monitoring are recommended if concomitant use is required. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Coadministration of tetrabenazine with other drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68107/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):[4] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[5] \"Product Information. Xenazine (tetrabenazine).\" Prestwick Pharmaceuticals Inc, Washington DC, VA.[6] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[7] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[8] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[9] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[11] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Cimetidine, Esomeprazole, More", "alternatives_b": "Dextromethorphan, Dalfampridine, Sodium oxybate, Riluzole, Inotersen, Amifampridine, Tafamidis", "updated_at": 1767369485}, {"id": 68021, "ingredient1": "Clarithromycin", "ingredient2": "Thalidomide", "severity": "Moderate", "effect": "Thalidomide can cause bradycardia and may have additive effects with other drugs that decrease heart rate. Cases of bradycardia have been associated with thalidomide use, some requiring medical interventions. The clinical significance and underlying etiology of the bradycardia observed with thalidomide treatment have not been established. However, the potential for additive bradycardic effects should be considered when used with other drugs that slow cardiac conduction such as beta-blockers, calcium channel blockers, digitalis, flecainide, moricizine, and propafenone. Non-cardiac drugs that may also cause bradycardia include atazanavir, lacosamide, lithium, mefloquine, succinylcholine, H2-receptor antagonists, tricyclic antidepressants, and anticholinesterase or cholinergic agents. Because bradycardia is a risk factor for torsade de pointes arrhythmia, concerns also exist when thalidomide is used with drugs that prolong the QT interval or cause torsade de pointes.", "source": "DDInter", "management_text": "Caution is advised when thalidomide is used with drugs that can slow the heart rate or induce torsade de pointes arrhythmia. Patients should be monitored for bradycardia, atrioventricular block and syncope, and advised to seek medical attention if they experience dizziness, lightheadedness, fainting, shortness of breath, or slow or irregular heartbeat. A dose reduction of thalidomide or discontinuation may be required.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when thalidomide is used with drugs that can slow the heart rate or induce torsade de pointes arrhythmia.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68108/", "reference_text": "[1] \"Product Information. Thalomid (thalidomide).\" Celgene Corporation, Warren, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[5] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[6] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[7] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[8] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[9] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Abatacept, Anakinra, More", "alternatives_b": "Tetracycline, Dexlansoprazole, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Esomeprazole, Vonoprazan, Lincomycin, Troleandomycin, Dirithromycin", "updated_at": 1767369485}, {"id": 68022, "ingredient1": "Clarithromycin", "ingredient2": "Theophylline", "severity": "Moderate", "effect": "Coadministration with certain macrolide antibiotics may increase the serum concentrations of theophylline, which may result in toxicity. The proposed mechanism is macrolide inhibition of CYP450 3A4, the isoenzyme partially responsible for the metabolic clearance of theophylline.", "source": "DDInter", "management_text": "Pharmacologic response and serum theophylline levels should be monitored more closely whenever a macrolide antibiotic is added to or withdrawn from therapy, and the methylxanthine dosage adjusted as necessary.", "mechanism_text": "Metabolism", "recommendation": "Pharmacologic response and serum theophylline levels should be monitored more closely whenever a macrolide antibiotic is added to or withdrawn from therapy, and the methylxanthine dosage adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68109/", "reference_text": "[1] Upton RA \"Pharmacokinetic interactions between theophylline and other medication (Part I).\" Clin Pharmacokinet 20 (1991): 66-80[2] Amsden GW \"Erythromycin, clarithromycin, and azithromycin: are the differences real?\" Clin Ther 18 (1996): 56-72[3] Amsden GW \"Macrolides versus azalides: a drug interaction update.\" Ann Pharmacother 29 (1995): 906-17[4] Principi N, Esposito S \"Comparative tolerability of erythromycin and newer macrolide antibacterials in paediatric: Patients.\" Drug Safety 20 (1999): 25-41[5] Descotes J, Andre P, Evreux JC \"Pharmacokinetic drug interactions with macrolide antibiotics.\" J Antimicrob Chemother 15 (1985): 659-64[6] Rockwood RP, Embardo LS \"Theophylline, ciprofloxacin, erythromycin: a potentially harmful regimen.\" Ann Pharmacother 27 (1993): 651-2[7] von Rosenstiel NA, Adam D \"Macrolide antibacterials. Drug interactions of clinical significance.\" Drug Saf 13 (1995): 105-22[8] Reisz G, Pingleton SK, Melethil S, Ryan PB \"The effect of erythromycin on theophylline pharmacokinetics in chronic bronchitis.\" Am Rev Respir Dis 127 (1983): 581-4[9] Jonkman JH, Upton RA \"Pharmacokinetic drug interactions with theophylline.\" Clin Pharmacokinet 9 (1984): 309-34[10] Ludden TM \"Pharmacokinetic interactions of the macrolide antibiotics.\" Clin Pharmacokinet 10 (1985): 63-79[11] Hildebrandt R, Moller H, Gundert-Remy U \"Influence of theophylline on the renal clearance of erythromycin.\" Int J Clin Pharmacol Ther Toxicol 25 (1987): 601-4[12] May DC, Jarboe CH, Ellenburg DT, et al \"The effects of erythromycin on theophylline elimination in normal males.\" J Clin Pharmacol 22 (1982): 125-30[13] Gillum JG, Israel DS, Scott RB, Climo MW, Polk RE \"Effect of combination therapy with ciprofloxacin and clarithromycin on theophylline pharmacokinetics in healthy volunteers.\" Antimicrob Agents Chemother 40 (1996): 1715-6[14] Richer C, Mathieu M, Bah H, Thuillez C, Duroux P, Giudicelli JF \"Theophylline kinetics and ventilatory flow in bronchial asthma and chronic airflow obstruction: influence of erythromycin.\" Clin Pharmacol Ther 31 (1982): 579-86[15] Pfeifer HJ, Greenblatt DJ, Friedman P \"Effects of three antibiotics on theophylline kinetics.\" Clin Pharmacol Ther 26 (1979): 36-40[16] Prince RA, Wing DS, Weinberger MM, et al \"Effect of erythromycin on theophylline kinetics.\" J Allergy Clin Immunol 68 (1981): 427-31[17] Kozak PP, Cummins LH, Gillman SH \"Administration of erythromycin to patients on theophylline.\" J Allergy Clin Immunol 60 (1977): 149-51[18] Zarowitz BJ, Szefler SJ, Lasezkay GM \"Effect of erythromycin base on theophylline kinetics.\" Clin Pharmacol Ther 29 (1981): 601-5[19] Bachmann K, Nunlee M, Martin M, et al \"Changes in the steady-state pharmacokinetics of theophylline during treatment with dirithromycin.\" J Clin Pharmacol 30 (1990): 1001-5[20] Maddux MS, Leeds NH, Organek HW, Hasegawa GR, Bauman JL \"The effect of erythromycin on theophylline pharmacokinetics at steady state.\" Chest 81 (1982): 563-5[21] Pollak PT, Slayter KL \"Reduced serum theophylline concentrations after discontinuation of azithromycin: evidence for an unusual interaction.\" Pharmacotherapy 17 (1997): 827-9[22] Wiggins J, Arbab O, Ayres JG, Skinner C \"Elevated serum theophylline concentration following cessation of erythromycin treatment.\" Eur J Respir Dis 68 (1986): 298-300[23] Kamada AK, Hill MR, Brenner AM, Szefler SJ \"Effect of low-dose troleandomycin on theophylline clearance: implications for therapeutic drug monitoring.\" Pharmacotherapy 12 (1992): 98-102[24] Parish RA, Haulman NJ, Burns RM \"Interaction of theophylline with erythromycin base in a patient with seizure activity.\" Pediatrics 72 (1983): 828-30[25] Branigan TA, Robbins RA, Cady WJ, et al \"The effects of erythromycin on the absorption and disposition kinetics of theophylline.\" Eur J Clin Pharmacol 21 (1981): 115-20[26] Renton KW, Gray JD, Hung OR \"Depression of theophylline elimination by erythromycin.\" Clin Pharmacol Ther 30 (1981): 422-6[27] Bachmann K, Jauregui L, Sides G, Sullivan TJ \"Steady-state pharmacokinetics of theophylline in COPD patients treated with dirithromycin.\" J Clin Pharmacol 33 (1993): 861-5[28] Peters DH, Friedel HA, McTavish D \"Azithromycin: a review of its antimicrobial activity, pharmacokinetic properties and clinical efficacy.\" Drugs 44 (1992): 750-99[29] Iliopoulou A, Aldhous ME, Johnston A, Turner P \"Pharmacokinetic interaction between theophylline and erythromycin.\" Br J Clin Pharmacol 14 (1982): 495-9[30] Nahata M \"Drug interactions with azithromycin and the macrolides: an overview.\" J Antimicrob Chemother 37 Suppl C (1996): 133-42[31] Tenenbein M \"Theophylline toxicity due to drug interaction.\" J Emerg Med 7 (1989): 249-51[32] Paulsen O, Hoglund P, Nilsson LG, Bengtsson HI \"The interaction of erythromycin with theophylline.\" Eur J Clin Pharmacol 32 (1987): 493-8", "alternatives_a": "Omalizumab, Tezepelumab, Benralizumab, Caffeine, Reslizumab, Dyphylline, Mepolizumab, Roflumilast, Bromotheophylline", "alternatives_b": "Tinidazole, Levofloxacin, Dexlansoprazole, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Vonoprazan, Amoxicillin, Lincomycin, Clindamycin", "updated_at": 1767369485}, {"id": 68023, "ingredient1": "Clarithromycin", "ingredient2": "Tioguanine", "severity": "Moderate", "effect": "The concomitant or sequential use of other agents known to induce hepatotoxicity may potentiate the risk of liver injury associated with thioguanine. A high risk of liver toxicity characterized by vascular endothelial damage has been reported with long-term continuous use of thioguanine, particularly in children receiving the drug as part of maintenance therapy for acute lymphoblastic leukemia and in other conditions associated with continuous use.", "source": "DDInter", "management_text": "The risk of hepatic injury should be considered when thioguanine is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Baseline and regular monitoring of hepatic function is recommended. Thioguanine therapy should be discontinued if there is evidence of toxic hepatitis or biliary stasis, as reversal of signs and symptoms of liver toxicity have been reported upon withdrawal. Early indications of liver toxicity are signs associated with portal hypertension such as thrombocytopenia out of proportion with neutropenia and splenomegaly. Elevations of liver enzymes have also been reported, but do not always occur.", "mechanism_text": "Synergism", "recommendation": "The risk of hepatic injury should be considered when thioguanine is used with other potentially hepatotoxic agents (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68110/", "reference_text": "[1] \"Product Information. Aubagio (teriflunomide).\" Genzyme Corporation, Cambridge, MA.[2] \"Product Information. Tabloid (thioguanine).\" Prasco Laboratories, Cincinnati, OH.", "alternatives_a": "Fluorouracil, Cladribine, Trifluridine, Floxuridine, Nelarabine, Pralatrexate, Decitabine, Azacitidine, Capecitabine", "alternatives_b": "Tinidazole, Dexlansoprazole, Rabeprazole, Metronidazole, Vonoprazan, Amoxicillin, Pantoprazole, Misoprostol, Esomeprazole, Ranitidine, Sucralfate, More", "updated_at": 1767369485}, {"id": 68024, "ingredient1": "Clarithromycin", "ingredient2": "Thioridazine", "severity": "Major", "effect": "Thioridazine can cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, certain agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive parasympatholytic and central nervous system-depressant effects when used in combination with thioridazine. Excessive parasympatholytic effects may include paralytic ileus, hyperthermia, mydriasis, blurred vision, tachycardia, urinary retention, psychosis, and seizures.", "source": "DDInter", "management_text": "Coadministration of thioridazine with other drugs that can prolong the QT interval is considered contraindicated.", "mechanism_text": "Synergism", "recommendation": "Coadministration of thioridazine with other drugs that can prolong the QT interval is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68111/", "reference_text": "[1] \"Product Information. Mellaril (thioridazine).\" Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Liberatore MA, Robinson DS \"Torsade de pointes: a mechanism for sudden death associated with neuroleptic drug therapy?\" J Clin Psychopharmacol 4 (1984): 143-6[4] Fletcher GF, Kazamias TM \"Cardiotoxic effects of Mellaril: conduction disturbances and supraventricular arrhythmias.\" Am Heart J 78 (1969): 135-8[5] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] Glassman AH, Bigger JT Jr \"Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death.\" Am J Psychiatry 158 (2001): 1774-82[8] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[9] Hartigan-Go K, Bateman DN, Nyberg G, Martensson E, Thomas SHL \"Concentration-related pharmacodynamic effects of thioridazine and its metabolites in humans.\" Clin Pharmacol Ther 60 (1996): 543-53[10] Honig PK, Wortham DC, Zamani K, et al \"Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences.\" JAMA 269 (1993): 1513-8[11] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[12] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P \"Torsades de pointes after terfenadine-itraconazole interaction.\" BMJ 306 (1993): 186[13] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[14] Mathews DR, McNutt B, Okerholm R, et al \"Torsades de pointes occurring in association with terfenadine use.\" JAMA 266 (1991): 2375-6[15] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL \"Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram.\" Clin Pharmacol Ther 59 (1996): 383-8[16] Zechnich AD, Haxby DG \"Drug interactions associated with terfenadine and related nonsedating antihistamines.\" West J Med 164 (1996): 68-9[17] Hsieh MH, Chen SA, Chiang CE, et al. \"Drug-induced torsades de pointes in one patient with congenital long QT syndrome.\" Int J Cardiol 54 (1996): 85-8[18] Woosley RL \"Cardiac actions of antihistamines.\" Annu Rev Pharmacol Toxicol 36 (1996): 233-52[19] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP \"Torsades-de-pointes induced by erythromycin and terfenadine.\" Am J Emerg Med 12 (1994): 636-8[20] Zimmermann M, Duruz H, Guinand O, et al \"Torsades de Pointes after treatment with terfenadine and ketoconazole.\" Eur Heart J 13 (1992): 1002-3[21] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG \"Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance.\" Clin Pharmacol Ther 61 (1997): 401-9[22] Honig PK, Wortham DC, Lazarev A, Cantilena LR \"Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine.\" J Clin Pharmacol 36 (1996): 345-51[23] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr \"Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin.\" Clin Pharmacol Ther 52 (1992): 231-8[24] Monahan BP, Ferguson CL, Killeavy ES, et al \"Torsades de pointes occurring in association with terfenadine use.\" JAMA 264 (1990): 2788-90[25] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[26] Cortese LM, Bjornson DC \"Potential interaction between terfenadine and macrolide antibiotics.\" Clin Pharm 11 (1992): 675", "alternatives_a": "Loxapine, Molindone, Thiothixene", "alternatives_b": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Nizatidine, Esomeprazole, Ranitidine, More", "updated_at": 1767369485}, {"id": 68025, "ingredient1": "Clarithromycin", "ingredient2": "Ticagrelor", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of ticagrelor, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Concomitant use of ticagrelor with potent CYP450 3A4 inhibitors is considered contraindicated by some foreign authorities. The U.S. labeling for ticagrelor recommends avoiding use with potent CYP450 3A4 inhibitors. Labeling for itraconazole, a potent CYP450 3A4 inhibitor, specifically contraindicates use with ticagrelor during and for 2 weeks after treatment with itraconazole.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of ticagrelor with potent CYP450 3A4 inhibitors is considered contraindicated by some foreign authorities.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68112/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Brilinta (ticagrelor).\" Astra-Zeneca Pharmaceuticals, Wilmington, DE.[4] \"Product Information. Sporanox (itraconazole).\" Janssen Pharmaceutica, Titusville, NJ.[5] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[6] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Tinidazole, Dexlansoprazole, Rabeprazole, Metronidazole, Vonoprazan, Amoxicillin, Pantoprazole, Misoprostol, Esomeprazole, Ranitidine, Levofloxacin, More", "alternatives_b": "Iloprost, Lepirudin, Urokinase, Cangrelor, Caplacizumab, Argatroban, Prasugrel, Desirudin, Eptifibatide, Streptokinase, Tinzaparin, More", "updated_at": 1767369485}, {"id": 68026, "ingredient1": "Clarithromycin", "ingredient2": "Ticarcillin", "severity": "Minor", "effect": "Although some in vitro data indicate synergism between macrolide antibiotics and penicillins, other in vitro data indicate antagonism. When these drugs are given together, neither has predictable therapeutic efficacy. Data are available for erythromycin, although theoretically this interaction could occur with any macrolide. Except for monitoring of the effectiveness of antibiotic therapy, no special precautions appear to be necessary.", "source": "DDInter", "management_text": "-", "mechanism_text": "Others", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68113/", "reference_text": "[1] Strom J \"Penicillin and erythromycin singly and in combination in scarlatina therapy and the interference between them.\" Antibiot Chemother 11 (1961): 694-7[2] Cohn JR, Jungkind DL, Baker JS \"In vitro antagonism by erythromycin of the bactericidal action of antimicrobial agents against common respiratory pathogens.\" Antimicrob Agents Chemother 18 (1980): 872-6[3] Penn RL, Ward TT, Steigbigel RT \"Effects of erythromycin in combination with penicillin, ampicillin, or gentamicin on the growth of listeria monocytogenes.\" Antimicrob Agents Chemother 22 (1982): 289-94", "alternatives_a": "Tinidazole, Dexlansoprazole, Rabeprazole, Metronidazole, Vonoprazan, Amoxicillin, Pantoprazole, Misoprostol, Esomeprazole, Ranitidine, Levofloxacin, More", "alternatives_b": "Tazobactam, Sulbactam", "updated_at": 1767369485}, {"id": 68027, "ingredient1": "Clarithromycin", "ingredient2": "Tipranavir", "severity": "Moderate", "effect": "Coadministration of clarithromycin with tipranavir and low-dose ritonavir may result in increased plasma concentrations of both clarithromycin and tipranavir. The proposed mechanism is competitive inhibition of CYP450 3A4, the isoenzyme responsible for the metabolic clearance of all three drugs.", "source": "DDInter", "management_text": "No dosage adjustment of tipranavir or clarithromycin is necessary for patients with normal renal function. For patients with creatinine clearance between 30 and 60 mL/min, the dosage of clarithromycin should be reduced by 50%. For patients with creatinine clearance below 30 mL/min, the dosage of clarithromycin should be reduced by 75%.", "mechanism_text": "Metabolism", "recommendation": "No dosage adjustment of tipranavir or clarithromycin is necessary for patients with normal renal function.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68114/", "reference_text": "[1] \"Product Information. Aptivus (tipranavir).\" Boehringer-Ingelheim, Ridgefield, CT.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[5] \"Product Information. Aptivus (tipranavir).\" Boehringer-Ingelheim, Ridgefield, CT.[6] Cheng KL, Nafziger AN, Peloquin CA, Amsden GW \"Effect of grapefruit juice on clarithromycin pharmacokinetics.\" Antimicrob Agents Chemother 42 (1998): 927-9", "alternatives_a": "Glecaprevir, Tenofovir alafenamide, Cabotegravir, Lenacapavir, Velpatasvir, Voxilaprevir, Maribavir, Pibrentasvir, Rimantadine, Elvitegravir, Valganciclovir, More", "alternatives_b": "Pantoprazole, Levofloxacin, Tetracycline, Rabeprazole, Dexlansoprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Famotidine, Cimetidine, Nizatidine, More", "updated_at": 1767369485}, {"id": 68028, "ingredient1": "Clarithromycin", "ingredient2": "Tizanidine", "severity": "Moderate", "effect": "Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.", "source": "DDInter", "management_text": "Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution and clinical monitoring are recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68115/", "reference_text": "[1] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):[2] Witchel HJ, Hancox JC, Nutt DJ \"Psychotropic drugs, cardiac arrhythmia, and sudden death.\" J Clin Psychopharmacol 23 (2003): 58-77[3] Iannini PB \"Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval.\" Expert Opin Drug Saf 1 (2002): 121-8[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[6] Glassman AH, Bigger JT Jr \"Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death.\" Am J Psychiatry 158 (2001): 1774-82[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] Honig PK, Wortham DC, Zamani K, et al \"Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences.\" JAMA 269 (1993): 1513-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[10] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P \"Torsades de pointes after terfenadine-itraconazole interaction.\" BMJ 306 (1993): 186[11] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[12] Mathews DR, McNutt B, Okerholm R, et al \"Torsades de pointes occurring in association with terfenadine use.\" JAMA 266 (1991): 2375-6[13] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL \"Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram.\" Clin Pharmacol Ther 59 (1996): 383-8[14] Zechnich AD, Haxby DG \"Drug interactions associated with terfenadine and related nonsedating antihistamines.\" West J Med 164 (1996): 68-9[15] Hsieh MH, Chen SA, Chiang CE, et al. \"Drug-induced torsades de pointes in one patient with congenital long QT syndrome.\" Int J Cardiol 54 (1996): 85-8[16] Woosley RL \"Cardiac actions of antihistamines.\" Annu Rev Pharmacol Toxicol 36 (1996): 233-52[17] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP \"Torsades-de-pointes induced by erythromycin and terfenadine.\" Am J Emerg Med 12 (1994): 636-8[18] Zimmermann M, Duruz H, Guinand O, et al \"Torsades de Pointes after treatment with terfenadine and ketoconazole.\" Eur Heart J 13 (1992): 1002-3[19] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG \"Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance.\" Clin Pharmacol Ther 61 (1997): 401-9[20] Honig PK, Wortham DC, Lazarev A, Cantilena LR \"Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine.\" J Clin Pharmacol 36 (1996): 345-51[21] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr \"Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin.\" Clin Pharmacol Ther 52 (1992): 231-8[22] Monahan BP, Ferguson CL, Killeavy ES, et al \"Torsades de pointes occurring in association with terfenadine use.\" JAMA 264 (1990): 2788-90[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[24] Cortese LM, Bjornson DC \"Potential interaction between terfenadine and macrolide antibiotics.\" Clin Pharm 11 (1992): 675", "alternatives_a": "Baclofen, Chlorzoxazone, Orphenadrine, Chlormezanone", "alternatives_b": "Tinidazole, Dexlansoprazole, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Esomeprazole, Vonoprazan, Lincomycin, Troleandomycin, Dirithromycin", "updated_at": 1767369485}, {"id": 68029, "ingredient1": "Clarithromycin", "ingredient2": "Tofacitinib", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of tofacitinib, which is metabolized by the isoenzyme. Side effects including lymphopenia, neutropenia, anemia, serious infections, and hyperlipidemia may be increased.", "source": "DDInter", "management_text": "The dosage of tofacitinib should be reduced by 50% when used with potent CYP450 3A4 inhibitors. For example, the dose for patients receiving 10 mg twice daily should be reduced to 5 mg twice daily and the dose for patients receiving 5 mg twice daily should be reduced to 5 mg once daily. For patients receiving 11 mg once daily of the extended-release formulation, the dose should be reduced to 5 mg once daily of the immediate-release formulation. The dose for patients receiving 3.2 mg twice daily should be reduced to 3.2 mg once daily and the dose for patients receiving 4 mg twice daily should be reduced to 4 mg once daily.", "mechanism_text": "Metabolism", "recommendation": "The dosage of tofacitinib should be reduced by 50% when used with potent CYP450 3A4 inhibitors.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68116/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Xeljanz (tofacitinib).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.[4] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[5] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Tinidazole, Pantoprazole, Levofloxacin, Dexlansoprazole, Rabeprazole, Sucralfate, Tetracycline, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Famotidine, More", "alternatives_b": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Abatacept, Anakinra, More", "updated_at": 1767369485}, {"id": 68030, "ingredient1": "Clarithromycin", "ingredient2": "Tolazamide", "severity": "Moderate", "effect": "Limited data suggest that clarithromycin may potentiate the hypoglycemic effect of sulfonylureas in susceptible individuals such as the elderly and patients with renal impairment. The exact mechanism is unknown but may involve clarithromycin displacement of sulfonylureas from plasma protein binding sites.", "source": "DDInter", "management_text": "Clarithromycin should be prescribed cautiously to diabetic patients with renal impairment who are receiving sulfonylurea therapy, particularly if they are also elderly. Patients should be advised to regularly monitor their blood sugar and counseled on how to recognize and treat hypoglycemia, which may include symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, and palpitations. The physician should be notified if an interaction is suspected.", "mechanism_text": "Distribution", "recommendation": "Clarithromycin should be prescribed cautiously to diabetic patients with renal impairment who are receiving sulfonylurea therapy, particularly if they are also elderly.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68117/", "reference_text": "[1] Bussing R, Gende A \"Severe hypoglycemia from clarithromycin-sulfonylurea drug interaction.\" Diabetes Care 25 (2002): 1659-61[2] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[3] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[4] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[5] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[6] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[7] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[8] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[9] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[10] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[11] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[12] Cheng KL, Nafziger AN, Peloquin CA, Amsden GW \"Effect of grapefruit juice on clarithromycin pharmacokinetics.\" Antimicrob Agents Chemother 42 (1998): 927-9", "alternatives_a": "Guar gum", "alternatives_b": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Vonoprazan, Amoxicillin, Lansoprazole, More", "updated_at": 1767369485}, {"id": 68031, "ingredient1": "Clarithromycin", "ingredient2": "Tolbutamide", "severity": "Moderate", "effect": "Limited data suggest that clarithromycin may potentiate the hypoglycemic effect of sulfonylureas in susceptible individuals such as the elderly and patients with renal impairment. The exact mechanism is unknown but may involve clarithromycin displacement of sulfonylureas from plasma protein binding sites.", "source": "DDInter", "management_text": "Clarithromycin should be prescribed cautiously to diabetic patients with renal impairment who are receiving sulfonylurea therapy, particularly if they are also elderly. Patients should be advised to regularly monitor their blood sugar and counseled on how to recognize and treat hypoglycemia, which may include symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, and palpitations. The physician should be notified if an interaction is suspected.", "mechanism_text": "Distribution", "recommendation": "Clarithromycin should be prescribed cautiously to diabetic patients with renal impairment who are receiving sulfonylurea therapy, particularly if they are also elderly.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68118/", "reference_text": "[1] Bussing R, Gende A \"Severe hypoglycemia from clarithromycin-sulfonylurea drug interaction.\" Diabetes Care 25 (2002): 1659-61[2] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[3] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[4] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[5] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[6] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[7] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[8] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[9] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[10] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[11] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[12] Cheng KL, Nafziger AN, Peloquin CA, Amsden GW \"Effect of grapefruit juice on clarithromycin pharmacokinetics.\" Antimicrob Agents Chemother 42 (1998): 927-9", "alternatives_a": "Methacholine, Hexaminolevulinate, Secretin human, Methylene blue, Sermorelin, Sorbitol, Magnesium sulfate, Vitamin A, Caffeine, Metyrapone, Edrophonium, More", "alternatives_b": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Vonoprazan, Amoxicillin, Lansoprazole, More", "updated_at": 1767369485}, {"id": 68032, "ingredient1": "Clarithromycin", "ingredient2": "Tolterodine", "severity": "Moderate", "effect": "Coadministration with drugs that are inhibitors of CYP450 3A4 may increase the plasma concentrations of tolterodine, which is partially metabolized by the isoenzyme. The possibility of prolonged and/or increased pharmacologic effects of tolterodine should be considered. Although tolterodine is primarily metabolized by CYP450 2D6, there is some evidence that CYP450 3A4 may play a minor role, thus any alteration in its activity levels could conceivably affect the metabolism of tolterodine.", "source": "DDInter", "management_text": "The manufacturer recommends a maximum tolterodine dosage of 1 mg twice daily in patients receiving concomitant CYP450 3A4 inhibitors. Close clinical and laboratory monitoring is advised whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy. Patients should be advised to notify their physician if they experience an irregular heartbeat, severe blurry vision, difficulty urinating, dry mouth, headache, drowsiness, dizziness, or GI upset.", "mechanism_text": "Metabolism", "recommendation": "The manufacturer recommends a maximum tolterodine dosage of 1 mg twice daily in patients receiving concomitant CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68119/", "reference_text": "[1] \"Product Information. Detrol (tolterodine).\" Pharmacia and Upjohn, Kalamazoo, MI.[2] Brynne N, Forslund C, Hallen B, Gustafsson LL, Bertilsson L \"Ketoconazole inhibits the metabolism of tolterodine in subjects with deficient CYP2D6 activity.\" Br J Clin Pharmacol 48 (1999): 564-72", "alternatives_a": "Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Trospium, Acetohydroxamic acid, Yohimbine, Flavoxate, Phenyl salicylate, Ammonium chloride, Dimethyl sulfoxide", "alternatives_b": "Tinidazole, Dexlansoprazole, Bismuth subcitrate potassium, Rifabutin, Esomeprazole, Levofloxacin, Lincomycin, Dirithromycin", "updated_at": 1767369485}, {"id": 68033, "ingredient1": "Clarithromycin", "ingredient2": "Tolvaptan", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of vasopressin receptor antagonists conivaptan and tolvaptan, both of which are almost exclusively metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Concomitant use of conivaptan or tolvaptan with potent CYP450 3A4 inhibitors is considered contraindicated. Some authorities recommend avoiding concomitant use of conivaptan or tolvaptan during and for 2 weeks after treatment with itraconazole.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of conivaptan or tolvaptan with potent CYP450 3A4 inhibitors is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68120/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] \"Product Information. Sporanox (itraconazole).\" Janssen Pharmaceutica, Titusville, NJ.[3] \"Product Information. Samsca (tolvaptan).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[4] \"Product Information. Vaprisol (conivaptan).\" Cumberland Pharmaceuticals Inc, Nashville, TN.[5] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[6] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[7] \"Product Information. Samsca (tolvaptan).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Tinidazole, Dexlansoprazole, Rabeprazole, Metronidazole, Vonoprazan, Amoxicillin, Pantoprazole, Misoprostol, Esomeprazole, Ranitidine, Levofloxacin, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68034, "ingredient1": "Clarithromycin", "ingredient2": "Toremifene", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of toremifene, which is primarily metabolized by the isoenzyme. Because toremifene is associated with dose- and concentration-dependent prolongation of the QT interval, increased levels may potentiate the risk of ventricular arrhythmias such as torsade de pointes and sudden death.", "source": "DDInter", "management_text": "The use of toremifene in combination with potent CYP450 3A4 inhibitors such as itraconazole, ketoconazole, voriconazole, nefazodone, delavirdine, protease inhibitors, and ketolide and certain macrolide antibiotics should generally be avoided. If treatment with one of these agents is required, interruption of toremifene therapy should be considered. Otherwise, patients who require concomitant treatment should be closely monitored. In patients at increased risk, electrocardiograms (ECGs) should be obtained at baseline and as clinically indicated. Complete blood counts, electrolyte levels (calcium, magnesium, potassium), and liver function tests should also be obtained periodically. Patients should be advised to contact their physician if they experience vaginal bleeding or potential signs of blood clots such as chest pain, shortness of breath, sudden loss of vision, and pain, redness or swelling in an extremity. Patients should seek immediate medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, palpitations, or syncope.", "mechanism_text": "Metabolism", "recommendation": "The use of toremifene in combination with potent CYP450 3A4 inhibitors such as itraconazole, ketoconazole, voriconazole, nefazodone, delavirdine, protease inhibitors, and ketolide and certain macrolide antibiotics should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68121/", "reference_text": "[1] \"Product Information. Fareston (toremifene).\" Schering Laboratories, Kenilworth, NJ.[2] \"Product Information. Fareston (toremifene).\" Schering Laboratories, Kenilworth, NJ.[3] Therapeutic Research Faculty \"Natural Medicines Comprehensive Database. Available from: URL: http://www.naturaldatabase.com.\" ([1995-2008...]):[4] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[5] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Anastrozole, Aminoglutethimide, Exemestane, Fulvestrant", "alternatives_b": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Nizatidine, Esomeprazole, Ranitidine, More", "updated_at": 1767369485}, {"id": 68035, "ingredient1": "Clarithromycin", "ingredient2": "Trabectedin", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of trabectedin, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Concomitant use of trabectedin with potent CYP450 3A4 inhibitors should generally be avoided. Some authorities recommend avoiding concomitant use of trabectedin during and for 2 weeks after treatment with itraconazole. If a potent CYP450 3A4 inhibitor is required for short-term use (i.e., less than 14 days), it is advisable to administer the CYP450 3A4 inhibitor one week after the trabectedin infusion and discontinue it the day prior to the next infusion. Close monitoring for toxicities such as myelosuppression, rhabdomyolysis, hepatotoxicity, and cardiomyopathy is recommended during long-term coadministration, and the trabectedin dosage adjusted accordingly or treatment discontinued as necessary.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of trabectedin with potent CYP450 3A4 inhibitors should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68122/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Yondelis (trabectedin).\" Janssen Pharmaceuticals, Titusville, NJ.[4] Machiels JP, Staddon A, Herremans C, et al. \"Impact of cytochrome P450 3A4 inducer and inhibitor on the pharmacokinetics of trabectedin in patients with advanced malignancies: open-label, multicenter studies.\" Cancer Chemother Pharmacol 74 (2014): 729-37[5] \"Product Information. Sporanox (itraconazole).\" Janssen Pharmaceutica, Titusville, NJ.[6] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[7] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[8] \"Product Information. Yondelis (trabectedin).\" Janssen Pharmaceuticals, Titusville, NJ.[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Pantoprazole, Tetracycline, Rabeprazole, Dexlansoprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Famotidine, Nizatidine, Esomeprazole, Ranitidine, More", "alternatives_b": "Topotecan, Teniposide", "updated_at": 1767369485}, {"id": 68036, "ingredient1": "Clarithromycin", "ingredient2": "Trazodone", "severity": "Moderate", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may increase the plasma concentrations and pharmacologic effects of trazodone, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "If concomitant use cannot be avoided, a lower dosage of trazodone should be considered during coadministration with a potent CYP450 3A4 inhibitor. Pharmacologic response to trazodone should be monitored more closely whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy, and the trazodone dosage adjusted as necessary. Patients should seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitations, irregular heartbeat, shortness of breath, or syncope.", "mechanism_text": "Metabolism", "recommendation": "If concomitant use cannot be avoided, a lower dosage of trazodone should be considered during coadministration with a potent CYP450 3A4 inhibitor.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68123/", "reference_text": "[1] \"Product Information. Oleptro (traZODone).\" Labopharm Inc, Laval, AL.[2] Mazur A, Strasberg B, Kusniec J, Sclarovsky S \"QT prolongation and polymorphous ventricular tachycardia associated with trasodone-amiodarone combination.\" Int J Cardiol 52 (1995): 27-9[3] \"Product Information. Stribild (cobicistat/elvitegravir/emtricitabine/tenofov).\" Gilead Sciences, Foster City, CA.[4] Dattilo PB, Nordin C \"Prolonged QT associated with an overdose of trazodone.\" J Clin Psychiatry 68 (2007): 1309-10[5] \"Product Information. Crixivan (indinavir).\" Merck & Co, Inc, West Point, PA.[6] Levenson JL \"Prolonged QT interval after trazodone overdose.\" Am J Psychiatry 156 (1999): 969-70[7] \"Product Information. Lexiva (fosamprenavir).\" GlaxoSmithKline, Research Triangle Park, NC.[8] \"Product Information. Desyrel (trazodone).\" Bristol-Myers Squibb, Princeton, NJ.[9] Goodnick PJ, Jerry J, Parra F \"Psychotropic drugs and the ECG: focus on the QTc interval.\" Expert Opin Pharmacother 3 (2002): 479-98[10] \"Product Information. Agenerase (amprenavir).\" Glaxo Wellcome, Research Triangle Pk, NC.[11] \"Product Information. Viracept (nelfinavir).\" Agouron Pharma Inc, La Jolla, CA.[12] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical, Abbott Park, IL.[13] Greenblatt DJ, von Moltke LL, Harmatz JS, et al. \"Short-term exposure to low-dose ritonavir impairs clearance and enhances adverse effects of trazodone.\" J Clin Pharmacol 43 (2003): 414-22[14] \"Product Information. Reyataz (atazanavir).\" Bristol-Myers Squibb, Princeton, NJ.[15] \"Product Information. Prezista (darunavir).\" Ortho Biotech Inc, Bridgewater, NJ.[16] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[17] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[18] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[19] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[20] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[21] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Phenelzine, Tranylcypromine, Desvenlafaxine, Isocarboxazid, Oxitriptan, Vortioxetine, Milnacipran, Tryptophan, Esketamine", "alternatives_b": "Tinidazole, Tetracycline, Dexlansoprazole, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Cimetidine, Esomeprazole, Vonoprazan, Lincomycin, Dirithromycin", "updated_at": 1767369485}, {"id": 68037, "ingredient1": "Clarithromycin", "ingredient2": "Tretinoin", "severity": "Moderate", "effect": "Coadministration with potent inhibitors of CYP450 2C8, 2C9, and/or 3A4 may increase the plasma concentrations and toxicities of tretinoin, which is a substrate of these isoenzymes. There have been isolated reports of pseudotumour cerebri, hypercalcemia, and acute renal failure in patients receiving tretinoin with fluconazole, itraconazole or voriconazole, all of which are considered potent inhibitors of at least one CYP450 isoenzyme involved in the metabolism of tretinoin. The conditions resolved following interruption of tretinoin therapy and/or discontinuation of the azole antifungal agent.", "source": "DDInter", "management_text": "Caution is advised when tretinoin is prescribed in combination with potent inhibitors of CYP450 2C8, 2C9, and/or 3A4. Patients should be closely monitored and advised to seek medical attention immediately if they develop early symptoms of pseudotumour cerebri such as headache, nausea, vomiting, visual disturbances, photosensitivity, and tinnitus.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when tretinoin is prescribed in combination with potent inhibitors of CYP450 2C8, 2C9, and/or 3A4.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68124/", "reference_text": "[1] Cordoba R, Ramirez E, Lei SH, et al. \"Hypercalcemia due to an interaction of all-trans retinoic acid (ATRA) and itraconazole therapy for acute promyelocytic leukemia successfully treated with zoledronic acid.\" Eur J Clin Pharmacol 64 (2008): 1031-2[2] Adamson PC \"Pharmacokinetics of all-trans-retinoic acid: clinical implications in acute promyelocytic leukemia.\" Semin Hematol 31 (1994): 14-7[3] Hameed DA, el-Metwally TH \"The effectiveness of retinoic acid treatment in bladder cancer: impact on recurrence, survival and TGFalpha and VEGF as end-point biomarkers.\" Cancer Biol Ther 7 (2008): 92-100[4] Lotan Y, Lotan R \"Prevention of bladder cancer recurrence by retinoic acid-ketoconazole: a promising strategy?\" Cancer Biol Ther 7 (2008): 101-2[5] \"Product Information. Vesanoid (tretinoin).\" Roche Laboratories, Nutley, NJ.[6] Kizaki M, Ueno H, Yamazoe Y, et al \"Mechanisms of retinoid resistance in leukemic cells: possible role of cytochrome P450 and P-glycoprotein.\" Blood 87 (1996): 725-33[7] Dixon KS, Hassoun A \"Pseudotumor cerebri due to the potentiation of all-trans retinoic acid by voriconazole.\" J Am Pharm Assoc (2003) 50 (2010): 742-4[8] Muindi JRF, Young CW, Warrell RP \"Clinical pharmacology of all-trans retinoic acid.\" Leukemia 8 (1994): 1807-12[9] Rigas JR, Francis PA, Muindi JR, Kris MG, Huselton C, DeGrazia F, Orazem JP, Young CW, Warrell RP Jr \"Constitutive variability in the pharmacokinetics of the natural retinoid, all-trans-retinoic acid, and its modulation by ketoconazole.\" J Natl Cancer Inst 85 (1993): 1921-6[10] Moresco G, Martinello F, Souza LC \"[Acute renal failure in patient treated with ATRA and amphotericin B: case report].\" J Bras Nefrol 33 (2011): 276-81[11] Marill J, Cresteil T, Lanotte M, Chabot GG \"Identification of human cytochrome P450s involved in the formation of all-trans-retinoic acid principal metabolites.\" Mol Pharmacol 58 (2000): 1341-8", "alternatives_a": "Pertuzumab, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Ixazomib, Enasidenib, Mitotane, Niraparib, Porfimer sodium, More", "alternatives_b": "Tinidazole, Dexlansoprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Esomeprazole, Vonoprazan, Lincomycin, Dirithromycin", "updated_at": 1767369485}, {"id": 68038, "ingredient1": "Clarithromycin", "ingredient2": "Triamcinolone (nasal)", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations and pharmacologic effects of corticosteroids, which are primarily metabolized by the isoenzyme. The interaction has been reported with potent inhibitors such as clarithromycin, erythromycin, itraconazole, nefazodone, cobicistat, and ritonavir during concomitant use of various corticosteroids, including inhaled, nasal, and ophthalmic formulations. Systemic corticosteroid adverse effects may occur following intensive or long-term continuous ophthalmic corticosteroid therapy. Cushing's syndrome and adrenal insufficiency have been attributed to the interaction.", "source": "DDInter", "management_text": "The possibility of increased corticosteroid effects should be considered during coadministration with potent and moderate CYP450 3A4 inhibitors. When indicated for intranasal or inhalational use, alternative corticosteroids such as beclomethasone, which is less dependent on CYP450 3A4 metabolism, should be considered, particularly if long term treatment is required. Patients should be monitored for signs and symptoms of hypercorticism such as acne, striae, thinning of the skin, easy bruising, moon facies, dorsocervical \"buffalo\" hump, truncal obesity, increased appetite, acute weight gain, edema, hypertension, hirsutism, hyperhidrosis, proximal muscle wasting and weakness, glucose intolerance, exacerbation of preexisting diabetes, depression, and menstrual disorders. Other systemic glucocorticoid effects may include adrenal suppression, immunosuppression, posterior subcapsular cataracts, glaucoma, bone loss, and growth retardation in children and adolescents. Following extensive use with a potent CYP450 3A4 inhibitor, a progressive dosage reduction may be required over a longer period if the corticosteroid is to be withdrawn from therapy, as there may be a significant risk of adrenal suppression.", "mechanism_text": "Metabolism", "recommendation": "The possibility of increased corticosteroid effects should be considered during coadministration with potent and moderate CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68125/", "reference_text": "[1] Edsbacker S, Andersson T \"Pharmacokinetics of budesonide (Entocort EC) capsules for Crohn's disease.\" Clin Pharmacokinet 43 (2004): 803-21[2] Finkenbine RD, Frye MD \"Case of psychosis due to prednisone-clarithromycin interaction.\" Gen Hosp Psychiat 20 (1998): 325-6[3] Soldatos G, Sztal-Mazer S, Woolley I, Stockigt J \"Exogenous glucocorticoid excess as a result of ritonavir-fluticasone interaction.\" Intern Med J 35 (2005): 67-8[4] Kandrotas RJ, Slaughter RL, Brass C, Jusko WJ \"Ketoconazole effects on methylprednisolone disposition and their joint suppression of endogenous cortisol.\" Clin Pharmacol Ther 42 (1987): 465-70[5] Raaska K, Niemi M, Neuvonen M, Neuvonen PJ, Kivisto KT \"Plasma concentrations of inhaled budesonide and its effects on plasma cortisol are increased by the cytochrome P4503A4 inhibitor itraconazole.\" Clin Pharmacol Ther 72 (2002): 362-369[6] Ulrich B, Frey FJ, Speck RF, Frey BM \"Pharmacokinetics/pharmacodynamics of ketoconazole-prednisolone interaction.\" J Pharmacol Exp Ther 260 (1992): 487-90[7] Zurcher RM, Frey BM, Frey FJ \"Impact of ketoconazole on the metabolism of prednisolone.\" Clin Pharmacol Ther 45 (1989): 366-72[8] Busse KH, Formentini E, Alfaro RM, Kovacs JA, Penzak SR \"Influence of antiretroviral drugs on the pharmacokinetics of prednisolone in HIV-infected individuals.\" J Acquir Immune Defic Syndr 48 (2008): 561-6[9] Yamashita SK, Ludwig EA, Middleton E Jr, Jusko WJ \"Lack of pharmacokinetic and pharmacodynamic interactions between ketoconazole and prednisolone.\" Clin Pharmacol Ther 49 (1991): 558-70[10] Hillebrand-Haverkort ME, Prummel MF, ten Veen JH \"Ritonavir-induced Cushing's syndrome in a patient treated with nasal fluticasone.\" AIDS 13 (1999): 1803[11] Kotlyar M, Brewer ER, Golding M, Carson SW \"Nefazodone inhibits methylprednisolone disposition and enhances its adrenal-suppressant effect.\" J Clin Psychopharmacol 23 (2003): 652-6[12] Itkin IH, Menzel ML \"The use of macrolide antibiotic substances in the treatment of asthma.\" J Allergy Clin Immunol 45 (1970): 146-62[13] Skov M, Main KM, Sillesen IB, Muller J, Koch C, Lanng S \"Iatrogenic adrenal insufficiency as a side-effect of combined treatment of itraconazole and budesonide.\" Eur Respir J 20 (2002): 127-33[14] Samaras K, Pett S, Gowers A, McMurchie M, Cooper DA \"Iatrogenic Cushing's syndrome with osteoporosis and secondary adrenal failure in HIV-infected patients receiving inhaled corticosteroids and ritonavir-boosted protease inhibitors: six cases.\" J Clin Endocrinol Metab 90 (2005): 4394-8[15] Garey KW, Rubinstein I, Gotfried MH, Khan IJ, Varma S, Danziger LH \"Long-term clarithromycin decreases prednisone requirements in elderly patients with prednisone-dependent asthma.\" Chest 118 (2000): 1826-7[16] Glynn AM, Slaughter RL, Brass C, et al \"Effects of ketoconazole on methylprednisolone pharmacokinetics and cortisol secretion.\" Clin Pharmacol Ther 39 (1986): 654-9[17] LaForce CF, Szefler SJ, Miller MF, Ebling W, Brenner M \"Inhibition of methylprednisolone elimination in the presence of erythromycin therapy.\" J Allergy Clin Immunol 72 (1983): 34-9[18] Lebrun-Vignes B, Archer VC, Diquest B, et al. \"Effect of itraconazole on the pharmacokinetics of prednisolone and methylprednisolone and cortisol secretion in healthy subjects.\" Br J Clin Pharmacol 51 (2001): 443-50[19] Varis T, Kivisto KT, Neuvonen PJ \"The effect of itraconazole on the pharmacokinetics and pharmacodynamics of oral prednisolone.\" Eur J Clin Pharmacol 56 (2000): 57-60[20] Bolland MJ, Bagg W, Thomas MG, Lucas JA, Ticehurst R, Black PN \"Cushing's syndrome due to interaction between inhaled corticosteroids and itraconazole.\" Ann Pharmacother 38 (2004): 46-9[21] Gupta SK, Dube MP \"Exogenous Cushing syndrome mimicking human immunodeficiency virus lipodystrophy.\" Clin Infect Dis 35 (2002): E69-71[22] Varis T, Kaukonen KM, Kivisto KT, Neuvonen PJ \"Plasma concentrations and effects of oral methylprednisolone are considerably increased by itraconazole.\" Clin Pharmacol Ther 64 (1998): 363-8[23] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[24] Couturier J, Steele M, Hussey L, Pawliuk G \"Steroid-induced mania in an adolescent: risk factors and management.\" Can J Clin Pharmacol 8 (2001): 109-12[25] Varis T, Backman JT, Kivisto KT, Neuvonen PJ \"Diltiazem and mibefradil increase the plasma concentrations and greatly enhance the adrenal-suppressant effect of oral methylprednisolone.\" Clin Pharmacol Ther 67 (2000): 215-21[26] Bhumbra NA, Sahloff EG, Oehrtman SJ, Horner JM \"Exogenous Cushing syndrome with inhaled fluticasone in a child receiving lopinavir/ritonavir.\" Ann Pharmacother 41 (2007): 1306-9[27] Main KM, Skov M, Sillesen IB, et al. \"Cushing's syndrome due to pharmacological interaction in a cystic fibrosis patient.\" Acta Paediatr 91 (2002): 1008-11[28] Penzak SR, Formentini E, Alfaro RM, Long M, Natarajan V, Kovacs J \"Prednisolone pharmacokinetics in the presence and absence of ritonavir after oral prednisone administration to healthy volunteers.\" J Acquir Immune Defic Syndr 40 (2005): 573-80[29] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[30] \"Product Information. Zokinvy (lonafarnib).\" Eiger BioPharmaceuticals, Palo Alto, CA.", "alternatives_a": "Mometasone furoate, Amcinonide, Fluocinolone acetonide, Hydrocortisone butyrate, Fluocinonide, Fluorometholone, Beclomethasone dipropionate, Mupirocin, Mometasone furoate, Vitamin A, Ephedrine, More", "alternatives_b": "Tinidazole, Dexlansoprazole, Rabeprazole, Metronidazole, Vonoprazan, Amoxicillin, Pantoprazole, Misoprostol, Esomeprazole, Ranitidine, Levofloxacin, More", "updated_at": 1767369485}, {"id": 68039, "ingredient1": "Clarithromycin", "ingredient2": "Triamcinolone (ophthalmic)", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations and pharmacologic effects of corticosteroids, which are primarily metabolized by the isoenzyme. The interaction has been reported with potent inhibitors such as clarithromycin, erythromycin, itraconazole, nefazodone, cobicistat, and ritonavir during concomitant use of various corticosteroids, including inhaled, nasal, and ophthalmic formulations. Systemic corticosteroid adverse effects may occur following intensive or long-term continuous ophthalmic corticosteroid therapy. Cushing's syndrome and adrenal insufficiency have been attributed to the interaction.", "source": "DDInter", "management_text": "The possibility of increased corticosteroid effects should be considered during coadministration with potent and moderate CYP450 3A4 inhibitors. When indicated for intranasal or inhalational use, alternative corticosteroids such as beclomethasone, which is less dependent on CYP450 3A4 metabolism, should be considered, particularly if long term treatment is required. Patients should be monitored for signs and symptoms of hypercorticism such as acne, striae, thinning of the skin, easy bruising, moon facies, dorsocervical \"buffalo\" hump, truncal obesity, increased appetite, acute weight gain, edema, hypertension, hirsutism, hyperhidrosis, proximal muscle wasting and weakness, glucose intolerance, exacerbation of preexisting diabetes, depression, and menstrual disorders. Other systemic glucocorticoid effects may include adrenal suppression, immunosuppression, posterior subcapsular cataracts, glaucoma, bone loss, and growth retardation in children and adolescents. Following extensive use with a potent CYP450 3A4 inhibitor, a progressive dosage reduction may be required over a longer period if the corticosteroid is to be withdrawn from therapy, as there may be a significant risk of adrenal suppression.", "mechanism_text": "Metabolism", "recommendation": "The possibility of increased corticosteroid effects should be considered during coadministration with potent and moderate CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68126/", "reference_text": "[1] Edsbacker S, Andersson T \"Pharmacokinetics of budesonide (Entocort EC) capsules for Crohn's disease.\" Clin Pharmacokinet 43 (2004): 803-21[2] Finkenbine RD, Frye MD \"Case of psychosis due to prednisone-clarithromycin interaction.\" Gen Hosp Psychiat 20 (1998): 325-6[3] Soldatos G, Sztal-Mazer S, Woolley I, Stockigt J \"Exogenous glucocorticoid excess as a result of ritonavir-fluticasone interaction.\" Intern Med J 35 (2005): 67-8[4] Kandrotas RJ, Slaughter RL, Brass C, Jusko WJ \"Ketoconazole effects on methylprednisolone disposition and their joint suppression of endogenous cortisol.\" Clin Pharmacol Ther 42 (1987): 465-70[5] Raaska K, Niemi M, Neuvonen M, Neuvonen PJ, Kivisto KT \"Plasma concentrations of inhaled budesonide and its effects on plasma cortisol are increased by the cytochrome P4503A4 inhibitor itraconazole.\" Clin Pharmacol Ther 72 (2002): 362-369[6] Ulrich B, Frey FJ, Speck RF, Frey BM \"Pharmacokinetics/pharmacodynamics of ketoconazole-prednisolone interaction.\" J Pharmacol Exp Ther 260 (1992): 487-90[7] Zurcher RM, Frey BM, Frey FJ \"Impact of ketoconazole on the metabolism of prednisolone.\" Clin Pharmacol Ther 45 (1989): 366-72[8] Busse KH, Formentini E, Alfaro RM, Kovacs JA, Penzak SR \"Influence of antiretroviral drugs on the pharmacokinetics of prednisolone in HIV-infected individuals.\" J Acquir Immune Defic Syndr 48 (2008): 561-6[9] Yamashita SK, Ludwig EA, Middleton E Jr, Jusko WJ \"Lack of pharmacokinetic and pharmacodynamic interactions between ketoconazole and prednisolone.\" Clin Pharmacol Ther 49 (1991): 558-70[10] Hillebrand-Haverkort ME, Prummel MF, ten Veen JH \"Ritonavir-induced Cushing's syndrome in a patient treated with nasal fluticasone.\" AIDS 13 (1999): 1803[11] Kotlyar M, Brewer ER, Golding M, Carson SW \"Nefazodone inhibits methylprednisolone disposition and enhances its adrenal-suppressant effect.\" J Clin Psychopharmacol 23 (2003): 652-6[12] Itkin IH, Menzel ML \"The use of macrolide antibiotic substances in the treatment of asthma.\" J Allergy Clin Immunol 45 (1970): 146-62[13] Skov M, Main KM, Sillesen IB, Muller J, Koch C, Lanng S \"Iatrogenic adrenal insufficiency as a side-effect of combined treatment of itraconazole and budesonide.\" Eur Respir J 20 (2002): 127-33[14] Samaras K, Pett S, Gowers A, McMurchie M, Cooper DA \"Iatrogenic Cushing's syndrome with osteoporosis and secondary adrenal failure in HIV-infected patients receiving inhaled corticosteroids and ritonavir-boosted protease inhibitors: six cases.\" J Clin Endocrinol Metab 90 (2005): 4394-8[15] Garey KW, Rubinstein I, Gotfried MH, Khan IJ, Varma S, Danziger LH \"Long-term clarithromycin decreases prednisone requirements in elderly patients with prednisone-dependent asthma.\" Chest 118 (2000): 1826-7[16] Glynn AM, Slaughter RL, Brass C, et al \"Effects of ketoconazole on methylprednisolone pharmacokinetics and cortisol secretion.\" Clin Pharmacol Ther 39 (1986): 654-9[17] LaForce CF, Szefler SJ, Miller MF, Ebling W, Brenner M \"Inhibition of methylprednisolone elimination in the presence of erythromycin therapy.\" J Allergy Clin Immunol 72 (1983): 34-9[18] Lebrun-Vignes B, Archer VC, Diquest B, et al. \"Effect of itraconazole on the pharmacokinetics of prednisolone and methylprednisolone and cortisol secretion in healthy subjects.\" Br J Clin Pharmacol 51 (2001): 443-50[19] Varis T, Kivisto KT, Neuvonen PJ \"The effect of itraconazole on the pharmacokinetics and pharmacodynamics of oral prednisolone.\" Eur J Clin Pharmacol 56 (2000): 57-60[20] Bolland MJ, Bagg W, Thomas MG, Lucas JA, Ticehurst R, Black PN \"Cushing's syndrome due to interaction between inhaled corticosteroids and itraconazole.\" Ann Pharmacother 38 (2004): 46-9[21] Gupta SK, Dube MP \"Exogenous Cushing syndrome mimicking human immunodeficiency virus lipodystrophy.\" Clin Infect Dis 35 (2002): E69-71[22] Varis T, Kaukonen KM, Kivisto KT, Neuvonen PJ \"Plasma concentrations and effects of oral methylprednisolone are considerably increased by itraconazole.\" Clin Pharmacol Ther 64 (1998): 363-8[23] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[24] Couturier J, Steele M, Hussey L, Pawliuk G \"Steroid-induced mania in an adolescent: risk factors and management.\" Can J Clin Pharmacol 8 (2001): 109-12[25] Varis T, Backman JT, Kivisto KT, Neuvonen PJ \"Diltiazem and mibefradil increase the plasma concentrations and greatly enhance the adrenal-suppressant effect of oral methylprednisolone.\" Clin Pharmacol Ther 67 (2000): 215-21[26] Bhumbra NA, Sahloff EG, Oehrtman SJ, Horner JM \"Exogenous Cushing syndrome with inhaled fluticasone in a child receiving lopinavir/ritonavir.\" Ann Pharmacother 41 (2007): 1306-9[27] Main KM, Skov M, Sillesen IB, et al. \"Cushing's syndrome due to pharmacological interaction in a cystic fibrosis patient.\" Acta Paediatr 91 (2002): 1008-11[28] Penzak SR, Formentini E, Alfaro RM, Long M, Natarajan V, Kovacs J \"Prednisolone pharmacokinetics in the presence and absence of ritonavir after oral prednisone administration to healthy volunteers.\" J Acquir Immune Defic Syndr 40 (2005): 573-80[29] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[30] \"Product Information. Zokinvy (lonafarnib).\" Eiger BioPharmaceuticals, Palo Alto, CA.", "alternatives_a": "Mometasone furoate, Amcinonide, Fluocinolone acetonide, Hydrocortisone butyrate, Fluocinonide, Fluorometholone, Beclomethasone dipropionate, Mupirocin, Mometasone furoate, Vitamin A, Ephedrine, More", "alternatives_b": "Tinidazole, Dexlansoprazole, Rabeprazole, Metronidazole, Vonoprazan, Amoxicillin, Pantoprazole, Misoprostol, Esomeprazole, Ranitidine, Levofloxacin, More", "updated_at": 1767369485}, {"id": 68040, "ingredient1": "Clarithromycin", "ingredient2": "Triazolam", "severity": "Moderate", "effect": "The macrolide antibiotics clarithromycin and erythromycin may increase and prolong the CNS effects of certain benzodiazepines. The mechanism is inhibition of CYP450 3A4 hepatic oxidation of the benzodiazepines. The effect appears most pronounced with oral midazolam and triazolam.", "source": "DDInter", "management_text": "The use of oral midazolam or triazolam in combination with clarithromycin or erythromycin should generally be avoided. Some authorities consider the use of oral midazolam with clarithromycin contraindicated. Patients receiving triazolam or IV midazolam in combination with erythromycin or clarithromycin should be monitored for excessive or prolonged sedation. Dose adjustment of the benzodiazepine should be considered. Some authorities suggest a dose reduction of midazolam during long-term IV infusion of up to 50% of the initial dose followed by careful titration. Non-interacting benzodiazepines or antimicrobials may be considered as alternatives.", "mechanism_text": "Metabolism", "recommendation": "The use of oral midazolam or triazolam in combination with clarithromycin or erythromycin should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68127/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] \"Product Information. Versed (midazolam).\" Roche Laboratories, Nutley, NJ.[3] \"Product Information. Halcion (triazolam).\" Pharmacia and Upjohn, Kalamazoo, MI.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Welling PG, Huang H, Hewitt PF, Lyons LL \"Bioavailability of erythromycin stearate: influence of food and fluid volume.\" J Pharm Sci 67 (1978): 764-6[6] Welling PG \"Influence of food and diet on gastrointestinal drug absorption: a review.\" J Pharmacokinet Biopharm 5 (1977): 291-334[7] Randinitis EJ, Sedman AJ, Welling PG, Kinkel AW \"Effect of a high-fat meal on the bioavailability of a polymer-coated erythromycin particle tablet formulation.\" J Clin Pharmacol 29 (1989): 79-84[8] Coyne TC, Shum S, Chun AH, Jeansonne L, Shirkey HC \"Bioavailability of erythromycin ethylsuccinate in pediatric patients.\" J Clin Pharmacol 18 (1978): 194-202[9] Malmborg AS \"Effect of food on absorption of erythromycin. A study of two derivatives, the stearate and the base.\" J Antimicrob Chemother 5 (1979): 591-9[10] Welling PG, Elliott RL, Pitterle ME, et al \"Plasma levels following single and repeated doses of erythromycin estolate and erythromycin stearate.\" J Pharm Sci 68 (1979): 150-5[11] Kanazawa S, Ohkubo T, Sugawara K \"The effects of grapefruit juice on the pharmacokinetics of erythromycin.\" Eur J Clin Pharmacol 56 (2001): 799-803[12] Kupferschmidt HHT, Ha HR, Ziegler WH, Meier PJ, Krahenbuhl S \"Interaction between grapefruit juice and midazolam in humans.\" Clin Pharmacol Ther 58 (1995): 20-8[13] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[14] \"Product Information. Valium (diazepam).\" Roche Laboratories, Nutley, NJ.[15] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[16] \"Product Information. Halcion (triazolam).\" Pharmacia and Upjohn, Kalamazoo, MI.[17] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[18] \"Product Information. Xanax (alprazolam).\" Pharmacia and Upjohn, Kalamazoo, MI.", "alternatives_a": "Methohexital, Methylphenobarbital, Pentobarbital, Dichloralphenazone, Valerian, Butabarbital, Secobarbital, Chloral hydrate, Paraldehyde, Ethchlorvynol, Amobarbital, More", "alternatives_b": "Tinidazole, Levofloxacin, Tetracycline, Dexlansoprazole, Bismuth subcitrate potassium, Esomeprazole, Vonoprazan, Amoxicillin, Dirithromycin, Lincomycin, Azithromycin, Clindamycin", "updated_at": 1767369485}, {"id": 68041, "ingredient1": "Clarithromycin", "ingredient2": "Triclabendazole", "severity": "Moderate", "effect": "Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.", "source": "DDInter", "management_text": "Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution and clinical monitoring are recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68128/", "reference_text": "[1] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):[2] Witchel HJ, Hancox JC, Nutt DJ \"Psychotropic drugs, cardiac arrhythmia, and sudden death.\" J Clin Psychopharmacol 23 (2003): 58-77[3] Iannini PB \"Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval.\" Expert Opin Drug Saf 1 (2002): 121-8[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[6] Glassman AH, Bigger JT Jr \"Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death.\" Am J Psychiatry 158 (2001): 1774-82[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] Honig PK, Wortham DC, Zamani K, et al \"Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences.\" JAMA 269 (1993): 1513-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[10] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P \"Torsades de pointes after terfenadine-itraconazole interaction.\" BMJ 306 (1993): 186[11] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[12] Mathews DR, McNutt B, Okerholm R, et al \"Torsades de pointes occurring in association with terfenadine use.\" JAMA 266 (1991): 2375-6[13] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL \"Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram.\" Clin Pharmacol Ther 59 (1996): 383-8[14] Zechnich AD, Haxby DG \"Drug interactions associated with terfenadine and related nonsedating antihistamines.\" West J Med 164 (1996): 68-9[15] Hsieh MH, Chen SA, Chiang CE, et al. \"Drug-induced torsades de pointes in one patient with congenital long QT syndrome.\" Int J Cardiol 54 (1996): 85-8[16] Woosley RL \"Cardiac actions of antihistamines.\" Annu Rev Pharmacol Toxicol 36 (1996): 233-52[17] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP \"Torsades-de-pointes induced by erythromycin and terfenadine.\" Am J Emerg Med 12 (1994): 636-8[18] Zimmermann M, Duruz H, Guinand O, et al \"Torsades de Pointes after treatment with terfenadine and ketoconazole.\" Eur Heart J 13 (1992): 1002-3[19] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG \"Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance.\" Clin Pharmacol Ther 61 (1997): 401-9[20] Honig PK, Wortham DC, Lazarev A, Cantilena LR \"Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine.\" J Clin Pharmacol 36 (1996): 345-51[21] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr \"Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin.\" Clin Pharmacol Ther 52 (1992): 231-8[22] Monahan BP, Ferguson CL, Killeavy ES, et al \"Torsades de pointes occurring in association with terfenadine use.\" JAMA 264 (1990): 2788-90[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[24] Cortese LM, Bjornson DC \"Potential interaction between terfenadine and macrolide antibiotics.\" Clin Pharm 11 (1992): 675", "alternatives_a": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Cimetidine, Esomeprazole, More", "alternatives_b": "Praziquantel, Oxamniquine", "updated_at": 1767369485}, {"id": 68042, "ingredient1": "Clarithromycin", "ingredient2": "Trifluoperazine", "severity": "Moderate", "effect": "Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.", "source": "DDInter", "management_text": "Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution and clinical monitoring are recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68129/", "reference_text": "[1] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):[2] Witchel HJ, Hancox JC, Nutt DJ \"Psychotropic drugs, cardiac arrhythmia, and sudden death.\" J Clin Psychopharmacol 23 (2003): 58-77[3] Iannini PB \"Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval.\" Expert Opin Drug Saf 1 (2002): 121-8[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[6] Glassman AH, Bigger JT Jr \"Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death.\" Am J Psychiatry 158 (2001): 1774-82[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] Honig PK, Wortham DC, Zamani K, et al \"Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences.\" JAMA 269 (1993): 1513-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[10] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P \"Torsades de pointes after terfenadine-itraconazole interaction.\" BMJ 306 (1993): 186[11] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[12] Mathews DR, McNutt B, Okerholm R, et al \"Torsades de pointes occurring in association with terfenadine use.\" JAMA 266 (1991): 2375-6[13] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL \"Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram.\" Clin Pharmacol Ther 59 (1996): 383-8[14] Zechnich AD, Haxby DG \"Drug interactions associated with terfenadine and related nonsedating antihistamines.\" West J Med 164 (1996): 68-9[15] Hsieh MH, Chen SA, Chiang CE, et al. \"Drug-induced torsades de pointes in one patient with congenital long QT syndrome.\" Int J Cardiol 54 (1996): 85-8[16] Woosley RL \"Cardiac actions of antihistamines.\" Annu Rev Pharmacol Toxicol 36 (1996): 233-52[17] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP \"Torsades-de-pointes induced by erythromycin and terfenadine.\" Am J Emerg Med 12 (1994): 636-8[18] Zimmermann M, Duruz H, Guinand O, et al \"Torsades de Pointes after treatment with terfenadine and ketoconazole.\" Eur Heart J 13 (1992): 1002-3[19] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG \"Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance.\" Clin Pharmacol Ther 61 (1997): 401-9[20] Honig PK, Wortham DC, Lazarev A, Cantilena LR \"Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine.\" J Clin Pharmacol 36 (1996): 345-51[21] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr \"Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin.\" Clin Pharmacol Ther 52 (1992): 231-8[22] Monahan BP, Ferguson CL, Killeavy ES, et al \"Torsades de pointes occurring in association with terfenadine use.\" JAMA 264 (1990): 2788-90[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[24] Cortese LM, Bjornson DC \"Potential interaction between terfenadine and macrolide antibiotics.\" Clin Pharm 11 (1992): 675", "alternatives_a": "Loxapine, Molindone, Thiothixene", "alternatives_b": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Cimetidine, Esomeprazole, Ranitidine, More", "updated_at": 1767369485}, {"id": 68043, "ingredient1": "Clarithromycin", "ingredient2": "Triflupromazine", "severity": "Moderate", "effect": "Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.", "source": "DDInter", "management_text": "Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution and clinical monitoring are recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68130/", "reference_text": "[1] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):[2] Witchel HJ, Hancox JC, Nutt DJ \"Psychotropic drugs, cardiac arrhythmia, and sudden death.\" J Clin Psychopharmacol 23 (2003): 58-77[3] Iannini PB \"Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval.\" Expert Opin Drug Saf 1 (2002): 121-8[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[6] Glassman AH, Bigger JT Jr \"Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death.\" Am J Psychiatry 158 (2001): 1774-82[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] Honig PK, Wortham DC, Zamani K, et al \"Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences.\" JAMA 269 (1993): 1513-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[10] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P \"Torsades de pointes after terfenadine-itraconazole interaction.\" BMJ 306 (1993): 186[11] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[12] Mathews DR, McNutt B, Okerholm R, et al \"Torsades de pointes occurring in association with terfenadine use.\" JAMA 266 (1991): 2375-6[13] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL \"Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram.\" Clin Pharmacol Ther 59 (1996): 383-8[14] Zechnich AD, Haxby DG \"Drug interactions associated with terfenadine and related nonsedating antihistamines.\" West J Med 164 (1996): 68-9[15] Hsieh MH, Chen SA, Chiang CE, et al. \"Drug-induced torsades de pointes in one patient with congenital long QT syndrome.\" Int J Cardiol 54 (1996): 85-8[16] Woosley RL \"Cardiac actions of antihistamines.\" Annu Rev Pharmacol Toxicol 36 (1996): 233-52[17] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP \"Torsades-de-pointes induced by erythromycin and terfenadine.\" Am J Emerg Med 12 (1994): 636-8[18] Zimmermann M, Duruz H, Guinand O, et al \"Torsades de Pointes after treatment with terfenadine and ketoconazole.\" Eur Heart J 13 (1992): 1002-3[19] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG \"Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance.\" Clin Pharmacol Ther 61 (1997): 401-9[20] Honig PK, Wortham DC, Lazarev A, Cantilena LR \"Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine.\" J Clin Pharmacol 36 (1996): 345-51[21] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr \"Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin.\" Clin Pharmacol Ther 52 (1992): 231-8[22] Monahan BP, Ferguson CL, Killeavy ES, et al \"Torsades de pointes occurring in association with terfenadine use.\" JAMA 264 (1990): 2788-90[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[24] Cortese LM, Bjornson DC \"Potential interaction between terfenadine and macrolide antibiotics.\" Clin Pharm 11 (1992): 675", "alternatives_a": "Loxapine, Molindone, Thiothixene", "alternatives_b": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Cimetidine, Esomeprazole, Ranitidine, More", "updated_at": 1767369485}, {"id": 68044, "ingredient1": "Alimemazine", "ingredient2": "Clarithromycin", "severity": "Moderate", "effect": "Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.", "source": "DDInter", "management_text": "Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution and clinical monitoring are recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68131/", "reference_text": "[1] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):[2] Witchel HJ, Hancox JC, Nutt DJ \"Psychotropic drugs, cardiac arrhythmia, and sudden death.\" J Clin Psychopharmacol 23 (2003): 58-77[3] Iannini PB \"Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval.\" Expert Opin Drug Saf 1 (2002): 121-8[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[6] Glassman AH, Bigger JT Jr \"Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death.\" Am J Psychiatry 158 (2001): 1774-82[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] Honig PK, Wortham DC, Zamani K, et al \"Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences.\" JAMA 269 (1993): 1513-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[10] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P \"Torsades de pointes after terfenadine-itraconazole interaction.\" BMJ 306 (1993): 186[11] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[12] Mathews DR, McNutt B, Okerholm R, et al \"Torsades de pointes occurring in association with terfenadine use.\" JAMA 266 (1991): 2375-6[13] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL \"Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram.\" Clin Pharmacol Ther 59 (1996): 383-8[14] Zechnich AD, Haxby DG \"Drug interactions associated with terfenadine and related nonsedating antihistamines.\" West J Med 164 (1996): 68-9[15] Hsieh MH, Chen SA, Chiang CE, et al. \"Drug-induced torsades de pointes in one patient with congenital long QT syndrome.\" Int J Cardiol 54 (1996): 85-8[16] Woosley RL \"Cardiac actions of antihistamines.\" Annu Rev Pharmacol Toxicol 36 (1996): 233-52[17] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP \"Torsades-de-pointes induced by erythromycin and terfenadine.\" Am J Emerg Med 12 (1994): 636-8[18] Zimmermann M, Duruz H, Guinand O, et al \"Torsades de Pointes after treatment with terfenadine and ketoconazole.\" Eur Heart J 13 (1992): 1002-3[19] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG \"Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance.\" Clin Pharmacol Ther 61 (1997): 401-9[20] Honig PK, Wortham DC, Lazarev A, Cantilena LR \"Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine.\" J Clin Pharmacol 36 (1996): 345-51[21] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr \"Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin.\" Clin Pharmacol Ther 52 (1992): 231-8[22] Monahan BP, Ferguson CL, Killeavy ES, et al \"Torsades de pointes occurring in association with terfenadine use.\" JAMA 264 (1990): 2788-90[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[24] Cortese LM, Bjornson DC \"Potential interaction between terfenadine and macrolide antibiotics.\" Clin Pharm 11 (1992): 675", "alternatives_a": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Cimetidine, Esomeprazole, Ranitidine, More", "alternatives_b": "Mepyramine, Levocetirizine, Chlorcyclizine, Acrivastine, Triprolidine, Tripelennamine, Dexbrompheniramine, Clemastine, Doxylamine, Meclizine, Cyclizine, More", "updated_at": 1767369485}, {"id": 68045, "ingredient1": "Clarithromycin", "ingredient2": "Trimipramine", "severity": "Moderate", "effect": "Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.", "source": "DDInter", "management_text": "Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution and clinical monitoring are recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68132/", "reference_text": "[1] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):[2] Witchel HJ, Hancox JC, Nutt DJ \"Psychotropic drugs, cardiac arrhythmia, and sudden death.\" J Clin Psychopharmacol 23 (2003): 58-77[3] Iannini PB \"Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval.\" Expert Opin Drug Saf 1 (2002): 121-8[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[6] Glassman AH, Bigger JT Jr \"Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death.\" Am J Psychiatry 158 (2001): 1774-82[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] Honig PK, Wortham DC, Zamani K, et al \"Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences.\" JAMA 269 (1993): 1513-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[10] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P \"Torsades de pointes after terfenadine-itraconazole interaction.\" BMJ 306 (1993): 186[11] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[12] Mathews DR, McNutt B, Okerholm R, et al \"Torsades de pointes occurring in association with terfenadine use.\" JAMA 266 (1991): 2375-6[13] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL \"Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram.\" Clin Pharmacol Ther 59 (1996): 383-8[14] Zechnich AD, Haxby DG \"Drug interactions associated with terfenadine and related nonsedating antihistamines.\" West J Med 164 (1996): 68-9[15] Hsieh MH, Chen SA, Chiang CE, et al. \"Drug-induced torsades de pointes in one patient with congenital long QT syndrome.\" Int J Cardiol 54 (1996): 85-8[16] Woosley RL \"Cardiac actions of antihistamines.\" Annu Rev Pharmacol Toxicol 36 (1996): 233-52[17] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP \"Torsades-de-pointes induced by erythromycin and terfenadine.\" Am J Emerg Med 12 (1994): 636-8[18] Zimmermann M, Duruz H, Guinand O, et al \"Torsades de Pointes after treatment with terfenadine and ketoconazole.\" Eur Heart J 13 (1992): 1002-3[19] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG \"Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance.\" Clin Pharmacol Ther 61 (1997): 401-9[20] Honig PK, Wortham DC, Lazarev A, Cantilena LR \"Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine.\" J Clin Pharmacol 36 (1996): 345-51[21] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr \"Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin.\" Clin Pharmacol Ther 52 (1992): 231-8[22] Monahan BP, Ferguson CL, Killeavy ES, et al \"Torsades de pointes occurring in association with terfenadine use.\" JAMA 264 (1990): 2788-90[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[24] Cortese LM, Bjornson DC \"Potential interaction between terfenadine and macrolide antibiotics.\" Clin Pharm 11 (1992): 675", "alternatives_a": "Phenelzine, Tranylcypromine, Desvenlafaxine, Isocarboxazid, Oxitriptan, Vortioxetine, Milnacipran, Tryptophan, Esketamine", "alternatives_b": "Tinidazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Nizatidine, Esomeprazole, Vonoprazan, More", "updated_at": 1767369485}, {"id": 68046, "ingredient1": "Clarithromycin", "ingredient2": "Triptorelin", "severity": "Moderate", "effect": "Long-term androgen deprivation therapy can prolong the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, the extent of drug-induced QT prolongation is dependent on the particular drug(s) involved and dosage(s) of the drug(s).", "source": "DDInter", "management_text": "The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval. Electrolyte abnormalities should be corrected prior to initiating therapy, and periodic monitoring of electrocardiograms and electrolytes should be considered.", "mechanism_text": "Synergism", "recommendation": "The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68133/", "reference_text": "[1] \"Product Information. Vantas (histrelin).\" Endo Pharmaceuticals (formally Indevus Pharmaceuticals Inc), Lexington, MA.[2] \"Product Information. Zoladex (goserelin).\" Zeneca Pharmaceuticals, Wilmington, DE.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Trelstar (triptorelin)\" Pharmacia and Upjohn, Kalamazoo, MI.[5] \"Product Information. Firmagon (degarelix).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[6] \"Product Information. Lupron (leuprolide).\" TAP Pharmaceuticals Inc, Deerfield, IL.[7] \"Product Information. Eligard (leuprolide).\" Sanofi Winthrop Pharmaceuticals, New York, NY.[8] \"Product Information. Plenaxis (abarelix).\" Praecis Pharmaceuticals Inc, Waltham, MA.", "alternatives_a": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Cimetidine, Esomeprazole, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68047, "ingredient1": "Clarithromycin", "ingredient2": "Troglitazone", "severity": "Moderate", "effect": "Concomitant use of insulin and other antidiabetic agents with clarithromycin may cause significant hypoglycemia. There have been rare reports of hypoglycemia in patients treated with clarithromycin, some of whom were taking oral hypoglycemic agents or insulin. The exact mechanism of interaction has not been established. With certain hypoglycemic drugs such as nateglinide, pioglitazone, repaglinide and rosiglitazone, inhibition of the CYP450 3A4 isoenzyme by clarithromycin may be involved.", "source": "DDInter", "management_text": "Caution is advised if clarithromycin is prescribed to patients receiving antidiabetic agents. Patients should be advised to regularly monitor their blood sugar and counseled on how to recognize and treat hypoglycemia, which may include symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if clarithromycin is prescribed to patients receiving antidiabetic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68134/", "reference_text": "[1] Otsuka SH \"Severe hypoglycemia from helicobacter pylori triple-drug therapy and insulin detemir drug interaction.\" Pharmacotherapy 33 (2013): e45-9[2] Niemi M, Neuvonen PJ, Kivisto KT \"The cytochrome P4503A4 inhibitor clarithromycin increases the plasma concentrations and effects of repaglinide.\" Clin Pharmacol Ther 70 (2001): 58-65[3] Schelleman H, Bilker WB, Brensinger CM, Wan F, Hennessy S \"Anti-infectives and the risk of severe hypoglycemia in users of glipizide or glyburide.\" Clin Pharmacol Ther 88 (2010): 214-22[4] Khamaisi M, Leitersdorf E \"Severe hypoglycemia from clarithromycin-repaglinide drug interaction.\" Pharmacotherapy 28 (2008): 682-4[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Leiba A, Leibowitz A, Grossman E \"An unusual case of hypoglycemia in a diabetic patient.\" Ann Emerg Med 44 (2004): 427-8[7] Bussing R, Gende A \"Severe hypoglycemia from clarithromycin-sulfonylurea drug interaction.\" Diabetes Care 25 (2002): 1659-61[8] \"Product Information. Biaxin (clarithromycin).\" Abbott Pharmaceutical, Abbott Park, IL.[9] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[10] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[11] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[12] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[13] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[14] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[15] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[16] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[17] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[18] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[19] Cheng KL, Nafziger AN, Peloquin CA, Amsden GW \"Effect of grapefruit juice on clarithromycin pharmacokinetics.\" Antimicrob Agents Chemother 42 (1998): 927-9", "alternatives_a": "Guar gum", "alternatives_b": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Famotidine, Rifabutin, Cimetidine, More", "updated_at": 1767369485}, {"id": 68048, "ingredient1": "Clarithromycin", "ingredient2": "Tucatinib", "severity": "Moderate", "effect": "Coadministration with tucatinib may increase the plasma concentrations of CYP450 3A4 substrates. The mechanism involves tucatinib-mediated inhibition of CYP450 3A isoenzymes.", "source": "DDInter", "management_text": "Caution is advised when tucatinib is used concomitantly with drugs that undergo metabolism by CYP450 3A4. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever tucatinib is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when tucatinib is used concomitantly with drugs that undergo metabolism by CYP450 3A4.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68135/", "reference_text": "[1] \"Product Information. Tukysa (tucatinib).\" Seattle Genetics Inc, Bothell, WA.", "alternatives_a": "Pantoprazole, Levofloxacin, Tetracycline, Rabeprazole, Dexlansoprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Famotidine, Cimetidine, More", "alternatives_b": "Alpelisib, Trametinib, Dacomitinib, Tivozanib, Alectinib", "updated_at": 1767369485}, {"id": 68049, "ingredient1": "Clarithromycin", "ingredient2": "Typhoid vaccine (live)", "severity": "Major", "effect": "INTERVAL: The use of live, attenuated oral typhoid vaccine with antibacterial sulfonamides or other antibiotics may result in a diminished immunologic response to the vaccine. Some antibiotics may be active against the vaccine strain of Salmonella typhi (Ty21a), thereby preventing a sufficient degree of multiplication to occur in order to induce a protective immune response.", "source": "DDInter", "management_text": "Live, attenuated oral typhoid vaccine should not be administered during and for at least 3 days before and after treatment with antibacterial sulfonamides or other antibiotics. A longer interval should be considered following treatment with long-acting antibiotics (e.g., azithromycin). If malaria prophylaxis is needed, the same 3-day interval at the minimum should be observed between antimalarials and the vaccine. However, chloroquine, mefloquine, and pyrimethamine-sulfadoxine may be given concomitantly with the vaccine. Alternatively, parenteral typhoid vaccine (typhoid Vi polysaccharide vaccine) may be considered if coadministration with antibacterial agents is required.", "mechanism_text": "Others", "recommendation": "Live, attenuated oral typhoid vaccine should not be administered during and for at least 3 days before and after treatment with antibacterial sulfonamides or other antibiotics.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68136/", "reference_text": "[1] UK government \"Typhoid. Available from: URL: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/148512/Green-Book-Chapter-33-dh_125348.pdf.\" ([cited 2014]):[2] American Medical Association, Division of Drugs and Toxicology \"Drug evaluations annual 1994.\" Chicago, IL: American Medical Association; (1994):[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] CDC. Centers for Disease Control and Prevention \"Typhoid & Paratyphoid Fever. Available from: URL: http://wwwnc.cdc.gov/travel/yellowbook/2014/chapter-3-infectious-diseases-related-to-travel/typhoid-and-paratyphoid-fever.\" ([2013]):", "alternatives_a": "Pantoprazole, Rabeprazole, Dexlansoprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Famotidine, Cimetidine, Esomeprazole, Ranitidine, Nizatidine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68050, "ingredient1": "Clarithromycin", "ingredient2": "Ubrogepant", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of ubrogepant, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Concomitant use of potent CYP450 3A4 inhibitors is contraindicated with ubrogepant.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of potent CYP450 3A4 inhibitors is contraindicated with ubrogepant.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68137/", "reference_text": "[1] \"Product Information. Ubrelvy (ubrogepant).\" Allergan Inc, Irvine, CA.[2] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[3] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[4] \"Product Information. Ubrelvy (ubrogepant).\" Allergan Inc, Irvine, CA.", "alternatives_a": "Tinidazole, Pantoprazole, Levofloxacin, Dexlansoprazole, Rabeprazole, Sucralfate, Tetracycline, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Famotidine, More", "alternatives_b": "Frovatriptan, Eptinezumab, Lasmiditan, Rizatriptan, Galcanezumab, Zolmitriptan, Erenumab, Fremanezumab", "updated_at": 1767369485}, {"id": 68051, "ingredient1": "Clarithromycin", "ingredient2": "Ulipristal", "severity": "Minor", "effect": "Coadministration with CYP450 3A4 inhibitors may increase the plasma concentrations of ulipristal, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "-", "mechanism_text": "Metabolism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68138/", "reference_text": "[1] \"Product Information. ella (ulipristal).\" Afaxys Inc., Charleston, SC.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Accolate (zafirlukast).\" Zeneca Pharmaceuticals, Wilmington, DE.", "alternatives_a": "Tinidazole, Pantoprazole, Levofloxacin, Dexlansoprazole, Rabeprazole, Sucralfate, Tetracycline, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Famotidine, More", "alternatives_b": "Estetrol, Prasterone, Danazol, Bazedoxifene", "updated_at": 1767369485}, {"id": 68052, "ingredient1": "Clarithromycin", "ingredient2": "Upadacitinib", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of upadacitinib, which is primarily metabolized by the isoenzyme. Side effects including lymphopenia, neutropenia, anemia, serious infections, and hyperlipidemia may be increased.", "source": "DDInter", "management_text": "Caution is recommended if upadacitinib is used with potent CYP450 3A4 inhibitors. Pharmacologic effects of upadacitinib should be monitored more closely whenever a potent CYP450 3A4 inhibitor is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is recommended if upadacitinib is used with potent CYP450 3A4 inhibitors.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68139/", "reference_text": "[1] \"Product Information. Rinvoq (upadacitinib).\" AbbVie US LLC, North Chicago, IL.[2] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[3] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Tinidazole, Pantoprazole, Levofloxacin, Dexlansoprazole, Rabeprazole, Sucralfate, Tetracycline, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Famotidine, More", "alternatives_b": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Abatacept, Anakinra, More", "updated_at": 1767369485}, {"id": 68053, "ingredient1": "Clarithromycin", "ingredient2": "Valbenazine", "severity": "Major", "effect": "Coadministration with a strong CYP450 3A4 inhibitor may increase the systemic exposure and risk of adverse effects of valbenazine, including somnolence and QT interval prolongation. The proposed mechanism is decreased clearance due to inhibition of CYP450 3A4 activity. Increased concentrations of valbenazine and its active metabolite, (+)-alfa-dihydrotetrabenazine, may lead to clinically significant prolongation of the QT interval. In addition, central nervous system-depressant effects may be additively or synergistically increased in patients taking valbenazine with certain other drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "Pharmacologic response to valbenazine should be monitored more closely whenever a strong inhibitor of CYP450 3A4 (e.g., itraconazole, ketoconazole, clarithromycin) is added to or withdrawn from therapy. Valbenazine is not recommended for use in patients with congenital long QT syndrome or with arrhythmias associated with a prolonged QT interval. Assessment of baseline QT interval and periodic monitoring during therapy may be considered. The manufacturer recommends reducing the dose of valbenazine to 40 mg once daily during concomitant administration with strong CYP450 3A4 inhibitors. Valbenazine dosage may be increased accordingly if these agents are discontinued. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope. When valbenazine is used in combination with other drugs that cause CNS depression, patients should be monitored for potentially excessive or prolonged CNS depression. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their doctor if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Metabolism", "recommendation": "Pharmacologic response to valbenazine should be monitored more closely whenever a strong inhibitor of CYP450 3A4 (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68140/", "reference_text": "[1] \"Product Information. Ingrezza (valbenazine).\" Neurocrine Biosciences, Inc., San Diego, CA.[2] \"Product Information. Ingrezza (valbenazine).\" Neurocrine Biosciences, Inc., San Diego, CA.[3] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[4] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Cimetidine, Esomeprazole, Ranitidine, More", "alternatives_b": "Dextromethorphan, Dalfampridine, Sodium oxybate, Riluzole, Inotersen, Amifampridine, Tafamidis", "updated_at": 1767369485}, {"id": 68054, "ingredient1": "Clarithromycin", "ingredient2": "Valdecoxib", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 2C9 and/or 3A4 may increase the plasma concentrations of valdecoxib, which is metabolized by these isoenzymes.", "source": "DDInter", "management_text": "The possibility of prolonged and/or increased pharmacologic effects of valdecoxib or parecoxib, including serious adverse effects such as gastrointestinal ulceration and bleeding, should be considered during concomitant therapy with CYP450 2C9 or 3A4 inhibitors, particularly combination (2C9/3A4) inhibitors such as fluconazole, fluvoxamine, imatinib, and zafirlukast. Dose reductions of the COX-2 inhibitor may be required.", "mechanism_text": "Metabolism", "recommendation": "The possibility of prolonged and/or increased pharmacologic effects of valdecoxib or parecoxib, including serious adverse effects such as gastrointestinal ulceration and bleeding, should be considered during concomitant therapy with CYP450 2C9 or 3A4 inhibitors, particularly combination (2C9/3A4) inhibitors such as fluconazole, fluvoxamine, imatinib, and zafirlukast.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68141/", "reference_text": "[1] \"Product Information. Bextra (valdecoxib).\" Pharmacia Corporation, Peapack, NJ.", "alternatives_a": "Fenoprofen, Meclofenamic acid, Phenylbutazone, Glucosamine, Chondroitin sulfate, Piroxicam, Flurbiprofen, Tolmetin, Sulindac", "alternatives_b": "Tinidazole, Dexlansoprazole, Bismuth subcitrate potassium, Rifabutin, Esomeprazole, Vonoprazan, Lincomycin, Dirithromycin", "updated_at": 1767369485}, {"id": 68055, "ingredient1": "Clarithromycin", "ingredient2": "Vandetanib", "severity": "Major", "effect": "Vandetanib can cause concentration-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of vandetanib with other drugs that can prolong the QT interval should generally be avoided. Should treatment with other QT-prolonging drugs be required, the manufacturer recommends more frequent monitoring of the ECG as well as serum potassium, magnesium, and calcium levels.", "mechanism_text": "Synergism", "recommendation": "Coadministration of vandetanib with other drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68142/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Vandetanib (vandetanib).\" Astra-Zeneca Pharmaceuticals, Wilmington, DE.[4] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[5] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[6] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Tinidazole, Tetracycline, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Cimetidine, Nizatidine, Vonoprazan, Amoxicillin, Dirithromycin, Lincomycin, More", "alternatives_b": "Alpelisib, Trametinib, Dacomitinib, Tivozanib, Alectinib", "updated_at": 1767369485}, {"id": 68056, "ingredient1": "Clarithromycin", "ingredient2": "Vardenafil", "severity": "Major", "effect": "Coadministration with erythromycin or clarithromycin may significantly increase the plasma concentrations of vardenafil. The mechanism is inhibition of CYP450 3A4 by erythromycin and clarithromycin. CYP450 3A4 is the isoenzyme primarily responsible for the metabolic clearance of vardenafil. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk is dependent on underlying risk factors such as congenital long QT syndrome, cardiac disease, electrolyte disturbances (e.g., hypokalemia, hypomagnesemia), and concomitant use of multiple agents associated with QT interval prolongation.", "source": "DDInter", "management_text": "Some authorities recommend that patients treated with clarithromycin should not receive more than a single 2.5 mg dose of vardenafil within a 24-hour period and those treated with erythromycin should not receive more than a single 5 mg dose of vardenafil within a 24-hour period. Patients should be advised to promptly notify their physician if they experience pain or tightness in the chest or jaw, irregular heartbeat, nausea, shortness of breath, visual disturbances, syncope, or prolonged erection (greater than 4 hours).", "mechanism_text": "Metabolism", "recommendation": "Some authorities recommend that patients treated with clarithromycin should not receive more than a single 2.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68143/", "reference_text": "[1] \"Product Information. Levitra (vardenafil).\" Bayer, West Haven, CT.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] Welling PG, Huang H, Hewitt PF, Lyons LL \"Bioavailability of erythromycin stearate: influence of food and fluid volume.\" J Pharm Sci 67 (1978): 764-6[5] Welling PG \"Influence of food and diet on gastrointestinal drug absorption: a review.\" J Pharmacokinet Biopharm 5 (1977): 291-334[6] Randinitis EJ, Sedman AJ, Welling PG, Kinkel AW \"Effect of a high-fat meal on the bioavailability of a polymer-coated erythromycin particle tablet formulation.\" J Clin Pharmacol 29 (1989): 79-84[7] Coyne TC, Shum S, Chun AH, Jeansonne L, Shirkey HC \"Bioavailability of erythromycin ethylsuccinate in pediatric patients.\" J Clin Pharmacol 18 (1978): 194-202[8] Malmborg AS \"Effect of food on absorption of erythromycin. A study of two derivatives, the stearate and the base.\" J Antimicrob Chemother 5 (1979): 591-9[9] Welling PG, Elliott RL, Pitterle ME, et al \"Plasma levels following single and repeated doses of erythromycin estolate and erythromycin stearate.\" J Pharm Sci 68 (1979): 150-5[10] Kanazawa S, Ohkubo T, Sugawara K \"The effects of grapefruit juice on the pharmacokinetics of erythromycin.\" Eur J Clin Pharmacol 56 (2001): 799-803[11] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[12] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[13] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[14] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[15] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[16] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[17] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[18] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[19] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[20] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[21] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[22] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[23] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[24] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[25] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[26] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[27] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[28] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[29] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[30] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[31] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[32] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[33] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[34] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[35] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[36] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[37] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[38] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[39] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[40] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[41] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[42] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402", "alternatives_a": "Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Trospium, Acetohydroxamic acid, Yohimbine, Flavoxate, Phenyl salicylate, Ammonium chloride, Dimethyl sulfoxide", "alternatives_b": "Tinidazole, Tetracycline, Dexlansoprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Nizatidine, Esomeprazole, Amoxicillin, Dirithromycin, More", "updated_at": 1767369485}, {"id": 68057, "ingredient1": "Clarithromycin", "ingredient2": "Vasopressin", "severity": "Moderate", "effect": "Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.", "source": "DDInter", "management_text": "Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution and clinical monitoring are recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68144/", "reference_text": "[1] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):[2] Witchel HJ, Hancox JC, Nutt DJ \"Psychotropic drugs, cardiac arrhythmia, and sudden death.\" J Clin Psychopharmacol 23 (2003): 58-77[3] Iannini PB \"Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval.\" Expert Opin Drug Saf 1 (2002): 121-8[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[6] Glassman AH, Bigger JT Jr \"Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death.\" Am J Psychiatry 158 (2001): 1774-82[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] Honig PK, Wortham DC, Zamani K, et al \"Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences.\" JAMA 269 (1993): 1513-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[10] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P \"Torsades de pointes after terfenadine-itraconazole interaction.\" BMJ 306 (1993): 186[11] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[12] Mathews DR, McNutt B, Okerholm R, et al \"Torsades de pointes occurring in association with terfenadine use.\" JAMA 266 (1991): 2375-6[13] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL \"Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram.\" Clin Pharmacol Ther 59 (1996): 383-8[14] Zechnich AD, Haxby DG \"Drug interactions associated with terfenadine and related nonsedating antihistamines.\" West J Med 164 (1996): 68-9[15] Hsieh MH, Chen SA, Chiang CE, et al. \"Drug-induced torsades de pointes in one patient with congenital long QT syndrome.\" Int J Cardiol 54 (1996): 85-8[16] Woosley RL \"Cardiac actions of antihistamines.\" Annu Rev Pharmacol Toxicol 36 (1996): 233-52[17] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP \"Torsades-de-pointes induced by erythromycin and terfenadine.\" Am J Emerg Med 12 (1994): 636-8[18] Zimmermann M, Duruz H, Guinand O, et al \"Torsades de Pointes after treatment with terfenadine and ketoconazole.\" Eur Heart J 13 (1992): 1002-3[19] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG \"Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance.\" Clin Pharmacol Ther 61 (1997): 401-9[20] Honig PK, Wortham DC, Lazarev A, Cantilena LR \"Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine.\" J Clin Pharmacol 36 (1996): 345-51[21] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr \"Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin.\" Clin Pharmacol Ther 52 (1992): 231-8[22] Monahan BP, Ferguson CL, Killeavy ES, et al \"Torsades de pointes occurring in association with terfenadine use.\" JAMA 264 (1990): 2788-90[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[24] Cortese LM, Bjornson DC \"Potential interaction between terfenadine and macrolide antibiotics.\" Clin Pharm 11 (1992): 675", "alternatives_a": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Cimetidine, Esomeprazole, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68058, "ingredient1": "Clarithromycin", "ingredient2": "Vemurafenib", "severity": "Major", "effect": "Vemurafenib can cause concentration-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of vemurafenib with other drugs that can prolong the QT interval is not recommended. ECG and serum electrolytes, including potassium, magnesium and calcium, should be monitored before starting vemurafenib therapy and after dose modification.", "mechanism_text": "Synergism", "recommendation": "Coadministration of vemurafenib with other drugs that can prolong the QT interval is not recommended.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68145/", "reference_text": "[1] \"Product Information. Zelboraf (vemurafenib).\" Genentech, South San Francisco, CA.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[6] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Cimetidine, Esomeprazole, Ranitidine, More", "alternatives_b": "Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Lactic acid, Methazolamide, Trichlormethiazide, Probenecid, Tioconazole, Brinzolamide, Furazolidone, More", "updated_at": 1767369485}, {"id": 68059, "ingredient1": "Clarithromycin", "ingredient2": "Venetoclax", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of venetoclax, which is primarily metabolized by the isoenzyme. Additionally, inhibition of P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) efflux transporters by ketoconazole may contribute. Increased venetoclax exposure may potentiate the risk of tumor lysis syndrome, particularly at initiation of therapy and during the dosage ramp-up phase, as well as other adverse effects such as diarrhea, nausea, vomiting, neutropenia, anemia, and thrombocytopenia.", "source": "DDInter", "management_text": "Concomitant use of potent CYP450 3A4 inhibitors at initiation and during the dosage ramp-up phase of venetoclax is considered contraindicated. If a potent CYP450 3A4 inhibitor is required after the ramp-up phase, the manufacturer recommends that venetoclax dosage be reduced by at least 75%. The dosage used prior to initiating the CYP450 3A4 inhibitor may be resumed 2 to 3 days after discontinuation of the inhibitor.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of potent CYP450 3A4 inhibitors at initiation and during the dosage ramp-up phase of venetoclax is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68146/", "reference_text": "[1] \"Product Information. Venclexta (venetoclax).\" AbbVie US LLC, North Chicago, IL.[2] \"Product Information. Venclexta (venetoclax).\" AbbVie US LLC, North Chicago, IL.[3] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[4] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Tinidazole, Pantoprazole, Levofloxacin, Dexlansoprazole, Rabeprazole, Sucralfate, Tetracycline, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Famotidine, More", "alternatives_b": "Pertuzumab, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Ixazomib, Enasidenib, Mitotane, Niraparib, Porfimer sodium, More", "updated_at": 1767369485}, {"id": 68060, "ingredient1": "Clarithromycin", "ingredient2": "Venlafaxine", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 such as azole antifungal agents and ketolide/macrolide antibiotics may increase the plasma concentrations of venlafaxine and its metabolite, O-desmethylvenlafaxine (ODV). The possibility of prolonged and/or increased pharmacologic effects of venlafaxine should be considered. Venlafaxine may cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval such as azole antifungal agents and ketolide/macrolide antibiotics may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is recommended when venlafaxine is used with CYP450 3A4 inhibitors that can prolong the QT interval such as azole antifungal agents and ketolide/macrolide antibiotics. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Metabolism", "recommendation": "Caution is recommended when venlafaxine is used with CYP450 3A4 inhibitors that can prolong the QT interval such as azole antifungal agents and ketolide/macrolide antibiotics.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68147/", "reference_text": "[1] \"Product Information. Effexor (venlafaxine).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[5] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[6] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[7] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[8] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[9] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Phenelzine, Tranylcypromine, Desvenlafaxine, Isocarboxazid, Oxitriptan, Vortioxetine, Milnacipran, Tryptophan, Esketamine", "alternatives_b": "Tinidazole, Dexlansoprazole, Bismuth subcitrate potassium, Rifabutin, Esomeprazole, Lincomycin, Dirithromycin", "updated_at": 1767369485}, {"id": 68061, "ingredient1": "Clarithromycin", "ingredient2": "Verapamil", "severity": "Moderate", "effect": "Coadministration with certain macrolide antibiotics may increase the plasma concentrations and pharmacologic effects of verapamil. The proposed mechanism is macrolide inhibition of CYP450 3A4, the isoenzyme responsible for hepatic first-pass and systemic metabolic clearance of verapamil. Macrolides that may significantly inhibit CYP450 3A4 include clarithromycin, erythromycin, and troleandomycin. Azithromycin and dirithromycin are generally believed to have little, if any, effect on CYP450 3A4. Clinically, the interaction is supported by isolated case reports of elderly patients stabilized on verapamil and other medications who developed symptoms of verapamil toxicity (e.g., hypotension, bradycardia, atrioventricular block) within 2 to 7 days after initiation of erythromycin or clarithromycin therapy. One of the patients also had QT interval prolongation, which may be induced by elevated levels of erythromycin secondary to inhibition of intestinal P-glycoprotein and CYP450 3A4 by verapamil. The interaction was also suspected in a 53-year-old woman who was started on verapamil and clarithromycin concurrently and developed bradycardia, dizziness, hypotension and fainting after 24 hours. In all cases, discontinuation or dosage reduction of verapamil in addition to supportive care led to resolution of symptoms.", "source": "DDInter", "management_text": "Caution is advised if verapamil must be used with clarithromycin, erythromycin or troleandomycin, particularly in susceptible patients such as the elderly or debilitated. Cardiac function and pharmacologic response to verapamil should be monitored more closely whenever the macrolide antibiotic is added to or withdrawn from therapy in patients stabilized on their verapamil regimen, and the dosage adjusted as necessary. Azithromycin and dirithromycin may be safer alternatives during therapy with verapamil.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if verapamil must be used with clarithromycin, erythromycin or troleandomycin, particularly in susceptible patients such as the elderly or debilitated.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68148/", "reference_text": "[1] Steenbergen JA, Stauffer VL \"Potential macrolide interaction with verapamil.\" Ann Pharmacother 32 (1998): 387-8[2] Kaeser YA, Brunner F, Drewe J, Haefeli WE \"Severe hypotension and bradycardia associated with verapamil and clarithromycin.\" Am J Health Syst Pharm 55 (1998): 2417-8[3] Goldschmidt N, Azaz-Livshits T, Gotsman, Nir-Paz R, Ben-Yehuda A, Muszkat M \"Compound cardiac toxicity of oral erythromycin and verapamil.\" Ann Pharmacother 35 (2001): 1396-9[4] Bailey DG, Dresser GK \"Natural products and adverse drug interactions.\" Can Med Assoc J 170 (2004): 1531-2[5] Ho PC, Ghose K, Saville D, Wanwimolruk S \"Effect of grapefruit juice on pharmacokinetics and pharmacodynamics of verapamil enantiomers in healthy volunteers.\" Eur J Clin Pharmacol 56 (2000): 693-8[6] Pillai U, Muzaffar J, Sandeep S, Yancey A \"Grapefruit juice and verapamil: a toxic cocktail.\" South Med J 102 (2009): 308-9[7] McAllister RG, Jr \"Clinical pharmacology of slow channel blocking agents.\" Prog Cardiovasc Dis 25 (1982): 83-102[8] \"Product Information. Covera-HS (verapamil).\" Searle, Skokie, IL.[9] Fuhr U, Muller-Peltzer H, Kern R, et al. \"Effects of grapefruit juice and smoking on verapamil concentrations in steady state.\" Eur J Clin Pharmacol 58 (2002): 45-53[10] Arayne MS, Sultana N, Bibi Z \"Review: grape fruit juice - drug interactions.\" Pak J Pharm Sci 18 (2005): 45-57[11] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions. 1998.\" Br J Clin Pharmacol 58 (2004): S831-40; discussion S841-3[12] Zaidenstein R, Dishi V, Gips M, Soback S, Cohen N, Weissgarten J, Blatt A, Golik A \"The effect of grapefruit juice on the pharmacokinetics of orally administered verapamil.\" Eur J Clin Pharmacol 54 (1998): 337-40", "alternatives_a": "Moexipril, Perindopril, Benazepril, Trandolapril, Fosinopril", "alternatives_b": "Tinidazole, Dexlansoprazole, Bismuth subcitrate potassium, Esomeprazole, Vonoprazan, Levofloxacin, Lincomycin, Dirithromycin", "updated_at": 1767369485}, {"id": 68062, "ingredient1": "Clarithromycin", "ingredient2": "Vilazodone", "severity": "Major", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of vilazodone, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "The maintenance dosage of vilazodone should be reduced to 20 mg/day when used with potent CYP450 3A4 inhibitors.", "mechanism_text": "Metabolism", "recommendation": "The maintenance dosage of vilazodone should be reduced to 20 mg/day when used with potent CYP450 3A4 inhibitors.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68149/", "reference_text": "[1] \"Product Information. Viibryd (vilazodone).\" Trovis Pharmaceuticals LLC, New Haven, CT.[2] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[3] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[4] \"Product Information. Viibryd (vilazodone).\" Trovis Pharmaceuticals LLC, New Haven, CT.", "alternatives_a": "Tinidazole, Dexlansoprazole, Rabeprazole, Metronidazole, Vonoprazan, Amoxicillin, Pantoprazole, Misoprostol, Esomeprazole, Ranitidine, Levofloxacin, More", "alternatives_b": "Phenelzine, Tranylcypromine, Desvenlafaxine, Isocarboxazid, Oxitriptan, Vortioxetine, Milnacipran, Tryptophan, Esketamine", "updated_at": 1767369485}, {"id": 68063, "ingredient1": "Clarithromycin", "ingredient2": "Vinblastine", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 and/or P-glycoprotein may significantly increase the plasma concentrations of vinca alkaloids, which are substrates of both the hepatic microsomal isoenzyme and intracellular efflux transporter.", "source": "DDInter", "management_text": "Concomitant use of vinca alkaloids with potent CYP450 3A4 and/or P-glycoprotein inhibitors should be avoided if possible. Some authorities recommend avoiding concomitant use of vinca alkaloids during and for 2 weeks after treatment with itraconazole. Otherwise, conservative dosing of the antineoplastic should be considered, and the patient closely monitored for toxicity. Based on the known half-life of vinca alkaloids (24 to 48 hours), the time course of interaction is expected to be approximately 5 to 7 days. Patients should be advised to seek medical attention if they experience symptoms that could indicate neuro- or myelotoxicity, including constipation, abdominal pain or bloating, urinary retention, paresthesia, paralysis, muscle weakness, hearing loss, seizures, erratic blood pressure changes, unusual or excessive bleeding, easy bruising, pallor, fatigue, dizziness, lightheadedness, fever, chills, and sore throat. Following discontinuation of the potent CYP450 3A4 inhibitor, a washout period of approximately one week should be allowed before the antineoplastic dosage is adjusted upward to the previous dosage.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of vinca alkaloids with potent CYP450 3A4 and/or P-glycoprotein inhibitors should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68150/", "reference_text": "[1] Bermudez M, Fuster JL, Llinares E, Galera A, Gonzalez C \"Itraconazole-related increased vincristine neurotoxicity: case report and review of literature.\" J Pediatr Hematol Oncol 27 (2005): 389-392[2] \"Product Information. Velban (vinblastine).\" Lilly, Eli and Company, Indianapolis, IN.[3] Porter CC, Carver AE, Albano EA \"Vincristine induced peripheral neuropathy potentiated by voriconazole in a patient with previously undiagnosed CMT1X.\" Pediatr Blood Cancer 52 (2009): 298-300[4] Gillies J, Hung KA, Fitzsimons E, Soutar R \"Severe vincristine toxicity in combination with itraconazole.\" Clin Lab Haematol 20 (1998): 123-4[5] Eiden C, Palenzuela G, Hillaire-Buys D, et al. \"Posaconazole-increased vincristine neurotoxicity in a child: a case report.\" J Pediatr Hematol Oncol 31 (2009): 292-5[6] Bohme A, Ganser A, Hoelzer D \"Aggravation of vincristine-induced neurotoxicity by itraconazole in the treatment of adult ALL.\" Ann Hematol 71 (1995): 311-2[7] Sathiapalan RK, El-Solh H \"Enhanced vincristine neurotoxicity from drug interactions: case report and review of literature.\" Pediatr Hematol Oncol 18 (2001): 543-6[8] Cerner Multum, Inc. \"Australian Product Information.\" O 0[9] Jain S, Kapoor G \"Severe life threatening neurotoxicity in a child with acute lymphoblastic leukemia receiving posaconazole and vincristine.\" Pediatr Blood Cancer 54 (2010): 783[10] Antoniou T, Tseng AL \"Interactions between antiretrovirals and antineoplastic drug therapy.\" Clin Pharmacokinet 44 (2005): 111-145[11] Murphy JA, Ross LM, Gibson BE \"Vincristine toxicity in five children with acute lymphoblastic leukaemia.\" Lancet 346 (1995): 443[12] Tobe SW, Siu LL, Jamal SA, Skorecki KL, Murphy GF, Warner E \"Vinblastine and erythromycin: an unrecognized serious drug interaction.\" Cancer Chemother Pharmacol 35 (1995): 188-90[13] Zhou-Pan XR, Seree E, Zhou XJ, et al \"Involvement of human liver cytochrome P450 3A in vinblastine metabolism: drug interactions.\" Cancer Res 53 (1993): 5121-6[14] van Schie RM, Bruggemann RJ, Hoogerbrugge PM, Te Loo DM \"Effect of azole antifungal therapy on vincristine toxicity in childhood acute lymphoblastic leukaemia.\" J Antimicrob Chemother 66 (2011): 1853-6[15] Kamaluddin M, McNally P, Breatnach F, et al \"Potentiation of vincristine toxicity by itraconazole in children with lymphoid malignancies.\" Acta Paediatr 90 (2001): 1204-7[16] Ariffin H, Omar KZ, Ang EL, Shekhar K \"Severe vincristine neurotoxicity with concomitant use of itraconazole.\" J Paediatr Child Health 39 (2003): 638-9[17] Mantadakis E, Amoiridis G, Kondi A, Kalmanti M \"Possible increase of the neurotoxicity of vincristine by the concurrent use of posaconazole in a young adult with leukemia.\" J Pediatr Hematol Oncol 29 (2007): 130[18] Kotb R, Vincent I, Dulioust A, et al. \"Life-threatening interaction between antiretroviral therapy and vinblastine in HIV-associated multicentric Castleman's disease.\" Eur J Haematol 76 (2006): 269-71[19] Jeng MR, Feusner J \"Itraconazole-enhanced vincristine neurotoxicity in a child with acute lymphoblastic leukemia.\" Pediatr Hematol Oncol 18 (2001): 137-42[20] Corona G, Vaccher E, Spina M, Toffoli G \"Potential hazard drug-drug interaction between boosted protease inhibitors and vinblastine in HIV patients with Hodgkin's lymphoma.\" AIDS 27 (2013): 1033-5[21] Yano R, Tani D, Watanabe K, et al. \"Evaluation of potential interaction between vinorelbine and clarithromycin.\" Ann Pharmacother 43 (2009): 453-8[22] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[23] Bosque E \"Possible drug interaction between itraconazole and vinorelbine tartrate leading to death after one dose of chemotherapy.\" Ann Intern Med 134 (2001): 427[24] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[25] Moriyama B, Falade-Nwulia O, Leung J, et al. \"Prolonged half-life of voriconazole in a CYP2C19 homozygous poor metabolizer receiving vincristine chemotherapy: avoiding a serious adverse drug interaction.\" Mycoses 54 (2011): e877-9[26] Zhou XJ, Zhou-Pan XR, Gauthier T, Placidi M, Maurel P, Rahmani R \"Human liver microsomal cytochrome P450 3A isozymes mediated vindesine biotransformation. Metabolic drug interactions.\" Biochem Pharmacol 45 (1993): 853-61[27] Chan JD \"Pharmacokinetic drug interactions of vinca alkaloids: summary of case reports.\" Pharmacotherapy 18 (1998): 1304-7[28] Chen S, Wu D, Sun A, et al \"Itraconazole-enhanced vindesine neurotoxicity in adult acute lymphoblastic leukaemia.\" Am J Hematol 82 (2007): 942[29] Carrion C, Espinosa E, Herrero A, Garcia B \"Possible vincristine-isoniazid interaction.\" Ann Pharmacother 29 (1995): 201[30] Kivisto KT, Kroemer HK, Eichelbaum M \"The role of human cytochrome p450 enzymes in the metabolism of anticancer agents: implications for drug interactions.\" Br J Clin Pharmacol 40 (1995): 523-30[31] Harnicar S, Adel N, Jurcic J \"Modification of vincristine dosing during concomitant azole therapy in adult acute lymphoblastic leukemia patients.\" J Oncol Pharm Pract 15 (2009): 175-82[32] Haddad A, Davis M, Lagman R \"The pharmacological importance of cytochrome CYP3A4 in the palliation of symptoms: review and recommendations for avoiding adverse drug interactions.\" Support Care Cancer 15 (2007): 251-7[33] Fedeli L, Colozza M, Boschetti E, et al. \"Pharmacokinetics of vincristine in cancer patients treated with nifedipine.\" Cancer 64 (1989): 1805-11[34] Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y \"Potentiation of vincristine and adriamycin effects in human hemopoietic tumor cell lines by calcium antagonists and calmodulin inhibitors.\" Cancer Res 43 (1983): 2267-72[35] Leveque D, Santucci R, Pavillet J, Herbrecht R, Bergerat JP \"Paralytic ileus possibly associated with interaction between ritonavir/lopinavir and vincristine.\" Pharm World Sci 31 (2009): 619-21[36] Kajita J, Kuwabara T, Kobayashi H, Kobayashi S \"CYP3A4 is mainly responsibile for the metabolism of a new vinca alkaloid, vinorelbine, in human liver microsomes.\" Drug Metab Dispos 28 (2000): 1121-7[37] \"Product Information. Oncovin (vincristine).\" Lilly, Eli and Company, Indianapolis, IN.[38] Bashir H, Motl S, Metzger ML, et al. \"Itraconazole-enhanced chemotherapy toxicity in a patient with Hodgkin lymphoma.\" J Pediatr Hematol Oncol 28 (2006): 33-35[39] Takahashi N, Kameoka Y, Yamanaka Y, et al. \"Itraconazole oral solution enhanced vincristine neurotoxicity in five patients with malignant lymphoma.\" Intern Med 47 (2008): 651-3[40] \"Product Information. Sporanox (itraconazole).\" Janssen Pharmaceutica, Titusville, NJ.[41] Sathiapalan RK, Al-Nasser A, El-Solh H, Al-Mohsen I, Al-Jumaah S \"Vincristine-itraconazole interaction: cause for increasing concern.\" J Pediatr Hematol Oncol 24 (2002): 591", "alternatives_a": "Topotecan, Teniposide", "alternatives_b": "Tetracycline, Rabeprazole, Dexlansoprazole, Sucralfate, Bismuth subcitrate potassium, Cimetidine, Esomeprazole, Ranitidine, Nizatidine, Vonoprazan, Amoxicillin, More", "updated_at": 1767369485}, {"id": 68064, "ingredient1": "Clarithromycin", "ingredient2": "Vincristine", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 and/or P-glycoprotein may significantly increase the plasma concentrations of vinca alkaloids, which are substrates of both the hepatic microsomal isoenzyme and intracellular efflux transporter.", "source": "DDInter", "management_text": "Concomitant use of vinca alkaloids with potent CYP450 3A4 and/or P-glycoprotein inhibitors should be avoided if possible. Some authorities recommend avoiding concomitant use of vinca alkaloids during and for 2 weeks after treatment with itraconazole. Otherwise, conservative dosing of the antineoplastic should be considered, and the patient closely monitored for toxicity. Based on the known half-life of vinca alkaloids (24 to 48 hours), the time course of interaction is expected to be approximately 5 to 7 days. Patients should be advised to seek medical attention if they experience symptoms that could indicate neuro- or myelotoxicity, including constipation, abdominal pain or bloating, urinary retention, paresthesia, paralysis, muscle weakness, hearing loss, seizures, erratic blood pressure changes, unusual or excessive bleeding, easy bruising, pallor, fatigue, dizziness, lightheadedness, fever, chills, and sore throat. Following discontinuation of the potent CYP450 3A4 inhibitor, a washout period of approximately one week should be allowed before the antineoplastic dosage is adjusted upward to the previous dosage.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of vinca alkaloids with potent CYP450 3A4 and/or P-glycoprotein inhibitors should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68151/", "reference_text": "[1] Bermudez M, Fuster JL, Llinares E, Galera A, Gonzalez C \"Itraconazole-related increased vincristine neurotoxicity: case report and review of literature.\" J Pediatr Hematol Oncol 27 (2005): 389-392[2] \"Product Information. Velban (vinblastine).\" Lilly, Eli and Company, Indianapolis, IN.[3] Porter CC, Carver AE, Albano EA \"Vincristine induced peripheral neuropathy potentiated by voriconazole in a patient with previously undiagnosed CMT1X.\" Pediatr Blood Cancer 52 (2009): 298-300[4] Gillies J, Hung KA, Fitzsimons E, Soutar R \"Severe vincristine toxicity in combination with itraconazole.\" Clin Lab Haematol 20 (1998): 123-4[5] Eiden C, Palenzuela G, Hillaire-Buys D, et al. \"Posaconazole-increased vincristine neurotoxicity in a child: a case report.\" J Pediatr Hematol Oncol 31 (2009): 292-5[6] Bohme A, Ganser A, Hoelzer D \"Aggravation of vincristine-induced neurotoxicity by itraconazole in the treatment of adult ALL.\" Ann Hematol 71 (1995): 311-2[7] Sathiapalan RK, El-Solh H \"Enhanced vincristine neurotoxicity from drug interactions: case report and review of literature.\" Pediatr Hematol Oncol 18 (2001): 543-6[8] Cerner Multum, Inc. \"Australian Product Information.\" O 0[9] Jain S, Kapoor G \"Severe life threatening neurotoxicity in a child with acute lymphoblastic leukemia receiving posaconazole and vincristine.\" Pediatr Blood Cancer 54 (2010): 783[10] Antoniou T, Tseng AL \"Interactions between antiretrovirals and antineoplastic drug therapy.\" Clin Pharmacokinet 44 (2005): 111-145[11] Murphy JA, Ross LM, Gibson BE \"Vincristine toxicity in five children with acute lymphoblastic leukaemia.\" Lancet 346 (1995): 443[12] Tobe SW, Siu LL, Jamal SA, Skorecki KL, Murphy GF, Warner E \"Vinblastine and erythromycin: an unrecognized serious drug interaction.\" Cancer Chemother Pharmacol 35 (1995): 188-90[13] Zhou-Pan XR, Seree E, Zhou XJ, et al \"Involvement of human liver cytochrome P450 3A in vinblastine metabolism: drug interactions.\" Cancer Res 53 (1993): 5121-6[14] van Schie RM, Bruggemann RJ, Hoogerbrugge PM, Te Loo DM \"Effect of azole antifungal therapy on vincristine toxicity in childhood acute lymphoblastic leukaemia.\" J Antimicrob Chemother 66 (2011): 1853-6[15] Kamaluddin M, McNally P, Breatnach F, et al \"Potentiation of vincristine toxicity by itraconazole in children with lymphoid malignancies.\" Acta Paediatr 90 (2001): 1204-7[16] Ariffin H, Omar KZ, Ang EL, Shekhar K \"Severe vincristine neurotoxicity with concomitant use of itraconazole.\" J Paediatr Child Health 39 (2003): 638-9[17] Mantadakis E, Amoiridis G, Kondi A, Kalmanti M \"Possible increase of the neurotoxicity of vincristine by the concurrent use of posaconazole in a young adult with leukemia.\" J Pediatr Hematol Oncol 29 (2007): 130[18] Kotb R, Vincent I, Dulioust A, et al. \"Life-threatening interaction between antiretroviral therapy and vinblastine in HIV-associated multicentric Castleman's disease.\" Eur J Haematol 76 (2006): 269-71[19] Jeng MR, Feusner J \"Itraconazole-enhanced vincristine neurotoxicity in a child with acute lymphoblastic leukemia.\" Pediatr Hematol Oncol 18 (2001): 137-42[20] Corona G, Vaccher E, Spina M, Toffoli G \"Potential hazard drug-drug interaction between boosted protease inhibitors and vinblastine in HIV patients with Hodgkin's lymphoma.\" AIDS 27 (2013): 1033-5[21] Yano R, Tani D, Watanabe K, et al. \"Evaluation of potential interaction between vinorelbine and clarithromycin.\" Ann Pharmacother 43 (2009): 453-8[22] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[23] Bosque E \"Possible drug interaction between itraconazole and vinorelbine tartrate leading to death after one dose of chemotherapy.\" Ann Intern Med 134 (2001): 427[24] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[25] Moriyama B, Falade-Nwulia O, Leung J, et al. \"Prolonged half-life of voriconazole in a CYP2C19 homozygous poor metabolizer receiving vincristine chemotherapy: avoiding a serious adverse drug interaction.\" Mycoses 54 (2011): e877-9[26] Zhou XJ, Zhou-Pan XR, Gauthier T, Placidi M, Maurel P, Rahmani R \"Human liver microsomal cytochrome P450 3A isozymes mediated vindesine biotransformation. Metabolic drug interactions.\" Biochem Pharmacol 45 (1993): 853-61[27] Chan JD \"Pharmacokinetic drug interactions of vinca alkaloids: summary of case reports.\" Pharmacotherapy 18 (1998): 1304-7[28] Chen S, Wu D, Sun A, et al \"Itraconazole-enhanced vindesine neurotoxicity in adult acute lymphoblastic leukaemia.\" Am J Hematol 82 (2007): 942[29] Carrion C, Espinosa E, Herrero A, Garcia B \"Possible vincristine-isoniazid interaction.\" Ann Pharmacother 29 (1995): 201[30] Kivisto KT, Kroemer HK, Eichelbaum M \"The role of human cytochrome p450 enzymes in the metabolism of anticancer agents: implications for drug interactions.\" Br J Clin Pharmacol 40 (1995): 523-30[31] Harnicar S, Adel N, Jurcic J \"Modification of vincristine dosing during concomitant azole therapy in adult acute lymphoblastic leukemia patients.\" J Oncol Pharm Pract 15 (2009): 175-82[32] Haddad A, Davis M, Lagman R \"The pharmacological importance of cytochrome CYP3A4 in the palliation of symptoms: review and recommendations for avoiding adverse drug interactions.\" Support Care Cancer 15 (2007): 251-7[33] Fedeli L, Colozza M, Boschetti E, et al. \"Pharmacokinetics of vincristine in cancer patients treated with nifedipine.\" Cancer 64 (1989): 1805-11[34] Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y \"Potentiation of vincristine and adriamycin effects in human hemopoietic tumor cell lines by calcium antagonists and calmodulin inhibitors.\" Cancer Res 43 (1983): 2267-72[35] Leveque D, Santucci R, Pavillet J, Herbrecht R, Bergerat JP \"Paralytic ileus possibly associated with interaction between ritonavir/lopinavir and vincristine.\" Pharm World Sci 31 (2009): 619-21[36] Kajita J, Kuwabara T, Kobayashi H, Kobayashi S \"CYP3A4 is mainly responsibile for the metabolism of a new vinca alkaloid, vinorelbine, in human liver microsomes.\" Drug Metab Dispos 28 (2000): 1121-7[37] \"Product Information. Oncovin (vincristine).\" Lilly, Eli and Company, Indianapolis, IN.[38] Bashir H, Motl S, Metzger ML, et al. \"Itraconazole-enhanced chemotherapy toxicity in a patient with Hodgkin lymphoma.\" J Pediatr Hematol Oncol 28 (2006): 33-35[39] Takahashi N, Kameoka Y, Yamanaka Y, et al. \"Itraconazole oral solution enhanced vincristine neurotoxicity in five patients with malignant lymphoma.\" Intern Med 47 (2008): 651-3[40] \"Product Information. Sporanox (itraconazole).\" Janssen Pharmaceutica, Titusville, NJ.[41] Sathiapalan RK, Al-Nasser A, El-Solh H, Al-Mohsen I, Al-Jumaah S \"Vincristine-itraconazole interaction: cause for increasing concern.\" J Pediatr Hematol Oncol 24 (2002): 591", "alternatives_a": "Topotecan, Teniposide", "alternatives_b": "Tetracycline, Dexlansoprazole, Misoprostol, Bismuth subcitrate potassium, Cimetidine, Esomeprazole, Vonoprazan, Lincomycin, Azithromycin, Dirithromycin", "updated_at": 1767369485}, {"id": 68065, "ingredient1": "Clarithromycin", "ingredient2": "Vincristine (liposome)", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 and/or P-glycoprotein may significantly increase the plasma concentrations of vinca alkaloids, which are substrates of both the hepatic microsomal isoenzyme and intracellular efflux transporter.", "source": "DDInter", "management_text": "Concomitant use of vinca alkaloids with potent CYP450 3A4 and/or P-glycoprotein inhibitors should be avoided if possible. Some authorities recommend avoiding concomitant use of vinca alkaloids during and for 2 weeks after treatment with itraconazole. Otherwise, conservative dosing of the antineoplastic should be considered, and the patient closely monitored for toxicity. Based on the known half-life of vinca alkaloids (24 to 48 hours), the time course of interaction is expected to be approximately 5 to 7 days. Patients should be advised to seek medical attention if they experience symptoms that could indicate neuro- or myelotoxicity, including constipation, abdominal pain or bloating, urinary retention, paresthesia, paralysis, muscle weakness, hearing loss, seizures, erratic blood pressure changes, unusual or excessive bleeding, easy bruising, pallor, fatigue, dizziness, lightheadedness, fever, chills, and sore throat. Following discontinuation of the potent CYP450 3A4 inhibitor, a washout period of approximately one week should be allowed before the antineoplastic dosage is adjusted upward to the previous dosage.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of vinca alkaloids with potent CYP450 3A4 and/or P-glycoprotein inhibitors should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68152/", "reference_text": "[1] Bermudez M, Fuster JL, Llinares E, Galera A, Gonzalez C \"Itraconazole-related increased vincristine neurotoxicity: case report and review of literature.\" J Pediatr Hematol Oncol 27 (2005): 389-392[2] \"Product Information. Velban (vinblastine).\" Lilly, Eli and Company, Indianapolis, IN.[3] Porter CC, Carver AE, Albano EA \"Vincristine induced peripheral neuropathy potentiated by voriconazole in a patient with previously undiagnosed CMT1X.\" Pediatr Blood Cancer 52 (2009): 298-300[4] Gillies J, Hung KA, Fitzsimons E, Soutar R \"Severe vincristine toxicity in combination with itraconazole.\" Clin Lab Haematol 20 (1998): 123-4[5] Eiden C, Palenzuela G, Hillaire-Buys D, et al. \"Posaconazole-increased vincristine neurotoxicity in a child: a case report.\" J Pediatr Hematol Oncol 31 (2009): 292-5[6] Bohme A, Ganser A, Hoelzer D \"Aggravation of vincristine-induced neurotoxicity by itraconazole in the treatment of adult ALL.\" Ann Hematol 71 (1995): 311-2[7] Sathiapalan RK, El-Solh H \"Enhanced vincristine neurotoxicity from drug interactions: case report and review of literature.\" Pediatr Hematol Oncol 18 (2001): 543-6[8] Cerner Multum, Inc. \"Australian Product Information.\" O 0[9] Jain S, Kapoor G \"Severe life threatening neurotoxicity in a child with acute lymphoblastic leukemia receiving posaconazole and vincristine.\" Pediatr Blood Cancer 54 (2010): 783[10] Antoniou T, Tseng AL \"Interactions between antiretrovirals and antineoplastic drug therapy.\" Clin Pharmacokinet 44 (2005): 111-145[11] Murphy JA, Ross LM, Gibson BE \"Vincristine toxicity in five children with acute lymphoblastic leukaemia.\" Lancet 346 (1995): 443[12] Tobe SW, Siu LL, Jamal SA, Skorecki KL, Murphy GF, Warner E \"Vinblastine and erythromycin: an unrecognized serious drug interaction.\" Cancer Chemother Pharmacol 35 (1995): 188-90[13] Zhou-Pan XR, Seree E, Zhou XJ, et al \"Involvement of human liver cytochrome P450 3A in vinblastine metabolism: drug interactions.\" Cancer Res 53 (1993): 5121-6[14] van Schie RM, Bruggemann RJ, Hoogerbrugge PM, Te Loo DM \"Effect of azole antifungal therapy on vincristine toxicity in childhood acute lymphoblastic leukaemia.\" J Antimicrob Chemother 66 (2011): 1853-6[15] Kamaluddin M, McNally P, Breatnach F, et al \"Potentiation of vincristine toxicity by itraconazole in children with lymphoid malignancies.\" Acta Paediatr 90 (2001): 1204-7[16] Ariffin H, Omar KZ, Ang EL, Shekhar K \"Severe vincristine neurotoxicity with concomitant use of itraconazole.\" J Paediatr Child Health 39 (2003): 638-9[17] Mantadakis E, Amoiridis G, Kondi A, Kalmanti M \"Possible increase of the neurotoxicity of vincristine by the concurrent use of posaconazole in a young adult with leukemia.\" J Pediatr Hematol Oncol 29 (2007): 130[18] Kotb R, Vincent I, Dulioust A, et al. \"Life-threatening interaction between antiretroviral therapy and vinblastine in HIV-associated multicentric Castleman's disease.\" Eur J Haematol 76 (2006): 269-71[19] Jeng MR, Feusner J \"Itraconazole-enhanced vincristine neurotoxicity in a child with acute lymphoblastic leukemia.\" Pediatr Hematol Oncol 18 (2001): 137-42[20] Corona G, Vaccher E, Spina M, Toffoli G \"Potential hazard drug-drug interaction between boosted protease inhibitors and vinblastine in HIV patients with Hodgkin's lymphoma.\" AIDS 27 (2013): 1033-5[21] Yano R, Tani D, Watanabe K, et al. \"Evaluation of potential interaction between vinorelbine and clarithromycin.\" Ann Pharmacother 43 (2009): 453-8[22] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[23] Bosque E \"Possible drug interaction between itraconazole and vinorelbine tartrate leading to death after one dose of chemotherapy.\" Ann Intern Med 134 (2001): 427[24] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[25] Moriyama B, Falade-Nwulia O, Leung J, et al. \"Prolonged half-life of voriconazole in a CYP2C19 homozygous poor metabolizer receiving vincristine chemotherapy: avoiding a serious adverse drug interaction.\" Mycoses 54 (2011): e877-9[26] Zhou XJ, Zhou-Pan XR, Gauthier T, Placidi M, Maurel P, Rahmani R \"Human liver microsomal cytochrome P450 3A isozymes mediated vindesine biotransformation. Metabolic drug interactions.\" Biochem Pharmacol 45 (1993): 853-61[27] Chan JD \"Pharmacokinetic drug interactions of vinca alkaloids: summary of case reports.\" Pharmacotherapy 18 (1998): 1304-7[28] Chen S, Wu D, Sun A, et al \"Itraconazole-enhanced vindesine neurotoxicity in adult acute lymphoblastic leukaemia.\" Am J Hematol 82 (2007): 942[29] Carrion C, Espinosa E, Herrero A, Garcia B \"Possible vincristine-isoniazid interaction.\" Ann Pharmacother 29 (1995): 201[30] Kivisto KT, Kroemer HK, Eichelbaum M \"The role of human cytochrome p450 enzymes in the metabolism of anticancer agents: implications for drug interactions.\" Br J Clin Pharmacol 40 (1995): 523-30[31] Harnicar S, Adel N, Jurcic J \"Modification of vincristine dosing during concomitant azole therapy in adult acute lymphoblastic leukemia patients.\" J Oncol Pharm Pract 15 (2009): 175-82[32] Haddad A, Davis M, Lagman R \"The pharmacological importance of cytochrome CYP3A4 in the palliation of symptoms: review and recommendations for avoiding adverse drug interactions.\" Support Care Cancer 15 (2007): 251-7[33] Fedeli L, Colozza M, Boschetti E, et al. \"Pharmacokinetics of vincristine in cancer patients treated with nifedipine.\" Cancer 64 (1989): 1805-11[34] Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y \"Potentiation of vincristine and adriamycin effects in human hemopoietic tumor cell lines by calcium antagonists and calmodulin inhibitors.\" Cancer Res 43 (1983): 2267-72[35] Leveque D, Santucci R, Pavillet J, Herbrecht R, Bergerat JP \"Paralytic ileus possibly associated with interaction between ritonavir/lopinavir and vincristine.\" Pharm World Sci 31 (2009): 619-21[36] Kajita J, Kuwabara T, Kobayashi H, Kobayashi S \"CYP3A4 is mainly responsibile for the metabolism of a new vinca alkaloid, vinorelbine, in human liver microsomes.\" Drug Metab Dispos 28 (2000): 1121-7[37] \"Product Information. Oncovin (vincristine).\" Lilly, Eli and Company, Indianapolis, IN.[38] Bashir H, Motl S, Metzger ML, et al. \"Itraconazole-enhanced chemotherapy toxicity in a patient with Hodgkin lymphoma.\" J Pediatr Hematol Oncol 28 (2006): 33-35[39] Takahashi N, Kameoka Y, Yamanaka Y, et al. \"Itraconazole oral solution enhanced vincristine neurotoxicity in five patients with malignant lymphoma.\" Intern Med 47 (2008): 651-3[40] \"Product Information. Sporanox (itraconazole).\" Janssen Pharmaceutica, Titusville, NJ.[41] Sathiapalan RK, Al-Nasser A, El-Solh H, Al-Mohsen I, Al-Jumaah S \"Vincristine-itraconazole interaction: cause for increasing concern.\" J Pediatr Hematol Oncol 24 (2002): 591", "alternatives_a": "Topotecan, Teniposide", "alternatives_b": "Pantoprazole, Tetracycline, Rabeprazole, Dexlansoprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Famotidine, Cimetidine, Esomeprazole, Ranitidine, More", "updated_at": 1767369485}, {"id": 68066, "ingredient1": "Clarithromycin", "ingredient2": "Vinorelbine", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 and/or P-glycoprotein may significantly increase the plasma concentrations of vinca alkaloids, which are substrates of both the hepatic microsomal isoenzyme and intracellular efflux transporter.", "source": "DDInter", "management_text": "Concomitant use of vinca alkaloids with potent CYP450 3A4 and/or P-glycoprotein inhibitors should be avoided if possible. Some authorities recommend avoiding concomitant use of vinca alkaloids during and for 2 weeks after treatment with itraconazole. Otherwise, conservative dosing of the antineoplastic should be considered, and the patient closely monitored for toxicity. Based on the known half-life of vinca alkaloids (24 to 48 hours), the time course of interaction is expected to be approximately 5 to 7 days. Patients should be advised to seek medical attention if they experience symptoms that could indicate neuro- or myelotoxicity, including constipation, abdominal pain or bloating, urinary retention, paresthesia, paralysis, muscle weakness, hearing loss, seizures, erratic blood pressure changes, unusual or excessive bleeding, easy bruising, pallor, fatigue, dizziness, lightheadedness, fever, chills, and sore throat. Following discontinuation of the potent CYP450 3A4 inhibitor, a washout period of approximately one week should be allowed before the antineoplastic dosage is adjusted upward to the previous dosage.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of vinca alkaloids with potent CYP450 3A4 and/or P-glycoprotein inhibitors should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68153/", "reference_text": "[1] Bermudez M, Fuster JL, Llinares E, Galera A, Gonzalez C \"Itraconazole-related increased vincristine neurotoxicity: case report and review of literature.\" J Pediatr Hematol Oncol 27 (2005): 389-392[2] \"Product Information. Velban (vinblastine).\" Lilly, Eli and Company, Indianapolis, IN.[3] Porter CC, Carver AE, Albano EA \"Vincristine induced peripheral neuropathy potentiated by voriconazole in a patient with previously undiagnosed CMT1X.\" Pediatr Blood Cancer 52 (2009): 298-300[4] Gillies J, Hung KA, Fitzsimons E, Soutar R \"Severe vincristine toxicity in combination with itraconazole.\" Clin Lab Haematol 20 (1998): 123-4[5] Eiden C, Palenzuela G, Hillaire-Buys D, et al. \"Posaconazole-increased vincristine neurotoxicity in a child: a case report.\" J Pediatr Hematol Oncol 31 (2009): 292-5[6] Bohme A, Ganser A, Hoelzer D \"Aggravation of vincristine-induced neurotoxicity by itraconazole in the treatment of adult ALL.\" Ann Hematol 71 (1995): 311-2[7] Sathiapalan RK, El-Solh H \"Enhanced vincristine neurotoxicity from drug interactions: case report and review of literature.\" Pediatr Hematol Oncol 18 (2001): 543-6[8] Cerner Multum, Inc. \"Australian Product Information.\" O 0[9] Jain S, Kapoor G \"Severe life threatening neurotoxicity in a child with acute lymphoblastic leukemia receiving posaconazole and vincristine.\" Pediatr Blood Cancer 54 (2010): 783[10] Antoniou T, Tseng AL \"Interactions between antiretrovirals and antineoplastic drug therapy.\" Clin Pharmacokinet 44 (2005): 111-145[11] Murphy JA, Ross LM, Gibson BE \"Vincristine toxicity in five children with acute lymphoblastic leukaemia.\" Lancet 346 (1995): 443[12] Tobe SW, Siu LL, Jamal SA, Skorecki KL, Murphy GF, Warner E \"Vinblastine and erythromycin: an unrecognized serious drug interaction.\" Cancer Chemother Pharmacol 35 (1995): 188-90[13] Zhou-Pan XR, Seree E, Zhou XJ, et al \"Involvement of human liver cytochrome P450 3A in vinblastine metabolism: drug interactions.\" Cancer Res 53 (1993): 5121-6[14] van Schie RM, Bruggemann RJ, Hoogerbrugge PM, Te Loo DM \"Effect of azole antifungal therapy on vincristine toxicity in childhood acute lymphoblastic leukaemia.\" J Antimicrob Chemother 66 (2011): 1853-6[15] Kamaluddin M, McNally P, Breatnach F, et al \"Potentiation of vincristine toxicity by itraconazole in children with lymphoid malignancies.\" Acta Paediatr 90 (2001): 1204-7[16] Ariffin H, Omar KZ, Ang EL, Shekhar K \"Severe vincristine neurotoxicity with concomitant use of itraconazole.\" J Paediatr Child Health 39 (2003): 638-9[17] Mantadakis E, Amoiridis G, Kondi A, Kalmanti M \"Possible increase of the neurotoxicity of vincristine by the concurrent use of posaconazole in a young adult with leukemia.\" J Pediatr Hematol Oncol 29 (2007): 130[18] Kotb R, Vincent I, Dulioust A, et al. \"Life-threatening interaction between antiretroviral therapy and vinblastine in HIV-associated multicentric Castleman's disease.\" Eur J Haematol 76 (2006): 269-71[19] Jeng MR, Feusner J \"Itraconazole-enhanced vincristine neurotoxicity in a child with acute lymphoblastic leukemia.\" Pediatr Hematol Oncol 18 (2001): 137-42[20] Corona G, Vaccher E, Spina M, Toffoli G \"Potential hazard drug-drug interaction between boosted protease inhibitors and vinblastine in HIV patients with Hodgkin's lymphoma.\" AIDS 27 (2013): 1033-5[21] Yano R, Tani D, Watanabe K, et al. \"Evaluation of potential interaction between vinorelbine and clarithromycin.\" Ann Pharmacother 43 (2009): 453-8[22] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[23] Bosque E \"Possible drug interaction between itraconazole and vinorelbine tartrate leading to death after one dose of chemotherapy.\" Ann Intern Med 134 (2001): 427[24] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[25] Moriyama B, Falade-Nwulia O, Leung J, et al. \"Prolonged half-life of voriconazole in a CYP2C19 homozygous poor metabolizer receiving vincristine chemotherapy: avoiding a serious adverse drug interaction.\" Mycoses 54 (2011): e877-9[26] Zhou XJ, Zhou-Pan XR, Gauthier T, Placidi M, Maurel P, Rahmani R \"Human liver microsomal cytochrome P450 3A isozymes mediated vindesine biotransformation. Metabolic drug interactions.\" Biochem Pharmacol 45 (1993): 853-61[27] Chan JD \"Pharmacokinetic drug interactions of vinca alkaloids: summary of case reports.\" Pharmacotherapy 18 (1998): 1304-7[28] Chen S, Wu D, Sun A, et al \"Itraconazole-enhanced vindesine neurotoxicity in adult acute lymphoblastic leukaemia.\" Am J Hematol 82 (2007): 942[29] Carrion C, Espinosa E, Herrero A, Garcia B \"Possible vincristine-isoniazid interaction.\" Ann Pharmacother 29 (1995): 201[30] Kivisto KT, Kroemer HK, Eichelbaum M \"The role of human cytochrome p450 enzymes in the metabolism of anticancer agents: implications for drug interactions.\" Br J Clin Pharmacol 40 (1995): 523-30[31] Harnicar S, Adel N, Jurcic J \"Modification of vincristine dosing during concomitant azole therapy in adult acute lymphoblastic leukemia patients.\" J Oncol Pharm Pract 15 (2009): 175-82[32] Haddad A, Davis M, Lagman R \"The pharmacological importance of cytochrome CYP3A4 in the palliation of symptoms: review and recommendations for avoiding adverse drug interactions.\" Support Care Cancer 15 (2007): 251-7[33] Fedeli L, Colozza M, Boschetti E, et al. \"Pharmacokinetics of vincristine in cancer patients treated with nifedipine.\" Cancer 64 (1989): 1805-11[34] Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y \"Potentiation of vincristine and adriamycin effects in human hemopoietic tumor cell lines by calcium antagonists and calmodulin inhibitors.\" Cancer Res 43 (1983): 2267-72[35] Leveque D, Santucci R, Pavillet J, Herbrecht R, Bergerat JP \"Paralytic ileus possibly associated with interaction between ritonavir/lopinavir and vincristine.\" Pharm World Sci 31 (2009): 619-21[36] Kajita J, Kuwabara T, Kobayashi H, Kobayashi S \"CYP3A4 is mainly responsibile for the metabolism of a new vinca alkaloid, vinorelbine, in human liver microsomes.\" Drug Metab Dispos 28 (2000): 1121-7[37] \"Product Information. Oncovin (vincristine).\" Lilly, Eli and Company, Indianapolis, IN.[38] Bashir H, Motl S, Metzger ML, et al. \"Itraconazole-enhanced chemotherapy toxicity in a patient with Hodgkin lymphoma.\" J Pediatr Hematol Oncol 28 (2006): 33-35[39] Takahashi N, Kameoka Y, Yamanaka Y, et al. \"Itraconazole oral solution enhanced vincristine neurotoxicity in five patients with malignant lymphoma.\" Intern Med 47 (2008): 651-3[40] \"Product Information. Sporanox (itraconazole).\" Janssen Pharmaceutica, Titusville, NJ.[41] Sathiapalan RK, Al-Nasser A, El-Solh H, Al-Mohsen I, Al-Jumaah S \"Vincristine-itraconazole interaction: cause for increasing concern.\" J Pediatr Hematol Oncol 24 (2002): 591", "alternatives_a": "Topotecan, Teniposide", "alternatives_b": "Tetracycline, Dexlansoprazole, Sucralfate, Bismuth subcitrate potassium, Cimetidine, Esomeprazole, Nizatidine, Vonoprazan, Amoxicillin, Lincomycin, Azithromycin, Dirithromycin", "updated_at": 1767369485}, {"id": 68067, "ingredient1": "Clarithromycin", "ingredient2": "Vismodegib", "severity": "Moderate", "effect": "Coadministration with inhibitors of P-glycoprotein may increase the plasma concentrations of vismodegib, which has been shown in vitro to be a substrate of the efflux transporter. The potential for increased pharmacologic effects of vismodegib, including adverse effects such as muscle spasm, alopecia, dysgeusia/ageusia, weight loss, fatigue, nausea, vomiting, diarrhea, decreased appetite, constipation and arthralgia, should be considered.", "source": "DDInter", "management_text": "Caution is advised if vismodegib is used in combination with P-glycoprotein inhibitors.", "mechanism_text": "Others", "recommendation": "Caution is advised if vismodegib is used in combination with P-glycoprotein inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68154/", "reference_text": "[1] \"Product Information. Erivedge (vismodegib).\" Genentech, South San Francisco, CA.[2] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):", "alternatives_a": "Tinidazole, Levofloxacin, Tetracycline, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Rifabutin, Vonoprazan, Amoxicillin, Dirithromycin, More", "alternatives_b": "Pertuzumab, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Ixazomib, Enasidenib, Mitotane, Niraparib, Porfimer sodium, More", "updated_at": 1767369485}, {"id": 68068, "ingredient1": "Clarithromycin", "ingredient2": "Vorapaxar", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of vorapaxar, which is a substrate of the isoenzyme.", "source": "DDInter", "management_text": "Concomitant use of vorapaxar with potent CYP450 3A4 inhibitors should generally be avoided. Some authorities recommend avoiding concomitant use of vorapaxar during and for 2 weeks after treatment with itraconazole.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of vorapaxar with potent CYP450 3A4 inhibitors should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68155/", "reference_text": "[1] \"Product Information. Zontivity (vorapaxar).\" Merck & Company Inc, Whitehouse Station, NJ.[2] \"Product Information. Sporanox (itraconazole).\" Janssen Pharmaceutica, Titusville, NJ.[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[5] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Tinidazole, Dexlansoprazole, Rabeprazole, Metronidazole, Vonoprazan, Amoxicillin, Pantoprazole, Misoprostol, Esomeprazole, Ranitidine, Levofloxacin, More", "alternatives_b": "Iloprost, Lepirudin, Urokinase, Cangrelor, Caplacizumab, Argatroban, Prasugrel, Desirudin, Eptifibatide, Streptokinase, Tinzaparin, More", "updated_at": 1767369485}, {"id": 68069, "ingredient1": "Clarithromycin", "ingredient2": "Voriconazole", "severity": "Moderate", "effect": "Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.", "source": "DDInter", "management_text": "Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution and clinical monitoring are recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68156/", "reference_text": "[1] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):[2] Witchel HJ, Hancox JC, Nutt DJ \"Psychotropic drugs, cardiac arrhythmia, and sudden death.\" J Clin Psychopharmacol 23 (2003): 58-77[3] Iannini PB \"Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval.\" Expert Opin Drug Saf 1 (2002): 121-8[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[6] Glassman AH, Bigger JT Jr \"Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death.\" Am J Psychiatry 158 (2001): 1774-82[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] Honig PK, Wortham DC, Zamani K, et al \"Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences.\" JAMA 269 (1993): 1513-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[10] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P \"Torsades de pointes after terfenadine-itraconazole interaction.\" BMJ 306 (1993): 186[11] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[12] Mathews DR, McNutt B, Okerholm R, et al \"Torsades de pointes occurring in association with terfenadine use.\" JAMA 266 (1991): 2375-6[13] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL \"Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram.\" Clin Pharmacol Ther 59 (1996): 383-8[14] Zechnich AD, Haxby DG \"Drug interactions associated with terfenadine and related nonsedating antihistamines.\" West J Med 164 (1996): 68-9[15] Hsieh MH, Chen SA, Chiang CE, et al. \"Drug-induced torsades de pointes in one patient with congenital long QT syndrome.\" Int J Cardiol 54 (1996): 85-8[16] Woosley RL \"Cardiac actions of antihistamines.\" Annu Rev Pharmacol Toxicol 36 (1996): 233-52[17] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP \"Torsades-de-pointes induced by erythromycin and terfenadine.\" Am J Emerg Med 12 (1994): 636-8[18] Zimmermann M, Duruz H, Guinand O, et al \"Torsades de Pointes after treatment with terfenadine and ketoconazole.\" Eur Heart J 13 (1992): 1002-3[19] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG \"Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance.\" Clin Pharmacol Ther 61 (1997): 401-9[20] Honig PK, Wortham DC, Lazarev A, Cantilena LR \"Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine.\" J Clin Pharmacol 36 (1996): 345-51[21] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr \"Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin.\" Clin Pharmacol Ther 52 (1992): 231-8[22] Monahan BP, Ferguson CL, Killeavy ES, et al \"Torsades de pointes occurring in association with terfenadine use.\" JAMA 264 (1990): 2788-90[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[24] Cortese LM, Bjornson DC \"Potential interaction between terfenadine and macrolide antibiotics.\" Clin Pharm 11 (1992): 675", "alternatives_a": "Flucytosine, Anidulafungin, Micafungin, Oteseconazole", "alternatives_b": "Tinidazole, Tetracycline, Misoprostol, Bismuth subcitrate potassium, Nizatidine, Vonoprazan, Amoxicillin, Lincomycin, Dirithromycin", "updated_at": 1767369485}, {"id": 68070, "ingredient1": "Clarithromycin", "ingredient2": "Voxelotor", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the systemic exposure (AUC) to voxelotor, which has been shown to be a substrate of this isoenzyme.", "source": "DDInter", "management_text": "The use of voxelotor with potent CYP450 3A4 inhibitors should generally be avoided. Alternative therapeutic agents with less inhibitory potential should be considered whenever possible. If coadministration is required, the manufacturer recommends reducing the voxelotor dose to 1000 mg once daily. Patients should be closely monitored for signs of voxelotor-related adverse effects, including headache, diarrhea, abdominal pain, nausea, and vomiting.", "mechanism_text": "Metabolism", "recommendation": "The use of voxelotor with potent CYP450 3A4 inhibitors should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68157/", "reference_text": "[1] \"Product Information. Oxbryta (voxelotor).\" Global Blood Therapeutics, Inc., South San Francisco, CA.[2] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[3] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[4] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[5] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[6] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[7] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[8] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[9] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[10] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[11] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[12] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[13] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[14] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[15] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[16] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[17] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[18] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[19] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[20] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[21] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[22] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[23] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[24] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[25] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[26] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[27] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[28] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[29] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[30] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[31] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[32] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[33] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31", "alternatives_a": "Pantoprazole, Levofloxacin, Tetracycline, Rabeprazole, Dexlansoprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Famotidine, Cimetidine, More", "alternatives_b": "Hemin, Conestat alfa, Betibeglogene autotemcel, Hyaluronidase, Streptokinase, Human C1-esterase inhibitor, Crizanlizumab, Lanadelumab, Icatibant", "updated_at": 1767369485}, {"id": 68071, "ingredient1": "Clarithromycin", "ingredient2": "Warfarin", "severity": "Major", "effect": "Coadministration with clarithromycin or erythromycin may infrequently but substantially enhance the hypoprothrombinemic effect of warfarin and other coumarin anticoagulants. The exact mechanism of interaction is unknown. Data from clinical studies have not supported a significant, predictable pharmacodynamic or pharmacokinetic interaction in general. Although both macrolides are potent inhibitors of CYP450 3A4 and can inhibit metabolism of the R(+) enantiomer of warfarin, the overall effect on racemic warfarin pharmacokinetics appears to be minor.", "source": "DDInter", "management_text": "Given the potential for clinically significant interaction and even fatality in the occasional, susceptible patient, close monitoring is recommended if clarithromycin or erythromycin is prescribed during coumarin anticoagulant therapy. The INR should be checked frequently and coumarin dosage adjusted accordingly, particularly following initiation or discontinuation of macrolide therapy in patients who are stabilized on their anticoagulant regimen. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools. The same precaution may be applicable during therapy with other oral anticoagulants (e.g., indandiones) and other similar macrolides (e.g., troleandomycin), although clinical data are lacking.", "mechanism_text": "Metabolism", "recommendation": "Given the potential for clinically significant interaction and even fatality in the occasional, susceptible patient, close monitoring is recommended if clarithromycin or erythromycin is prescribed during coumarin anticoagulant therapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68158/", "reference_text": "[1] O'Donnell D \"Antibiotic-induced potentiation of oral anticoagulant agents.\" Med J Aust 150 (1989): 163-4[2] Hassell D, Utt JK \"Suspected interaction: warfarin and erythromycin.\" South Med J 78 (1985): 1015-6[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Grau E, Real E, Pastor E \"Interaction between clarithromycin and oral anticoagulants.\" Ann Pharmacother 30 (1996): 1495-6[5] Kiran N, Azam S, Dhakam S \"Clarithromycin induced digoxin toxicity: case report and review.\" J Pak Med Assoc 54 (2004): 440-1[6] Gooderham MJ, Bolli P, Fernandez PG \"Concomitant digoxin toxicity and warfarin interaction in a patient receiving clarithromycin.\" Ann Pharmacother 33 (1999): 796-9[7] Schwartz J, Bachmann K, Perrigo E \"Interaction between warfarin and erythromycin.\" South Med J 76 (1983): 91-3[8] Visser LE, Penning-Van Bees FJ, Harrie Kasbergen AA, et al. \"Overanticoagulation associated with combined use of antibacterial drugs and acenocoumarol or phenprocoumon anticoagulants.\" Thromb Haemost 88 (2002): 705-10[9] Bartle WR \"Possible warfarin-erythromycin interaction.\" Arch Intern Med 140 (1980): 985-7[10] Grau E, Fontcuberta J, Felez J \"Erythromycin-oral anticoagulants interaction.\" Arch Intern Med 146 (1986): 1639[11] Recker MW, Kier KL \"Potential interaction between clarithromycin and warfarin.\" Ann Pharmacother 31 (1997): 996-8[12] Sato RI, Gray DR, Brown SE \"Warfarin interaction with erythromycin.\" Arch Intern Med 144 (1984): 2413-4[13] Weibert RT, Lorentz SM, Townsend RJ, et al \"Effect of erythromycin in patients receiving long-term warfarin therapy.\" Clin Pharm 8 (1989): 210-4[14] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994): 676-83[15] Husserl FE \"Erythromycin-warfarin interaction.\" Arch Intern Med 143 (1983): 1831, 1836[16] Ansell J, Hirsh J, Poller L, Bussey H, Jacobson A, Hylek E \"The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.\" Chest 126(3 Suppl) (2004): 204S-233S[17] Loeliger EA, van der Esch B, Mattern MJ, Hemker HC \"The biological disappearance rate of prothrombin, factors VII, IX and X from plasma in hypothyroidism, hyperthyroidism, and during fever.\" Thromb Diath Haemorrh 10 (1963): 267-77[18] Bachmann K, Schwartz JI, Forney R Jr, Frogameni A, Jauregui LE \"The effect of erythromycin on the disposition kinetics of warfarin.\" Pharmacology 28 (1984): 171-6[19] Bodiford AB, Kessler FO, Fermo JD, Ragucci KR \"Elevated international normalized ratio with the consumption of grapefruit and use of warfarin.\" SAGE Open Med Case Rep 0 (2013): 1-3[20] Guo LQ, Yamazoe Y \"Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines.\" Acta Pharmacol Sin 25 (2004): 129-36[21] Kempin SJ \"Warfarin resistance caused by broccoli.\" N Engl J Med 308 (1983): 1229-30[22] Lee M, Schwartz RN, Sharifi R \"Warfarin resistance and vitamin K.\" Ann Intern Med 94 (1981): 140-1[23] Brandin H, Myrberg O, Rundlof T, Arvidsson AK, Brenning G \"Adverse effects by artificial grapefruit seed extract products in patients on warfarin therapy.\" Eur J Clin Pharmacol 63 (2007): 565-70[24] Sullivan DM, Ford MA, Boyden TW \"Grapefruit juice and the response to warfarin.\" Am J Health Syst Pharm 55 (1998): 1581-3[25] Harrell CC, Kline SS \"Vitamin K-supplemented snacks containing olestra: Implication for patients taking warfarin.\" Jama J Am Med Assn 282 (1999): 1133-4[26] Grant P \"Warfarin and cranberry juice: an interaction?\" J Heart Valve Dis 13 (2004): 25-6[27] Kazmier FJ, Spittell JA Jr \"Coumarin drug interactions.\" Mayo Clin Proc 45 (1970): 249-55[28] Ge B, Zhang Z, Zuo Z \"Updates on the clinical evidenced herb-warfarin interactions.\" Evid Based Complement Alternat Med 2014 (2014): 957362[29] Kuykendall JR, Houle MD, Rhodes RS \"Possible warfarin failure due to interaction with smokeless tobacco.\" Ann Pharmacother 38 (2004): 595-7[30] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[31] Zallman JA, Lee DP, Jeffrey PL \"Liquid nutrition as a cause of warfarin resistance.\" Am J Hosp Pharm 38 (1981): 1174[32] Watson AJ, Pegg M, Green JR \"Enteral feeds may antagonise warfarin.\" Br Med J 288 (1984): 557[33] Monterrey-Rodriguez J \"Interaction between warfarin and mango fruit.\" Ann Pharmacother 36 (2002): 940-1[34] MHRA. Mediciines and Healthcare products Regulatory Agency. Committee on Safety of Medicines \"Possible interaction between warfarin and cranberry juice. Available from: URL: http://medicines.mhra.gov.uk/ourwork/monitorsafequalmed/currentproblems/currentproblems.htm.\" ([2003 Sept]):[35] Karlson B, Leijd B, Hellstrom K \"On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment.\" Acta Med Scand 220 (1986): 347-50[36] Griffiths AP, Beddall A, Pegler S \"Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin.\" J R Soc Health 128 (2008): 324-6[37] Roberts D, Flanagan P \"Case report: Cranberry juice and warfarin.\" Home Healthc Nurse 29 (2011): 92-7[38] O'Reilly RA, Rytand DA \"\"Resistance\" to warfarin due to unrecognized vitamin K supplementation.\" N Engl J Med 303 (1980): 160-1[39] Parr MD, Record KE, Griffith GL, et al \"Effect of enteral nutrition on warfarin therapy.\" Clin Pharm 1 (1982): 274-6[40] Andersen P, Godal HC \"Predictable reduction in anticoagulant activity of warfarin by small amounts of vitamin K.\" Acta Med Scand 198 (1975): 269-70[41] Cambria-Kiely JA \"Effect of soy milk on warfarin efficacy.\" Ann Pharmacother 36 (2002): 1893-6[42] Howard PA, Hannaman KN \"Warfarin resistance linked to enteral nutrition products.\" J Am Diet Assoc 85 (1985): 713-5[43] Rindone JP, Murphy TW \"Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding.\" Am J Ther 13 (2006): 283-4[44] Suvarna R, Pirmohamed M, Henderson L \"Possible interaction between warfarin and cranberry juice.\" BMJ 327 (2003): 1454[45] Beckey NP, Korman LB, Parra D \"Effect of the moderate consumption of olestra in patients receiving long-term warfarin therapy.\" Pharmacotherapy 19 (1999): 1075-9[46] Westfall LK \"An unrecognized cause of warfarin resistance.\" Drug Intell Clin Pharm 15 (1981): 131[47] Walker FB \"Myocardial infarction after diet-induced warfarin resistance.\" Arch Intern Med 144 (1984): 2089-90[48] Pedersen FM, Hamberg O, Hess K, Ovesen L \"The effect of dietary vitamin K on warfarin-induced anticoagulation.\" J Intern Med 229 (1991): 517-20[49] Griffith LD, Olvey SE, Triplett WC \"Increasing prothrombin times in a warfarin-treated patient upon withdrawal of ensure plus.\" Crit Care Med 10 (1982): 799-800[50] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994): 676-83[51] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[52] Chow WH, Chow TC, Tse TM, Tai YT, Lee WT \"Anticoagulation instability with life-threatening complication after dietary modification.\" Postgrad Med J 66 (1990): 855-7[53] Hamann GL, Campbell JD, George CM \"Warfarin-cranberry juice interaction.\" Ann Pharmacother 45 (2011): e17[54] MacLeod SM, Sellers EM \"Pharmacodynamic and pharmacokinetic drug interactions with coumarin anticoagulants.\" Drugs 11 (1976): 461-70[55] Jarvis S, Li C, Bogle RG \"Possible interaction between pomegranate juice and warfarin.\" Emerg Med J 27 (2010): 74-5", "alternatives_a": "Iloprost, Lepirudin, Urokinase, Cangrelor, Caplacizumab, Argatroban, Prasugrel, Desirudin, Eptifibatide, Streptokinase, Tinzaparin, More", "alternatives_b": "Vonoprazan, Bismuth subcitrate potassium, Dirithromycin", "updated_at": 1767369485}, {"id": 68072, "ingredient1": "Clarithromycin", "ingredient2": "Zanubrutinib", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of zanubrutinib, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "The manufacturer recommends reducing the dosage of zanubrutinib to 80 mg once daily when coadministered with potent CYP450 3A4 inhibitors. Patients should be closely monitored for development of zanubrutinib-related toxicities, and further dosage adjustments made or treatment withheld as needed in accordance with the product labeling. Following discontinuation of the CYP450 3A4 inhibitor, the previous dosage of zanubrutinib should be resumed.", "mechanism_text": "Metabolism", "recommendation": "The manufacturer recommends reducing the dosage of zanubrutinib to 80 mg once daily when coadministered with potent CYP450 3A4 inhibitors.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68159/", "reference_text": "[1] \"Product Information. Brukinsa (zanubrutinib).\" BeiGene USA, Inc, San Mateo, CA.[2] \"Product Information. Brukinsa (zanubrutinib).\" BeiGene USA, Inc, San Mateo, CA.", "alternatives_a": "Tinidazole, Pantoprazole, Levofloxacin, Dexlansoprazole, Rabeprazole, Sucralfate, Tetracycline, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Famotidine, More", "alternatives_b": "Alpelisib, Trametinib, Dacomitinib, Tivozanib, Alectinib", "updated_at": 1767369485}, {"id": 68073, "ingredient1": "Clarithromycin", "ingredient2": "Ziprasidone", "severity": "Major", "effect": "Ziprasidone can cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Excessive parasympatholytic effects may include paralytic ileus, hyperthermia, mydriasis, blurred vision, tachycardia, urinary retention, psychosis, and seizures.", "source": "DDInter", "management_text": "Coadministration of ziprasidone with other drugs that can prolong the QT interval is considered contraindicated.", "mechanism_text": "Synergism", "recommendation": "Coadministration of ziprasidone with other drugs that can prolong the QT interval is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68160/", "reference_text": "[1] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Geodon (ziprasidone).\" Pfizer US Pharmaceuticals, New York, NY.[4] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Glassman AH, Bigger JT Jr \"Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death.\" Am J Psychiatry 158 (2001): 1774-82[7] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[8] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[9] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[10] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Loxapine, Molindone, Thiothixene", "alternatives_b": "Tinidazole, Tetracycline, Dexlansoprazole, Misoprostol, Bismuth subcitrate potassium, Nizatidine, Esomeprazole, Amoxicillin, Dirithromycin, Lincomycin, Clindamycin", "updated_at": 1767369485}, {"id": 68074, "ingredient1": "Clarithromycin", "ingredient2": "Zolpidem", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of zolpidem, which is partially metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Caution is advised when zolpidem is used with CYP450 3A4 inhibitors. Patients should be advised to avoid driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until they know how the medications affect them, and to notify their physician if they experience excessive somnolence or dizziness.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when zolpidem is used with CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68161/", "reference_text": "[1] Luurila H, Kivisto KT, Neuvonen PJ \"Effect of itraconazole on the pharmacokinetics and pharmacodynamics of zolpidem.\" Eur J Clin Pharmacol 54 (1998): 163-6[2] Greenblatt DJ, vonMoltke LL, Harmatz JS, Mertzanis P, Graf JA, Durol ALB, Counihan M, RothSchechter B, Shader RI \"Kinetic and dynamic interaction study of zolpidem with ketoconazole, itraconazole, and fluconazole.\" Clin Pharmacol Ther 64 (1998): 661-71[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Greenblatt DJ, von Moltke LL, Harmatz JS, et al. \"Differential impairment of triazolam and zolpidem clearance by ritonavir.\" J Acquir Immune Defic Syndr 24 (2000): 129-36[5] Saari TI, Laine K, Leino K, Valtonen M, Neuvonen PJ, Olkkola KT \"Effect of voriconazole on the pharmacokinetics and pharmacodynamics of zolpidem in healthy subjects.\" Br J Clin Pharmacol 63 (2007): 116-20[6] Farkas D, Volak L, Harmatz J, von Moltke L, Court M, Greenblatt D \"Short-term clarithromycin administration impairs clearance and enhances pharmacodynamic effects of trazodone but not of zolpidem.\" Clin Pharmacol Ther 85 (2009): 644-50[7] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical, Abbott Park, IL.[8] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[9] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.", "alternatives_a": "Methohexital, Methylphenobarbital, Pentobarbital, Dichloralphenazone, Valerian, Butabarbital, Secobarbital, Chloral hydrate, Paraldehyde, Ethchlorvynol, Amobarbital, More", "alternatives_b": "Tinidazole, Dexlansoprazole, Bismuth subcitrate potassium, Esomeprazole, Levofloxacin, Lincomycin, Dirithromycin", "updated_at": 1767369485}, {"id": 68075, "ingredient1": "Clarithromycin", "ingredient2": "Zonisamide", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of zonisamide, which is metabolized by the isoenzyme. While clinical data are lacking, the possibility of prolonged and/or increased pharmacologic effects of zonisamide should be considered.", "source": "DDInter", "management_text": "Dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy. Patients should be advised to notify their physician if they experience symptoms such as severe drowsiness, confusion, loss of coordination, depression, aphasia, decreased sweating, fever, loss of seizure control, or slow pulse.", "mechanism_text": "Metabolism", "recommendation": "Dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68162/", "reference_text": "[1] Nakasa H, Nakamura H, Ono S, Tsutsui M, Kiuchi M, Ohmori S, Kitada M \"Prediction of drug-drug interactions of zonisamide metabolism in humans from in vitro data.\" Eur J Clin Pharmacol 54 (1998): 177-83[2] \"Product Information. Zonegran (zonisamide)\" Elan Pharmaceuticals, S. San Francisco, CA.[3] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[4] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[5] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[6] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Tiagabine, Brivaracetam, Rufinamide, Methsuximide, Paramethadione, Fenfluramine, Eslicarbazepine, Phensuximide, Methylphenobarbital, Phenacemide, Primidone, More", "alternatives_b": "Tinidazole, Levofloxacin, Tetracycline, Dexlansoprazole, Misoprostol, Bismuth subcitrate potassium, Esomeprazole, Amoxicillin, Dirithromycin, Lincomycin, Azithromycin, Clindamycin", "updated_at": 1767369485}, {"id": 68076, "ingredient1": "Amoxapine", "ingredient2": "Clemastine", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination. Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome. Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation. Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures. Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked. Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68163/", "reference_text": "[1] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82[2] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978): 1097-100[3] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967): 1112-3[4] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973): 348-50[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965): 749-56[6] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986): 571[7] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970): 1787-90[8] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994): 619-20[9] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986): 339-41[10] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983): 174-8[12] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983): 957-9[13] \"Product Information. Cogentin (benztropine).\" Merck & Co, Inc, West Point, PA.[14] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981): 313-7[15] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978): 243-4[16] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[17] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[18] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[19] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Lidocaine, Tetracaine, Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine", "alternatives_b": "Vilazodone, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Bupropion", "updated_at": 1767369485}, {"id": 68077, "ingredient1": "Clemastine", "ingredient2": "Azatadine", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination. Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome. Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation. Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures. Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked. Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68164/", "reference_text": "[1] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82[2] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978): 1097-100[3] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967): 1112-3[4] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973): 348-50[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965): 749-56[6] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986): 571[7] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970): 1787-90[8] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994): 619-20[9] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986): 339-41[10] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983): 174-8[12] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983): 957-9[13] \"Product Information. Cogentin (benztropine).\" Merck & Co, Inc, West Point, PA.[14] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981): 313-7[15] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978): 243-4[16] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[17] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[18] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[19] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Tripelennamine, Lidocaine, Tetracaine, Methdilazine, Azatadine, Ketotifen, Alimemazine, Fexofenadine, Loratadine, Phenindamine, Desloratadine, More", "alternatives_b": "Clemastine, Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole", "updated_at": 1767369485}, {"id": 68078, "ingredient1": "Clemastine", "ingredient2": "Belladonna", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination. Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome. Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation. Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures. Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked. Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68165/", "reference_text": "[1] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82[2] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978): 1097-100[3] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967): 1112-3[4] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973): 348-50[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965): 749-56[6] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986): 571[7] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970): 1787-90[8] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994): 619-20[9] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986): 339-41[10] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983): 174-8[12] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983): 957-9[13] \"Product Information. Cogentin (benztropine).\" Merck & Co, Inc, West Point, PA.[14] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981): 313-7[15] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978): 243-4[16] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[17] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[18] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[19] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Lidocaine, Tetracaine, Ketotifen, Levocetirizine, Cetirizine, Fexofenadine, Loratadine, Trimethobenzamide, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68079, "ingredient1": "Clemastine", "ingredient2": "Butabarbital", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68166/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Nitrazepam, Zopiclone", "alternatives_b": "Tetracaine, Pheniramine, Ketotifen, Chlorcyclizine, Azelastine, Fexofenadine, Dexchlorpheniramine, Loratadine, Phenindamine, Astemizole, Desloratadine, More", "updated_at": 1767369485}, {"id": 68080, "ingredient1": "Clemastine", "ingredient2": "Candida albicans", "severity": "Moderate", "effect": "INTERVAL: Antihistamines may diminish the response to diagnostic skin test antigens. Falsely insignificant or false-negative results may occur in such patients.", "source": "DDInter", "management_text": "Antihistamines should be discontinued approximately 2 to 4 days prior to skin testing procedures.", "mechanism_text": "Others", "recommendation": "Antihistamines should be discontinued approximately 2 to 4 days prior to skin testing procedures.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68167/", "reference_text": "[1] \"Multum Information Services, Inc. Expert Review Panel\"[2] NLM. National Library of Medicine. NIH. National Institutes of Health \"Trichophyton for intradermal skin testing (trichophyton mentagrophytes and trichophyton rubrum) injection [Allermed Laboratories, Inc.] Available from: URL: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=aaeffe62-b538-43ca-a3b9-47e28b765d89\" ([cited 2014]):[3] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[4] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[5] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[6] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Tripelennamine, Lidocaine, Tetracaine, Doxepin, Methdilazine, Azatadine, Ketotifen, Doxylamine, Meclizine, Dimenhydrinate, Alimemazine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68081, "ingredient1": "Clemastine", "ingredient2": "Pentoxyverine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68168/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Lidocaine, Tetracaine, Ketotifen, Levocetirizine, Chlorcyclizine, Cetirizine, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "Benzonatate", "updated_at": 1767369485}, {"id": 68082, "ingredient1": "Clofedanol", "ingredient2": "Clemastine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68169/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Lidocaine, Tetracaine, Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "Benzonatate", "updated_at": 1767369485}, {"id": 68083, "ingredient1": "Clemastine", "ingredient2": "Chloral hydrate", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68170/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Tripelennamine, Lidocaine, Tetracaine, Methdilazine, Azatadine, Ketotifen, Alimemazine, Chlorcyclizine, Fexofenadine, Loratadine, Phenindamine, More", "alternatives_b": "Nitrazepam, Zopiclone", "updated_at": 1767369485}, {"id": 68084, "ingredient1": "Clemastine", "ingredient2": "Chlorcyclizine", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination. Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome. Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation. Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures. Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked. Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68171/", "reference_text": "[1] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82[2] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978): 1097-100[3] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967): 1112-3[4] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973): 348-50[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965): 749-56[6] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986): 571[7] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970): 1787-90[8] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994): 619-20[9] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986): 339-41[10] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983): 174-8[12] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983): 957-9[13] \"Product Information. Cogentin (benztropine).\" Merck & Co, Inc, West Point, PA.[14] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981): 313-7[15] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978): 243-4[16] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[17] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[18] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[19] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Lidocaine, Tetracaine, Ketotifen, Chlorcyclizine, Fexofenadine, Loratadine, Trimethobenzamide, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "Clemastine, Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole", "updated_at": 1767369485}, {"id": 68085, "ingredient1": "Clemastine", "ingredient2": "Chlormezanone", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68172/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Lidocaine, Tetracaine, Pheniramine, Tripelennamine, Doxepin, Methdilazine, Azatadine, Ketotifen, Alimemazine, Chlorcyclizine, Fexofenadine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68086, "ingredient1": "Clemastine", "ingredient2": "Chlorphenesin", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68173/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Tripelennamine, Lidocaine, Tetracaine, Pheniramine, Methdilazine, Azatadine, Ketotifen, Alimemazine, Chlorcyclizine, Fexofenadine, Thiethylperazine, More", "alternatives_b": "Salicylic acid, Fluconazole, Selenium Sulfide, Thiabendazole, Miconazole, Nystatin, Ciclopirox, Griseofulvin, Ketoconazole, Terbinafine, Econazole, More", "updated_at": 1767369485}, {"id": 68087, "ingredient1": "Clemastine", "ingredient2": "Chlorpromazine", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination. Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome. Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation. Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures. Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked. Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68174/", "reference_text": "[1] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82[2] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978): 1097-100[3] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967): 1112-3[4] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973): 348-50[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965): 749-56[6] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986): 571[7] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970): 1787-90[8] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994): 619-20[9] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986): 339-41[10] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983): 174-8[12] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983): 957-9[13] \"Product Information. Cogentin (benztropine).\" Merck & Co, Inc, West Point, PA.[14] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981): 313-7[15] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978): 243-4[16] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[17] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[18] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[19] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Tetracaine, Azelastine, Ketotifen, Desloratadine, Fexofenadine", "alternatives_b": "Amisulpride, Pimavanserin", "updated_at": 1767369485}, {"id": 68088, "ingredient1": "Clidinium", "ingredient2": "Clemastine", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination. Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome. Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation. Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures. Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked. Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68175/", "reference_text": "[1] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82[2] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978): 1097-100[3] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967): 1112-3[4] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973): 348-50[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965): 749-56[6] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986): 571[7] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970): 1787-90[8] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994): 619-20[9] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986): 339-41[10] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983): 174-8[12] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983): 957-9[13] \"Product Information. Cogentin (benztropine).\" Merck & Co, Inc, West Point, PA.[14] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981): 313-7[15] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978): 243-4[16] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[17] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[18] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[19] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Lidocaine, Tetracaine, Ketotifen, Levocetirizine, Cetirizine, Fexofenadine, Loratadine, Trimethobenzamide, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68089, "ingredient1": "Clobazam", "ingredient2": "Clemastine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68176/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68090, "ingredient1": "Clomipramine", "ingredient2": "Clemastine", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination. Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome. Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation. Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures. Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked. Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68177/", "reference_text": "[1] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82[2] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978): 1097-100[3] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967): 1112-3[4] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973): 348-50[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965): 749-56[6] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986): 571[7] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970): 1787-90[8] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994): 619-20[9] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986): 339-41[10] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983): 174-8[12] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983): 957-9[13] \"Product Information. Cogentin (benztropine).\" Merck & Co, Inc, West Point, PA.[14] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981): 313-7[15] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978): 243-4[16] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[17] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[18] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[19] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Lidocaine, Tetracaine, Azelastine, Ketotifen, Loratadine", "alternatives_b": "Vilazodone, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Bupropion", "updated_at": 1767369485}, {"id": 68091, "ingredient1": "Clonazepam", "ingredient2": "Clemastine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68178/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Pheniramine, Ketotifen, Dexchlorpheniramine, Astemizole, Azelastine, Terfenadine, Pheniramine", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 68092, "ingredient1": "Clonidine", "ingredient2": "Clemastine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68179/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Tetracaine, Pheniramine, Ketotifen, Dexchlorpheniramine, Astemizole, Azelastine, Terfenadine, Pheniramine", "alternatives_b": "Latanoprost, Methazolamide, Neostigmine, Pilocarpine, Betaxolol, Diclofenamide, Bimatoprost, Travoprost, Carteolol, Brinzolamide, Acetazolamide, More", "updated_at": 1767369485}, {"id": 68093, "ingredient1": "Clorazepic acid", "ingredient2": "Clemastine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68180/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68094, "ingredient1": "Clozapine", "ingredient2": "Clemastine", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination. Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome. Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation. Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures. Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked. Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68181/", "reference_text": "[1] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82[2] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978): 1097-100[3] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967): 1112-3[4] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973): 348-50[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965): 749-56[6] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986): 571[7] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970): 1787-90[8] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994): 619-20[9] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986): 339-41[10] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983): 174-8[12] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983): 957-9[13] \"Product Information. Cogentin (benztropine).\" Merck & Co, Inc, West Point, PA.[14] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981): 313-7[15] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978): 243-4[16] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[17] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[18] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[19] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Lidocaine, Tetracaine, Azelastine, Ketotifen", "alternatives_b": "Amisulpride, Pimavanserin", "updated_at": 1767369485}, {"id": 68095, "ingredient1": "Coccidioides immitis spherule", "ingredient2": "Clemastine", "severity": "Moderate", "effect": "INTERVAL: Antihistamines may diminish the response to diagnostic skin test antigens. Falsely insignificant or false-negative results may occur in such patients.", "source": "DDInter", "management_text": "Antihistamines should be discontinued approximately 2 to 4 days prior to skin testing procedures.", "mechanism_text": "Others", "recommendation": "Antihistamines should be discontinued approximately 2 to 4 days prior to skin testing procedures.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68182/", "reference_text": "[1] \"Multum Information Services, Inc. Expert Review Panel\"[2] NLM. National Library of Medicine. NIH. National Institutes of Health \"Trichophyton for intradermal skin testing (trichophyton mentagrophytes and trichophyton rubrum) injection [Allermed Laboratories, Inc.] Available from: URL: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=aaeffe62-b538-43ca-a3b9-47e28b765d89\" ([cited 2014]):[3] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[4] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[5] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[6] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Tripelennamine, Lidocaine, Tetracaine, Doxepin, Methdilazine, Azatadine, Ketotifen, Doxylamine, Meclizine, Dimenhydrinate, Alimemazine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68096, "ingredient1": "Cyclizine", "ingredient2": "Clemastine", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination. Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome. Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation. Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures. Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked. Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68183/", "reference_text": "[1] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82[2] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978): 1097-100[3] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967): 1112-3[4] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973): 348-50[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965): 749-56[6] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986): 571[7] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970): 1787-90[8] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994): 619-20[9] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986): 339-41[10] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983): 174-8[12] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983): 957-9[13] \"Product Information. Cogentin (benztropine).\" Merck & Co, Inc, West Point, PA.[14] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981): 313-7[15] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978): 243-4[16] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[17] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[18] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[19] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Tripelennamine, Lidocaine, Tetracaine, Methdilazine, Azatadine, Ketotifen, Alimemazine, Fexofenadine, Loratadine, Phenindamine, Desloratadine, More", "alternatives_b": "Clemastine, Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole", "updated_at": 1767369485}, {"id": 68097, "ingredient1": "Cyclobenzaprine", "ingredient2": "Clemastine", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination. Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome. Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation. Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures. Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked. Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68184/", "reference_text": "[1] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82[2] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978): 1097-100[3] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967): 1112-3[4] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973): 348-50[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965): 749-56[6] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986): 571[7] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970): 1787-90[8] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994): 619-20[9] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986): 339-41[10] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983): 174-8[12] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983): 957-9[13] \"Product Information. Cogentin (benztropine).\" Merck & Co, Inc, West Point, PA.[14] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981): 313-7[15] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978): 243-4[16] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[17] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[18] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[19] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Tetracaine, Azelastine, Ketotifen, Terfenadine, Astemizole", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68098, "ingredient1": "Cyproheptadine", "ingredient2": "Clemastine", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination. Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome. Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation. Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures. Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked. Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68185/", "reference_text": "[1] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82[2] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978): 1097-100[3] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967): 1112-3[4] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973): 348-50[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965): 749-56[6] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986): 571[7] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970): 1787-90[8] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994): 619-20[9] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986): 339-41[10] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983): 174-8[12] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983): 957-9[13] \"Product Information. Cogentin (benztropine).\" Merck & Co, Inc, West Point, PA.[14] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981): 313-7[15] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978): 243-4[16] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[17] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[18] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[19] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Lidocaine, Tetracaine, Ketotifen, Fexofenadine, Cyproheptadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "Clemastine, Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole", "updated_at": 1767369485}, {"id": 68099, "ingredient1": "Dantrolene", "ingredient2": "Clemastine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68186/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Lidocaine, Tetracaine, Pheniramine, Methdilazine, Ketotifen, Chlorcyclizine, Fexofenadine, Thiethylperazine, Loratadine, Phenindamine, Astemizole, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68100, "ingredient1": "Darifenacin", "ingredient2": "Clemastine", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination. Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome. Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation. Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures. Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked. Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68187/", "reference_text": "[1] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82[2] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978): 1097-100[3] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967): 1112-3[4] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973): 348-50[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965): 749-56[6] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986): 571[7] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970): 1787-90[8] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994): 619-20[9] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986): 339-41[10] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983): 174-8[12] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983): 957-9[13] \"Product Information. Cogentin (benztropine).\" Merck & Co, Inc, West Point, PA.[14] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981): 313-7[15] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978): 243-4[16] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[17] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[18] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[19] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Lidocaine, Tetracaine, Ketotifen, Levocetirizine, Trimethobenzamide, Azelastine, Terfenadine, Astemizole", "alternatives_b": "Pentosan polysulfate, Calcium chloride, Phenazopyridine, Sildenafil, Mirabegron, Alprostadil, Acetohydroxamic acid, Yohimbine, Avanafil, Papaverine, Vardenafil, More", "updated_at": 1767369485}, {"id": 68101, "ingredient1": "Demecarium (ophthalmic)", "ingredient2": "Clemastine", "severity": "Moderate", "effect": "Theoretically, anticholinergic agents and other agents with significant anticholinergic activity (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, class IA antiarrhythmics especially disopyramide) may antagonize the effects of topically administered cholinergic agents such as acetylcholine, carbachol, demecarium, echothiophate, isoflurophate, physostigmine, and pilocarpine. The proposed mechanism involves opposing pharmacodynamic action on muscarinic receptor sites in ocular tissue. This interaction is sometimes desirable and is the basis for using atropine in the treatment of excessive muscarinic side effects and cholinergic crisis induced by cholinergic overdose.", "source": "DDInter", "management_text": "Patients receiving long-term therapy with anticholinergic agents should be monitored for potentially diminished therapeutic (miotic) response to ophthalmic cholinergic therapy, and dosages adjusted as necessary.", "mechanism_text": "Antagonism", "recommendation": "Patients receiving long-term therapy with anticholinergic agents should be monitored for potentially diminished therapeutic (miotic) response to ophthalmic cholinergic therapy, and dosages adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68188/", "reference_text": "[1] \"Product Information. Pilopine HS (pilocarpine ophthalmic).\" Alcon Laboratories Inc, Fort Worth, TX.[2] \"Multum Information Services, Inc. Expert Review Panel\"", "alternatives_a": "Tripelennamine, Lidocaine, Tetracaine, Methdilazine, Azatadine, Ketotifen, Alimemazine, Levocetirizine, Cetirizine, Fexofenadine, Loratadine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68102, "ingredient1": "Desipramine", "ingredient2": "Clemastine", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination. Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome. Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation. Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures. Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked. Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68189/", "reference_text": "[1] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82[2] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978): 1097-100[3] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967): 1112-3[4] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973): 348-50[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965): 749-56[6] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986): 571[7] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970): 1787-90[8] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994): 619-20[9] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986): 339-41[10] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983): 174-8[12] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983): 957-9[13] \"Product Information. Cogentin (benztropine).\" Merck & Co, Inc, West Point, PA.[14] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981): 313-7[15] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978): 243-4[16] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[17] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[18] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[19] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Lidocaine, Tetracaine, Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine", "alternatives_b": "Vilazodone, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Bupropion", "updated_at": 1767369485}, {"id": 68103, "ingredient1": "Desvenlafaxine", "ingredient2": "Clemastine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68190/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Lidocaine, Tetracaine, Ketotifen, Chlorcyclizine, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "Vilazodone, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Bupropion", "updated_at": 1767369485}, {"id": 68104, "ingredient1": "Deutetrabenazine", "ingredient2": "Clemastine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68191/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Lidocaine, Tetracaine, Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine", "alternatives_b": "Dalfampridine, Riluzole, Inotersen, Amifampridine, Tafamidis", "updated_at": 1767369485}, {"id": 68105, "ingredient1": "Dexbrompheniramine", "ingredient2": "Clemastine", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination. Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome. Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation. Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures. Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked. Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68192/", "reference_text": "[1] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82[2] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978): 1097-100[3] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967): 1112-3[4] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973): 348-50[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965): 749-56[6] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986): 571[7] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970): 1787-90[8] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994): 619-20[9] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986): 339-41[10] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983): 174-8[12] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983): 957-9[13] \"Product Information. Cogentin (benztropine).\" Merck & Co, Inc, West Point, PA.[14] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981): 313-7[15] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978): 243-4[16] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[17] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[18] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[19] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Lidocaine, Tetracaine, Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine, Dexbrompheniramine, Terfenadine, Astemizole", "alternatives_b": "Clemastine, Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole", "updated_at": 1767369485}, {"id": 68106, "ingredient1": "Dexmedetomidine", "ingredient2": "Clemastine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68193/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Tetracaine, Ketotifen, Fexofenadine, Phenindamine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "Nitrazepam, Zopiclone", "updated_at": 1767369485}, {"id": 68107, "ingredient1": "Dezocine", "ingredient2": "Clemastine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68194/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Tripelennamine, Lidocaine, Tetracaine, Methdilazine, Azatadine, Ketotifen, Alimemazine, Fexofenadine, Loratadine, Phenindamine, Desloratadine, More", "alternatives_b": "Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "updated_at": 1767369485}, {"id": 68108, "ingredient1": "Diazepam", "ingredient2": "Clemastine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68195/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Pheniramine, Ketotifen, Dexchlorpheniramine, Astemizole, Azelastine, Terfenadine, Pheniramine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68109, "ingredient1": "Dicyclomine", "ingredient2": "Clemastine", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination. Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome. Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation. Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures. Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked. Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68196/", "reference_text": "[1] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82[2] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978): 1097-100[3] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967): 1112-3[4] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973): 348-50[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965): 749-56[6] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986): 571[7] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970): 1787-90[8] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994): 619-20[9] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986): 339-41[10] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983): 174-8[12] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983): 957-9[13] \"Product Information. Cogentin (benztropine).\" Merck & Co, Inc, West Point, PA.[14] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981): 313-7[15] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978): 243-4[16] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[17] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[18] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[19] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Tetracaine, Ketotifen, Levocetirizine, Trimethobenzamide, Azelastine, Terfenadine, Astemizole", "alternatives_b": "Papaverine, Alosetron, Isometheptene", "updated_at": 1767369485}, {"id": 68110, "ingredient1": "Dimenhydrinate", "ingredient2": "Clemastine", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination. Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome. Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation. Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures. Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked. Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68197/", "reference_text": "[1] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82[2] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978): 1097-100[3] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967): 1112-3[4] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973): 348-50[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965): 749-56[6] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986): 571[7] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970): 1787-90[8] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994): 619-20[9] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986): 339-41[10] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983): 174-8[12] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983): 957-9[13] \"Product Information. Cogentin (benztropine).\" Merck & Co, Inc, West Point, PA.[14] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981): 313-7[15] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978): 243-4[16] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[17] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[18] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[19] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Lidocaine, Tetracaine, Ketotifen, Dimenhydrinate, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "Clemastine, Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole", "updated_at": 1767369485}, {"id": 68111, "ingredient1": "Diphenhydramine", "ingredient2": "Clemastine", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination. Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome. Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation. Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures. Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked. Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68198/", "reference_text": "[1] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82[2] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978): 1097-100[3] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967): 1112-3[4] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973): 348-50[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965): 749-56[6] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986): 571[7] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970): 1787-90[8] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994): 619-20[9] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986): 339-41[10] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983): 174-8[12] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983): 957-9[13] \"Product Information. Cogentin (benztropine).\" Merck & Co, Inc, West Point, PA.[14] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981): 313-7[15] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978): 243-4[16] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[17] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[18] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[19] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Lidocaine, Tetracaine, Diphenhydramine, Ketotifen, Fexofenadine, Loratadine, Desloratadine, Diphenhydramine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "Lidocaine, Tetracaine, Clemastine, Clemastine, Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole", "updated_at": 1767369485}, {"id": 68112, "ingredient1": "Disopyramide", "ingredient2": "Clemastine", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination. Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome. Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation. Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures. Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked. Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68199/", "reference_text": "[1] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82[2] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978): 1097-100[3] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967): 1112-3[4] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973): 348-50[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965): 749-56[6] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986): 571[7] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970): 1787-90[8] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994): 619-20[9] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986): 339-41[10] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983): 174-8[12] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983): 957-9[13] \"Product Information. Cogentin (benztropine).\" Merck & Co, Inc, West Point, PA.[14] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981): 313-7[15] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978): 243-4[16] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[17] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[18] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[19] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Quinidine, Amiodarone, Dronedarone, Lidocaine, Propafenone, Procainamide, Tocainide, Flecainide, Mexiletine, Dofetilide, Bretylium, More", "alternatives_b": "Tetracaine, Ketotifen, Levocetirizine, Cetirizine, Fexofenadine, Loratadine, Trimethobenzamide, Desloratadine, Azelastine", "updated_at": 1767369485}, {"id": 68113, "ingredient1": "Clemastine", "ingredient2": "Valproic acid", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68200/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Tetracaine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 68114, "ingredient1": "Donepezil", "ingredient2": "Clemastine", "severity": "Moderate", "effect": "Due to opposing effects, agents that possess anticholinergic activity (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; class IA antiarrhythmics especially disopyramide; carbamazepine; cimetidine; ranitidine) may negate the already small pharmacologic benefits of acetylcholinesterase inhibitors in the treatment of dementia. These agents may also adversely affect elderly patients in general. Clinically significant mental status changes associated with anticholinergic agents can range from mild cognitive impairment to delirium, and patients with Alzheimer's disease and other dementia are especially sensitive.", "source": "DDInter", "management_text": "Drugs that possess anticholinergic activity should generally be avoided in patients with Alzheimer's disease or other cognitive impairment, regardless of whether they are receiving an acetylcholinesterase inhibitor. For patients requiring treatment to counteract adverse effects of acetylcholinesterase inhibitor therapy (e.g., gastrointestinal intolerance, urinary problems), an agent without anticholinergic properties should be used whenever possible. Otherwise, a dosage reduction, slower titration, or even discontinuation of the acetylcholinesterase inhibitor should be considered. For patients who are already receiving an acetylcholinesterase inhibitor with anticholinergic agents, every attempt should be made to discontinue the latter or substitute them with less anticholinergic alternatives.", "mechanism_text": "Antagonism", "recommendation": "Drugs that possess anticholinergic activity should generally be avoided in patients with Alzheimer's disease or other cognitive impairment, regardless of whether they are receiving an acetylcholinesterase inhibitor.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68201/", "reference_text": "[1] Katz IR, Sands LP, Bilker W, DiFilippo S, Boyce A, D'Angelo K \"Identification of medications that cause cognitive impairment in older people: the case of oxybutynin chloride.\" J Am Geriatr Soc 46 (1998): 8-13[2] Edwards KR, O'Connor JT \"Risk of delirium with concomitant use of tolterodine and acetylcholinesterase inhibitors.\" J Am Geriatr Soc 50 (2002): 1165-6[3] Carnahan RM, Lund BC, Perry PJ, Chrischilles EA \"The concurrent use of anticholinergics and cholinesterase inhibitors: rare event or common practice?\" J Am Geriatr Soc 52 (2004): 2082-7[4] Fick DM, Cooper JW, Wade WE, Waller JL, Maclean JR, Beers MH \"Updating the Beers criteria for potentially inappropriate medication use in older adults: results of a US consensus panel of experts.\" Arch Intern Med 163 (2003): 2716-2724[5] Beers MH, Ouslander JG, Rollingher I, Reuben DB, Brooks J, Beck JC \"Explicit criteria for determining inappropriate medication use in nursing home residents.\" Arch Intern Med 151 (1991): 1825-32[6] Roe CM, Anderson MJ, Spivack B \"Use of anticholinergic medications by older adults with dementia.\" J Am Geriatr Soc 50 (2002): 836-42", "alternatives_a": "Tetracaine, Levocetirizine, Azelastine, Ketotifen, Trimethobenzamide", "alternatives_b": "Ginkgo biloba, Aducanumab", "updated_at": 1767369485}, {"id": 68115, "ingredient1": "Doxepin", "ingredient2": "Clemastine", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination. Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome. Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation. Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures. Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked. Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68202/", "reference_text": "[1] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82[2] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978): 1097-100[3] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967): 1112-3[4] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973): 348-50[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965): 749-56[6] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986): 571[7] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970): 1787-90[8] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994): 619-20[9] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986): 339-41[10] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983): 174-8[12] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983): 957-9[13] \"Product Information. Cogentin (benztropine).\" Merck & Co, Inc, West Point, PA.[14] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981): 313-7[15] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978): 243-4[16] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[17] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[18] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[19] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Tetracaine, Doxepin, Azelastine", "alternatives_b": "Vilazodone, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Bupropion, Lidocaine, Tetracaine, Clemastine", "updated_at": 1767369485}, {"id": 68116, "ingredient1": "Doxepin (topical)", "ingredient2": "Clemastine", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination. Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome. Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation. Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures. Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked. Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68203/", "reference_text": "[1] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82[2] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978): 1097-100[3] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967): 1112-3[4] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973): 348-50[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965): 749-56[6] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986): 571[7] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970): 1787-90[8] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994): 619-20[9] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986): 339-41[10] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983): 174-8[12] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983): 957-9[13] \"Product Information. Cogentin (benztropine).\" Merck & Co, Inc, West Point, PA.[14] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981): 313-7[15] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978): 243-4[16] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[17] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[18] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[19] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Lidocaine, Tetracaine, Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "Vilazodone, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Bupropion, Lidocaine, Tetracaine, Clemastine", "updated_at": 1767369485}, {"id": 68117, "ingredient1": "Doxylamine", "ingredient2": "Clemastine", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination. Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome. Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation. Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures. Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked. Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68204/", "reference_text": "[1] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82[2] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978): 1097-100[3] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967): 1112-3[4] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973): 348-50[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965): 749-56[6] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986): 571[7] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970): 1787-90[8] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994): 619-20[9] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986): 339-41[10] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983): 174-8[12] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983): 957-9[13] \"Product Information. Cogentin (benztropine).\" Merck & Co, Inc, West Point, PA.[14] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981): 313-7[15] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978): 243-4[16] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[17] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[18] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[19] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Lidocaine, Tetracaine, Ketotifen, Fexofenadine, Loratadine, Desloratadine, Doxylamine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "Clemastine, Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole", "updated_at": 1767369485}, {"id": 68118, "ingredient1": "Dronabinol", "ingredient2": "Clemastine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68205/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Lidocaine, Tetracaine, Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "Granisetron, Rolapitant, Aprepitant, Dolasetron, Ondansetron, Palonosetron", "updated_at": 1767369485}, {"id": 68119, "ingredient1": "Droperidol", "ingredient2": "Clemastine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68206/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Tetracaine, Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine", "alternatives_b": "Amisulpride, Pimavanserin", "updated_at": 1767369485}, {"id": 68120, "ingredient1": "Duloxetine", "ingredient2": "Clemastine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68207/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Tripelennamine, Tetracaine, Ketotifen, Chlorcyclizine, Tripelennamine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "Vilazodone, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Bupropion", "updated_at": 1767369485}, {"id": 68121, "ingredient1": "Echothiophate (ophthalmic)", "ingredient2": "Clemastine", "severity": "Moderate", "effect": "Theoretically, anticholinergic agents and other agents with significant anticholinergic activity (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, class IA antiarrhythmics especially disopyramide) may antagonize the effects of topically administered cholinergic agents such as acetylcholine, carbachol, demecarium, echothiophate, isoflurophate, physostigmine, and pilocarpine. The proposed mechanism involves opposing pharmacodynamic action on muscarinic receptor sites in ocular tissue. This interaction is sometimes desirable and is the basis for using atropine in the treatment of excessive muscarinic side effects and cholinergic crisis induced by cholinergic overdose.", "source": "DDInter", "management_text": "Patients receiving long-term therapy with anticholinergic agents should be monitored for potentially diminished therapeutic (miotic) response to ophthalmic cholinergic therapy, and dosages adjusted as necessary.", "mechanism_text": "Antagonism", "recommendation": "Patients receiving long-term therapy with anticholinergic agents should be monitored for potentially diminished therapeutic (miotic) response to ophthalmic cholinergic therapy, and dosages adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68208/", "reference_text": "[1] \"Product Information. Pilopine HS (pilocarpine ophthalmic).\" Alcon Laboratories Inc, Fort Worth, TX.[2] \"Multum Information Services, Inc. Expert Review Panel\"", "alternatives_a": "Lidocaine, Tetracaine, Ketotifen, Levocetirizine, Cetirizine, Fexofenadine, Loratadine, Trimethobenzamide, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68122, "ingredient1": "Eluxadoline", "ingredient2": "Clemastine", "severity": "Moderate", "effect": "The risk of constipation and serious constipation-related adverse reactions may be increased when eluxadoline is used with other drugs that are also associated with this adverse effect.", "source": "DDInter", "management_text": "Concomitant use of eluxadoline with other drugs that can cause constipation such as alosetron, anticholinergics, and opioids should generally be avoided. Loperamide may be used occasionally for acute management of severe diarrhea, but chronic use is not recommended, and it should be discontinued immediately if constipation occurs. Eluxadoline should also be discontinued if constipation occurs for more than 4 days.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of eluxadoline with other drugs that can cause constipation such as alosetron, anticholinergics, and opioids should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68209/", "reference_text": "[1] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.", "alternatives_a": "Lidocaine, Tetracaine, Ketotifen, Levocetirizine, Cetirizine, Loratadine, Trimethobenzamide, Desloratadine, Azelastine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68123, "ingredient1": "Escitalopram", "ingredient2": "Clemastine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68210/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Lidocaine, Tetracaine, Ketotifen, Fexofenadine, Dexchlorpheniramine, Loratadine, Desloratadine, Azelastine", "alternatives_b": "Vilazodone, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Bupropion", "updated_at": 1767369485}, {"id": 68124, "ingredient1": "Esketamine", "ingredient2": "Clemastine", "severity": "Moderate", "effect": "Concomitant use of esketamine with central nervous system (CNS) depressants may increase sedation and impairment of attention, judgment, thinking, reaction speed, and psychomotor skills.", "source": "DDInter", "management_text": "Caution is advised and patients should be closely monitored during concomitant use of esketamine with CNS depressants. Due to the risk of delayed or prolonged sedation and other adverse effects, patients should be monitored for at least 2 hours after esketamine administration, followed by an assessment to determine when the patient is considered clinically stable and ready to leave the healthcare setting. Patients should be instructed not to engage in potentially hazardous activities, such as driving a motor vehicle or operating machinery, until the next day after a restful sleep.", "mechanism_text": "Synergism", "recommendation": "Caution is advised and patients should be closely monitored during concomitant use of esketamine with CNS depressants.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68211/", "reference_text": "[1] \"Product Information. Spravato (esketamine).\" Janssen Pharmaceuticals, Titusville, NJ.[2] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[3] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[4] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[5] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Lidocaine, Tetracaine, Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "Vilazodone, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Bupropion, Halothane, Isoflurane, Nitrous oxide, More", "updated_at": 1767369485}, {"id": 68125, "ingredient1": "Eslicarbazepine", "ingredient2": "Clemastine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68212/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Tetracaine, Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 68126, "ingredient1": "Estazolam", "ingredient2": "Clemastine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68213/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Pheniramine, Methdilazine, Ketotifen, Chlorcyclizine, Fexofenadine, Thiethylperazine, Phenindamine, Astemizole, Desloratadine, Azelastine, Terfenadine, Pheniramine", "alternatives_b": "Nitrazepam, Zopiclone", "updated_at": 1767369485}, {"id": 68127, "ingredient1": "Eszopiclone", "ingredient2": "Clemastine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68214/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Lidocaine, Tetracaine, Ketotifen, Chlorcyclizine, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "Nitrazepam, Zopiclone", "updated_at": 1767369485}, {"id": 68128, "ingredient1": "Ethchlorvynol", "ingredient2": "Clemastine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68215/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Nitrazepam, Zopiclone", "alternatives_b": "Lidocaine, Tetracaine, Tripelennamine, Pheniramine, Promethazine, Ketotifen, Chlorcyclizine, Triprolidine, Tripelennamine, Azelastine, Promethazine, More", "updated_at": 1767369485}, {"id": 68129, "ingredient1": "Ethosuximide", "ingredient2": "Clemastine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68216/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Lidocaine, Tetracaine, Pheniramine, Ketotifen, Fexofenadine, Loratadine, Astemizole, Desloratadine, Azelastine, Terfenadine, Pheniramine", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 68130, "ingredient1": "Ethotoin", "ingredient2": "Clemastine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68217/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Tetracaine, Pheniramine, Methdilazine, Ketotifen, Chlorcyclizine, Azelastine, Fexofenadine, Thiethylperazine, Dexchlorpheniramine, Loratadine, Phenindamine, More", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 68131, "ingredient1": "Ezogabine", "ingredient2": "Clemastine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68218/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Lidocaine, Tetracaine, Ketotifen, Azelastine, Fexofenadine, Thiethylperazine, Loratadine, Desloratadine, Methdilazine", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 68132, "ingredient1": "Felbamate", "ingredient2": "Clemastine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68219/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Tetracaine, Pheniramine, Methdilazine, Ketotifen, Chlorcyclizine, Fexofenadine, Thiethylperazine, Dexchlorpheniramine, Loratadine, Phenindamine, Astemizole, More", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 68133, "ingredient1": "Fesoterodine", "ingredient2": "Clemastine", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination. Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome. Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation. Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures. Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked. Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68220/", "reference_text": "[1] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82[2] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978): 1097-100[3] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967): 1112-3[4] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973): 348-50[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965): 749-56[6] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986): 571[7] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970): 1787-90[8] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994): 619-20[9] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986): 339-41[10] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983): 174-8[12] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983): 957-9[13] \"Product Information. Cogentin (benztropine).\" Merck & Co, Inc, West Point, PA.[14] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981): 313-7[15] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978): 243-4[16] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[17] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[18] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[19] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Lidocaine, Tetracaine, Ketotifen, Levocetirizine, Cetirizine, Fexofenadine, Loratadine, Trimethobenzamide, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "Pentosan polysulfate, Calcium chloride, Phenazopyridine, Sildenafil, Mirabegron, Alprostadil, Acetohydroxamic acid, Yohimbine, Avanafil, Papaverine, Vardenafil, More", "updated_at": 1767369485}, {"id": 68134, "ingredient1": "Flavoxate", "ingredient2": "Clemastine", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination. Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome. Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation. Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures. Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked. Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68221/", "reference_text": "[1] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82[2] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978): 1097-100[3] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967): 1112-3[4] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973): 348-50[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965): 749-56[6] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986): 571[7] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970): 1787-90[8] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994): 619-20[9] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986): 339-41[10] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983): 174-8[12] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983): 957-9[13] \"Product Information. Cogentin (benztropine).\" Merck & Co, Inc, West Point, PA.[14] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981): 313-7[15] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978): 243-4[16] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[17] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[18] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[19] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Lidocaine, Tetracaine, Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "Pentosan polysulfate, Calcium chloride, Phenazopyridine, Sildenafil, Mirabegron, Alprostadil, Acetohydroxamic acid, Yohimbine, Avanafil, Papaverine, Vardenafil, More", "updated_at": 1767369485}, {"id": 68135, "ingredient1": "Flibanserin", "ingredient2": "Clemastine", "severity": "Moderate", "effect": "The central nervous system (CNS) effects of flibanserin such as somnolence and fatigue may be potentiated by concomitant use of other agents with CNS depressant effects. The risk of CNS depression is increased if flibanserin is taken during waking hours or with alcohol or other CNS depressants.", "source": "DDInter", "management_text": "Patients receiving flibanserin with other agents that can cause CNS depression should be apprised of the potential for increased adverse effects such as drowsiness, dizziness, lightheadedness, and fatigue. Patients should not drive, operate machinery, or engage in hazardous activities requiring mental alertness and motor coordination for at least 6 hours after taking flibanserin.", "mechanism_text": "Synergism", "recommendation": "Patients receiving flibanserin with other agents that can cause CNS depression should be apprised of the potential for increased adverse effects such as drowsiness, dizziness, lightheadedness, and fatigue.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68222/", "reference_text": "[1] \"Product Information. Addyi (flibanserin).\" Sprout Pharmaceuticals, Raleigh, NC.[2] \"Product Information. Addyi (flibanserin).\" Sprout Pharmaceuticals, Raleigh, NC.[3] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[4] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[5] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[6] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Lidocaine, Tetracaine, Ketotifen, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "Ritodrine, Bremelanotide, Cabergoline, Black cohosh, Naproxen, Ibuprofen", "updated_at": 1767369485}, {"id": 68136, "ingredient1": "Fluoxetine", "ingredient2": "Clemastine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68223/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Tetracaine, Pheniramine, Ketotifen, Chlorcyclizine, Dexchlorpheniramine, Azelastine, Pheniramine", "alternatives_b": "Vilazodone, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Bupropion", "updated_at": 1767369485}, {"id": 68137, "ingredient1": "Fluphenazine", "ingredient2": "Clemastine", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination. Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome. Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation. Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures. Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked. Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68224/", "reference_text": "[1] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82[2] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978): 1097-100[3] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967): 1112-3[4] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973): 348-50[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965): 749-56[6] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986): 571[7] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970): 1787-90[8] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994): 619-20[9] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986): 339-41[10] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983): 174-8[12] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983): 957-9[13] \"Product Information. Cogentin (benztropine).\" Merck & Co, Inc, West Point, PA.[14] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981): 313-7[15] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978): 243-4[16] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[17] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[18] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[19] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Tetracaine, Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine", "alternatives_b": "Amisulpride, Pimavanserin", "updated_at": 1767369485}, {"id": 68138, "ingredient1": "Flurazepam", "ingredient2": "Clemastine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68225/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Pheniramine, Ketotifen, Dexchlorpheniramine, Loratadine, Astemizole, Desloratadine, Azelastine, Terfenadine, Pheniramine", "alternatives_b": "Nitrazepam, Zopiclone", "updated_at": 1767369485}, {"id": 68139, "ingredient1": "Glycopyrronium (topical)", "ingredient2": "Clemastine", "severity": "Moderate", "effect": "The potential exists for additive anticholinergic effects such as mydriasis, blurred vision, heat intolerance, fever, dry mouth, tachycardia, urinary retention, constipation, and glaucoma (onset or exacerbation) when topical or inhaled anticholinergic agents are used with each other or with other agents that possess anticholinergic properties. The risk of systemic anticholinergic effects following topical administration depends on variables such as strength of the product, size of the application area, frequency of application, and use of occlusive dressing. Systemic effects are uncommon following oral inhalation or nasal administration due to the poor absorption of quaternary ammonium compounds from gastrointestinal and nasal mucosa.", "source": "DDInter", "management_text": "Topical and inhaled anticholinergic preparations should preferably not be used in combination with other anticholinergic agents or agents with significant anticholinergic effects such as antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, and class IA antiarrhythmics (especially disopyramide). Caution is advised if concomitant use cannot be avoided, particularly in the elderly and those with significantly impaired renal and/or hepatic function.", "mechanism_text": "Synergism", "recommendation": "Topical and inhaled anticholinergic preparations should preferably not be used in combination with other anticholinergic agents or agents with significant anticholinergic effects such as antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, and class IA antiarrhythmics (especially disopyramide).", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68226/", "reference_text": "[1] \"Product Information. Qbrexza (glycopyrrolate topical).\" Dermira, Inc., Menlo Park, CA.[2] \"Product Information. Anoro Ellipta (umeclidinium-vilanterol).\" GlaxoSmithKline, Research Triangle Park, NC.[3] \"Product Information. Combivent (albuterol-ipratropium).\" Boehringer-Ingelheim, Ridgefield, CT.[4] \"Product Information. Atrovent (ipratropium).\" Boehringer-Ingelheim, Ridgefield, CT.[5] \"Product Information. Yupelri (revefenacin).\" Mylan Specialty, Morgantown, WV.[6] \"Product Information. Tudorza Pressair (aclidinium).\" Forest Pharmaceuticals, St. Louis, MO.[7] \"Product Information. Spiriva (tiotropium).\" Boehringer Ingelheim, Ridgefield, CT.[8] Cole JM, Sheehan AH, Jordan JK \"Concomitant use of ipratropium and tiotropium in chronic obstructive plmonary disease.\" Ann Pharmacother 46 (2012): 1717-21[9] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[10] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[11] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[12] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Lidocaine, Tetracaine, Ketotifen, Levocetirizine, Cetirizine, Fexofenadine, Loratadine, Trimethobenzamide, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68140, "ingredient1": "Halazepam", "ingredient2": "Clemastine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68227/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Tripelennamine, Pheniramine, Methdilazine, Azatadine, Ketotifen, Meclizine, Alimemazine, Fexofenadine, Thiethylperazine, Dexchlorpheniramine, Loratadine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68141, "ingredient1": "Haloperidol", "ingredient2": "Clemastine", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination. Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome. Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation. Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures. Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked. Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68228/", "reference_text": "[1] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82[2] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978): 1097-100[3] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967): 1112-3[4] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973): 348-50[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965): 749-56[6] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986): 571[7] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970): 1787-90[8] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994): 619-20[9] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986): 339-41[10] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983): 174-8[12] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983): 957-9[13] \"Product Information. Cogentin (benztropine).\" Merck & Co, Inc, West Point, PA.[14] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981): 313-7[15] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978): 243-4[16] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[17] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[18] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[19] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Tetracaine, Azelastine, Ketotifen, Desloratadine", "alternatives_b": "Amisulpride, Pimavanserin", "updated_at": 1767369485}, {"id": 68142, "ingredient1": "Diamorphine", "ingredient2": "Clemastine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68229/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Tripelennamine, Lidocaine, Tetracaine, Methdilazine, Azatadine, Ketotifen, Alimemazine, Fexofenadine, Loratadine, Phenindamine, Desloratadine, More", "alternatives_b": "Acamprosate, Naltrexone, Varenicline, Disulfiram, Nalmefene, Nicotine", "updated_at": 1767369485}, {"id": 68143, "ingredient1": "Histamine", "ingredient2": "Clemastine", "severity": "Moderate", "effect": "Antihistamines may suppress the patient's response to histamine phosphate. The length of suppression varies and is dependent on the patient, type of antihistamine, and the duration of antihistamine therapy. The duration of suppression may range from 24 hours with chlorpheniramine or up to several weeks with second-generation antihistamines.", "source": "DDInter", "management_text": "Clinicians should be aware of the potential for falsely insignificant or false-negative results when administering histamine phosphate to patients treated with antihistamines.", "mechanism_text": "Others", "recommendation": "Clinicians should be aware of the potential for falsely insignificant or false-negative results when administering histamine phosphate to patients treated with antihistamines.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68230/", "reference_text": "[1] \"Product Information. Histatrol (histamine phosphate).\" Center Laboratories, Port Washington, NY.[2] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[3] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[4] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[5] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Lidocaine, Tetracaine, Ketotifen, Dimenhydrinate, Meclizine, Thiethylperazine, Trimethobenzamide, Doxylamine, Azelastine, Cyclizine", "alternatives_b": "Interferon alfa-n1, Oprelvekin, Sipuleucel-T, Elapegademase, Interferon beta-1b, Peginterferon alfa-2a, Ropeginterferon alfa-2b, Interferon alfacon-1, Peginterferon beta-1a, Interferon beta-1a, Aldesleukin, More", "updated_at": 1767369485}, {"id": 68144, "ingredient1": "Hyaluronidase", "ingredient2": "Clemastine", "severity": "Minor", "effect": "Larger amounts of hyaluronidase may be required to achieve equivalent dispersing effects if patients are concomitantly receiving large doses of salicylates, cortisone, ACTH, estrogens, or antihistamines. These drugs may render tissues partially resistant to the dispersing action of hyaluronidase.", "source": "DDInter", "management_text": "-", "mechanism_text": "Others", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68231/", "reference_text": "[1] \"Product Information. Vitrase (hyaluronidase).\" Bausch and Lomb, Rochester, NY.[2] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[3] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[4] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[5] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[6] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[7] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[8] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[9] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[10] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[11] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[12] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[13] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[14] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[15] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[16] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[17] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[18] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[19] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[20] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[21] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[22] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[23] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[24] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[25] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[26] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[27] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[28] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[29] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[30] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[31] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[32] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[33] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[34] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T \"Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol.\" Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[35] Weber A, Jager R, Borner A, et al. \"Can grapefruit juice influence ethinyl estradiol bioavailability?\" Contraception 53 (1996): 41-7", "alternatives_a": "Doxepin, Ketotifen, Dimenhydrinate, Meclizine, Thiethylperazine, Trimethobenzamide, Doxylamine, Azelastine, Cyclizine", "alternatives_b": "Hemin, Voxelotor, Conestat alfa, Betibeglogene autotemcel, Streptokinase, Human C1-esterase inhibitor, Berotralstat, Lanadelumab, Icatibant, Crizanlizumab", "updated_at": 1767369485}, {"id": 68145, "ingredient1": "Hydromorphone", "ingredient2": "Clemastine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68232/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Tetracaine, Ketotifen, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "updated_at": 1767369485}, {"id": 68146, "ingredient1": "Hydroxyzine", "ingredient2": "Clemastine", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination. Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome. Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation. Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures. Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked. Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68233/", "reference_text": "[1] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82[2] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978): 1097-100[3] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967): 1112-3[4] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973): 348-50[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965): 749-56[6] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986): 571[7] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970): 1787-90[8] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994): 619-20[9] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986): 339-41[10] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983): 174-8[12] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983): 957-9[13] \"Product Information. Cogentin (benztropine).\" Merck & Co, Inc, West Point, PA.[14] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981): 313-7[15] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978): 243-4[16] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[17] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[18] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[19] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Tetracaine, Azelastine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68147, "ingredient1": "Ifosfamide", "ingredient2": "Clemastine", "severity": "Moderate", "effect": "Centrally-acting agents such as antiemetics, sedatives, narcotics, or antihistamines may add to the neurotoxic effects of ifosfamide. Administration of ifosfamide can cause CNS toxicity, which necessitates careful monitoring of the patient. Neurologic manifestations include somnolence, confusion, hallucinations, blurred vision, psychotic behavior, extrapyramidal symptoms, urinary incontinence, seizures, and in some instances, coma. There have also been reports of peripheral neuropathy. Ifosfamide neurotoxicity may occur within a few hours to a few days after initial administration and typically resolves within 48 to 72 hours of ifosfamide discontinuation.", "source": "DDInter", "management_text": "Due to the potential for additive effects, centrally-acting agents should be used with caution in combination with ifosfamide. If ifosfamide-induced encephalopathy occurs, both ifosfamide and non-essential concomitant CNS agents should be discontinued. Supportive therapy should be initiated and maintained until complete resolution of neurotoxicity.", "mechanism_text": "Synergism", "recommendation": "Due to the potential for additive effects, centrally-acting agents should be used with caution in combination with ifosfamide.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68234/", "reference_text": "[1] Simonian NA, Gilliam FG, Chiappa KH \"Ifosfamide causes a diazepam-sensitive encephalopathy.\" Neurology 43 (1993): 2700-2[2] \"Product Information. Ifex (ifosfamide).\" Bristol-Myers Squibb, Princeton, NJ.[3] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[4] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[5] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[6] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "Temozolomide, Thiotepa, Carmustine, Cyclophosphamide, Busulfan, Streptozocin, Chlorambucil, Lomustine, Dacarbazine, Mechlorethamine, Bendamustine, More", "updated_at": 1767369485}, {"id": 68148, "ingredient1": "Iloperidone", "ingredient2": "Clemastine", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination. Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome. Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation. Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures. Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked. Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68235/", "reference_text": "[1] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82[2] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978): 1097-100[3] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967): 1112-3[4] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973): 348-50[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965): 749-56[6] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986): 571[7] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970): 1787-90[8] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994): 619-20[9] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986): 339-41[10] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983): 174-8[12] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983): 957-9[13] \"Product Information. Cogentin (benztropine).\" Merck & Co, Inc, West Point, PA.[14] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981): 313-7[15] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978): 243-4[16] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[17] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[18] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[19] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Lidocaine, Tetracaine, Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine", "alternatives_b": "Amisulpride, Pimavanserin", "updated_at": 1767369485}, {"id": 68149, "ingredient1": "Imipramine", "ingredient2": "Clemastine", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination. Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome. Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation. Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures. Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked. Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68236/", "reference_text": "[1] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82[2] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978): 1097-100[3] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967): 1112-3[4] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973): 348-50[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965): 749-56[6] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986): 571[7] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970): 1787-90[8] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994): 619-20[9] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986): 339-41[10] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983): 174-8[12] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983): 957-9[13] \"Product Information. Cogentin (benztropine).\" Merck & Co, Inc, West Point, PA.[14] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981): 313-7[15] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978): 243-4[16] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[17] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[18] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[19] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Lidocaine, Tetracaine, Azelastine, Ketotifen, Desloratadine", "alternatives_b": "Vilazodone, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Bupropion", "updated_at": 1767369485}, {"id": 68150, "ingredient1": "Ipratropium", "ingredient2": "Clemastine", "severity": "Moderate", "effect": "The potential exists for additive anticholinergic effects such as mydriasis, blurred vision, heat intolerance, fever, dry mouth, tachycardia, urinary retention, constipation, and glaucoma (onset or exacerbation) when topical or inhaled anticholinergic agents are used with each other or with other agents that possess anticholinergic properties. The risk of systemic anticholinergic effects following topical administration depends on variables such as strength of the product, size of the application area, frequency of application, and use of occlusive dressing. Systemic effects are uncommon following oral inhalation or nasal administration due to the poor absorption of quaternary ammonium compounds from gastrointestinal and nasal mucosa.", "source": "DDInter", "management_text": "Topical and inhaled anticholinergic preparations should preferably not be used in combination with other anticholinergic agents or agents with significant anticholinergic effects such as antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, and class IA antiarrhythmics (especially disopyramide). Caution is advised if concomitant use cannot be avoided, particularly in the elderly and those with significantly impaired renal and/or hepatic function.", "mechanism_text": "Synergism", "recommendation": "Topical and inhaled anticholinergic preparations should preferably not be used in combination with other anticholinergic agents or agents with significant anticholinergic effects such as antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, and class IA antiarrhythmics (especially disopyramide).", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68237/", "reference_text": "[1] \"Product Information. Qbrexza (glycopyrrolate topical).\" Dermira, Inc., Menlo Park, CA.[2] \"Product Information. Anoro Ellipta (umeclidinium-vilanterol).\" GlaxoSmithKline, Research Triangle Park, NC.[3] \"Product Information. Combivent (albuterol-ipratropium).\" Boehringer-Ingelheim, Ridgefield, CT.[4] \"Product Information. Atrovent (ipratropium).\" Boehringer-Ingelheim, Ridgefield, CT.[5] \"Product Information. Yupelri (revefenacin).\" Mylan Specialty, Morgantown, WV.[6] \"Product Information. Tudorza Pressair (aclidinium).\" Forest Pharmaceuticals, St. Louis, MO.[7] \"Product Information. Spiriva (tiotropium).\" Boehringer Ingelheim, Ridgefield, CT.[8] Cole JM, Sheehan AH, Jordan JK \"Concomitant use of ipratropium and tiotropium in chronic obstructive plmonary disease.\" Ann Pharmacother 46 (2012): 1717-21[9] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[10] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[11] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[12] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Lidocaine, Tetracaine, Ketotifen, Levocetirizine, Cetirizine, Fexofenadine, Loratadine, Trimethobenzamide, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "Ciclesonide, Mometasone furoate, Budesonide, Flunisolide, Fluticasone, Cromoglicic acid, Betamethasone, Nedocromil, Triamcinolone, Beclomethasone dipropionate, Flunisolide, More", "updated_at": 1767369485}, {"id": 68151, "ingredient1": "Ipratropium (nasal)", "ingredient2": "Clemastine", "severity": "Minor", "effect": "Theoretically, the potential exists for additive anticholinergic effects such as mydriasis, blurred vision, heat intolerance, fever, dry mouth, tachycardia, urinary retention, constipation, and glaucoma (new onset or exacerbation) when ipratropium nasal spray is used with other agents that possess anticholinergic properties (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, class IA antiarrhythmics especially disopyramide). However, due to the poor systemic absorption of ipratropium when administered nasally, the interaction would be unlikely at regularly recommended dosages.", "source": "DDInter", "management_text": "-", "mechanism_text": "Synergism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68238/", "reference_text": "[1] \"Product Information. Atrovent nasal spray (ipratropium nasal).\" Boehringer-Ingelheim, Ridgefield, CT.[2] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[5] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Lidocaine, Tetracaine, Ketotifen, Levocetirizine, Cetirizine, Fexofenadine, Loratadine, Trimethobenzamide, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "Ciclesonide, Mometasone furoate, Budesonide, Flunisolide, Fluticasone, Cromoglicic acid, Betamethasone, Nedocromil, Triamcinolone, Beclomethasone dipropionate, Flunisolide, More", "updated_at": 1767369485}, {"id": 68152, "ingredient1": "Isocarboxazid", "ingredient2": "Clemastine", "severity": "Moderate", "effect": "Coadministration of monoamine oxidase inhibitors (MAOIs) and antihistamines may result in additive central nervous system depressant effects. In addition, limited data suggest that MAOIs may potentiate and prolong the anticholinergic effects of antihistamines due to inhibition of catecholamine degradation, which may lead to overstimulation of the sympathetic nervous system.", "source": "DDInter", "management_text": "Prescribing antihistamines in combination with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, linezolid, procarbazine) should generally be avoided. If concomitant treatment is unavoidable, patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "Prescribing antihistamines in combination with MAOIs or other agents that possess MAOI activity (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68239/", "reference_text": "[1] Kahn DA \"Possible toxic interaction between cyproheptadine and phenelzine.\" Am J Psychiatry 144 (1987): 1242-3[2] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[3] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[4] Ferry T, Ponceau B, Simon M, et al. \"Possibly linezolid-induced peripheral and central neurotoxicity: report of four cases.\" Infection 33 (2005): 151-4[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Serio RN \"Acute delirium associated with combined diphenhydramine and linezolid use.\" Ann Pharmacother 38 (2004): 62-5[7] \"Product Information. Benadryl (diphenhydramine).\" Parke-Davis, Morris Plains, NJ.[8] Cerner Multum, Inc. \"Australian Product Information.\" O 0[9] \"Product Information. Periactin (cyproheptadine).\" Merck & Co, Inc, West Point, PA.[10] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[11] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[12] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[13] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[14] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[15] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[16] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[17] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[18] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[19] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[20] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[21] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[22] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[23] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[24] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[25] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[26] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[27] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[28] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80[29] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[30] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[31] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[32] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Lidocaine, Tetracaine, Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "Vilazodone, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Bupropion", "updated_at": 1767369485}, {"id": 68153, "ingredient1": "Isoflurophate (ophthalmic)", "ingredient2": "Clemastine", "severity": "Moderate", "effect": "Theoretically, anticholinergic agents and other agents with significant anticholinergic activity (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, class IA antiarrhythmics especially disopyramide) may antagonize the effects of topically administered cholinergic agents such as acetylcholine, carbachol, demecarium, echothiophate, isoflurophate, physostigmine, and pilocarpine. The proposed mechanism involves opposing pharmacodynamic action on muscarinic receptor sites in ocular tissue. This interaction is sometimes desirable and is the basis for using atropine in the treatment of excessive muscarinic side effects and cholinergic crisis induced by cholinergic overdose.", "source": "DDInter", "management_text": "Patients receiving long-term therapy with anticholinergic agents should be monitored for potentially diminished therapeutic (miotic) response to ophthalmic cholinergic therapy, and dosages adjusted as necessary.", "mechanism_text": "Antagonism", "recommendation": "Patients receiving long-term therapy with anticholinergic agents should be monitored for potentially diminished therapeutic (miotic) response to ophthalmic cholinergic therapy, and dosages adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68240/", "reference_text": "[1] \"Product Information. Pilopine HS (pilocarpine ophthalmic).\" Alcon Laboratories Inc, Fort Worth, TX.[2] \"Multum Information Services, Inc. Expert Review Panel\"", "alternatives_a": "Tripelennamine, Lidocaine, Tetracaine, Methdilazine, Azatadine, Ketotifen, Alimemazine, Levocetirizine, Cetirizine, Fexofenadine, Loratadine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68154, "ingredient1": "Clemastine", "ingredient2": "Kava", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68241/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Lidocaine, Tetracaine, Ketotifen, Levocetirizine, Chlorcyclizine, Cetirizine, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68155, "ingredient1": "Clemastine", "ingredient2": "Ketamine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68242/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Tetracaine, Pheniramine, Ketotifen, Chlorcyclizine, Acrivastine, Fexofenadine, Dexchlorpheniramine, Loratadine, Astemizole, Desloratadine, Azelastine, More", "alternatives_b": "Halothane, Isoflurane, Nitrous oxide, Desflurane, Propofol, Enflurane, Sevoflurane, Etomidate", "updated_at": 1767369485}, {"id": 68156, "ingredient1": "Clemastine", "ingredient2": "Lamotrigine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68243/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Tetracaine, Pheniramine, Methdilazine, Azatadine, Ketotifen, Meclizine, Thiethylperazine, Dexchlorpheniramine, Phenindamine, Astemizole, Azelastine, More", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 68157, "ingredient1": "Clemastine", "ingredient2": "Lasmiditan", "severity": "Moderate", "effect": "Coadministration with alcohol or other central nervous system (CNS) depressants may enhance the sedative effects of lasmiditan and increase the likelihood and/or severity of cognitive and/or neuropsychiatric adverse reactions. Patients treated with lasmiditan are at risk of CNS depression, including dizziness and sedation, as well as driving impairment.", "source": "DDInter", "management_text": "Caution is advised during coadministration of lasmiditan with alcohol, other CNS depressants, or other agents that cause sedation. Patients should be advised against driving and other activities that require complete mental alertness for at least 8 hours after lasmiditan is administered.", "mechanism_text": "Synergism", "recommendation": "Caution is advised during coadministration of lasmiditan with alcohol, other CNS depressants, or other agents that cause sedation.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68244/", "reference_text": "[1] \"Product Information. Reyvow (lasmiditan).\" Lilly, Eli and Company, Indianapolis, IN.[2] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[3] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[4] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[5] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Lidocaine, Tetracaine, Ketotifen, Loratadine, Desloratadine, Azelastine, Astemizole", "alternatives_b": "Frovatriptan, Dihydroergotamine, Rimegepant, Eptinezumab, Atogepant, Eletriptan, Rizatriptan, Ubrogepant, Ergotamine, Naratriptan, Galcanezumab, More", "updated_at": 1767369485}, {"id": 68158, "ingredient1": "Clemastine", "ingredient2": "Lemborexant", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68245/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Tetracaine, Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "Nitrazepam, Zopiclone", "updated_at": 1767369485}, {"id": 68159, "ingredient1": "Clemastine", "ingredient2": "Levetiracetam", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68246/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Tetracaine, Pheniramine, Ketotifen, Meclizine, Azelastine, Thiethylperazine, Dexchlorpheniramine, Phenindamine, Astemizole, Methdilazine, Terfenadine, Pheniramine", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 68160, "ingredient1": "Clemastine", "ingredient2": "Levocetirizine", "severity": "Moderate", "effect": "Concurrent use of cetirizine or levocetirizine with alcohol or other agents that exhibit central nervous system (CNS) depressant effects may result in additive impairment of mental alertness and performance.", "source": "DDInter", "management_text": "Concomitant use of cetirizine or levocetirizine with alcohol or other CNS depressants should generally be avoided if possible. In the event that they are used together, patients should be counseled against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of cetirizine or levocetirizine with alcohol or other CNS depressants should generally be avoided if possible.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68247/", "reference_text": "[1] \"Product Information. Zyrtec (cetirizine).\" Pfizer US Pharmaceuticals, New York, NY.[2] \"Product Information. Xyzal (levocetirizine).\" UCB Pharma Inc, Smyrna, GA.[3] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[4] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[5] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[6] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[7] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[8] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[9] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[10] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Lidocaine, Tetracaine, Ketotifen, Levocetirizine, Cetirizine, Acrivastine, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "Clemastine, Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole", "updated_at": 1767369485}, {"id": 68161, "ingredient1": "Clemastine", "ingredient2": "Levacetylmethadol", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68248/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Tripelennamine, Lidocaine, Tetracaine, Methdilazine, Azatadine, Ketotifen, Alimemazine, Fexofenadine, Loratadine, Phenindamine, Desloratadine, More", "alternatives_b": "Acamprosate, Naltrexone, Varenicline, Disulfiram, Nalmefene, Nicotine", "updated_at": 1767369485}, {"id": 68162, "ingredient1": "Clemastine", "ingredient2": "Levorphanol", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68249/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Lidocaine, Tetracaine, Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68163, "ingredient1": "Clemastine", "ingredient2": "Linezolid", "severity": "Moderate", "effect": "Coadministration of monoamine oxidase inhibitors (MAOIs) and antihistamines may result in additive central nervous system depressant effects. In addition, limited data suggest that MAOIs may potentiate and prolong the anticholinergic effects of antihistamines due to inhibition of catecholamine degradation, which may lead to overstimulation of the sympathetic nervous system.", "source": "DDInter", "management_text": "Prescribing antihistamines in combination with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, linezolid, procarbazine) should generally be avoided. If concomitant treatment is unavoidable, patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "Prescribing antihistamines in combination with MAOIs or other agents that possess MAOI activity (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68250/", "reference_text": "[1] Kahn DA \"Possible toxic interaction between cyproheptadine and phenelzine.\" Am J Psychiatry 144 (1987): 1242-3[2] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[3] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[4] Ferry T, Ponceau B, Simon M, et al. \"Possibly linezolid-induced peripheral and central neurotoxicity: report of four cases.\" Infection 33 (2005): 151-4[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Serio RN \"Acute delirium associated with combined diphenhydramine and linezolid use.\" Ann Pharmacother 38 (2004): 62-5[7] \"Product Information. Benadryl (diphenhydramine).\" Parke-Davis, Morris Plains, NJ.[8] Cerner Multum, Inc. \"Australian Product Information.\" O 0[9] \"Product Information. Periactin (cyproheptadine).\" Merck & Co, Inc, West Point, PA.[10] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[11] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[12] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[13] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[14] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[15] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[16] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[17] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[18] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[19] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[20] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[21] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[22] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[23] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[24] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[25] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[26] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[27] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[28] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80[29] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[30] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[31] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[32] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Tetracaine, Ketotifen, Dimenhydrinate, Meclizine, Levocetirizine, Trimethobenzamide, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "Tinidazole, Bacitracin, Polymyxin B, Oritavancin, Daptomycin, Vancomycin, Metronidazole, Telavancin, Methenamine, Spectinomycin, Lefamulin, More", "updated_at": 1767369485}, {"id": 68164, "ingredient1": "Clemastine", "ingredient2": "Lithium carbonate", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68251/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Lidocaine, Tetracaine, Pheniramine, Ketotifen, Chlorcyclizine, Fexofenadine, Dexchlorpheniramine, Loratadine, Desloratadine, Azelastine, Pheniramine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68165, "ingredient1": "Clemastine", "ingredient2": "Lofexidine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68252/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Lidocaine, Tetracaine, Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine", "alternatives_b": "Acamprosate, Naltrexone, Varenicline, Disulfiram, Nalmefene, Nicotine", "updated_at": 1767369485}, {"id": 68166, "ingredient1": "Clemastine", "ingredient2": "Lorazepam", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68253/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Pheniramine, Ketotifen, Dexchlorpheniramine, Astemizole, Azelastine, Terfenadine, Pheniramine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68167, "ingredient1": "Clemastine", "ingredient2": "Loxapine", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination. Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome. Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation. Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures. Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked. Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68254/", "reference_text": "[1] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82[2] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978): 1097-100[3] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967): 1112-3[4] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973): 348-50[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965): 749-56[6] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986): 571[7] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970): 1787-90[8] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994): 619-20[9] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986): 339-41[10] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983): 174-8[12] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983): 957-9[13] \"Product Information. Cogentin (benztropine).\" Merck & Co, Inc, West Point, PA.[14] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981): 313-7[15] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978): 243-4[16] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[17] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[18] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[19] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Lidocaine, Tetracaine, Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "Amisulpride, Pimavanserin", "updated_at": 1767369485}, {"id": 68168, "ingredient1": "Clemastine", "ingredient2": "Lumateperone", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination. Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome. Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation. Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures. Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked. Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68255/", "reference_text": "[1] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82[2] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978): 1097-100[3] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967): 1112-3[4] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973): 348-50[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965): 749-56[6] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986): 571[7] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970): 1787-90[8] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994): 619-20[9] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986): 339-41[10] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983): 174-8[12] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983): 957-9[13] \"Product Information. Cogentin (benztropine).\" Merck & Co, Inc, West Point, PA.[14] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981): 313-7[15] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978): 243-4[16] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[17] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[18] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[19] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Lidocaine, Tetracaine, Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "Amisulpride, Pimavanserin", "updated_at": 1767369485}, {"id": 68169, "ingredient1": "Clemastine", "ingredient2": "Lurasidone", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination. Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome. Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation. Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures. Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked. Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68256/", "reference_text": "[1] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82[2] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978): 1097-100[3] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967): 1112-3[4] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973): 348-50[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965): 749-56[6] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986): 571[7] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970): 1787-90[8] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994): 619-20[9] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986): 339-41[10] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983): 174-8[12] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983): 957-9[13] \"Product Information. Cogentin (benztropine).\" Merck & Co, Inc, West Point, PA.[14] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981): 313-7[15] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978): 243-4[16] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[17] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[18] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[19] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Lidocaine, Tetracaine, Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "Amisulpride, Pimavanserin", "updated_at": 1767369485}, {"id": 68170, "ingredient1": "Clemastine", "ingredient2": "Maprotiline", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination. Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome. Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation. Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures. Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked. Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68257/", "reference_text": "[1] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82[2] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978): 1097-100[3] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967): 1112-3[4] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973): 348-50[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965): 749-56[6] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986): 571[7] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970): 1787-90[8] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994): 619-20[9] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986): 339-41[10] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983): 174-8[12] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983): 957-9[13] \"Product Information. Cogentin (benztropine).\" Merck & Co, Inc, West Point, PA.[14] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981): 313-7[15] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978): 243-4[16] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[17] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[18] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[19] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Lidocaine, Tetracaine, Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine", "alternatives_b": "Vilazodone, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Bupropion", "updated_at": 1767369485}, {"id": 68171, "ingredient1": "Clemastine", "ingredient2": "Meclizine", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination. Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome. Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation. Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures. Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked. Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68258/", "reference_text": "[1] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82[2] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978): 1097-100[3] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967): 1112-3[4] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973): 348-50[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965): 749-56[6] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986): 571[7] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970): 1787-90[8] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994): 619-20[9] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986): 339-41[10] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983): 174-8[12] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983): 957-9[13] \"Product Information. Cogentin (benztropine).\" Merck & Co, Inc, West Point, PA.[14] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981): 313-7[15] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978): 243-4[16] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[17] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[18] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[19] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Lidocaine, Tetracaine, Ketotifen, Meclizine, Fexofenadine, Loratadine, Trimethobenzamide, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "Clemastine, Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole", "updated_at": 1767369485}, {"id": 68172, "ingredient1": "Clemastine", "ingredient2": "Memantine", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination. Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome. Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation. Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures. Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked. Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68259/", "reference_text": "[1] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82[2] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978): 1097-100[3] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967): 1112-3[4] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973): 348-50[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965): 749-56[6] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986): 571[7] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970): 1787-90[8] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994): 619-20[9] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986): 339-41[10] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983): 174-8[12] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983): 957-9[13] \"Product Information. Cogentin (benztropine).\" Merck & Co, Inc, West Point, PA.[14] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981): 313-7[15] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978): 243-4[16] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[17] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[18] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[19] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Tetracaine, Pheniramine, Ketotifen, Levocetirizine, Dexchlorpheniramine, Trimethobenzamide, Astemizole, Azelastine, Terfenadine, Pheniramine", "alternatives_b": "Ginkgo biloba, Aducanumab", "updated_at": 1767369485}, {"id": 68173, "ingredient1": "Clemastine", "ingredient2": "Mepenzolate", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination. Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome. Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation. Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures. Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked. Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68260/", "reference_text": "[1] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82[2] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978): 1097-100[3] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967): 1112-3[4] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973): 348-50[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965): 749-56[6] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986): 571[7] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970): 1787-90[8] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994): 619-20[9] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986): 339-41[10] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983): 174-8[12] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983): 957-9[13] \"Product Information. Cogentin (benztropine).\" Merck & Co, Inc, West Point, PA.[14] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981): 313-7[15] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978): 243-4[16] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[17] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[18] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[19] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Lidocaine, Tetracaine, Ketotifen, Levocetirizine, Cetirizine, Fexofenadine, Loratadine, Trimethobenzamide, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "Papaverine, Alosetron, Isometheptene", "updated_at": 1767369485}, {"id": 68174, "ingredient1": "Clemastine", "ingredient2": "Meperidine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68261/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Tetracaine, Azelastine, Ketotifen, Terfenadine, Astemizole", "alternatives_b": "Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "updated_at": 1767369485}, {"id": 68175, "ingredient1": "Clemastine", "ingredient2": "Mephenytoin", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68262/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Tetracaine, Pheniramine, Methdilazine, Ketotifen, Chlorcyclizine, Azelastine, Fexofenadine, Thiethylperazine, Dexchlorpheniramine, Loratadine, Phenindamine, More", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 68176, "ingredient1": "Clemastine", "ingredient2": "Methylphenobarbital", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68263/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Tetracaine, Pheniramine, Ketotifen, Chlorcyclizine, Azelastine, Fexofenadine, Dexchlorpheniramine, Loratadine, Phenindamine, Astemizole, Desloratadine, More", "alternatives_b": "Lacosamide, Nitrazepam, Zopiclone", "updated_at": 1767369485}, {"id": 68177, "ingredient1": "Clemastine", "ingredient2": "Meprobamate", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68264/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Doxepin, Tetracaine, Pheniramine, Ketotifen, Chlorcyclizine, Fexofenadine, Dexchlorpheniramine, Loratadine, Astemizole, Desloratadine, Azelastine, More", "alternatives_b": "Nitrazepam, Zopiclone", "updated_at": 1767369485}, {"id": 68178, "ingredient1": "Clemastine", "ingredient2": "Mesoridazine", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination. Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome. Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation. Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures. Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked. Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68265/", "reference_text": "[1] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82[2] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978): 1097-100[3] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967): 1112-3[4] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973): 348-50[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965): 749-56[6] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986): 571[7] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970): 1787-90[8] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994): 619-20[9] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986): 339-41[10] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983): 174-8[12] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983): 957-9[13] \"Product Information. Cogentin (benztropine).\" Merck & Co, Inc, West Point, PA.[14] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981): 313-7[15] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978): 243-4[16] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[17] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[18] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[19] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Lidocaine, Tetracaine, Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine", "alternatives_b": "Amisulpride, Pimavanserin", "updated_at": 1767369485}, {"id": 68179, "ingredient1": "Clemastine", "ingredient2": "Metaxalone", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68266/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Lidocaine, Tetracaine, Pheniramine, Methdilazine, Ketotifen, Chlorcyclizine, Azelastine, Fexofenadine, Thiethylperazine, Dexchlorpheniramine, Loratadine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68180, "ingredient1": "Clemastine", "ingredient2": "Methadone", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68267/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Tetracaine, Azelastine, Ketotifen, Loratadine, Desloratadine", "alternatives_b": "Acamprosate, Naltrexone, Varenicline, Disulfiram, Nalmefene, Nicotine, Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "updated_at": 1767369485}, {"id": 68181, "ingredient1": "Clemastine", "ingredient2": "Methdilazine", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination. Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome. Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation. Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures. Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked. Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68268/", "reference_text": "[1] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82[2] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978): 1097-100[3] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967): 1112-3[4] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973): 348-50[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965): 749-56[6] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986): 571[7] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970): 1787-90[8] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994): 619-20[9] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986): 339-41[10] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983): 174-8[12] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983): 957-9[13] \"Product Information. Cogentin (benztropine).\" Merck & Co, Inc, West Point, PA.[14] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981): 313-7[15] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978): 243-4[16] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[17] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[18] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[19] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Tripelennamine, Lidocaine, Tetracaine, Methdilazine, Azatadine, Ketotifen, Alimemazine, Fexofenadine, Loratadine, Trimethobenzamide, Phenindamine, More", "alternatives_b": "Clemastine, Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole", "updated_at": 1767369485}, {"id": 68182, "ingredient1": "Clemastine", "ingredient2": "Methocarbamol", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68269/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Tetracaine, Pheniramine, Ketotifen, Meclizine, Azelastine, Thiethylperazine, Dexchlorpheniramine, Phenindamine, Astemizole, Methdilazine, Terfenadine, Pheniramine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68183, "ingredient1": "Clemastine", "ingredient2": "Methotrimeprazine", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination. Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome. Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation. Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures. Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked. Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68270/", "reference_text": "[1] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82[2] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978): 1097-100[3] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967): 1112-3[4] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973): 348-50[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965): 749-56[6] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986): 571[7] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970): 1787-90[8] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994): 619-20[9] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986): 339-41[10] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983): 174-8[12] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983): 957-9[13] \"Product Information. Cogentin (benztropine).\" Merck & Co, Inc, West Point, PA.[14] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981): 313-7[15] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978): 243-4[16] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[17] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[18] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[19] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Tripelennamine, Lidocaine, Tetracaine, Methdilazine, Azatadine, Ketotifen, Alimemazine, Fexofenadine, Loratadine, Trimethobenzamide, Phenindamine, More", "alternatives_b": "Amisulpride, Pimavanserin", "updated_at": 1767369485}, {"id": 68184, "ingredient1": "Clemastine", "ingredient2": "Methscopolamine", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination. Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome. Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation. Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures. Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked. Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68271/", "reference_text": "[1] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82[2] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978): 1097-100[3] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967): 1112-3[4] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973): 348-50[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965): 749-56[6] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986): 571[7] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970): 1787-90[8] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994): 619-20[9] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986): 339-41[10] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983): 174-8[12] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983): 957-9[13] \"Product Information. Cogentin (benztropine).\" Merck & Co, Inc, West Point, PA.[14] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981): 313-7[15] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978): 243-4[16] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[17] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[18] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[19] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Lidocaine, Tetracaine, Ketotifen, Levocetirizine, Cetirizine, Fexofenadine, Loratadine, Trimethobenzamide, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "Tropicamide, Ephedrine, Ketorolac, Phenylephrine", "updated_at": 1767369485}, {"id": 68185, "ingredient1": "Clemastine", "ingredient2": "Methsuximide", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68272/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Lidocaine, Tetracaine, Pheniramine, Ketotifen, Chlorcyclizine, Fexofenadine, Dexchlorpheniramine, Loratadine, Astemizole, Desloratadine, Azelastine, More", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 68186, "ingredient1": "Clemastine", "ingredient2": "Metoclopramide", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68273/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Pheniramine, Ketotifen, Chlorcyclizine, Dexchlorpheniramine, Trimethobenzamide, Astemizole, Azelastine, Terfenadine, Pheniramine", "alternatives_b": "Cisapride", "updated_at": 1767369485}, {"id": 68187, "ingredient1": "Clemastine", "ingredient2": "Metyrosine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68274/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Lidocaine, Tetracaine, Ketotifen, Levocetirizine, Chlorcyclizine, Cetirizine, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "Macitentan, Riociguat, Tadalafil, Bosentan, Ambrisentan", "updated_at": 1767369485}, {"id": 68188, "ingredient1": "Clemastine", "ingredient2": "Midazolam", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68275/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Pheniramine, Ketotifen, Fexofenadine, Dexchlorpheniramine, Astemizole, Desloratadine, Azelastine, Terfenadine, Pheniramine", "alternatives_b": "Nitrazepam, Zopiclone", "updated_at": 1767369485}, {"id": 68189, "ingredient1": "Clemastine", "ingredient2": "Mirtazapine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68276/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Tetracaine, Pheniramine, Ketotifen, Meclizine, Azelastine, Thiethylperazine, Dexchlorpheniramine, Phenindamine, Methdilazine, Pheniramine", "alternatives_b": "Vilazodone, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Bupropion", "updated_at": 1767369485}, {"id": 68190, "ingredient1": "Clemastine", "ingredient2": "Molindone", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination. Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome. Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation. Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures. Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked. Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68277/", "reference_text": "[1] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82[2] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978): 1097-100[3] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967): 1112-3[4] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973): 348-50[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965): 749-56[6] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986): 571[7] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970): 1787-90[8] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994): 619-20[9] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986): 339-41[10] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983): 174-8[12] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983): 957-9[13] \"Product Information. Cogentin (benztropine).\" Merck & Co, Inc, West Point, PA.[14] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981): 313-7[15] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978): 243-4[16] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[17] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[18] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[19] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Lidocaine, Tetracaine, Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "Amisulpride, Pimavanserin", "updated_at": 1767369485}, {"id": 68191, "ingredient1": "Clemastine", "ingredient2": "Morphine (liposomal)", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68278/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Tripelennamine, Tetracaine, Pheniramine, Methdilazine, Azatadine, Ketotifen, Alimemazine, Chlorcyclizine, Acrivastine, Fexofenadine, Thiethylperazine, More", "alternatives_b": "Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "updated_at": 1767369485}, {"id": 68192, "ingredient1": "Clemastine", "ingredient2": "Nabilone", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68279/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Lidocaine, Tetracaine, Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "Granisetron, Rolapitant, Aprepitant, Dolasetron, Ondansetron, Palonosetron", "updated_at": 1767369485}, {"id": 68193, "ingredient1": "Clemastine", "ingredient2": "Nalbuphine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68280/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Tetracaine, Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "updated_at": 1767369485}, {"id": 68194, "ingredient1": "Clemastine", "ingredient2": "Nefazodone", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68281/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Tetracaine, Pheniramine, Methdilazine, Ketotifen, Meclizine, Chlorcyclizine, Thiethylperazine, Dexchlorpheniramine, Phenindamine, Azelastine, Pheniramine", "alternatives_b": "Vilazodone, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Bupropion", "updated_at": 1767369485}, {"id": 68195, "ingredient1": "Clemastine", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination. Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome. Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation. Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures. Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked. Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68282/", "reference_text": "[1] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82[2] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978): 1097-100[3] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967): 1112-3[4] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973): 348-50[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965): 749-56[6] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986): 571[7] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970): 1787-90[8] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994): 619-20[9] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986): 339-41[10] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983): 174-8[12] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983): 957-9[13] \"Product Information. Cogentin (benztropine).\" Merck & Co, Inc, West Point, PA.[14] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981): 313-7[15] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978): 243-4[16] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[17] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[18] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[19] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Tetracaine, Azelastine, Ketotifen, Desloratadine", "alternatives_b": "Vilazodone, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Bupropion", "updated_at": 1767369485}, {"id": 68196, "ingredient1": "Clemastine", "ingredient2": "Olanzapine", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination. Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome. Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation. Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures. Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked. Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68283/", "reference_text": "[1] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82[2] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978): 1097-100[3] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967): 1112-3[4] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973): 348-50[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965): 749-56[6] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986): 571[7] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970): 1787-90[8] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994): 619-20[9] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986): 339-41[10] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983): 174-8[12] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983): 957-9[13] \"Product Information. Cogentin (benztropine).\" Merck & Co, Inc, West Point, PA.[14] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981): 313-7[15] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978): 243-4[16] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[17] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[18] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[19] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Tetracaine, Azelastine, Ketotifen", "alternatives_b": "Amisulpride, Pimavanserin", "updated_at": 1767369485}, {"id": 68197, "ingredient1": "Clemastine", "ingredient2": "Oliceridine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68284/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Lidocaine, Tetracaine, Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine", "alternatives_b": "Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "updated_at": 1767369485}, {"id": 68198, "ingredient1": "Clemastine", "ingredient2": "Olopatadine (nasal)", "severity": "Moderate", "effect": "Concurrent use of olopatadine nasal spray with alcohol or other central nervous system (CNS) depressants may result in additive impairment of mental alertness and performance. Somnolence has been reported in some patients using olopatadine nasal spray in clinical trials.", "source": "DDInter", "management_text": "Concomitant use of olopatadine nasal spray with alcohol or other CNS depressants should generally be avoided if possible. In the event that they are used together, patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their doctor if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of olopatadine nasal spray with alcohol or other CNS depressants should generally be avoided if possible.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68285/", "reference_text": "[1] \"Product Information. Patanase (olopatadine nasal).\" Alcon Laboratories Inc, Fort Worth, TX.[2] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[3] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[4] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[5] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[6] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[7] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[8] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[9] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Lidocaine, Tetracaine, Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68199, "ingredient1": "Clemastine", "ingredient2": "Opicapone", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68286/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Lidocaine, Tetracaine, Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "Selegiline, Cabergoline", "updated_at": 1767369485}, {"id": 68200, "ingredient1": "Clemastine", "ingredient2": "Opium", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68287/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Lidocaine, Tetracaine, Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "updated_at": 1767369485}, {"id": 68201, "ingredient1": "Clemastine", "ingredient2": "Orphenadrine", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination. Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome. Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation. Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures. Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked. Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68288/", "reference_text": "[1] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82[2] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978): 1097-100[3] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967): 1112-3[4] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973): 348-50[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965): 749-56[6] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986): 571[7] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970): 1787-90[8] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994): 619-20[9] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986): 339-41[10] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983): 174-8[12] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983): 957-9[13] \"Product Information. Cogentin (benztropine).\" Merck & Co, Inc, West Point, PA.[14] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981): 313-7[15] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978): 243-4[16] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[17] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[18] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[19] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Tetracaine, Ketotifen, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68202, "ingredient1": "Clemastine", "ingredient2": "Oxazepam", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68289/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Pheniramine, Ketotifen, Chlorcyclizine, Dexchlorpheniramine, Astemizole, Azelastine, Terfenadine, Pheniramine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68203, "ingredient1": "Clemastine", "ingredient2": "Oxcarbazepine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68290/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Tetracaine, Chlorcyclizine, Azelastine", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 68204, "ingredient1": "Clemastine", "ingredient2": "Oxybutynin", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination. Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome. Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation. Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures. Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked. Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68291/", "reference_text": "[1] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82[2] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978): 1097-100[3] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967): 1112-3[4] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973): 348-50[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965): 749-56[6] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986): 571[7] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970): 1787-90[8] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994): 619-20[9] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986): 339-41[10] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983): 174-8[12] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983): 957-9[13] \"Product Information. Cogentin (benztropine).\" Merck & Co, Inc, West Point, PA.[14] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981): 313-7[15] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978): 243-4[16] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[17] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[18] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[19] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Tetracaine, Ketotifen, Levocetirizine, Trimethobenzamide, Azelastine, Terfenadine, Astemizole", "alternatives_b": "Pentosan polysulfate, Calcium chloride, Phenazopyridine, Sildenafil, Mirabegron, Alprostadil, Acetohydroxamic acid, Yohimbine, Avanafil, Papaverine, Vardenafil, More", "updated_at": 1767369485}, {"id": 68205, "ingredient1": "Clemastine", "ingredient2": "Oxycodone", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68292/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Tetracaine, Azelastine, Ketotifen, Terfenadine, Astemizole", "alternatives_b": "Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "updated_at": 1767369485}, {"id": 68206, "ingredient1": "Clemastine", "ingredient2": "Oxymorphone", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68293/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Lidocaine, Tetracaine, Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "updated_at": 1767369485}, {"id": 68207, "ingredient1": "Clemastine", "ingredient2": "Ozanimod", "severity": "Moderate", "effect": "Coadministration of monoamine oxidase inhibitors (MAOIs) and antihistamines may result in additive central nervous system depressant effects. In addition, limited data suggest that MAOIs may potentiate and prolong the anticholinergic effects of antihistamines due to inhibition of catecholamine degradation, which may lead to overstimulation of the sympathetic nervous system.", "source": "DDInter", "management_text": "Prescribing antihistamines in combination with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, linezolid, procarbazine) should generally be avoided. If concomitant treatment is unavoidable, patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "Prescribing antihistamines in combination with MAOIs or other agents that possess MAOI activity (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68294/", "reference_text": "[1] Kahn DA \"Possible toxic interaction between cyproheptadine and phenelzine.\" Am J Psychiatry 144 (1987): 1242-3[2] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[3] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[4] Ferry T, Ponceau B, Simon M, et al. \"Possibly linezolid-induced peripheral and central neurotoxicity: report of four cases.\" Infection 33 (2005): 151-4[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Serio RN \"Acute delirium associated with combined diphenhydramine and linezolid use.\" Ann Pharmacother 38 (2004): 62-5[7] \"Product Information. Benadryl (diphenhydramine).\" Parke-Davis, Morris Plains, NJ.[8] Cerner Multum, Inc. \"Australian Product Information.\" O 0[9] \"Product Information. Periactin (cyproheptadine).\" Merck & Co, Inc, West Point, PA.[10] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[11] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[12] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[13] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[14] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[15] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[16] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[17] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[18] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[19] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[20] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[21] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[22] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[23] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[24] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[25] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[26] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[27] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[28] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80[29] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[30] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[31] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[32] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Lidocaine, Tetracaine, Mepyramine, Tripelennamine, Pheniramine, Ketotifen, Mepyramine, Levocetirizine, Chlorcyclizine, Cetirizine, Acrivastine, More", "alternatives_b": "Golimumab, Cyclosporine, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, More", "updated_at": 1767369485}, {"id": 68208, "ingredient1": "Clemastine", "ingredient2": "Paliperidone", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination. Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome. Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation. Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures. Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked. Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68295/", "reference_text": "[1] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82[2] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978): 1097-100[3] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967): 1112-3[4] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973): 348-50[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965): 749-56[6] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986): 571[7] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970): 1787-90[8] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994): 619-20[9] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986): 339-41[10] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983): 174-8[12] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983): 957-9[13] \"Product Information. Cogentin (benztropine).\" Merck & Co, Inc, West Point, PA.[14] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981): 313-7[15] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978): 243-4[16] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[17] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[18] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[19] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Lidocaine, Tetracaine, Ketotifen, Azelastine, Fexofenadine, Thiethylperazine, Desloratadine, Methdilazine", "alternatives_b": "Amisulpride, Pimavanserin", "updated_at": 1767369485}, {"id": 68209, "ingredient1": "Clemastine", "ingredient2": "Paraldehyde", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68296/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Tripelennamine, Lidocaine, Tetracaine, Pheniramine, Methdilazine, Azatadine, Ketotifen, Meclizine, Alimemazine, Chlorcyclizine, Fexofenadine, More", "alternatives_b": "Nitrazepam, Zopiclone", "updated_at": 1767369485}, {"id": 68210, "ingredient1": "Clemastine", "ingredient2": "Paramethadione", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68297/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Tripelennamine, Lidocaine, Tetracaine, Pheniramine, Methdilazine, Azatadine, Ketotifen, Meclizine, Alimemazine, Chlorcyclizine, Fexofenadine, More", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 68211, "ingredient1": "Clemastine", "ingredient2": "Paroxetine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68298/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Tetracaine, Pheniramine, Chlorcyclizine, Dexchlorpheniramine, Phenindamine, Meclizine, Pheniramine", "alternatives_b": "Vilazodone, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Bupropion", "updated_at": 1767369485}, {"id": 68212, "ingredient1": "Clemastine", "ingredient2": "Pentazocine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68299/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Lidocaine, Tetracaine, Ketotifen, Fexofenadine, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "updated_at": 1767369485}, {"id": 68213, "ingredient1": "Clemastine", "ingredient2": "Pentobarbital", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68300/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Tetracaine, Pheniramine, Ketotifen, Chlorcyclizine, Fexofenadine, Loratadine, Astemizole, Desloratadine, Azelastine, Terfenadine, Pheniramine", "alternatives_b": "Nitrazepam, Zopiclone", "updated_at": 1767369485}, {"id": 68214, "ingredient1": "Clemastine", "ingredient2": "Perampanel", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68301/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Lidocaine, Tetracaine, Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 68215, "ingredient1": "Clemastine", "ingredient2": "Pergolide", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68302/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Lidocaine, Tetracaine, Ketotifen, Levocetirizine, Cetirizine, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "Selegiline, Cabergoline", "updated_at": 1767369485}, {"id": 68216, "ingredient1": "Clemastine", "ingredient2": "Perphenazine", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination. Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome. Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation. Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures. Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked. Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68303/", "reference_text": "[1] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82[2] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978): 1097-100[3] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967): 1112-3[4] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973): 348-50[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965): 749-56[6] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986): 571[7] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970): 1787-90[8] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994): 619-20[9] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986): 339-41[10] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983): 174-8[12] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983): 957-9[13] \"Product Information. Cogentin (benztropine).\" Merck & Co, Inc, West Point, PA.[14] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981): 313-7[15] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978): 243-4[16] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[17] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[18] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[19] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Tetracaine, Azelastine, Ketotifen, Loratadine, Desloratadine", "alternatives_b": "Amisulpride, Pimavanserin", "updated_at": 1767369485}, {"id": 68217, "ingredient1": "Clemastine", "ingredient2": "Phenacemide", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68304/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Tripelennamine, Lidocaine, Tetracaine, Pheniramine, Methdilazine, Azatadine, Ketotifen, Meclizine, Alimemazine, Chlorcyclizine, Fexofenadine, More", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 68218, "ingredient1": "Clemastine", "ingredient2": "Phenelzine", "severity": "Moderate", "effect": "Coadministration of monoamine oxidase inhibitors (MAOIs) and antihistamines may result in additive central nervous system depressant effects. In addition, limited data suggest that MAOIs may potentiate and prolong the anticholinergic effects of antihistamines due to inhibition of catecholamine degradation, which may lead to overstimulation of the sympathetic nervous system.", "source": "DDInter", "management_text": "Prescribing antihistamines in combination with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, linezolid, procarbazine) should generally be avoided. If concomitant treatment is unavoidable, patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "Prescribing antihistamines in combination with MAOIs or other agents that possess MAOI activity (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68305/", "reference_text": "[1] Kahn DA \"Possible toxic interaction between cyproheptadine and phenelzine.\" Am J Psychiatry 144 (1987): 1242-3[2] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[3] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[4] Ferry T, Ponceau B, Simon M, et al. \"Possibly linezolid-induced peripheral and central neurotoxicity: report of four cases.\" Infection 33 (2005): 151-4[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Serio RN \"Acute delirium associated with combined diphenhydramine and linezolid use.\" Ann Pharmacother 38 (2004): 62-5[7] \"Product Information. Benadryl (diphenhydramine).\" Parke-Davis, Morris Plains, NJ.[8] Cerner Multum, Inc. \"Australian Product Information.\" O 0[9] \"Product Information. Periactin (cyproheptadine).\" Merck & Co, Inc, West Point, PA.[10] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[11] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[12] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[13] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[14] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[15] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[16] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[17] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[18] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[19] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[20] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[21] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[22] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[23] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[24] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[25] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[26] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[27] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[28] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80[29] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[30] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[31] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[32] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Lidocaine, Tetracaine, Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "Vilazodone, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Bupropion", "updated_at": 1767369485}, {"id": 68219, "ingredient1": "Clemastine", "ingredient2": "Phenindamine", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination. Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome. Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation. Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures. Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked. Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68306/", "reference_text": "[1] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82[2] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978): 1097-100[3] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967): 1112-3[4] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973): 348-50[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965): 749-56[6] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986): 571[7] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970): 1787-90[8] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994): 619-20[9] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986): 339-41[10] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983): 174-8[12] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983): 957-9[13] \"Product Information. Cogentin (benztropine).\" Merck & Co, Inc, West Point, PA.[14] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981): 313-7[15] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978): 243-4[16] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[17] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[18] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[19] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Tripelennamine, Lidocaine, Tetracaine, Methdilazine, Azatadine, Ketotifen, Alimemazine, Fexofenadine, Loratadine, Trimethobenzamide, Phenindamine, More", "alternatives_b": "Clemastine, Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole", "updated_at": 1767369485}, {"id": 68220, "ingredient1": "Clemastine", "ingredient2": "Phenobarbital", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68307/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "Nitrazepam, Zopiclone, Lacosamide", "updated_at": 1767369485}, {"id": 68221, "ingredient1": "Clemastine", "ingredient2": "Phensuximide", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68308/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Tripelennamine, Lidocaine, Tetracaine, Pheniramine, Methdilazine, Azatadine, Ketotifen, Meclizine, Alimemazine, Chlorcyclizine, Fexofenadine, More", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 68222, "ingredient1": "Clemastine", "ingredient2": "Phenytoin", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68309/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Lacosamide", "alternatives_b": "Pheniramine, Ketotifen, Chlorcyclizine, Dexchlorpheniramine, Astemizole, Azelastine, Terfenadine, Pheniramine", "updated_at": 1767369485}, {"id": 68223, "ingredient1": "Clemastine", "ingredient2": "Physostigmine", "severity": "Moderate", "effect": "Due to opposing effects, agents that possess anticholinergic activity (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; class IA antiarrhythmics especially disopyramide; carbamazepine; cimetidine; ranitidine) may negate the already small pharmacologic benefits of acetylcholinesterase inhibitors in the treatment of dementia. These agents may also adversely affect elderly patients in general. Clinically significant mental status changes associated with anticholinergic agents can range from mild cognitive impairment to delirium, and patients with Alzheimer's disease and other dementia are especially sensitive.", "source": "DDInter", "management_text": "Drugs that possess anticholinergic activity should generally be avoided in patients with Alzheimer's disease or other cognitive impairment, regardless of whether they are receiving an acetylcholinesterase inhibitor. For patients requiring treatment to counteract adverse effects of acetylcholinesterase inhibitor therapy (e.g., gastrointestinal intolerance, urinary problems), an agent without anticholinergic properties should be used whenever possible. Otherwise, a dosage reduction, slower titration, or even discontinuation of the acetylcholinesterase inhibitor should be considered. For patients who are already receiving an acetylcholinesterase inhibitor with anticholinergic agents, every attempt should be made to discontinue the latter or substitute them with less anticholinergic alternatives.", "mechanism_text": "Antagonism", "recommendation": "Drugs that possess anticholinergic activity should generally be avoided in patients with Alzheimer's disease or other cognitive impairment, regardless of whether they are receiving an acetylcholinesterase inhibitor.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68310/", "reference_text": "[1] Katz IR, Sands LP, Bilker W, DiFilippo S, Boyce A, D'Angelo K \"Identification of medications that cause cognitive impairment in older people: the case of oxybutynin chloride.\" J Am Geriatr Soc 46 (1998): 8-13[2] Edwards KR, O'Connor JT \"Risk of delirium with concomitant use of tolterodine and acetylcholinesterase inhibitors.\" J Am Geriatr Soc 50 (2002): 1165-6[3] Carnahan RM, Lund BC, Perry PJ, Chrischilles EA \"The concurrent use of anticholinergics and cholinesterase inhibitors: rare event or common practice?\" J Am Geriatr Soc 52 (2004): 2082-7[4] Fick DM, Cooper JW, Wade WE, Waller JL, Maclean JR, Beers MH \"Updating the Beers criteria for potentially inappropriate medication use in older adults: results of a US consensus panel of experts.\" Arch Intern Med 163 (2003): 2716-2724[5] Beers MH, Ouslander JG, Rollingher I, Reuben DB, Brooks J, Beck JC \"Explicit criteria for determining inappropriate medication use in nursing home residents.\" Arch Intern Med 151 (1991): 1825-32[6] Roe CM, Anderson MJ, Spivack B \"Use of anticholinergic medications by older adults with dementia.\" J Am Geriatr Soc 50 (2002): 836-42", "alternatives_a": "Lidocaine, Tetracaine, Ketotifen, Levocetirizine, Cetirizine, Fexofenadine, Loratadine, Trimethobenzamide, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "Latanoprost, Methazolamide, Neostigmine, Pilocarpine, Betaxolol, Diclofenamide, Bimatoprost, Travoprost, Carteolol, Brinzolamide, Acetazolamide, More", "updated_at": 1767369485}, {"id": 68224, "ingredient1": "Clemastine", "ingredient2": "Physostigmine (ophthalmic)", "severity": "Moderate", "effect": "Theoretically, anticholinergic agents and other agents with significant anticholinergic activity (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, class IA antiarrhythmics especially disopyramide) may antagonize the effects of topically administered cholinergic agents such as acetylcholine, carbachol, demecarium, echothiophate, isoflurophate, physostigmine, and pilocarpine. The proposed mechanism involves opposing pharmacodynamic action on muscarinic receptor sites in ocular tissue. This interaction is sometimes desirable and is the basis for using atropine in the treatment of excessive muscarinic side effects and cholinergic crisis induced by cholinergic overdose.", "source": "DDInter", "management_text": "Patients receiving long-term therapy with anticholinergic agents should be monitored for potentially diminished therapeutic (miotic) response to ophthalmic cholinergic therapy, and dosages adjusted as necessary.", "mechanism_text": "Antagonism", "recommendation": "Patients receiving long-term therapy with anticholinergic agents should be monitored for potentially diminished therapeutic (miotic) response to ophthalmic cholinergic therapy, and dosages adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68311/", "reference_text": "[1] \"Product Information. Pilopine HS (pilocarpine ophthalmic).\" Alcon Laboratories Inc, Fort Worth, TX.[2] \"Multum Information Services, Inc. Expert Review Panel\"", "alternatives_a": "Lidocaine, Tetracaine, Ketotifen, Levocetirizine, Cetirizine, Fexofenadine, Loratadine, Trimethobenzamide, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68225, "ingredient1": "Clemastine", "ingredient2": "Pilocarpine (ophthalmic)", "severity": "Moderate", "effect": "Theoretically, anticholinergic agents and other agents with significant anticholinergic activity (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, class IA antiarrhythmics especially disopyramide) may antagonize the effects of topically administered cholinergic agents such as acetylcholine, carbachol, demecarium, echothiophate, isoflurophate, physostigmine, and pilocarpine. The proposed mechanism involves opposing pharmacodynamic action on muscarinic receptor sites in ocular tissue. This interaction is sometimes desirable and is the basis for using atropine in the treatment of excessive muscarinic side effects and cholinergic crisis induced by cholinergic overdose.", "source": "DDInter", "management_text": "Patients receiving long-term therapy with anticholinergic agents should be monitored for potentially diminished therapeutic (miotic) response to ophthalmic cholinergic therapy, and dosages adjusted as necessary.", "mechanism_text": "Antagonism", "recommendation": "Patients receiving long-term therapy with anticholinergic agents should be monitored for potentially diminished therapeutic (miotic) response to ophthalmic cholinergic therapy, and dosages adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68312/", "reference_text": "[1] \"Product Information. Pilopine HS (pilocarpine ophthalmic).\" Alcon Laboratories Inc, Fort Worth, TX.[2] \"Multum Information Services, Inc. Expert Review Panel\"", "alternatives_a": "Lidocaine, Tetracaine, Ketotifen, Levocetirizine, Cetirizine, Fexofenadine, Loratadine, Trimethobenzamide, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68226, "ingredient1": "Clemastine", "ingredient2": "Pimozide", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination. Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome. Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation. Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures. Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked. Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68313/", "reference_text": "[1] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82[2] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978): 1097-100[3] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967): 1112-3[4] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973): 348-50[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965): 749-56[6] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986): 571[7] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970): 1787-90[8] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994): 619-20[9] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986): 339-41[10] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983): 174-8[12] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983): 957-9[13] \"Product Information. Cogentin (benztropine).\" Merck & Co, Inc, West Point, PA.[14] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981): 313-7[15] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978): 243-4[16] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[17] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[18] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[19] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Lidocaine, Tetracaine, Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine", "alternatives_b": "Amisulpride, Pimavanserin", "updated_at": 1767369485}, {"id": 68227, "ingredient1": "Clemastine", "ingredient2": "Pitolisant", "severity": "Moderate", "effect": "Because pitolisant enhances the activity of histaminergic neurons in the brain, centrally acting histamine H1-receptor antagonists or medicines with H1-receptor antagonist properties (e.g., tri- and tetracyclic antidepressants) may impair the efficacy of pitolisant.", "source": "DDInter", "management_text": "According to the manufacturer, coadministration of pitolisant with centrally acting H1-receptor antagonists or tri- and tetracyclic antidepressants should be avoided.", "mechanism_text": "Antagonism", "recommendation": "According to the manufacturer, coadministration of pitolisant with centrally acting H1-receptor antagonists or tri- and tetracyclic antidepressants should be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68314/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Wakix (pitolisant).\" Harmony Biosciences, LLC, Plymouth Meeting, PA.[3] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[4] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[5] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[6] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Lidocaine, Tetracaine, Ketotifen, Dimenhydrinate, Meclizine, Thiethylperazine, Trimethobenzamide, Azelastine, Cyclizine", "alternatives_b": "Dalfampridine, Riluzole, Inotersen, Amifampridine, Tafamidis", "updated_at": 1767369485}, {"id": 68228, "ingredient1": "Clemastine", "ingredient2": "Potassium chloride", "severity": "Major", "effect": "Concomitant use of agents with anticholinergic properties (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, the class IA antiarrhythmic disopyramide) may potentiate the risk of upper gastrointestinal injury associated with oral solid formulations of potassium chloride. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents, thereby creating a high localized concentration of potassium ions in the region of a dissolving tablet or capsule and increasing the contact time with GI mucosa. Solid formulations of potassium chloride have been associated with upper GI bleeding and small bowel ulceration, stenosis, perforation, and obstruction.", "source": "DDInter", "management_text": "The use of oral solid formulations of potassium chloride is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects. A liquid formulation of potassium chloride should be considered. Patients prescribed a solid oral formulation should be advised to discontinue potassium therapy and contact their physician if they experience potential symptoms of upper GI injury such as severe vomiting, abdominal pain, distention, and gastrointestinal bleeding.", "mechanism_text": "Absorption", "recommendation": "The use of oral solid formulations of potassium chloride is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68315/", "reference_text": "[1] Lofgren RP, Rothe PR, Carlson GJ \"Jejunal perforation associated with slow-release potassium chloride therapy.\" South Med J 75 (1982): 1154-5[2] Leijonmarck CE, Raf L \"Ulceration of the small intestine due to slow-release potassium chloride tablets.\" Acta Chir Scand 151 (1985): 273-8[3] Weiss SM, Rutenberg HL, Paskin DL, Zaren HA \"Gut lesions due to slow-release KCI tablets.\" N Engl J Med 296 (1977): 111-2[4] McMahon FG, Ryan JR, Akdamar K, Ertan A \"Effect of potassium chloride supplements on upper gastrointestinal mucosa.\" Clin Pharmacol Ther 35 (1984): 852-5[5] Wynn V \"Potassium chloride and bowel ulceration.\" Br Med J 5477 (1965): 1546[6] Leijonmarck CE, Raf L \"Gastrointestinal lesions and potassium chloride supplements.\" Lancet 1 (1985): 56-7[7] McMahon FG, Ryan JR, Akdamar K, Ertan A \"Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial.\" Lancet 2 (1982): 1059-61[8] Heffernan SJ, Murphy JJ \"Ulceration of small intestine and slow-release potassium tablets.\" Br Med J 2 (1975): 746[9] \"Product Information. K-Dur (potassium chloride).\" Schering Laboratories, Kenilworth, NJ.[10] Lambert JR, Newman A \"Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy.\" Am J Gastroenterol 73 (1980): 508-11[11] Farquharson-Roberts MA, Giddings AE, Nunn AJ \"Perforation of small bowel due to slow release potassium chloride (slow-K).\" Br Med J 3 (1975): 206[12] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[14] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[15] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Tetracaine, Ketotifen, Levocetirizine, Trimethobenzamide, Terfenadine, Astemizole", "alternatives_b": "Potassium bicarbonate, Potassium gluconate, Calcium chloride, Zinc sulfate, Magnesium sulfate, Sodium acetate, Arginine, Sodium glycerophosphate, Zinc chloride, Tromethamine, Sodium phosphate, monobasic, More", "updated_at": 1767369485}, {"id": 68229, "ingredient1": "Clemastine", "ingredient2": "Pramipexole", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68316/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Tetracaine, Ketotifen, Phenindamine, Meclizine, Terfenadine, Astemizole", "alternatives_b": "Selegiline, Cabergoline", "updated_at": 1767369485}, {"id": 68230, "ingredient1": "Clemastine", "ingredient2": "Pregabalin", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68317/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Lacosamide", "alternatives_b": "Tetracaine, Azelastine, Ketotifen, Terfenadine, Astemizole", "updated_at": 1767369485}, {"id": 68231, "ingredient1": "Clemastine", "ingredient2": "Primidone", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68318/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Tetracaine, Azelastine, Ketotifen, Terfenadine, Astemizole", "alternatives_b": "Nitrazepam, Zopiclone, Lacosamide", "updated_at": 1767369485}, {"id": 68232, "ingredient1": "Clemastine", "ingredient2": "Procarbazine", "severity": "Moderate", "effect": "Coadministration of monoamine oxidase inhibitors (MAOIs) and antihistamines may result in additive central nervous system depressant effects. In addition, limited data suggest that MAOIs may potentiate and prolong the anticholinergic effects of antihistamines due to inhibition of catecholamine degradation, which may lead to overstimulation of the sympathetic nervous system.", "source": "DDInter", "management_text": "Prescribing antihistamines in combination with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, linezolid, procarbazine) should generally be avoided. If concomitant treatment is unavoidable, patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "Prescribing antihistamines in combination with MAOIs or other agents that possess MAOI activity (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68319/", "reference_text": "[1] Kahn DA \"Possible toxic interaction between cyproheptadine and phenelzine.\" Am J Psychiatry 144 (1987): 1242-3[2] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[3] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[4] Ferry T, Ponceau B, Simon M, et al. \"Possibly linezolid-induced peripheral and central neurotoxicity: report of four cases.\" Infection 33 (2005): 151-4[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Serio RN \"Acute delirium associated with combined diphenhydramine and linezolid use.\" Ann Pharmacother 38 (2004): 62-5[7] \"Product Information. Benadryl (diphenhydramine).\" Parke-Davis, Morris Plains, NJ.[8] Cerner Multum, Inc. \"Australian Product Information.\" O 0[9] \"Product Information. Periactin (cyproheptadine).\" Merck & Co, Inc, West Point, PA.[10] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[11] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[12] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[13] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[14] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[15] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[16] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[17] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[18] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[19] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[20] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[21] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[22] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[23] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[24] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[25] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[26] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[27] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[28] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80[29] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[30] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[31] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[32] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Lidocaine, Tetracaine, Ketotifen, Dimenhydrinate, Meclizine, Fexofenadine, Loratadine, Trimethobenzamide, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "Pertuzumab, Olaparib, Oxaliplatin, Rucaparib, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, More", "updated_at": 1767369485}, {"id": 68233, "ingredient1": "Clemastine", "ingredient2": "Prochlorperazine", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination. Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome. Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation. Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures. Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked. Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68320/", "reference_text": "[1] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82[2] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978): 1097-100[3] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967): 1112-3[4] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973): 348-50[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965): 749-56[6] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986): 571[7] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970): 1787-90[8] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994): 619-20[9] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986): 339-41[10] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983): 174-8[12] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983): 957-9[13] \"Product Information. Cogentin (benztropine).\" Merck & Co, Inc, West Point, PA.[14] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981): 313-7[15] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978): 243-4[16] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[17] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[18] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[19] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Tetracaine, Azelastine, Ketotifen, Trimethobenzamide", "alternatives_b": "Amisulpride, Pimavanserin", "updated_at": 1767369485}, {"id": 68234, "ingredient1": "Clemastine", "ingredient2": "Procyclidine", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination. Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome. Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation. Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures. Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked. Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68321/", "reference_text": "[1] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82[2] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978): 1097-100[3] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967): 1112-3[4] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973): 348-50[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965): 749-56[6] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986): 571[7] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970): 1787-90[8] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994): 619-20[9] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986): 339-41[10] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983): 174-8[12] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983): 957-9[13] \"Product Information. Cogentin (benztropine).\" Merck & Co, Inc, West Point, PA.[14] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981): 313-7[15] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978): 243-4[16] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[17] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[18] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[19] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Lidocaine, Tetracaine, Ketotifen, Fexofenadine, Trimethobenzamide, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68235, "ingredient1": "Clemastine", "ingredient2": "Promazine", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination. Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome. Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation. Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures. Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked. Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68322/", "reference_text": "[1] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82[2] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978): 1097-100[3] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967): 1112-3[4] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973): 348-50[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965): 749-56[6] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986): 571[7] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970): 1787-90[8] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994): 619-20[9] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986): 339-41[10] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983): 174-8[12] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983): 957-9[13] \"Product Information. Cogentin (benztropine).\" Merck & Co, Inc, West Point, PA.[14] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981): 313-7[15] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978): 243-4[16] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[17] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[18] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[19] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Tripelennamine, Lidocaine, Tetracaine, Methdilazine, Azatadine, Ketotifen, Alimemazine, Fexofenadine, Loratadine, Phenindamine, Desloratadine, More", "alternatives_b": "Amisulpride, Pimavanserin", "updated_at": 1767369485}, {"id": 68236, "ingredient1": "Clemastine", "ingredient2": "Promethazine", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination. Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome. Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation. Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures. Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked. Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68323/", "reference_text": "[1] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82[2] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978): 1097-100[3] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967): 1112-3[4] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973): 348-50[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965): 749-56[6] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986): 571[7] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970): 1787-90[8] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994): 619-20[9] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986): 339-41[10] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983): 174-8[12] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983): 957-9[13] \"Product Information. Cogentin (benztropine).\" Merck & Co, Inc, West Point, PA.[14] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981): 313-7[15] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978): 243-4[16] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[17] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[18] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[19] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Tetracaine, Promethazine, Azelastine, Ketotifen, Promethazine", "alternatives_b": "Clemastine, Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole, Lidocaine, Tetracaine, Clemastine, More", "updated_at": 1767369485}, {"id": 68237, "ingredient1": "Clemastine", "ingredient2": "Propantheline", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination. Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome. Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation. Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures. Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked. Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68324/", "reference_text": "[1] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82[2] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978): 1097-100[3] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967): 1112-3[4] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973): 348-50[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965): 749-56[6] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986): 571[7] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970): 1787-90[8] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994): 619-20[9] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986): 339-41[10] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983): 174-8[12] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983): 957-9[13] \"Product Information. Cogentin (benztropine).\" Merck & Co, Inc, West Point, PA.[14] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981): 313-7[15] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978): 243-4[16] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[17] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[18] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[19] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Lidocaine, Tetracaine, Ketotifen, Levocetirizine, Cetirizine, Fexofenadine, Loratadine, Trimethobenzamide, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "Papaverine, Alosetron, Isometheptene", "updated_at": 1767369485}, {"id": 68238, "ingredient1": "Clemastine", "ingredient2": "Propiomazine", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination. Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome. Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation. Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures. Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked. Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68325/", "reference_text": "[1] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82[2] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978): 1097-100[3] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967): 1112-3[4] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973): 348-50[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965): 749-56[6] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986): 571[7] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970): 1787-90[8] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994): 619-20[9] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986): 339-41[10] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983): 174-8[12] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983): 957-9[13] \"Product Information. Cogentin (benztropine).\" Merck & Co, Inc, West Point, PA.[14] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981): 313-7[15] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978): 243-4[16] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[17] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[18] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[19] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Tripelennamine, Lidocaine, Tetracaine, Methdilazine, Azatadine, Ketotifen, Alimemazine, Fexofenadine, Loratadine, Phenindamine, Desloratadine, More", "alternatives_b": "Nitrazepam, Zopiclone", "updated_at": 1767369485}, {"id": 68239, "ingredient1": "Dextropropoxyphene", "ingredient2": "Clemastine", "severity": "Major", "effect": "Sedatives, tranquilizers, muscle relaxants, antidepressants, and other central nervous system (CNS) depressants may have additive CNS- and/or respiratory-depressant effects with propoxyphene. Misuse of propoxyphene, either alone or in combination with other CNS depressants, has been a major cause of drug-related deaths, particularly in patients with a history of emotional disturbances, suicidal ideation, or alcohol and drug abuse. Pharmacokinetically, propoxyphene is an inhibitor of CYP450 2D6 and may increase the plasma concentrations of many psychotropic agents that are metabolized by the isoenzyme such as phenothiazines, haloperidol, risperidone, phenobarbital, and some tricyclic antidepressants and serotonin reuptake inhibitors.", "source": "DDInter", "management_text": "Caution is advised if propoxyphene is used with sedatives, tranquilizers, muscle relaxants, antidepressants, and other CNS depressants, particularly in the elderly and in patients with a history of emotional disturbances, suicidal ideation, or alcohol and drug abuse. Dosage reductions may be appropriate. Patients should be monitored for potentially excessive or prolonged CNS and respiratory depression and other CNS adverse effects. Patients should be warned not to exceed recommended dosages, to avoid alcohol, and to avoid activities requiring mental alertness until they know how these agents affect them.", "mechanism_text": "Metabolism, Synergism", "recommendation": "Caution is advised if propoxyphene is used with sedatives, tranquilizers, muscle relaxants, antidepressants, and other CNS depressants, particularly in the elderly and in patients with a history of emotional disturbances, suicidal ideation, or alcohol and drug abuse.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68326/", "reference_text": "[1] Hansen BS, Dam M, Brandt J, et al \"Influence of dextropropoxyphene on steady state serum levels and protein binding of three anti-epileptic drugs in man.\" Acta Neurol Scand 61 (1980): 357-67[2] Peterson GR, Covault HP, Hostetler RM \"Acute inhibition of microsomal drug metabolism by propoxphene in narcotic tolerant/dependent mice.\" Life Sci 22 (1978): 2087-96[3] Abernethy DR, Greenblatt DJ, Morse DS, Shader RI \"Interaction of propoxyphene with diazepam, alprazolam and lorazepam.\" Br J Clin Pharmacol 19 (1985): 51-7[4] Abernethy DR, Greenblatt DJ, Steel K, Shader RI \"Impairment of hepatic drug oxidation by propoxyphene.\" Ann Intern Med 97 (1982): 223-4[5] Puckett WH Jr, Visconti JA \"Orphenadrine and propoxyphene.\" N Engl J Med 283 (1970): 544[6] Pearson RE, Salter FJ \"Drug interaction? Orphenadrine with propoxyphene.\" N Engl J Med 282 (1970): 1215[7] Shorr RI, Griffin MR, Daugherty JR, Ray WA \"Opioid analgesics and the risk of hip fracture in the elderly: codeine and propoxyphene.\" J Gerontol 47 (1992): m111-5[8] \"Product Information. Darvon (propoxyphene).\" Lilly, Eli and Company, Indianapolis, IN.[9] \"Product Information. Darvon (propoxyphene).\" Lilly, Eli and Company, Indianapolis, IN.[10] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[11] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[12] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[13] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Lidocaine, Tetracaine, Ketotifen, Levocetirizine, Cetirizine, Acrivastine, Fexofenadine, Loratadine, Desloratadine, Azelastine", "alternatives_b": "Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "updated_at": 1767369485}, {"id": 68240, "ingredient1": "Clemastine", "ingredient2": "Protriptyline", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination. Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome. Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation. Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures. Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked. Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68327/", "reference_text": "[1] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82[2] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978): 1097-100[3] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967): 1112-3[4] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973): 348-50[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965): 749-56[6] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986): 571[7] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970): 1787-90[8] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994): 619-20[9] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986): 339-41[10] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983): 174-8[12] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983): 957-9[13] \"Product Information. Cogentin (benztropine).\" Merck & Co, Inc, West Point, PA.[14] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981): 313-7[15] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978): 243-4[16] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[17] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[18] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[19] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Lidocaine, Tetracaine, Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine", "alternatives_b": "Vilazodone, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Bupropion", "updated_at": 1767369485}, {"id": 68241, "ingredient1": "Clemastine", "ingredient2": "Mepyramine", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination. Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome. Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation. Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures. Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked. Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68328/", "reference_text": "[1] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82[2] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978): 1097-100[3] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967): 1112-3[4] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973): 348-50[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965): 749-56[6] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986): 571[7] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970): 1787-90[8] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994): 619-20[9] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986): 339-41[10] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983): 174-8[12] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983): 957-9[13] \"Product Information. Cogentin (benztropine).\" Merck & Co, Inc, West Point, PA.[14] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981): 313-7[15] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978): 243-4[16] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[17] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[18] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[19] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Lidocaine, Tetracaine, Mepyramine, Ketotifen, Mepyramine, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "Lidocaine, Tetracaine, Clemastine, Clemastine, Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole", "updated_at": 1767369485}, {"id": 68242, "ingredient1": "Clemastine", "ingredient2": "Quazepam", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68329/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Pheniramine, Ketotifen, Meclizine, Azelastine, Thiethylperazine, Dexchlorpheniramine, Phenindamine, Astemizole, Methdilazine, Terfenadine, Pheniramine", "alternatives_b": "Nitrazepam, Zopiclone", "updated_at": 1767369485}, {"id": 68243, "ingredient1": "Clemastine", "ingredient2": "Quetiapine", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination. Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome. Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation. Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures. Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked. Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68330/", "reference_text": "[1] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82[2] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978): 1097-100[3] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967): 1112-3[4] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973): 348-50[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965): 749-56[6] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986): 571[7] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970): 1787-90[8] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994): 619-20[9] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986): 339-41[10] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983): 174-8[12] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983): 957-9[13] \"Product Information. Cogentin (benztropine).\" Merck & Co, Inc, West Point, PA.[14] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981): 313-7[15] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978): 243-4[16] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[17] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[18] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[19] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Tetracaine, Ketotifen", "alternatives_b": "Amisulpride, Pimavanserin", "updated_at": 1767369485}, {"id": 68244, "ingredient1": "Clemastine", "ingredient2": "Ramelteon", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68331/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Lidocaine, Tetracaine, Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "Nitrazepam, Zopiclone", "updated_at": 1767369485}, {"id": 68245, "ingredient1": "Clemastine", "ingredient2": "Ranolazine", "severity": "Minor", "effect": "Coadministration with inhibitors of CYP450 2D6 may modestly increase the plasma concentrations of ranolazine, which is partially metabolized by the isoenzyme. When ranolazine 1000 mg twice a day was given to healthy volunteers with the potent CYP450 2D6 inhibitor paroxetine at 20 mg once a day, mean steady-state ranolazine plasma concentrations increased by 1.2-fold. This is not considered clinically significant, and no dosage adjustment of ranolazine is required when used with CYP450 2D6 inhibitors.", "source": "DDInter", "management_text": "-", "mechanism_text": "Metabolism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68332/", "reference_text": "[1] \"Product Information. Ranexa (ranolazine).\" Calmoseptine Inc, Huntington Beach, CA.[2] \"Product Information. Ranexa (ranolazine).\" Calmoseptine Inc, Huntington Beach, CA.[3] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[4] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[5] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[6] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Alprostadil, Indomethacin, Ibuprofen, Ubidecarenone, Ivabradine, Adenosine, Regadenoson", "alternatives_b": "Lidocaine, Tetracaine, Pheniramine, Mepyramine, Ketotifen, Mepyramine, Levocetirizine, Chlorcyclizine, Acrivastine, Triprolidine, Azelastine, More", "updated_at": 1767369485}, {"id": 68246, "ingredient1": "Clemastine", "ingredient2": "Rasagiline", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68333/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Lidocaine, Tetracaine, Ketotifen, Levocetirizine, Cetirizine, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "Selegiline, Cabergoline", "updated_at": 1767369485}, {"id": 68247, "ingredient1": "Clemastine", "ingredient2": "Remifentanil", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68334/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Tetracaine, Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "Halothane, Isoflurane, Nitrous oxide, Desflurane, Propofol, Enflurane, Sevoflurane, Etomidate", "updated_at": 1767369485}, {"id": 68248, "ingredient1": "Clemastine", "ingredient2": "Remimazolam", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68335/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "Nitrazepam, Zopiclone", "updated_at": 1767369485}, {"id": 68249, "ingredient1": "Clemastine", "ingredient2": "Revefenacin", "severity": "Moderate", "effect": "The potential exists for additive anticholinergic effects such as mydriasis, blurred vision, heat intolerance, fever, dry mouth, tachycardia, urinary retention, constipation, and glaucoma (onset or exacerbation) when topical or inhaled anticholinergic agents are used with each other or with other agents that possess anticholinergic properties. The risk of systemic anticholinergic effects following topical administration depends on variables such as strength of the product, size of the application area, frequency of application, and use of occlusive dressing. Systemic effects are uncommon following oral inhalation or nasal administration due to the poor absorption of quaternary ammonium compounds from gastrointestinal and nasal mucosa.", "source": "DDInter", "management_text": "Topical and inhaled anticholinergic preparations should preferably not be used in combination with other anticholinergic agents or agents with significant anticholinergic effects such as antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, and class IA antiarrhythmics (especially disopyramide). Caution is advised if concomitant use cannot be avoided, particularly in the elderly and those with significantly impaired renal and/or hepatic function.", "mechanism_text": "Synergism", "recommendation": "Topical and inhaled anticholinergic preparations should preferably not be used in combination with other anticholinergic agents or agents with significant anticholinergic effects such as antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, and class IA antiarrhythmics (especially disopyramide).", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68336/", "reference_text": "[1] \"Product Information. Qbrexza (glycopyrrolate topical).\" Dermira, Inc., Menlo Park, CA.[2] \"Product Information. Anoro Ellipta (umeclidinium-vilanterol).\" GlaxoSmithKline, Research Triangle Park, NC.[3] \"Product Information. Combivent (albuterol-ipratropium).\" Boehringer-Ingelheim, Ridgefield, CT.[4] \"Product Information. Atrovent (ipratropium).\" Boehringer-Ingelheim, Ridgefield, CT.[5] \"Product Information. Yupelri (revefenacin).\" Mylan Specialty, Morgantown, WV.[6] \"Product Information. Tudorza Pressair (aclidinium).\" Forest Pharmaceuticals, St. Louis, MO.[7] \"Product Information. Spiriva (tiotropium).\" Boehringer Ingelheim, Ridgefield, CT.[8] Cole JM, Sheehan AH, Jordan JK \"Concomitant use of ipratropium and tiotropium in chronic obstructive plmonary disease.\" Ann Pharmacother 46 (2012): 1717-21[9] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[10] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[11] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[12] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Lidocaine, Tetracaine, Ketotifen, Levocetirizine, Cetirizine, Fexofenadine, Loratadine, Trimethobenzamide, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "Ciclesonide, Mometasone furoate, Budesonide, Flunisolide, Fluticasone, Cromoglicic acid, Betamethasone, Nedocromil, Triamcinolone, Beclomethasone dipropionate", "updated_at": 1767369485}, {"id": 68250, "ingredient1": "Clemastine", "ingredient2": "Botulinum toxin type B", "severity": "Moderate", "effect": "Use of anticholinergic drugs after administration of botulinum toxin may potentiate systemic anticholinergic effects such as dry mouth, blurred vision, and urinary disorders. Botulinum toxin inhibits the release of acetylcholine from peripheral cholinergic nerve endings, thus additive or synergistic anticholinergic effects may occur when these agents are used together.", "source": "DDInter", "management_text": "Patients should be advised that systemic anticholinergic side effects such as dry mouth, blurred vision, and urinary disorders may increase if agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) are used after administration of botulinum toxin.", "mechanism_text": "Synergism", "recommendation": "Patients should be advised that systemic anticholinergic side effects such as dry mouth, blurred vision, and urinary disorders may increase if agents with anticholinergic properties (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68337/", "reference_text": "[1] \"Product Information. Botox (onabotulinumtoxin A).\" Allergan Inc, Irvine, CA.[2] \"Product Information. Myobloc (botulinum toxin type B)\" Elan Pharmaceuticals, S. San Francisco, CA.[3] \"Product Information. Xeomin (botulinum toxin type A (obsolete) (botulinum toxin type A)).\" Merz Pharmaceuticals, Greensboro, NC.[4] \"Product Information. Jeuveau (prabotulinumtoxinA).\" Evolus, Inc., Santa Barbara, CA.[5] \"Product Information. Dysport (abobotulinumtoxinA).\" Tercica Inc, Brisbane, CA.[6] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] \"Product Information. Sanctura (trospium chloride).\" Odyssey Pharmaceutical, East Hanover, NJ.", "alternatives_a": "Lidocaine, Tetracaine, Ketotifen, Levocetirizine, Cetirizine, Fexofenadine, Loratadine, Trimethobenzamide, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68251, "ingredient1": "Clemastine", "ingredient2": "Risperidone", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination. Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome. Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation. Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures. Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked. Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68338/", "reference_text": "[1] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82[2] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978): 1097-100[3] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967): 1112-3[4] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973): 348-50[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965): 749-56[6] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986): 571[7] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970): 1787-90[8] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994): 619-20[9] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986): 339-41[10] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983): 174-8[12] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983): 957-9[13] \"Product Information. Cogentin (benztropine).\" Merck & Co, Inc, West Point, PA.[14] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981): 313-7[15] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978): 243-4[16] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[17] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[18] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[19] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Tetracaine, Azelastine, Ketotifen", "alternatives_b": "Amisulpride, Pimavanserin", "updated_at": 1767369485}, {"id": 68252, "ingredient1": "Clemastine", "ingredient2": "Rivastigmine", "severity": "Moderate", "effect": "Due to opposing effects, agents that possess anticholinergic activity (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; class IA antiarrhythmics especially disopyramide; carbamazepine; cimetidine; ranitidine) may negate the already small pharmacologic benefits of acetylcholinesterase inhibitors in the treatment of dementia. These agents may also adversely affect elderly patients in general. Clinically significant mental status changes associated with anticholinergic agents can range from mild cognitive impairment to delirium, and patients with Alzheimer's disease and other dementia are especially sensitive.", "source": "DDInter", "management_text": "Drugs that possess anticholinergic activity should generally be avoided in patients with Alzheimer's disease or other cognitive impairment, regardless of whether they are receiving an acetylcholinesterase inhibitor. For patients requiring treatment to counteract adverse effects of acetylcholinesterase inhibitor therapy (e.g., gastrointestinal intolerance, urinary problems), an agent without anticholinergic properties should be used whenever possible. Otherwise, a dosage reduction, slower titration, or even discontinuation of the acetylcholinesterase inhibitor should be considered. For patients who are already receiving an acetylcholinesterase inhibitor with anticholinergic agents, every attempt should be made to discontinue the latter or substitute them with less anticholinergic alternatives.", "mechanism_text": "Antagonism", "recommendation": "Drugs that possess anticholinergic activity should generally be avoided in patients with Alzheimer's disease or other cognitive impairment, regardless of whether they are receiving an acetylcholinesterase inhibitor.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68339/", "reference_text": "[1] Katz IR, Sands LP, Bilker W, DiFilippo S, Boyce A, D'Angelo K \"Identification of medications that cause cognitive impairment in older people: the case of oxybutynin chloride.\" J Am Geriatr Soc 46 (1998): 8-13[2] Edwards KR, O'Connor JT \"Risk of delirium with concomitant use of tolterodine and acetylcholinesterase inhibitors.\" J Am Geriatr Soc 50 (2002): 1165-6[3] Carnahan RM, Lund BC, Perry PJ, Chrischilles EA \"The concurrent use of anticholinergics and cholinesterase inhibitors: rare event or common practice?\" J Am Geriatr Soc 52 (2004): 2082-7[4] Fick DM, Cooper JW, Wade WE, Waller JL, Maclean JR, Beers MH \"Updating the Beers criteria for potentially inappropriate medication use in older adults: results of a US consensus panel of experts.\" Arch Intern Med 163 (2003): 2716-2724[5] Beers MH, Ouslander JG, Rollingher I, Reuben DB, Brooks J, Beck JC \"Explicit criteria for determining inappropriate medication use in nursing home residents.\" Arch Intern Med 151 (1991): 1825-32[6] Roe CM, Anderson MJ, Spivack B \"Use of anticholinergic medications by older adults with dementia.\" J Am Geriatr Soc 50 (2002): 836-42", "alternatives_a": "Tetracaine, Ketotifen, Levocetirizine, Cetirizine, Trimethobenzamide, Azelastine", "alternatives_b": "Ginkgo biloba, Aducanumab", "updated_at": 1767369485}, {"id": 68253, "ingredient1": "Clemastine", "ingredient2": "Ropinirole", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68340/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Selegiline, Cabergoline", "alternatives_b": "Tetracaine, Pheniramine, Ketotifen, Dexchlorpheniramine, Phenindamine, Astemizole, Meclizine, Terfenadine, Pheniramine", "updated_at": 1767369485}, {"id": 68254, "ingredient1": "Clemastine", "ingredient2": "Rotigotine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68341/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Lidocaine, Tetracaine, Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "Selegiline, Cabergoline", "updated_at": 1767369485}, {"id": 68255, "ingredient1": "Clemastine", "ingredient2": "Rufinamide", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68342/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Tetracaine, Ketotifen, Fexofenadine, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 68256, "ingredient1": "Clemastine", "ingredient2": "Scopolamine", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination. Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome. Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation. Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures. Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked. Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68343/", "reference_text": "[1] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82[2] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978): 1097-100[3] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967): 1112-3[4] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973): 348-50[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965): 749-56[6] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986): 571[7] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970): 1787-90[8] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994): 619-20[9] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986): 339-41[10] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983): 174-8[12] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983): 957-9[13] \"Product Information. Cogentin (benztropine).\" Merck & Co, Inc, West Point, PA.[14] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981): 313-7[15] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978): 243-4[16] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[17] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[18] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[19] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Tetracaine, Ketotifen, Levocetirizine, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "Nitrazepam, Zopiclone, Tropicamide, Ephedrine, Ketorolac, Phenylephrine, Granisetron, Rolapitant, Aprepitant, Dolasetron, Ondansetron, Palonosetron", "updated_at": 1767369485}, {"id": 68257, "ingredient1": "Clemastine", "ingredient2": "Secobarbital", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68344/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Tetracaine, Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "Nitrazepam, Zopiclone", "updated_at": 1767369485}, {"id": 68258, "ingredient1": "Clemastine", "ingredient2": "Sertraline", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68345/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Tetracaine, Pheniramine, Ketotifen, Meclizine, Chlorcyclizine, Thiethylperazine, Dexchlorpheniramine, Phenindamine, Methdilazine, Pheniramine", "alternatives_b": "Vilazodone, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Bupropion", "updated_at": 1767369485}, {"id": 68259, "ingredient1": "Clemastine", "ingredient2": "Sibutramine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68346/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Lidocaine, Tetracaine, Pheniramine, Azatadine, Ketotifen, Meclizine, Chlorcyclizine, Thiethylperazine, Dexchlorpheniramine, Phenindamine, Astemizole, More", "alternatives_b": "Dexfenfluramine, Naltrexone, Ephedrine, Bupropion, Phentermine, Orlistat, Lorcaserin, Diethylpropion, Mazindol", "updated_at": 1767369485}, {"id": 68260, "ingredient1": "Iodide I-123", "ingredient2": "Clemastine", "severity": "Moderate", "effect": "INTERVAL: Certain drugs may affect the pharmacokinetics, pharmacodynamics, and/or diagnostic results of radioiodides.", "source": "DDInter", "management_text": "Antithyroid agents such as carbimazole or propylthiouracil should generally be withheld for 1 week before administration of sodium iodide I-131 or I-123, and for a few days afterward. Salicylates, steroids, anticoagulants, antihistamines, antiparasitics, penicillins, sulfonamides, tolbutamide, thiopental, and nitroprusside should generally be withheld for 1 week. Amiodarone, lithium, and benzodiazepines should be withheld for at least 4 weeks.", "mechanism_text": "Others", "recommendation": "Antithyroid agents such as carbimazole or propylthiouracil should generally be withheld for 1 week before administration of sodium iodide I-131 or I-123, and for a few days afterward.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68347/", "reference_text": "[1] \"Product Information. Sodium Iodide I-123 (sodium iodide I-123).\" GE Healthcare, Princeton, NJ.[2] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[3] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[4] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[5] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Lidocaine, Tetracaine, Doxepin, Ketotifen, Dimenhydrinate, Meclizine, Thiethylperazine, Trimethobenzamide, Doxylamine, Azelastine, Cyclizine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68261, "ingredient1": "Iodide I-131", "ingredient2": "Clemastine", "severity": "Moderate", "effect": "INTERVAL: Certain drugs may affect the pharmacokinetics, pharmacodynamics, and/or diagnostic results of radioiodides.", "source": "DDInter", "management_text": "Antithyroid agents such as carbimazole or propylthiouracil should generally be withheld for 1 week before administration of sodium iodide I-131 or I-123, and for a few days afterward. Salicylates, steroids, anticoagulants, antihistamines, antiparasitics, penicillins, sulfonamides, tolbutamide, thiopental, and nitroprusside should generally be withheld for 1 week. Amiodarone, lithium, and benzodiazepines should be withheld for at least 4 weeks.", "mechanism_text": "Others", "recommendation": "Antithyroid agents such as carbimazole or propylthiouracil should generally be withheld for 1 week before administration of sodium iodide I-131 or I-123, and for a few days afterward.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68348/", "reference_text": "[1] \"Product Information. Sodium Iodide I-123 (sodium iodide I-123).\" GE Healthcare, Princeton, NJ.[2] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[3] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[4] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[5] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Lidocaine, Tetracaine, Doxepin, Ketotifen, Dimenhydrinate, Meclizine, Thiethylperazine, Trimethobenzamide, Doxylamine, Azelastine, Cyclizine", "alternatives_b": "Ibritumomab tiuxetan, Tositumomab", "updated_at": 1767369485}, {"id": 68262, "ingredient1": "Clemastine", "ingredient2": "Sodium oxybate", "severity": "Major", "effect": "The central nervous system and respiratory depressant effects of sodium oxybate, which is the sodium salt of gamma hydroxybutyrate (GHB), may be potentiated by concomitant use of other agents with CNS depressant effects. An increased risk of serious adverse reactions such as respiratory depression, hypotension, profound sedation, syncope, coma, and even death should be considered.", "source": "DDInter", "management_text": "Concomitant use of sodium oxybate with other CNS depressants should be avoided whenever possible. Otherwise, close monitoring and/or dosage reductions should be considered. If short-term use of a CNS depressant is required (e.g., post- or perioperative opioid), a temporary interruption of sodium oxybate therapy may be appropriate.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of sodium oxybate with other CNS depressants should be avoided whenever possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68349/", "reference_text": "[1] \"Product Information. Xyrem (sodium oxybate).\" Orphan Medical, Minnetonka, MN.[2] \"Product Information. Xywav (calcium/magnesium/potass/sodium oxybates).\" Jazz Pharmaceuticals, Palo Alto, CA.[3] \"Product Information. Xyrem (sodium oxybate).\" Orphan Medical, Minnetonka, MN.[4] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[5] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[6] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[7] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Lidocaine, Tetracaine, Pheniramine, Ketotifen, Levocetirizine, Cetirizine, Fexofenadine, Loratadine, Astemizole, Desloratadine, Azelastine, More", "alternatives_b": "Halothane, Isoflurane, Nitrous oxide, Desflurane, Propofol, Enflurane, Sevoflurane, Etomidate, Dalfampridine, Riluzole, Inotersen, More", "updated_at": 1767369485}, {"id": 68263, "ingredient1": "Clemastine", "ingredient2": "Solifenacin", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination. Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome. Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation. Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures. Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked. Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68350/", "reference_text": "[1] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82[2] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978): 1097-100[3] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967): 1112-3[4] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973): 348-50[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965): 749-56[6] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986): 571[7] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970): 1787-90[8] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994): 619-20[9] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986): 339-41[10] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983): 174-8[12] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983): 957-9[13] \"Product Information. Cogentin (benztropine).\" Merck & Co, Inc, West Point, PA.[14] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981): 313-7[15] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978): 243-4[16] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[17] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[18] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[19] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Lidocaine, Tetracaine, Ketotifen, Levocetirizine, Cetirizine, Fexofenadine, Loratadine, Trimethobenzamide, Desloratadine, Azelastine", "alternatives_b": "Pentosan polysulfate, Calcium chloride, Phenazopyridine, Sildenafil, Mirabegron, Alprostadil, Acetohydroxamic acid, Yohimbine, Avanafil, Papaverine, Vardenafil, More", "updated_at": 1767369485}, {"id": 68264, "ingredient1": "Clemastine", "ingredient2": "St. John's Wort", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68351/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Tetracaine, Pheniramine, Methdilazine, Azatadine, Ketotifen, Meclizine, Chlorcyclizine, Thiethylperazine, Dexchlorpheniramine, Loratadine, Phenindamine, More", "alternatives_b": "Vilazodone, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Bupropion", "updated_at": 1767369485}, {"id": 68265, "ingredient1": "Clemastine", "ingredient2": "Stiripentol", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68352/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Tetracaine, Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine, Astemizole", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 68266, "ingredient1": "Clemastine", "ingredient2": "Sufentanil", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68353/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Tetracaine, Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "Halothane, Isoflurane, Nitrous oxide, Desflurane, Propofol, Enflurane, Sevoflurane, Etomidate", "updated_at": 1767369485}, {"id": 68267, "ingredient1": "Clemastine", "ingredient2": "Suvorexant", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68354/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Lidocaine, Tetracaine, Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "Nitrazepam, Zopiclone", "updated_at": 1767369485}, {"id": 68268, "ingredient1": "Clemastine", "ingredient2": "Tacrine", "severity": "Moderate", "effect": "Due to opposing effects, agents that possess anticholinergic activity (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; class IA antiarrhythmics especially disopyramide; carbamazepine; cimetidine; ranitidine) may negate the already small pharmacologic benefits of acetylcholinesterase inhibitors in the treatment of dementia. These agents may also adversely affect elderly patients in general. Clinically significant mental status changes associated with anticholinergic agents can range from mild cognitive impairment to delirium, and patients with Alzheimer's disease and other dementia are especially sensitive.", "source": "DDInter", "management_text": "Drugs that possess anticholinergic activity should generally be avoided in patients with Alzheimer's disease or other cognitive impairment, regardless of whether they are receiving an acetylcholinesterase inhibitor. For patients requiring treatment to counteract adverse effects of acetylcholinesterase inhibitor therapy (e.g., gastrointestinal intolerance, urinary problems), an agent without anticholinergic properties should be used whenever possible. Otherwise, a dosage reduction, slower titration, or even discontinuation of the acetylcholinesterase inhibitor should be considered. For patients who are already receiving an acetylcholinesterase inhibitor with anticholinergic agents, every attempt should be made to discontinue the latter or substitute them with less anticholinergic alternatives.", "mechanism_text": "Antagonism", "recommendation": "Drugs that possess anticholinergic activity should generally be avoided in patients with Alzheimer's disease or other cognitive impairment, regardless of whether they are receiving an acetylcholinesterase inhibitor.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68355/", "reference_text": "[1] Katz IR, Sands LP, Bilker W, DiFilippo S, Boyce A, D'Angelo K \"Identification of medications that cause cognitive impairment in older people: the case of oxybutynin chloride.\" J Am Geriatr Soc 46 (1998): 8-13[2] Edwards KR, O'Connor JT \"Risk of delirium with concomitant use of tolterodine and acetylcholinesterase inhibitors.\" J Am Geriatr Soc 50 (2002): 1165-6[3] Carnahan RM, Lund BC, Perry PJ, Chrischilles EA \"The concurrent use of anticholinergics and cholinesterase inhibitors: rare event or common practice?\" J Am Geriatr Soc 52 (2004): 2082-7[4] Fick DM, Cooper JW, Wade WE, Waller JL, Maclean JR, Beers MH \"Updating the Beers criteria for potentially inappropriate medication use in older adults: results of a US consensus panel of experts.\" Arch Intern Med 163 (2003): 2716-2724[5] Beers MH, Ouslander JG, Rollingher I, Reuben DB, Brooks J, Beck JC \"Explicit criteria for determining inappropriate medication use in nursing home residents.\" Arch Intern Med 151 (1991): 1825-32[6] Roe CM, Anderson MJ, Spivack B \"Use of anticholinergic medications by older adults with dementia.\" J Am Geriatr Soc 50 (2002): 836-42", "alternatives_a": "Lidocaine, Tetracaine, Ketotifen, Levocetirizine, Cetirizine, Fexofenadine, Loratadine, Trimethobenzamide, Desloratadine, Azelastine", "alternatives_b": "Ginkgo biloba, Aducanumab", "updated_at": 1767369485}, {"id": 68269, "ingredient1": "Clemastine", "ingredient2": "Tapentadol", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68356/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Lidocaine, Tetracaine, Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "updated_at": 1767369485}, {"id": 68270, "ingredient1": "Clemastine", "ingredient2": "Tasimelteon", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68357/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Lidocaine, Tetracaine, Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "Nitrazepam, Zopiclone", "updated_at": 1767369485}, {"id": 68271, "ingredient1": "Clemastine", "ingredient2": "Temazepam", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68358/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Nitrazepam, Zopiclone", "alternatives_b": "Pheniramine, Ketotifen, Chlorcyclizine, Dexchlorpheniramine, Astemizole, Azelastine, Terfenadine, Pheniramine", "updated_at": 1767369485}, {"id": 68272, "ingredient1": "Clemastine", "ingredient2": "Tetrabenazine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68359/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Lidocaine, Tetracaine, Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine", "alternatives_b": "Dalfampridine, Riluzole, Inotersen, Amifampridine, Tafamidis", "updated_at": 1767369485}, {"id": 68273, "ingredient1": "Clemastine", "ingredient2": "Thalidomide", "severity": "Moderate", "effect": "Thalidomide can commonly cause drowsiness/sedation and may have additive effects with other drugs that cause central nervous system (CNS) depression.", "source": "DDInter", "management_text": "Caution is advised when thalidomide is used with other CNS depressants such as anticonvulsants, antihistamines, antidepressants, antipsychotics, anxiolytics, opioids, and sedatives/hypnotics. Patients should be advised to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities. Dosage reductions may be necessary. Thalidomide should preferably be administered at bedtime to reduce the impact of somnolence. Alcohol use is not recommended.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when thalidomide is used with other CNS depressants such as anticonvulsants, antihistamines, antidepressants, antipsychotics, anxiolytics, opioids, and sedatives/hypnotics.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68360/", "reference_text": "[1] \"Product Information. Thalomid (thalidomide).\" Celgene Corporation, Warren, NJ.[2] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[3] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[4] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[5] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[6] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[7] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[8] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[9] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Tetracaine, Chlorcyclizine, Ketotifen, Dimenhydrinate, Azelastine", "alternatives_b": "Golimumab, Cyclosporine, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, More", "updated_at": 1767369485}, {"id": 68274, "ingredient1": "Clemastine", "ingredient2": "Thiethylperazine", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination. Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome. Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation. Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures. Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked. Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68361/", "reference_text": "[1] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82[2] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978): 1097-100[3] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967): 1112-3[4] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973): 348-50[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965): 749-56[6] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986): 571[7] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970): 1787-90[8] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994): 619-20[9] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986): 339-41[10] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983): 174-8[12] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983): 957-9[13] \"Product Information. Cogentin (benztropine).\" Merck & Co, Inc, West Point, PA.[14] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981): 313-7[15] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978): 243-4[16] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[17] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[18] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[19] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Lidocaine, Tetracaine, Ketotifen, Fexofenadine, Thiethylperazine, Trimethobenzamide, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "Clemastine, Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole", "updated_at": 1767369485}, {"id": 68275, "ingredient1": "Clemastine", "ingredient2": "Thiopental", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68362/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Lidocaine, Tetracaine, Pheniramine, Azatadine, Ketotifen, Azelastine, Fexofenadine, Triprolidine, Loratadine, Dexchlorpheniramine, Astemizole, More", "alternatives_b": "Halothane, Isoflurane, Nitrous oxide, Desflurane, Propofol, Enflurane, Sevoflurane, Etomidate, Nitrazepam, Zopiclone", "updated_at": 1767369485}, {"id": 68276, "ingredient1": "Clemastine", "ingredient2": "Thioridazine", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination. Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome. Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation. Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures. Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked. Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68363/", "reference_text": "[1] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82[2] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978): 1097-100[3] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967): 1112-3[4] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973): 348-50[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965): 749-56[6] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986): 571[7] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970): 1787-90[8] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994): 619-20[9] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986): 339-41[10] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983): 174-8[12] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983): 957-9[13] \"Product Information. Cogentin (benztropine).\" Merck & Co, Inc, West Point, PA.[14] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981): 313-7[15] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978): 243-4[16] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[17] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[18] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[19] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Lidocaine, Tetracaine, Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine", "alternatives_b": "Amisulpride, Pimavanserin", "updated_at": 1767369485}, {"id": 68277, "ingredient1": "Clemastine", "ingredient2": "Thiothixene", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination. Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome. Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation. Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures. Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked. Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68364/", "reference_text": "[1] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82[2] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978): 1097-100[3] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967): 1112-3[4] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973): 348-50[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965): 749-56[6] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986): 571[7] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970): 1787-90[8] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994): 619-20[9] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986): 339-41[10] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983): 174-8[12] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983): 957-9[13] \"Product Information. Cogentin (benztropine).\" Merck & Co, Inc, West Point, PA.[14] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981): 313-7[15] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978): 243-4[16] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[17] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[18] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[19] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Lidocaine, Tetracaine, Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "Amisulpride, Pimavanserin", "updated_at": 1767369485}, {"id": 68278, "ingredient1": "Clemastine", "ingredient2": "Tiagabine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68365/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Tetracaine, Pheniramine, Methdilazine, Azatadine, Ketotifen, Meclizine, Thiethylperazine, Dexchlorpheniramine, Phenindamine, Astemizole, Desloratadine, More", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 68279, "ingredient1": "Clemastine", "ingredient2": "Tiotropium", "severity": "Moderate", "effect": "The potential exists for additive anticholinergic effects such as mydriasis, blurred vision, heat intolerance, fever, dry mouth, tachycardia, urinary retention, constipation, and glaucoma (onset or exacerbation) when topical or inhaled anticholinergic agents are used with each other or with other agents that possess anticholinergic properties. The risk of systemic anticholinergic effects following topical administration depends on variables such as strength of the product, size of the application area, frequency of application, and use of occlusive dressing. Systemic effects are uncommon following oral inhalation or nasal administration due to the poor absorption of quaternary ammonium compounds from gastrointestinal and nasal mucosa.", "source": "DDInter", "management_text": "Topical and inhaled anticholinergic preparations should preferably not be used in combination with other anticholinergic agents or agents with significant anticholinergic effects such as antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, and class IA antiarrhythmics (especially disopyramide). Caution is advised if concomitant use cannot be avoided, particularly in the elderly and those with significantly impaired renal and/or hepatic function.", "mechanism_text": "Synergism", "recommendation": "Topical and inhaled anticholinergic preparations should preferably not be used in combination with other anticholinergic agents or agents with significant anticholinergic effects such as antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, and class IA antiarrhythmics (especially disopyramide).", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68366/", "reference_text": "[1] \"Product Information. Qbrexza (glycopyrrolate topical).\" Dermira, Inc., Menlo Park, CA.[2] \"Product Information. Anoro Ellipta (umeclidinium-vilanterol).\" GlaxoSmithKline, Research Triangle Park, NC.[3] \"Product Information. Combivent (albuterol-ipratropium).\" Boehringer-Ingelheim, Ridgefield, CT.[4] \"Product Information. Atrovent (ipratropium).\" Boehringer-Ingelheim, Ridgefield, CT.[5] \"Product Information. Yupelri (revefenacin).\" Mylan Specialty, Morgantown, WV.[6] \"Product Information. Tudorza Pressair (aclidinium).\" Forest Pharmaceuticals, St. Louis, MO.[7] \"Product Information. Spiriva (tiotropium).\" Boehringer Ingelheim, Ridgefield, CT.[8] Cole JM, Sheehan AH, Jordan JK \"Concomitant use of ipratropium and tiotropium in chronic obstructive plmonary disease.\" Ann Pharmacother 46 (2012): 1717-21[9] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[10] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[11] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[12] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Tetracaine, Levocetirizine, Trimethobenzamide, Terfenadine, Astemizole", "alternatives_b": "Mometasone furoate, Terbutaline, Budesonide, Mometasone, Epinephrine, Olodaterol, Fluticasone, Cromoglicic acid, Salbutamol, Orciprenaline, Pirbuterol, More", "updated_at": 1767369485}, {"id": 68280, "ingredient1": "Clemastine", "ingredient2": "Tizanidine", "severity": "Moderate", "effect": "The sedative effect of tizanidine may be potentiated by concomitant use of other agents with central nervous system (CNS) depressant effects. In addition, tizanidine and many of these agents (e.g., alcohol, anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, muscle relaxants) also can exhibit hypotensive effects, which may be additive during coadministration and may increase the risk of symptomatic hypotension and orthostasis, particularly during initiation of therapy or dose escalation. Tizanidine itself is a central alpha-2 adrenergic agonist. Pharmacologic studies have found tizanidine to possess between 1/10 to 1/50 of the potency of clonidine, a structurally similar agent, in lowering blood pressure.", "source": "DDInter", "management_text": "Caution is advised and more gradual dose titration may be appropriate when tizanidine is used with other substances that can cause CNS depression and/or hypotension, particularly in elderly or debilitated patients. Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to avoid rising abruptly from a sitting or recumbent position. Patients should contact their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or excessive CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "Caution is advised and more gradual dose titration may be appropriate when tizanidine is used with other substances that can cause CNS depression and/or hypotension, particularly in elderly or debilitated patients.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68367/", "reference_text": "[1] \"Product Information. Zanaflex (tizanidine).\" Acorda Therapeutics, Hawthorne, NY.[2] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[3] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[4] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[5] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Tetracaine, Azelastine, Ketotifen", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68281, "ingredient1": "Clemastine", "ingredient2": "Tolcapone", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68368/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Lidocaine, Tetracaine, Pheniramine, Ketotifen, Meclizine, Fexofenadine, Dexchlorpheniramine, Loratadine, Phenindamine, Astemizole, Desloratadine, More", "alternatives_b": "Selegiline, Cabergoline", "updated_at": 1767369485}, {"id": 68282, "ingredient1": "Clemastine", "ingredient2": "Tolterodine", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination. Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome. Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation. Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures. Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked. Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68369/", "reference_text": "[1] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82[2] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978): 1097-100[3] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967): 1112-3[4] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973): 348-50[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965): 749-56[6] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986): 571[7] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970): 1787-90[8] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994): 619-20[9] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986): 339-41[10] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983): 174-8[12] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983): 957-9[13] \"Product Information. Cogentin (benztropine).\" Merck & Co, Inc, West Point, PA.[14] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981): 313-7[15] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978): 243-4[16] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[17] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[18] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[19] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Tetracaine, Ketotifen, Levocetirizine, Trimethobenzamide, Terfenadine, Astemizole", "alternatives_b": "Pentosan polysulfate, Calcium chloride, Phenazopyridine, Sildenafil, Mirabegron, Alprostadil, Acetohydroxamic acid, Yohimbine, Avanafil, Papaverine, Vardenafil, More", "updated_at": 1767369485}, {"id": 68283, "ingredient1": "Clemastine", "ingredient2": "Topiramate", "severity": "Major", "effect": "Certain drugs such as carbonic anhydrase inhibitors and drugs with anticholinergic activity (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, disopyramide) may potentiate the risk of oligohidrosis and hyperthermia associated occasionally with the use of topiramate, particularly in pediatric patients. These agents may alter electrolyte and fluid balance (carbonic anhydrase inhibition), inhibit peripheral sweating mechanisms (anticholinergic effect), and/or interfere with core body temperature regulation in the hypothalamus (neuroleptics and phenothiazines), resulting in the inability to adjust to temperature changes, especially in hot weather. Also, agents with anticholinergic activity frequently cause drowsiness and other central nervous system-depressant effects, which may be additively or synergistically increased in patients also treated with topiramate.", "source": "DDInter", "management_text": "Caution is advised when topiramate is prescribed with other drugs that predispose patients to heat-related disorders, including carbonic anhydrase inhibitors and drugs with anticholinergic activity. Patients, particularly pediatric patients, should be monitored closely for evidence of decreased sweating and increased body temperature, especially in warm or hot weather. Proper hydration before and during vigorous activities or exposure to warm temperatures is recommended. Patients (or their guardians or caregivers) should contact their physician immediately if they are not sweating as usual, with or without a fever. Ambulatory patients treated with topiramate and agents with anticholinergic activity should also be made aware of the possibility of additive CNS effects (e.g., drowsiness, dizziness, lightheadedness, confusion) and counseled to avoid activities requiring mental alertness until they know how these agents affect them.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when topiramate is prescribed with other drugs that predispose patients to heat-related disorders, including carbonic anhydrase inhibitors and drugs with anticholinergic activity.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68370/", "reference_text": "[1] \"Product Information. Topamax (topiramate).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[2] \"Product Information. Ionamin (phentermine).\" Rhone-Poulenc Rorer, Collegeville, PA.[3] Mendelson J, Jones RT, Upton R, Jacob P 3rd \"Methamphetamine and ethanol interactions in humans.\" Clin Pharmacol Ther 57 (1995): 559-68[4] \"Product Information. Didrex (benzphetamine)\" Pharmacia and Upjohn, Kalamazoo, MI.[5] \"Product Information. Suprenza (phentermine).\" Akrimax Pharmaceuticals, Cranford, NJ.[6] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[7] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[8] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[9] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Lacosamide", "alternatives_b": "Tetracaine, Ketotifen, Terfenadine, Astemizole", "updated_at": 1767369485}, {"id": 68284, "ingredient1": "Clemastine", "ingredient2": "Tranylcypromine", "severity": "Moderate", "effect": "Coadministration of monoamine oxidase inhibitors (MAOIs) and antihistamines may result in additive central nervous system depressant effects. In addition, limited data suggest that MAOIs may potentiate and prolong the anticholinergic effects of antihistamines due to inhibition of catecholamine degradation, which may lead to overstimulation of the sympathetic nervous system.", "source": "DDInter", "management_text": "Prescribing antihistamines in combination with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, linezolid, procarbazine) should generally be avoided. If concomitant treatment is unavoidable, patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "Prescribing antihistamines in combination with MAOIs or other agents that possess MAOI activity (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68371/", "reference_text": "[1] Kahn DA \"Possible toxic interaction between cyproheptadine and phenelzine.\" Am J Psychiatry 144 (1987): 1242-3[2] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[3] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[4] Ferry T, Ponceau B, Simon M, et al. \"Possibly linezolid-induced peripheral and central neurotoxicity: report of four cases.\" Infection 33 (2005): 151-4[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Serio RN \"Acute delirium associated with combined diphenhydramine and linezolid use.\" Ann Pharmacother 38 (2004): 62-5[7] \"Product Information. Benadryl (diphenhydramine).\" Parke-Davis, Morris Plains, NJ.[8] Cerner Multum, Inc. \"Australian Product Information.\" O 0[9] \"Product Information. Periactin (cyproheptadine).\" Merck & Co, Inc, West Point, PA.[10] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[11] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[12] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[13] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[14] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[15] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[16] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[17] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[18] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[19] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[20] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[21] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[22] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[23] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[24] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[25] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[26] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[27] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[28] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80[29] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[30] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[31] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[32] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Lidocaine, Tetracaine, Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "Vilazodone, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Bupropion", "updated_at": 1767369485}, {"id": 68285, "ingredient1": "Clemastine", "ingredient2": "Trazodone", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68372/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Tetracaine, Pheniramine, Azelastine, Ketotifen, Dexchlorpheniramine, Pheniramine", "alternatives_b": "Vilazodone, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Bupropion", "updated_at": 1767369485}, {"id": 68286, "ingredient1": "Clemastine", "ingredient2": "Triazolam", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68373/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Pheniramine, Ketotifen, Astemizole, Desloratadine, Azelastine, Terfenadine, Pheniramine", "alternatives_b": "Nitrazepam, Zopiclone", "updated_at": 1767369485}, {"id": 68287, "ingredient1": "Clemastine", "ingredient2": "Trichophyton mentagrophytes", "severity": "Moderate", "effect": "INTERVAL: Antihistamines may diminish the response to diagnostic skin test antigens. Falsely insignificant or false-negative results may occur in such patients.", "source": "DDInter", "management_text": "Antihistamines should be discontinued approximately 2 to 4 days prior to skin testing procedures.", "mechanism_text": "Others", "recommendation": "Antihistamines should be discontinued approximately 2 to 4 days prior to skin testing procedures.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68374/", "reference_text": "[1] \"Multum Information Services, Inc. Expert Review Panel\"[2] NLM. National Library of Medicine. NIH. National Institutes of Health \"Trichophyton for intradermal skin testing (trichophyton mentagrophytes and trichophyton rubrum) injection [Allermed Laboratories, Inc.] Available from: URL: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=aaeffe62-b538-43ca-a3b9-47e28b765d89\" ([cited 2014]):[3] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[4] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[5] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[6] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Lidocaine, Doxepin, Tetracaine, Pheniramine, Ketotifen, Dimenhydrinate, Meclizine, Thiethylperazine, Dexchlorpheniramine, Trimethobenzamide, Doxylamine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68288, "ingredient1": "Clemastine", "ingredient2": "Trifluoperazine", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination. Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome. Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation. Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures. Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked. Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68375/", "reference_text": "[1] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82[2] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978): 1097-100[3] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967): 1112-3[4] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973): 348-50[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965): 749-56[6] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986): 571[7] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970): 1787-90[8] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994): 619-20[9] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986): 339-41[10] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983): 174-8[12] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983): 957-9[13] \"Product Information. Cogentin (benztropine).\" Merck & Co, Inc, West Point, PA.[14] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981): 313-7[15] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978): 243-4[16] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[17] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[18] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[19] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Lidocaine, Tetracaine, Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine", "alternatives_b": "Amisulpride, Pimavanserin", "updated_at": 1767369485}, {"id": 68289, "ingredient1": "Clemastine", "ingredient2": "Triflupromazine", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination. Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome. Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation. Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures. Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked. Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68376/", "reference_text": "[1] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82[2] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978): 1097-100[3] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967): 1112-3[4] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973): 348-50[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965): 749-56[6] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986): 571[7] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970): 1787-90[8] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994): 619-20[9] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986): 339-41[10] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983): 174-8[12] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983): 957-9[13] \"Product Information. Cogentin (benztropine).\" Merck & Co, Inc, West Point, PA.[14] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981): 313-7[15] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978): 243-4[16] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[17] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[18] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[19] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Tripelennamine, Lidocaine, Tetracaine, Methdilazine, Azatadine, Ketotifen, Alimemazine, Fexofenadine, Loratadine, Phenindamine, Desloratadine, More", "alternatives_b": "Amisulpride, Pimavanserin", "updated_at": 1767369485}, {"id": 68290, "ingredient1": "Clemastine", "ingredient2": "Trihexyphenidyl", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination. Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome. Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation. Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures. Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked. Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68377/", "reference_text": "[1] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82[2] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978): 1097-100[3] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967): 1112-3[4] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973): 348-50[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965): 749-56[6] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986): 571[7] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970): 1787-90[8] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994): 619-20[9] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986): 339-41[10] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983): 174-8[12] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983): 957-9[13] \"Product Information. Cogentin (benztropine).\" Merck & Co, Inc, West Point, PA.[14] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981): 313-7[15] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978): 243-4[16] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[17] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[18] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[19] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Lidocaine, Tetracaine, Ketotifen, Fexofenadine, Trimethobenzamide, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68291, "ingredient1": "Alimemazine", "ingredient2": "Clemastine", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination. Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome. Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation. Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures. Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked. Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68378/", "reference_text": "[1] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82[2] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978): 1097-100[3] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967): 1112-3[4] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973): 348-50[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965): 749-56[6] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986): 571[7] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970): 1787-90[8] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994): 619-20[9] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986): 339-41[10] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983): 174-8[12] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983): 957-9[13] \"Product Information. Cogentin (benztropine).\" Merck & Co, Inc, West Point, PA.[14] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981): 313-7[15] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978): 243-4[16] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[17] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[18] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[19] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Tripelennamine, Lidocaine, Tetracaine, Methdilazine, Azatadine, Ketotifen, Alimemazine, Fexofenadine, Loratadine, Phenindamine, Desloratadine, More", "alternatives_b": "Clemastine, Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole", "updated_at": 1767369485}, {"id": 68292, "ingredient1": "Clemastine", "ingredient2": "Trimethadione", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68379/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Lidocaine, Tetracaine, Pheniramine, Methdilazine, Ketotifen, Chlorcyclizine, Azelastine, Fexofenadine, Thiethylperazine, Dexchlorpheniramine, Loratadine, More", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 68293, "ingredient1": "Clemastine", "ingredient2": "Trimethobenzamide", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68380/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Lidocaine, Tetracaine, Pheniramine, Methdilazine, Ketotifen, Chlorcyclizine, Azelastine, Fexofenadine, Thiethylperazine, Dexchlorpheniramine, Loratadine, More", "alternatives_b": "Clemastine, Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole", "updated_at": 1767369485}, {"id": 68294, "ingredient1": "Clemastine", "ingredient2": "Trimipramine", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination. Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome. Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation. Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures. Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked. Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68381/", "reference_text": "[1] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82[2] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978): 1097-100[3] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967): 1112-3[4] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973): 348-50[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965): 749-56[6] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986): 571[7] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970): 1787-90[8] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994): 619-20[9] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986): 339-41[10] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983): 174-8[12] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983): 957-9[13] \"Product Information. Cogentin (benztropine).\" Merck & Co, Inc, West Point, PA.[14] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981): 313-7[15] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978): 243-4[16] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[17] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[18] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[19] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Lidocaine, Tetracaine, Ketotifen, Fexofenadine, Triprolidine, Desloratadine, Azelastine", "alternatives_b": "Vilazodone, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Bupropion", "updated_at": 1767369485}, {"id": 68295, "ingredient1": "Clemastine", "ingredient2": "Tripelennamine", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination. Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome. Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation. Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures. Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked. Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68382/", "reference_text": "[1] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82[2] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978): 1097-100[3] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967): 1112-3[4] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973): 348-50[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965): 749-56[6] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986): 571[7] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970): 1787-90[8] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994): 619-20[9] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986): 339-41[10] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983): 174-8[12] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983): 957-9[13] \"Product Information. Cogentin (benztropine).\" Merck & Co, Inc, West Point, PA.[14] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981): 313-7[15] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978): 243-4[16] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[17] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[18] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[19] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Tripelennamine, Lidocaine, Tetracaine, Methdilazine, Azatadine, Ketotifen, Alimemazine, Fexofenadine, Loratadine, Phenindamine, Desloratadine, More", "alternatives_b": "Clemastine, Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole, Lidocaine, Tetracaine, Clemastine", "updated_at": 1767369485}, {"id": 68296, "ingredient1": "Clemastine", "ingredient2": "Triprolidine", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination. Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome. Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation. Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures. Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked. Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68383/", "reference_text": "[1] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82[2] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978): 1097-100[3] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967): 1112-3[4] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973): 348-50[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965): 749-56[6] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986): 571[7] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970): 1787-90[8] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994): 619-20[9] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986): 339-41[10] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983): 174-8[12] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983): 957-9[13] \"Product Information. Cogentin (benztropine).\" Merck & Co, Inc, West Point, PA.[14] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981): 313-7[15] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978): 243-4[16] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[17] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[18] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[19] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Lidocaine, Tetracaine, Ketotifen, Fexofenadine, Triprolidine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "Clemastine, Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole", "updated_at": 1767369485}, {"id": 68297, "ingredient1": "Clemastine", "ingredient2": "Trospium", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination. Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome. Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation. Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures. Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked. Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68384/", "reference_text": "[1] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82[2] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978): 1097-100[3] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967): 1112-3[4] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973): 348-50[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965): 749-56[6] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986): 571[7] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970): 1787-90[8] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994): 619-20[9] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986): 339-41[10] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983): 174-8[12] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983): 957-9[13] \"Product Information. Cogentin (benztropine).\" Merck & Co, Inc, West Point, PA.[14] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981): 313-7[15] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978): 243-4[16] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[17] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[18] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[19] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Pentosan polysulfate, Calcium chloride, Phenazopyridine, Sildenafil, Mirabegron, Alprostadil, Acetohydroxamic acid, Yohimbine, Avanafil, Papaverine, Vardenafil, More", "alternatives_b": "Lidocaine, Tetracaine, Ketotifen, Levocetirizine, Cetirizine, Fexofenadine, Loratadine, Trimethobenzamide, Desloratadine, Azelastine, Terfenadine, Astemizole", "updated_at": 1767369485}, {"id": 68298, "ingredient1": "Clemastine", "ingredient2": "Tuberculin purified protein derivative", "severity": "Moderate", "effect": "INTERVAL: Antihistamines may diminish the response to diagnostic skin test antigens. Falsely insignificant or false-negative results may occur in such patients.", "source": "DDInter", "management_text": "Antihistamines should be discontinued approximately 2 to 4 days prior to skin testing procedures.", "mechanism_text": "Others", "recommendation": "Antihistamines should be discontinued approximately 2 to 4 days prior to skin testing procedures.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68385/", "reference_text": "[1] \"Multum Information Services, Inc. Expert Review Panel\"[2] NLM. National Library of Medicine. NIH. National Institutes of Health \"Trichophyton for intradermal skin testing (trichophyton mentagrophytes and trichophyton rubrum) injection [Allermed Laboratories, Inc.] Available from: URL: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=aaeffe62-b538-43ca-a3b9-47e28b765d89\" ([cited 2014]):[3] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[4] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[5] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[6] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Lidocaine, Tetracaine, Doxepin, Ketotifen, Dimenhydrinate, Meclizine, Thiethylperazine, Trimethobenzamide, Doxylamine, Azelastine, Cyclizine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68299, "ingredient1": "Clemastine", "ingredient2": "Umeclidinium", "severity": "Moderate", "effect": "The potential exists for additive anticholinergic effects such as mydriasis, blurred vision, heat intolerance, fever, dry mouth, tachycardia, urinary retention, constipation, and glaucoma (onset or exacerbation) when topical or inhaled anticholinergic agents are used with each other or with other agents that possess anticholinergic properties. The risk of systemic anticholinergic effects following topical administration depends on variables such as strength of the product, size of the application area, frequency of application, and use of occlusive dressing. Systemic effects are uncommon following oral inhalation or nasal administration due to the poor absorption of quaternary ammonium compounds from gastrointestinal and nasal mucosa.", "source": "DDInter", "management_text": "Topical and inhaled anticholinergic preparations should preferably not be used in combination with other anticholinergic agents or agents with significant anticholinergic effects such as antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, and class IA antiarrhythmics (especially disopyramide). Caution is advised if concomitant use cannot be avoided, particularly in the elderly and those with significantly impaired renal and/or hepatic function.", "mechanism_text": "Synergism", "recommendation": "Topical and inhaled anticholinergic preparations should preferably not be used in combination with other anticholinergic agents or agents with significant anticholinergic effects such as antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, and class IA antiarrhythmics (especially disopyramide).", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68386/", "reference_text": "[1] \"Product Information. Qbrexza (glycopyrrolate topical).\" Dermira, Inc., Menlo Park, CA.[2] \"Product Information. Anoro Ellipta (umeclidinium-vilanterol).\" GlaxoSmithKline, Research Triangle Park, NC.[3] \"Product Information. Combivent (albuterol-ipratropium).\" Boehringer-Ingelheim, Ridgefield, CT.[4] \"Product Information. Atrovent (ipratropium).\" Boehringer-Ingelheim, Ridgefield, CT.[5] \"Product Information. Yupelri (revefenacin).\" Mylan Specialty, Morgantown, WV.[6] \"Product Information. Tudorza Pressair (aclidinium).\" Forest Pharmaceuticals, St. Louis, MO.[7] \"Product Information. Spiriva (tiotropium).\" Boehringer Ingelheim, Ridgefield, CT.[8] Cole JM, Sheehan AH, Jordan JK \"Concomitant use of ipratropium and tiotropium in chronic obstructive plmonary disease.\" Ann Pharmacother 46 (2012): 1717-21[9] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[10] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[11] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[12] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Lidocaine, Tetracaine, Ketotifen, Levocetirizine, Cetirizine, Fexofenadine, Loratadine, Trimethobenzamide, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "Mometasone furoate, Terbutaline, Budesonide, Mometasone, Epinephrine, Olodaterol, Fluticasone, Cromoglicic acid, Salbutamol, Orciprenaline, Pirbuterol, More", "updated_at": 1767369485}, {"id": 68300, "ingredient1": "Clemastine", "ingredient2": "Valbenazine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68387/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Lidocaine, Tetracaine, Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine", "alternatives_b": "Dalfampridine, Riluzole, Inotersen, Amifampridine, Tafamidis", "updated_at": 1767369485}, {"id": 68301, "ingredient1": "Clemastine", "ingredient2": "Valerian", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68388/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Lidocaine, Tetracaine, Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "Nitrazepam, Zopiclone", "updated_at": 1767369485}, {"id": 68302, "ingredient1": "Clemastine", "ingredient2": "Venlafaxine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68389/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Tetracaine, Pheniramine, Ketotifen, Meclizine, Chlorcyclizine, Thiethylperazine, Dexchlorpheniramine, Phenindamine, Methdilazine, Pheniramine", "alternatives_b": "Vilazodone, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Bupropion", "updated_at": 1767369485}, {"id": 68303, "ingredient1": "Clemastine", "ingredient2": "Vigabatrin", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68390/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Lidocaine, Tetracaine, Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 68304, "ingredient1": "Clemastine", "ingredient2": "Zaleplon", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68391/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Tetracaine, Pheniramine, Ketotifen, Meclizine, Azelastine, Thiethylperazine, Dexchlorpheniramine, Phenindamine, Astemizole, Methdilazine, Terfenadine, Pheniramine", "alternatives_b": "Nitrazepam, Zopiclone", "updated_at": 1767369485}, {"id": 68305, "ingredient1": "Clemastine", "ingredient2": "Ziconotide", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68392/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Lidocaine, Tetracaine, Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "Salicylic acid, Acetaminophen, Choline salicylate, Diflunisal, Methoxyflurane, Salsalate, Acetylsalicylic acid", "updated_at": 1767369485}, {"id": 68306, "ingredient1": "Clemastine", "ingredient2": "Ziprasidone", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination. Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome. Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation. Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures. Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked. Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68393/", "reference_text": "[1] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82[2] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978): 1097-100[3] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967): 1112-3[4] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973): 348-50[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965): 749-56[6] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986): 571[7] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970): 1787-90[8] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994): 619-20[9] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986): 339-41[10] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983): 174-8[12] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983): 957-9[13] \"Product Information. Cogentin (benztropine).\" Merck & Co, Inc, West Point, PA.[14] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981): 313-7[15] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978): 243-4[16] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[17] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[18] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[19] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Amisulpride, Pimavanserin", "alternatives_b": "Tetracaine, Azelastine, Ketotifen", "updated_at": 1767369485}, {"id": 68307, "ingredient1": "Clemastine", "ingredient2": "Zolpidem", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68394/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Tetracaine, Pheniramine, Meclizine, Thiethylperazine, Dexchlorpheniramine, Phenindamine, Astemizole, Methdilazine, Terfenadine, Pheniramine", "alternatives_b": "Nitrazepam, Zopiclone", "updated_at": 1767369485}, {"id": 68308, "ingredient1": "Clemastine", "ingredient2": "Zonisamide", "severity": "Major", "effect": "Certain drugs such as carbonic anhydrase inhibitors and drugs with anticholinergic activity (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, disopyramide) may potentiate the risk of oligohidrosis and hyperthermia associated occasionally with the use of zonisamide, particularly in pediatric patients. These agents may alter electrolyte and fluid balance (carbonic anhydrase inhibition), inhibit peripheral sweating mechanisms (anticholinergic effect), and/or interfere with core body temperature regulation in the hypothalamus (neuroleptics and phenothiazines), resulting in the inability to adjust to temperature changes, especially in hot weather. Also, agents with anticholinergic activity frequently cause drowsiness and other central nervous system-depressant effects, which may be additively or synergistically increased in patients also treated with zonisamide.", "source": "DDInter", "management_text": "Caution is advised when zonisamide is prescribed with other drugs that predispose patients to heat-related disorders, including carbonic anhydrase inhibitors and drugs with anticholinergic activity. Patients, particularly pediatric patients, should be monitored closely for evidence of decreased sweating and increased body temperature, especially in warm or hot weather. Proper hydration before and during vigorous activities or exposure to warm temperatures is recommended. Patients (or their guardians or caregivers) should contact their physician immediately if they are not sweating as usual, with or without a fever. Ambulatory patients treated with zonisamide and agents with anticholinergic activity should also be made aware of the possibility of additive CNS effects (e.g., drowsiness, dizziness, lightheadedness, confusion) and counseled to avoid activities requiring mental alertness until they know how these agents affect them.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when zonisamide is prescribed with other drugs that predispose patients to heat-related disorders, including carbonic anhydrase inhibitors and drugs with anticholinergic activity.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68395/", "reference_text": "[1] \"Product Information. Zonegran (zonisamide)\" Elan Pharmaceuticals, S. San Francisco, CA.[2] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[3] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[4] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[5] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[6] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[7] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[8] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[9] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Tetracaine, Ketotifen, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "Lacosamide, Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, More", "updated_at": 1767369485}, {"id": 68309, "ingredient1": "Abarelix", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia are known risk factors for torsade de pointes associated with QT interval prolongation.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68396/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[5] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[8] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[9] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[10] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[11] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Darolutamide, Anastrozole, Fulvestrant, Letrozole, Aminoglutethimide, Exemestane", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 68310, "ingredient1": "Abiraterone", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia are known risk factors for torsade de pointes associated with QT interval prolongation.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68397/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[5] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[8] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[9] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[10] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[11] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Darolutamide, Anastrozole, Fulvestrant, Letrozole, Aminoglutethimide, Exemestane", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Naldemedine, More", "updated_at": 1767369485}, {"id": 68311, "ingredient1": "Acetazolamide", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations. Fluid and electrolyte disturbances can lead to serious adverse events including cardiac arrhythmias, seizures, and renal impairment.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment. Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered. Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing. Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68398/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Diovan (valsartan).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Cozaar (losartan).\" Merck & Co, Inc, West Point, PA.[5] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[6] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Simeprevir, Rosuvastatin, Lactic acid, Mitapivat, Amphotericin B, Ciclopirox, Darunavir, Probenecid, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 68312, "ingredient1": "Acetohexamide", "ingredient2": "Magnesium oxide", "severity": "Moderate", "effect": "INTERVAL: Some antacids have been reported to increase the rate of absorption and, rarely, the extent of absorption of oral sulfonylureas. The hypoglycemic effects of these agents may be altered.", "source": "DDInter", "management_text": "Sulfonylureas should be administered at least two hours before or after antacids when possible. Regular monitoring of blood sugar is advisable. In addition, patients should be apprised of the signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nausea, hunger, tremor, weakness, sweating, palpitations), how to treat it, and to contact their physician if it occurs.", "mechanism_text": "Absorption", "recommendation": "Sulfonylureas should be administered at least two hours before or after antacids when possible.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68399/", "reference_text": "[1] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[2] Prendergast BD \"Glyburide and glipizide, second-generation oral sulfonylurea hypoglycemic agents.\" Clin Pharm 3 (1984): 473-85[3] \"Product Information. Micronase (glyburide).\" Pharmacia and Upjohn, Kalamazoo, MI.[4] Kivisto KT, Neuvonen PJ \"Effect of magnesium hydroxide on the absorption and efficacy of tolbutamide and chlorpropamide.\" Eur J Clin Pharmacol 42 (1992): 675-80[5] Kolterman OG \"Glyburide in non-insulin-dependent diabetes: an update.\" Clin Ther 14 (1992): 196-213[6] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[7] Kivisto KT, Neuvonen PJ \"Enhancement of absorption and effect of glipizide by magnesium hydroxide.\" Clin Pharmacol Ther 49 (1991): 39-43[8] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[9] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[10] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[11] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[12] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[13] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[14] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[15] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[16] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[17] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Guar gum, Pramlintide, Alogliptin, Empagliflozin, Dulaglutide, Exenatide, Miglitol, Albiglutide, Rosiglitazone, Ertugliflozin, Semaglutide, More", "alternatives_b": "Magaldrate, Magnesium gluconate, Sodium sulfate, Zinc sulfate, Magnesium sulfate, Magnesium aspartate, Magnesium lactate, Magnesium citrate, Sodium chloride, Zinc gluconate, Magnesium chloride, More", "updated_at": 1767369485}, {"id": 68313, "ingredient1": "Salbutamol", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia are known risk factors for torsade de pointes associated with QT interval prolongation.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68400/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[5] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[8] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[9] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[10] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[11] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Formoterol, Cromoglicic acid, Ipratropium, Isoprenaline, Tiotropium, Beclomethasone dipropionate, Budesonide, Glycopyrronium, Aclidinium, Mometasone, Fluticasone, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Naldemedine, Prucalopride, More", "updated_at": 1767369485}, {"id": 68314, "ingredient1": "Aldesleukin", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline. Rare cases of generalized tonic-clonic seizures and/or loss of consciousness in association with low serum osmolality and electrolyte abnormalities (e.g., hyponatremia, hypokalemia, hypocalcemia, hypomagnesemia) have been reported with the use of bowel cleansing products in patients with no prior history of seizures. The condition resolved with correction of fluid and electrolyte abnormalities.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68401/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.[9] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.", "alternatives_a": "Oprelvekin, Sipuleucel-T, Elapegademase, Ropeginterferon alfa-2b, Sargramostim, Histamine, Pegademase, Pegfilgrastim, Filgrastim, Glatiramer", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 68315, "ingredient1": "Alfentanil", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline. Rare cases of generalized tonic-clonic seizures and/or loss of consciousness in association with low serum osmolality and electrolyte abnormalities (e.g., hyponatremia, hypokalemia, hypocalcemia, hypomagnesemia) have been reported with the use of bowel cleansing products in patients with no prior history of seizures. The condition resolved with correction of fluid and electrolyte abnormalities.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68402/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.[9] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.", "alternatives_a": "Thiopental, Sodium oxybate, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Enflurane, Esketamine, Etomidate, Ketamine", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, More", "updated_at": 1767369485}, {"id": 68316, "ingredient1": "Alfuzosin", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia are known risk factors for torsade de pointes associated with QT interval prolongation.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68403/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[5] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[8] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[9] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[10] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[11] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Tamsulosin, Terazosin, Tadalafil, Finasteride, Silodosin, Dutasteride", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 68317, "ingredient1": "Aluminum hydroxide", "ingredient2": "Citric acid", "severity": "Major", "effect": "The concomitant administration of aluminum-containing products (e.g., antacids and phosphate binders) and citrates may significantly increase serum aluminum concentrations, resulting in toxicity. Citrates enhance the gastrointestinal absorption of aluminum by an unknown mechanism, which may involve the formation of a soluble aluminum-citrate complex. Patients with end-stage renal disease are particularly at risk of developing hyperaluminemia and encephalopathy. Fatalities have been reported.", "source": "DDInter", "management_text": "The concomitant use of aluminum- and citrate-containing products should be avoided in renally impaired patients. Some experts also recommend that healthy patients should separate doses of aluminum-containing antacids and citrates by 2 to 3 hours.", "mechanism_text": "Absorption", "recommendation": "The concomitant use of aluminum- and citrate-containing products should be avoided in renally impaired patients.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68404/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Davies NT \"Anti-nutrient factors affecting mineral utilization.\" Proc Nutr Soc 38 (1979): 121-8[5] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] Mangels AR \"Bone nutrients for vegetarians.\" Am J Clin Nutr 100 (2014): epub[9] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"", "alternatives_a": "Glutamic acid", "alternatives_b": "Magnesium oxide, Magaldrate, Calcium carbonate, Magnesium hydroxide, Magnesium carbonate", "updated_at": 1767369485}, {"id": 68318, "ingredient1": "Amantadine", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline. Rare cases of generalized tonic-clonic seizures and/or loss of consciousness in association with low serum osmolality and electrolyte abnormalities (e.g., hyponatremia, hypokalemia, hypocalcemia, hypomagnesemia) have been reported with the use of bowel cleansing products in patients with no prior history of seizures. The condition resolved with correction of fluid and electrolyte abnormalities.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68405/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.[9] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.", "alternatives_a": "Ropinirole, Opicapone, Cabergoline, Rasagiline, Entacapone, Selegiline, Tolcapone, Rotigotine, Bromocriptine, Pergolide, Pramipexole, More", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, More", "updated_at": 1767369485}, {"id": 68319, "ingredient1": "Amifampridine", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline. Rare cases of generalized tonic-clonic seizures and/or loss of consciousness in association with low serum osmolality and electrolyte abnormalities (e.g., hyponatremia, hypokalemia, hypocalcemia, hypomagnesemia) have been reported with the use of bowel cleansing products in patients with no prior history of seizures. The condition resolved with correction of fluid and electrolyte abnormalities.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68406/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.[9] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.", "alternatives_a": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "alternatives_b": "Dextromethorphan, Sodium oxybate, Riluzole, Inotersen, Tafamidis", "updated_at": 1767369485}, {"id": 68320, "ingredient1": "Amikacin", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate. The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis. The clinical significance of this effect remains unknown.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic. If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Others", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68407/", "reference_text": "[1] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[3] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference) Available from: URL: http://www.mhra.gov.uk/spc-pil/index.htm.\"[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[6] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[7] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Ganciclovir, Acyclovir, Famciclovir, Trifluridine, Chlorhexidine, Povidone-iodine, Mupirocin, Tinidazole", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, More", "updated_at": 1767369485}, {"id": 68321, "ingredient1": "Amikacin (liposome)", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate. The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis. The clinical significance of this effect remains unknown.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic. If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Others", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68408/", "reference_text": "[1] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[3] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference) Available from: URL: http://www.mhra.gov.uk/spc-pil/index.htm.\"[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[6] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[7] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Ganciclovir, Acyclovir, Famciclovir, Trifluridine, Chlorhexidine, Povidone-iodine, Mupirocin, Tinidazole", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, More", "updated_at": 1767369485}, {"id": 68322, "ingredient1": "Amiloride", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations. Fluid and electrolyte disturbances can lead to serious adverse events including cardiac arrhythmias, seizures, and renal impairment.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment. Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered. Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing. Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68409/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Diovan (valsartan).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Cozaar (losartan).\" Merck & Co, Inc, West Point, PA.[5] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[6] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Eplerenone, Finerenone", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 68323, "ingredient1": "Aminophylline", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline. Rare cases of generalized tonic-clonic seizures and/or loss of consciousness in association with low serum osmolality and electrolyte abnormalities (e.g., hyponatremia, hypokalemia, hypocalcemia, hypomagnesemia) have been reported with the use of bowel cleansing products in patients with no prior history of seizures. The condition resolved with correction of fluid and electrolyte abnormalities.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68410/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.[9] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.", "alternatives_a": "Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Montelukast, Dyphylline, Mepolizumab, Roflumilast, Pentoxifylline, More", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, More", "updated_at": 1767369485}, {"id": 68324, "ingredient1": "Aminosalicylic acid", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate. The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis. The clinical significance of this effect remains unknown.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic. If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Others", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68411/", "reference_text": "[1] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[3] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference) Available from: URL: http://www.mhra.gov.uk/spc-pil/index.htm.\"[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[6] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[7] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Pyridoxine, Pretomanid", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, More", "updated_at": 1767369485}, {"id": 68325, "ingredient1": "Amiodarone", "ingredient2": "Picosulfuric acid", "severity": "Major", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval. Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly. Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68412/", "reference_text": "[1] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[2] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[9] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[10] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[11] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[12] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[13] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Tocainide, Moricizine, Bretylium", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Plecanatide, Lubiprostone, Methylcellulose, Magnesium oxide, Linaclotide, Naloxone, Magnesium carbonate", "updated_at": 1767369485}, {"id": 68326, "ingredient1": "Amisulpride", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; hydroxychloroquine; mefloquine), and some narcotic analgesics. The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that can prolong the QT interval, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; mefloquine; halofantrine; lumefantrine), and some narcotic analgesics (methadone; propoxyphene).", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68413/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[6] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[9] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[10] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[11] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[12] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[13] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[14] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[15] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Phenolphthalein, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68327, "ingredient1": "Amitriptyline", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; hydroxychloroquine; mefloquine), and some narcotic analgesics. The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that can prolong the QT interval, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; mefloquine; halofantrine; lumefantrine), and some narcotic analgesics (methadone; propoxyphene).", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68414/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[6] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[9] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[10] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[11] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[12] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[13] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[14] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[15] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "St. John's Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine", "alternatives_b": "Alvimopan, Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, Magnesium carbonate, More", "updated_at": 1767369485}, {"id": 68328, "ingredient1": "Amoxapine", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; hydroxychloroquine; mefloquine), and some narcotic analgesics. The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that can prolong the QT interval, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; mefloquine; halofantrine; lumefantrine), and some narcotic analgesics (methadone; propoxyphene).", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68415/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[6] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[9] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[10] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[11] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[12] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[13] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[14] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[15] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "St. John's Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 68329, "ingredient1": "Amoxicillin", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate. The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis. The clinical significance of this effect remains unknown.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic. If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Others", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68416/", "reference_text": "[1] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[3] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference) Available from: URL: http://www.mhra.gov.uk/spc-pil/index.htm.\"[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[6] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[7] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Tinidazole, Pantoprazole, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Famotidine, Cimetidine, Esomeprazole, Ranitidine, More", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, Sodium sulfate, More", "updated_at": 1767369485}, {"id": 68330, "ingredient1": "Ampicillin", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate. The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis. The clinical significance of this effect remains unknown.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic. If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Others", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68417/", "reference_text": "[1] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[3] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference) Available from: URL: http://www.mhra.gov.uk/spc-pil/index.htm.\"[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[6] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[7] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Tazobactam, Sulbactam, Ganciclovir, Acyclovir, Famciclovir, Trifluridine, Chlorhexidine, Povidone-iodine", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, Sodium sulfate, More", "updated_at": 1767369485}, {"id": 68331, "ingredient1": "Amprenavir", "ingredient2": "Magnesium oxide", "severity": "Moderate", "effect": "INTERVAL: Concurrent administration of antacids or other agents with acid-neutralizing effects may decrease the oral bioavailability of amprenavir and reduce its concentrations in plasma. Amprenavir solubility decreases with increasing pH, thus reduction in gastric acidity may interfere with dissolution of the drug. Subtherapeutic antiretroviral drug levels may lead to reduced viral susceptibility and development of resistance. In contrast, the prodrug fosamprenavir appears to be less affected by antacids.", "source": "DDInter", "management_text": "Amprenavir should be administered at least 1 hour before or after antacids or other oral preparations containing antacids (e.g., didanosine buffered tablets or pediatric oral solution).", "mechanism_text": "Absorption", "recommendation": "Amprenavir should be administered at least 1 hour before or after antacids or other oral preparations containing antacids (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68418/", "reference_text": "[1] \"Product Information. Agenerase (amprenavir).\" Glaxo Wellcome, Research Triangle Pk, NC.[2] \"Product Information. Lexiva (fosamprenavir).\" GlaxoSmithKline, Research Triangle Park, NC.[3] \"Product Information. Agenerase (amprenavir).\" Glaxo Wellcome, Research Triangle Pk, NC.[4] Demarles D, Gillotin C, Bonaventure-Paci S, Vincent I, Fosse S, Taburet AM \"Single-dose pharmacokinetics of amprenavir coadministered with grapefruit juice.\" Antimicrob Agents Chemother 46 (2002): 1589-1590", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Valaciclovir, Zanamivir, Lenacapavir, Telaprevir, Etravirine, More", "alternatives_b": "Magnesium gluconate, Sodium sulfate, Zinc sulfate, Magnesium sulfate, Magnesium aspartate, Magnesium lactate, Magnesium citrate, Sodium chloride, Zinc gluconate, Magnesium chloride, Alvimopan, More", "updated_at": 1767369485}, {"id": 68332, "ingredient1": "Anagrelide", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia are known risk factors for torsade de pointes associated with QT interval prolongation.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68419/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[5] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[8] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[9] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[10] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[11] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Pertuzumab, Olaparib, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 68333, "ingredient1": "Picosulfuric acid", "ingredient2": "Apalutamide", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; hydroxychloroquine; mefloquine), and some narcotic analgesics. The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that can prolong the QT interval, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; mefloquine; halofantrine; lumefantrine), and some narcotic analgesics (methadone; propoxyphene).", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68420/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[6] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[9] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[10] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[11] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[12] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[13] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[14] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[15] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Prucalopride, Linaclotide, More", "alternatives_b": "Darolutamide, Anastrozole, Fulvestrant, Letrozole, Aminoglutethimide, Exemestane", "updated_at": 1767369485}, {"id": 68334, "ingredient1": "Picosulfuric acid", "ingredient2": "Apomorphine", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia are known risk factors for torsade de pointes associated with QT interval prolongation.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68421/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[5] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[8] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[9] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[10] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[11] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Darifenacin, Tadalafil, Ammonium chloride, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, Trospium, Flavoxate, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 68335, "ingredient1": "Picosulfuric acid", "ingredient2": "Aripiprazole", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline. Rare cases of generalized tonic-clonic seizures and/or loss of consciousness in association with low serum osmolality and electrolyte abnormalities (e.g., hyponatremia, hypokalemia, hypocalcemia, hypomagnesemia) have been reported with the use of bowel cleansing products in patients with no prior history of seizures. The condition resolved with correction of fluid and electrolyte abnormalities.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68422/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.[9] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.", "alternatives_a": "Alvimopan, Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, Magnesium carbonate, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68336, "ingredient1": "Picosulfuric acid", "ingredient2": "Arsenic trioxide", "severity": "Major", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval. Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly. Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68423/", "reference_text": "[1] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[2] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[9] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[10] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[11] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[12] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[13] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Pertuzumab, Olaparib, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 68337, "ingredient1": "Picosulfuric acid", "ingredient2": "Asenapine", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; hydroxychloroquine; mefloquine), and some narcotic analgesics. The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that can prolong the QT interval, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; mefloquine; halofantrine; lumefantrine), and some narcotic analgesics (methadone; propoxyphene).", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68424/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[6] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[9] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[10] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[11] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[12] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[13] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[14] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[15] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68338, "ingredient1": "Acetylsalicylic acid", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations. Fluid and electrolyte disturbances can lead to serious adverse events including cardiac arrhythmias, seizures, and renal impairment.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment. Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered. Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing. Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68425/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Diovan (valsartan).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Cozaar (losartan).\" Merck & Co, Inc, West Point, PA.[5] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[6] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Ticagrelor, Betrixaban, Clopidogrel, Apixaban, Rivaroxaban, Iloprost, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, Dipyridamole, More", "alternatives_b": "Alvimopan, Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Prucalopride, Linaclotide, Plecanatide, Magnesium citrate, More", "updated_at": 1767369485}, {"id": 68339, "ingredient1": "Picosulfuric acid", "ingredient2": "Astemizole", "severity": "Major", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval. Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly. Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68426/", "reference_text": "[1] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[2] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[9] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[10] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[11] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[12] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[13] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Ketotifen, Mepyramine, Levocetirizine, Chlorcyclizine, Cetirizine, Acrivastine, Triprolidine, Tripelennamine, Azelastine, Dexbrompheniramine, Clemastine, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Phenolphthalein, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, More", "updated_at": 1767369485}, {"id": 68340, "ingredient1": "Picosulfuric acid", "ingredient2": "Atomoxetine", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; hydroxychloroquine; mefloquine), and some narcotic analgesics. The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that can prolong the QT interval, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; mefloquine; halofantrine; lumefantrine), and some narcotic analgesics (methadone; propoxyphene).", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68427/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[6] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[9] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[10] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[11] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[12] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[13] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[14] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[15] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Solriamfetol, Caffeine, Armodafinil, Citicoline, Modafinil", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Naldemedine, More", "updated_at": 1767369485}, {"id": 68341, "ingredient1": "Picosulfuric acid", "ingredient2": "Atovaquone", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate. The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis. The clinical significance of this effect remains unknown.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic. If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Others", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68428/", "reference_text": "[1] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[3] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference) Available from: URL: http://www.mhra.gov.uk/spc-pil/index.htm.\"[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[6] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[7] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Tinidazole, Quinacrine, Nitazoxanide, Artesunate, Lumefantrine, Artemether, Pyrimethamine, Tafenoquine, Proguanil", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, More", "updated_at": 1767369485}, {"id": 68342, "ingredient1": "Azilsartan medoxomil", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations. Fluid and electrolyte disturbances can lead to serious adverse events including cardiac arrhythmias, seizures, and renal impairment.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment. Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered. Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing. Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68429/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Diovan (valsartan).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Cozaar (losartan).\" Merck & Co, Inc, West Point, PA.[5] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[6] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Amlodipine, Sacubitril, Aliskiren, Nebivolol", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 68343, "ingredient1": "Azithromycin", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate. The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis. Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic. If concomitant use is required, additional bowel cleansing and colonoscopy may be required. The recommended dosage and duration of treatment with sodium picosulfate should not be exceeded. In addition, patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68430/", "reference_text": "[1] Muller-Lissner SA \"Adverse effects of laxatives: fact and fiction.\" Pharmacology 47 (1993): 138-45[2] Schaefer DC, Cheskin LJ \"Constipation in the elderly.\" Am Fam Physician 58 (1998): 907-14[3] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[4] Chin RL \"Laxative-induced hypokalemia.\" Ann Emerg Med 32 (1998): 517-8[5] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference) Available from: URL: http://www.mhra.gov.uk/spc-pil/index.htm.\"[9] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[10] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[11] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[12] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Tinidazole, Ganciclovir, Acyclovir, Famciclovir, Trifluridine, Chlorhexidine, Povidone-iodine", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Magnesium oxide, Plecanatide, Lubiprostone, Methylcellulose, Prucalopride, Linaclotide, Naloxone", "updated_at": 1767369485}, {"id": 68344, "ingredient1": "Aztreonam", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate. The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis. The clinical significance of this effect remains unknown.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic. If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Others", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68431/", "reference_text": "[1] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[3] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference) Available from: URL: http://www.mhra.gov.uk/spc-pil/index.htm.\"[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[6] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[7] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Imipenem", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, More", "updated_at": 1767369485}, {"id": 68345, "ingredient1": "Bacampicillin", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate. The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis. The clinical significance of this effect remains unknown.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic. If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Others", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68432/", "reference_text": "[1] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[3] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference) Available from: URL: http://www.mhra.gov.uk/spc-pil/index.htm.\"[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[6] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[7] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Tazobactam, Sulbactam", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Prucalopride, More", "updated_at": 1767369485}, {"id": 68346, "ingredient1": "Bacitracin", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate. The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis. The clinical significance of this effect remains unknown.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic. If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Others", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68433/", "reference_text": "[1] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[3] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference) Available from: URL: http://www.mhra.gov.uk/spc-pil/index.htm.\"[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[6] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[7] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Tinidazole, Mupirocin, Chlorhexidine, Povidone-iodine", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, More", "updated_at": 1767369485}, {"id": 68347, "ingredient1": "Bedaquiline", "ingredient2": "Picosulfuric acid", "severity": "Major", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval. Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly. Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68434/", "reference_text": "[1] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[2] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[9] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[10] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[11] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[12] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[13] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Pyridoxine, Pretomanid", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 68348, "ingredient1": "Benazepril", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations. Fluid and electrolyte disturbances can lead to serious adverse events including cardiac arrhythmias, seizures, and renal impairment.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment. Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered. Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing. Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68435/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Diovan (valsartan).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Cozaar (losartan).\" Merck & Co, Inc, West Point, PA.[5] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[6] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Felodipine, Amlodipine, Verapamil, Bisoprolol", "alternatives_b": "Alvimopan, Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Prucalopride, Linaclotide, Plecanatide, More", "updated_at": 1767369485}, {"id": 68349, "ingredient1": "Bendroflumethiazide", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations. Fluid and electrolyte disturbances can lead to serious adverse events including cardiac arrhythmias, seizures, and renal impairment.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment. Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered. Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing. Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68436/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Diovan (valsartan).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Cozaar (losartan).\" Merck & Co, Inc, West Point, PA.[5] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[6] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Simeprevir, Rosuvastatin, Lactic acid, Mitapivat, Amphotericin B, Ciclopirox, Darunavir, Probenecid, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 68350, "ingredient1": "Benznidazole", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate. The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis. The clinical significance of this effect remains unknown.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic. If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Others", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68437/", "reference_text": "[1] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[3] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference) Available from: URL: http://www.mhra.gov.uk/spc-pil/index.htm.\"[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[6] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[7] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, More", "alternatives_b": "Miltefosine, Nifurtimox", "updated_at": 1767369485}, {"id": 68351, "ingredient1": "Benzphetamine", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline. Rare cases of generalized tonic-clonic seizures and/or loss of consciousness in association with low serum osmolality and electrolyte abnormalities (e.g., hyponatremia, hypokalemia, hypocalcemia, hypomagnesemia) have been reported with the use of bowel cleansing products in patients with no prior history of seizures. The condition resolved with correction of fluid and electrolyte abnormalities.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68438/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.[9] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.", "alternatives_a": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Prucalopride, Linaclotide, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68352, "ingredient1": "Benzthiazide", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations. Fluid and electrolyte disturbances can lead to serious adverse events including cardiac arrhythmias, seizures, and renal impairment.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment. Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered. Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing. Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68439/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Diovan (valsartan).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Cozaar (losartan).\" Merck & Co, Inc, West Point, PA.[5] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[6] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Simeprevir, Rosuvastatin, Lactic acid, Mitapivat, Amphotericin B, Ciclopirox, Darunavir, Probenecid, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Phenolphthalein, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, More", "updated_at": 1767369485}, {"id": 68353, "ingredient1": "Bepridil", "ingredient2": "Picosulfuric acid", "severity": "Major", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval. Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly. Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68440/", "reference_text": "[1] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[2] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[9] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[10] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[11] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[12] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[13] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Phenolphthalein, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Magnesium oxide, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68354, "ingredient1": "Betamethasone", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The overuse or abuse of laxatives can cause significant loss of electrolytes and potentiate the risk of hypokalemia associated with corticosteroid therapy. Corticosteroids promote the retention of sodium and water and the excretion of potassium. Although these effects are primarily associated with mineralocorticoids like fludrocortisone, they may also occur with higher dosages of glucocorticoids or adrenocorticotropic agents, particularly if given systemically for longer than brief periods.", "source": "DDInter", "management_text": "In general, laxatives should only be used on a short-term, intermittent basis in recommended dosages. During concomitant therapy with corticosteroids, particularly if fludrocortisone or large doses of a glucocorticoid or adrenocorticotropic agent is given, patients should be counseled to recognize potential signs and symptoms of hypokalemia such as fatigue, myalgia, and muscle weakness. If maintenance of bowel regularity is required, patients should be advised to exercise and increase fiber in the diet and/or consider the use of bulk-forming laxatives.", "mechanism_text": "Antagonism", "recommendation": "In general, laxatives should only be used on a short-term, intermittent basis in recommended dosages.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68441/", "reference_text": "[1] Chin RL \"Laxative-induced hypokalemia.\" Ann Emerg Med 32 (1998): 517-8[2] Blumenthal M, Goldberg A, Brinckmann J, eds. \"Herbal Medicine: Expanded Commission E Monographs.\" Newton, MA: Integrative Medicine Communications (2000):[3] Muller-Lissner SA \"Adverse effects of laxatives: fact and fiction.\" Pharmacology 47 (1993): 138-45[4] Seale JP, Compton MR \"Side-effects of corticosteroid agents.\" Med J Aust 144 (1986): 139-42[5] Swartz SL, Dluhy RG \"Corticosteroids: clinical pharmacology and therapeutic use.\" Drugs 16 (1978): 238-55[6] Lieberman P, Patterson R, Kunske R \"Complications of long-term steroid therapy for asthma.\" J Allergy Clin Immunol 49 (1972): 329-36[7] Ramsahoye BH, Davies SV, el-Gaylani N, Sandeman D, Scanlon MF \"The mineralocorticoid effects of high dose hydrocortisone.\" BMJ 310 (1995): 656-7", "alternatives_a": "Ciclesonide, Mupirocin, Mometasone furoate, Budesonide, Mometasone, Epinephrine, Flunisolide, Olopatadine, Vitamin A, Fluticasone, Ipratropium, More", "alternatives_b": "Alvimopan, Sodium sulfate, Sorbitol, Methylnaltrexone, Tegaserod, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Naldemedine, More", "updated_at": 1767369485}, {"id": 68355, "ingredient1": "Bethanechol", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline. Rare cases of generalized tonic-clonic seizures and/or loss of consciousness in association with low serum osmolality and electrolyte abnormalities (e.g., hyponatremia, hypokalemia, hypocalcemia, hypomagnesemia) have been reported with the use of bowel cleansing products in patients with no prior history of seizures. The condition resolved with correction of fluid and electrolyte abnormalities.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68442/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.[9] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.", "alternatives_a": "Ambenonium, Pilocarpine, Cevimeline, Pyridostigmine", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 68356, "ingredient1": "Bicalutamide", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia are known risk factors for torsade de pointes associated with QT interval prolongation.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68443/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[5] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[8] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[9] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[10] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[11] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Darolutamide, Anastrozole, Fulvestrant, Letrozole, Aminoglutethimide, Exemestane, Megestrol acetate, Ethinylestradiol, Diethylstilbestrol, Medroxyprogesterone acetate", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Naldemedine, More", "updated_at": 1767369485}, {"id": 68357, "ingredient1": "Blinatumomab", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline. Rare cases of generalized tonic-clonic seizures and/or loss of consciousness in association with low serum osmolality and electrolyte abnormalities (e.g., hyponatremia, hypokalemia, hypocalcemia, hypomagnesemia) have been reported with the use of bowel cleansing products in patients with no prior history of seizures. The condition resolved with correction of fluid and electrolyte abnormalities.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68444/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.[9] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.", "alternatives_a": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 68358, "ingredient1": "Brexpiprazole", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline. Rare cases of generalized tonic-clonic seizures and/or loss of consciousness in association with low serum osmolality and electrolyte abnormalities (e.g., hyponatremia, hypokalemia, hypocalcemia, hypomagnesemia) have been reported with the use of bowel cleansing products in patients with no prior history of seizures. The condition resolved with correction of fluid and electrolyte abnormalities.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68445/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.[9] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.", "alternatives_a": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68359, "ingredient1": "Bromfenac", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations. Fluid and electrolyte disturbances can lead to serious adverse events including cardiac arrhythmias, seizures, and renal impairment.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment. Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered. Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing. Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68446/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Diovan (valsartan).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Cozaar (losartan).\" Merck & Co, Inc, West Point, PA.[5] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[6] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Fluocinolone acetonide, Fluorometholone", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 68360, "ingredient1": "Bumetanide", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations. Fluid and electrolyte disturbances can lead to serious adverse events including cardiac arrhythmias, seizures, and renal impairment.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment. Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered. Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing. Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68447/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Diovan (valsartan).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Cozaar (losartan).\" Merck & Co, Inc, West Point, PA.[5] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[6] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Simeprevir, Rosuvastatin, Lactic acid, Mitapivat, Amphotericin B, Ciclopirox, Darunavir, Probenecid, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Naldemedine, Prucalopride, More", "updated_at": 1767369485}, {"id": 68361, "ingredient1": "Buprenorphine", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; hydroxychloroquine; mefloquine), and some narcotic analgesics. The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that can prolong the QT interval, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; mefloquine; halofantrine; lumefantrine), and some narcotic analgesics (methadone; propoxyphene).", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68448/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[6] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[9] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[10] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[11] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[12] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[13] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[14] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[15] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Acamprosate, Naltrexone, Varenicline, Disulfiram, Nalmefene, Nicotine, Dihydrocodeine, Acetaminophen, Naloxone, Naltrexone", "alternatives_b": "Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Phenolphthalein, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 68362, "ingredient1": "Bupropion", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline. Rare cases of generalized tonic-clonic seizures and/or loss of consciousness in association with low serum osmolality and electrolyte abnormalities (e.g., hyponatremia, hypokalemia, hypocalcemia, hypomagnesemia) have been reported with the use of bowel cleansing products in patients with no prior history of seizures. The condition resolved with correction of fluid and electrolyte abnormalities.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68449/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.[9] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.", "alternatives_a": "Lorcaserin, Orlistat, Naltrexone, St. John's Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine", "alternatives_b": "Alvimopan, Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, Magnesium carbonate, More", "updated_at": 1767369485}, {"id": 68363, "ingredient1": "Butorphanol", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline. Rare cases of generalized tonic-clonic seizures and/or loss of consciousness in association with low serum osmolality and electrolyte abnormalities (e.g., hyponatremia, hypokalemia, hypocalcemia, hypomagnesemia) have been reported with the use of bowel cleansing products in patients with no prior history of seizures. The condition resolved with correction of fluid and electrolyte abnormalities.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68450/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.[9] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.", "alternatives_a": "Dihydrocodeine, Acetaminophen, Naloxone, Naltrexone", "alternatives_b": "Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, More", "updated_at": 1767369485}, {"id": 68364, "ingredient1": "Cabozantinib", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia are known risk factors for torsade de pointes associated with QT interval prolongation.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68451/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[5] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[8] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[9] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[10] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[11] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Imatinib, Dabrafenib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Selumetinib, Cobimetinib, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Prucalopride, More", "updated_at": 1767369485}, {"id": 68365, "ingredient1": "Capreomycin", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate. The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis. The clinical significance of this effect remains unknown.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic. If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Others", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68452/", "reference_text": "[1] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[3] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference) Available from: URL: http://www.mhra.gov.uk/spc-pil/index.htm.\"[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[6] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[7] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Pyridoxine, Pretomanid", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, More", "updated_at": 1767369485}, {"id": 68366, "ingredient1": "Captopril", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations. Fluid and electrolyte disturbances can lead to serious adverse events including cardiac arrhythmias, seizures, and renal impairment.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment. Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered. Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing. Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68453/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Diovan (valsartan).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Cozaar (losartan).\" Merck & Co, Inc, West Point, PA.[5] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[6] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Felodipine, Amlodipine, Verapamil, Bisoprolol", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Phenolphthalein, Naloxegol, Plecanatide, Magnesium citrate, Bisacodyl, Lactitol, Lubiprostone, More", "updated_at": 1767369485}, {"id": 68367, "ingredient1": "Carbenicillin", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate. The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis. The clinical significance of this effect remains unknown.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic. If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Others", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68454/", "reference_text": "[1] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[3] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference) Available from: URL: http://www.mhra.gov.uk/spc-pil/index.htm.\"[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[6] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[7] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Tazobactam, Sulbactam", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, More", "updated_at": 1767369485}, {"id": 68368, "ingredient1": "Iron", "ingredient2": "Magnesium oxide", "severity": "Moderate", "effect": "INTERVAL: The bioavailability of orally administered iron may be reduced by concomitant administration of antacids or other agents with acid-neutralizing effects. The exact mechanism is unknown but may involve reduced iron solubility due to increase in gastric pH and/or reduced absorption due to complexation or precipitation of the iron.", "source": "DDInter", "management_text": "To minimize the potential for interaction, it may be appropriate to administer oral iron preparations at least two hours apart from antacids or other agents with acid-neutralizing effects.", "mechanism_text": "Absorption", "recommendation": "To minimize the potential for interaction, it may be appropriate to administer oral iron preparations at least two hours apart from antacids or other agents with acid-neutralizing effects.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68455/", "reference_text": "[1] Gugler R, Allgayer H \"Effects of antacids on the clinical pharmacokinetics of drugs. An update.\" Clin Pharmacokinet 18 (1990): 210-9[2] Coste JF, De Barbi VA, Keil LB, Needle MA \"In-vitro interactions of oral hemantics and antacid suspensions.\" Curr Ther Res Clin Exp 22 (1977): 205-16[3] Coste JF, de Bari VA, Keil LB, Needle MA \"In-vitro interactions of oral hematinics.\" Curr Ther Res Clin Exp 22 (1977): 205-15[4] Rastogi SP, Padilla F, Boyd CM \"Effect of aluminum hydroxide on iron absorption.\" Kidney Int 8 (1975): 417[5] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[6] Ekenved G, Halvorsen L, Solvell L \"Influence of a liquid antacid on the absorption of different iron salts.\" Scand J Haematol Suppl 28 (1976): 65-77[7] O'Neil-Cutting MA, Crosby WH \"The effect of antacids on the absorption of simultaneously ingested iron.\" JAMA 255 (1986): 1468-70[8] Wallace KL, Curry SC, LoVecchio F, Raschke R \"Effect of magnesium hydroxide on iron absorption after ferrous sulfate.\" Ann Emerg Med 34 (1999): 685-6[9] Snyder BK, Clark RF \"Effect of magnesium hydroxide administration on iron absorption after a supratherapeutic dose of ferrous sulfate in human volunteers: A randomized controlled trial.\" Ann Emerg Med 33 (1999): 400-5[10] Corby DG, McCullen AH, Chadwick EW, Decker WJ \"Effect of orally administered magnesium hydroxide in experimental iron intoxication.\" J Toxicol Clin Toxicol 23 (1985-86): 489-99[11] Pruchnicki MC, Coyle JD, Hoshaw-Woodard S, Bay WH \"Effect of phosphate binders on supplemental iron absorption in healthy subjects.\" J Clin Pharmacol 42 (2002): 1171-6[12] Hall GJ, Davis AE \"Inhibition of iron absorption by magnesium trisilicate.\" Med J Aust 2 (1969): 95-6", "alternatives_a": "Magnesium sulfate, Magnesium aspartate, Magnesium lactate, Magnesium citrate, Sodium chloride, Magnesium gluconate, Magnesium chloride, Alvimopan, Sorbitol, Tegaserod, Naloxegol, More", "alternatives_b": "Iron sucrose, Cyanocobalamin, Folic acid", "updated_at": 1767369485}, {"id": 68369, "ingredient1": "Cariprazine", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline. Rare cases of generalized tonic-clonic seizures and/or loss of consciousness in association with low serum osmolality and electrolyte abnormalities (e.g., hyponatremia, hypokalemia, hypocalcemia, hypomagnesemia) have been reported with the use of bowel cleansing products in patients with no prior history of seizures. The condition resolved with correction of fluid and electrolyte abnormalities.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68456/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.[9] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.", "alternatives_a": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68370, "ingredient1": "Carteolol", "ingredient2": "Magnesium oxide", "severity": "Minor", "effect": "Concurrent administration with aluminum and magnesium antacids has been shown to decrease the oral bioavailability of certain beta-blockers, although data are conflicting. The exact mechanism of interaction is unknown but may involve cation binding of beta-blockers or a reduction in the dissolution rate due to increased gastric pH. Based on available data, the clinical significance of this potential interaction is difficult to determine. As a precaution, patients may want to consider separating the administration times of beta-blockers and antacids or other aluminum- or magnesium-containing products by at least 2 hours.", "source": "DDInter", "management_text": "-", "mechanism_text": "Absorption", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68457/", "reference_text": "[1] D'Arcy PF, McElnay JC \"Drug-antacid interactions: assessment of clinical importance.\" Drug Intell Clin Pharm 21 (1987): 607-17[2] Regardh CG, Lundborg P, Persson BA \"The effect of antacid, metoclopramide, and propantheline on the bioavailability of metoprolol and atenolol.\" Biopharm Drug Dispos 2 (1981): 79-87[3] Hong CY, Hu SC, Lin SJ, Chiang BN \"Lack of influence of aluminum hydroxide on the bioavailability and beta-adrenoceptor blocking activity of propranolol.\" Int J Clin Pharmacol Ther Toxicol 23 (1985): 244-6[4] Kirch W, Schafer-Korting M, Axthelm T, Kohler H, Mutschler E \"Interaction of atenolol with furosemide and calcium and aluminum salts.\" Clin Pharmacol Ther 30 (1981): 429-35[5] Laer S, Neumann J, Scholz H \"Interaction between sotalol and an antacid preparation.\" Br J Clin Pharmacol 43 (1997): 269-72[6] Gugler R, Allgayer H \"Effects of antacids on the clinical pharmacokinetics of drugs. An update.\" Clin Pharmacokinet 18 (1990): 210-9[7] Dobbs JH, Skoutakis VA, Acchiardo SR, Dobbs BR \"Effects of aluminum hydroxide on the absorption of propranolol.\" Curr Ther Res Clin Exp 21 (1977): 887-92", "alternatives_a": "Latanoprost, Apraclonidine, Methazolamide, Neostigmine, Pilocarpine, Clonidine, Physostigmine, Acetylcholine, Diclofenamide, Bimatoprost, Travoprost, More", "alternatives_b": "Magaldrate, Magnesium gluconate, Sodium sulfate, Zinc sulfate, Magnesium sulfate, Magnesium aspartate, Magnesium lactate, Magnesium citrate, Sodium chloride, Zinc gluconate, Magnesium chloride, More", "updated_at": 1767369485}, {"id": 68371, "ingredient1": "Cefaclor", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate. The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis. The clinical significance of this effect remains unknown.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic. If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Others", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68458/", "reference_text": "[1] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[3] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference) Available from: URL: http://www.mhra.gov.uk/spc-pil/index.htm.\"[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[6] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[7] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Imipenem", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, More", "updated_at": 1767369485}, {"id": 68372, "ingredient1": "Cefadroxil", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate. The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis. The clinical significance of this effect remains unknown.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic. If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Others", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68459/", "reference_text": "[1] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[3] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference) Available from: URL: http://www.mhra.gov.uk/spc-pil/index.htm.\"[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[6] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[7] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Imipenem", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, Sodium sulfate, More", "updated_at": 1767369485}, {"id": 68373, "ingredient1": "Cefamandole", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate. The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis. The clinical significance of this effect remains unknown.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic. If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Others", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68460/", "reference_text": "[1] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[3] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference) Available from: URL: http://www.mhra.gov.uk/spc-pil/index.htm.\"[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[6] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[7] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Imipenem", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, More", "updated_at": 1767369485}, {"id": 68374, "ingredient1": "Cefazolin", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate. The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis. The clinical significance of this effect remains unknown.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic. If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Others", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68461/", "reference_text": "[1] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[3] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference) Available from: URL: http://www.mhra.gov.uk/spc-pil/index.htm.\"[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[6] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[7] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Imipenem", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, Sodium sulfate, More", "updated_at": 1767369485}, {"id": 68375, "ingredient1": "Cefepime", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate. The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis. The clinical significance of this effect remains unknown.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic. If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Others", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68462/", "reference_text": "[1] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[3] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference) Available from: URL: http://www.mhra.gov.uk/spc-pil/index.htm.\"[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[6] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[7] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Imipenem, Tinidazole", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, Sodium sulfate, More", "updated_at": 1767369485}, {"id": 68376, "ingredient1": "Cefiderocol", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate. The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis. The clinical significance of this effect remains unknown.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic. If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Others", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68463/", "reference_text": "[1] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[3] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference) Available from: URL: http://www.mhra.gov.uk/spc-pil/index.htm.\"[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[6] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[7] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "alternatives_b": "Imipenem", "updated_at": 1767369485}, {"id": 68377, "ingredient1": "Cefixime", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate. The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis. The clinical significance of this effect remains unknown.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic. If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Others", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68464/", "reference_text": "[1] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[3] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference) Available from: URL: http://www.mhra.gov.uk/spc-pil/index.htm.\"[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[6] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[7] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Imipenem, Tinidazole", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, More", "updated_at": 1767369485}, {"id": 68378, "ingredient1": "Cefmetazole", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate. The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis. The clinical significance of this effect remains unknown.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic. If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Others", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68465/", "reference_text": "[1] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[3] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference) Available from: URL: http://www.mhra.gov.uk/spc-pil/index.htm.\"[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[6] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[7] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Imipenem", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, More", "updated_at": 1767369485}, {"id": 68379, "ingredient1": "Cefonicid", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate. The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis. The clinical significance of this effect remains unknown.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic. If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Others", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68466/", "reference_text": "[1] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[3] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference) Available from: URL: http://www.mhra.gov.uk/spc-pil/index.htm.\"[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[6] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[7] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Imipenem", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, More", "updated_at": 1767369485}, {"id": 68380, "ingredient1": "Cefoperazone", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate. The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis. The clinical significance of this effect remains unknown.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic. If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Others", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68467/", "reference_text": "[1] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[3] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference) Available from: URL: http://www.mhra.gov.uk/spc-pil/index.htm.\"[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[6] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[7] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Imipenem", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, More", "updated_at": 1767369485}, {"id": 68381, "ingredient1": "Cefotaxime", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate. The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis. The clinical significance of this effect remains unknown.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic. If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Others", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68468/", "reference_text": "[1] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[3] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference) Available from: URL: http://www.mhra.gov.uk/spc-pil/index.htm.\"[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[6] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[7] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Imipenem", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, Sodium sulfate, More", "updated_at": 1767369485}, {"id": 68382, "ingredient1": "Cefotetan", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate. The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis. The clinical significance of this effect remains unknown.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic. If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Others", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68469/", "reference_text": "[1] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[3] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference) Available from: URL: http://www.mhra.gov.uk/spc-pil/index.htm.\"[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[6] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[7] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Imipenem", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, More", "updated_at": 1767369485}, {"id": 68383, "ingredient1": "Cefoxitin", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate. The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis. The clinical significance of this effect remains unknown.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic. If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Others", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68470/", "reference_text": "[1] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[3] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference) Available from: URL: http://www.mhra.gov.uk/spc-pil/index.htm.\"[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[6] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[7] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Imipenem", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, More", "updated_at": 1767369485}, {"id": 68384, "ingredient1": "Cefpodoxime", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate. The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis. The clinical significance of this effect remains unknown.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic. If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Others", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68471/", "reference_text": "[1] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[3] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference) Available from: URL: http://www.mhra.gov.uk/spc-pil/index.htm.\"[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[6] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[7] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Imipenem", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Prucalopride, Sodium sulfate, More", "updated_at": 1767369485}, {"id": 68385, "ingredient1": "Cefprozil", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate. The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis. The clinical significance of this effect remains unknown.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic. If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Others", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68472/", "reference_text": "[1] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[3] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference) Available from: URL: http://www.mhra.gov.uk/spc-pil/index.htm.\"[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[6] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[7] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Imipenem", "alternatives_b": "Alvimopan, Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, Sodium sulfate, More", "updated_at": 1767369485}, {"id": 68386, "ingredient1": "Ceftaroline fosamil", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate. The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis. The clinical significance of this effect remains unknown.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic. If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Others", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68473/", "reference_text": "[1] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[3] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference) Available from: URL: http://www.mhra.gov.uk/spc-pil/index.htm.\"[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[6] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[7] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Imipenem", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, More", "updated_at": 1767369485}, {"id": 68387, "ingredient1": "Ceftazidime", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate. The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis. The clinical significance of this effect remains unknown.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic. If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Others", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68474/", "reference_text": "[1] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[3] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference) Available from: URL: http://www.mhra.gov.uk/spc-pil/index.htm.\"[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[6] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[7] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Imipenem", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, Sodium sulfate, More", "updated_at": 1767369485}, {"id": 68388, "ingredient1": "Ceftibuten", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate. The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis. The clinical significance of this effect remains unknown.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic. If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Others", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68475/", "reference_text": "[1] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[3] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference) Available from: URL: http://www.mhra.gov.uk/spc-pil/index.htm.\"[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[6] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[7] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Imipenem", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, More", "updated_at": 1767369485}, {"id": 68389, "ingredient1": "Ceftizoxime", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate. The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis. The clinical significance of this effect remains unknown.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic. If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Others", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68476/", "reference_text": "[1] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[3] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference) Available from: URL: http://www.mhra.gov.uk/spc-pil/index.htm.\"[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[6] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[7] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Imipenem", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, More", "updated_at": 1767369485}, {"id": 68390, "ingredient1": "Ceftriaxone", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate. The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis. The clinical significance of this effect remains unknown.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic. If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Others", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68477/", "reference_text": "[1] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[3] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference) Available from: URL: http://www.mhra.gov.uk/spc-pil/index.htm.\"[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[6] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[7] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Imipenem", "alternatives_b": "Alvimopan, Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, Sodium sulfate, Prucalopride, More", "updated_at": 1767369485}, {"id": 68391, "ingredient1": "Celecoxib", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations. Fluid and electrolyte disturbances can lead to serious adverse events including cardiac arrhythmias, seizures, and renal impairment.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment. Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered. Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing. Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68478/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Diovan (valsartan).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Cozaar (losartan).\" Merck & Co, Inc, West Point, PA.[5] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[6] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Dihydrocodeine, Acetaminophen, Naloxone, Naltrexone, Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole, Tamsulosin, Tinidazole, More", "alternatives_b": "Alvimopan, Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, Magnesium carbonate, More", "updated_at": 1767369485}, {"id": 68392, "ingredient1": "Picosulfuric acid", "ingredient2": "Microcrystalline cellulose", "severity": "Minor", "effect": "According to some manufacturers, bulk-forming laxatives may reduce the efficacy of bowel cleansing products containing sodium picosulfate, magnesium oxide, and citric acid anhydrous. The mechanism of interaction has not been described, and clinical significance is unknown.", "source": "DDInter", "management_text": "-", "mechanism_text": "Others", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68479/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Metamucil (psyllium).\" Procter and Gamble Pharmaceutic, Cincinnati, OH.[3] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[4] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Alvimopan, Sorbitol, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Magnesium citrate, Bisacodyl, Lubiprostone, Methylcellulose, Naldemedine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68393, "ingredient1": "Cephalexin", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate. The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis. The clinical significance of this effect remains unknown.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic. If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Others", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68480/", "reference_text": "[1] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[3] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference) Available from: URL: http://www.mhra.gov.uk/spc-pil/index.htm.\"[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[6] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[7] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Imipenem", "alternatives_b": "Alvimopan, Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, Sodium sulfate, Prucalopride, More", "updated_at": 1767369485}, {"id": 68394, "ingredient1": "Cefalotin", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate. The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis. The clinical significance of this effect remains unknown.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic. If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Others", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68481/", "reference_text": "[1] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[3] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference) Available from: URL: http://www.mhra.gov.uk/spc-pil/index.htm.\"[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[6] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[7] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Imipenem", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, More", "updated_at": 1767369485}, {"id": 68395, "ingredient1": "Cefapirin", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate. The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis. The clinical significance of this effect remains unknown.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic. If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Others", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68482/", "reference_text": "[1] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[3] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference) Available from: URL: http://www.mhra.gov.uk/spc-pil/index.htm.\"[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[6] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[7] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Imipenem", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, More", "updated_at": 1767369485}, {"id": 68396, "ingredient1": "Cefradine", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate. The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis. The clinical significance of this effect remains unknown.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic. If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Others", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68483/", "reference_text": "[1] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[3] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference) Available from: URL: http://www.mhra.gov.uk/spc-pil/index.htm.\"[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[6] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[7] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Imipenem", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, More", "updated_at": 1767369485}, {"id": 68397, "ingredient1": "Chloramphenicol", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate. The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis. The clinical significance of this effect remains unknown.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic. If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Others", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68484/", "reference_text": "[1] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[3] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference) Available from: URL: http://www.mhra.gov.uk/spc-pil/index.htm.\"[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[6] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[7] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Mupirocin, Chlorhexidine, Miconazole, Vitamin A, Isotretinoin, Fluorometholone, Tretinoin, Azelaic acid, Adapalene, Ganciclovir, Acyclovir, More", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Bisacodyl, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, Sodium sulfate, Prucalopride, Linaclotide, More", "updated_at": 1767369485}, {"id": 68398, "ingredient1": "Chlorothiazide", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations. Fluid and electrolyte disturbances can lead to serious adverse events including cardiac arrhythmias, seizures, and renal impairment.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment. Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered. Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing. Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68485/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Diovan (valsartan).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Cozaar (losartan).\" Merck & Co, Inc, West Point, PA.[5] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[6] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Simeprevir, Rosuvastatin, Lactic acid, Mitapivat, Amphotericin B, Ciclopirox, Darunavir, Probenecid, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Naldemedine, More", "updated_at": 1767369485}, {"id": 68399, "ingredient1": "Chlorpromazine", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; hydroxychloroquine; mefloquine), and some narcotic analgesics. The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that can prolong the QT interval, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; mefloquine; halofantrine; lumefantrine), and some narcotic analgesics (methadone; propoxyphene).", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68486/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[6] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[9] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[10] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[11] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[12] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[13] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[14] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[15] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Naldemedine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68400, "ingredient1": "Chlorthalidone", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations. Fluid and electrolyte disturbances can lead to serious adverse events including cardiac arrhythmias, seizures, and renal impairment.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment. Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered. Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing. Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68487/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Diovan (valsartan).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Cozaar (losartan).\" Merck & Co, Inc, West Point, PA.[5] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[6] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Simeprevir, Rosuvastatin, Lactic acid, Mitapivat, Amphotericin B, Ciclopirox, Darunavir, Probenecid, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 68401, "ingredient1": "Cilostazol", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia are known risk factors for torsade de pointes associated with QT interval prolongation.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68488/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[5] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[8] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[9] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[10] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[11] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Ticagrelor, Betrixaban, Clopidogrel, Apixaban, Rivaroxaban, Iloprost, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, Dipyridamole, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 68402, "ingredient1": "Ciprofloxacin", "ingredient2": "Citric acid", "severity": "Moderate", "effect": "Urinary alkalinizers such as citrates may decrease the solubility of fluoroquinolones in the urine and increase the risk of crystalluria.", "source": "DDInter", "management_text": "Concomitant use should generally be avoided. Patients receiving this combination should be monitored for signs of renal toxicity and crystalluria.", "mechanism_text": "Excretion", "recommendation": "Concomitant use should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68489/", "reference_text": "[1] \"Multum Information Services, Inc. Expert Review Panel\"[2] \"Product Information. Cipro (ciprofloxacin).\" Bayer, West Haven, CT.", "alternatives_a": "Tinidazole, Tetracycline, Cefepime, Fluconazole, Metronidazole, Cefuroxime, Secnidazole, Cefixime, Azithromycin, Amikacin, Tetracycline, More", "alternatives_b": "Glutamic acid, Pancrelipase", "updated_at": 1767369485}, {"id": 68403, "ingredient1": "Cisapride", "ingredient2": "Picosulfuric acid", "severity": "Major", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval. Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly. Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68490/", "reference_text": "[1] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[2] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[9] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[10] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[11] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[12] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[13] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68404, "ingredient1": "Citalopram", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; hydroxychloroquine; mefloquine), and some narcotic analgesics. The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that can prolong the QT interval, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; mefloquine; halofantrine; lumefantrine), and some narcotic analgesics (methadone; propoxyphene).", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68491/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[6] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[9] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[10] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[11] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[12] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[13] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[14] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[15] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "St. John's Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Naldemedine, Prucalopride, More", "updated_at": 1767369485}, {"id": 68405, "ingredient1": "Clarithromycin", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate. The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis. Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic. If concomitant use is required, additional bowel cleansing and colonoscopy may be required. The recommended dosage and duration of treatment with sodium picosulfate should not be exceeded. In addition, patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68492/", "reference_text": "[1] Muller-Lissner SA \"Adverse effects of laxatives: fact and fiction.\" Pharmacology 47 (1993): 138-45[2] Schaefer DC, Cheskin LJ \"Constipation in the elderly.\" Am Fam Physician 58 (1998): 907-14[3] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[4] Chin RL \"Laxative-induced hypokalemia.\" Ann Emerg Med 32 (1998): 517-8[5] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference) Available from: URL: http://www.mhra.gov.uk/spc-pil/index.htm.\"[9] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[10] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[11] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[12] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Tinidazole, Pantoprazole, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Famotidine, Cimetidine, Esomeprazole, Ranitidine, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Magnesium oxide, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Prucalopride, Linaclotide, More", "updated_at": 1767369485}, {"id": 68406, "ingredient1": "Clindamycin", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate. The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis. The clinical significance of this effect remains unknown.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic. If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Others", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68493/", "reference_text": "[1] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[3] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference) Available from: URL: http://www.mhra.gov.uk/spc-pil/index.htm.\"[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[6] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[7] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Vitamin A, Isotretinoin, Fluorometholone, Tretinoin, Azelaic acid, Adapalene, Tamsulosin, Tinidazole, Ascorbic acid, Simeprevir, Rosuvastatin, More", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, Sodium sulfate, More", "updated_at": 1767369485}, {"id": 68407, "ingredient1": "Clobazam", "ingredient2": "Magnesium oxide", "severity": "Minor", "effect": "number of studies have reported that antacids can delay the gastrointestinal absorption and reduce the peak plasma concentration (Cmax) of some benzodiazepines, including clorazepate, chlordiazepoxide and diazepam, although the overall extent of absorption is generally not affected. The exact mechanism of interaction is unknown, but may involve delayed gastric emptying or cation binding of the benzodiazepine.", "source": "DDInter", "management_text": "-", "mechanism_text": "Absorption", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68494/", "reference_text": "[1] Greenblatt DJ, Allen MD, MacLaughlin DS, Harmatz JS, Shader RI \"Diazepam absorption: effect of antacids and food.\" Clin Pharmacol Ther 24 (1978): 600-9[2] Kroboth PD, Smith RB, Silver MR, Rault R, Sorkin MI, Puschett JB, Juhl RP \"Effects of end stage renal disease and aluminium hydroxide on triazolam pharmacokinetics.\" Br J Clin Pharmacol 19 (1985): 839-42[3] Greenblatt DJ, Shader RI, Harmatz JS, Franke K, Koch-Weser J \"Absorption rate, blood concentrations, and early response to oral chlordiazepoxide.\" Am J Psychiatry 134 (1977): 559-62[4] Shader RI, Ciraulo DA, Greenblatt DJ, Harmatz JS \"Steady-state plasma desmethyldiazepam during long-term clorazepate use: effects of antacids.\" Clin Pharmacol Ther 31 (1982): 180-3[5] Greenblatt DJ, Shader RI, Harmatz JS, Franke K, Koch-Weser J \"Influence of magnesium and aluminum hydroxide mixture on chlordiazepoxide absorption.\" Clin Pharmacol Ther 19 (1976): 234-9[6] Kroboth PD, Smith RB, Rault R, Silver MR, Sorkin MI, Puschett JB, Juhl RP \"Effects of end-stage renal disease and aluminum hydroxide on temazepam kinetics.\" Clin Pharmacol Ther 37 (1985): 453-9[7] Chun AH, Carrigan PJ, Hoffman DJ, Kershner RP, Stuart JD \"Effect of antacids on absorption of clorazepate.\" Clin Pharmacol Ther 22 (1977): 329-35[8] Nair SG, Gamble JA, Dundee JW, Howard PJ \"The influence of three antacids on the absorption and clinical action of oral diazepam.\" Br J Anaesth 48 (1976): 1175-80[9] Shader RI, Georgotas A, Greenblatt DJ, Harmatz JS, Allen MD \"Impaired absorption of desmethyldiazepam from clorazepate by magnesium aluminum hydroxide.\" Clin Pharmacol Ther 24 (1978): 308-15[10] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[11] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[12] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[13] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Meprobamate, Buspirone, Hydroxyzine", "alternatives_b": "Magnesium gluconate, Sodium sulfate, Zinc sulfate, Magnesium sulfate, Magnesium aspartate, Magnesium lactate, Magnesium citrate, Sodium chloride, Zinc gluconate, Magnesium chloride, Alvimopan, More", "updated_at": 1767369485}, {"id": 68408, "ingredient1": "Clofazimine", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate. The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis. Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic. If concomitant use is required, additional bowel cleansing and colonoscopy may be required. The recommended dosage and duration of treatment with sodium picosulfate should not be exceeded. In addition, patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68495/", "reference_text": "[1] Muller-Lissner SA \"Adverse effects of laxatives: fact and fiction.\" Pharmacology 47 (1993): 138-45[2] Schaefer DC, Cheskin LJ \"Constipation in the elderly.\" Am Fam Physician 58 (1998): 907-14[3] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[4] Chin RL \"Laxative-induced hypokalemia.\" Ann Emerg Med 32 (1998): 517-8[5] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference) Available from: URL: http://www.mhra.gov.uk/spc-pil/index.htm.\"[9] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[10] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[11] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[12] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68409, "ingredient1": "Clomipramine", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; hydroxychloroquine; mefloquine), and some narcotic analgesics. The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that can prolong the QT interval, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; mefloquine; halofantrine; lumefantrine), and some narcotic analgesics (methadone; propoxyphene).", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68496/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[6] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[9] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[10] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[11] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[12] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[13] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[14] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[15] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "St. John's Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, More", "updated_at": 1767369485}, {"id": 68410, "ingredient1": "Clonazepam", "ingredient2": "Magnesium oxide", "severity": "Minor", "effect": "number of studies have reported that antacids can delay the gastrointestinal absorption and reduce the peak plasma concentration (Cmax) of some benzodiazepines, including clorazepate, chlordiazepoxide and diazepam, although the overall extent of absorption is generally not affected. The exact mechanism of interaction is unknown, but may involve delayed gastric emptying or cation binding of the benzodiazepine.", "source": "DDInter", "management_text": "-", "mechanism_text": "Absorption", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68497/", "reference_text": "[1] Greenblatt DJ, Allen MD, MacLaughlin DS, Harmatz JS, Shader RI \"Diazepam absorption: effect of antacids and food.\" Clin Pharmacol Ther 24 (1978): 600-9[2] Kroboth PD, Smith RB, Silver MR, Rault R, Sorkin MI, Puschett JB, Juhl RP \"Effects of end stage renal disease and aluminium hydroxide on triazolam pharmacokinetics.\" Br J Clin Pharmacol 19 (1985): 839-42[3] Greenblatt DJ, Shader RI, Harmatz JS, Franke K, Koch-Weser J \"Absorption rate, blood concentrations, and early response to oral chlordiazepoxide.\" Am J Psychiatry 134 (1977): 559-62[4] Shader RI, Ciraulo DA, Greenblatt DJ, Harmatz JS \"Steady-state plasma desmethyldiazepam during long-term clorazepate use: effects of antacids.\" Clin Pharmacol Ther 31 (1982): 180-3[5] Greenblatt DJ, Shader RI, Harmatz JS, Franke K, Koch-Weser J \"Influence of magnesium and aluminum hydroxide mixture on chlordiazepoxide absorption.\" Clin Pharmacol Ther 19 (1976): 234-9[6] Kroboth PD, Smith RB, Rault R, Silver MR, Sorkin MI, Puschett JB, Juhl RP \"Effects of end-stage renal disease and aluminum hydroxide on temazepam kinetics.\" Clin Pharmacol Ther 37 (1985): 453-9[7] Chun AH, Carrigan PJ, Hoffman DJ, Kershner RP, Stuart JD \"Effect of antacids on absorption of clorazepate.\" Clin Pharmacol Ther 22 (1977): 329-35[8] Nair SG, Gamble JA, Dundee JW, Howard PJ \"The influence of three antacids on the absorption and clinical action of oral diazepam.\" Br J Anaesth 48 (1976): 1175-80[9] Shader RI, Georgotas A, Greenblatt DJ, Harmatz JS, Allen MD \"Impaired absorption of desmethyldiazepam from clorazepate by magnesium aluminum hydroxide.\" Clin Pharmacol Ther 24 (1978): 308-15[10] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[11] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[12] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[13] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Brivaracetam, Topiramate, Ezogabine, Cenobamate, Lamotrigine, Methylphenobarbital, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Oxcarbazepine, More", "alternatives_b": "Magnesium gluconate, Sodium sulfate, Zinc sulfate, Magnesium sulfate, Magnesium aspartate, Magnesium lactate, Magnesium citrate, Sodium chloride, Zinc gluconate, Magnesium chloride, Alvimopan, More", "updated_at": 1767369485}, {"id": 68411, "ingredient1": "Clorazepic acid", "ingredient2": "Magnesium oxide", "severity": "Minor", "effect": "number of studies have reported that antacids can delay the gastrointestinal absorption and reduce the peak plasma concentration (Cmax) of some benzodiazepines, including clorazepate, chlordiazepoxide and diazepam, although the overall extent of absorption is generally not affected. The exact mechanism of interaction is unknown, but may involve delayed gastric emptying or cation binding of the benzodiazepine.", "source": "DDInter", "management_text": "-", "mechanism_text": "Absorption", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68498/", "reference_text": "[1] Greenblatt DJ, Allen MD, MacLaughlin DS, Harmatz JS, Shader RI \"Diazepam absorption: effect of antacids and food.\" Clin Pharmacol Ther 24 (1978): 600-9[2] Kroboth PD, Smith RB, Silver MR, Rault R, Sorkin MI, Puschett JB, Juhl RP \"Effects of end stage renal disease and aluminium hydroxide on triazolam pharmacokinetics.\" Br J Clin Pharmacol 19 (1985): 839-42[3] Greenblatt DJ, Shader RI, Harmatz JS, Franke K, Koch-Weser J \"Absorption rate, blood concentrations, and early response to oral chlordiazepoxide.\" Am J Psychiatry 134 (1977): 559-62[4] Shader RI, Ciraulo DA, Greenblatt DJ, Harmatz JS \"Steady-state plasma desmethyldiazepam during long-term clorazepate use: effects of antacids.\" Clin Pharmacol Ther 31 (1982): 180-3[5] Greenblatt DJ, Shader RI, Harmatz JS, Franke K, Koch-Weser J \"Influence of magnesium and aluminum hydroxide mixture on chlordiazepoxide absorption.\" Clin Pharmacol Ther 19 (1976): 234-9[6] Kroboth PD, Smith RB, Rault R, Silver MR, Sorkin MI, Puschett JB, Juhl RP \"Effects of end-stage renal disease and aluminum hydroxide on temazepam kinetics.\" Clin Pharmacol Ther 37 (1985): 453-9[7] Chun AH, Carrigan PJ, Hoffman DJ, Kershner RP, Stuart JD \"Effect of antacids on absorption of clorazepate.\" Clin Pharmacol Ther 22 (1977): 329-35[8] Nair SG, Gamble JA, Dundee JW, Howard PJ \"The influence of three antacids on the absorption and clinical action of oral diazepam.\" Br J Anaesth 48 (1976): 1175-80[9] Shader RI, Georgotas A, Greenblatt DJ, Harmatz JS, Allen MD \"Impaired absorption of desmethyldiazepam from clorazepate by magnesium aluminum hydroxide.\" Clin Pharmacol Ther 24 (1978): 308-15[10] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[11] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[12] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[13] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Meprobamate, Buspirone, Hydroxyzine", "alternatives_b": "Magnesium gluconate, Sodium sulfate, Zinc sulfate, Magnesium sulfate, Magnesium aspartate, Magnesium lactate, Magnesium citrate, Sodium chloride, Zinc gluconate, Magnesium chloride, Alvimopan, More", "updated_at": 1767369485}, {"id": 68412, "ingredient1": "Cloxacillin", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate. The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis. The clinical significance of this effect remains unknown.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic. If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Others", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68499/", "reference_text": "[1] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[3] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference) Available from: URL: http://www.mhra.gov.uk/spc-pil/index.htm.\"[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[6] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[7] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Tazobactam, Sulbactam", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, More", "updated_at": 1767369485}, {"id": 68413, "ingredient1": "Clozapine", "ingredient2": "Picosulfuric acid", "severity": "Major", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval. Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly. Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68500/", "reference_text": "[1] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[2] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[9] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[10] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[11] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[12] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[13] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68414, "ingredient1": "Cocaine (nasal)", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline. Rare cases of generalized tonic-clonic seizures and/or loss of consciousness in association with low serum osmolality and electrolyte abnormalities (e.g., hyponatremia, hypokalemia, hypocalcemia, hypomagnesemia) have been reported with the use of bowel cleansing products in patients with no prior history of seizures. The condition resolved with correction of fluid and electrolyte abnormalities.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68501/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.[9] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.", "alternatives_a": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68415, "ingredient1": "Codeine", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline. Rare cases of generalized tonic-clonic seizures and/or loss of consciousness in association with low serum osmolality and electrolyte abnormalities (e.g., hyponatremia, hypokalemia, hypocalcemia, hypomagnesemia) have been reported with the use of bowel cleansing products in patients with no prior history of seizures. The condition resolved with correction of fluid and electrolyte abnormalities.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68502/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.[9] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.", "alternatives_a": "Dihydrocodeine, Acetaminophen, Naloxone, Naltrexone, Benzonatate, Clofedanol, Dextromethorphan, Pentoxyverine", "alternatives_b": "Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, More", "updated_at": 1767369485}, {"id": 68416, "ingredient1": "Colistimethate", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate. The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis. The clinical significance of this effect remains unknown.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic. If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Others", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68503/", "reference_text": "[1] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[3] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference) Available from: URL: http://www.mhra.gov.uk/spc-pil/index.htm.\"[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[6] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[7] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68417, "ingredient1": "Corticotropin", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The overuse or abuse of laxatives can cause significant loss of electrolytes and potentiate the risk of hypokalemia associated with corticosteroid therapy. Corticosteroids promote the retention of sodium and water and the excretion of potassium. Although these effects are primarily associated with mineralocorticoids like fludrocortisone, they may also occur with higher dosages of glucocorticoids or adrenocorticotropic agents, particularly if given systemically for longer than brief periods.", "source": "DDInter", "management_text": "In general, laxatives should only be used on a short-term, intermittent basis in recommended dosages. During concomitant therapy with corticosteroids, particularly if fludrocortisone or large doses of a glucocorticoid or adrenocorticotropic agent is given, patients should be counseled to recognize potential signs and symptoms of hypokalemia such as fatigue, myalgia, and muscle weakness. If maintenance of bowel regularity is required, patients should be advised to exercise and increase fiber in the diet and/or consider the use of bulk-forming laxatives.", "mechanism_text": "Antagonism", "recommendation": "In general, laxatives should only be used on a short-term, intermittent basis in recommended dosages.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68504/", "reference_text": "[1] Chin RL \"Laxative-induced hypokalemia.\" Ann Emerg Med 32 (1998): 517-8[2] Blumenthal M, Goldberg A, Brinckmann J, eds. \"Herbal Medicine: Expanded Commission E Monographs.\" Newton, MA: Integrative Medicine Communications (2000):[3] Muller-Lissner SA \"Adverse effects of laxatives: fact and fiction.\" Pharmacology 47 (1993): 138-45[4] Seale JP, Compton MR \"Side-effects of corticosteroid agents.\" Med J Aust 144 (1986): 139-42[5] Swartz SL, Dluhy RG \"Corticosteroids: clinical pharmacology and therapeutic use.\" Drugs 16 (1978): 238-55[6] Lieberman P, Patterson R, Kunske R \"Complications of long-term steroid therapy for asthma.\" J Allergy Clin Immunol 49 (1972): 329-36[7] Ramsahoye BH, Davies SV, el-Gaylani N, Sandeman D, Scanlon MF \"The mineralocorticoid effects of high dose hydrocortisone.\" BMJ 310 (1995): 656-7", "alternatives_a": "Mecasermin, Sermorelin, Tesamorelin, Thyrotropin alfa, Somatrem, Somatotropin, Mecasermin rinfabate, Pegvisomant, Somapacitan", "alternatives_b": "Alvimopan, Sodium sulfate, Sorbitol, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 68418, "ingredient1": "Tetracosactide", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The overuse or abuse of laxatives can cause significant loss of electrolytes and potentiate the risk of hypokalemia associated with corticosteroid therapy. Corticosteroids promote the retention of sodium and water and the excretion of potassium. Although these effects are primarily associated with mineralocorticoids like fludrocortisone, they may also occur with higher dosages of glucocorticoids or adrenocorticotropic agents, particularly if given systemically for longer than brief periods.", "source": "DDInter", "management_text": "In general, laxatives should only be used on a short-term, intermittent basis in recommended dosages. During concomitant therapy with corticosteroids, particularly if fludrocortisone or large doses of a glucocorticoid or adrenocorticotropic agent is given, patients should be counseled to recognize potential signs and symptoms of hypokalemia such as fatigue, myalgia, and muscle weakness. If maintenance of bowel regularity is required, patients should be advised to exercise and increase fiber in the diet and/or consider the use of bulk-forming laxatives.", "mechanism_text": "Antagonism", "recommendation": "In general, laxatives should only be used on a short-term, intermittent basis in recommended dosages.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68505/", "reference_text": "[1] Chin RL \"Laxative-induced hypokalemia.\" Ann Emerg Med 32 (1998): 517-8[2] Blumenthal M, Goldberg A, Brinckmann J, eds. \"Herbal Medicine: Expanded Commission E Monographs.\" Newton, MA: Integrative Medicine Communications (2000):[3] Muller-Lissner SA \"Adverse effects of laxatives: fact and fiction.\" Pharmacology 47 (1993): 138-45[4] Seale JP, Compton MR \"Side-effects of corticosteroid agents.\" Med J Aust 144 (1986): 139-42[5] Swartz SL, Dluhy RG \"Corticosteroids: clinical pharmacology and therapeutic use.\" Drugs 16 (1978): 238-55[6] Lieberman P, Patterson R, Kunske R \"Complications of long-term steroid therapy for asthma.\" J Allergy Clin Immunol 49 (1972): 329-36[7] Ramsahoye BH, Davies SV, el-Gaylani N, Sandeman D, Scanlon MF \"The mineralocorticoid effects of high dose hydrocortisone.\" BMJ 310 (1995): 656-7", "alternatives_a": "Mecasermin, Sermorelin, Tesamorelin, Thyrotropin alfa, Somatrem, Somatotropin, Mecasermin rinfabate, Pegvisomant, Somapacitan", "alternatives_b": "Alvimopan, Sodium sulfate, Sorbitol, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 68419, "ingredient1": "Crizotinib", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia are known risk factors for torsade de pointes associated with QT interval prolongation.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68506/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[5] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[8] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[9] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[10] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[11] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Imatinib, Dabrafenib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Selumetinib, Cobimetinib, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Prucalopride, More", "updated_at": 1767369485}, {"id": 68420, "ingredient1": "Cyclobenzaprine", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline. Rare cases of generalized tonic-clonic seizures and/or loss of consciousness in association with low serum osmolality and electrolyte abnormalities (e.g., hyponatremia, hypokalemia, hypocalcemia, hypomagnesemia) have been reported with the use of bowel cleansing products in patients with no prior history of seizures. The condition resolved with correction of fluid and electrolyte abnormalities.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68507/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.[9] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.", "alternatives_a": "Carisoprodol, Orphenadrine, Chlorzoxazone, Baclofen, Methocarbamol, Chlormezanone", "alternatives_b": "Alvimopan, Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, Magnesium carbonate, More", "updated_at": 1767369485}, {"id": 68421, "ingredient1": "Cycloserine", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate. The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis. The clinical significance of this effect remains unknown.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic. If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Others", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68508/", "reference_text": "[1] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[3] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference) Available from: URL: http://www.mhra.gov.uk/spc-pil/index.htm.\"[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[6] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[7] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Pyridoxine, Pretomanid", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 68422, "ingredient1": "Dabrafenib", "ingredient2": "Magnesium oxide", "severity": "Moderate", "effect": "Drugs that alter the pH of the upper gastrointestinal tract may affect the solubility of dabrafenib and reduce its bioavailability. The interaction has not been formally studied with H2-receptor antagonists or antacids; however, the solubility of dabrafenib is known to be pH-dependent. It has been reported to be very slightly soluble at pH 1 and practically insoluble above pH 4 in aqueous media.", "source": "DDInter", "management_text": "Until more information is available, caution is advised if dabrafenib is used in combination with H2-receptor antagonists or antacids. The potential for diminished therapeutic effects of dabrafenib should be considered, and pharmacologic response should be closely monitored.", "mechanism_text": "Absorption", "recommendation": "Until more information is available, caution is advised if dabrafenib is used in combination with H2-receptor antagonists or antacids.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68509/", "reference_text": "[1] \"Product Information. Prevacid (lansoprazole).\" TAP Pharmaceuticals Inc, Deerfield, IL.[2] \"Product Information. Zantac (ranitidine).\" Glaxo Wellcome, Research Triangle Park, NC.[3] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[4] \"Product Information. Dexilant (dexlansoprazole).\" Takeda Pharmaceuticals America, Lincolnshire, IL.[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Aciphex (rabeprazole)\" Janssen Pharmaceuticals, Titusville, NJ.[8] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Magnesium gluconate, Sodium sulfate, Zinc sulfate, Magnesium sulfate, Magnesium aspartate, Magnesium lactate, Magnesium citrate, Sodium chloride, Zinc gluconate, Magnesium chloride, Alvimopan, More", "alternatives_b": "Entrectinib, Imatinib, Pralsetinib, Asciminib, Dacomitinib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Vemurafenib, More", "updated_at": 1767369485}, {"id": 68423, "ingredient1": "Dalbavancin", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate. The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis. The clinical significance of this effect remains unknown.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic. If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Others", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68510/", "reference_text": "[1] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[3] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference) Available from: URL: http://www.mhra.gov.uk/spc-pil/index.htm.\"[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[6] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[7] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Tinidazole", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, More", "updated_at": 1767369485}, {"id": 68424, "ingredient1": "Dalfampridine", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline. Rare cases of generalized tonic-clonic seizures and/or loss of consciousness in association with low serum osmolality and electrolyte abnormalities (e.g., hyponatremia, hypokalemia, hypocalcemia, hypomagnesemia) have been reported with the use of bowel cleansing products in patients with no prior history of seizures. The condition resolved with correction of fluid and electrolyte abnormalities.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68511/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.[9] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.", "alternatives_a": "Dextromethorphan, Sodium oxybate, Riluzole, Inotersen, Tafamidis", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, More", "updated_at": 1767369485}, {"id": 68425, "ingredient1": "Dapsone", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate. The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis. The clinical significance of this effect remains unknown.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic. If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Others", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68512/", "reference_text": "[1] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[3] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference) Available from: URL: http://www.mhra.gov.uk/spc-pil/index.htm.\"[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[6] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[7] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Vitamin A, Isotretinoin, Fluorometholone, Tretinoin, Azelaic acid, Adapalene", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, Sodium sulfate, More", "updated_at": 1767369485}, {"id": 68426, "ingredient1": "Daptomycin", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate. The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis. The clinical significance of this effect remains unknown.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic. If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Others", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68513/", "reference_text": "[1] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[3] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference) Available from: URL: http://www.mhra.gov.uk/spc-pil/index.htm.\"[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[6] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[7] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Tinidazole", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, More", "updated_at": 1767369485}, {"id": 68427, "ingredient1": "Dasatinib", "ingredient2": "Magnesium oxide", "severity": "Moderate", "effect": "INTERVAL: Nonclinical data indicate that the solubility of dasatinib is pH-dependent. Therefore, coadministration with antacids or agents with acid-neutralizing effects may reduce the oral bioavailability of dasatinib.", "source": "DDInter", "management_text": "Patients treated with dasatinib should avoid taking antacids or oral medications that contain antacids (e.g., didanosine buffered tablets or paediatric oral solution) for at least two hours before and two hours after administration of dasatinib.", "mechanism_text": "Absorption", "recommendation": "Patients treated with dasatinib should avoid taking antacids or oral medications that contain antacids (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68514/", "reference_text": "[1] \"Product Information. Sprycel (dasatinib).\" Bristol-Myers Squibb, Princeton, NJ.[2] \"Product Information. Sprycel (dasatinib).\" Bristol-Myers Squibb, Princeton, NJ.[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Entrectinib, Imatinib, Pralsetinib, Asciminib, Dacomitinib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Vemurafenib, More", "alternatives_b": "Magnesium gluconate, Zinc sulfate, Magnesium sulfate, Magnesium aspartate, Magnesium lactate, Sodium chloride, Zinc gluconate, Magnesium chloride, Alvimopan, Sorbitol, Magnesium sulfate, More", "updated_at": 1767369485}, {"id": 68428, "ingredient1": "Daunorubicin", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia are known risk factors for torsade de pointes associated with QT interval prolongation.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68515/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[5] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[8] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[9] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[10] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[11] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Valrubicin, Plicamycin, Ixabepilone, Mitoxantrone, Bleomycin, Mitomycin, Dactinomycin, Pertuzumab, Olaparib, Bortezomib, Tisagenlecleucel, More", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 68429, "ingredient1": "Daunorubicin (liposomal)", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia are known risk factors for torsade de pointes associated with QT interval prolongation.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68516/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[5] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[8] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[9] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[10] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[11] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Valrubicin, Plicamycin, Ixabepilone, Mitoxantrone, Bleomycin, Mitomycin, Dactinomycin, Pertuzumab, Olaparib, Bortezomib, Tisagenlecleucel, More", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, More", "updated_at": 1767369485}, {"id": 68430, "ingredient1": "Deferiprone", "ingredient2": "Magnesium oxide", "severity": "Moderate", "effect": "INTERVAL: Deferiprone has the potential to bind polyvalent cations such as aluminum, iron and zinc, which may reduce its effectiveness. However, concurrent use with foods, mineral supplements, or antacids that contain polyvalent cations has not been studied.", "source": "DDInter", "management_text": "A minimum 4-hour interval is recommended between the administration of deferiprone and mineral supplements or oral medications that contain antacids (e.g., didanosine buffered tablets or pediatric oral solution) or other polyvalent cations.", "mechanism_text": "Absorption", "recommendation": "A minimum 4-hour interval is recommended between the administration of deferiprone and mineral supplements or oral medications that contain antacids (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68517/", "reference_text": "[1] \"Product Information. Ferriprox (deferiprone).\" ApoPharma USA Inc, Rockville, MD.", "alternatives_a": "Sodium chloride, Sodium sulfate, Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, More", "alternatives_b": "Hydroxocobalamin, Fomepizole, Ipecac, Nitrous acid, Dexrazoxane, Oxygen, Lanthanum carbonate, Difelikefalin, Cobicistat, Deferoxamine, Levoleucovorin, More", "updated_at": 1767369485}, {"id": 68431, "ingredient1": "Deflazacort", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The overuse or abuse of laxatives can cause significant loss of electrolytes and potentiate the risk of hypokalemia associated with corticosteroid therapy. Corticosteroids promote the retention of sodium and water and the excretion of potassium. Although these effects are primarily associated with mineralocorticoids like fludrocortisone, they may also occur with higher dosages of glucocorticoids or adrenocorticotropic agents, particularly if given systemically for longer than brief periods.", "source": "DDInter", "management_text": "In general, laxatives should only be used on a short-term, intermittent basis in recommended dosages. During concomitant therapy with corticosteroids, particularly if fludrocortisone or large doses of a glucocorticoid or adrenocorticotropic agent is given, patients should be counseled to recognize potential signs and symptoms of hypokalemia such as fatigue, myalgia, and muscle weakness. If maintenance of bowel regularity is required, patients should be advised to exercise and increase fiber in the diet and/or consider the use of bulk-forming laxatives.", "mechanism_text": "Antagonism", "recommendation": "In general, laxatives should only be used on a short-term, intermittent basis in recommended dosages.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68518/", "reference_text": "[1] Chin RL \"Laxative-induced hypokalemia.\" Ann Emerg Med 32 (1998): 517-8[2] Blumenthal M, Goldberg A, Brinckmann J, eds. \"Herbal Medicine: Expanded Commission E Monographs.\" Newton, MA: Integrative Medicine Communications (2000):[3] Muller-Lissner SA \"Adverse effects of laxatives: fact and fiction.\" Pharmacology 47 (1993): 138-45[4] Seale JP, Compton MR \"Side-effects of corticosteroid agents.\" Med J Aust 144 (1986): 139-42[5] Swartz SL, Dluhy RG \"Corticosteroids: clinical pharmacology and therapeutic use.\" Drugs 16 (1978): 238-55[6] Lieberman P, Patterson R, Kunske R \"Complications of long-term steroid therapy for asthma.\" J Allergy Clin Immunol 49 (1972): 329-36[7] Ramsahoye BH, Davies SV, el-Gaylani N, Sandeman D, Scanlon MF \"The mineralocorticoid effects of high dose hydrocortisone.\" BMJ 310 (1995): 656-7", "alternatives_a": "Alvimopan, Sodium sulfate, Sorbitol, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68432, "ingredient1": "Degarelix", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia are known risk factors for torsade de pointes associated with QT interval prolongation.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68519/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[5] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[8] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[9] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[10] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[11] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Darolutamide, Anastrozole, Fulvestrant, Letrozole, Aminoglutethimide, Exemestane", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 68433, "ingredient1": "Delafloxacin", "ingredient2": "Magnesium oxide", "severity": "Moderate", "effect": "INTERVAL: Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics. Absorption may also be reduced by sucralfate, which contains aluminum, as well as other polyvalent cations such as iron and zinc. The mechanism is chelation of quinolones by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract.", "source": "DDInter", "management_text": "When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.", "mechanism_text": "Absorption", "recommendation": "When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68520/", "reference_text": "[1] Teng R, Dogolo LC, Willavize SA, Friedman HL, Vincent J \"Effect of Maalox and omeprazole on the bioavailability of trovafloxacin.\" J Antimicrob Chemother 39 Suppl B (1997): 93-7[2] Noyes M, Polk RE \"Norfloxacin and absorption of magnesium-aluminum.\" Ann Intern Med 109 (1988): 168-9[3] Nix DE, Wilton JH, Ronald B, Distlerath L, Williams VC, Norman A \"Inhibition of norfloxacin absorption by antacids.\" Antimicrob Agents Chemother 34 (1990): 432-5[4] \"Product Information. Zagam (sparfloxacin).\" Rhone-Poulenc Rorer, Collegeville, PA.[5] \"Product Information. Factive (gemifloxacin).\" GeneSoft Inc, San Francisco, CA.[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[7] Johnson RD, Dorr MB, Talbot GH, Caille G \"Effect of Maalox on the oral absorption of sparfloxacin.\" Clin Ther 20 (1998): 1149-58[8] Zix JA, Geerdes-Fenge HF, Rau M, Vockler J, Borner K, Koeppe P, Lode H \"Pharmacokinetics of sparfloxacin and interaction with cisapride and sucralfate.\" Antimicrob Agents Chemother 41 (1997): 1668-72[9] Shimada J, Shiba K, Oguma T, et al \"Effect of antacid on absorption of the quinolone lomefloxacin.\" Antimicrob Agents Chemother 36 (1992): 1219-24[10] Wadworth AN, Goa KL \"Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use.\" Drugs 42 (1991): 1018-60[11] Deppermann KM, Lode H, Hoffken G, Tschink G, Kalz C, Koeppe P \"Influence of ranitidine, pirenzepine, and aluminum magnesium hydroxide on the bioavailability of various antibiotics, including amoxicillin, cephalexin, doxycycline, and amoxicillin-clavulanic acid.\" Antimicrob Agents Chemother 33 (1989): 1901-7[12] \"Product Information. Raxar (grepafloxacin).\" Glaxo Wellcome, Research Triangle Park, NC.[13] Yuk JH \"Ciprofloxacin levels when receiving sucralfate.\" J Am Geriatr Soc 262 (1989): 901[14] Nix DE, Watson WA, Lener ME, et al \"Effects of aluminum and magnesium antacids and ranitidine on the absorption of ciprofloxacin.\" Clin Pharmacol Ther 46 (1989): 700-5[15] Spivey JM, Cummings DM, Pierson NR \"Failure of prostatitis treatment secondary to probable ciprofloxacin-sucralfate drug interaction.\" Pharmacotherapy 16 (1996): 314-6[16] Honig PK, Gillespie BK \"Clinical significance of pharmacokinetic drug interactions with over-the-counter (OTC) drugs.\" Clin Pharmacokinet 35 (1998): 167-71[17] Allen A, Vousden M, Porter A, Lewis A \"Effect of Maalox((R)) on the bioavailability of oral gemifloxacin in healthy volunteers.\" Chemotherapy 45 (1999): 504-11[18] Garrelts JC, Godley PJ, Peterie JD, Gerlach EH, Yakshe CC \"Sucralfate significantly reduces ciprofloxacin concentrations in serum.\" Antimicrob Agents Chemother 34 (1990): 931-3[19] Lehto P, Kivisto KT \"Different effects of products containing metal ions on the absorption of lomefloxacin.\" Clin Pharmacol Ther 56 (1994): 477-82[20] Lehto P, Kivisto KT \"Effect of sucralfate on absorption of norfloxacin and ofloxacin.\" Antimicrob Agents Chemother 38 (1994): 248-51[21] Akerele JO, Okhamafe AO \"Influence of oral co-administered metallic drugs on ofloxacin pharmacokinetics.\" J Antimicrob Chemother 28 (1991): 87-94[22] Campbell NR, Kara M, Hasinoff BB, Haddara WM, McKay DW \"Norfloxacin interaction with antacids and minerals.\" Br J Clin Pharmacol 33 (1992): 115-6[23] \"Product Information. Levaquin (levofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[24] Grasela TH Jr, Schentag JJ, Sedman AJ, et al \"Inhibition of enoxacin absorption by antacids or ranitidine.\" Antimicrob Agents Chemother 33 (1989): 615-7[25] Sahai J, Healy DP, Stotka J, Polk RE \"The influence of chronic administration of calcium carbonate on the bioavailability of oral ciprofloxacin.\" Br J Clin Pharmacol 35 (1993): 302-4[26] Parpia SH, Nix DE, Hejmanowski LG, Goldstein HR, Wilton JH, Schentag JJ \"Sucralfate reduces the gastrointestinal absorption of norfloxacin.\" Antimicrob Agents Chemother 33 (1989): 99-102[27] Frost RW, Lasseter KC, Noe AJ, Shamblen EC, Lettieri JT \"Effects of aluminum hydroxide and calcium carbonate antacids on the bioavailability of ciprofloxacin.\" Antimicrob Agents Chemother 36 (1992): 830-2[28] Polk RE, Helay DP, Sahai J, Drwal L, Racht E \"Effect of ferrous sulfate and multivitamins with zinc on absorption of ciprofloxacin in normal volunteers.\" Antimicrob Agents Chemother 33 (1989): 1841-4[29] \"Product Information. Baxdela (delafloxacin).\" Melinta Therapeutics, Lincolnshire, IL.[30] Kamberi M, Nakashima H, Ogawa K, Oda N, Nakano S \"The effect of staggered dosing of sucralfate on oral bioavailability of sparfloxacin.\" Br J Clin Pharmacol 49 (2000): 98-103[31] Lober S, Ziege S, Rau M, Schreiber G, Mignot A, Koeppe P, Lode H \"Pharmacokinetics of gatifloxacin and interaction with an antacid containing aluminum and magnesium.\" Antimicrob Agents Chemother 43 (1999): 1067-71[32] \"Product Information. Trovan (trovafloxacin).\" Pfizer US Pharmaceuticals, New York, NY.", "alternatives_a": "Sodium chloride, Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Prucalopride, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68434, "ingredient1": "Delavirdine", "ingredient2": "Magnesium oxide", "severity": "Moderate", "effect": "INTERVAL: Aluminum and magnesium containing antacids have been reported to decrease the bioavailability of delavirdine by an average of 41%. The mechanism may be related to decreased absorption of delavirdine. Other antacids may also interact.", "source": "DDInter", "management_text": "Delavirdine administration should be separated by at least 1 hour from one of these preparations.", "mechanism_text": "Absorption", "recommendation": "Delavirdine administration should be separated by at least 1 hour from one of these preparations.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68521/", "reference_text": "[1] \"Product Information. Rescriptor (delavirdine).\" Pharmacia and Upjohn, Kalamazoo, MI.", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Valaciclovir, Zanamivir, Lenacapavir, Telaprevir, Etravirine, More", "alternatives_b": "Magnesium gluconate, Sodium sulfate, Zinc sulfate, Magnesium sulfate, Magnesium aspartate, Magnesium lactate, Magnesium citrate, Sodium chloride, Zinc gluconate, Magnesium chloride, Alvimopan, More", "updated_at": 1767369485}, {"id": 68435, "ingredient1": "Demeclocycline", "ingredient2": "Magnesium oxide", "severity": "Moderate", "effect": "INTERVAL: Administration of a tetracycline with aluminum, calcium, or magnesium salts significantly decreases tetracycline serum concentrations. The proposed mechanism is chelation of tetracycline by the cation, forming an insoluble complex that is poorly absorbed from the gastrointestinal tract. The interaction has also been reported with parenteral doxycycline and oral antacids.", "source": "DDInter", "management_text": "The administration of tetracyclines and preparations containing aluminum, magnesium, or calcium should be separated by two to four hours.", "mechanism_text": "Absorption", "recommendation": "The administration of tetracyclines and preparations containing aluminum, magnesium, or calcium should be separated by two to four hours.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68522/", "reference_text": "[1] Nguyen VX, Nix DE, Gillikin S, Schentag JJ \"Effect of oral antacid administration on the pharmacokinetics of intravenous doxycycline.\" Antimicrob Agents Chemother 33 (1989): 434-6[2] Gotz VP, Ryerson GG \"Evaluation of tetracycline on theophylline disposition in patients with chronic obstructive airways disease.\" Drug Intell Clin Pharm 20 (1986): 694-6[3] Upton RA \"Pharmacokinetic interactions between theophylline and other medication (Part I).\" Clin Pharmacokinet 20 (1991): 66-80[4] \"Product Information. Nuzyra (omadacycline).\" Paratek Pharmaceuticals, Inc., Boston, MA.[5] \"Product Information. Seysara (sarecycline).\" Allergan Inc, Irvine, CA.[6] McCormack JP, Reid SE, Lawson LM \"Theophylline toxicity induced by tetracycline.\" Clin Pharm 9 (1990): 546-9[7] Neuvonen PJ \"Interactions with the absorption of tetracyclines.\" Drugs 11 (1976): 45-54[8] D'Arcy PF, McElnay JC \"Drug-antacid interactions: assessment of clinical importance.\" Drug Intell Clin Pharm 21 (1987): 607-17[9] \"Product Information. Declomycin (demeclocycline).\" Lederle Laboratories, Wayne, NJ.[10] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[11] Garty M, Hurwitz A \"Effect of cimetidine and antacids on gastrointestinal absorption of tetracycline.\" Clin Pharmacol Ther 28 (1980): 203-7[12] Deppermann KM, Lode H, Hoffken G, Tschink G, Kalz C, Koeppe P \"Influence of ranitidine, pirenzepine, and aluminum magnesium hydroxide on the bioavailability of various antibiotics, including amoxicillin, cephalexin, doxycycline, and amoxicillin-clavulanic acid.\" Antimicrob Agents Chemother 33 (1989): 1901-7[13] Covington TR, Lawson LC, Young LL, eds. \"Handbook of Nonprescription Drugs. 10th ed.\" Washington, DC: American Pharmaceutical Association (1993):[14] \"Product Information. Achromycin (tetracycline).\" Lederle Laboratories, Wayne, NJ.[15] \"Product Information. Declomycin (demeclocycline).\" Lederle Laboratories, Wayne, NJ.", "alternatives_a": "Tigecycline, Eravacycline, Mupirocin, Rifamycin, Bacitracin, Chloramphenicol, Rifaximin, Gentamicin, Amikacin, Neomycin", "alternatives_b": "Sodium chloride, Sodium sulfate, Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, More", "updated_at": 1767369485}, {"id": 68436, "ingredient1": "Desipramine", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; hydroxychloroquine; mefloquine), and some narcotic analgesics. The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that can prolong the QT interval, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; mefloquine; halofantrine; lumefantrine), and some narcotic analgesics (methadone; propoxyphene).", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68523/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[6] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[9] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[10] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[11] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[12] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[13] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[14] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[15] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "St. John's Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 68437, "ingredient1": "Desvenlafaxine", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline. Rare cases of generalized tonic-clonic seizures and/or loss of consciousness in association with low serum osmolality and electrolyte abnormalities (e.g., hyponatremia, hypokalemia, hypocalcemia, hypomagnesemia) have been reported with the use of bowel cleansing products in patients with no prior history of seizures. The condition resolved with correction of fluid and electrolyte abnormalities.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68524/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.[9] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.", "alternatives_a": "St. John's Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 68438, "ingredient1": "Deutetrabenazine", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia are known risk factors for torsade de pointes associated with QT interval prolongation.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68525/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[5] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[8] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[9] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[10] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[11] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "alternatives_b": "Dextromethorphan, Sodium oxybate, Riluzole, Inotersen, Tafamidis", "updated_at": 1767369485}, {"id": 68439, "ingredient1": "Dexamethasone", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The overuse or abuse of laxatives can cause significant loss of electrolytes and potentiate the risk of hypokalemia associated with corticosteroid therapy. Corticosteroids promote the retention of sodium and water and the excretion of potassium. Although these effects are primarily associated with mineralocorticoids like fludrocortisone, they may also occur with higher dosages of glucocorticoids or adrenocorticotropic agents, particularly if given systemically for longer than brief periods.", "source": "DDInter", "management_text": "In general, laxatives should only be used on a short-term, intermittent basis in recommended dosages. During concomitant therapy with corticosteroids, particularly if fludrocortisone or large doses of a glucocorticoid or adrenocorticotropic agent is given, patients should be counseled to recognize potential signs and symptoms of hypokalemia such as fatigue, myalgia, and muscle weakness. If maintenance of bowel regularity is required, patients should be advised to exercise and increase fiber in the diet and/or consider the use of bulk-forming laxatives.", "mechanism_text": "Antagonism", "recommendation": "In general, laxatives should only be used on a short-term, intermittent basis in recommended dosages.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68526/", "reference_text": "[1] Chin RL \"Laxative-induced hypokalemia.\" Ann Emerg Med 32 (1998): 517-8[2] Blumenthal M, Goldberg A, Brinckmann J, eds. \"Herbal Medicine: Expanded Commission E Monographs.\" Newton, MA: Integrative Medicine Communications (2000):[3] Muller-Lissner SA \"Adverse effects of laxatives: fact and fiction.\" Pharmacology 47 (1993): 138-45[4] Seale JP, Compton MR \"Side-effects of corticosteroid agents.\" Med J Aust 144 (1986): 139-42[5] Swartz SL, Dluhy RG \"Corticosteroids: clinical pharmacology and therapeutic use.\" Drugs 16 (1978): 238-55[6] Lieberman P, Patterson R, Kunske R \"Complications of long-term steroid therapy for asthma.\" J Allergy Clin Immunol 49 (1972): 329-36[7] Ramsahoye BH, Davies SV, el-Gaylani N, Sandeman D, Scanlon MF \"The mineralocorticoid effects of high dose hydrocortisone.\" BMJ 310 (1995): 656-7", "alternatives_a": "Ciclesonide, Mupirocin, Mometasone furoate, Budesonide, Mometasone, Epinephrine, Flunisolide, Olopatadine, Vitamin A, Fluticasone, Ipratropium, More", "alternatives_b": "Alvimopan, Sodium sulfate, Sorbitol, Methylnaltrexone, Plecanatide, Lubiprostone, Methylcellulose, Prucalopride, Linaclotide, Magnesium carbonate", "updated_at": 1767369485}, {"id": 68440, "ingredient1": "Dexfenfluramine", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline. Rare cases of generalized tonic-clonic seizures and/or loss of consciousness in association with low serum osmolality and electrolyte abnormalities (e.g., hyponatremia, hypokalemia, hypocalcemia, hypomagnesemia) have been reported with the use of bowel cleansing products in patients with no prior history of seizures. The condition resolved with correction of fluid and electrolyte abnormalities.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68527/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.[9] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.", "alternatives_a": "Lorcaserin, Orlistat, Naltrexone", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 68441, "ingredient1": "Dexmethylphenidate", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline. Rare cases of generalized tonic-clonic seizures and/or loss of consciousness in association with low serum osmolality and electrolyte abnormalities (e.g., hyponatremia, hypokalemia, hypocalcemia, hypomagnesemia) have been reported with the use of bowel cleansing products in patients with no prior history of seizures. The condition resolved with correction of fluid and electrolyte abnormalities.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68528/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.[9] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.", "alternatives_a": "Solriamfetol, Caffeine, Armodafinil, Citicoline, Modafinil", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 68442, "ingredient1": "Dextroamphetamine", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline. Rare cases of generalized tonic-clonic seizures and/or loss of consciousness in association with low serum osmolality and electrolyte abnormalities (e.g., hyponatremia, hypokalemia, hypocalcemia, hypomagnesemia) have been reported with the use of bowel cleansing products in patients with no prior history of seizures. The condition resolved with correction of fluid and electrolyte abnormalities.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68529/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.[9] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.", "alternatives_a": "Solriamfetol, Caffeine, Armodafinil, Citicoline, Modafinil", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Prucalopride, Linaclotide, More", "updated_at": 1767369485}, {"id": 68443, "ingredient1": "Dezocine", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline. Rare cases of generalized tonic-clonic seizures and/or loss of consciousness in association with low serum osmolality and electrolyte abnormalities (e.g., hyponatremia, hypokalemia, hypocalcemia, hypomagnesemia) have been reported with the use of bowel cleansing products in patients with no prior history of seizures. The condition resolved with correction of fluid and electrolyte abnormalities.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68530/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.[9] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.", "alternatives_a": "Dihydrocodeine, Acetaminophen, Naloxone, Naltrexone", "alternatives_b": "Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, More", "updated_at": 1767369485}, {"id": 68444, "ingredient1": "Diazepam", "ingredient2": "Magnesium oxide", "severity": "Minor", "effect": "number of studies have reported that antacids can delay the gastrointestinal absorption and reduce the peak plasma concentration (Cmax) of some benzodiazepines, including clorazepate, chlordiazepoxide and diazepam, although the overall extent of absorption is generally not affected. The exact mechanism of interaction is unknown, but may involve delayed gastric emptying or cation binding of the benzodiazepine.", "source": "DDInter", "management_text": "-", "mechanism_text": "Absorption", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68531/", "reference_text": "[1] Greenblatt DJ, Allen MD, MacLaughlin DS, Harmatz JS, Shader RI \"Diazepam absorption: effect of antacids and food.\" Clin Pharmacol Ther 24 (1978): 600-9[2] Kroboth PD, Smith RB, Silver MR, Rault R, Sorkin MI, Puschett JB, Juhl RP \"Effects of end stage renal disease and aluminium hydroxide on triazolam pharmacokinetics.\" Br J Clin Pharmacol 19 (1985): 839-42[3] Greenblatt DJ, Shader RI, Harmatz JS, Franke K, Koch-Weser J \"Absorption rate, blood concentrations, and early response to oral chlordiazepoxide.\" Am J Psychiatry 134 (1977): 559-62[4] Shader RI, Ciraulo DA, Greenblatt DJ, Harmatz JS \"Steady-state plasma desmethyldiazepam during long-term clorazepate use: effects of antacids.\" Clin Pharmacol Ther 31 (1982): 180-3[5] Greenblatt DJ, Shader RI, Harmatz JS, Franke K, Koch-Weser J \"Influence of magnesium and aluminum hydroxide mixture on chlordiazepoxide absorption.\" Clin Pharmacol Ther 19 (1976): 234-9[6] Kroboth PD, Smith RB, Rault R, Silver MR, Sorkin MI, Puschett JB, Juhl RP \"Effects of end-stage renal disease and aluminum hydroxide on temazepam kinetics.\" Clin Pharmacol Ther 37 (1985): 453-9[7] Chun AH, Carrigan PJ, Hoffman DJ, Kershner RP, Stuart JD \"Effect of antacids on absorption of clorazepate.\" Clin Pharmacol Ther 22 (1977): 329-35[8] Nair SG, Gamble JA, Dundee JW, Howard PJ \"The influence of three antacids on the absorption and clinical action of oral diazepam.\" Br J Anaesth 48 (1976): 1175-80[9] Shader RI, Georgotas A, Greenblatt DJ, Harmatz JS, Allen MD \"Impaired absorption of desmethyldiazepam from clorazepate by magnesium aluminum hydroxide.\" Clin Pharmacol Ther 24 (1978): 308-15[10] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[11] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[12] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[13] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Meprobamate, Buspirone, Hydroxyzine", "alternatives_b": "Magnesium gluconate, Sodium sulfate, Zinc sulfate, Magnesium sulfate, Magnesium aspartate, Magnesium lactate, Magnesium citrate, Sodium chloride, Zinc gluconate, Magnesium chloride, Alvimopan, More", "updated_at": 1767369485}, {"id": 68445, "ingredient1": "Diclofenamide", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations. Fluid and electrolyte disturbances can lead to serious adverse events including cardiac arrhythmias, seizures, and renal impairment.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment. Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered. Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing. Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68532/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Diovan (valsartan).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Cozaar (losartan).\" Merck & Co, Inc, West Point, PA.[5] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[6] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Simeprevir, Rosuvastatin, Lactic acid, Mitapivat, Amphotericin B, Ciclopirox, Darunavir, Probenecid, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 68446, "ingredient1": "Diclofenac", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations. Fluid and electrolyte disturbances can lead to serious adverse events including cardiac arrhythmias, seizures, and renal impairment.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment. Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered. Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing. Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68533/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Diovan (valsartan).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Cozaar (losartan).\" Merck & Co, Inc, West Point, PA.[5] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[6] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Fluocinolone acetonide, Fluorometholone, Fluocinolone acetonide, Fluorometholone, Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole, Tolazoline, Rabeprazole, More", "alternatives_b": "Alvimopan, Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Magnesium carbonate, Plecanatide, More", "updated_at": 1767369485}, {"id": 68447, "ingredient1": "Dicloxacillin", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate. The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis. The clinical significance of this effect remains unknown.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic. If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Others", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68534/", "reference_text": "[1] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[3] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference) Available from: URL: http://www.mhra.gov.uk/spc-pil/index.htm.\"[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[6] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[7] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Tazobactam, Sulbactam", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, More", "updated_at": 1767369485}, {"id": 68448, "ingredient1": "Dicoumarol", "ingredient2": "Magnesium oxide", "severity": "Minor", "effect": "Limited data suggest that concurrent administration of magnesium hydroxide or magnesium oxide may increase the oral bioavailability of dicumarol. The mechanism of interaction is unknown. Given the widespread use of magnesium antacids and the limited evidence of a clinically significant interaction, no special precautions appear to be necessary when dicumarol is prescribed with magnesium hydroxide or magnesium oxide. However, a switch to a different antacid may be appropriate if an interaction is suspected.", "source": "DDInter", "management_text": "-", "mechanism_text": "Synergism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68535/", "reference_text": "[1] D'Arcy PF, McElnay JC \"Drug-antacid interactions: assessment of clinical importance.\" Drug Intell Clin Pharm 21 (1987): 607-17[2] Ambre JJ, Fischer LJ \"Effect of coadministration of aluminum and magnesium hydroxides on absorption of anticoagulants in man.\" Clin Pharmacol Ther 14 (1973): 231-7[3] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Guo LQ, Yamazoe Y \"Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines.\" Acta Pharmacol Sin 25 (2004): 129-36[6] Bodiford AB, Kessler FO, Fermo JD, Ragucci KR \"Elevated international normalized ratio with the consumption of grapefruit and use of warfarin.\" SAGE Open Med Case Rep 0 (2013): 1-3[7] Suvarna R, Pirmohamed M, Henderson L \"Possible interaction between warfarin and cranberry juice.\" BMJ 327 (2003): 1454[8] Lee M, Schwartz RN, Sharifi R \"Warfarin resistance and vitamin K.\" Ann Intern Med 94 (1981): 140-1[9] Beckey NP, Korman LB, Parra D \"Effect of the moderate consumption of olestra in patients receiving long-term warfarin therapy.\" Pharmacotherapy 19 (1999): 1075-9[10] Brandin H, Myrberg O, Rundlof T, Arvidsson AK, Brenning G \"Adverse effects by artificial grapefruit seed extract products in patients on warfarin therapy.\" Eur J Clin Pharmacol 63 (2007): 565-70[11] Kempin SJ \"Warfarin resistance caused by broccoli.\" N Engl J Med 308 (1983): 1229-30[12] Westfall LK \"An unrecognized cause of warfarin resistance.\" Drug Intell Clin Pharm 15 (1981): 131[13] Kuykendall JR, Houle MD, Rhodes RS \"Possible warfarin failure due to interaction with smokeless tobacco.\" Ann Pharmacother 38 (2004): 595-7[14] Walker FB \"Myocardial infarction after diet-induced warfarin resistance.\" Arch Intern Med 144 (1984): 2089-90[15] Pedersen FM, Hamberg O, Hess K, Ovesen L \"The effect of dietary vitamin K on warfarin-induced anticoagulation.\" J Intern Med 229 (1991): 517-20[16] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[17] Griffith LD, Olvey SE, Triplett WC \"Increasing prothrombin times in a warfarin-treated patient upon withdrawal of ensure plus.\" Crit Care Med 10 (1982): 799-800[18] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994): 676-83[19] MHRA. Mediciines and Healthcare products Regulatory Agency. Committee on Safety of Medicines \"Possible interaction between warfarin and cranberry juice. Available from: URL: http://medicines.mhra.gov.uk/ourwork/monitorsafequalmed/currentproblems/currentproblems.htm.\" ([2003 Sept]):[20] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[21] Karlson B, Leijd B, Hellstrom K \"On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment.\" Acta Med Scand 220 (1986): 347-50[22] O'Reilly RA, Rytand DA \"\"Resistance\" to warfarin due to unrecognized vitamin K supplementation.\" N Engl J Med 303 (1980): 160-1[23] Kazmier FJ, Spittell JA Jr \"Coumarin drug interactions.\" Mayo Clin Proc 45 (1970): 249-55[24] Cambria-Kiely JA \"Effect of soy milk on warfarin efficacy.\" Ann Pharmacother 36 (2002): 1893-6[25] Chow WH, Chow TC, Tse TM, Tai YT, Lee WT \"Anticoagulation instability with life-threatening complication after dietary modification.\" Postgrad Med J 66 (1990): 855-7[26] Hamann GL, Campbell JD, George CM \"Warfarin-cranberry juice interaction.\" Ann Pharmacother 45 (2011): e17[27] Monterrey-Rodriguez J \"Interaction between warfarin and mango fruit.\" Ann Pharmacother 36 (2002): 940-1[28] Griffiths AP, Beddall A, Pegler S \"Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin.\" J R Soc Health 128 (2008): 324-6[29] Roberts D, Flanagan P \"Case report: Cranberry juice and warfarin.\" Home Healthc Nurse 29 (2011): 92-7[30] MacLeod SM, Sellers EM \"Pharmacodynamic and pharmacokinetic drug interactions with coumarin anticoagulants.\" Drugs 11 (1976): 461-70[31] Jarvis S, Li C, Bogle RG \"Possible interaction between pomegranate juice and warfarin.\" Emerg Med J 27 (2010): 74-5[32] Parr MD, Record KE, Griffith GL, et al \"Effect of enteral nutrition on warfarin therapy.\" Clin Pharm 1 (1982): 274-6[33] Sullivan DM, Ford MA, Boyden TW \"Grapefruit juice and the response to warfarin.\" Am J Health Syst Pharm 55 (1998): 1581-3[34] Howard PA, Hannaman KN \"Warfarin resistance linked to enteral nutrition products.\" J Am Diet Assoc 85 (1985): 713-5[35] Rindone JP, Murphy TW \"Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding.\" Am J Ther 13 (2006): 283-4[36] Harrell CC, Kline SS \"Vitamin K-supplemented snacks containing olestra: Implication for patients taking warfarin.\" Jama J Am Med Assn 282 (1999): 1133-4[37] Grant P \"Warfarin and cranberry juice: an interaction?\" J Heart Valve Dis 13 (2004): 25-6[38] Ge B, Zhang Z, Zuo Z \"Updates on the clinical evidenced herb-warfarin interactions.\" Evid Based Complement Alternat Med 2014 (2014): 957362[39] Zallman JA, Lee DP, Jeffrey PL \"Liquid nutrition as a cause of warfarin resistance.\" Am J Hosp Pharm 38 (1981): 1174[40] Watson AJ, Pegg M, Green JR \"Enteral feeds may antagonise warfarin.\" Br Med J 288 (1984): 557[41] Andersen P, Godal HC \"Predictable reduction in anticoagulant activity of warfarin by small amounts of vitamin K.\" Acta Med Scand 198 (1975): 269-70", "alternatives_a": "Ticagrelor, Betrixaban, Apixaban, Cilostazol, Rivaroxaban, Clopidogrel, Iloprost, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, More", "alternatives_b": "Magaldrate, Magnesium carbonate, Calcium carbonate, Aluminum hydroxide, Magnesium gluconate, Sodium sulfate, Zinc sulfate, Magnesium sulfate, Magnesium aspartate, Magnesium lactate, Magnesium citrate, More", "updated_at": 1767369485}, {"id": 68449, "ingredient1": "Diethylpropion", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline. Rare cases of generalized tonic-clonic seizures and/or loss of consciousness in association with low serum osmolality and electrolyte abnormalities (e.g., hyponatremia, hypokalemia, hypocalcemia, hypomagnesemia) have been reported with the use of bowel cleansing products in patients with no prior history of seizures. The condition resolved with correction of fluid and electrolyte abnormalities.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68536/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.[9] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.", "alternatives_a": "Lorcaserin, Orlistat, Naltrexone", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 68450, "ingredient1": "Diflunisal", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations. Fluid and electrolyte disturbances can lead to serious adverse events including cardiac arrhythmias, seizures, and renal impairment.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment. Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered. Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing. Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68537/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Diovan (valsartan).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Cozaar (losartan).\" Merck & Co, Inc, West Point, PA.[5] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[6] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Acetaminophen, Ziconotide, Methoxyflurane", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Prucalopride, Linaclotide, More", "updated_at": 1767369485}, {"id": 68451, "ingredient1": "Digitoxin", "ingredient2": "Picosulfuric acid", "severity": "Minor", "effect": "Due to a potential risk of water or electrolyte imbalance, the manufacturer recommends caution during concomitant administration of sodium picosulfate with cardiac glycosides, lithium, nonsteroidal anti-inflammatory agents, or drugs which may cause SIADH. The clinical significance is unknown.", "source": "DDInter", "management_text": "-", "mechanism_text": "Others", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68538/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] McElnay JC, Harron DW, D'Arcy PF, Eagle MR \"Interaction of digoxin with antacid constituents.\" Br Med J 1 (1978): 1554[3] Saris SD, Lowenthal DT, Affrime MB \"Steady-state digoxin concentration during oral mexiletine administration.\" Curr Ther Res Clin Exp 34 (1983): 662-6[4] D'Arcy PF, McElnay JC \"Drug-antacid interactions: assessment of clinical importance.\" Drug Intell Clin Pharm 21 (1987): 607-17[5] Brown DD, Juhl RP \"Decreased bioavailability of digoxin due to antacids and kaolin-pectin.\" N Engl J Med 295 (1976): 1034-7[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[7] Rodin SM, Johnson BF \"Pharmacokinetic interactions with digoxin.\" Clin Pharmacokinet 15 (1988): 227-44[8] Allen MD, Greenblatt DJ, Harmatz JS, Smith TW \"Effect of magnesium--aluminum hydroxide and kaolin--pectin on absorption of digoxin from tablets and capsules.\" J Clin Pharmacol 21 (1981): 26-30[9] Bonelli J, Hruby K, Magometschnigg D, Hitzenberger G, Kaik G \"The bio-availability of beta-acetyldigoxine alone and combined with aluminum hydroxide and magnesium hydroxide (Alucol).\" Int J Clin Pharmacol Biopharm 15 (1977): 337-9[10] Marcus FI \"Pharmacokinetic interactions between digoxin and other drugs.\" J Am Coll Cardiol 5 (1985): a82-90[11] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[12] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.[13] Darcy PF \"Nutrient-drug interactions.\" Adverse Drug React Toxicol Rev 14 (1995): 233-54[14] Becquemont L, Verstuyft C, Kerb R, et al. \"Effect of grapefruit juice on digoxin pharmacokinetics in humans.\" Clin Pharmacol Ther 70 (2001): 311-6", "alternatives_a": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Prucalopride, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68452, "ingredient1": "Digoxin", "ingredient2": "Picosulfuric acid", "severity": "Minor", "effect": "Due to a potential risk of water or electrolyte imbalance, the manufacturer recommends caution during concomitant administration of sodium picosulfate with cardiac glycosides, lithium, nonsteroidal anti-inflammatory agents, or drugs which may cause SIADH. The clinical significance is unknown.", "source": "DDInter", "management_text": "-", "mechanism_text": "Others", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68539/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] McElnay JC, Harron DW, D'Arcy PF, Eagle MR \"Interaction of digoxin with antacid constituents.\" Br Med J 1 (1978): 1554[3] Saris SD, Lowenthal DT, Affrime MB \"Steady-state digoxin concentration during oral mexiletine administration.\" Curr Ther Res Clin Exp 34 (1983): 662-6[4] D'Arcy PF, McElnay JC \"Drug-antacid interactions: assessment of clinical importance.\" Drug Intell Clin Pharm 21 (1987): 607-17[5] Brown DD, Juhl RP \"Decreased bioavailability of digoxin due to antacids and kaolin-pectin.\" N Engl J Med 295 (1976): 1034-7[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[7] Rodin SM, Johnson BF \"Pharmacokinetic interactions with digoxin.\" Clin Pharmacokinet 15 (1988): 227-44[8] Allen MD, Greenblatt DJ, Harmatz JS, Smith TW \"Effect of magnesium--aluminum hydroxide and kaolin--pectin on absorption of digoxin from tablets and capsules.\" J Clin Pharmacol 21 (1981): 26-30[9] Bonelli J, Hruby K, Magometschnigg D, Hitzenberger G, Kaik G \"The bio-availability of beta-acetyldigoxine alone and combined with aluminum hydroxide and magnesium hydroxide (Alucol).\" Int J Clin Pharmacol Biopharm 15 (1977): 337-9[10] Marcus FI \"Pharmacokinetic interactions between digoxin and other drugs.\" J Am Coll Cardiol 5 (1985): a82-90[11] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[12] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.[13] Darcy PF \"Nutrient-drug interactions.\" Adverse Drug React Toxicol Rev 14 (1995): 233-54[14] Becquemont L, Verstuyft C, Kerb R, et al. \"Effect of grapefruit juice on digoxin pharmacokinetics in humans.\" Clin Pharmacol Ther 70 (2001): 311-6", "alternatives_a": "Alvimopan, Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Prucalopride, Linaclotide, Plecanatide, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68453, "ingredient1": "Dihydrotachysterol", "ingredient2": "Magnesium oxide", "severity": "Moderate", "effect": "Use of magnesium-containing products with a vitamin D analog may increase the risk of hypermagnesemia, particularly in chronic renal dialysis patients, due to potentially additive pharmacologic effects. Chronic hypermagnesemia may have a role in the pathogenesis of adynamic bone disease in dialysis patients.", "source": "DDInter", "management_text": "Patients on chronic renal dialysis treated with a vitamin D analog should avoid magnesium-containing products.", "mechanism_text": "Synergism", "recommendation": "Patients on chronic renal dialysis treated with a vitamin D analog should avoid magnesium-containing products.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68540/", "reference_text": "[1] \"Product Information. Zemplar (paricalcitol).\" Abbott Pharmaceutical, Abbott Park, IL.[2] \"Product Information. One-Alpha (alfacalcidol).\" Pharmel Inc, Montreal, IN.[3] \"Product Information. Rocaltrol (calcitriol).\" Roche Laboratories, Nutley, NJ.[4] \"Product Information. Hectorol (doxercalciferol).\" Genzyme Corporation, Cambridge, MA.", "alternatives_a": "Vitamin A, Beta carotene", "alternatives_b": "Magaldrate, Calcium carbonate, Aluminum hydroxide, Sodium sulfate, Zinc sulfate, Magnesium aspartate, Sodium chloride, Zinc gluconate, Alvimopan, Sorbitol, Tegaserod, More", "updated_at": 1767369485}, {"id": 68454, "ingredient1": "Disopyramide", "ingredient2": "Picosulfuric acid", "severity": "Major", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval. Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly. Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68541/", "reference_text": "[1] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[2] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[9] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[10] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[11] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[12] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[13] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Tocainide, Moricizine, Bretylium", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 68455, "ingredient1": "Valproic acid", "ingredient2": "Magnesium oxide", "severity": "Minor", "effect": "Limited data suggest that concurrent administration of antacids may increase the bioavailability of valproic acid. The mechanism of interaction is unknown. Equivalent doses of antacids containing either aluminum hydroxide-magnesium trisilicate or calcium carbonate also increased the AUC of valproic acid, but the differences were not statistically significant.", "source": "DDInter", "management_text": "-", "mechanism_text": "Absorption", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68542/", "reference_text": "[1] May CA, Garnett WR, Small RE, Pellock JM \"Effects of three antacids on the bioavailability of valproic acid.\" Clin Pharm 1 (1982): 244-7[2] \"Product Information. Depakote (divalproex sodium).\" Abbott Pharmaceutical, Abbott Park, IL.[3] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[4] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[5] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[6] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Brivaracetam, Topiramate, Ezogabine, Cenobamate, Lamotrigine, Methylphenobarbital, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Oxcarbazepine, More", "alternatives_b": "Magnesium gluconate, Sodium sulfate, Zinc sulfate, Magnesium sulfate, Magnesium aspartate, Magnesium lactate, Magnesium citrate, Sodium chloride, Zinc gluconate, Magnesium chloride, Alvimopan, More", "updated_at": 1767369485}, {"id": 68456, "ingredient1": "Dofetilide", "ingredient2": "Picosulfuric acid", "severity": "Major", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval. Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly. Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68543/", "reference_text": "[1] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[2] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[9] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[10] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[11] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[12] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[13] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Tocainide, Moricizine, Bretylium", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 68457, "ingredient1": "Dolasetron", "ingredient2": "Picosulfuric acid", "severity": "Major", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval. Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly. Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68544/", "reference_text": "[1] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[2] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[9] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[10] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[11] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[12] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[13] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Aprepitant, Scopolamine, Nabilone, Rolapitant", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Naldemedine, More", "updated_at": 1767369485}, {"id": 68458, "ingredient1": "Donepezil", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline. Rare cases of generalized tonic-clonic seizures and/or loss of consciousness in association with low serum osmolality and electrolyte abnormalities (e.g., hyponatremia, hypokalemia, hypocalcemia, hypomagnesemia) have been reported with the use of bowel cleansing products in patients with no prior history of seizures. The condition resolved with correction of fluid and electrolyte abnormalities.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68545/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.[9] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.", "alternatives_a": "Memantine, Ginkgo biloba, Aducanumab", "alternatives_b": "Alvimopan, Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, Magnesium carbonate, More", "updated_at": 1767369485}, {"id": 68459, "ingredient1": "Doripenem", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate. The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis. The clinical significance of this effect remains unknown.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic. If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Others", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68546/", "reference_text": "[1] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[3] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference) Available from: URL: http://www.mhra.gov.uk/spc-pil/index.htm.\"[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[6] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[7] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Imipenem", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, More", "updated_at": 1767369485}, {"id": 68460, "ingredient1": "Doxapram", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline. Rare cases of generalized tonic-clonic seizures and/or loss of consciousness in association with low serum osmolality and electrolyte abnormalities (e.g., hyponatremia, hypokalemia, hypocalcemia, hypomagnesemia) have been reported with the use of bowel cleansing products in patients with no prior history of seizures. The condition resolved with correction of fluid and electrolyte abnormalities.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68547/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.[9] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.", "alternatives_a": "Nitric Oxide, Ivacaftor, Elexacaftor, Lumacaftor", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 68461, "ingredient1": "Doxepin", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; hydroxychloroquine; mefloquine), and some narcotic analgesics. The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that can prolong the QT interval, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; mefloquine; halofantrine; lumefantrine), and some narcotic analgesics (methadone; propoxyphene).", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68548/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[6] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[9] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[10] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[11] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[12] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[13] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[14] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[15] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "St. John's Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine, Clemastine, Tetracaine, Mepyramine, Diphenhydramine, Tripelennamine, Pheniramine", "alternatives_b": "Alvimopan, Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, Magnesium carbonate, More", "updated_at": 1767369485}, {"id": 68462, "ingredient1": "Doxepin (topical)", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; hydroxychloroquine; mefloquine), and some narcotic analgesics. The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that can prolong the QT interval, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; mefloquine; halofantrine; lumefantrine), and some narcotic analgesics (methadone; propoxyphene).", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68549/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[6] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[9] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[10] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[11] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[12] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[13] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[14] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[15] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "St. John's Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine, Clemastine, Tetracaine, Mepyramine, Diphenhydramine, Tripelennamine, Pheniramine", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 68463, "ingredient1": "Doxercalciferol", "ingredient2": "Magnesium oxide", "severity": "Moderate", "effect": "Use of magnesium-containing products with a vitamin D analog may increase the risk of hypermagnesemia, particularly in chronic renal dialysis patients, due to potentially additive pharmacologic effects. Chronic hypermagnesemia may have a role in the pathogenesis of adynamic bone disease in dialysis patients.", "source": "DDInter", "management_text": "Patients on chronic renal dialysis treated with a vitamin D analog should avoid magnesium-containing products.", "mechanism_text": "Synergism", "recommendation": "Patients on chronic renal dialysis treated with a vitamin D analog should avoid magnesium-containing products.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68550/", "reference_text": "[1] \"Product Information. Zemplar (paricalcitol).\" Abbott Pharmaceutical, Abbott Park, IL.[2] \"Product Information. One-Alpha (alfacalcidol).\" Pharmel Inc, Montreal, IN.[3] \"Product Information. Rocaltrol (calcitriol).\" Roche Laboratories, Nutley, NJ.[4] \"Product Information. Hectorol (doxercalciferol).\" Genzyme Corporation, Cambridge, MA.", "alternatives_a": "Magaldrate, Calcium carbonate, Zinc gluconate, Sodium sulfate, Zinc sulfate, Sodium chloride, Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, More", "alternatives_b": "Etelcalcetide, Cinacalcet, Salmon calcitonin", "updated_at": 1767369485}, {"id": 68464, "ingredient1": "Doxorubicin", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia are known risk factors for torsade de pointes associated with QT interval prolongation.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68551/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[5] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[8] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[9] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[10] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[11] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Valrubicin, Plicamycin, Ixabepilone, Mitoxantrone, Bleomycin, Mitomycin, Dactinomycin", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, More", "updated_at": 1767369485}, {"id": 68465, "ingredient1": "Doxorubicin (liposomal)", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia are known risk factors for torsade de pointes associated with QT interval prolongation.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68552/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[5] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[8] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[9] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[10] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[11] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Valrubicin, Plicamycin, Ixabepilone, Mitoxantrone, Bleomycin, Mitomycin, Dactinomycin", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, More", "updated_at": 1767369485}, {"id": 68466, "ingredient1": "Doxycycline", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate. The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis. The clinical significance of this effect remains unknown.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic. If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Others", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68553/", "reference_text": "[1] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[3] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference) Available from: URL: http://www.mhra.gov.uk/spc-pil/index.htm.\"[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[6] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[7] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Amphotericin B, Miconazole, Clotrimazole, Epinephrine, Chlorhexidine", "alternatives_b": "Alvimopan, Sodium sulfate, Sorbitol, Methylnaltrexone, Phenolphthalein, Naloxegol, Plecanatide, Bisacodyl, Lactitol, Sodium phosphate, monobasic, Lubiprostone, More", "updated_at": 1767369485}, {"id": 68467, "ingredient1": "Dronabinol", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline. Rare cases of generalized tonic-clonic seizures and/or loss of consciousness in association with low serum osmolality and electrolyte abnormalities (e.g., hyponatremia, hypokalemia, hypocalcemia, hypomagnesemia) have been reported with the use of bowel cleansing products in patients with no prior history of seizures. The condition resolved with correction of fluid and electrolyte abnormalities.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68554/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.[9] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.", "alternatives_a": "Aprepitant, Scopolamine, Nabilone, Rolapitant", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 68468, "ingredient1": "Dronedarone", "ingredient2": "Picosulfuric acid", "severity": "Major", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval. Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly. Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68555/", "reference_text": "[1] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[2] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[9] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[10] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[11] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[12] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[13] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Tocainide, Moricizine, Bretylium", "alternatives_b": "Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Magnesium oxide, Linaclotide, Naloxone, Magnesium carbonate", "updated_at": 1767369485}, {"id": 68469, "ingredient1": "Droperidol", "ingredient2": "Picosulfuric acid", "severity": "Major", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval. Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly. Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68556/", "reference_text": "[1] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[2] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[9] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[10] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[11] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[12] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[13] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Naldemedine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68470, "ingredient1": "Duloxetine", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline. Rare cases of generalized tonic-clonic seizures and/or loss of consciousness in association with low serum osmolality and electrolyte abnormalities (e.g., hyponatremia, hypokalemia, hypocalcemia, hypomagnesemia) have been reported with the use of bowel cleansing products in patients with no prior history of seizures. The condition resolved with correction of fluid and electrolyte abnormalities.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68557/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.[9] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.", "alternatives_a": "St. John's Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine", "alternatives_b": "Alvimopan, Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Prucalopride, Linaclotide, Plecanatide, Magnesium citrate, More", "updated_at": 1767369485}, {"id": 68471, "ingredient1": "Efavirenz", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; hydroxychloroquine; mefloquine), and some narcotic analgesics. The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that can prolong the QT interval, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; mefloquine; halofantrine; lumefantrine), and some narcotic analgesics (methadone; propoxyphene).", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68558/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[6] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[9] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[10] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[11] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[12] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[13] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[14] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[15] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Prucalopride, More", "updated_at": 1767369485}, {"id": 68472, "ingredient1": "Eltrombopag", "ingredient2": "Magnesium oxide", "severity": "Moderate", "effect": "INTERVAL: Products containing aluminum, calcium, iron, magnesium, zinc and other polyvalent cations such as antacids or mineral supplements can significantly reduce the gastrointestinal absorption of eltrombopag due to chelation.", "source": "DDInter", "management_text": "Eltrombopag should be taken on an empty stomach at least 2 hours before or 4 hours after oral medications that contain antacids (e.g., didanosine buffered tablets or pediatric oral solution), aluminum, calcium, iron, magnesium, zinc or other polyvalent cations.", "mechanism_text": "Absorption", "recommendation": "Eltrombopag should be taken on an empty stomach at least 2 hours before or 4 hours after oral medications that contain antacids (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68559/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Promacta (eltrombopag).\" GlaxoSmithKline, Research Triangle Park, NC.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Promacta (eltrombopag).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Sodium chloride, Sodium sulfate, Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, More", "alternatives_b": "Romiplostim, Fostamatinib, Avatrombopag, Emicizumab, Coagulation factor VIIa Recombinant Human, Coagulation factor X human, Phylloquinone, Lusutrombopag, Anti-inhibitor coagulant complex, Antihemophilic factor, human recombinant, Fibrinogen human, More", "updated_at": 1767369485}, {"id": 68473, "ingredient1": "Elvitegravir", "ingredient2": "Magnesium oxide", "severity": "Moderate", "effect": "INTERVAL: The concomitant use of antacids may significantly decrease the plasma concentrations of elvitegravir. The mechanism of interaction has not been described. In contrast, when the antacid was given 4 hours before or 4 hours after elvitegravir, no significant differences were observed in elvitegravir pharmacokinetics compared to administration of elvitegravir alone.", "source": "DDInter", "management_text": "Antacid-containing preparations should be administered at least 2 hours before or 2 hours after the elvitegravir dose. Alternatively, H2-receptor antagonists or proton pump inhibitors may be considered, with no dosage adjustment needed.", "mechanism_text": "Others", "recommendation": "Antacid-containing preparations should be administered at least 2 hours before or 2 hours after the elvitegravir dose.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68560/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] \"Product Information. Stribild (cobicistat/elvitegravir/emtricitabine/tenofov).\" Gilead Sciences, Foster City, CA.[3] \"Product Information. Vitekta (elvitegravir).\" Gilead Sciences, Foster City, CA.[4] \"Product Information. Stribild (cobicistat/elvitegravir/emtricitabine/tenofov).\" Gilead Sciences, Foster City, CA.", "alternatives_a": "Sodium chloride, Sodium sulfate, Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, More", "alternatives_b": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Valaciclovir, Zanamivir, Lenacapavir, Telaprevir, Etravirine, More", "updated_at": 1767369485}, {"id": 68474, "ingredient1": "Enalapril", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations. Fluid and electrolyte disturbances can lead to serious adverse events including cardiac arrhythmias, seizures, and renal impairment.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment. Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered. Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing. Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68561/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Diovan (valsartan).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Cozaar (losartan).\" Merck & Co, Inc, West Point, PA.[5] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[6] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Felodipine, Amlodipine, Verapamil, Bisoprolol", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Phenolphthalein, Naloxegol, Plecanatide, Magnesium citrate, Bisacodyl, Lactitol, Lubiprostone, More", "updated_at": 1767369485}, {"id": 68475, "ingredient1": "Encorafenib", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia are known risk factors for torsade de pointes associated with QT interval prolongation.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68562/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[5] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[8] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[9] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[10] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[11] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Prucalopride, More", "alternatives_b": "Imatinib, Dabrafenib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Selumetinib, Cobimetinib, More", "updated_at": 1767369485}, {"id": 68476, "ingredient1": "Enoxacin", "ingredient2": "Citric acid", "severity": "Moderate", "effect": "Urinary alkalinizers such as citrates may decrease the solubility of fluoroquinolones in the urine and increase the risk of crystalluria.", "source": "DDInter", "management_text": "Concomitant use should generally be avoided. Patients receiving this combination should be monitored for signs of renal toxicity and crystalluria.", "mechanism_text": "Excretion", "recommendation": "Concomitant use should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68563/", "reference_text": "[1] \"Multum Information Services, Inc. Expert Review Panel\"[2] \"Product Information. Cipro (ciprofloxacin).\" Bayer, West Haven, CT.", "alternatives_a": "Delafloxacin", "alternatives_b": "Glutamic acid, Pancrelipase", "updated_at": 1767369485}, {"id": 68477, "ingredient1": "Entrectinib", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia are known risk factors for torsade de pointes associated with QT interval prolongation.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68564/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[5] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[8] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[9] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[10] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[11] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Naldemedine, More", "alternatives_b": "Imatinib, Dabrafenib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Selumetinib, Cobimetinib, More", "updated_at": 1767369485}, {"id": 68478, "ingredient1": "Enzalutamide", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; hydroxychloroquine; mefloquine), and some narcotic analgesics. The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that can prolong the QT interval, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; mefloquine; halofantrine; lumefantrine), and some narcotic analgesics (methadone; propoxyphene).", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68565/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[6] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[9] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[10] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[11] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[12] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[13] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[14] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[15] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Darolutamide, Anastrozole, Fulvestrant, Letrozole, Aminoglutethimide, Exemestane", "alternatives_b": "Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Prucalopride, Linaclotide, More", "updated_at": 1767369485}, {"id": 68479, "ingredient1": "Ephedrine", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline. Rare cases of generalized tonic-clonic seizures and/or loss of consciousness in association with low serum osmolality and electrolyte abnormalities (e.g., hyponatremia, hypokalemia, hypocalcemia, hypomagnesemia) have been reported with the use of bowel cleansing products in patients with no prior history of seizures. The condition resolved with correction of fluid and electrolyte abnormalities.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68566/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.[9] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.", "alternatives_a": "Homatropine, Atropine, Scopolamine, Methscopolamine, Tropicamide, Phenylephrine, Ciclesonide, Mupirocin, Mometasone furoate, Budesonide, Mometasone, More", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 68480, "ingredient1": "Epirubicin", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia are known risk factors for torsade de pointes associated with QT interval prolongation.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68567/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[5] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[8] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[9] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[10] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[11] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Valrubicin, Plicamycin, Ixabepilone, Mitoxantrone, Bleomycin, Mitomycin, Dactinomycin", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 68481, "ingredient1": "Eprosartan", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations. Fluid and electrolyte disturbances can lead to serious adverse events including cardiac arrhythmias, seizures, and renal impairment.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment. Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered. Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing. Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68568/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Diovan (valsartan).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Cozaar (losartan).\" Merck & Co, Inc, West Point, PA.[5] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[6] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Amlodipine, Sacubitril, Aliskiren, Nebivolol", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 68482, "ingredient1": "Eravacycline", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate. The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis. The clinical significance of this effect remains unknown.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic. If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Others", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68569/", "reference_text": "[1] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[3] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference) Available from: URL: http://www.mhra.gov.uk/spc-pil/index.htm.\"[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[6] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[7] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68483, "ingredient1": "Erdafitinib", "ingredient2": "Magnesium oxide", "severity": "Major", "effect": "Coadministration with agents that can alter serum phosphate levels may affect the initial dosage determination of erdafitinib. The mechanism appears to be related to the pharmacodynamic effects of fibroblast growth factor receptor (FGFR) inhibition by erdafitinib. Inhibition of the FGFR receptor has been shown to lead to an increase in serum phosphate levels.", "source": "DDInter", "management_text": "The manufacturer recommends that concomitant use of erdafitinib with agents that may alter serum phosphate levels be avoided before its initial dose increase period, which is between days 14 to 21 of starting erdafitinib therapy and is based on serum phosphate levels. After the initial dose increase period, an oral phosphate binder may be appropriate in the management of patients with serum phosphate levels greater than 7 mg/dL. If concomitant use with agents known to increase serum phosphate levels is required after this initial dose increase period, close monitoring of patient tolerability and serum phosphate levels is recommended.", "mechanism_text": "Others", "recommendation": "The manufacturer recommends that concomitant use of erdafitinib with agents that may alter serum phosphate levels be avoided before its initial dose increase period, which is between days 14 to 21 of starting erdafitinib therapy and is based on serum phosphate levels.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68570/", "reference_text": "[1] \"Product Information. Balversa (erdafitinib).\" Janssen Products, LP, Horsham, PA.", "alternatives_a": "Zinc gluconate, Sodium sulfate, Zinc sulfate, Sodium chloride, Alvimopan, Sorbitol, Tegaserod, Bisacodyl, Lactulose, Methylnaltrexone, Lactitol, More", "alternatives_b": "Entrectinib, Imatinib, Pralsetinib, Asciminib, Dacomitinib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Vemurafenib, More", "updated_at": 1767369485}, {"id": 68484, "ingredient1": "Ergocalciferol", "ingredient2": "Magnesium oxide", "severity": "Moderate", "effect": "Use of magnesium-containing products with a vitamin D analog may increase the risk of hypermagnesemia, particularly in chronic renal dialysis patients, due to potentially additive pharmacologic effects. Chronic hypermagnesemia may have a role in the pathogenesis of adynamic bone disease in dialysis patients.", "source": "DDInter", "management_text": "Patients on chronic renal dialysis treated with a vitamin D analog should avoid magnesium-containing products.", "mechanism_text": "Synergism", "recommendation": "Patients on chronic renal dialysis treated with a vitamin D analog should avoid magnesium-containing products.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68571/", "reference_text": "[1] \"Product Information. Zemplar (paricalcitol).\" Abbott Pharmaceutical, Abbott Park, IL.[2] \"Product Information. One-Alpha (alfacalcidol).\" Pharmel Inc, Montreal, IN.[3] \"Product Information. Rocaltrol (calcitriol).\" Roche Laboratories, Nutley, NJ.[4] \"Product Information. Hectorol (doxercalciferol).\" Genzyme Corporation, Cambridge, MA.", "alternatives_a": "Vitamin A, Beta carotene", "alternatives_b": "Magaldrate, Calcium carbonate, Aluminum hydroxide, Zinc gluconate, Sodium sulfate, Zinc sulfate, Sodium chloride, Alvimopan, Sorbitol, Tegaserod, Naloxegol, More", "updated_at": 1767369485}, {"id": 68485, "ingredient1": "Eribulin", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia are known risk factors for torsade de pointes associated with QT interval prolongation.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68572/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[5] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[8] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[9] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[10] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[11] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Pertuzumab, Olaparib, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 68486, "ingredient1": "Erlotinib", "ingredient2": "Magnesium oxide", "severity": "Moderate", "effect": "INTERVAL: Concurrent administration of antacids or other agents with acid-neutralizing effects may decrease the oral bioavailability of erlotinib and reduce its concentrations in plasma. The solubility of erlotinib decreases when the pH is over 5, resulting in reduced absorption.", "source": "DDInter", "management_text": "If an antacid or other agent with acid-neutralizing effects is required during erlotinib therapy, it should be administered at least 4 hours before or 2 hours after the daily dose of erlotinib.", "mechanism_text": "Absorption", "recommendation": "If an antacid or other agent with acid-neutralizing effects is required during erlotinib therapy, it should be administered at least 4 hours before or 2 hours after the daily dose of erlotinib.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68573/", "reference_text": "[1] \"Product Information. Tarceva (erlotinib).\" Genentech, South San Francisco, CA.[2] Duong S, Leung M \"Should the concomitant use of erlotinib and acid-reducing agents be avoided? The drug interaction between erlotinib and acid-reducing agents.\" J Oncol Pharm Pract 17 (2011): 448-52[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Li J, Zhao M, He P, Hidalgo M, Baker SD \"Differential metabolism of gefitinib and erlotinib by human cytochrome p450 enzymes.\" Clin Cancer Res 13 (2007): 3731-7[6] \"Product Information. Tarceva (erlotinib).\" Genentech, South San Francisco, CA.", "alternatives_a": "Entrectinib, Imatinib, Pralsetinib, Asciminib, Dacomitinib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Vemurafenib, More", "alternatives_b": "Magnesium gluconate, Sodium sulfate, Zinc sulfate, Magnesium sulfate, Magnesium aspartate, Magnesium lactate, Magnesium citrate, Sodium chloride, Zinc gluconate, Magnesium chloride, Alvimopan, More", "updated_at": 1767369485}, {"id": 68487, "ingredient1": "Ertapenem", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate. The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis. The clinical significance of this effect remains unknown.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic. If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Others", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68574/", "reference_text": "[1] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[3] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference) Available from: URL: http://www.mhra.gov.uk/spc-pil/index.htm.\"[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[6] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[7] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Imipenem", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 68488, "ingredient1": "Erythromycin", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate. The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis. Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic. If concomitant use is required, additional bowel cleansing and colonoscopy may be required. The recommended dosage and duration of treatment with sodium picosulfate should not be exceeded. In addition, patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68575/", "reference_text": "[1] Muller-Lissner SA \"Adverse effects of laxatives: fact and fiction.\" Pharmacology 47 (1993): 138-45[2] Schaefer DC, Cheskin LJ \"Constipation in the elderly.\" Am Fam Physician 58 (1998): 907-14[3] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[4] Chin RL \"Laxative-induced hypokalemia.\" Ann Emerg Med 32 (1998): 517-8[5] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference) Available from: URL: http://www.mhra.gov.uk/spc-pil/index.htm.\"[9] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[10] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[11] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[12] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Vitamin A, Isotretinoin, Fluorometholone, Tretinoin, Azelaic acid, Adapalene, Ganciclovir, Acyclovir, Famciclovir, Trifluridine, Chlorhexidine, Povidone-iodine", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Plecanatide, Lubiprostone, Methylcellulose, Prucalopride, Linaclotide, Naloxone", "updated_at": 1767369485}, {"id": 68489, "ingredient1": "Escitalopram", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; hydroxychloroquine; mefloquine), and some narcotic analgesics. The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that can prolong the QT interval, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; mefloquine; halofantrine; lumefantrine), and some narcotic analgesics (methadone; propoxyphene).", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68576/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[6] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[9] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[10] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[11] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[12] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[13] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[14] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[15] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "St. John's Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Naldemedine, More", "updated_at": 1767369485}, {"id": 68490, "ingredient1": "Estazolam", "ingredient2": "Magnesium oxide", "severity": "Minor", "effect": "number of studies have reported that antacids can delay the gastrointestinal absorption and reduce the peak plasma concentration (Cmax) of some benzodiazepines, including clorazepate, chlordiazepoxide and diazepam, although the overall extent of absorption is generally not affected. The exact mechanism of interaction is unknown, but may involve delayed gastric emptying or cation binding of the benzodiazepine.", "source": "DDInter", "management_text": "-", "mechanism_text": "Absorption", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68577/", "reference_text": "[1] Greenblatt DJ, Allen MD, MacLaughlin DS, Harmatz JS, Shader RI \"Diazepam absorption: effect of antacids and food.\" Clin Pharmacol Ther 24 (1978): 600-9[2] Kroboth PD, Smith RB, Silver MR, Rault R, Sorkin MI, Puschett JB, Juhl RP \"Effects of end stage renal disease and aluminium hydroxide on triazolam pharmacokinetics.\" Br J Clin Pharmacol 19 (1985): 839-42[3] Greenblatt DJ, Shader RI, Harmatz JS, Franke K, Koch-Weser J \"Absorption rate, blood concentrations, and early response to oral chlordiazepoxide.\" Am J Psychiatry 134 (1977): 559-62[4] Shader RI, Ciraulo DA, Greenblatt DJ, Harmatz JS \"Steady-state plasma desmethyldiazepam during long-term clorazepate use: effects of antacids.\" Clin Pharmacol Ther 31 (1982): 180-3[5] Greenblatt DJ, Shader RI, Harmatz JS, Franke K, Koch-Weser J \"Influence of magnesium and aluminum hydroxide mixture on chlordiazepoxide absorption.\" Clin Pharmacol Ther 19 (1976): 234-9[6] Kroboth PD, Smith RB, Rault R, Silver MR, Sorkin MI, Puschett JB, Juhl RP \"Effects of end-stage renal disease and aluminum hydroxide on temazepam kinetics.\" Clin Pharmacol Ther 37 (1985): 453-9[7] Chun AH, Carrigan PJ, Hoffman DJ, Kershner RP, Stuart JD \"Effect of antacids on absorption of clorazepate.\" Clin Pharmacol Ther 22 (1977): 329-35[8] Nair SG, Gamble JA, Dundee JW, Howard PJ \"The influence of three antacids on the absorption and clinical action of oral diazepam.\" Br J Anaesth 48 (1976): 1175-80[9] Shader RI, Georgotas A, Greenblatt DJ, Harmatz JS, Allen MD \"Impaired absorption of desmethyldiazepam from clorazepate by magnesium aluminum hydroxide.\" Clin Pharmacol Ther 24 (1978): 308-15[10] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[11] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[12] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[13] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Suvorexant, Methohexital, Methylphenobarbital, Zolpidem, Pentobarbital, Zaleplon, Dichloralphenazone, Valerian, Butabarbital, Secobarbital, Chloral hydrate, More", "alternatives_b": "Magnesium gluconate, Sodium sulfate, Zinc sulfate, Magnesium sulfate, Magnesium aspartate, Magnesium lactate, Magnesium citrate, Sodium chloride, Zinc gluconate, Magnesium chloride, Alvimopan, More", "updated_at": 1767369485}, {"id": 68491, "ingredient1": "Etacrynic acid", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations. Fluid and electrolyte disturbances can lead to serious adverse events including cardiac arrhythmias, seizures, and renal impairment.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment. Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered. Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing. Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68578/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Diovan (valsartan).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Cozaar (losartan).\" Merck & Co, Inc, West Point, PA.[5] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[6] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68492, "ingredient1": "Ethambutol", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate. The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis. The clinical significance of this effect remains unknown.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic. If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Others", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68579/", "reference_text": "[1] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[3] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference) Available from: URL: http://www.mhra.gov.uk/spc-pil/index.htm.\"[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[6] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[7] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Pyridoxine, Pretomanid", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, More", "updated_at": 1767369485}, {"id": 68493, "ingredient1": "Ethionamide", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate. The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis. The clinical significance of this effect remains unknown.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic. If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Others", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68580/", "reference_text": "[1] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[3] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference) Available from: URL: http://www.mhra.gov.uk/spc-pil/index.htm.\"[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[6] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[7] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Pyridoxine, Pretomanid", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, More", "updated_at": 1767369485}, {"id": 68494, "ingredient1": "Etidronic acid", "ingredient2": "Magnesium oxide", "severity": "Moderate", "effect": "INTERVAL: Products containing aluminum, calcium, magnesium and other polyvalent cations such as antacids or vitamin with mineral supplements are likely to interfere with the gastrointestinal absorption of oral bisphosphonates.", "source": "DDInter", "management_text": "Antacids or other oral medications containing aluminum, calcium, magnesium and other polyvalent cations should be administered at least 2 hours before or 2 hours after the bisphosphonate dose.", "mechanism_text": "Absorption", "recommendation": "Antacids or other oral medications containing aluminum, calcium, magnesium and other polyvalent cations should be administered at least 2 hours before or 2 hours after the bisphosphonate dose.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68581/", "reference_text": "[1] \"Product Information. Boniva (ibandronate).\" Roche Laboratories, Nutley, NJ.[2] \"Product Information. Fosamax (alendronate).\" Merck & Co, Inc, West Point, PA.[3] \"Product Information. Skelid (tilundronate).\" Sanofi Winthrop Pharmaceuticals, New York, NY.[4] Darcy PF \"Nutrient-drug interactions.\" Adverse Drug React Toxicol Rev 14 (1995): 233-54[5] \"Product Information. Bonefos (clodronate).\" Rhone-Poulenc Rorer Canada Inc, Laval, QC.[6] \"Product Information. Actonel (risedronate).\" Procter and Gamble Pharmaceuticals, Cincinnati, OH.[7] \"Product Information. Skelid (tilundronate).\" Sanofi Winthrop Pharmaceuticals, New York, NY.", "alternatives_a": "Vosoritide, Denosumab, Burosumab, Romosozumab, Zoledronic acid, Pamidronic acid", "alternatives_b": "Sodium chloride, Sodium sulfate, Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, More", "updated_at": 1767369485}, {"id": 68495, "ingredient1": "Etodolac", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations. Fluid and electrolyte disturbances can lead to serious adverse events including cardiac arrhythmias, seizures, and renal impairment.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment. Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered. Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing. Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68582/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Diovan (valsartan).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Cozaar (losartan).\" Merck & Co, Inc, West Point, PA.[5] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[6] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole", "alternatives_b": "Alvimopan, Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Magnesium carbonate, Plecanatide, More", "updated_at": 1767369485}, {"id": 68496, "ingredient1": "Ezogabine", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia are known risk factors for torsade de pointes associated with QT interval prolongation.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68583/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[5] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[8] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[9] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[10] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[11] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Brivaracetam, Topiramate, Cenobamate, Lamotrigine, Methylphenobarbital, Phenytoin, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Oxcarbazepine, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Prucalopride, More", "updated_at": 1767369485}, {"id": 68497, "ingredient1": "Fenfluramine", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline. Rare cases of generalized tonic-clonic seizures and/or loss of consciousness in association with low serum osmolality and electrolyte abnormalities (e.g., hyponatremia, hypokalemia, hypocalcemia, hypomagnesemia) have been reported with the use of bowel cleansing products in patients with no prior history of seizures. The condition resolved with correction of fluid and electrolyte abnormalities.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68584/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.[9] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.", "alternatives_a": "Lorcaserin, Orlistat, Naltrexone, Brivaracetam, Topiramate, Cenobamate, Lamotrigine, Methylphenobarbital, Phenytoin, Ethosuximide, Lacosamide, More", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 68498, "ingredient1": "Fenoprofen", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations. Fluid and electrolyte disturbances can lead to serious adverse events including cardiac arrhythmias, seizures, and renal impairment.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment. Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered. Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing. Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68585/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Diovan (valsartan).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Cozaar (losartan).\" Merck & Co, Inc, West Point, PA.[5] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[6] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 68499, "ingredient1": "Fentanyl", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline. Rare cases of generalized tonic-clonic seizures and/or loss of consciousness in association with low serum osmolality and electrolyte abnormalities (e.g., hyponatremia, hypokalemia, hypocalcemia, hypomagnesemia) have been reported with the use of bowel cleansing products in patients with no prior history of seizures. The condition resolved with correction of fluid and electrolyte abnormalities.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68586/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.[9] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.", "alternatives_a": "Thiopental, Sodium oxybate, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Enflurane, Esketamine, Etomidate, Ketamine, Dihydrocodeine, More", "alternatives_b": "Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, Magnesium carbonate, Plecanatide, More", "updated_at": 1767369485}, {"id": 68500, "ingredient1": "Ferrous fumarate", "ingredient2": "Magnesium oxide", "severity": "Moderate", "effect": "INTERVAL: The bioavailability of orally administered iron may be reduced by concomitant administration of antacids or other agents with acid-neutralizing effects. The exact mechanism is unknown but may involve reduced iron solubility due to increase in gastric pH and/or reduced absorption due to complexation or precipitation of the iron.", "source": "DDInter", "management_text": "To minimize the potential for interaction, it may be appropriate to administer oral iron preparations at least two hours apart from antacids or other agents with acid-neutralizing effects.", "mechanism_text": "Absorption", "recommendation": "To minimize the potential for interaction, it may be appropriate to administer oral iron preparations at least two hours apart from antacids or other agents with acid-neutralizing effects.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68587/", "reference_text": "[1] Gugler R, Allgayer H \"Effects of antacids on the clinical pharmacokinetics of drugs. An update.\" Clin Pharmacokinet 18 (1990): 210-9[2] Coste JF, De Barbi VA, Keil LB, Needle MA \"In-vitro interactions of oral hemantics and antacid suspensions.\" Curr Ther Res Clin Exp 22 (1977): 205-16[3] Coste JF, de Bari VA, Keil LB, Needle MA \"In-vitro interactions of oral hematinics.\" Curr Ther Res Clin Exp 22 (1977): 205-15[4] Rastogi SP, Padilla F, Boyd CM \"Effect of aluminum hydroxide on iron absorption.\" Kidney Int 8 (1975): 417[5] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[6] Ekenved G, Halvorsen L, Solvell L \"Influence of a liquid antacid on the absorption of different iron salts.\" Scand J Haematol Suppl 28 (1976): 65-77[7] O'Neil-Cutting MA, Crosby WH \"The effect of antacids on the absorption of simultaneously ingested iron.\" JAMA 255 (1986): 1468-70[8] Wallace KL, Curry SC, LoVecchio F, Raschke R \"Effect of magnesium hydroxide on iron absorption after ferrous sulfate.\" Ann Emerg Med 34 (1999): 685-6[9] Snyder BK, Clark RF \"Effect of magnesium hydroxide administration on iron absorption after a supratherapeutic dose of ferrous sulfate in human volunteers: A randomized controlled trial.\" Ann Emerg Med 33 (1999): 400-5[10] Corby DG, McCullen AH, Chadwick EW, Decker WJ \"Effect of orally administered magnesium hydroxide in experimental iron intoxication.\" J Toxicol Clin Toxicol 23 (1985-86): 489-99[11] Pruchnicki MC, Coyle JD, Hoshaw-Woodard S, Bay WH \"Effect of phosphate binders on supplemental iron absorption in healthy subjects.\" J Clin Pharmacol 42 (2002): 1171-6[12] Hall GJ, Davis AE \"Inhibition of iron absorption by magnesium trisilicate.\" Med J Aust 2 (1969): 95-6", "alternatives_a": "Magnesium sulfate, Magnesium aspartate, Magnesium lactate, Magnesium citrate, Sodium chloride, Magnesium gluconate, Magnesium chloride, Alvimopan, Sorbitol, Tegaserod, Naloxegol, More", "alternatives_b": "Iron sucrose, Cyanocobalamin, Folic acid", "updated_at": 1767369485}, {"id": 68501, "ingredient1": "Ferrous gluconate", "ingredient2": "Magnesium oxide", "severity": "Moderate", "effect": "INTERVAL: The bioavailability of orally administered iron may be reduced by concomitant administration of antacids or other agents with acid-neutralizing effects. The exact mechanism is unknown but may involve reduced iron solubility due to increase in gastric pH and/or reduced absorption due to complexation or precipitation of the iron.", "source": "DDInter", "management_text": "To minimize the potential for interaction, it may be appropriate to administer oral iron preparations at least two hours apart from antacids or other agents with acid-neutralizing effects.", "mechanism_text": "Absorption", "recommendation": "To minimize the potential for interaction, it may be appropriate to administer oral iron preparations at least two hours apart from antacids or other agents with acid-neutralizing effects.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68588/", "reference_text": "[1] Gugler R, Allgayer H \"Effects of antacids on the clinical pharmacokinetics of drugs. An update.\" Clin Pharmacokinet 18 (1990): 210-9[2] Coste JF, De Barbi VA, Keil LB, Needle MA \"In-vitro interactions of oral hemantics and antacid suspensions.\" Curr Ther Res Clin Exp 22 (1977): 205-16[3] Coste JF, de Bari VA, Keil LB, Needle MA \"In-vitro interactions of oral hematinics.\" Curr Ther Res Clin Exp 22 (1977): 205-15[4] Rastogi SP, Padilla F, Boyd CM \"Effect of aluminum hydroxide on iron absorption.\" Kidney Int 8 (1975): 417[5] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[6] Ekenved G, Halvorsen L, Solvell L \"Influence of a liquid antacid on the absorption of different iron salts.\" Scand J Haematol Suppl 28 (1976): 65-77[7] O'Neil-Cutting MA, Crosby WH \"The effect of antacids on the absorption of simultaneously ingested iron.\" JAMA 255 (1986): 1468-70[8] Wallace KL, Curry SC, LoVecchio F, Raschke R \"Effect of magnesium hydroxide on iron absorption after ferrous sulfate.\" Ann Emerg Med 34 (1999): 685-6[9] Snyder BK, Clark RF \"Effect of magnesium hydroxide administration on iron absorption after a supratherapeutic dose of ferrous sulfate in human volunteers: A randomized controlled trial.\" Ann Emerg Med 33 (1999): 400-5[10] Corby DG, McCullen AH, Chadwick EW, Decker WJ \"Effect of orally administered magnesium hydroxide in experimental iron intoxication.\" J Toxicol Clin Toxicol 23 (1985-86): 489-99[11] Pruchnicki MC, Coyle JD, Hoshaw-Woodard S, Bay WH \"Effect of phosphate binders on supplemental iron absorption in healthy subjects.\" J Clin Pharmacol 42 (2002): 1171-6[12] Hall GJ, Davis AE \"Inhibition of iron absorption by magnesium trisilicate.\" Med J Aust 2 (1969): 95-6", "alternatives_a": "Magnesium sulfate, Magnesium aspartate, Magnesium lactate, Magnesium citrate, Sodium chloride, Magnesium gluconate, Magnesium chloride, Alvimopan, Sorbitol, Tegaserod, Naloxegol, More", "alternatives_b": "Iron sucrose, Cyanocobalamin, Folic acid", "updated_at": 1767369485}, {"id": 68502, "ingredient1": "Ferrous sulfate anhydrous", "ingredient2": "Magnesium oxide", "severity": "Moderate", "effect": "INTERVAL: The bioavailability of orally administered iron may be reduced by concomitant administration of antacids or other agents with acid-neutralizing effects. The exact mechanism is unknown but may involve reduced iron solubility due to increase in gastric pH and/or reduced absorption due to complexation or precipitation of the iron.", "source": "DDInter", "management_text": "To minimize the potential for interaction, it may be appropriate to administer oral iron preparations at least two hours apart from antacids or other agents with acid-neutralizing effects.", "mechanism_text": "Absorption", "recommendation": "To minimize the potential for interaction, it may be appropriate to administer oral iron preparations at least two hours apart from antacids or other agents with acid-neutralizing effects.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68589/", "reference_text": "[1] Gugler R, Allgayer H \"Effects of antacids on the clinical pharmacokinetics of drugs. An update.\" Clin Pharmacokinet 18 (1990): 210-9[2] Coste JF, De Barbi VA, Keil LB, Needle MA \"In-vitro interactions of oral hemantics and antacid suspensions.\" Curr Ther Res Clin Exp 22 (1977): 205-16[3] Coste JF, de Bari VA, Keil LB, Needle MA \"In-vitro interactions of oral hematinics.\" Curr Ther Res Clin Exp 22 (1977): 205-15[4] Rastogi SP, Padilla F, Boyd CM \"Effect of aluminum hydroxide on iron absorption.\" Kidney Int 8 (1975): 417[5] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[6] Ekenved G, Halvorsen L, Solvell L \"Influence of a liquid antacid on the absorption of different iron salts.\" Scand J Haematol Suppl 28 (1976): 65-77[7] O'Neil-Cutting MA, Crosby WH \"The effect of antacids on the absorption of simultaneously ingested iron.\" JAMA 255 (1986): 1468-70[8] Wallace KL, Curry SC, LoVecchio F, Raschke R \"Effect of magnesium hydroxide on iron absorption after ferrous sulfate.\" Ann Emerg Med 34 (1999): 685-6[9] Snyder BK, Clark RF \"Effect of magnesium hydroxide administration on iron absorption after a supratherapeutic dose of ferrous sulfate in human volunteers: A randomized controlled trial.\" Ann Emerg Med 33 (1999): 400-5[10] Corby DG, McCullen AH, Chadwick EW, Decker WJ \"Effect of orally administered magnesium hydroxide in experimental iron intoxication.\" J Toxicol Clin Toxicol 23 (1985-86): 489-99[11] Pruchnicki MC, Coyle JD, Hoshaw-Woodard S, Bay WH \"Effect of phosphate binders on supplemental iron absorption in healthy subjects.\" J Clin Pharmacol 42 (2002): 1171-6[12] Hall GJ, Davis AE \"Inhibition of iron absorption by magnesium trisilicate.\" Med J Aust 2 (1969): 95-6", "alternatives_a": "Magnesium sulfate, Magnesium aspartate, Magnesium lactate, Magnesium citrate, Sodium chloride, Magnesium gluconate, Magnesium chloride, Alvimopan, Sorbitol, Tegaserod, Naloxegol, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68503, "ingredient1": "Fidaxomicin", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate. The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis. The clinical significance of this effect remains unknown.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic. If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Others", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68590/", "reference_text": "[1] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[3] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference) Available from: URL: http://www.mhra.gov.uk/spc-pil/index.htm.\"[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[6] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[7] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Nystatin, Amphotericin B, Miconazole", "alternatives_b": "Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, Sodium sulfate, Linaclotide, More", "updated_at": 1767369485}, {"id": 68504, "ingredient1": "Flecainide", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia are known risk factors for torsade de pointes associated with QT interval prolongation.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68591/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[5] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[8] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[9] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[10] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[11] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Tocainide, Moricizine, Bretylium", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 68505, "ingredient1": "Fluconazole", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia are known risk factors for torsade de pointes associated with QT interval prolongation.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68592/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[5] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[8] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[9] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[10] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[11] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Tinidazole, Caspofungin, Micafungin, Amphotericin B, Itraconazole, Miconazole, Oteseconazole, Flucytosine, Anidulafungin, Selenium Sulfide, Thiabendazole, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Magnesium oxide, Plecanatide, Lubiprostone, Methylcellulose, Prucalopride, Linaclotide, Magnesium carbonate", "updated_at": 1767369485}, {"id": 68506, "ingredient1": "Fludeoxyglucose (18F)", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Certain medications may interfere with the results of diagnostic studies using fludeoxyglucose F18 by increasing or decreasing uptake of the agent into tissues.", "source": "DDInter", "management_text": "Clinicians should be aware of possible diagnostic interference associated with the following medications: colony-stimulating factors may increase uptake in spleen and bone marrow; glucose-induced hyperglycemia may interfere with uptake; dopamine and insulin may decrease myocardial and tumor cell uptake; laxative-induced intestinal muscle activity and/or irritation may increase intestinal uptake.", "mechanism_text": "Absorption", "recommendation": "Clinicians should be aware of possible diagnostic interference associated with the following medications: colony-stimulating factors may increase uptake in spleen and bone marrow; glucose-induced hyperglycemia may interfere with uptake; dopamine and insulin may decrease myocardial and tumor cell uptake; laxative-induced intestinal muscle activity and/or irritation may increase intestinal uptake.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68593/", "reference_text": "[1] \"Multum Information Services, Inc. Expert Review Panel\"[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Metamucil (psyllium).\" Procter and Gamble Pharmaceutic, Cincinnati, OH.", "alternatives_a": "Alvimopan, Sodium sulfate, Sorbitol, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Sodium phosphate, monobasic, Lubiprostone, Mannitol, More", "alternatives_b": "Capromab pendetide, Gallium Ga-68 gozetotide, Indium In-111 pentetreotide", "updated_at": 1767369485}, {"id": 68507, "ingredient1": "Fludrocortisone", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The overuse or abuse of laxatives can cause significant loss of electrolytes and potentiate the risk of hypokalemia associated with corticosteroid therapy. Corticosteroids promote the retention of sodium and water and the excretion of potassium. Although these effects are primarily associated with mineralocorticoids like fludrocortisone, they may also occur with higher dosages of glucocorticoids or adrenocorticotropic agents, particularly if given systemically for longer than brief periods.", "source": "DDInter", "management_text": "In general, laxatives should only be used on a short-term, intermittent basis in recommended dosages. During concomitant therapy with corticosteroids, particularly if fludrocortisone or large doses of a glucocorticoid or adrenocorticotropic agent is given, patients should be counseled to recognize potential signs and symptoms of hypokalemia such as fatigue, myalgia, and muscle weakness. If maintenance of bowel regularity is required, patients should be advised to exercise and increase fiber in the diet and/or consider the use of bulk-forming laxatives.", "mechanism_text": "Antagonism", "recommendation": "In general, laxatives should only be used on a short-term, intermittent basis in recommended dosages.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68594/", "reference_text": "[1] Chin RL \"Laxative-induced hypokalemia.\" Ann Emerg Med 32 (1998): 517-8[2] Blumenthal M, Goldberg A, Brinckmann J, eds. \"Herbal Medicine: Expanded Commission E Monographs.\" Newton, MA: Integrative Medicine Communications (2000):[3] Muller-Lissner SA \"Adverse effects of laxatives: fact and fiction.\" Pharmacology 47 (1993): 138-45[4] Seale JP, Compton MR \"Side-effects of corticosteroid agents.\" Med J Aust 144 (1986): 139-42[5] Swartz SL, Dluhy RG \"Corticosteroids: clinical pharmacology and therapeutic use.\" Drugs 16 (1978): 238-55[6] Lieberman P, Patterson R, Kunske R \"Complications of long-term steroid therapy for asthma.\" J Allergy Clin Immunol 49 (1972): 329-36[7] Ramsahoye BH, Davies SV, el-Gaylani N, Sandeman D, Scanlon MF \"The mineralocorticoid effects of high dose hydrocortisone.\" BMJ 310 (1995): 656-7", "alternatives_a": "Fluocinolone acetonide, Fluocinolone acetonide, Fluorometholone", "alternatives_b": "Alvimopan, Sodium sulfate, Sorbitol, Methylnaltrexone, Tegaserod, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Naldemedine, More", "updated_at": 1767369485}, {"id": 68508, "ingredient1": "Fluoxetine", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; hydroxychloroquine; mefloquine), and some narcotic analgesics. The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that can prolong the QT interval, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; mefloquine; halofantrine; lumefantrine), and some narcotic analgesics (methadone; propoxyphene).", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68595/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[6] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[9] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[10] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[11] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[12] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[13] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[14] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[15] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "St. John's Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Naldemedine, Prucalopride, More", "updated_at": 1767369485}, {"id": 68509, "ingredient1": "Fluphenazine", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; hydroxychloroquine; mefloquine), and some narcotic analgesics. The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that can prolong the QT interval, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; mefloquine; halofantrine; lumefantrine), and some narcotic analgesics (methadone; propoxyphene).", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68596/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[6] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[9] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[10] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[11] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[12] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[13] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[14] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[15] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Naldemedine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68510, "ingredient1": "Flurazepam", "ingredient2": "Magnesium oxide", "severity": "Minor", "effect": "number of studies have reported that antacids can delay the gastrointestinal absorption and reduce the peak plasma concentration (Cmax) of some benzodiazepines, including clorazepate, chlordiazepoxide and diazepam, although the overall extent of absorption is generally not affected. The exact mechanism of interaction is unknown, but may involve delayed gastric emptying or cation binding of the benzodiazepine.", "source": "DDInter", "management_text": "-", "mechanism_text": "Absorption", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68597/", "reference_text": "[1] Greenblatt DJ, Allen MD, MacLaughlin DS, Harmatz JS, Shader RI \"Diazepam absorption: effect of antacids and food.\" Clin Pharmacol Ther 24 (1978): 600-9[2] Kroboth PD, Smith RB, Silver MR, Rault R, Sorkin MI, Puschett JB, Juhl RP \"Effects of end stage renal disease and aluminium hydroxide on triazolam pharmacokinetics.\" Br J Clin Pharmacol 19 (1985): 839-42[3] Greenblatt DJ, Shader RI, Harmatz JS, Franke K, Koch-Weser J \"Absorption rate, blood concentrations, and early response to oral chlordiazepoxide.\" Am J Psychiatry 134 (1977): 559-62[4] Shader RI, Ciraulo DA, Greenblatt DJ, Harmatz JS \"Steady-state plasma desmethyldiazepam during long-term clorazepate use: effects of antacids.\" Clin Pharmacol Ther 31 (1982): 180-3[5] Greenblatt DJ, Shader RI, Harmatz JS, Franke K, Koch-Weser J \"Influence of magnesium and aluminum hydroxide mixture on chlordiazepoxide absorption.\" Clin Pharmacol Ther 19 (1976): 234-9[6] Kroboth PD, Smith RB, Rault R, Silver MR, Sorkin MI, Puschett JB, Juhl RP \"Effects of end-stage renal disease and aluminum hydroxide on temazepam kinetics.\" Clin Pharmacol Ther 37 (1985): 453-9[7] Chun AH, Carrigan PJ, Hoffman DJ, Kershner RP, Stuart JD \"Effect of antacids on absorption of clorazepate.\" Clin Pharmacol Ther 22 (1977): 329-35[8] Nair SG, Gamble JA, Dundee JW, Howard PJ \"The influence of three antacids on the absorption and clinical action of oral diazepam.\" Br J Anaesth 48 (1976): 1175-80[9] Shader RI, Georgotas A, Greenblatt DJ, Harmatz JS, Allen MD \"Impaired absorption of desmethyldiazepam from clorazepate by magnesium aluminum hydroxide.\" Clin Pharmacol Ther 24 (1978): 308-15[10] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[11] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[12] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[13] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Suvorexant, Methohexital, Methylphenobarbital, Zolpidem, Pentobarbital, Zaleplon, Dichloralphenazone, Valerian, Butabarbital, Secobarbital, Chloral hydrate, More", "alternatives_b": "Magnesium gluconate, Sodium sulfate, Zinc sulfate, Magnesium sulfate, Magnesium aspartate, Magnesium lactate, Magnesium citrate, Sodium chloride, Zinc gluconate, Magnesium chloride, Alvimopan, More", "updated_at": 1767369485}, {"id": 68511, "ingredient1": "Flurbiprofen", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations. Fluid and electrolyte disturbances can lead to serious adverse events including cardiac arrhythmias, seizures, and renal impairment.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment. Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered. Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing. Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68598/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Diovan (valsartan).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Cozaar (losartan).\" Merck & Co, Inc, West Point, PA.[5] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[6] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Tolazoline, Rabeprazole, Dimethyl sulfoxide, Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole, Chlorhexidine, Povidone-iodine, Fluocinolone acetonide, Fluorometholone", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 68512, "ingredient1": "Flutamide", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia are known risk factors for torsade de pointes associated with QT interval prolongation.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68599/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[5] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[8] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[9] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[10] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[11] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Darolutamide, Anastrozole, Fulvestrant, Letrozole, Aminoglutethimide, Exemestane", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 68513, "ingredient1": "Fluvoxamine", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline. Rare cases of generalized tonic-clonic seizures and/or loss of consciousness in association with low serum osmolality and electrolyte abnormalities (e.g., hyponatremia, hypokalemia, hypocalcemia, hypomagnesemia) have been reported with the use of bowel cleansing products in patients with no prior history of seizures. The condition resolved with correction of fluid and electrolyte abnormalities.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68600/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.[9] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.", "alternatives_a": "St. John's Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, More", "updated_at": 1767369485}, {"id": 68514, "ingredient1": "Foscarnet", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; hydroxychloroquine; mefloquine), and some narcotic analgesics. The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that can prolong the QT interval, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; mefloquine; halofantrine; lumefantrine), and some narcotic analgesics (methadone; propoxyphene).", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68601/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[6] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[9] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[10] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[11] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[12] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[13] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[14] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[15] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 68515, "ingredient1": "Fosfomycin", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate. The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis. The clinical significance of this effect remains unknown.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic. If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Others", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68602/", "reference_text": "[1] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[3] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference) Available from: URL: http://www.mhra.gov.uk/spc-pil/index.htm.\"[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[6] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[7] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Tinidazole", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, More", "updated_at": 1767369485}, {"id": 68516, "ingredient1": "Fosinopril", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations. Fluid and electrolyte disturbances can lead to serious adverse events including cardiac arrhythmias, seizures, and renal impairment.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment. Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered. Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing. Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68603/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Diovan (valsartan).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Cozaar (losartan).\" Merck & Co, Inc, West Point, PA.[5] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[6] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Felodipine, Amlodipine, Verapamil, Bisoprolol", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Prucalopride, Linaclotide, More", "updated_at": 1767369485}, {"id": 68517, "ingredient1": "Fostemsavir", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia are known risk factors for torsade de pointes associated with QT interval prolongation.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68604/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[5] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[8] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[9] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[10] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[11] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "alternatives_b": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, More", "updated_at": 1767369485}, {"id": 68518, "ingredient1": "Furosemide", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations. Fluid and electrolyte disturbances can lead to serious adverse events including cardiac arrhythmias, seizures, and renal impairment.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment. Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered. Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing. Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68605/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Diovan (valsartan).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Cozaar (losartan).\" Merck & Co, Inc, West Point, PA.[5] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[6] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Simeprevir, Rosuvastatin, Lactic acid, Mitapivat, Amphotericin B, Ciclopirox, Darunavir, Probenecid, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Naldemedine, Prucalopride, More", "updated_at": 1767369485}, {"id": 68519, "ingredient1": "Gabapentin", "ingredient2": "Magnesium oxide", "severity": "Minor", "effect": "Aluminum hydroxide and magnesium hydroxide antacids may decrease the bioavailability of gabapentin by as much as 20%. A dose of aluminum or magnesium hydroxide should precede a dose of gabapentin by at least two hours. Other antacids that contain aluminum or magnesium may interact with gabapentin in a similar fashion.", "source": "DDInter", "management_text": "-", "mechanism_text": "Absorption", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68606/", "reference_text": "[1] \"Product Information. Neurontin (gabapentin).\" Parke-Davis, Morris Plains, NJ.[2] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[3] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[4] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[5] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Brivaracetam, Topiramate, Ezogabine, Cenobamate, Lamotrigine, Methylphenobarbital, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Oxcarbazepine, More", "alternatives_b": "Calcium carbonate, Magnesium gluconate, Sodium sulfate, Zinc sulfate, Magnesium sulfate, Magnesium aspartate, Magnesium lactate, Magnesium citrate, Sodium chloride, Zinc gluconate, Magnesium chloride, More", "updated_at": 1767369485}, {"id": 68520, "ingredient1": "Galantamine", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline. Rare cases of generalized tonic-clonic seizures and/or loss of consciousness in association with low serum osmolality and electrolyte abnormalities (e.g., hyponatremia, hypokalemia, hypocalcemia, hypomagnesemia) have been reported with the use of bowel cleansing products in patients with no prior history of seizures. The condition resolved with correction of fluid and electrolyte abnormalities.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68607/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.[9] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.", "alternatives_a": "Memantine, Ginkgo biloba, Aducanumab", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 68521, "ingredient1": "Gatifloxacin", "ingredient2": "Citric acid", "severity": "Moderate", "effect": "Urinary alkalinizers such as citrates may decrease the solubility of fluoroquinolones in the urine and increase the risk of crystalluria.", "source": "DDInter", "management_text": "Concomitant use should generally be avoided. Patients receiving this combination should be monitored for signs of renal toxicity and crystalluria.", "mechanism_text": "Excretion", "recommendation": "Concomitant use should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68608/", "reference_text": "[1] \"Multum Information Services, Inc. Expert Review Panel\"[2] \"Product Information. Cipro (ciprofloxacin).\" Bayer, West Haven, CT.", "alternatives_a": "Rifamycin, Kanamycin, Ampicillin, Azithromycin, Acyclovir, Netilmicin, Polymyxin B, Famciclovir, Cefuroxime, Trifluridine, Tobramycin, More", "alternatives_b": "Glutamic acid, Pancrelipase", "updated_at": 1767369485}, {"id": 68522, "ingredient1": "Gemifloxacin", "ingredient2": "Citric acid", "severity": "Moderate", "effect": "Urinary alkalinizers such as citrates may decrease the solubility of fluoroquinolones in the urine and increase the risk of crystalluria.", "source": "DDInter", "management_text": "Concomitant use should generally be avoided. Patients receiving this combination should be monitored for signs of renal toxicity and crystalluria.", "mechanism_text": "Excretion", "recommendation": "Concomitant use should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68609/", "reference_text": "[1] \"Multum Information Services, Inc. Expert Review Panel\"[2] \"Product Information. Cipro (ciprofloxacin).\" Bayer, West Haven, CT.", "alternatives_a": "Delafloxacin", "alternatives_b": "Glutamic acid, Pancrelipase", "updated_at": 1767369485}, {"id": 68523, "ingredient1": "Gentamicin", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate. The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis. The clinical significance of this effect remains unknown.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic. If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Others", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68610/", "reference_text": "[1] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[3] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference) Available from: URL: http://www.mhra.gov.uk/spc-pil/index.htm.\"[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[6] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[7] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Ganciclovir, Acyclovir, Famciclovir, Trifluridine, Chlorhexidine, Povidone-iodine, Chlorhexidine, Miconazole, Mupirocin, Chlorhexidine", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, Sodium sulfate, More", "updated_at": 1767369485}, {"id": 68524, "ingredient1": "Gilteritinib", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia are known risk factors for torsade de pointes associated with QT interval prolongation.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68611/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[5] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[8] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[9] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[10] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[11] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Alvimopan, Sorbitol, Magnesium sulfate, Tegaserod, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Magnesium oxide, Linaclotide, Naloxone, Magnesium carbonate", "alternatives_b": "Imatinib, Dabrafenib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Selumetinib, Cobimetinib, More", "updated_at": 1767369485}, {"id": 68525, "ingredient1": "Glasdegib", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia are known risk factors for torsade de pointes associated with QT interval prolongation.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68612/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[5] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[8] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[9] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[10] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[11] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Magnesium oxide, Linaclotide, More", "alternatives_b": "Pertuzumab, Olaparib, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, More", "updated_at": 1767369485}, {"id": 68526, "ingredient1": "Glimepiride", "ingredient2": "Magnesium oxide", "severity": "Moderate", "effect": "INTERVAL: Some antacids have been reported to increase the rate of absorption and, rarely, the extent of absorption of oral sulfonylureas. The hypoglycemic effects of these agents may be altered.", "source": "DDInter", "management_text": "Sulfonylureas should be administered at least two hours before or after antacids when possible. Regular monitoring of blood sugar is advisable. In addition, patients should be apprised of the signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nausea, hunger, tremor, weakness, sweating, palpitations), how to treat it, and to contact their physician if it occurs.", "mechanism_text": "Absorption", "recommendation": "Sulfonylureas should be administered at least two hours before or after antacids when possible.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68613/", "reference_text": "[1] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[2] Prendergast BD \"Glyburide and glipizide, second-generation oral sulfonylurea hypoglycemic agents.\" Clin Pharm 3 (1984): 473-85[3] \"Product Information. Micronase (glyburide).\" Pharmacia and Upjohn, Kalamazoo, MI.[4] Kivisto KT, Neuvonen PJ \"Effect of magnesium hydroxide on the absorption and efficacy of tolbutamide and chlorpropamide.\" Eur J Clin Pharmacol 42 (1992): 675-80[5] Kolterman OG \"Glyburide in non-insulin-dependent diabetes: an update.\" Clin Ther 14 (1992): 196-213[6] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[7] Kivisto KT, Neuvonen PJ \"Enhancement of absorption and effect of glipizide by magnesium hydroxide.\" Clin Pharmacol Ther 49 (1991): 39-43[8] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[9] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[10] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[11] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[12] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[13] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[14] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[15] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[16] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[17] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Guar gum, Pramlintide, Alogliptin, Empagliflozin, Dulaglutide, Exenatide, Miglitol, Albiglutide, Rosiglitazone, Ertugliflozin, Semaglutide, More", "alternatives_b": "Magnesium gluconate, Sodium sulfate, Zinc sulfate, Magnesium sulfate, Magnesium aspartate, Magnesium lactate, Magnesium citrate, Sodium chloride, Zinc gluconate, Magnesium chloride, Alvimopan, More", "updated_at": 1767369485}, {"id": 68527, "ingredient1": "Glipizide", "ingredient2": "Magnesium oxide", "severity": "Moderate", "effect": "INTERVAL: Some antacids have been reported to increase the rate of absorption and, rarely, the extent of absorption of oral sulfonylureas. The hypoglycemic effects of these agents may be altered.", "source": "DDInter", "management_text": "Sulfonylureas should be administered at least two hours before or after antacids when possible. Regular monitoring of blood sugar is advisable. In addition, patients should be apprised of the signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nausea, hunger, tremor, weakness, sweating, palpitations), how to treat it, and to contact their physician if it occurs.", "mechanism_text": "Absorption", "recommendation": "Sulfonylureas should be administered at least two hours before or after antacids when possible.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68614/", "reference_text": "[1] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[2] Prendergast BD \"Glyburide and glipizide, second-generation oral sulfonylurea hypoglycemic agents.\" Clin Pharm 3 (1984): 473-85[3] \"Product Information. Micronase (glyburide).\" Pharmacia and Upjohn, Kalamazoo, MI.[4] Kivisto KT, Neuvonen PJ \"Effect of magnesium hydroxide on the absorption and efficacy of tolbutamide and chlorpropamide.\" Eur J Clin Pharmacol 42 (1992): 675-80[5] Kolterman OG \"Glyburide in non-insulin-dependent diabetes: an update.\" Clin Ther 14 (1992): 196-213[6] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[7] Kivisto KT, Neuvonen PJ \"Enhancement of absorption and effect of glipizide by magnesium hydroxide.\" Clin Pharmacol Ther 49 (1991): 39-43[8] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[9] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[10] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[11] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[12] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[13] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[14] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[15] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[16] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[17] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Guar gum, Pramlintide, Alogliptin, Empagliflozin, Dulaglutide, Exenatide, Miglitol, Albiglutide, Rosiglitazone, Ertugliflozin, Semaglutide, More", "alternatives_b": "Magnesium gluconate, Sodium sulfate, Zinc sulfate, Magnesium sulfate, Magnesium aspartate, Magnesium lactate, Magnesium citrate, Sodium chloride, Zinc gluconate, Magnesium chloride, Alvimopan, More", "updated_at": 1767369485}, {"id": 68528, "ingredient1": "Glyburide", "ingredient2": "Magnesium oxide", "severity": "Moderate", "effect": "INTERVAL: Some antacids have been reported to increase the rate of absorption and, rarely, the extent of absorption of oral sulfonylureas. The hypoglycemic effects of these agents may be altered.", "source": "DDInter", "management_text": "Sulfonylureas should be administered at least two hours before or after antacids when possible. Regular monitoring of blood sugar is advisable. In addition, patients should be apprised of the signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nausea, hunger, tremor, weakness, sweating, palpitations), how to treat it, and to contact their physician if it occurs.", "mechanism_text": "Absorption", "recommendation": "Sulfonylureas should be administered at least two hours before or after antacids when possible.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68615/", "reference_text": "[1] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[2] Prendergast BD \"Glyburide and glipizide, second-generation oral sulfonylurea hypoglycemic agents.\" Clin Pharm 3 (1984): 473-85[3] \"Product Information. Micronase (glyburide).\" Pharmacia and Upjohn, Kalamazoo, MI.[4] Kivisto KT, Neuvonen PJ \"Effect of magnesium hydroxide on the absorption and efficacy of tolbutamide and chlorpropamide.\" Eur J Clin Pharmacol 42 (1992): 675-80[5] Kolterman OG \"Glyburide in non-insulin-dependent diabetes: an update.\" Clin Ther 14 (1992): 196-213[6] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[7] Kivisto KT, Neuvonen PJ \"Enhancement of absorption and effect of glipizide by magnesium hydroxide.\" Clin Pharmacol Ther 49 (1991): 39-43[8] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[9] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[10] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[11] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[12] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[13] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[14] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[15] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[16] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[17] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Guar gum, Pramlintide, Alogliptin, Empagliflozin, Dulaglutide, Exenatide, Miglitol, Albiglutide, Rosiglitazone, Ertugliflozin, Semaglutide, More", "alternatives_b": "Magnesium gluconate, Sodium sulfate, Zinc sulfate, Magnesium sulfate, Magnesium aspartate, Magnesium lactate, Magnesium citrate, Sodium chloride, Zinc gluconate, Magnesium chloride, Alvimopan, More", "updated_at": 1767369485}, {"id": 68529, "ingredient1": "Goserelin", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia are known risk factors for torsade de pointes associated with QT interval prolongation.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68616/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[5] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[8] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[9] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[10] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[11] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Megestrol acetate, Ethinylestradiol, Diethylstilbestrol, Medroxyprogesterone acetate", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 68530, "ingredient1": "Granisetron", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia are known risk factors for torsade de pointes associated with QT interval prolongation.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68617/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[5] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[8] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[9] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[10] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[11] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Aprepitant, Scopolamine, Nabilone, Rolapitant", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Naldemedine, More", "updated_at": 1767369485}, {"id": 68531, "ingredient1": "Grepafloxacin", "ingredient2": "Picosulfuric acid", "severity": "Major", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval. Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly. Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68618/", "reference_text": "[1] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[2] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[9] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[10] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[11] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[12] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[13] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Alvimopan, Sorbitol, Methylnaltrexone, Tegaserod, Phenolphthalein, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Naldemedine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68532, "ingredient1": "Halazepam", "ingredient2": "Magnesium oxide", "severity": "Minor", "effect": "number of studies have reported that antacids can delay the gastrointestinal absorption and reduce the peak plasma concentration (Cmax) of some benzodiazepines, including clorazepate, chlordiazepoxide and diazepam, although the overall extent of absorption is generally not affected. The exact mechanism of interaction is unknown, but may involve delayed gastric emptying or cation binding of the benzodiazepine.", "source": "DDInter", "management_text": "-", "mechanism_text": "Absorption", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68619/", "reference_text": "[1] Greenblatt DJ, Allen MD, MacLaughlin DS, Harmatz JS, Shader RI \"Diazepam absorption: effect of antacids and food.\" Clin Pharmacol Ther 24 (1978): 600-9[2] Kroboth PD, Smith RB, Silver MR, Rault R, Sorkin MI, Puschett JB, Juhl RP \"Effects of end stage renal disease and aluminium hydroxide on triazolam pharmacokinetics.\" Br J Clin Pharmacol 19 (1985): 839-42[3] Greenblatt DJ, Shader RI, Harmatz JS, Franke K, Koch-Weser J \"Absorption rate, blood concentrations, and early response to oral chlordiazepoxide.\" Am J Psychiatry 134 (1977): 559-62[4] Shader RI, Ciraulo DA, Greenblatt DJ, Harmatz JS \"Steady-state plasma desmethyldiazepam during long-term clorazepate use: effects of antacids.\" Clin Pharmacol Ther 31 (1982): 180-3[5] Greenblatt DJ, Shader RI, Harmatz JS, Franke K, Koch-Weser J \"Influence of magnesium and aluminum hydroxide mixture on chlordiazepoxide absorption.\" Clin Pharmacol Ther 19 (1976): 234-9[6] Kroboth PD, Smith RB, Rault R, Silver MR, Sorkin MI, Puschett JB, Juhl RP \"Effects of end-stage renal disease and aluminum hydroxide on temazepam kinetics.\" Clin Pharmacol Ther 37 (1985): 453-9[7] Chun AH, Carrigan PJ, Hoffman DJ, Kershner RP, Stuart JD \"Effect of antacids on absorption of clorazepate.\" Clin Pharmacol Ther 22 (1977): 329-35[8] Nair SG, Gamble JA, Dundee JW, Howard PJ \"The influence of three antacids on the absorption and clinical action of oral diazepam.\" Br J Anaesth 48 (1976): 1175-80[9] Shader RI, Georgotas A, Greenblatt DJ, Harmatz JS, Allen MD \"Impaired absorption of desmethyldiazepam from clorazepate by magnesium aluminum hydroxide.\" Clin Pharmacol Ther 24 (1978): 308-15[10] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[11] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[12] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[13] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Meprobamate, Buspirone, Hydroxyzine", "alternatives_b": "Magaldrate, Magnesium gluconate, Sodium sulfate, Zinc sulfate, Magnesium sulfate, Magnesium aspartate, Magnesium lactate, Magnesium citrate, Sodium chloride, Zinc gluconate, Magnesium chloride, More", "updated_at": 1767369485}, {"id": 68533, "ingredient1": "Halofantrine", "ingredient2": "Picosulfuric acid", "severity": "Major", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval. Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly. Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68620/", "reference_text": "[1] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[2] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[9] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[10] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[11] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[12] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[13] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Artesunate, Lumefantrine, Artemether, Pyrimethamine, Tafenoquine, Proguanil", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 68534, "ingredient1": "Haloperidol", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; hydroxychloroquine; mefloquine), and some narcotic analgesics. The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that can prolong the QT interval, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; mefloquine; halofantrine; lumefantrine), and some narcotic analgesics (methadone; propoxyphene).", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68621/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[6] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[9] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[10] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[11] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[12] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[13] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[14] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[15] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Naldemedine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68535, "ingredient1": "Halothane", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia are known risk factors for torsade de pointes associated with QT interval prolongation.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68622/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[5] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[8] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[9] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[10] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[11] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Thiopental, Sodium oxybate, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Enflurane, Esketamine, Etomidate, Ketamine", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 68536, "ingredient1": "Diamorphine", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline. Rare cases of generalized tonic-clonic seizures and/or loss of consciousness in association with low serum osmolality and electrolyte abnormalities (e.g., hyponatremia, hypokalemia, hypocalcemia, hypomagnesemia) have been reported with the use of bowel cleansing products in patients with no prior history of seizures. The condition resolved with correction of fluid and electrolyte abnormalities.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68623/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.[9] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.", "alternatives_a": "Acamprosate, Naltrexone, Varenicline, Disulfiram, Nalmefene, Nicotine", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 68537, "ingredient1": "Histrelin", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia are known risk factors for torsade de pointes associated with QT interval prolongation.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68624/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[5] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[8] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[9] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[10] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[11] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Megestrol acetate, Ethinylestradiol, Diethylstilbestrol, Medroxyprogesterone acetate", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 68538, "ingredient1": "Hydrochlorothiazide", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations. Fluid and electrolyte disturbances can lead to serious adverse events including cardiac arrhythmias, seizures, and renal impairment.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment. Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered. Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing. Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68625/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Diovan (valsartan).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Cozaar (losartan).\" Merck & Co, Inc, West Point, PA.[5] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[6] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Felodipine, Amlodipine, Verapamil, Bisoprolol, Amlodipine, Sacubitril, Aliskiren, Nebivolol, Amlodipine, Aliskiren, Tamsulosin, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Naldemedine, More", "updated_at": 1767369485}, {"id": 68539, "ingredient1": "Hydrocodone", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline. Rare cases of generalized tonic-clonic seizures and/or loss of consciousness in association with low serum osmolality and electrolyte abnormalities (e.g., hyponatremia, hypokalemia, hypocalcemia, hypomagnesemia) have been reported with the use of bowel cleansing products in patients with no prior history of seizures. The condition resolved with correction of fluid and electrolyte abnormalities.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68626/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.[9] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.", "alternatives_a": "Benzonatate, Clofedanol, Dextromethorphan, Pentoxyverine", "alternatives_b": "Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, More", "updated_at": 1767369485}, {"id": 68540, "ingredient1": "Hydrocortisone", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The overuse or abuse of laxatives can cause significant loss of electrolytes and potentiate the risk of hypokalemia associated with corticosteroid therapy. Corticosteroids promote the retention of sodium and water and the excretion of potassium. Although these effects are primarily associated with mineralocorticoids like fludrocortisone, they may also occur with higher dosages of glucocorticoids or adrenocorticotropic agents, particularly if given systemically for longer than brief periods.", "source": "DDInter", "management_text": "In general, laxatives should only be used on a short-term, intermittent basis in recommended dosages. During concomitant therapy with corticosteroids, particularly if fludrocortisone or large doses of a glucocorticoid or adrenocorticotropic agent is given, patients should be counseled to recognize potential signs and symptoms of hypokalemia such as fatigue, myalgia, and muscle weakness. If maintenance of bowel regularity is required, patients should be advised to exercise and increase fiber in the diet and/or consider the use of bulk-forming laxatives.", "mechanism_text": "Antagonism", "recommendation": "In general, laxatives should only be used on a short-term, intermittent basis in recommended dosages.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68627/", "reference_text": "[1] Chin RL \"Laxative-induced hypokalemia.\" Ann Emerg Med 32 (1998): 517-8[2] Blumenthal M, Goldberg A, Brinckmann J, eds. \"Herbal Medicine: Expanded Commission E Monographs.\" Newton, MA: Integrative Medicine Communications (2000):[3] Muller-Lissner SA \"Adverse effects of laxatives: fact and fiction.\" Pharmacology 47 (1993): 138-45[4] Seale JP, Compton MR \"Side-effects of corticosteroid agents.\" Med J Aust 144 (1986): 139-42[5] Swartz SL, Dluhy RG \"Corticosteroids: clinical pharmacology and therapeutic use.\" Drugs 16 (1978): 238-55[6] Lieberman P, Patterson R, Kunske R \"Complications of long-term steroid therapy for asthma.\" J Allergy Clin Immunol 49 (1972): 329-36[7] Ramsahoye BH, Davies SV, el-Gaylani N, Sandeman D, Scanlon MF \"The mineralocorticoid effects of high dose hydrocortisone.\" BMJ 310 (1995): 656-7", "alternatives_a": "Fluocinolone acetonide, Fluorometholone, Amphotericin B, Miconazole, Clotrimazole, Epinephrine, Chlorhexidine, Fluocinolone acetonide, Fluorometholone, Mometasone furoate, Amcinonide, More", "alternatives_b": "Alvimopan, Sodium sulfate, Sorbitol, Methylnaltrexone, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Naldemedine, Prucalopride, Linaclotide, Magnesium carbonate", "updated_at": 1767369485}, {"id": 68541, "ingredient1": "Hydroflumethiazide", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations. Fluid and electrolyte disturbances can lead to serious adverse events including cardiac arrhythmias, seizures, and renal impairment.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment. Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered. Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing. Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68628/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Diovan (valsartan).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Cozaar (losartan).\" Merck & Co, Inc, West Point, PA.[5] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[6] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Simeprevir, Rosuvastatin, Lactic acid, Mitapivat, Amphotericin B, Ciclopirox, Darunavir, Probenecid, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 68542, "ingredient1": "Hydromorphone", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline. Rare cases of generalized tonic-clonic seizures and/or loss of consciousness in association with low serum osmolality and electrolyte abnormalities (e.g., hyponatremia, hypokalemia, hypocalcemia, hypomagnesemia) have been reported with the use of bowel cleansing products in patients with no prior history of seizures. The condition resolved with correction of fluid and electrolyte abnormalities.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68629/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.[9] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.", "alternatives_a": "Dihydrocodeine, Acetaminophen, Naloxone, Naltrexone", "alternatives_b": "Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, Magnesium carbonate, Plecanatide, More", "updated_at": 1767369485}, {"id": 68543, "ingredient1": "Hydroxychloroquine", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; hydroxychloroquine; mefloquine), and some narcotic analgesics. The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that can prolong the QT interval, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; mefloquine; halofantrine; lumefantrine), and some narcotic analgesics (methadone; propoxyphene).", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68630/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[6] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[9] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[10] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[11] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[12] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[13] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[14] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[15] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Artesunate, Lumefantrine, Artemether, Pyrimethamine, Tafenoquine, Proguanil", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Naldemedine, Prucalopride, More", "updated_at": 1767369485}, {"id": 68544, "ingredient1": "Hydroxyzine", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia are known risk factors for torsade de pointes associated with QT interval prolongation.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68631/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[5] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[8] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[9] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[10] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[11] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Clobazam, Meprobamate, Alprazolam, Lorazepam, Chlordiazepoxide, Halazepam, Clorazepic acid, Buspirone, Diazepam, Oxazepam", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Naldemedine, More", "updated_at": 1767369485}, {"id": 68545, "ingredient1": "Ibuprofen", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations. Fluid and electrolyte disturbances can lead to serious adverse events including cardiac arrhythmias, seizures, and renal impairment.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment. Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered. Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing. Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68632/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Diovan (valsartan).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Cozaar (losartan).\" Merck & Co, Inc, West Point, PA.[5] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[6] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Ritodrine, Bremelanotide, Flibanserin, Cabergoline, Black cohosh, Bromocriptine, Alprostadil, Ubidecarenone, Ivabradine, Adenosine, Regadenoson, More", "alternatives_b": "Alvimopan, Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Magnesium carbonate, Plecanatide, More", "updated_at": 1767369485}, {"id": 68546, "ingredient1": "Ibutilide", "ingredient2": "Picosulfuric acid", "severity": "Major", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval. Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly. Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68633/", "reference_text": "[1] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[2] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[9] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[10] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[11] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[12] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[13] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Tocainide, Moricizine, Bretylium", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 68547, "ingredient1": "Idarubicin", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia are known risk factors for torsade de pointes associated with QT interval prolongation.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68634/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[5] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[8] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[9] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[10] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[11] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Valrubicin, Plicamycin, Ixabepilone, Mitoxantrone, Bleomycin, Mitomycin, Dactinomycin", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 68548, "ingredient1": "Iloperidone", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; hydroxychloroquine; mefloquine), and some narcotic analgesics. The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that can prolong the QT interval, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; mefloquine; halofantrine; lumefantrine), and some narcotic analgesics (methadone; propoxyphene).", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68635/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[6] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[9] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[10] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[11] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[12] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[13] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[14] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[15] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68549, "ingredient1": "Imipramine", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; hydroxychloroquine; mefloquine), and some narcotic analgesics. The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that can prolong the QT interval, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; mefloquine; halofantrine; lumefantrine), and some narcotic analgesics (methadone; propoxyphene).", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68636/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[6] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[9] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[10] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[11] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[12] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[13] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[14] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[15] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "St. John's Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine", "alternatives_b": "Alvimopan, Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, Magnesium carbonate, More", "updated_at": 1767369485}, {"id": 68550, "ingredient1": "Indapamide", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations. Fluid and electrolyte disturbances can lead to serious adverse events including cardiac arrhythmias, seizures, and renal impairment.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment. Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered. Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing. Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68637/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Diovan (valsartan).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Cozaar (losartan).\" Merck & Co, Inc, West Point, PA.[5] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[6] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Felodipine, Amlodipine, Verapamil, Bisoprolol, Tamsulosin, Tinidazole, Ascorbic acid, Simeprevir, Rosuvastatin, Lactic acid, Mitapivat, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 68551, "ingredient1": "Indomethacin", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations. Fluid and electrolyte disturbances can lead to serious adverse events including cardiac arrhythmias, seizures, and renal impairment.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment. Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered. Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing. Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68638/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Diovan (valsartan).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Cozaar (losartan).\" Merck & Co, Inc, West Point, PA.[5] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[6] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Fluocinolone acetonide, Fluorometholone, Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole, Fluocinolone acetonide, Fluorometholone, Tolazoline, Rabeprazole, More", "alternatives_b": "Alvimopan, Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Prucalopride, Plecanatide, Magnesium citrate, Lubiprostone, More", "updated_at": 1767369485}, {"id": 68552, "ingredient1": "Inotuzumab ozogamicin", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia are known risk factors for torsade de pointes associated with QT interval prolongation.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68639/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[5] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[8] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[9] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[10] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[11] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 68553, "ingredient1": "Interferon alfa-2a, Recombinant", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline. Rare cases of generalized tonic-clonic seizures and/or loss of consciousness in association with low serum osmolality and electrolyte abnormalities (e.g., hyponatremia, hypokalemia, hypocalcemia, hypomagnesemia) have been reported with the use of bowel cleansing products in patients with no prior history of seizures. The condition resolved with correction of fluid and electrolyte abnormalities.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68640/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.[9] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.", "alternatives_a": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68554, "ingredient1": "Interferon alfa-2b", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline. Rare cases of generalized tonic-clonic seizures and/or loss of consciousness in association with low serum osmolality and electrolyte abnormalities (e.g., hyponatremia, hypokalemia, hypocalcemia, hypomagnesemia) have been reported with the use of bowel cleansing products in patients with no prior history of seizures. The condition resolved with correction of fluid and electrolyte abnormalities.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68641/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.[9] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.", "alternatives_a": "Oprelvekin, Sipuleucel-T, Elapegademase, Ropeginterferon alfa-2b, Sargramostim, Histamine, Pegademase, Pegfilgrastim, Filgrastim, Glatiramer", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 68555, "ingredient1": "Interferon alfa-n1", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline. Rare cases of generalized tonic-clonic seizures and/or loss of consciousness in association with low serum osmolality and electrolyte abnormalities (e.g., hyponatremia, hypokalemia, hypocalcemia, hypomagnesemia) have been reported with the use of bowel cleansing products in patients with no prior history of seizures. The condition resolved with correction of fluid and electrolyte abnormalities.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68642/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.[9] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.", "alternatives_a": "Oprelvekin, Sipuleucel-T, Elapegademase, Ropeginterferon alfa-2b, Sargramostim, Histamine, Pegademase, Pegfilgrastim, Filgrastim, Glatiramer", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 68556, "ingredient1": "Interferon alfa-n3", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline. Rare cases of generalized tonic-clonic seizures and/or loss of consciousness in association with low serum osmolality and electrolyte abnormalities (e.g., hyponatremia, hypokalemia, hypocalcemia, hypomagnesemia) have been reported with the use of bowel cleansing products in patients with no prior history of seizures. The condition resolved with correction of fluid and electrolyte abnormalities.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68643/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.[9] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.", "alternatives_a": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68557, "ingredient1": "Interferon alfacon-1", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline. Rare cases of generalized tonic-clonic seizures and/or loss of consciousness in association with low serum osmolality and electrolyte abnormalities (e.g., hyponatremia, hypokalemia, hypocalcemia, hypomagnesemia) have been reported with the use of bowel cleansing products in patients with no prior history of seizures. The condition resolved with correction of fluid and electrolyte abnormalities.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68644/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.[9] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.", "alternatives_a": "Oprelvekin, Sipuleucel-T, Elapegademase, Ropeginterferon alfa-2b, Sargramostim, Histamine, Pegademase, Pegfilgrastim, Filgrastim, Glatiramer", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 68558, "ingredient1": "Interferon beta-1a", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline. Rare cases of generalized tonic-clonic seizures and/or loss of consciousness in association with low serum osmolality and electrolyte abnormalities (e.g., hyponatremia, hypokalemia, hypocalcemia, hypomagnesemia) have been reported with the use of bowel cleansing products in patients with no prior history of seizures. The condition resolved with correction of fluid and electrolyte abnormalities.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68645/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.[9] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.", "alternatives_a": "Oprelvekin, Sipuleucel-T, Elapegademase, Ropeginterferon alfa-2b, Sargramostim, Histamine, Pegademase, Pegfilgrastim, Filgrastim, Glatiramer", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 68559, "ingredient1": "Interferon beta-1b", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline. Rare cases of generalized tonic-clonic seizures and/or loss of consciousness in association with low serum osmolality and electrolyte abnormalities (e.g., hyponatremia, hypokalemia, hypocalcemia, hypomagnesemia) have been reported with the use of bowel cleansing products in patients with no prior history of seizures. The condition resolved with correction of fluid and electrolyte abnormalities.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68646/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.[9] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.", "alternatives_a": "Oprelvekin, Sipuleucel-T, Elapegademase, Ropeginterferon alfa-2b, Sargramostim, Histamine, Pegademase, Pegfilgrastim, Filgrastim, Glatiramer", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, More", "updated_at": 1767369485}, {"id": 68560, "ingredient1": "Interferon gamma-1b", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline. Rare cases of generalized tonic-clonic seizures and/or loss of consciousness in association with low serum osmolality and electrolyte abnormalities (e.g., hyponatremia, hypokalemia, hypocalcemia, hypomagnesemia) have been reported with the use of bowel cleansing products in patients with no prior history of seizures. The condition resolved with correction of fluid and electrolyte abnormalities.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68647/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.[9] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.", "alternatives_a": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68561, "ingredient1": "Irbesartan", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations. Fluid and electrolyte disturbances can lead to serious adverse events including cardiac arrhythmias, seizures, and renal impairment.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment. Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered. Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing. Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68648/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Diovan (valsartan).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Cozaar (losartan).\" Merck & Co, Inc, West Point, PA.[5] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[6] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Amlodipine, Sacubitril, Aliskiren, Nebivolol", "alternatives_b": "Alvimopan, Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, Magnesium carbonate, More", "updated_at": 1767369485}, {"id": 68562, "ingredient1": "Irinotecan", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Because irinotecan has been reported to cause diarrhea in the majority of treated patients, the use of laxatives may not be appropriate during irinotecan therapy.", "source": "DDInter", "management_text": "In patients requiring laxatives for constipation associated with narcotic administration, the standard regimen may be continued under supervision of the clinician. However, patients should be advised to inform their physician of any changes in their bowel habit so that dosage adjustments or discontinuation of laxatives may be done promptly.", "mechanism_text": "Synergism", "recommendation": "In patients requiring laxatives for constipation associated with narcotic administration, the standard regimen may be continued under supervision of the clinician.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68649/", "reference_text": "[1] \"Product Information. Camptosar (irinotecan).\" Pharmacia and Upjohn, Kalamazoo, MI.", "alternatives_a": "Trabectedin, Cabazitaxel, Vinblastine, Paclitaxel, Vincristine, Topotecan, Teniposide, Vinorelbine, Etoposide, Docetaxel", "alternatives_b": "Alvimopan, Sodium sulfate, Sorbitol, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Sodium phosphate, monobasic, Lubiprostone, Methylcellulose, More", "updated_at": 1767369485}, {"id": 68563, "ingredient1": "Irinotecan (liposomal)", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Because irinotecan has been reported to cause diarrhea in the majority of treated patients, the use of laxatives may not be appropriate during irinotecan therapy.", "source": "DDInter", "management_text": "In patients requiring laxatives for constipation associated with narcotic administration, the standard regimen may be continued under supervision of the clinician. However, patients should be advised to inform their physician of any changes in their bowel habit so that dosage adjustments or discontinuation of laxatives may be done promptly.", "mechanism_text": "Synergism", "recommendation": "In patients requiring laxatives for constipation associated with narcotic administration, the standard regimen may be continued under supervision of the clinician.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68650/", "reference_text": "[1] \"Product Information. Camptosar (irinotecan).\" Pharmacia and Upjohn, Kalamazoo, MI.", "alternatives_a": "Trabectedin, Cabazitaxel, Vinblastine, Paclitaxel, Vincristine, Topotecan, Teniposide, Vinorelbine, Etoposide, Docetaxel", "alternatives_b": "Alvimopan, Sodium sulfate, Sorbitol, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Sodium phosphate, monobasic, Lubiprostone, Methylcellulose, More", "updated_at": 1767369485}, {"id": 68564, "ingredient1": "Iron protein succinylate", "ingredient2": "Magnesium oxide", "severity": "Moderate", "effect": "INTERVAL: The bioavailability of orally administered iron may be reduced by concomitant administration of antacids or other agents with acid-neutralizing effects. The exact mechanism is unknown but may involve reduced iron solubility due to increase in gastric pH and/or reduced absorption due to complexation or precipitation of the iron.", "source": "DDInter", "management_text": "To minimize the potential for interaction, it may be appropriate to administer oral iron preparations at least two hours apart from antacids or other agents with acid-neutralizing effects.", "mechanism_text": "Absorption", "recommendation": "To minimize the potential for interaction, it may be appropriate to administer oral iron preparations at least two hours apart from antacids or other agents with acid-neutralizing effects.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68651/", "reference_text": "[1] Gugler R, Allgayer H \"Effects of antacids on the clinical pharmacokinetics of drugs. An update.\" Clin Pharmacokinet 18 (1990): 210-9[2] Coste JF, De Barbi VA, Keil LB, Needle MA \"In-vitro interactions of oral hemantics and antacid suspensions.\" Curr Ther Res Clin Exp 22 (1977): 205-16[3] Coste JF, de Bari VA, Keil LB, Needle MA \"In-vitro interactions of oral hematinics.\" Curr Ther Res Clin Exp 22 (1977): 205-15[4] Rastogi SP, Padilla F, Boyd CM \"Effect of aluminum hydroxide on iron absorption.\" Kidney Int 8 (1975): 417[5] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[6] Ekenved G, Halvorsen L, Solvell L \"Influence of a liquid antacid on the absorption of different iron salts.\" Scand J Haematol Suppl 28 (1976): 65-77[7] O'Neil-Cutting MA, Crosby WH \"The effect of antacids on the absorption of simultaneously ingested iron.\" JAMA 255 (1986): 1468-70[8] Wallace KL, Curry SC, LoVecchio F, Raschke R \"Effect of magnesium hydroxide on iron absorption after ferrous sulfate.\" Ann Emerg Med 34 (1999): 685-6[9] Snyder BK, Clark RF \"Effect of magnesium hydroxide administration on iron absorption after a supratherapeutic dose of ferrous sulfate in human volunteers: A randomized controlled trial.\" Ann Emerg Med 33 (1999): 400-5[10] Corby DG, McCullen AH, Chadwick EW, Decker WJ \"Effect of orally administered magnesium hydroxide in experimental iron intoxication.\" J Toxicol Clin Toxicol 23 (1985-86): 489-99[11] Pruchnicki MC, Coyle JD, Hoshaw-Woodard S, Bay WH \"Effect of phosphate binders on supplemental iron absorption in healthy subjects.\" J Clin Pharmacol 42 (2002): 1171-6[12] Hall GJ, Davis AE \"Inhibition of iron absorption by magnesium trisilicate.\" Med J Aust 2 (1969): 95-6", "alternatives_a": "Magaldrate, Magnesium sulfate, Magnesium aspartate, Magnesium lactate, Magnesium citrate, Sodium chloride, Magnesium gluconate, Magnesium chloride, Alvimopan, Sorbitol, Tegaserod, More", "alternatives_b": "Iron sucrose, Cyanocobalamin, Folic acid", "updated_at": 1767369485}, {"id": 68565, "ingredient1": "Isocarboxazid", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline. Rare cases of generalized tonic-clonic seizures and/or loss of consciousness in association with low serum osmolality and electrolyte abnormalities (e.g., hyponatremia, hypokalemia, hypocalcemia, hypomagnesemia) have been reported with the use of bowel cleansing products in patients with no prior history of seizures. The condition resolved with correction of fluid and electrolyte abnormalities.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68652/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.[9] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.", "alternatives_a": "St. John's Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 68566, "ingredient1": "Isoniazid", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate. The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis. The clinical significance of this effect remains unknown.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic. If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Others", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68653/", "reference_text": "[1] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[3] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference) Available from: URL: http://www.mhra.gov.uk/spc-pil/index.htm.\"[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[6] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[7] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Pyridoxine, Pretomanid", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, Sodium sulfate, Prucalopride, More", "updated_at": 1767369485}, {"id": 68567, "ingredient1": "Itraconazole", "ingredient2": "Magnesium oxide", "severity": "Moderate", "effect": "INTERVAL: The dissolution of itraconazole requires an acidic environment. Antacids and some aluminum, calcium, or magnesium containing salts decrease the acidity of the stomach and can reduce the bioavailability and subsequent therapeutic effect of itraconazole.", "source": "DDInter", "management_text": "Separation of doses by two or more hours is recommended.", "mechanism_text": "Absorption", "recommendation": "Separation of doses by two or more hours is recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68654/", "reference_text": "[1] Carlson JA, Mann HJ, Canafax DM \"Effect of pH on disintegration and dissolution of ketoconazole tablets.\" Am J Hosp Pharm 40 (1983): 1334-6[2] Brass C, Galgiani JN, Blaschke TF, et al \"Disposition of ketoconazole, an oral antifungal, in humans.\" Antimicrob Agents Chemother 21 (1982): 151-8[3] Van der Meer JW, Keuning JJ \"The influence of gastric acidity on the bio-availability of ketoconazole.\" J Antimicrob Chemother 6 (1980): 552-4[4] Katz HI \"Drug interactions of the newer oral antifungal agents.\" Br J Dermatol 141 (1999): 26-32[5] \"Product Information. Sporanox (itraconazole).\" Janssen Pharmaceutica, Titusville, NJ.[6] \"Product Information. Sporanox oral solution (itraconazole).\" Janssen Pharmaceutica, Titusville, NJ.[7] \"Product Information. Sporanox (itraconazole).\" Janssen Pharmaceutica, Titusville, NJ.[8] Van Peer A, Woestenborghs R, Heykants J, et al \"The effects of food and dose on the oral systemic availability of itraconazole in healthy subjects.\" Eur J Clin Pharmacol 36 (1989): 423-6[9] Penzak SR, Gubbins PO, Gurley BJ, Wang PL, Saccente M \"Grapefruit juice decreases the systemic availability of itraconazole capsules in healthy volunteers.\" Ther Drug Monit 21 (1999): 304-9[10] Katz HI \"Drug interactions of the newer oral antifungal agents.\" Br J Dermatol 141 (1999): 26-32[11] Kawakami M, Suzuki K, Ishizuka T, Hidaka T, Matsuki Y, Nakamura H \"Effect of grapefruit juice on pharmacokinetics of itraconazole in healthy subjects.\" Int J Clin Pharmacol Ther 36 (1998): 306-8[12] Barone JA, Koh JG, Bierman RH, Colaizzi JL, Swanson KA, Gaffar MC, Moskovitz BL, Mechlinski W, Van de Velde V \"Food interaction and steady-state pharmacokinetics of itraconazole capsules in healthy male volunteers.\" Antimicrob Agents Chemother 37 (1993): 778-84[13] Wishart JM \"The influence of food on the pharmacokinetics of itraconazole in patients with superficial fungal infection.\" J Am Acad Dermatol 17 (1987): 220-3[14] Zimmermann T, Yeates RA, Albrecht M, Laufen H, Wildfeuer A \"Influence of concomitant food intake on the gastrointestinal absorption of fluconazole and itraconazole in japanese subjects.\" Int J Clin Pharmacol Res 14 (1994): 87-93[15] Barone JA, Moskotitz BL, Guarnieri J, Hassell AE, Colaizzi JL, Bierman RH, Jessen L \"Food interaction and steady-state pharmacokinetics of itraconazole oral solution in healthy volunteers.\" Pharmacotherapy 18 (1998): 295-301", "alternatives_a": "Fluconazole, Caspofungin, Micafungin, Amphotericin B, Miconazole, Posaconazole, Oteseconazole, Flucytosine, Anidulafungin, Voriconazole", "alternatives_b": "Magnesium gluconate, Sodium sulfate, Zinc sulfate, Magnesium sulfate, Magnesium aspartate, Magnesium lactate, Magnesium citrate, Sodium chloride, Zinc gluconate, Magnesium chloride, Alvimopan, More", "updated_at": 1767369485}, {"id": 68568, "ingredient1": "Picosulfuric acid", "ingredient2": "Ivosidenib", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia are known risk factors for torsade de pointes associated with QT interval prolongation.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68655/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[5] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[8] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[9] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[10] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[11] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Naldemedine, More", "alternatives_b": "Pertuzumab, Olaparib, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, More", "updated_at": 1767369485}, {"id": 68569, "ingredient1": "Picosulfuric acid", "ingredient2": "Kanamycin", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate. The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis. The clinical significance of this effect remains unknown.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic. If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Others", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68656/", "reference_text": "[1] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[3] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference) Available from: URL: http://www.mhra.gov.uk/spc-pil/index.htm.\"[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[6] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[7] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Ganciclovir, Acyclovir, Famciclovir, Trifluridine, Chlorhexidine, Povidone-iodine, Nystatin, Amphotericin B, Miconazole", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, Sodium sulfate, More", "updated_at": 1767369485}, {"id": 68570, "ingredient1": "Magnesium oxide", "ingredient2": "Ketoconazole", "severity": "Moderate", "effect": "INTERVAL: The dissolution of oral ketoconazole requires an acidic environment. Medications that decrease the acidity of the stomach, such as omeprazole or H2 antagonists can reduce the bioavailability of ketoconazole by 75% to 80%. Antacids are also expected to impair ketoconazole absorption.", "source": "DDInter", "management_text": "It is recommended to administer antacids at least 1 hour before or 2 hours after ketoconazole. Patients should be monitored for altered antifungal effects and the ketoconazole dosage adjusted if necessary.", "mechanism_text": "Absorption", "recommendation": "It is recommended to administer antacids at least 1 hour before or 2 hours after ketoconazole.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68657/", "reference_text": "[1] Chin TWF, Loeb M, Fong IW \"Effects of an acidic beverage (coca-cola) on absorption of ketoconazole.\" Antimicrob Agents Chemother 39 (1995): 1671-5[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Van der Meer JW, Keuning JJ \"The influence of gastric acidity on the bio-availability of ketoconazole.\" J Antimicrob Chemother 6 (1980): 552-4[4] Cerner Multum, Inc \"ANVISA Bulrio Eletrnico. Available from: URL: http://www.anvisa.gov.br/datavisa/fila_bula/index.asp.\" O 0 (2015):[5] \"Product Information. Ketoconazole (ketoconazole).\" Mylan Pharmaceuticals Inc, Morgantown, WV.[6] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[7] Brass C, Galgiani JN, Blaschke TF, et al \"Disposition of ketoconazole, an oral antifungal, in humans.\" Antimicrob Agents Chemother 21 (1982): 151-8[8] Carlson JA, Mann HJ, Canafax DM \"Effect of pH on disintegration and dissolution of ketoconazole tablets.\" Am J Hosp Pharm 40 (1983): 1334-6", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, Simeprevir, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, More", "alternatives_b": "Magnesium gluconate, Zinc sulfate, Magnesium sulfate, Magnesium aspartate, Magnesium lactate, Sodium chloride, Zinc gluconate, Magnesium chloride, Alvimopan, Sorbitol, Magnesium sulfate, More", "updated_at": 1767369485}, {"id": 68571, "ingredient1": "Picosulfuric acid", "ingredient2": "Ketoprofen", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations. Fluid and electrolyte disturbances can lead to serious adverse events including cardiac arrhythmias, seizures, and renal impairment.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment. Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered. Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing. Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68658/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Diovan (valsartan).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Cozaar (losartan).\" Merck & Co, Inc, West Point, PA.[5] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[6] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole, Tolazoline, Rabeprazole, Dimethyl sulfoxide", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Magnesium carbonate, More", "updated_at": 1767369485}, {"id": 68572, "ingredient1": "Picosulfuric acid", "ingredient2": "Ketorolac", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations. Fluid and electrolyte disturbances can lead to serious adverse events including cardiac arrhythmias, seizures, and renal impairment.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment. Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered. Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing. Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68659/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Diovan (valsartan).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Cozaar (losartan).\" Merck & Co, Inc, West Point, PA.[5] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[6] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole, Homatropine, Atropine, Scopolamine, Methscopolamine, Tropicamide, Phenylephrine, More", "alternatives_b": "Alvimopan, Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Magnesium carbonate, Plecanatide, More", "updated_at": 1767369485}, {"id": 68573, "ingredient1": "Magnesium oxide", "ingredient2": "Labetalol", "severity": "Minor", "effect": "Concurrent administration with aluminum and magnesium antacids has been shown to decrease the oral bioavailability of certain beta-blockers, although data are conflicting. The exact mechanism of interaction is unknown but may involve cation binding of beta-blockers or a reduction in the dissolution rate due to increased gastric pH. Based on available data, the clinical significance of this potential interaction is difficult to determine. As a precaution, patients may want to consider separating the administration times of beta-blockers and antacids or other aluminum- or magnesium-containing products by at least 2 hours.", "source": "DDInter", "management_text": "-", "mechanism_text": "Absorption", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68660/", "reference_text": "[1] D'Arcy PF, McElnay JC \"Drug-antacid interactions: assessment of clinical importance.\" Drug Intell Clin Pharm 21 (1987): 607-17[2] Regardh CG, Lundborg P, Persson BA \"The effect of antacid, metoclopramide, and propantheline on the bioavailability of metoprolol and atenolol.\" Biopharm Drug Dispos 2 (1981): 79-87[3] Hong CY, Hu SC, Lin SJ, Chiang BN \"Lack of influence of aluminum hydroxide on the bioavailability and beta-adrenoceptor blocking activity of propranolol.\" Int J Clin Pharmacol Ther Toxicol 23 (1985): 244-6[4] Kirch W, Schafer-Korting M, Axthelm T, Kohler H, Mutschler E \"Interaction of atenolol with furosemide and calcium and aluminum salts.\" Clin Pharmacol Ther 30 (1981): 429-35[5] Laer S, Neumann J, Scholz H \"Interaction between sotalol and an antacid preparation.\" Br J Clin Pharmacol 43 (1997): 269-72[6] Gugler R, Allgayer H \"Effects of antacids on the clinical pharmacokinetics of drugs. An update.\" Clin Pharmacokinet 18 (1990): 210-9[7] Dobbs JH, Skoutakis VA, Acchiardo SR, Dobbs BR \"Effects of aluminum hydroxide on the absorption of propranolol.\" Curr Ther Res Clin Exp 21 (1977): 887-92", "alternatives_a": "Esmolol", "alternatives_b": "Magnesium gluconate, Sodium sulfate, Zinc sulfate, Magnesium sulfate, Magnesium aspartate, Magnesium lactate, Magnesium citrate, Sodium chloride, Zinc gluconate, Magnesium chloride, Alvimopan, More", "updated_at": 1767369485}, {"id": 68574, "ingredient1": "Picosulfuric acid", "ingredient2": "Lactulose", "severity": "Moderate", "effect": "In the treatment of portal-systemic encephalopathy, the loose stools produced by concomitant use of other laxatives may falsely suggest that adequate lactulose dosage has been achieved.", "source": "DDInter", "management_text": "The use of other laxatives should generally be avoided when lactulose is prescribed for portal-systemic encephalopathy, especially during the initial phase of therapy.", "mechanism_text": "Others", "recommendation": "The use of other laxatives should generally be avoided when lactulose is prescribed for portal-systemic encephalopathy, especially during the initial phase of therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68661/", "reference_text": "[1] \"Product Information. Cephulac (lactulose).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[2] \"Product Information. Generlac (lactulose).\" Morton Grove Pharmaceuticals Inc, Morton Grove, IL.[3] \"Product Information. Enulose (lactulose).\" United Research Laboratories/Mutual Pharmaceutical Company, Philadelphia, PA.[4] \"Product Information. Chronulac (lactulose).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[5] \"Product Information. Metamucil (psyllium).\" Procter and Gamble Pharmaceutic, Cincinnati, OH.", "alternatives_a": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, Prucalopride, More", "alternatives_b": "Alvimopan, Sorbitol, Lactulose, Methylnaltrexone, Naloxegol, Plecanatide, Lactitol, Lubiprostone, Naldemedine, Prucalopride, Sodium sulfate", "updated_at": 1767369485}, {"id": 68575, "ingredient1": "Picosulfuric acid", "ingredient2": "Lapatinib", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia are known risk factors for torsade de pointes associated with QT interval prolongation.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68662/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[5] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[8] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[9] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[10] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[11] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Imatinib, Dabrafenib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Selumetinib, Cobimetinib, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Prucalopride, More", "updated_at": 1767369485}, {"id": 68576, "ingredient1": "Picosulfuric acid", "ingredient2": "Lefamulin", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia are known risk factors for torsade de pointes associated with QT interval prolongation.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68663/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[5] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[8] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[9] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[10] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[11] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Prucalopride, More", "alternatives_b": "Tinidazole", "updated_at": 1767369485}, {"id": 68577, "ingredient1": "Picosulfuric acid", "ingredient2": "Lenvatinib", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia are known risk factors for torsade de pointes associated with QT interval prolongation.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68664/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[5] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[8] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[9] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[10] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[11] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Imatinib, Dabrafenib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Selumetinib, Cobimetinib, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 68578, "ingredient1": "Picosulfuric acid", "ingredient2": "Leuprolide", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia are known risk factors for torsade de pointes associated with QT interval prolongation.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68665/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[5] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[8] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[9] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[10] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[11] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Megestrol acetate, Ethinylestradiol, Diethylstilbestrol, Medroxyprogesterone acetate", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 68579, "ingredient1": "Citric acid", "ingredient2": "Levofloxacin", "severity": "Moderate", "effect": "Urinary alkalinizers such as citrates may decrease the solubility of fluoroquinolones in the urine and increase the risk of crystalluria.", "source": "DDInter", "management_text": "Concomitant use should generally be avoided. Patients receiving this combination should be monitored for signs of renal toxicity and crystalluria.", "mechanism_text": "Excretion", "recommendation": "Concomitant use should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68666/", "reference_text": "[1] \"Multum Information Services, Inc. Expert Review Panel\"[2] \"Product Information. Cipro (ciprofloxacin).\" Bayer, West Haven, CT.", "alternatives_a": "Delafloxacin, Tinidazole, Dexlansoprazole, Rabeprazole, Metronidazole, Vonoprazan, Amoxicillin, Pantoprazole, Misoprostol, Esomeprazole, Ranitidine, More", "alternatives_b": "Glutamic acid, Pancrelipase", "updated_at": 1767369485}, {"id": 68580, "ingredient1": "Picosulfuric acid", "ingredient2": "Levacetylmethadol", "severity": "Major", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval. Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly. Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68667/", "reference_text": "[1] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[2] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[9] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[10] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[11] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[12] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[13] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Acamprosate, Naltrexone, Varenicline, Disulfiram, Nalmefene, Nicotine", "alternatives_b": "Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Phenolphthalein, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 68581, "ingredient1": "Picosulfuric acid", "ingredient2": "Levomilnacipran", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline. Rare cases of generalized tonic-clonic seizures and/or loss of consciousness in association with low serum osmolality and electrolyte abnormalities (e.g., hyponatremia, hypokalemia, hypocalcemia, hypomagnesemia) have been reported with the use of bowel cleansing products in patients with no prior history of seizures. The condition resolved with correction of fluid and electrolyte abnormalities.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68668/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.[9] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.", "alternatives_a": "St. John's Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 68582, "ingredient1": "Picosulfuric acid", "ingredient2": "Levorphanol", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline. Rare cases of generalized tonic-clonic seizures and/or loss of consciousness in association with low serum osmolality and electrolyte abnormalities (e.g., hyponatremia, hypokalemia, hypocalcemia, hypomagnesemia) have been reported with the use of bowel cleansing products in patients with no prior history of seizures. The condition resolved with correction of fluid and electrolyte abnormalities.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68669/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.[9] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.", "alternatives_a": "Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68583, "ingredient1": "Magnesium oxide", "ingredient2": "Levothyroxine", "severity": "Moderate", "effect": "INTERVAL: Concurrent administration of simethicone and/or antacid preparations may decrease the oral bioavailability of levothyroxine. Pharmacologic effects of levothyroxine may be reduced. The exact mechanism of interaction is unknown but may involve nonspecific adsorption of levothyroxine to polyvalent cations, resulting in an insoluble complex that is poorly absorbed from the gastrointestinal tract. Additionally, because gastric acidity is required for adequate levothyroxine absorption, agents that effect intragastric pH may reduce levothyroxine absorption.", "source": "DDInter", "management_text": "It is recommended to separate the times of administration of levothyroxine and simethicone and antacids or other antacid-containing preparations (e.g., didanosine buffered tablets or pediatric oral solution) by at least 4 hours. Monitoring of serum TSH levels is recommended. Patients with gastrointestinal or malabsorption disorders may be at a greater risk of developing clinical or subclinical hypothyroidism due to this interaction.", "mechanism_text": "Absorption", "recommendation": "It is recommended to separate the times of administration of levothyroxine and simethicone and antacids or other antacid-containing preparations (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68670/", "reference_text": "[1] Schneyer CR \"Calcium carbonate and reduction of levothyroxine efficacy.\" JAMA 279 (1998): 750[2] \"Product Information. Synthroid (levothyroxine).\" Abbott Pharmaceutical, Abbott Park, IL.[3] Neafsey PJ \"Levothyroxine and calcium interaction: timing is everything.\" Home Healthc Nurse 22 (2004): 338-9[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Campbell NR, Hasinoff BB, Stalts H, Rao B, Wong NC \"Ferrous sulfate reduces thyroxine efficacy in patients with hypothyroidism.\" Ann Intern Med 117 (1992): 1010-3[6] Singh N, Singh PN, Hershman JM \"Effect of calcium carbonate on the absorption of levothyroxine.\" JAMA 283 (2000): 2822-5[7] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[8] Sperber AD, Liel Y \"Evidence for interference with the intestinal absorption of levothyroxine sodium by aluminum hydroxide.\" Arch Intern Med 152 (1992): 183-4[9] Csako G, McGriff NJ, Rotman-Pikielny P, Sarlis NJ, Pucino F \"Exaggerated levothyroxine malabsorption due to calcium carbonate supplementation in gastrointestinal disorders.\" Ann Pharmacother 35 (2001): 1578-83[10] Cerner Multum, Inc. \"Australian Product Information.\" O 0[11] Liel Y, Sperber AD, Shany S \"Nonspecific intestinal adsorption of levothyroxine by aluminum hydroxide.\" Am J Med 97 (1994): 363-5[12] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[13] \"Product Information. Armour thyroid (thyroid desiccated).\" Forest Pharmaceuticals, St. Louis, MO.[14] \"Product Information. Synthroid (levothyroxine).\" Abbott Pharmaceutical, Abbott Park, IL.", "alternatives_a": "Magnesium gluconate, Sodium sulfate, Zinc sulfate, Magnesium sulfate, Magnesium aspartate, Magnesium lactate, Magnesium citrate, Sodium chloride, Zinc gluconate, Magnesium chloride, Alvimopan, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68584, "ingredient1": "Picosulfuric acid", "ingredient2": "Lidocaine", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline. Rare cases of generalized tonic-clonic seizures and/or loss of consciousness in association with low serum osmolality and electrolyte abnormalities (e.g., hyponatremia, hypokalemia, hypocalcemia, hypomagnesemia) have been reported with the use of bowel cleansing products in patients with no prior history of seizures. The condition resolved with correction of fluid and electrolyte abnormalities.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68671/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.[9] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.", "alternatives_a": "Procaine, Tetracaine, Clemastine, Tetracaine, Mepyramine, Diphenhydramine, Tripelennamine, Pheniramine, Chlorhexidine, Povidone-iodine, Tocainide, More", "alternatives_b": "Alvimopan, Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, Magnesium carbonate, More", "updated_at": 1767369485}, {"id": 68585, "ingredient1": "Picosulfuric acid", "ingredient2": "Linaclotide", "severity": "Minor", "effect": "The concomitant use of linaclotide with proton pump inhibitors, laxatives, or nonsteroidal anti-inflammatory drugs may increase the risk of diarrhea.", "source": "DDInter", "management_text": "-", "mechanism_text": "Others", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68672/", "reference_text": "[1] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[2] \"Product Information. Linzess (linaclotide).\" Forest Pharmaceuticals, St. Louis, MO.[3] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"", "alternatives_a": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, Prucalopride, More", "alternatives_b": "Alvimopan, Sodium sulfate, Sorbitol, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lactitol, Lubiprostone, Mannitol, More", "updated_at": 1767369485}, {"id": 68586, "ingredient1": "Picosulfuric acid", "ingredient2": "Lincomycin", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate. The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis. The clinical significance of this effect remains unknown.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic. If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Others", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68673/", "reference_text": "[1] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[3] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference) Available from: URL: http://www.mhra.gov.uk/spc-pil/index.htm.\"[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[6] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[7] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, Sodium sulfate, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68587, "ingredient1": "Picosulfuric acid", "ingredient2": "Lindane", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline. Rare cases of generalized tonic-clonic seizures and/or loss of consciousness in association with low serum osmolality and electrolyte abnormalities (e.g., hyponatremia, hypokalemia, hypocalcemia, hypomagnesemia) have been reported with the use of bowel cleansing products in patients with no prior history of seizures. The condition resolved with correction of fluid and electrolyte abnormalities.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68674/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.[9] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.", "alternatives_a": "Disulfiram", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 68588, "ingredient1": "Picosulfuric acid", "ingredient2": "Linezolid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate. The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis. The clinical significance of this effect remains unknown.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic. If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Others", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68675/", "reference_text": "[1] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[3] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference) Available from: URL: http://www.mhra.gov.uk/spc-pil/index.htm.\"[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[6] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[7] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Tinidazole", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, Sodium sulfate, More", "updated_at": 1767369485}, {"id": 68589, "ingredient1": "Magnesium oxide", "ingredient2": "Liothyronine", "severity": "Moderate", "effect": "INTERVAL: Concurrent administration of simethicone and/or antacid preparations may decrease the oral bioavailability of levothyroxine. Pharmacologic effects of levothyroxine may be reduced. The exact mechanism of interaction is unknown but may involve nonspecific adsorption of levothyroxine to polyvalent cations, resulting in an insoluble complex that is poorly absorbed from the gastrointestinal tract. Additionally, because gastric acidity is required for adequate levothyroxine absorption, agents that effect intragastric pH may reduce levothyroxine absorption.", "source": "DDInter", "management_text": "It is recommended to separate the times of administration of levothyroxine and simethicone and antacids or other antacid-containing preparations (e.g., didanosine buffered tablets or pediatric oral solution) by at least 4 hours. Monitoring of serum TSH levels is recommended. Patients with gastrointestinal or malabsorption disorders may be at a greater risk of developing clinical or subclinical hypothyroidism due to this interaction.", "mechanism_text": "Absorption", "recommendation": "It is recommended to separate the times of administration of levothyroxine and simethicone and antacids or other antacid-containing preparations (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68676/", "reference_text": "[1] Schneyer CR \"Calcium carbonate and reduction of levothyroxine efficacy.\" JAMA 279 (1998): 750[2] \"Product Information. Synthroid (levothyroxine).\" Abbott Pharmaceutical, Abbott Park, IL.[3] Neafsey PJ \"Levothyroxine and calcium interaction: timing is everything.\" Home Healthc Nurse 22 (2004): 338-9[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Campbell NR, Hasinoff BB, Stalts H, Rao B, Wong NC \"Ferrous sulfate reduces thyroxine efficacy in patients with hypothyroidism.\" Ann Intern Med 117 (1992): 1010-3[6] Singh N, Singh PN, Hershman JM \"Effect of calcium carbonate on the absorption of levothyroxine.\" JAMA 283 (2000): 2822-5[7] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[8] Sperber AD, Liel Y \"Evidence for interference with the intestinal absorption of levothyroxine sodium by aluminum hydroxide.\" Arch Intern Med 152 (1992): 183-4[9] Csako G, McGriff NJ, Rotman-Pikielny P, Sarlis NJ, Pucino F \"Exaggerated levothyroxine malabsorption due to calcium carbonate supplementation in gastrointestinal disorders.\" Ann Pharmacother 35 (2001): 1578-83[10] Cerner Multum, Inc. \"Australian Product Information.\" O 0[11] Liel Y, Sperber AD, Shany S \"Nonspecific intestinal adsorption of levothyroxine by aluminum hydroxide.\" Am J Med 97 (1994): 363-5[12] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[13] \"Product Information. Armour thyroid (thyroid desiccated).\" Forest Pharmaceuticals, St. Louis, MO.[14] \"Product Information. Synthroid (levothyroxine).\" Abbott Pharmaceutical, Abbott Park, IL.", "alternatives_a": "Magnesium gluconate, Sodium sulfate, Zinc sulfate, Magnesium sulfate, Magnesium aspartate, Magnesium lactate, Magnesium citrate, Sodium chloride, Zinc gluconate, Magnesium chloride, Alvimopan, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68590, "ingredient1": "Magnesium oxide", "ingredient2": "Liotrix", "severity": "Moderate", "effect": "INTERVAL: Concurrent administration of simethicone and/or antacid preparations may decrease the oral bioavailability of levothyroxine. Pharmacologic effects of levothyroxine may be reduced. The exact mechanism of interaction is unknown but may involve nonspecific adsorption of levothyroxine to polyvalent cations, resulting in an insoluble complex that is poorly absorbed from the gastrointestinal tract. Additionally, because gastric acidity is required for adequate levothyroxine absorption, agents that effect intragastric pH may reduce levothyroxine absorption.", "source": "DDInter", "management_text": "It is recommended to separate the times of administration of levothyroxine and simethicone and antacids or other antacid-containing preparations (e.g., didanosine buffered tablets or pediatric oral solution) by at least 4 hours. Monitoring of serum TSH levels is recommended. Patients with gastrointestinal or malabsorption disorders may be at a greater risk of developing clinical or subclinical hypothyroidism due to this interaction.", "mechanism_text": "Absorption", "recommendation": "It is recommended to separate the times of administration of levothyroxine and simethicone and antacids or other antacid-containing preparations (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68677/", "reference_text": "[1] Schneyer CR \"Calcium carbonate and reduction of levothyroxine efficacy.\" JAMA 279 (1998): 750[2] \"Product Information. Synthroid (levothyroxine).\" Abbott Pharmaceutical, Abbott Park, IL.[3] Neafsey PJ \"Levothyroxine and calcium interaction: timing is everything.\" Home Healthc Nurse 22 (2004): 338-9[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Campbell NR, Hasinoff BB, Stalts H, Rao B, Wong NC \"Ferrous sulfate reduces thyroxine efficacy in patients with hypothyroidism.\" Ann Intern Med 117 (1992): 1010-3[6] Singh N, Singh PN, Hershman JM \"Effect of calcium carbonate on the absorption of levothyroxine.\" JAMA 283 (2000): 2822-5[7] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[8] Sperber AD, Liel Y \"Evidence for interference with the intestinal absorption of levothyroxine sodium by aluminum hydroxide.\" Arch Intern Med 152 (1992): 183-4[9] Csako G, McGriff NJ, Rotman-Pikielny P, Sarlis NJ, Pucino F \"Exaggerated levothyroxine malabsorption due to calcium carbonate supplementation in gastrointestinal disorders.\" Ann Pharmacother 35 (2001): 1578-83[10] Cerner Multum, Inc. \"Australian Product Information.\" O 0[11] Liel Y, Sperber AD, Shany S \"Nonspecific intestinal adsorption of levothyroxine by aluminum hydroxide.\" Am J Med 97 (1994): 363-5[12] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[13] \"Product Information. Armour thyroid (thyroid desiccated).\" Forest Pharmaceuticals, St. Louis, MO.[14] \"Product Information. Synthroid (levothyroxine).\" Abbott Pharmaceutical, Abbott Park, IL.", "alternatives_a": "Magnesium gluconate, Sodium sulfate, Zinc sulfate, Magnesium sulfate, Magnesium aspartate, Magnesium lactate, Magnesium citrate, Sodium chloride, Zinc gluconate, Magnesium chloride, Alvimopan, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68591, "ingredient1": "Magnesium oxide", "ingredient2": "Lisdexamfetamine", "severity": "Moderate", "effect": "Gastrointestinal alkalinizing agents can increase the absorption of amphetamines by increasing the concentration of the non-ionized species of the amphetamine molecule.", "source": "DDInter", "management_text": "Concomitant administration of amphetamines and gastrointestinal alkalinizing agents such as antacids or other medications that contain antacids (e.g., didanosine buffered tablets or pediatric oral solution) should generally be avoided.", "mechanism_text": "Absorption", "recommendation": "Concomitant administration of amphetamines and gastrointestinal alkalinizing agents such as antacids or other medications that contain antacids (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68678/", "reference_text": "[1] \"Product Information. Adderall (amphetamine-dextroamphetamine)\" Shire Richwood Pharmaceutical Company, Florence, KY.[2] Mendelson J, Jones RT, Upton R, Jacob P 3rd \"Methamphetamine and ethanol interactions in humans.\" Clin Pharmacol Ther 57 (1995): 559-68[3] \"Product Information. Didrex (benzphetamine)\" Pharmacia and Upjohn, Kalamazoo, MI.[4] \"Product Information. Suprenza (phentermine).\" Akrimax Pharmaceuticals, Cranford, NJ.", "alternatives_a": "Pemoline, Atomoxetine, Solriamfetol, Caffeine, Methylphenidate, Dexmethylphenidate, Armodafinil, Citicoline, Modafinil", "alternatives_b": "Magnesium gluconate, Zinc sulfate, Magnesium sulfate, Magnesium aspartate, Magnesium lactate, Sodium chloride, Zinc gluconate, Magnesium chloride, Alvimopan, Sorbitol, Magnesium sulfate, More", "updated_at": 1767369485}, {"id": 68592, "ingredient1": "Picosulfuric acid", "ingredient2": "Lisinopril", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations. Fluid and electrolyte disturbances can lead to serious adverse events including cardiac arrhythmias, seizures, and renal impairment.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment. Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered. Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing. Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68679/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Diovan (valsartan).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Cozaar (losartan).\" Merck & Co, Inc, West Point, PA.[5] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[6] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Felodipine, Amlodipine, Verapamil, Bisoprolol, Amlodipine, Atorvastatin, Simvastatin, Lovastatin, Rosuvastatin, Niacin, Pravastatin, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Phenolphthalein, Naloxegol, Plecanatide, Magnesium citrate, Bisacodyl, Lactitol, Lubiprostone, More", "updated_at": 1767369485}, {"id": 68593, "ingredient1": "Picosulfuric acid", "ingredient2": "Lithium carbonate", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; hydroxychloroquine; mefloquine), and some narcotic analgesics. The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that can prolong the QT interval, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; mefloquine; halofantrine; lumefantrine), and some narcotic analgesics (methadone; propoxyphene).", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68680/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[6] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[9] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[10] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[11] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[12] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[13] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[14] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[15] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68594, "ingredient1": "Picosulfuric acid", "ingredient2": "Lofexidine", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia are known risk factors for torsade de pointes associated with QT interval prolongation.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68681/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[5] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[8] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[9] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[10] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[11] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Acamprosate, Naltrexone, Varenicline, Disulfiram, Nalmefene, Nicotine", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 68595, "ingredient1": "Citric acid", "ingredient2": "Lomefloxacin", "severity": "Moderate", "effect": "Urinary alkalinizers such as citrates may decrease the solubility of fluoroquinolones in the urine and increase the risk of crystalluria.", "source": "DDInter", "management_text": "Concomitant use should generally be avoided. Patients receiving this combination should be monitored for signs of renal toxicity and crystalluria.", "mechanism_text": "Excretion", "recommendation": "Concomitant use should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68682/", "reference_text": "[1] \"Multum Information Services, Inc. Expert Review Panel\"[2] \"Product Information. Cipro (ciprofloxacin).\" Bayer, West Haven, CT.", "alternatives_a": "Rifamycin, Kanamycin, Ampicillin, Azithromycin, Acyclovir, Netilmicin, Polymyxin B, Famciclovir, Cefuroxime, Trifluridine, Tobramycin, More", "alternatives_b": "Glutamic acid, Pancrelipase", "updated_at": 1767369485}, {"id": 68596, "ingredient1": "Picosulfuric acid", "ingredient2": "Loracarbef", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate. The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis. The clinical significance of this effect remains unknown.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic. If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Others", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68683/", "reference_text": "[1] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[3] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference) Available from: URL: http://www.mhra.gov.uk/spc-pil/index.htm.\"[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[6] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[7] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Imipenem", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, More", "updated_at": 1767369485}, {"id": 68597, "ingredient1": "Magnesium oxide", "ingredient2": "Lorazepam", "severity": "Minor", "effect": "number of studies have reported that antacids can delay the gastrointestinal absorption and reduce the peak plasma concentration (Cmax) of some benzodiazepines, including clorazepate, chlordiazepoxide and diazepam, although the overall extent of absorption is generally not affected. The exact mechanism of interaction is unknown, but may involve delayed gastric emptying or cation binding of the benzodiazepine.", "source": "DDInter", "management_text": "-", "mechanism_text": "Absorption", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68684/", "reference_text": "[1] Greenblatt DJ, Allen MD, MacLaughlin DS, Harmatz JS, Shader RI \"Diazepam absorption: effect of antacids and food.\" Clin Pharmacol Ther 24 (1978): 600-9[2] Kroboth PD, Smith RB, Silver MR, Rault R, Sorkin MI, Puschett JB, Juhl RP \"Effects of end stage renal disease and aluminium hydroxide on triazolam pharmacokinetics.\" Br J Clin Pharmacol 19 (1985): 839-42[3] Greenblatt DJ, Shader RI, Harmatz JS, Franke K, Koch-Weser J \"Absorption rate, blood concentrations, and early response to oral chlordiazepoxide.\" Am J Psychiatry 134 (1977): 559-62[4] Shader RI, Ciraulo DA, Greenblatt DJ, Harmatz JS \"Steady-state plasma desmethyldiazepam during long-term clorazepate use: effects of antacids.\" Clin Pharmacol Ther 31 (1982): 180-3[5] Greenblatt DJ, Shader RI, Harmatz JS, Franke K, Koch-Weser J \"Influence of magnesium and aluminum hydroxide mixture on chlordiazepoxide absorption.\" Clin Pharmacol Ther 19 (1976): 234-9[6] Kroboth PD, Smith RB, Rault R, Silver MR, Sorkin MI, Puschett JB, Juhl RP \"Effects of end-stage renal disease and aluminum hydroxide on temazepam kinetics.\" Clin Pharmacol Ther 37 (1985): 453-9[7] Chun AH, Carrigan PJ, Hoffman DJ, Kershner RP, Stuart JD \"Effect of antacids on absorption of clorazepate.\" Clin Pharmacol Ther 22 (1977): 329-35[8] Nair SG, Gamble JA, Dundee JW, Howard PJ \"The influence of three antacids on the absorption and clinical action of oral diazepam.\" Br J Anaesth 48 (1976): 1175-80[9] Shader RI, Georgotas A, Greenblatt DJ, Harmatz JS, Allen MD \"Impaired absorption of desmethyldiazepam from clorazepate by magnesium aluminum hydroxide.\" Clin Pharmacol Ther 24 (1978): 308-15[10] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[11] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[12] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[13] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Meprobamate, Buspirone, Hydroxyzine", "alternatives_b": "Magnesium gluconate, Sodium sulfate, Zinc sulfate, Magnesium sulfate, Magnesium aspartate, Magnesium lactate, Magnesium citrate, Sodium chloride, Zinc gluconate, Magnesium chloride, Alvimopan, More", "updated_at": 1767369485}, {"id": 68598, "ingredient1": "Picosulfuric acid", "ingredient2": "Losartan", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations. Fluid and electrolyte disturbances can lead to serious adverse events including cardiac arrhythmias, seizures, and renal impairment.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment. Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered. Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing. Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68685/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Diovan (valsartan).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Cozaar (losartan).\" Merck & Co, Inc, West Point, PA.[5] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[6] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Amlodipine, Sacubitril, Aliskiren, Nebivolol", "alternatives_b": "Alvimopan, Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, Magnesium carbonate, More", "updated_at": 1767369485}, {"id": 68599, "ingredient1": "Picosulfuric acid", "ingredient2": "Loxapine", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline. Rare cases of generalized tonic-clonic seizures and/or loss of consciousness in association with low serum osmolality and electrolyte abnormalities (e.g., hyponatremia, hypokalemia, hypocalcemia, hypomagnesemia) have been reported with the use of bowel cleansing products in patients with no prior history of seizures. The condition resolved with correction of fluid and electrolyte abnormalities.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68686/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.[9] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.", "alternatives_a": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68600, "ingredient1": "Picosulfuric acid", "ingredient2": "Lumateperone", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline. Rare cases of generalized tonic-clonic seizures and/or loss of consciousness in association with low serum osmolality and electrolyte abnormalities (e.g., hyponatremia, hypokalemia, hypocalcemia, hypomagnesemia) have been reported with the use of bowel cleansing products in patients with no prior history of seizures. The condition resolved with correction of fluid and electrolyte abnormalities.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68687/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.[9] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.", "alternatives_a": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68601, "ingredient1": "Picosulfuric acid", "ingredient2": "Lurasidone", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline. Rare cases of generalized tonic-clonic seizures and/or loss of consciousness in association with low serum osmolality and electrolyte abnormalities (e.g., hyponatremia, hypokalemia, hypocalcemia, hypomagnesemia) have been reported with the use of bowel cleansing products in patients with no prior history of seizures. The condition resolved with correction of fluid and electrolyte abnormalities.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68688/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.[9] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.", "alternatives_a": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68602, "ingredient1": "Picosulfuric acid", "ingredient2": "Macimorelin", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia are known risk factors for torsade de pointes associated with QT interval prolongation.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68689/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[5] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[8] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[9] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[10] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[11] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "alternatives_b": "Methacholine, Hexaminolevulinate, Secretin human, Methylene blue, Sermorelin, Sorbitol, Galactose, Magnesium sulfate, Gonadorelin, Vitamin A, Caffeine, More", "updated_at": 1767369485}, {"id": 68603, "ingredient1": "Magnesium carbonate", "ingredient2": "Magnesium oxide", "severity": "Moderate", "effect": "The concomitant administration of magnesium salts with other magnesium-containing preparations such as antacids or laxatives may increase the risk of magnesium toxicity, particularly in the presence of renal insufficiency. Magnesium toxicity may result in respiratory depression, neuromuscular depression, and heart block.", "source": "DDInter", "management_text": "Clinical and laboratory monitoring for signs of hypermagnesemia and magnesium toxicity is advisable, especially in high-risk patients (e.g., elderly or renally impaired patients).", "mechanism_text": "Synergism", "recommendation": "Clinical and laboratory monitoring for signs of hypermagnesemia and magnesium toxicity is advisable, especially in high-risk patients (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68690/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Magaldrate, Magnesium carbonate, Calcium carbonate, Aluminum hydroxide, Sodium sulfate, Zinc sulfate, Magnesium aspartate, Magnesium lactate, Magnesium citrate, Sodium chloride, Zinc gluconate, More", "alternatives_b": "Magaldrate, Magnesium oxide, Calcium carbonate, Aluminum hydroxide, Hydroxocobalamin, Fomepizole, Ipecac, Nitrous acid, Dexrazoxane, Oxygen, Lanthanum carbonate, More", "updated_at": 1767369485}, {"id": 68604, "ingredient1": "Magnesium chloride", "ingredient2": "Magnesium oxide", "severity": "Moderate", "effect": "The concomitant administration of magnesium salts with other magnesium-containing preparations such as antacids or laxatives may increase the risk of magnesium toxicity, particularly in the presence of renal insufficiency. Magnesium toxicity may result in respiratory depression, neuromuscular depression, and heart block.", "source": "DDInter", "management_text": "Clinical and laboratory monitoring for signs of hypermagnesemia and magnesium toxicity is advisable, especially in high-risk patients (e.g., elderly or renally impaired patients).", "mechanism_text": "Synergism", "recommendation": "Clinical and laboratory monitoring for signs of hypermagnesemia and magnesium toxicity is advisable, especially in high-risk patients (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68691/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Magaldrate, Calcium carbonate, Aluminum hydroxide, Sodium sulfate, Zinc sulfate, Sodium chloride, Zinc gluconate, Magnesium chloride, Alvimopan, Sorbitol, Tegaserod, More", "alternatives_b": "Sodium sulfate, Zinc sulfate, Magnesium aspartate, Magnesium lactate, Magnesium citrate, Sodium chloride, Magnesium oxide, Zinc gluconate, Calcium chloride, Potassium chloride, Sodium acetate, More", "updated_at": 1767369485}, {"id": 68605, "ingredient1": "Magnesium hydroxide", "ingredient2": "Magnesium oxide", "severity": "Moderate", "effect": "The concomitant administration of magnesium salts with other magnesium-containing preparations such as antacids or laxatives may increase the risk of magnesium toxicity, particularly in the presence of renal insufficiency. Magnesium toxicity may result in respiratory depression, neuromuscular depression, and heart block.", "source": "DDInter", "management_text": "Clinical and laboratory monitoring for signs of hypermagnesemia and magnesium toxicity is advisable, especially in high-risk patients (e.g., elderly or renally impaired patients).", "mechanism_text": "Synergism", "recommendation": "Clinical and laboratory monitoring for signs of hypermagnesemia and magnesium toxicity is advisable, especially in high-risk patients (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68692/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Magaldrate, Magnesium hydroxide, Calcium carbonate, Aluminum hydroxide, Sodium sulfate, Zinc sulfate, Magnesium aspartate, Magnesium lactate, Magnesium citrate, Sodium chloride, Zinc gluconate, More", "alternatives_b": "Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, More", "updated_at": 1767369485}, {"id": 68606, "ingredient1": "Magnesium sulfate", "ingredient2": "Magnesium oxide", "severity": "Moderate", "effect": "The concomitant administration of magnesium salts with other magnesium-containing preparations such as antacids or laxatives may increase the risk of magnesium toxicity, particularly in the presence of renal insufficiency. Magnesium toxicity may result in respiratory depression, neuromuscular depression, and heart block.", "source": "DDInter", "management_text": "Clinical and laboratory monitoring for signs of hypermagnesemia and magnesium toxicity is advisable, especially in high-risk patients (e.g., elderly or renally impaired patients).", "mechanism_text": "Synergism", "recommendation": "Clinical and laboratory monitoring for signs of hypermagnesemia and magnesium toxicity is advisable, especially in high-risk patients (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68693/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, Sodium sulfate, More", "alternatives_b": "Magaldrate, Calcium carbonate, Aluminum hydroxide, Sodium sulfate, Zinc sulfate, Magnesium sulfate, Sodium chloride, Zinc gluconate, Alvimopan, Sorbitol, Tegaserod, More", "updated_at": 1767369485}, {"id": 68607, "ingredient1": "Picosulfuric acid", "ingredient2": "Mannitol", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations. Fluid and electrolyte disturbances can lead to serious adverse events including cardiac arrhythmias, seizures, and renal impairment.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment. Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered. Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing. Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68694/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Diovan (valsartan).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Cozaar (losartan).\" Merck & Co, Inc, West Point, PA.[5] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[6] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Sorbitol, Sodium citrate, Magnesium citrate, Sodium bicarbonate, Sodium chloride, Chlorhexidine, Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 68608, "ingredient1": "Picosulfuric acid", "ingredient2": "Maprotiline", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; hydroxychloroquine; mefloquine), and some narcotic analgesics. The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that can prolong the QT interval, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; mefloquine; halofantrine; lumefantrine), and some narcotic analgesics (methadone; propoxyphene).", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68695/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[6] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[9] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[10] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[11] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[12] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[13] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[14] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[15] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "St. John's Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 68609, "ingredient1": "Picosulfuric acid", "ingredient2": "Mazindol", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline. Rare cases of generalized tonic-clonic seizures and/or loss of consciousness in association with low serum osmolality and electrolyte abnormalities (e.g., hyponatremia, hypokalemia, hypocalcemia, hypomagnesemia) have been reported with the use of bowel cleansing products in patients with no prior history of seizures. The condition resolved with correction of fluid and electrolyte abnormalities.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68696/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.[9] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.", "alternatives_a": "Lorcaserin, Orlistat, Naltrexone", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 68610, "ingredient1": "Picosulfuric acid", "ingredient2": "Meclofenamic acid", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations. Fluid and electrolyte disturbances can lead to serious adverse events including cardiac arrhythmias, seizures, and renal impairment.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment. Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered. Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing. Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68697/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Diovan (valsartan).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Cozaar (losartan).\" Merck & Co, Inc, West Point, PA.[5] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[6] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole, Tolazoline, Rabeprazole, Dimethyl sulfoxide", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 68611, "ingredient1": "Picosulfuric acid", "ingredient2": "Mefenamic acid", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations. Fluid and electrolyte disturbances can lead to serious adverse events including cardiac arrhythmias, seizures, and renal impairment.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment. Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered. Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing. Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68698/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Diovan (valsartan).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Cozaar (losartan).\" Merck & Co, Inc, West Point, PA.[5] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[6] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Prucalopride, Plecanatide, More", "updated_at": 1767369485}, {"id": 68612, "ingredient1": "Picosulfuric acid", "ingredient2": "Mefloquine", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; hydroxychloroquine; mefloquine), and some narcotic analgesics. The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that can prolong the QT interval, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; mefloquine; halofantrine; lumefantrine), and some narcotic analgesics (methadone; propoxyphene).", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68699/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[6] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[9] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[10] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[11] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[12] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[13] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[14] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[15] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Artesunate, Lumefantrine, Artemether, Pyrimethamine, Tafenoquine, Proguanil", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 68613, "ingredient1": "Picosulfuric acid", "ingredient2": "Meloxicam", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations. Fluid and electrolyte disturbances can lead to serious adverse events including cardiac arrhythmias, seizures, and renal impairment.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment. Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered. Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing. Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68700/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Diovan (valsartan).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Cozaar (losartan).\" Merck & Co, Inc, West Point, PA.[5] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[6] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Ropivacaine, Chloroprocaine, Levobupivacaine, Tetracaine, Bupivacaine, Mepivacaine, Procaine, Prilocaine, Articaine, Etidocaine, Rabeprazole, More", "alternatives_b": "Alvimopan, Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Magnesium carbonate, Plecanatide, More", "updated_at": 1767369485}, {"id": 68614, "ingredient1": "Picosulfuric acid", "ingredient2": "Meperidine", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline. Rare cases of generalized tonic-clonic seizures and/or loss of consciousness in association with low serum osmolality and electrolyte abnormalities (e.g., hyponatremia, hypokalemia, hypocalcemia, hypomagnesemia) have been reported with the use of bowel cleansing products in patients with no prior history of seizures. The condition resolved with correction of fluid and electrolyte abnormalities.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68701/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.[9] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.", "alternatives_a": "Dihydrocodeine, Acetaminophen, Naloxone, Naltrexone", "alternatives_b": "Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, Magnesium carbonate, Plecanatide, More", "updated_at": 1767369485}, {"id": 68615, "ingredient1": "Picosulfuric acid", "ingredient2": "Meropenem", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate. The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis. The clinical significance of this effect remains unknown.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic. If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Others", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68702/", "reference_text": "[1] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[3] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference) Available from: URL: http://www.mhra.gov.uk/spc-pil/index.htm.\"[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[6] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[7] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Imipenem", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 68616, "ingredient1": "Picosulfuric acid", "ingredient2": "Mesoridazine", "severity": "Major", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval. Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly. Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68703/", "reference_text": "[1] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[2] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[9] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[10] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[11] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[12] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[13] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Naldemedine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68617, "ingredient1": "Picosulfuric acid", "ingredient2": "Methadone", "severity": "Major", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval. Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly. Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68704/", "reference_text": "[1] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[2] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[9] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[10] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[11] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[12] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[13] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Acamprosate, Naltrexone, Varenicline, Disulfiram, Nalmefene, Nicotine, Dihydrocodeine, Acetaminophen, Naloxone, Naltrexone", "alternatives_b": "Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Naldemedine, More", "updated_at": 1767369485}, {"id": 68618, "ingredient1": "Picosulfuric acid", "ingredient2": "Metamfetamine", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline. Rare cases of generalized tonic-clonic seizures and/or loss of consciousness in association with low serum osmolality and electrolyte abnormalities (e.g., hyponatremia, hypokalemia, hypocalcemia, hypomagnesemia) have been reported with the use of bowel cleansing products in patients with no prior history of seizures. The condition resolved with correction of fluid and electrolyte abnormalities.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68705/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.[9] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.", "alternatives_a": "Solriamfetol, Caffeine, Armodafinil, Citicoline, Modafinil", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Prucalopride, Linaclotide, More", "updated_at": 1767369485}, {"id": 68619, "ingredient1": "Picosulfuric acid", "ingredient2": "Methazolamide", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations. Fluid and electrolyte disturbances can lead to serious adverse events including cardiac arrhythmias, seizures, and renal impairment.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment. Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered. Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing. Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68706/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Diovan (valsartan).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Cozaar (losartan).\" Merck & Co, Inc, West Point, PA.[5] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[6] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Simeprevir, Rosuvastatin, Lactic acid, Mitapivat, Amphotericin B, Ciclopirox, Darunavir, Probenecid, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 68620, "ingredient1": "Picosulfuric acid", "ingredient2": "Methdilazine", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline. Rare cases of generalized tonic-clonic seizures and/or loss of consciousness in association with low serum osmolality and electrolyte abnormalities (e.g., hyponatremia, hypokalemia, hypocalcemia, hypomagnesemia) have been reported with the use of bowel cleansing products in patients with no prior history of seizures. The condition resolved with correction of fluid and electrolyte abnormalities.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68707/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.[9] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.", "alternatives_a": "Ketotifen, Mepyramine, Levocetirizine, Chlorcyclizine, Cetirizine, Acrivastine, Triprolidine, Tripelennamine, Azelastine, Dexbrompheniramine, Clemastine, More", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Prucalopride, Linaclotide, More", "updated_at": 1767369485}, {"id": 68621, "ingredient1": "Picosulfuric acid", "ingredient2": "Methenamine", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate. The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis. The clinical significance of this effect remains unknown.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic. If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Others", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68708/", "reference_text": "[1] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[3] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference) Available from: URL: http://www.mhra.gov.uk/spc-pil/index.htm.\"[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[6] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[7] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Tinidazole", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Prucalopride, More", "updated_at": 1767369485}, {"id": 68622, "ingredient1": "Picosulfuric acid", "ingredient2": "Meticillin", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate. The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis. The clinical significance of this effect remains unknown.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic. If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Others", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68709/", "reference_text": "[1] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[3] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference) Available from: URL: http://www.mhra.gov.uk/spc-pil/index.htm.\"[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[6] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[7] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Tazobactam, Sulbactam", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, More", "updated_at": 1767369485}, {"id": 68623, "ingredient1": "Picosulfuric acid", "ingredient2": "Methotrimeprazine", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; hydroxychloroquine; mefloquine), and some narcotic analgesics. The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that can prolong the QT interval, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; mefloquine; halofantrine; lumefantrine), and some narcotic analgesics (methadone; propoxyphene).", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68710/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[6] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[9] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[10] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[11] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[12] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[13] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[14] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[15] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Phenolphthalein, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68624, "ingredient1": "Picosulfuric acid", "ingredient2": "Methylcellulose", "severity": "Minor", "effect": "According to some manufacturers, bulk-forming laxatives may reduce the efficacy of bowel cleansing products containing sodium picosulfate, magnesium oxide, and citric acid anhydrous. The mechanism of interaction has not been described, and clinical significance is unknown.", "source": "DDInter", "management_text": "-", "mechanism_text": "Others", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68711/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Metamucil (psyllium).\" Procter and Gamble Pharmaceutic, Cincinnati, OH.[3] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[4] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, Prucalopride, More", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 68625, "ingredient1": "Picosulfuric acid", "ingredient2": "Methylphenidate", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline. Rare cases of generalized tonic-clonic seizures and/or loss of consciousness in association with low serum osmolality and electrolyte abnormalities (e.g., hyponatremia, hypokalemia, hypocalcemia, hypomagnesemia) have been reported with the use of bowel cleansing products in patients with no prior history of seizures. The condition resolved with correction of fluid and electrolyte abnormalities.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68712/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.[9] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.", "alternatives_a": "Solriamfetol, Caffeine, Armodafinil, Citicoline, Modafinil", "alternatives_b": "Alvimopan, Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, Magnesium carbonate, More", "updated_at": 1767369485}, {"id": 68626, "ingredient1": "Picosulfuric acid", "ingredient2": "Methylprednisolone", "severity": "Moderate", "effect": "The overuse or abuse of laxatives can cause significant loss of electrolytes and potentiate the risk of hypokalemia associated with corticosteroid therapy. Corticosteroids promote the retention of sodium and water and the excretion of potassium. Although these effects are primarily associated with mineralocorticoids like fludrocortisone, they may also occur with higher dosages of glucocorticoids or adrenocorticotropic agents, particularly if given systemically for longer than brief periods.", "source": "DDInter", "management_text": "In general, laxatives should only be used on a short-term, intermittent basis in recommended dosages. During concomitant therapy with corticosteroids, particularly if fludrocortisone or large doses of a glucocorticoid or adrenocorticotropic agent is given, patients should be counseled to recognize potential signs and symptoms of hypokalemia such as fatigue, myalgia, and muscle weakness. If maintenance of bowel regularity is required, patients should be advised to exercise and increase fiber in the diet and/or consider the use of bulk-forming laxatives.", "mechanism_text": "Antagonism", "recommendation": "In general, laxatives should only be used on a short-term, intermittent basis in recommended dosages.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68713/", "reference_text": "[1] Chin RL \"Laxative-induced hypokalemia.\" Ann Emerg Med 32 (1998): 517-8[2] Blumenthal M, Goldberg A, Brinckmann J, eds. \"Herbal Medicine: Expanded Commission E Monographs.\" Newton, MA: Integrative Medicine Communications (2000):[3] Muller-Lissner SA \"Adverse effects of laxatives: fact and fiction.\" Pharmacology 47 (1993): 138-45[4] Seale JP, Compton MR \"Side-effects of corticosteroid agents.\" Med J Aust 144 (1986): 139-42[5] Swartz SL, Dluhy RG \"Corticosteroids: clinical pharmacology and therapeutic use.\" Drugs 16 (1978): 238-55[6] Lieberman P, Patterson R, Kunske R \"Complications of long-term steroid therapy for asthma.\" J Allergy Clin Immunol 49 (1972): 329-36[7] Ramsahoye BH, Davies SV, el-Gaylani N, Sandeman D, Scanlon MF \"The mineralocorticoid effects of high dose hydrocortisone.\" BMJ 310 (1995): 656-7", "alternatives_a": "Vitamin A, Isotretinoin, Fluorometholone, Tretinoin, Azelaic acid, Adapalene, Fluocinolone acetonide, Fluocinonide, Fluorometholone, Clobetasol, Beclomethasone dipropionate, More", "alternatives_b": "Alvimopan, Sodium sulfate, Sorbitol, Methylnaltrexone, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Naldemedine, Prucalopride, Linaclotide, Magnesium carbonate", "updated_at": 1767369485}, {"id": 68627, "ingredient1": "Picosulfuric acid", "ingredient2": "Metoclopramide", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline. Rare cases of generalized tonic-clonic seizures and/or loss of consciousness in association with low serum osmolality and electrolyte abnormalities (e.g., hyponatremia, hypokalemia, hypocalcemia, hypomagnesemia) have been reported with the use of bowel cleansing products in patients with no prior history of seizures. The condition resolved with correction of fluid and electrolyte abnormalities.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68714/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.[9] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.", "alternatives_a": "Alvimopan, Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, Magnesium carbonate, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68628, "ingredient1": "Picosulfuric acid", "ingredient2": "Metolazone", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations. Fluid and electrolyte disturbances can lead to serious adverse events including cardiac arrhythmias, seizures, and renal impairment.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment. Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered. Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing. Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68715/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Diovan (valsartan).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Cozaar (losartan).\" Merck & Co, Inc, West Point, PA.[5] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[6] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Simeprevir, Rosuvastatin, Lactic acid, Mitapivat, Amphotericin B, Ciclopirox, Darunavir, Probenecid, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Naldemedine, Prucalopride, More", "updated_at": 1767369485}, {"id": 68629, "ingredient1": "Metoprolol", "ingredient2": "Magnesium oxide", "severity": "Minor", "effect": "Concurrent administration with aluminum and magnesium antacids has been shown to decrease the oral bioavailability of certain beta-blockers, although data are conflicting. The exact mechanism of interaction is unknown but may involve cation binding of beta-blockers or a reduction in the dissolution rate due to increased gastric pH. Based on available data, the clinical significance of this potential interaction is difficult to determine. As a precaution, patients may want to consider separating the administration times of beta-blockers and antacids or other aluminum- or magnesium-containing products by at least 2 hours.", "source": "DDInter", "management_text": "-", "mechanism_text": "Absorption", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68716/", "reference_text": "[1] D'Arcy PF, McElnay JC \"Drug-antacid interactions: assessment of clinical importance.\" Drug Intell Clin Pharm 21 (1987): 607-17[2] Regardh CG, Lundborg P, Persson BA \"The effect of antacid, metoclopramide, and propantheline on the bioavailability of metoprolol and atenolol.\" Biopharm Drug Dispos 2 (1981): 79-87[3] Hong CY, Hu SC, Lin SJ, Chiang BN \"Lack of influence of aluminum hydroxide on the bioavailability and beta-adrenoceptor blocking activity of propranolol.\" Int J Clin Pharmacol Ther Toxicol 23 (1985): 244-6[4] Kirch W, Schafer-Korting M, Axthelm T, Kohler H, Mutschler E \"Interaction of atenolol with furosemide and calcium and aluminum salts.\" Clin Pharmacol Ther 30 (1981): 429-35[5] Laer S, Neumann J, Scholz H \"Interaction between sotalol and an antacid preparation.\" Br J Clin Pharmacol 43 (1997): 269-72[6] Gugler R, Allgayer H \"Effects of antacids on the clinical pharmacokinetics of drugs. An update.\" Clin Pharmacokinet 18 (1990): 210-9[7] Dobbs JH, Skoutakis VA, Acchiardo SR, Dobbs BR \"Effects of aluminum hydroxide on the absorption of propranolol.\" Curr Ther Res Clin Exp 21 (1977): 887-92", "alternatives_a": "Felodipine, Amlodipine, Nifedipine, Ivabradine, Esmolol", "alternatives_b": "Magnesium gluconate, Sodium sulfate, Zinc sulfate, Magnesium sulfate, Magnesium aspartate, Magnesium lactate, Magnesium citrate, Sodium chloride, Zinc gluconate, Magnesium chloride, Alvimopan, More", "updated_at": 1767369485}, {"id": 68630, "ingredient1": "Picosulfuric acid", "ingredient2": "Metronidazole", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate. The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis. The clinical significance of this effect remains unknown.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic. If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Others", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68717/", "reference_text": "[1] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[3] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference) Available from: URL: http://www.mhra.gov.uk/spc-pil/index.htm.\"[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[6] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[7] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Tinidazole, Pantoprazole, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Famotidine, Cimetidine, Esomeprazole, Ranitidine, More", "alternatives_b": "Alvimopan, Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, Sodium sulfate, Prucalopride, More", "updated_at": 1767369485}, {"id": 68631, "ingredient1": "Picosulfuric acid", "ingredient2": "Mexiletine", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline. Rare cases of generalized tonic-clonic seizures and/or loss of consciousness in association with low serum osmolality and electrolyte abnormalities (e.g., hyponatremia, hypokalemia, hypocalcemia, hypomagnesemia) have been reported with the use of bowel cleansing products in patients with no prior history of seizures. The condition resolved with correction of fluid and electrolyte abnormalities.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68718/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.[9] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.", "alternatives_a": "Tocainide, Moricizine, Bretylium", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 68632, "ingredient1": "Picosulfuric acid", "ingredient2": "Mezlocillin", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate. The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis. The clinical significance of this effect remains unknown.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic. If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Others", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68719/", "reference_text": "[1] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[3] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference) Available from: URL: http://www.mhra.gov.uk/spc-pil/index.htm.\"[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[6] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[7] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Tazobactam, Sulbactam", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, More", "updated_at": 1767369485}, {"id": 68633, "ingredient1": "Midazolam", "ingredient2": "Magnesium oxide", "severity": "Minor", "effect": "number of studies have reported that antacids can delay the gastrointestinal absorption and reduce the peak plasma concentration (Cmax) of some benzodiazepines, including clorazepate, chlordiazepoxide and diazepam, although the overall extent of absorption is generally not affected. The exact mechanism of interaction is unknown, but may involve delayed gastric emptying or cation binding of the benzodiazepine.", "source": "DDInter", "management_text": "-", "mechanism_text": "Absorption", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68720/", "reference_text": "[1] Greenblatt DJ, Allen MD, MacLaughlin DS, Harmatz JS, Shader RI \"Diazepam absorption: effect of antacids and food.\" Clin Pharmacol Ther 24 (1978): 600-9[2] Kroboth PD, Smith RB, Silver MR, Rault R, Sorkin MI, Puschett JB, Juhl RP \"Effects of end stage renal disease and aluminium hydroxide on triazolam pharmacokinetics.\" Br J Clin Pharmacol 19 (1985): 839-42[3] Greenblatt DJ, Shader RI, Harmatz JS, Franke K, Koch-Weser J \"Absorption rate, blood concentrations, and early response to oral chlordiazepoxide.\" Am J Psychiatry 134 (1977): 559-62[4] Shader RI, Ciraulo DA, Greenblatt DJ, Harmatz JS \"Steady-state plasma desmethyldiazepam during long-term clorazepate use: effects of antacids.\" Clin Pharmacol Ther 31 (1982): 180-3[5] Greenblatt DJ, Shader RI, Harmatz JS, Franke K, Koch-Weser J \"Influence of magnesium and aluminum hydroxide mixture on chlordiazepoxide absorption.\" Clin Pharmacol Ther 19 (1976): 234-9[6] Kroboth PD, Smith RB, Rault R, Silver MR, Sorkin MI, Puschett JB, Juhl RP \"Effects of end-stage renal disease and aluminum hydroxide on temazepam kinetics.\" Clin Pharmacol Ther 37 (1985): 453-9[7] Chun AH, Carrigan PJ, Hoffman DJ, Kershner RP, Stuart JD \"Effect of antacids on absorption of clorazepate.\" Clin Pharmacol Ther 22 (1977): 329-35[8] Nair SG, Gamble JA, Dundee JW, Howard PJ \"The influence of three antacids on the absorption and clinical action of oral diazepam.\" Br J Anaesth 48 (1976): 1175-80[9] Shader RI, Georgotas A, Greenblatt DJ, Harmatz JS, Allen MD \"Impaired absorption of desmethyldiazepam from clorazepate by magnesium aluminum hydroxide.\" Clin Pharmacol Ther 24 (1978): 308-15[10] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[11] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[12] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[13] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Suvorexant, Methohexital, Methylphenobarbital, Zolpidem, Pentobarbital, Zaleplon, Dichloralphenazone, Valerian, Butabarbital, Secobarbital, Chloral hydrate, More", "alternatives_b": "Magnesium gluconate, Sodium sulfate, Zinc sulfate, Magnesium sulfate, Magnesium aspartate, Magnesium lactate, Magnesium citrate, Sodium chloride, Zinc gluconate, Magnesium chloride, Alvimopan, More", "updated_at": 1767369485}, {"id": 68634, "ingredient1": "Picosulfuric acid", "ingredient2": "Midostaurin", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia are known risk factors for torsade de pointes associated with QT interval prolongation.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68721/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[5] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[8] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[9] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[10] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[11] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Imatinib, Dabrafenib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Selumetinib, Cobimetinib, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Naldemedine, More", "updated_at": 1767369485}, {"id": 68635, "ingredient1": "Picosulfuric acid", "ingredient2": "Mifepristone", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia are known risk factors for torsade de pointes associated with QT interval prolongation.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68722/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[5] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[8] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[9] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[10] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[11] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Ulipristal, Danazol, Ospemifene, Raloxifene, Bazedoxifene, Prasterone", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Prucalopride, More", "updated_at": 1767369485}, {"id": 68636, "ingredient1": "Picosulfuric acid", "ingredient2": "Milnacipran", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline. Rare cases of generalized tonic-clonic seizures and/or loss of consciousness in association with low serum osmolality and electrolyte abnormalities (e.g., hyponatremia, hypokalemia, hypocalcemia, hypomagnesemia) have been reported with the use of bowel cleansing products in patients with no prior history of seizures. The condition resolved with correction of fluid and electrolyte abnormalities.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68723/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.[9] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.", "alternatives_a": "St. John's Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 68637, "ingredient1": "Minocycline", "ingredient2": "Magnesium oxide", "severity": "Moderate", "effect": "INTERVAL: Administration of a tetracycline with aluminum, calcium, or magnesium salts significantly decreases tetracycline serum concentrations. The proposed mechanism is chelation of tetracycline by the cation, forming an insoluble complex that is poorly absorbed from the gastrointestinal tract. The interaction has also been reported with parenteral doxycycline and oral antacids.", "source": "DDInter", "management_text": "The administration of tetracyclines and preparations containing aluminum, magnesium, or calcium should be separated by two to four hours.", "mechanism_text": "Absorption", "recommendation": "The administration of tetracyclines and preparations containing aluminum, magnesium, or calcium should be separated by two to four hours.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68724/", "reference_text": "[1] Nguyen VX, Nix DE, Gillikin S, Schentag JJ \"Effect of oral antacid administration on the pharmacokinetics of intravenous doxycycline.\" Antimicrob Agents Chemother 33 (1989): 434-6[2] Gotz VP, Ryerson GG \"Evaluation of tetracycline on theophylline disposition in patients with chronic obstructive airways disease.\" Drug Intell Clin Pharm 20 (1986): 694-6[3] Upton RA \"Pharmacokinetic interactions between theophylline and other medication (Part I).\" Clin Pharmacokinet 20 (1991): 66-80[4] \"Product Information. Nuzyra (omadacycline).\" Paratek Pharmaceuticals, Inc., Boston, MA.[5] \"Product Information. Seysara (sarecycline).\" Allergan Inc, Irvine, CA.[6] McCormack JP, Reid SE, Lawson LM \"Theophylline toxicity induced by tetracycline.\" Clin Pharm 9 (1990): 546-9[7] Neuvonen PJ \"Interactions with the absorption of tetracyclines.\" Drugs 11 (1976): 45-54[8] D'Arcy PF, McElnay JC \"Drug-antacid interactions: assessment of clinical importance.\" Drug Intell Clin Pharm 21 (1987): 607-17[9] \"Product Information. Declomycin (demeclocycline).\" Lederle Laboratories, Wayne, NJ.[10] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[11] Garty M, Hurwitz A \"Effect of cimetidine and antacids on gastrointestinal absorption of tetracycline.\" Clin Pharmacol Ther 28 (1980): 203-7[12] Deppermann KM, Lode H, Hoffken G, Tschink G, Kalz C, Koeppe P \"Influence of ranitidine, pirenzepine, and aluminum magnesium hydroxide on the bioavailability of various antibiotics, including amoxicillin, cephalexin, doxycycline, and amoxicillin-clavulanic acid.\" Antimicrob Agents Chemother 33 (1989): 1901-7[13] Covington TR, Lawson LC, Young LL, eds. \"Handbook of Nonprescription Drugs. 10th ed.\" Washington, DC: American Pharmaceutical Association (1993):[14] \"Product Information. Achromycin (tetracycline).\" Lederle Laboratories, Wayne, NJ.[15] \"Product Information. Declomycin (demeclocycline).\" Lederle Laboratories, Wayne, NJ.", "alternatives_a": "Clindamycin, Vitamin A, Isotretinoin, Chloramphenicol, Fluorometholone, Tretinoin, Dapsone, Azelaic acid, Adapalene, Tigecycline, Eravacycline, More", "alternatives_b": "Sodium chloride, Sodium sulfate, Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, More", "updated_at": 1767369485}, {"id": 68638, "ingredient1": "Picosulfuric acid", "ingredient2": "Mirtazapine", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; hydroxychloroquine; mefloquine), and some narcotic analgesics. The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that can prolong the QT interval, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; mefloquine; halofantrine; lumefantrine), and some narcotic analgesics (methadone; propoxyphene).", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68725/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[6] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[9] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[10] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[11] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[12] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[13] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[14] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[15] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "St. John's Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Naldemedine, More", "updated_at": 1767369485}, {"id": 68639, "ingredient1": "Misoprostol", "ingredient2": "Magnesium oxide", "severity": "Moderate", "effect": "Magnesium-containing antacids can exacerbate misoprostol-induced diarrhea. Additionally, antacids in general can reduce the bioavailability of misoprostol acid (the active metabolite of misoprostol), although clinical trials of misoprostol conducted with concomitant antacid use suggest that this effect is not clinically important.", "source": "DDInter", "management_text": "Use of misoprostol in combination with magnesium-containing antacids is not recommended. If an antacid is needed, one that contains aluminum or calcium should be prescribed.", "mechanism_text": "Others", "recommendation": "Use of misoprostol in combination with magnesium-containing antacids is not recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68726/", "reference_text": "[1] Karim A, Rozek LF, Smith ME, Kowalski KG \"Effects of food and antacid on oral absorption of misoprostol, a synthetic prostaglandin E1 analog.\" J Clin Pharmacol 29 (1989): 439-43[2] \"Product Information. Arthrotec (diclofenac-misoprostol).\" Searle, Skokie, IL.", "alternatives_a": "Methylergometrine, Dinoprostone, Ergometrine, Oxytocin, Tinidazole, Pantoprazole, Dexlansoprazole, Rabeprazole, Sucralfate, Bismuth subcitrate potassium, Metronidazole, More", "alternatives_b": "Magnesium gluconate, Sodium sulfate, Zinc sulfate, Magnesium sulfate, Magnesium aspartate, Magnesium lactate, Magnesium citrate, Sodium chloride, Zinc gluconate, Magnesium chloride, Alvimopan, More", "updated_at": 1767369485}, {"id": 68640, "ingredient1": "Picosulfuric acid", "ingredient2": "Moexipril", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations. Fluid and electrolyte disturbances can lead to serious adverse events including cardiac arrhythmias, seizures, and renal impairment.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment. Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered. Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing. Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68727/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Diovan (valsartan).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Cozaar (losartan).\" Merck & Co, Inc, West Point, PA.[5] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[6] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Felodipine, Amlodipine, Verapamil, Bisoprolol", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Prucalopride, Linaclotide, More", "updated_at": 1767369485}, {"id": 68641, "ingredient1": "Picosulfuric acid", "ingredient2": "Molindone", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline. Rare cases of generalized tonic-clonic seizures and/or loss of consciousness in association with low serum osmolality and electrolyte abnormalities (e.g., hyponatremia, hypokalemia, hypocalcemia, hypomagnesemia) have been reported with the use of bowel cleansing products in patients with no prior history of seizures. The condition resolved with correction of fluid and electrolyte abnormalities.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68728/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.[9] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.", "alternatives_a": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68642, "ingredient1": "Picosulfuric acid", "ingredient2": "Morphine", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline. Rare cases of generalized tonic-clonic seizures and/or loss of consciousness in association with low serum osmolality and electrolyte abnormalities (e.g., hyponatremia, hypokalemia, hypocalcemia, hypomagnesemia) have been reported with the use of bowel cleansing products in patients with no prior history of seizures. The condition resolved with correction of fluid and electrolyte abnormalities.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68729/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.[9] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.", "alternatives_a": "Loperamide, Eluxadoline, Diphenoxylate, Difenoxin, Dihydrocodeine, Acetaminophen, Naloxone, Naltrexone", "alternatives_b": "Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, Magnesium carbonate, Plecanatide, More", "updated_at": 1767369485}, {"id": 68643, "ingredient1": "Picosulfuric acid", "ingredient2": "Morphine (liposomal)", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline. Rare cases of generalized tonic-clonic seizures and/or loss of consciousness in association with low serum osmolality and electrolyte abnormalities (e.g., hyponatremia, hypokalemia, hypocalcemia, hypomagnesemia) have been reported with the use of bowel cleansing products in patients with no prior history of seizures. The condition resolved with correction of fluid and electrolyte abnormalities.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68730/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.[9] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.", "alternatives_a": "Loperamide, Eluxadoline, Diphenoxylate, Difenoxin, Dihydrocodeine, Acetaminophen, Naloxone, Naltrexone", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, More", "updated_at": 1767369485}, {"id": 68644, "ingredient1": "Citric acid", "ingredient2": "Moxifloxacin", "severity": "Moderate", "effect": "Urinary alkalinizers such as citrates may decrease the solubility of fluoroquinolones in the urine and increase the risk of crystalluria.", "source": "DDInter", "management_text": "Concomitant use should generally be avoided. Patients receiving this combination should be monitored for signs of renal toxicity and crystalluria.", "mechanism_text": "Excretion", "recommendation": "Concomitant use should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68731/", "reference_text": "[1] \"Multum Information Services, Inc. Expert Review Panel\"[2] \"Product Information. Cipro (ciprofloxacin).\" Bayer, West Haven, CT.", "alternatives_a": "Rifamycin, Kanamycin, Ampicillin, Azithromycin, Acyclovir, Netilmicin, Polymyxin B, Famciclovir, Cefuroxime, Trifluridine, Tobramycin, More", "alternatives_b": "Glutamic acid, Pancrelipase", "updated_at": 1767369485}, {"id": 68645, "ingredient1": "Picosulfuric acid", "ingredient2": "Muromonab", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline. Rare cases of generalized tonic-clonic seizures and/or loss of consciousness in association with low serum osmolality and electrolyte abnormalities (e.g., hyponatremia, hypokalemia, hypocalcemia, hypomagnesemia) have been reported with the use of bowel cleansing products in patients with no prior history of seizures. The condition resolved with correction of fluid and electrolyte abnormalities.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68732/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.[9] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.", "alternatives_a": "Golimumab, Cyclosporine, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, More", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 68646, "ingredient1": "Mycophenolate mofetil", "ingredient2": "Magnesium oxide", "severity": "Moderate", "effect": "INTERVAL: Coadministration with antacids may decrease the oral bioavailability of mycophenolic acid. The exact mechanism of interaction is unknown but may involve chelation with polyvalent ions in antacids or enhanced drug solubility induced by an increase in gastric pH, or both. The interaction has been reported with magnesium/aluminum-containing antacids.", "source": "DDInter", "management_text": "Patients treated with oral mycophenolic acid who require an antacid or antacid-containing preparation (e.g., didanosine buffered tablets or pediatric oral solution) should separate the administration times of the medications by at least two hours.", "mechanism_text": "Absorption", "recommendation": "Patients treated with oral mycophenolic acid who require an antacid or antacid-containing preparation (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68733/", "reference_text": "[1] Lipsky JJ \"Mycophenolate mofetil.\" Lancet 348 (1996): 1357-9[2] Bullingham R, Shah J, Goldblum R, Schiff M \"Effects of food and antacid on the pharmacokinetics of single doses of mycophenolate mofetil in rheumatoid arthritis patients.\" Br J Clin Pharmacol 41 (1996): 513-6[3] \"Product Information. Myfortic (mycophenolic acid).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. CellCept (mycophenolate mofetil).\" Roche Laboratories, Nutley, NJ.[5] \"Product Information. Myfortic (mycophenolic acid).\" Novartis Pharmaceuticals, East Hanover, NJ.", "alternatives_a": "Magnesium gluconate, Magnesium sulfate, Magnesium aspartate, Magnesium lactate, Magnesium citrate, Sodium chloride, Sodium sulfate, Magnesium chloride, Alvimopan, Sorbitol, Tegaserod, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68647, "ingredient1": "Mycophenolic acid", "ingredient2": "Magnesium oxide", "severity": "Moderate", "effect": "INTERVAL: Coadministration with antacids may decrease the oral bioavailability of mycophenolic acid. The exact mechanism of interaction is unknown but may involve chelation with polyvalent ions in antacids or enhanced drug solubility induced by an increase in gastric pH, or both. The interaction has been reported with magnesium/aluminum-containing antacids.", "source": "DDInter", "management_text": "Patients treated with oral mycophenolic acid who require an antacid or antacid-containing preparation (e.g., didanosine buffered tablets or pediatric oral solution) should separate the administration times of the medications by at least two hours.", "mechanism_text": "Absorption", "recommendation": "Patients treated with oral mycophenolic acid who require an antacid or antacid-containing preparation (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68734/", "reference_text": "[1] Lipsky JJ \"Mycophenolate mofetil.\" Lancet 348 (1996): 1357-9[2] Bullingham R, Shah J, Goldblum R, Schiff M \"Effects of food and antacid on the pharmacokinetics of single doses of mycophenolate mofetil in rheumatoid arthritis patients.\" Br J Clin Pharmacol 41 (1996): 513-6[3] \"Product Information. Myfortic (mycophenolic acid).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. CellCept (mycophenolate mofetil).\" Roche Laboratories, Nutley, NJ.[5] \"Product Information. Myfortic (mycophenolic acid).\" Novartis Pharmaceuticals, East Hanover, NJ.", "alternatives_a": "Golimumab, Cyclosporine, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Methotrexate, More", "alternatives_b": "Magnesium gluconate, Magnesium sulfate, Magnesium aspartate, Magnesium lactate, Magnesium citrate, Sodium chloride, Sodium sulfate, Magnesium chloride, Alvimopan, Sorbitol, Tegaserod, More", "updated_at": 1767369485}, {"id": 68648, "ingredient1": "Picosulfuric acid", "ingredient2": "Nabumetone", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations. Fluid and electrolyte disturbances can lead to serious adverse events including cardiac arrhythmias, seizures, and renal impairment.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment. Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered. Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing. Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68735/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Diovan (valsartan).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Cozaar (losartan).\" Merck & Co, Inc, West Point, PA.[5] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[6] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole", "alternatives_b": "Alvimopan, Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Magnesium carbonate, Plecanatide, More", "updated_at": 1767369485}, {"id": 68649, "ingredient1": "Nadolol", "ingredient2": "Magnesium oxide", "severity": "Minor", "effect": "Concurrent administration with aluminum and magnesium antacids has been shown to decrease the oral bioavailability of certain beta-blockers, although data are conflicting. The exact mechanism of interaction is unknown but may involve cation binding of beta-blockers or a reduction in the dissolution rate due to increased gastric pH. Based on available data, the clinical significance of this potential interaction is difficult to determine. As a precaution, patients may want to consider separating the administration times of beta-blockers and antacids or other aluminum- or magnesium-containing products by at least 2 hours.", "source": "DDInter", "management_text": "-", "mechanism_text": "Absorption", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68736/", "reference_text": "[1] D'Arcy PF, McElnay JC \"Drug-antacid interactions: assessment of clinical importance.\" Drug Intell Clin Pharm 21 (1987): 607-17[2] Regardh CG, Lundborg P, Persson BA \"The effect of antacid, metoclopramide, and propantheline on the bioavailability of metoprolol and atenolol.\" Biopharm Drug Dispos 2 (1981): 79-87[3] Hong CY, Hu SC, Lin SJ, Chiang BN \"Lack of influence of aluminum hydroxide on the bioavailability and beta-adrenoceptor blocking activity of propranolol.\" Int J Clin Pharmacol Ther Toxicol 23 (1985): 244-6[4] Kirch W, Schafer-Korting M, Axthelm T, Kohler H, Mutschler E \"Interaction of atenolol with furosemide and calcium and aluminum salts.\" Clin Pharmacol Ther 30 (1981): 429-35[5] Laer S, Neumann J, Scholz H \"Interaction between sotalol and an antacid preparation.\" Br J Clin Pharmacol 43 (1997): 269-72[6] Gugler R, Allgayer H \"Effects of antacids on the clinical pharmacokinetics of drugs. An update.\" Clin Pharmacokinet 18 (1990): 210-9[7] Dobbs JH, Skoutakis VA, Acchiardo SR, Dobbs BR \"Effects of aluminum hydroxide on the absorption of propranolol.\" Curr Ther Res Clin Exp 21 (1977): 887-92", "alternatives_a": "Esmolol", "alternatives_b": "Magnesium gluconate, Sodium sulfate, Zinc sulfate, Magnesium sulfate, Magnesium aspartate, Magnesium lactate, Magnesium citrate, Sodium chloride, Zinc gluconate, Magnesium chloride, Alvimopan, More", "updated_at": 1767369485}, {"id": 68650, "ingredient1": "Picosulfuric acid", "ingredient2": "Nafcillin", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate. The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis. The clinical significance of this effect remains unknown.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic. If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Others", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68737/", "reference_text": "[1] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[3] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference) Available from: URL: http://www.mhra.gov.uk/spc-pil/index.htm.\"[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[6] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[7] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Tazobactam, Sulbactam", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Bisacodyl, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, Sodium sulfate, Prucalopride, More", "updated_at": 1767369485}, {"id": 68651, "ingredient1": "Picosulfuric acid", "ingredient2": "Nalbuphine", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline. Rare cases of generalized tonic-clonic seizures and/or loss of consciousness in association with low serum osmolality and electrolyte abnormalities (e.g., hyponatremia, hypokalemia, hypocalcemia, hypomagnesemia) have been reported with the use of bowel cleansing products in patients with no prior history of seizures. The condition resolved with correction of fluid and electrolyte abnormalities.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68738/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.[9] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.", "alternatives_a": "Dihydrocodeine, Acetaminophen, Naloxone, Naltrexone", "alternatives_b": "Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, More", "updated_at": 1767369485}, {"id": 68652, "ingredient1": "Citric acid", "ingredient2": "Nalidixic acid", "severity": "Moderate", "effect": "Urinary alkalinizers such as citrates may decrease the solubility of fluoroquinolones in the urine and increase the risk of crystalluria.", "source": "DDInter", "management_text": "Concomitant use should generally be avoided. Patients receiving this combination should be monitored for signs of renal toxicity and crystalluria.", "mechanism_text": "Excretion", "recommendation": "Concomitant use should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68739/", "reference_text": "[1] \"Multum Information Services, Inc. Expert Review Panel\"[2] \"Product Information. Cipro (ciprofloxacin).\" Bayer, West Haven, CT.", "alternatives_a": "Delafloxacin", "alternatives_b": "Glutamic acid, Pancrelipase", "updated_at": 1767369485}, {"id": 68653, "ingredient1": "Picosulfuric acid", "ingredient2": "Naproxen", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations. Fluid and electrolyte disturbances can lead to serious adverse events including cardiac arrhythmias, seizures, and renal impairment.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment. Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered. Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing. Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68740/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Diovan (valsartan).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Cozaar (losartan).\" Merck & Co, Inc, West Point, PA.[5] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[6] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Ritodrine, Bremelanotide, Flibanserin, Cabergoline, Black cohosh, Bromocriptine, Tolazoline, Rabeprazole, Dimethyl sulfoxide, Rabeprazole, Misoprostol, More", "alternatives_b": "Alvimopan, Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Prucalopride, Plecanatide, Magnesium citrate, Lubiprostone, More", "updated_at": 1767369485}, {"id": 68654, "ingredient1": "Nebivolol", "ingredient2": "Magnesium oxide", "severity": "Minor", "effect": "Concurrent administration with aluminum and magnesium antacids has been shown to decrease the oral bioavailability of certain beta-blockers, although data are conflicting. The exact mechanism of interaction is unknown but may involve cation binding of beta-blockers or a reduction in the dissolution rate due to increased gastric pH. Based on available data, the clinical significance of this potential interaction is difficult to determine. As a precaution, patients may want to consider separating the administration times of beta-blockers and antacids or other aluminum- or magnesium-containing products by at least 2 hours.", "source": "DDInter", "management_text": "-", "mechanism_text": "Absorption", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68741/", "reference_text": "[1] D'Arcy PF, McElnay JC \"Drug-antacid interactions: assessment of clinical importance.\" Drug Intell Clin Pharm 21 (1987): 607-17[2] Regardh CG, Lundborg P, Persson BA \"The effect of antacid, metoclopramide, and propantheline on the bioavailability of metoprolol and atenolol.\" Biopharm Drug Dispos 2 (1981): 79-87[3] Hong CY, Hu SC, Lin SJ, Chiang BN \"Lack of influence of aluminum hydroxide on the bioavailability and beta-adrenoceptor blocking activity of propranolol.\" Int J Clin Pharmacol Ther Toxicol 23 (1985): 244-6[4] Kirch W, Schafer-Korting M, Axthelm T, Kohler H, Mutschler E \"Interaction of atenolol with furosemide and calcium and aluminum salts.\" Clin Pharmacol Ther 30 (1981): 429-35[5] Laer S, Neumann J, Scholz H \"Interaction between sotalol and an antacid preparation.\" Br J Clin Pharmacol 43 (1997): 269-72[6] Gugler R, Allgayer H \"Effects of antacids on the clinical pharmacokinetics of drugs. An update.\" Clin Pharmacokinet 18 (1990): 210-9[7] Dobbs JH, Skoutakis VA, Acchiardo SR, Dobbs BR \"Effects of aluminum hydroxide on the absorption of propranolol.\" Curr Ther Res Clin Exp 21 (1977): 887-92", "alternatives_a": "Magnesium gluconate, Sodium sulfate, Zinc sulfate, Magnesium sulfate, Magnesium aspartate, Magnesium lactate, Magnesium citrate, Sodium chloride, Zinc gluconate, Magnesium chloride, Alvimopan, More", "alternatives_b": "Felodipine, Amlodipine, Nifedipine, Ivabradine, Amlodipine, Valsartan, Irbesartan, Hydrochlorothiazide, Losartan, Olmesartan, Azilsartan medoxomil, More", "updated_at": 1767369485}, {"id": 68655, "ingredient1": "Picosulfuric acid", "ingredient2": "Nefazodone", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline. Rare cases of generalized tonic-clonic seizures and/or loss of consciousness in association with low serum osmolality and electrolyte abnormalities (e.g., hyponatremia, hypokalemia, hypocalcemia, hypomagnesemia) have been reported with the use of bowel cleansing products in patients with no prior history of seizures. The condition resolved with correction of fluid and electrolyte abnormalities.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68742/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.[9] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.", "alternatives_a": "St. John's Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine", "alternatives_b": "Alvimopan, Sorbitol, Bisacodyl, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, Magnesium carbonate, Plecanatide, More", "updated_at": 1767369485}, {"id": 68656, "ingredient1": "Picosulfuric acid", "ingredient2": "Nelarabine", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline. Rare cases of generalized tonic-clonic seizures and/or loss of consciousness in association with low serum osmolality and electrolyte abnormalities (e.g., hyponatremia, hypokalemia, hypocalcemia, hypomagnesemia) have been reported with the use of bowel cleansing products in patients with no prior history of seizures. The condition resolved with correction of fluid and electrolyte abnormalities.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68743/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.[9] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.", "alternatives_a": "Methotrexate, Fluorouracil, Pemetrexed, Mercaptopurine, Cladribine, Clofarabine, Trifluridine, Floxuridine, Gemcitabine, Pralatrexate, Cytarabine, More", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 68657, "ingredient1": "Picosulfuric acid", "ingredient2": "Neomycin", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate. The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis. The clinical significance of this effect remains unknown.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic. If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Others", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68744/", "reference_text": "[1] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[3] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference) Available from: URL: http://www.mhra.gov.uk/spc-pil/index.htm.\"[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[6] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[7] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Nystatin, Amphotericin B, Miconazole, Chlorhexidine, Povidone-iodine, Mupirocin, Chlorhexidine, Amphotericin B, Miconazole, Clotrimazole, Epinephrine, More", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, Sodium sulfate, More", "updated_at": 1767369485}, {"id": 68658, "ingredient1": "Picosulfuric acid", "ingredient2": "Neostigmine", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline. Rare cases of generalized tonic-clonic seizures and/or loss of consciousness in association with low serum osmolality and electrolyte abnormalities (e.g., hyponatremia, hypokalemia, hypocalcemia, hypomagnesemia) have been reported with the use of bowel cleansing products in patients with no prior history of seizures. The condition resolved with correction of fluid and electrolyte abnormalities.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68745/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.[9] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.", "alternatives_a": "Ambenonium, Pilocarpine, Cevimeline, Pyridostigmine, Latanoprost, Apraclonidine, Pilocarpine, Clonidine, Acetylcholine, Betaxolol, Bimatoprost, More", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 68659, "ingredient1": "Neratinib", "ingredient2": "Magnesium oxide", "severity": "Moderate", "effect": "Coadministration with drugs that increase gastric pH may significantly decrease the oral bioavailability of neratinib. The solubility of neratinib is pH-dependent and increases as neratinib becomes protonated at acidic pH, thus an increase in pH may interfere with its absorption.", "source": "DDInter", "management_text": "Concomitant use of neratinib with drugs that increase gastric pH should generally be avoided. If acid-suppression therapy is required, short-acting antacids should be considered, with neratinib dosing separated by at least three hours after antacid administration.", "mechanism_text": "Absorption", "recommendation": "Concomitant use of neratinib with drugs that increase gastric pH should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68746/", "reference_text": "[1] \"Product Information. Nerlynx (neratinib).\" Puma Biotechnology, Inc., Los Angeles, CA.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Abbas R, Hug BA, Leister C, Burns J, Sonnichsen D \"Pharmacokinetics of oral neratinib during co-administration of ketoconazole in healthy subjects.\" Br J Clin Pharmacol 71 (2011): 522-7[4] \"Product Information. Nerlynx (neratinib).\" Puma Biotechnology, Inc., Los Angeles, CA.", "alternatives_a": "Magnesium gluconate, Sodium sulfate, Zinc sulfate, Magnesium sulfate, Magnesium aspartate, Magnesium lactate, Magnesium citrate, Sodium chloride, Zinc gluconate, Magnesium chloride, Alvimopan, More", "alternatives_b": "Entrectinib, Imatinib, Pralsetinib, Asciminib, Dacomitinib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Vemurafenib, More", "updated_at": 1767369485}, {"id": 68660, "ingredient1": "Picosulfuric acid", "ingredient2": "Netilmicin", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate. The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis. The clinical significance of this effect remains unknown.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic. If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Others", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68747/", "reference_text": "[1] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[3] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference) Available from: URL: http://www.mhra.gov.uk/spc-pil/index.htm.\"[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[6] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[7] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Ganciclovir, Acyclovir, Famciclovir, Trifluridine, Chlorhexidine, Povidone-iodine", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, More", "updated_at": 1767369485}, {"id": 68661, "ingredient1": "Picosulfuric acid", "ingredient2": "Nilotinib", "severity": "Major", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval. Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly. Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68748/", "reference_text": "[1] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[2] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[9] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[10] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[11] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[12] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[13] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Imatinib, Dabrafenib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Selumetinib, Cobimetinib, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Prucalopride, Linaclotide, Naloxone", "updated_at": 1767369485}, {"id": 68662, "ingredient1": "Picosulfuric acid", "ingredient2": "Nilutamide", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia are known risk factors for torsade de pointes associated with QT interval prolongation.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68749/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[5] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[8] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[9] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[10] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[11] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Darolutamide, Anastrozole, Fulvestrant, Letrozole, Aminoglutethimide, Exemestane", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 68663, "ingredient1": "Picosulfuric acid", "ingredient2": "Nitrofurantoin", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate. The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis. The clinical significance of this effect remains unknown.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic. If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Others", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68750/", "reference_text": "[1] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[3] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference) Available from: URL: http://www.mhra.gov.uk/spc-pil/index.htm.\"[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[6] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[7] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Tinidazole", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Prucalopride, Sodium sulfate, More", "updated_at": 1767369485}, {"id": 68664, "ingredient1": "Nizatidine", "ingredient2": "Magnesium oxide", "severity": "Minor", "effect": "Antacids and some aluminum, calcium, and magnesium salts may decrease the plasma concentrations of H2-receptor antagonists during oral coadministration. The mechanism of interaction is unknown, but may involve reduced oral absorption due to increased gastric pH. The clinical significance has not been established. As a precaution, patients may consider taking H2-receptor antagonists one to two hours before antacids.", "source": "DDInter", "management_text": "-", "mechanism_text": "Absorption", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68751/", "reference_text": "[1] Barzaghi N, Gatti G, Crema F, Perucca E \"Impaired bioavailability of famotidine given concurrently with a potent antacid.\" J Clin Pharmacol 29 (1989): 670-2[2] Albin H, Vincon G, Begaud B, Bistue C, Perez P \"Effect of aluminum phosphate on the bioavailability of ranitidine.\" Eur J Clin Pharmacol 32 (1987): 97-9[3] Covington TR, Lawson LC, Young LL, eds. \"Handbook of Nonprescription Drugs. 10th ed.\" Washington, DC: American Pharmaceutical Association (1993):[4] Donn KH, Eshelman FN, Plachetka JR, et al \"The effects of antacid and propantheline on the absorption of oral ranitidine.\" Pharmacotherapy 4 (1984): 89-92[5] Bachmann KA, Sullivan TJ, Jauregui L, Reese J, Miller K, Levine L \"Drug interactions of h-2-receptor antagonists.\" Scand J Gastroenterol 29 (1994): 14-9[6] Bodemar G, Norlander B, Walan A \"Diminished absorption of cimetidine caused by antacids.\" Lancet 02/24/79 (1979): 444-5[7] Russell WL, Lopez LM, Normann SA, et al \"Effect of antacids on predicted steady-state cimetidine concentrations.\" Dig Dis Sci 29 (1984): 385-9[8] Shelly DW, Doering PL, Russell WL, Guild RT, Lopez LM, Perrin J \"Effect of concomitant antacid administration on plasma cimetidine concentrations during repetitive dosing.\" Drug Intell Clin Pharm 20 (1986): 792-5[9] Steinberg WM, Lewis JH, Katz DM \"Antacids inhibit absorption of cimetidine.\" N Engl J Med 307 (1982): 400-4[10] Lin JH, Chremos AN, Kanovsky SM, Schwartz S, Yeh KC, Kann J \"Effects of antacids and food on absorption of famotidine.\" Br J Clin Pharmacol 24 (1987): 551-3[11] Mihaly GW, Marino AT, Webster LK, Jones DB, Louis WJ, Smallwood RA \"High dose of antacid (Mylanta II) reduces bioavailability of ranitidine.\" Br Med J 285 (1982): 998-9[12] Albin H, Vincon G, Demotes-Mainard F, et al \"Effect of aluminium phosphate on the bioavailability of cimetidine and prednisolone.\" Eur J Clin Pharmacol 26 (1984): 271-3", "alternatives_a": "Tinidazole, Pantoprazole, Dexlansoprazole, Rabeprazole, Sucralfate, Bismuth subcitrate potassium, Metronidazole, Rifabutin, Esomeprazole, Clarithromycin, Vonoprazan, More", "alternatives_b": "Magnesium gluconate, Sodium sulfate, Zinc sulfate, Magnesium sulfate, Magnesium aspartate, Magnesium lactate, Magnesium citrate, Sodium chloride, Zinc gluconate, Magnesium chloride, Alvimopan, More", "updated_at": 1767369485}, {"id": 68665, "ingredient1": "Citric acid", "ingredient2": "Norfloxacin", "severity": "Moderate", "effect": "Urinary alkalinizers such as citrates may decrease the solubility of fluoroquinolones in the urine and increase the risk of crystalluria.", "source": "DDInter", "management_text": "Concomitant use should generally be avoided. Patients receiving this combination should be monitored for signs of renal toxicity and crystalluria.", "mechanism_text": "Excretion", "recommendation": "Concomitant use should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68752/", "reference_text": "[1] \"Multum Information Services, Inc. Expert Review Panel\"[2] \"Product Information. Cipro (ciprofloxacin).\" Bayer, West Haven, CT.", "alternatives_a": "Tinidazole, Tetracycline, Cefepime, Fluconazole, Metronidazole, Cefuroxime, Secnidazole, Cefixime, Azithromycin, Amikacin, Rifamycin, More", "alternatives_b": "Glutamic acid, Pancrelipase", "updated_at": 1767369485}, {"id": 68666, "ingredient1": "Picosulfuric acid", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; hydroxychloroquine; mefloquine), and some narcotic analgesics. The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that can prolong the QT interval, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; mefloquine; halofantrine; lumefantrine), and some narcotic analgesics (methadone; propoxyphene).", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68753/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[6] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[9] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[10] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[11] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[12] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[13] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[14] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[15] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "St. John's Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine", "alternatives_b": "Alvimopan, Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, Magnesium carbonate, More", "updated_at": 1767369485}, {"id": 68667, "ingredient1": "Picosulfuric acid", "ingredient2": "Novobiocin", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate. The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis. The clinical significance of this effect remains unknown.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic. If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Others", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68754/", "reference_text": "[1] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[3] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference) Available from: URL: http://www.mhra.gov.uk/spc-pil/index.htm.\"[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[6] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[7] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68668, "ingredient1": "Citric acid", "ingredient2": "Ofloxacin", "severity": "Moderate", "effect": "Urinary alkalinizers such as citrates may decrease the solubility of fluoroquinolones in the urine and increase the risk of crystalluria.", "source": "DDInter", "management_text": "Concomitant use should generally be avoided. Patients receiving this combination should be monitored for signs of renal toxicity and crystalluria.", "mechanism_text": "Excretion", "recommendation": "Concomitant use should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68755/", "reference_text": "[1] \"Multum Information Services, Inc. Expert Review Panel\"[2] \"Product Information. Cipro (ciprofloxacin).\" Bayer, West Haven, CT.", "alternatives_a": "Delafloxacin, Tinidazole, Tetracycline, Cefepime, Fluconazole, Metronidazole, Cefuroxime, Secnidazole, Cefixime, Azithromycin, Amikacin, More", "alternatives_b": "Glutamic acid, Pancrelipase", "updated_at": 1767369485}, {"id": 68669, "ingredient1": "Picosulfuric acid", "ingredient2": "Olanzapine", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline. Rare cases of generalized tonic-clonic seizures and/or loss of consciousness in association with low serum osmolality and electrolyte abnormalities (e.g., hyponatremia, hypokalemia, hypocalcemia, hypomagnesemia) have been reported with the use of bowel cleansing products in patients with no prior history of seizures. The condition resolved with correction of fluid and electrolyte abnormalities.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68756/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.[9] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.", "alternatives_a": "Alvimopan, Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, Magnesium carbonate, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68670, "ingredient1": "Picosulfuric acid", "ingredient2": "Oliceridine", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; hydroxychloroquine; mefloquine), and some narcotic analgesics. The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that can prolong the QT interval, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; mefloquine; halofantrine; lumefantrine), and some narcotic analgesics (methadone; propoxyphene).", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68757/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[6] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[9] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[10] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[11] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[12] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[13] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[14] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[15] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Naldemedine, More", "alternatives_b": "Dihydrocodeine, Acetaminophen, Naloxone, Naltrexone", "updated_at": 1767369485}, {"id": 68671, "ingredient1": "Picosulfuric acid", "ingredient2": "Olmesartan", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations. Fluid and electrolyte disturbances can lead to serious adverse events including cardiac arrhythmias, seizures, and renal impairment.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment. Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered. Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing. Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68758/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Diovan (valsartan).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Cozaar (losartan).\" Merck & Co, Inc, West Point, PA.[5] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[6] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Amlodipine, Sacubitril, Aliskiren, Nebivolol", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 68672, "ingredient1": "Omadacycline", "ingredient2": "Magnesium oxide", "severity": "Moderate", "effect": "INTERVAL: Administration of a tetracycline with aluminum, calcium, or magnesium salts significantly decreases tetracycline serum concentrations. The proposed mechanism is chelation of tetracycline by the cation, forming an insoluble complex that is poorly absorbed from the gastrointestinal tract. The interaction has also been reported with parenteral doxycycline and oral antacids.", "source": "DDInter", "management_text": "The administration of tetracyclines and preparations containing aluminum, magnesium, or calcium should be separated by two to four hours.", "mechanism_text": "Absorption", "recommendation": "The administration of tetracyclines and preparations containing aluminum, magnesium, or calcium should be separated by two to four hours.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68759/", "reference_text": "[1] Nguyen VX, Nix DE, Gillikin S, Schentag JJ \"Effect of oral antacid administration on the pharmacokinetics of intravenous doxycycline.\" Antimicrob Agents Chemother 33 (1989): 434-6[2] Gotz VP, Ryerson GG \"Evaluation of tetracycline on theophylline disposition in patients with chronic obstructive airways disease.\" Drug Intell Clin Pharm 20 (1986): 694-6[3] Upton RA \"Pharmacokinetic interactions between theophylline and other medication (Part I).\" Clin Pharmacokinet 20 (1991): 66-80[4] \"Product Information. Nuzyra (omadacycline).\" Paratek Pharmaceuticals, Inc., Boston, MA.[5] \"Product Information. Seysara (sarecycline).\" Allergan Inc, Irvine, CA.[6] McCormack JP, Reid SE, Lawson LM \"Theophylline toxicity induced by tetracycline.\" Clin Pharm 9 (1990): 546-9[7] Neuvonen PJ \"Interactions with the absorption of tetracyclines.\" Drugs 11 (1976): 45-54[8] D'Arcy PF, McElnay JC \"Drug-antacid interactions: assessment of clinical importance.\" Drug Intell Clin Pharm 21 (1987): 607-17[9] \"Product Information. Declomycin (demeclocycline).\" Lederle Laboratories, Wayne, NJ.[10] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[11] Garty M, Hurwitz A \"Effect of cimetidine and antacids on gastrointestinal absorption of tetracycline.\" Clin Pharmacol Ther 28 (1980): 203-7[12] Deppermann KM, Lode H, Hoffken G, Tschink G, Kalz C, Koeppe P \"Influence of ranitidine, pirenzepine, and aluminum magnesium hydroxide on the bioavailability of various antibiotics, including amoxicillin, cephalexin, doxycycline, and amoxicillin-clavulanic acid.\" Antimicrob Agents Chemother 33 (1989): 1901-7[13] Covington TR, Lawson LC, Young LL, eds. \"Handbook of Nonprescription Drugs. 10th ed.\" Washington, DC: American Pharmaceutical Association (1993):[14] \"Product Information. Achromycin (tetracycline).\" Lederle Laboratories, Wayne, NJ.[15] \"Product Information. Declomycin (demeclocycline).\" Lederle Laboratories, Wayne, NJ.", "alternatives_a": "Sodium chloride, Sodium sulfate, Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, More", "alternatives_b": "Tigecycline, Eravacycline", "updated_at": 1767369485}, {"id": 68673, "ingredient1": "Picosulfuric acid", "ingredient2": "Ondansetron", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia are known risk factors for torsade de pointes associated with QT interval prolongation.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68760/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[5] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[8] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[9] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[10] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[11] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Aprepitant, Scopolamine, Nabilone, Rolapitant", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Naldemedine, Prucalopride, More", "updated_at": 1767369485}, {"id": 68674, "ingredient1": "Picosulfuric acid", "ingredient2": "Opium", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline. Rare cases of generalized tonic-clonic seizures and/or loss of consciousness in association with low serum osmolality and electrolyte abnormalities (e.g., hyponatremia, hypokalemia, hypocalcemia, hypomagnesemia) have been reported with the use of bowel cleansing products in patients with no prior history of seizures. The condition resolved with correction of fluid and electrolyte abnormalities.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68761/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.[9] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.", "alternatives_a": "Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, More", "alternatives_b": "Loperamide, Eluxadoline, Diphenoxylate, Difenoxin, Dihydrocodeine, Acetaminophen, Naloxone, Naltrexone", "updated_at": 1767369485}, {"id": 68675, "ingredient1": "Picosulfuric acid", "ingredient2": "Oritavancin", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate. The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis. The clinical significance of this effect remains unknown.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic. If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Others", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68762/", "reference_text": "[1] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[3] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference) Available from: URL: http://www.mhra.gov.uk/spc-pil/index.htm.\"[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[6] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[7] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Tinidazole", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, More", "updated_at": 1767369485}, {"id": 68676, "ingredient1": "Picosulfuric acid", "ingredient2": "Osilodrostat", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia are known risk factors for torsade de pointes associated with QT interval prolongation.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68763/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[5] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[8] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[9] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[10] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[11] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Prucalopride, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68677, "ingredient1": "Picosulfuric acid", "ingredient2": "Osimertinib", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia are known risk factors for torsade de pointes associated with QT interval prolongation.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68764/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[5] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[8] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[9] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[10] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[11] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "alternatives_b": "Imatinib, Dabrafenib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Selumetinib, Cobimetinib, More", "updated_at": 1767369485}, {"id": 68678, "ingredient1": "Picosulfuric acid", "ingredient2": "Oxacillin", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate. The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis. The clinical significance of this effect remains unknown.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic. If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Others", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68765/", "reference_text": "[1] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[3] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference) Available from: URL: http://www.mhra.gov.uk/spc-pil/index.htm.\"[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[6] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[7] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Tazobactam, Sulbactam", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, More", "updated_at": 1767369485}, {"id": 68679, "ingredient1": "Picosulfuric acid", "ingredient2": "Oxaliplatin", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia are known risk factors for torsade de pointes associated with QT interval prolongation.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68766/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[5] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[8] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[9] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[10] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[11] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Pertuzumab, Olaparib, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 68680, "ingredient1": "Picosulfuric acid", "ingredient2": "Oxamniquine", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline. Rare cases of generalized tonic-clonic seizures and/or loss of consciousness in association with low serum osmolality and electrolyte abnormalities (e.g., hyponatremia, hypokalemia, hypocalcemia, hypomagnesemia) have been reported with the use of bowel cleansing products in patients with no prior history of seizures. The condition resolved with correction of fluid and electrolyte abnormalities.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68767/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.[9] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.", "alternatives_a": "Praziquantel", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 68681, "ingredient1": "Picosulfuric acid", "ingredient2": "Oxaprozin", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations. Fluid and electrolyte disturbances can lead to serious adverse events including cardiac arrhythmias, seizures, and renal impairment.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment. Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered. Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing. Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68768/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Diovan (valsartan).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Cozaar (losartan).\" Merck & Co, Inc, West Point, PA.[5] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[6] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole", "alternatives_b": "Alvimopan, Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Magnesium carbonate, More", "updated_at": 1767369485}, {"id": 68682, "ingredient1": "Oxazepam", "ingredient2": "Magnesium oxide", "severity": "Minor", "effect": "number of studies have reported that antacids can delay the gastrointestinal absorption and reduce the peak plasma concentration (Cmax) of some benzodiazepines, including clorazepate, chlordiazepoxide and diazepam, although the overall extent of absorption is generally not affected. The exact mechanism of interaction is unknown, but may involve delayed gastric emptying or cation binding of the benzodiazepine.", "source": "DDInter", "management_text": "-", "mechanism_text": "Absorption", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68769/", "reference_text": "[1] Greenblatt DJ, Allen MD, MacLaughlin DS, Harmatz JS, Shader RI \"Diazepam absorption: effect of antacids and food.\" Clin Pharmacol Ther 24 (1978): 600-9[2] Kroboth PD, Smith RB, Silver MR, Rault R, Sorkin MI, Puschett JB, Juhl RP \"Effects of end stage renal disease and aluminium hydroxide on triazolam pharmacokinetics.\" Br J Clin Pharmacol 19 (1985): 839-42[3] Greenblatt DJ, Shader RI, Harmatz JS, Franke K, Koch-Weser J \"Absorption rate, blood concentrations, and early response to oral chlordiazepoxide.\" Am J Psychiatry 134 (1977): 559-62[4] Shader RI, Ciraulo DA, Greenblatt DJ, Harmatz JS \"Steady-state plasma desmethyldiazepam during long-term clorazepate use: effects of antacids.\" Clin Pharmacol Ther 31 (1982): 180-3[5] Greenblatt DJ, Shader RI, Harmatz JS, Franke K, Koch-Weser J \"Influence of magnesium and aluminum hydroxide mixture on chlordiazepoxide absorption.\" Clin Pharmacol Ther 19 (1976): 234-9[6] Kroboth PD, Smith RB, Rault R, Silver MR, Sorkin MI, Puschett JB, Juhl RP \"Effects of end-stage renal disease and aluminum hydroxide on temazepam kinetics.\" Clin Pharmacol Ther 37 (1985): 453-9[7] Chun AH, Carrigan PJ, Hoffman DJ, Kershner RP, Stuart JD \"Effect of antacids on absorption of clorazepate.\" Clin Pharmacol Ther 22 (1977): 329-35[8] Nair SG, Gamble JA, Dundee JW, Howard PJ \"The influence of three antacids on the absorption and clinical action of oral diazepam.\" Br J Anaesth 48 (1976): 1175-80[9] Shader RI, Georgotas A, Greenblatt DJ, Harmatz JS, Allen MD \"Impaired absorption of desmethyldiazepam from clorazepate by magnesium aluminum hydroxide.\" Clin Pharmacol Ther 24 (1978): 308-15[10] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[11] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[12] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[13] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Meprobamate, Buspirone, Hydroxyzine", "alternatives_b": "Magnesium gluconate, Sodium sulfate, Zinc sulfate, Magnesium sulfate, Magnesium aspartate, Magnesium lactate, Magnesium citrate, Sodium chloride, Zinc gluconate, Magnesium chloride, Alvimopan, More", "updated_at": 1767369485}, {"id": 68683, "ingredient1": "Picosulfuric acid", "ingredient2": "Oxtriphylline", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline. Rare cases of generalized tonic-clonic seizures and/or loss of consciousness in association with low serum osmolality and electrolyte abnormalities (e.g., hyponatremia, hypokalemia, hypocalcemia, hypomagnesemia) have been reported with the use of bowel cleansing products in patients with no prior history of seizures. The condition resolved with correction of fluid and electrolyte abnormalities.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68770/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.[9] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.", "alternatives_a": "Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Montelukast, Dyphylline, Mepolizumab, Roflumilast, Pentoxifylline, More", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 68684, "ingredient1": "Picosulfuric acid", "ingredient2": "Oxycodone", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline. Rare cases of generalized tonic-clonic seizures and/or loss of consciousness in association with low serum osmolality and electrolyte abnormalities (e.g., hyponatremia, hypokalemia, hypocalcemia, hypomagnesemia) have been reported with the use of bowel cleansing products in patients with no prior history of seizures. The condition resolved with correction of fluid and electrolyte abnormalities.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68771/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.[9] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.", "alternatives_a": "Dihydrocodeine, Acetaminophen, Naloxone, Naltrexone", "alternatives_b": "Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, Magnesium carbonate, Plecanatide, More", "updated_at": 1767369485}, {"id": 68685, "ingredient1": "Picosulfuric acid", "ingredient2": "Oxymorphone", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline. Rare cases of generalized tonic-clonic seizures and/or loss of consciousness in association with low serum osmolality and electrolyte abnormalities (e.g., hyponatremia, hypokalemia, hypocalcemia, hypomagnesemia) have been reported with the use of bowel cleansing products in patients with no prior history of seizures. The condition resolved with correction of fluid and electrolyte abnormalities.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68772/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.[9] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.", "alternatives_a": "Dihydrocodeine, Acetaminophen, Naloxone, Naltrexone", "alternatives_b": "Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, More", "updated_at": 1767369485}, {"id": 68686, "ingredient1": "Oxytetracycline", "ingredient2": "Magnesium oxide", "severity": "Moderate", "effect": "INTERVAL: Administration of a tetracycline with aluminum, calcium, or magnesium salts significantly decreases tetracycline serum concentrations. The proposed mechanism is chelation of tetracycline by the cation, forming an insoluble complex that is poorly absorbed from the gastrointestinal tract. The interaction has also been reported with parenteral doxycycline and oral antacids.", "source": "DDInter", "management_text": "The administration of tetracyclines and preparations containing aluminum, magnesium, or calcium should be separated by two to four hours.", "mechanism_text": "Absorption", "recommendation": "The administration of tetracyclines and preparations containing aluminum, magnesium, or calcium should be separated by two to four hours.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68773/", "reference_text": "[1] Nguyen VX, Nix DE, Gillikin S, Schentag JJ \"Effect of oral antacid administration on the pharmacokinetics of intravenous doxycycline.\" Antimicrob Agents Chemother 33 (1989): 434-6[2] Gotz VP, Ryerson GG \"Evaluation of tetracycline on theophylline disposition in patients with chronic obstructive airways disease.\" Drug Intell Clin Pharm 20 (1986): 694-6[3] Upton RA \"Pharmacokinetic interactions between theophylline and other medication (Part I).\" Clin Pharmacokinet 20 (1991): 66-80[4] \"Product Information. Nuzyra (omadacycline).\" Paratek Pharmaceuticals, Inc., Boston, MA.[5] \"Product Information. Seysara (sarecycline).\" Allergan Inc, Irvine, CA.[6] McCormack JP, Reid SE, Lawson LM \"Theophylline toxicity induced by tetracycline.\" Clin Pharm 9 (1990): 546-9[7] Neuvonen PJ \"Interactions with the absorption of tetracyclines.\" Drugs 11 (1976): 45-54[8] D'Arcy PF, McElnay JC \"Drug-antacid interactions: assessment of clinical importance.\" Drug Intell Clin Pharm 21 (1987): 607-17[9] \"Product Information. Declomycin (demeclocycline).\" Lederle Laboratories, Wayne, NJ.[10] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[11] Garty M, Hurwitz A \"Effect of cimetidine and antacids on gastrointestinal absorption of tetracycline.\" Clin Pharmacol Ther 28 (1980): 203-7[12] Deppermann KM, Lode H, Hoffken G, Tschink G, Kalz C, Koeppe P \"Influence of ranitidine, pirenzepine, and aluminum magnesium hydroxide on the bioavailability of various antibiotics, including amoxicillin, cephalexin, doxycycline, and amoxicillin-clavulanic acid.\" Antimicrob Agents Chemother 33 (1989): 1901-7[13] Covington TR, Lawson LC, Young LL, eds. \"Handbook of Nonprescription Drugs. 10th ed.\" Washington, DC: American Pharmaceutical Association (1993):[14] \"Product Information. Achromycin (tetracycline).\" Lederle Laboratories, Wayne, NJ.[15] \"Product Information. Declomycin (demeclocycline).\" Lederle Laboratories, Wayne, NJ.", "alternatives_a": "Tigecycline, Eravacycline, Rifamycin, Kanamycin, Ampicillin, Azithromycin, Acyclovir, Netilmicin, Polymyxin B, Famciclovir, Trifluridine, More", "alternatives_b": "Sodium chloride, Sodium sulfate, Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, More", "updated_at": 1767369485}, {"id": 68687, "ingredient1": "Picosulfuric acid", "ingredient2": "Oxytocin", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia are known risk factors for torsade de pointes associated with QT interval prolongation.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68774/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[5] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[8] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[9] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[10] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[11] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Methylergometrine, Misoprostol, Ergometrine, Dinoprostone, Terlipressin, Desmopressin", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 68688, "ingredient1": "Picosulfuric acid", "ingredient2": "Ozanimod", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia are known risk factors for torsade de pointes associated with QT interval prolongation.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68775/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[5] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[8] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[9] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[10] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[11] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Sodium phosphate, monobasic, Lubiprostone, Methylcellulose, More", "alternatives_b": "Golimumab, Cyclosporine, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, More", "updated_at": 1767369485}, {"id": 68689, "ingredient1": "Picosulfuric acid", "ingredient2": "Paliperidone", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; hydroxychloroquine; mefloquine), and some narcotic analgesics. The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that can prolong the QT interval, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; mefloquine; halofantrine; lumefantrine), and some narcotic analgesics (methadone; propoxyphene).", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68776/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[6] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[9] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[10] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[11] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[12] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[13] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[14] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[15] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68690, "ingredient1": "Picosulfuric acid", "ingredient2": "Palonosetron", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia are known risk factors for torsade de pointes associated with QT interval prolongation.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68777/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[5] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[8] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[9] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[10] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[11] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Aprepitant, Scopolamine, Nabilone, Rolapitant", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Naldemedine, More", "updated_at": 1767369485}, {"id": 68691, "ingredient1": "Picosulfuric acid", "ingredient2": "Panobinostat", "severity": "Major", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval. Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly. Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68778/", "reference_text": "[1] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[2] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[9] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[10] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[11] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[12] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[13] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Pertuzumab, Olaparib, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 68692, "ingredient1": "Paricalcitol", "ingredient2": "Magnesium oxide", "severity": "Moderate", "effect": "Use of magnesium-containing products with a vitamin D analog may increase the risk of hypermagnesemia, particularly in chronic renal dialysis patients, due to potentially additive pharmacologic effects. Chronic hypermagnesemia may have a role in the pathogenesis of adynamic bone disease in dialysis patients.", "source": "DDInter", "management_text": "Patients on chronic renal dialysis treated with a vitamin D analog should avoid magnesium-containing products.", "mechanism_text": "Synergism", "recommendation": "Patients on chronic renal dialysis treated with a vitamin D analog should avoid magnesium-containing products.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68779/", "reference_text": "[1] \"Product Information. Zemplar (paricalcitol).\" Abbott Pharmaceutical, Abbott Park, IL.[2] \"Product Information. One-Alpha (alfacalcidol).\" Pharmel Inc, Montreal, IN.[3] \"Product Information. Rocaltrol (calcitriol).\" Roche Laboratories, Nutley, NJ.[4] \"Product Information. Hectorol (doxercalciferol).\" Genzyme Corporation, Cambridge, MA.", "alternatives_a": "Etelcalcetide, Cinacalcet, Salmon calcitonin", "alternatives_b": "Magaldrate, Calcium carbonate, Zinc gluconate, Sodium sulfate, Zinc sulfate, Sodium chloride, Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, More", "updated_at": 1767369485}, {"id": 68693, "ingredient1": "Picosulfuric acid", "ingredient2": "Paromomycin", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate. The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis. The clinical significance of this effect remains unknown.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic. If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Others", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68780/", "reference_text": "[1] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[3] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference) Available from: URL: http://www.mhra.gov.uk/spc-pil/index.htm.\"[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[6] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[7] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Nystatin, Amphotericin B, Miconazole", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, More", "updated_at": 1767369485}, {"id": 68694, "ingredient1": "Picosulfuric acid", "ingredient2": "Paroxetine", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline. Rare cases of generalized tonic-clonic seizures and/or loss of consciousness in association with low serum osmolality and electrolyte abnormalities (e.g., hyponatremia, hypokalemia, hypocalcemia, hypomagnesemia) have been reported with the use of bowel cleansing products in patients with no prior history of seizures. The condition resolved with correction of fluid and electrolyte abnormalities.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68781/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.[9] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.", "alternatives_a": "St. John's Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine", "alternatives_b": "Alvimopan, Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, Magnesium carbonate, More", "updated_at": 1767369485}, {"id": 68695, "ingredient1": "Picosulfuric acid", "ingredient2": "Pasireotide", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia are known risk factors for torsade de pointes associated with QT interval prolongation.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68782/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[5] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[8] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[9] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[10] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[11] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Norethisterone, Nafarelin, Octreotide, Elagolix, Cetrorelix, Estradiol, Ganirelix, Lanreotide, Gonadorelin", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 68696, "ingredient1": "Patiromer", "ingredient2": "Magnesium oxide", "severity": "Major", "effect": "Systemic alkalosis has been reported when cation-exchange resins were administered orally in combination with nonabsorbable cation-donating preparations such as antacids or laxatives. The mechanism involves binding of the cation to the resin, which prevents the cation from neutralizing bicarbonate ions in the intestine and also interferes with the resin's potassium exchange capability.", "source": "DDInter", "management_text": "Nonabsorbable calcium, magnesium, or aluminum preparations such as antacids or laxatives should not be used in patients receiving oral cation-exchange resins. Alternatively, the interaction may be avoided by administering the resin as an enema.", "mechanism_text": "Others", "recommendation": "Nonabsorbable calcium, magnesium, or aluminum preparations such as antacids or laxatives should not be used in patients receiving oral cation-exchange resins.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68783/", "reference_text": "[1] Ziessman HA \"Alkalosis and seizure due to a cation-exchange resin and magnesium hydroxide.\" South Med J 69 (1976): 497-9[2] Madias NE, Levey AS \"Metabolic alkalosis due to absorption of \"nonabsorbable\" antacids.\" Am J Med 74 (1983): 155-8[3] \"Product Information. Resonium Calcium (calcium polystyrene sulfonate).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[4] \"Product Information. Kayexalate (sodium polystyrene sulfonate).\" Sanofi Winthrop Pharmaceuticals, New York, NY.[5] Baluarte HJ, Prebis J, Goldberg M, Gruskin AB \"Metabolic alkalosis in an anephric child caused by the combined use of Kayexalate and Basaljel.\" J Pediatr 92 (1978): 237-9[6] Foresti V \"Intestinal obstruction due to kayexalate in a patient concurrently treated with aluminum hydroxide and morphine sulfate.\" Clin Nephrol 41 (1994): 252[7] \"Product Information. Kayexalate (sodium polystyrene sulfonate).\" Sanofi Winthrop Pharmaceuticals, New York, NY.[8] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Sodium chloride, Sodium sulfate, Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68697, "ingredient1": "Pazopanib", "ingredient2": "Magnesium oxide", "severity": "Moderate", "effect": "Coadministration with drugs that increase gastric pH may significantly decrease the oral bioavailability of pazopanib and reduce its concentrations in plasma. The solubility of pazopanib is pH-dependent, thus an increase in pH may interfere with its absorption.", "source": "DDInter", "management_text": "Concomitant use of pazopanib with drugs that increase gastric pH should generally be avoided. If acid-suppression therapy is required, short-acting antacids should be considered, with dosing separated by several hours from pazopanib dosing.", "mechanism_text": "Absorption", "recommendation": "Concomitant use of pazopanib with drugs that increase gastric pH should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68784/", "reference_text": "[1] van Leeuwen RW, van Gelder T, Mathijssen RH, Jansman FG \"Drug-drug interactions with tyrosine-kinase inhibitors: a clinical perspective.\" Lancet Oncol 15 (2014): e315-e326[2] Yu G, Zheng QS, Wang DX, Zhou HH, Li GF \"Drug interactions between tyrosine-kinase inhibitors and acid suppressive agents: more than meets the eye.\" Lancet Oncol 15 (2014): e469-70[3] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Tan AR, Gibbon DG, Stein MN, et al. \"Effects of ketoconazole and esomeprazole on the pharmacokinetics of pazopanib in patients with solid tumors.\" Cancer Chemother Pharmacol 71 (2013): 1635-43[6] \"Product Information. Votrient (pazopanib).\" GlaxoSmithKline, Research Triangle Park, NC.[7] \"Product Information. Votrient (pazopanib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Magnesium gluconate, Zinc sulfate, Magnesium sulfate, Magnesium aspartate, Magnesium lactate, Sodium chloride, Zinc gluconate, Magnesium chloride, Alvimopan, Sorbitol, Magnesium sulfate, More", "alternatives_b": "Entrectinib, Imatinib, Pralsetinib, Asciminib, Dacomitinib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Vemurafenib, More", "updated_at": 1767369485}, {"id": 68698, "ingredient1": "Picosulfuric acid", "ingredient2": "Peginterferon alfa-2a", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline. Rare cases of generalized tonic-clonic seizures and/or loss of consciousness in association with low serum osmolality and electrolyte abnormalities (e.g., hyponatremia, hypokalemia, hypocalcemia, hypomagnesemia) have been reported with the use of bowel cleansing products in patients with no prior history of seizures. The condition resolved with correction of fluid and electrolyte abnormalities.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68785/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.[9] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.", "alternatives_a": "Oprelvekin, Sipuleucel-T, Elapegademase, Ropeginterferon alfa-2b, Sargramostim, Histamine, Pegademase, Pegfilgrastim, Filgrastim, Glatiramer", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 68699, "ingredient1": "Picosulfuric acid", "ingredient2": "Peginterferon alfa-2b", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline. Rare cases of generalized tonic-clonic seizures and/or loss of consciousness in association with low serum osmolality and electrolyte abnormalities (e.g., hyponatremia, hypokalemia, hypocalcemia, hypomagnesemia) have been reported with the use of bowel cleansing products in patients with no prior history of seizures. The condition resolved with correction of fluid and electrolyte abnormalities.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68786/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.[9] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.", "alternatives_a": "Oprelvekin, Sipuleucel-T, Elapegademase, Ropeginterferon alfa-2b, Sargramostim, Histamine, Pegademase, Pegfilgrastim, Filgrastim, Glatiramer", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 68700, "ingredient1": "Picosulfuric acid", "ingredient2": "Peginterferon beta-1a", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline. Rare cases of generalized tonic-clonic seizures and/or loss of consciousness in association with low serum osmolality and electrolyte abnormalities (e.g., hyponatremia, hypokalemia, hypocalcemia, hypomagnesemia) have been reported with the use of bowel cleansing products in patients with no prior history of seizures. The condition resolved with correction of fluid and electrolyte abnormalities.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68787/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.[9] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.", "alternatives_a": "Oprelvekin, Sipuleucel-T, Elapegademase, Ropeginterferon alfa-2b, Sargramostim, Histamine, Pegademase, Pegfilgrastim, Filgrastim, Glatiramer", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 68701, "ingredient1": "Picosulfuric acid", "ingredient2": "Pemoline", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline. Rare cases of generalized tonic-clonic seizures and/or loss of consciousness in association with low serum osmolality and electrolyte abnormalities (e.g., hyponatremia, hypokalemia, hypocalcemia, hypomagnesemia) have been reported with the use of bowel cleansing products in patients with no prior history of seizures. The condition resolved with correction of fluid and electrolyte abnormalities.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68788/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.[9] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.", "alternatives_a": "Solriamfetol, Caffeine, Armodafinil, Citicoline, Modafinil", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 68702, "ingredient1": "Penbutolol", "ingredient2": "Magnesium oxide", "severity": "Minor", "effect": "Concurrent administration with aluminum and magnesium antacids has been shown to decrease the oral bioavailability of certain beta-blockers, although data are conflicting. The exact mechanism of interaction is unknown but may involve cation binding of beta-blockers or a reduction in the dissolution rate due to increased gastric pH. Based on available data, the clinical significance of this potential interaction is difficult to determine. As a precaution, patients may want to consider separating the administration times of beta-blockers and antacids or other aluminum- or magnesium-containing products by at least 2 hours.", "source": "DDInter", "management_text": "-", "mechanism_text": "Absorption", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68789/", "reference_text": "[1] D'Arcy PF, McElnay JC \"Drug-antacid interactions: assessment of clinical importance.\" Drug Intell Clin Pharm 21 (1987): 607-17[2] Regardh CG, Lundborg P, Persson BA \"The effect of antacid, metoclopramide, and propantheline on the bioavailability of metoprolol and atenolol.\" Biopharm Drug Dispos 2 (1981): 79-87[3] Hong CY, Hu SC, Lin SJ, Chiang BN \"Lack of influence of aluminum hydroxide on the bioavailability and beta-adrenoceptor blocking activity of propranolol.\" Int J Clin Pharmacol Ther Toxicol 23 (1985): 244-6[4] Kirch W, Schafer-Korting M, Axthelm T, Kohler H, Mutschler E \"Interaction of atenolol with furosemide and calcium and aluminum salts.\" Clin Pharmacol Ther 30 (1981): 429-35[5] Laer S, Neumann J, Scholz H \"Interaction between sotalol and an antacid preparation.\" Br J Clin Pharmacol 43 (1997): 269-72[6] Gugler R, Allgayer H \"Effects of antacids on the clinical pharmacokinetics of drugs. An update.\" Clin Pharmacokinet 18 (1990): 210-9[7] Dobbs JH, Skoutakis VA, Acchiardo SR, Dobbs BR \"Effects of aluminum hydroxide on the absorption of propranolol.\" Curr Ther Res Clin Exp 21 (1977): 887-92", "alternatives_a": "Esmolol", "alternatives_b": "Magnesium gluconate, Sodium sulfate, Zinc sulfate, Magnesium sulfate, Magnesium aspartate, Magnesium lactate, Magnesium citrate, Sodium chloride, Zinc gluconate, Magnesium chloride, Alvimopan, More", "updated_at": 1767369485}, {"id": 68703, "ingredient1": "Penicillamine", "ingredient2": "Magnesium oxide", "severity": "Moderate", "effect": "INTERVAL: Oral administration of aluminum, copper, iron, zinc, magnesium, and possibly other minerals such as calcium may decrease the gastrointestinal absorption of penicillamine, and vice versa. The proposed mechanism involves chelation of penicillamine to polyvalent cations, which leads to formation of a nonabsorbable complex.", "source": "DDInter", "management_text": "Mineral supplements or other products containing polyvalent cations (e.g., antacids or preparations containing antacids such as didanosine buffered tablets or pediatric oral solution) should be administered at least two hours before or two hours after the penicillamine dose. In addition, pharmacologic response to penicillamine should be monitored more closely whenever these products are added to or withdrawn from therapy, and the penicillamine dosage adjusted as necessary.", "mechanism_text": "Absorption", "recommendation": "Mineral supplements or other products containing polyvalent cations (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68790/", "reference_text": "[1] Lyle WH \"Penicillamine and iron.\" Lancet 2 (1976): 420[2] \"Product Information. Cuprimine (penicillamine).\" Merck & Co, Inc, West Point, PA.[3] Netter P, Bannwarth B, Pere P, Nicolas A \"Clinical pharmacokinetics of D-penicillamine.\" Clin Pharmacokinet 13 (1987): 317-33[4] Haagsma CJ \"Clinically important drug interactions with disease-modifying antirheumatic drugs.\" Drugs Aging 13 (1998): 281-9[5] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[6] Joyce DA \"D-penicillamine pharmacokinetics and pharmacodynamics in man.\" Pharmacol Ther 42 (1989): 405-27[7] Osman MA, Patel RB, Schuna A, Sundstrom WR, Welling PG \"Reduction in oral penicillamine absorption by food, antacid and ferrous sulfate.\" Clin Pharmacol Ther 33 (1983): 465-70[8] Harkness JA, Blake DR \"Penicillamine nephropathy and iron.\" Lancet 2 (1982): 1368-9[9] Osman MA, Patel RB, Schuna A, Sundstrom WR, Welling PG \"Reduction in oral penicillamine absorption by food, antacid and ferrous sulfate.\" Clin Pharmacol Ther 33 (1983): 465-70[10] \"Product Information. Cuprimine (penicillamine).\" Merck & Co, Inc, West Point, PA.[11] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67", "alternatives_a": "Auranofin, Aurothioglucose, Sodium aurothiomalate", "alternatives_b": "Sodium chloride, Sodium sulfate, Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, More", "updated_at": 1767369485}, {"id": 68704, "ingredient1": "Benzylpenicillin", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate. The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis. The clinical significance of this effect remains unknown.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic. If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Others", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68791/", "reference_text": "[1] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[3] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference) Available from: URL: http://www.mhra.gov.uk/spc-pil/index.htm.\"[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[6] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[7] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Tazobactam, Sulbactam, Ganciclovir, Acyclovir, Famciclovir, Trifluridine, Chlorhexidine, Povidone-iodine", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, More", "updated_at": 1767369485}, {"id": 68705, "ingredient1": "Benzylpenicillin (potassium)", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate. The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis. The clinical significance of this effect remains unknown.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic. If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Others", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68792/", "reference_text": "[1] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[3] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference) Available from: URL: http://www.mhra.gov.uk/spc-pil/index.htm.\"[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[6] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[7] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Tazobactam, Sulbactam, Ganciclovir, Acyclovir, Famciclovir, Trifluridine, Chlorhexidine, Povidone-iodine", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, More", "updated_at": 1767369485}, {"id": 68706, "ingredient1": "Benzylpenicillin (sodium)", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate. The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis. The clinical significance of this effect remains unknown.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic. If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Others", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68793/", "reference_text": "[1] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[3] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference) Available from: URL: http://www.mhra.gov.uk/spc-pil/index.htm.\"[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[6] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[7] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Tazobactam, Sulbactam, Ganciclovir, Acyclovir, Famciclovir, Trifluridine, Chlorhexidine, Povidone-iodine", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, More", "updated_at": 1767369485}, {"id": 68707, "ingredient1": "Picosulfuric acid", "ingredient2": "Phenoxymethylpenicillin", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate. The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis. The clinical significance of this effect remains unknown.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic. If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Others", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68794/", "reference_text": "[1] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[3] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference) Available from: URL: http://www.mhra.gov.uk/spc-pil/index.htm.\"[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[6] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[7] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Tazobactam, Sulbactam", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, More", "updated_at": 1767369485}, {"id": 68708, "ingredient1": "Picosulfuric acid", "ingredient2": "Pentamidine", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia are known risk factors for torsade de pointes associated with QT interval prolongation.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68795/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[5] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[8] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[9] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[10] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[11] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Miltefosine, Nifurtimox", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 68709, "ingredient1": "Picosulfuric acid", "ingredient2": "Pentazocine", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline. Rare cases of generalized tonic-clonic seizures and/or loss of consciousness in association with low serum osmolality and electrolyte abnormalities (e.g., hyponatremia, hypokalemia, hypocalcemia, hypomagnesemia) have been reported with the use of bowel cleansing products in patients with no prior history of seizures. The condition resolved with correction of fluid and electrolyte abnormalities.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68796/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.[9] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.", "alternatives_a": "Dihydrocodeine, Acetaminophen, Naloxone, Naltrexone", "alternatives_b": "Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, More", "updated_at": 1767369485}, {"id": 68710, "ingredient1": "Picosulfuric acid", "ingredient2": "Perflutren", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia are known risk factors for torsade de pointes associated with QT interval prolongation.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68797/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[5] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[8] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[9] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[10] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[11] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68711, "ingredient1": "Picosulfuric acid", "ingredient2": "Perindopril", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations. Fluid and electrolyte disturbances can lead to serious adverse events including cardiac arrhythmias, seizures, and renal impairment.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment. Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered. Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing. Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68798/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Diovan (valsartan).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Cozaar (losartan).\" Merck & Co, Inc, West Point, PA.[5] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[6] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Felodipine, Amlodipine, Verapamil, Bisoprolol, Amlodipine, Atorvastatin, Simvastatin, Lovastatin, Rosuvastatin, Niacin, Pravastatin, More", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Prucalopride, Linaclotide, Plecanatide, More", "updated_at": 1767369485}, {"id": 68712, "ingredient1": "Picosulfuric acid", "ingredient2": "Perphenazine", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; hydroxychloroquine; mefloquine), and some narcotic analgesics. The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that can prolong the QT interval, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; mefloquine; halofantrine; lumefantrine), and some narcotic analgesics (methadone; propoxyphene).", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68799/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[6] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[9] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[10] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[11] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[12] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[13] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[14] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[15] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Naldemedine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68713, "ingredient1": "Pexidartinib", "ingredient2": "Magnesium oxide", "severity": "Moderate", "effect": "INTERVAL: Coadministration with acid-reducing agents may significantly decrease the bioavailability and therapeutic effects of pexidartinib. The proposed mechanism is a pH-dependent reduction in drug dissolution and/or absorption. The effect of coadministration with an H2-receptor antagonist or locally-acting antacids on pexidartinib pharmacokinetics is unknown.", "source": "DDInter", "management_text": "If acid-suppression therapy is required, pexidartinib may be administered 2 hours before or 2 hours after taking a locally-acting antacid, or if using an H2-receptor antagonist, administer pexidartinib at least 2 hours before or 10 hours after taking the H2-receptor antagonist. Concomitant use of pexidartinib with proton pump inhibitors should be avoided.", "mechanism_text": "Absorption", "recommendation": "If acid-suppression therapy is required, pexidartinib may be administered 2 hours before or 2 hours after taking a locally-acting antacid, or if using an H2-receptor antagonist, administer pexidartinib at least 2 hours before or 10 hours after taking the H2-receptor antagonist.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68800/", "reference_text": "[1] \"Product Information. Turalio (pexidartinib).\" Daiichi Sankyo, Inc., Parsippany, NJ.[2] \"Product Information. Turalio (pexidartinib).\" Daiichi Sankyo, Inc., Parsippany, NJ.", "alternatives_a": "Magnesium hydroxide, Magnesium gluconate, Sodium sulfate, Zinc sulfate, Magnesium sulfate, Magnesium aspartate, Magnesium lactate, Magnesium citrate, Sodium chloride, Zinc gluconate, Magnesium chloride, More", "alternatives_b": "Entrectinib, Imatinib, Pralsetinib, Asciminib, Dacomitinib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Vemurafenib, More", "updated_at": 1767369485}, {"id": 68714, "ingredient1": "Picosulfuric acid", "ingredient2": "Phendimetrazine", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline. Rare cases of generalized tonic-clonic seizures and/or loss of consciousness in association with low serum osmolality and electrolyte abnormalities (e.g., hyponatremia, hypokalemia, hypocalcemia, hypomagnesemia) have been reported with the use of bowel cleansing products in patients with no prior history of seizures. The condition resolved with correction of fluid and electrolyte abnormalities.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68801/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.[9] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.", "alternatives_a": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68715, "ingredient1": "Picosulfuric acid", "ingredient2": "Phenelzine", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline. Rare cases of generalized tonic-clonic seizures and/or loss of consciousness in association with low serum osmolality and electrolyte abnormalities (e.g., hyponatremia, hypokalemia, hypocalcemia, hypomagnesemia) have been reported with the use of bowel cleansing products in patients with no prior history of seizures. The condition resolved with correction of fluid and electrolyte abnormalities.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68802/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.[9] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.", "alternatives_a": "St. John's Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 68716, "ingredient1": "Picosulfuric acid", "ingredient2": "Phentermine", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline. Rare cases of generalized tonic-clonic seizures and/or loss of consciousness in association with low serum osmolality and electrolyte abnormalities (e.g., hyponatremia, hypokalemia, hypocalcemia, hypomagnesemia) have been reported with the use of bowel cleansing products in patients with no prior history of seizures. The condition resolved with correction of fluid and electrolyte abnormalities.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68803/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.[9] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.", "alternatives_a": "Lorcaserin, Orlistat, Naltrexone", "alternatives_b": "Alvimopan, Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, More", "updated_at": 1767369485}, {"id": 68717, "ingredient1": "Picosulfuric acid", "ingredient2": "Phenylbutazone", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations. Fluid and electrolyte disturbances can lead to serious adverse events including cardiac arrhythmias, seizures, and renal impairment.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment. Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered. Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing. Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68804/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Diovan (valsartan).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Cozaar (losartan).\" Merck & Co, Inc, West Point, PA.[5] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[6] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole, Tolazoline, Rabeprazole, Dimethyl sulfoxide", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Magnesium carbonate, More", "updated_at": 1767369485}, {"id": 68718, "ingredient1": "Picosulfuric acid", "ingredient2": "Phenylpropanolamine", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline. Rare cases of generalized tonic-clonic seizures and/or loss of consciousness in association with low serum osmolality and electrolyte abnormalities (e.g., hyponatremia, hypokalemia, hypocalcemia, hypomagnesemia) have been reported with the use of bowel cleansing products in patients with no prior history of seizures. The condition resolved with correction of fluid and electrolyte abnormalities.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68805/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.[9] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.", "alternatives_a": "Pseudoephedrine, Phenylephrine", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 68719, "ingredient1": "Phenytoin", "ingredient2": "Magnesium oxide", "severity": "Moderate", "effect": "INTERVAL: Concurrent administration of antacids may decrease the bioavailability of phenytoin. The mechanism of interaction is unknown. However, some studies have failed to find a significant interaction with these antacids.", "source": "DDInter", "management_text": "Given the narrow therapeutic index and the large interindividual variability in the pharmacokinetics of phenytoin, patients requiring concomitant antacid therapy should consider separating the times of administration by at least two to three hours if possible. Serum phenytoin levels and seizure activity should be monitored.", "mechanism_text": "Absorption", "recommendation": "Given the narrow therapeutic index and the large interindividual variability in the pharmacokinetics of phenytoin, patients requiring concomitant antacid therapy should consider separating the times of administration by at least two to three hours if possible.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68806/", "reference_text": "[1] \"Product Information. Dilantin (phenytoin).\" Parke-Davis, Morris Plains, NJ.[2] Kulshrestha K, Thomas M, Wadsworth J, Richens A \"Interaction between phenytoin and antacids.\" Br J Clin Pharmacol 6 (1978): 177-9[3] Carter BL, Garnett WR, Pellock JM, et al \"Effects of antacids on phenytoin bioavailability.\" Ther Drug Monit 3 (1981): 333-40[4] Chapron DJ, Kramer PA, Mariano SL, Hohnadel DC \"Effect of calcium and antacids on phenytoin bioavailability.\" Arch Neurol 36 (1979): 436-8[5] D'Arcy PF, McElnay JC \"Drug-antacid interactions: assessment of clinical importance.\" Drug Intell Clin Pharm 21 (1987): 607-17[6] Kutt H \"Interactions of antiepileptic drugs.\" Epilepsia 16 (1975): 393-402[7] O'Brien LS, Orme ML, Breckenridge AM \"Failure of antacids to alter the pharmacokinetics of phenytoin.\" Br J Clin Pharmacol 6 (1978): 176-7[8] Cerner Multum, Inc. \"Australian Product Information.\" O 0[9] Ozuna J, Friel P \"Effect of enteral tube feeding on serum phenytoin levels.\" J Neurosurg Nurs 16 (1984): 289-91[10] Fleisher D, Sheth N, Kou JH \"Phenytoin interaction with enteral feedings administered through nasogastric tubes.\" JPEN J Parenter Enteral Nutr 14 (1990): 513-6[11] Krueger KA, Garnett WR, Comstock TJ, Fitzsimmons WE, Karnes HT, Pellock JM \"Effect of two administration schedules of an enteral nutrient formula on phenytoin bioavailability.\" Epilepsia 28 (1987): 706-12[12] \"Product Information. Dilantin (phenytoin).\" Parke-Davis, Morris Plains, NJ.[13] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[14] Doak KK, Haas CE, Dunnigan KJ, et al. \"Bioavailability of phenytoin acid and phenytoin sodium with enteral feedings.\" Pharmacotherapy 18 (1998): 637-45[15] Rodman DP, Stevenson TL, Ray TR \"Phenytoin malabsorption after jejunostomy tube delivery.\" Pharmacotherapy 15 (1995): 801-5[16] Sellers EM, Holloway MR \"Drug kinetics and alcohol ingestion.\" Clin Pharmacokinet 3 (1978): 440-52[17] Guidry JR, Eastwood TF, Curry SC \"Phenytoin absorption in volunteers receiving selected enteral feedings.\" West J Med 150 (1989): 659-61[18] Marvel ME, Bertino JS \"Comparative effects of an elemental and a complex enteral feeding formulation on the absorption of phenytoin suspension.\" JPEN J Parenter Enteral Nutr 15 (1991): 316-8[19] Holtz L, Milton J, Sturek JK \"Compatibility of medications with enteral feedings.\" JPEN J Parenter Enteral Nutr 11 (1987): 183-6[20] Haley CJ, Nelson J \"Phenytoin-enteral feeding interaction.\" DICP 23 (1989): 796-8[21] Faraji B, Yu PP \"Serum phenytoin levels of patients on gastrostomy tube feeding.\" J Neurosci Nurs 30 (1998): 55-9[22] Au Yeung SC, Ensom MH \"Phenytoin and enteral feedings: does evidence support an interaction?\" Ann Pharmacother 34 (2000): 896-905[23] Sandor P, Sellers EM, Dumbrell M, Khouw V \"Effect of short- and long-term alcohol use on phenytoin kinetics in chronic alcoholics.\" Clin Pharmacol Ther 30 (1981): 390-7", "alternatives_a": "Brivaracetam, Topiramate, Ezogabine, Cenobamate, Lamotrigine, Methylphenobarbital, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Oxcarbazepine, More", "alternatives_b": "Magnesium gluconate, Sodium sulfate, Zinc sulfate, Magnesium sulfate, Magnesium aspartate, Magnesium lactate, Magnesium citrate, Sodium chloride, Zinc gluconate, Magnesium chloride, Alvimopan, More", "updated_at": 1767369485}, {"id": 68720, "ingredient1": "Picosulfuric acid", "ingredient2": "Physostigmine", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline. Rare cases of generalized tonic-clonic seizures and/or loss of consciousness in association with low serum osmolality and electrolyte abnormalities (e.g., hyponatremia, hypokalemia, hypocalcemia, hypomagnesemia) have been reported with the use of bowel cleansing products in patients with no prior history of seizures. The condition resolved with correction of fluid and electrolyte abnormalities.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68807/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.[9] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.", "alternatives_a": "Latanoprost, Apraclonidine, Pilocarpine, Clonidine, Acetylcholine, Betaxolol, Bimatoprost, Travoprost, Carteolol, Brinzolamide, Guanethidine, More", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 68721, "ingredient1": "Picosulfuric acid", "ingredient2": "Pimavanserin", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia are known risk factors for torsade de pointes associated with QT interval prolongation.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68808/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[5] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[8] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[9] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[10] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[11] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68722, "ingredient1": "Pimozide", "ingredient2": "Picosulfuric acid", "severity": "Major", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval. Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly. Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68809/", "reference_text": "[1] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[2] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[9] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[10] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[11] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[12] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[13] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68723, "ingredient1": "Pindolol", "ingredient2": "Magnesium oxide", "severity": "Minor", "effect": "Concurrent administration with aluminum and magnesium antacids has been shown to decrease the oral bioavailability of certain beta-blockers, although data are conflicting. The exact mechanism of interaction is unknown but may involve cation binding of beta-blockers or a reduction in the dissolution rate due to increased gastric pH. Based on available data, the clinical significance of this potential interaction is difficult to determine. As a precaution, patients may want to consider separating the administration times of beta-blockers and antacids or other aluminum- or magnesium-containing products by at least 2 hours.", "source": "DDInter", "management_text": "-", "mechanism_text": "Absorption", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68810/", "reference_text": "[1] D'Arcy PF, McElnay JC \"Drug-antacid interactions: assessment of clinical importance.\" Drug Intell Clin Pharm 21 (1987): 607-17[2] Regardh CG, Lundborg P, Persson BA \"The effect of antacid, metoclopramide, and propantheline on the bioavailability of metoprolol and atenolol.\" Biopharm Drug Dispos 2 (1981): 79-87[3] Hong CY, Hu SC, Lin SJ, Chiang BN \"Lack of influence of aluminum hydroxide on the bioavailability and beta-adrenoceptor blocking activity of propranolol.\" Int J Clin Pharmacol Ther Toxicol 23 (1985): 244-6[4] Kirch W, Schafer-Korting M, Axthelm T, Kohler H, Mutschler E \"Interaction of atenolol with furosemide and calcium and aluminum salts.\" Clin Pharmacol Ther 30 (1981): 429-35[5] Laer S, Neumann J, Scholz H \"Interaction between sotalol and an antacid preparation.\" Br J Clin Pharmacol 43 (1997): 269-72[6] Gugler R, Allgayer H \"Effects of antacids on the clinical pharmacokinetics of drugs. An update.\" Clin Pharmacokinet 18 (1990): 210-9[7] Dobbs JH, Skoutakis VA, Acchiardo SR, Dobbs BR \"Effects of aluminum hydroxide on the absorption of propranolol.\" Curr Ther Res Clin Exp 21 (1977): 887-92", "alternatives_a": "Esmolol", "alternatives_b": "Magnesium gluconate, Sodium sulfate, Zinc sulfate, Magnesium sulfate, Magnesium aspartate, Magnesium lactate, Magnesium citrate, Sodium chloride, Zinc gluconate, Magnesium chloride, Alvimopan, More", "updated_at": 1767369485}, {"id": 68724, "ingredient1": "Piperacillin", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate. The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis. The clinical significance of this effect remains unknown.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic. If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Others", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68811/", "reference_text": "[1] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[3] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference) Available from: URL: http://www.mhra.gov.uk/spc-pil/index.htm.\"[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[6] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[7] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Tazobactam, Sulbactam", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, More", "updated_at": 1767369485}, {"id": 68725, "ingredient1": "Piperazine", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline. Rare cases of generalized tonic-clonic seizures and/or loss of consciousness in association with low serum osmolality and electrolyte abnormalities (e.g., hyponatremia, hypokalemia, hypocalcemia, hypomagnesemia) have been reported with the use of bowel cleansing products in patients with no prior history of seizures. The condition resolved with correction of fluid and electrolyte abnormalities.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68812/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.[9] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.", "alternatives_a": "Thiabendazole, Levamisole, Pyrantel, Ivermectin, Mebendazole, Albendazole", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 68726, "ingredient1": "Piroxicam", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations. Fluid and electrolyte disturbances can lead to serious adverse events including cardiac arrhythmias, seizures, and renal impairment.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment. Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered. Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing. Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68813/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Diovan (valsartan).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Cozaar (losartan).\" Merck & Co, Inc, West Point, PA.[5] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[6] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole, Tolazoline, Rabeprazole, Dimethyl sulfoxide, Fluocinolone acetonide, Fluorometholone", "alternatives_b": "Alvimopan, Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Magnesium carbonate, Plecanatide, More", "updated_at": 1767369485}, {"id": 68727, "ingredient1": "Pitolisant", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia are known risk factors for torsade de pointes associated with QT interval prolongation.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68814/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[5] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[8] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[9] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[10] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[11] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Alvimopan, Sorbitol, Magnesium sulfate, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Prucalopride, More", "alternatives_b": "Dextromethorphan, Sodium oxybate, Riluzole, Inotersen, Tafamidis", "updated_at": 1767369485}, {"id": 68728, "ingredient1": "Plazomicin", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate. The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis. The clinical significance of this effect remains unknown.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic. If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Others", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68815/", "reference_text": "[1] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[3] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference) Available from: URL: http://www.mhra.gov.uk/spc-pil/index.htm.\"[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[6] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[7] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68729, "ingredient1": "Polyethylene glycol (3350)", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Concomitant use of stimulant laxatives (e.g., bisacodyl, sodium picosulfate) may increase the risk of serious gastrointestinal adverse effects associated with certain osmotic laxatives (e.g., polyethylene glycol (PEG), oral sulfate solution), such as colonic mucosal ulcerations or ischemic colitis. When administered in conjunction with an osmotic laxative such as PEG, increased intramural pressure secondary to increased peristalsis may lead to ischemic colitis and perforation.", "source": "DDInter", "management_text": "The manufacturers for some osmotic bowel cleansing products recommend avoiding the concurrent use of stimulant laxatives. However, stimulant laxatives, in particular bisacodyl and sodium picosulfate, are sometimes used with PEG in certain bowel cleansing regimens to help reduce dose volume and improve patient tolerability and acceptance. Please consult individual product labeling for specific recommendations and guidance. Patients using osmotic bowel cleansing products and stimulant laxatives who present with sudden abdominal pain, rectal bleeding, or other symptoms of ischemic colitis should be evaluated promptly.", "mechanism_text": "Synergism", "recommendation": "The manufacturers for some osmotic bowel cleansing products recommend avoiding the concurrent use of stimulant laxatives.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68816/", "reference_text": "[1] Vaizman K, Li J, Iswara K, Tenner S \"Ischemic colitis induced by the combination of Bisacodyl and polyethylene glycol in preparation for colonoscopy.\" Am J Gastroenterol 102 (2007): S267[2] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. MoviPrep (polyethylene glycol 3350 with electrolytes).\" Physicians Total Care, Tulsa, OK.[4] Adamcewicz M, Bearelly D, Porat G, Friedenberg FK \"Mechanism of action and toxicities of purgatives used for colonoscopy preparation.\" Expert Opin Drug Metab Toxicol 7 (2011): 89-101[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Baudet JS, Castro V, Redondo I \"Recurrent ischemic colitis induced by colonoscopy bowel lavage.\" Am J Gastroenterol 105 (2010): 700-1[7] \"Product Information. GaviLyte-H and Bisacodyl with Flavor Packs (bisacodyl-PEG 3350 with electrolytes).\" Gavis Pharmaceuticals, Somerset, NJ.[8] Anastassopoulos K, Farraye FA, Knight T, Colman S, Cleveland MvB, Pelham RW \"A comparative study of treatment-emergent adverse events following use of common bowel preparations among a colonoscopy screening population: results from a post-marketing observational study.\" Dig Dis Sci 61 (2016): 2993-3006[9] Belsey J, Epstein O, heresbach D \"Systematic review: adverse event reports for oral sodium phosphate and polyethylene glycol.\" Aliment Pharmacol Ther 29 (2009): 15-28[10] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[11] \"Product Information. Bi-Peglyte (bisacodyl-PEG 3350 with electrolytes).\" Pendopharm, Montreal, QC.[12] Hung SY, Chen HC, Chen WT \"A randomized trial comparing the bowel cleansing efficacy of sodium picosulfate/magnesium citrate and polyethylene glycol/Bisacodyl (The Bowklean Study)\" Sci Rep 10 (2020): 5604[13] Barbeau P, Wolfe D, Yazdi F, et.al \"Comparative safety of bowel cleansers: protocol for a systematic review and network meta-analysis.\" BMJ Open 8 (2018): e021892[14] \"Product Information. Plenvu (polyethylene glycol 3350 with electrolytes).\" Bausch Health US (formerly Valeant Pharmaceuticals), Bridgewater, NJ.[15] Ajani S, Hurt RT, Teeters DA, Bellmore LR \"Ischaemic colitis associated with oral contraceptive and bisacodyl use.\" BMJ Case Rep 2012 (2012):", "alternatives_a": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Naldemedine, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, Prucalopride, Sodium sulfate, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68730, "ingredient1": "Polyethylene glycol (3350 with electrolytes)", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Concomitant use of stimulant laxatives (e.g., bisacodyl, sodium picosulfate) may increase the risk of serious gastrointestinal adverse effects associated with certain osmotic laxatives (e.g., polyethylene glycol (PEG), oral sulfate solution), such as colonic mucosal ulcerations or ischemic colitis. When administered in conjunction with an osmotic laxative such as PEG, increased intramural pressure secondary to increased peristalsis may lead to ischemic colitis and perforation.", "source": "DDInter", "management_text": "The manufacturers for some osmotic bowel cleansing products recommend avoiding the concurrent use of stimulant laxatives. However, stimulant laxatives, in particular bisacodyl and sodium picosulfate, are sometimes used with PEG in certain bowel cleansing regimens to help reduce dose volume and improve patient tolerability and acceptance. Please consult individual product labeling for specific recommendations and guidance. Patients using osmotic bowel cleansing products and stimulant laxatives who present with sudden abdominal pain, rectal bleeding, or other symptoms of ischemic colitis should be evaluated promptly.", "mechanism_text": "Synergism", "recommendation": "The manufacturers for some osmotic bowel cleansing products recommend avoiding the concurrent use of stimulant laxatives.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68817/", "reference_text": "[1] Vaizman K, Li J, Iswara K, Tenner S \"Ischemic colitis induced by the combination of Bisacodyl and polyethylene glycol in preparation for colonoscopy.\" Am J Gastroenterol 102 (2007): S267[2] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. MoviPrep (polyethylene glycol 3350 with electrolytes).\" Physicians Total Care, Tulsa, OK.[4] Adamcewicz M, Bearelly D, Porat G, Friedenberg FK \"Mechanism of action and toxicities of purgatives used for colonoscopy preparation.\" Expert Opin Drug Metab Toxicol 7 (2011): 89-101[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Baudet JS, Castro V, Redondo I \"Recurrent ischemic colitis induced by colonoscopy bowel lavage.\" Am J Gastroenterol 105 (2010): 700-1[7] \"Product Information. GaviLyte-H and Bisacodyl with Flavor Packs (bisacodyl-PEG 3350 with electrolytes).\" Gavis Pharmaceuticals, Somerset, NJ.[8] Anastassopoulos K, Farraye FA, Knight T, Colman S, Cleveland MvB, Pelham RW \"A comparative study of treatment-emergent adverse events following use of common bowel preparations among a colonoscopy screening population: results from a post-marketing observational study.\" Dig Dis Sci 61 (2016): 2993-3006[9] Belsey J, Epstein O, heresbach D \"Systematic review: adverse event reports for oral sodium phosphate and polyethylene glycol.\" Aliment Pharmacol Ther 29 (2009): 15-28[10] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[11] \"Product Information. Bi-Peglyte (bisacodyl-PEG 3350 with electrolytes).\" Pendopharm, Montreal, QC.[12] Hung SY, Chen HC, Chen WT \"A randomized trial comparing the bowel cleansing efficacy of sodium picosulfate/magnesium citrate and polyethylene glycol/Bisacodyl (The Bowklean Study)\" Sci Rep 10 (2020): 5604[13] Barbeau P, Wolfe D, Yazdi F, et.al \"Comparative safety of bowel cleansers: protocol for a systematic review and network meta-analysis.\" BMJ Open 8 (2018): e021892[14] \"Product Information. Plenvu (polyethylene glycol 3350 with electrolytes).\" Bausch Health US (formerly Valeant Pharmaceuticals), Bridgewater, NJ.[15] Ajani S, Hurt RT, Teeters DA, Bellmore LR \"Ischaemic colitis associated with oral contraceptive and bisacodyl use.\" BMJ Case Rep 2012 (2012):", "alternatives_a": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Naldemedine, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, Prucalopride, Sodium sulfate, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68731, "ingredient1": "Polymyxin B", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate. The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis. The clinical significance of this effect remains unknown.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic. If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Others", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68818/", "reference_text": "[1] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[3] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference) Available from: URL: http://www.mhra.gov.uk/spc-pil/index.htm.\"[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[6] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[7] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Chlorhexidine, Miconazole, Chlorhexidine, Tinidazole, Nystatin, Amphotericin B, Miconazole, Ganciclovir, Acyclovir, Famciclovir, Trifluridine, More", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, More", "updated_at": 1767369485}, {"id": 68732, "ingredient1": "Polythiazide", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations. Fluid and electrolyte disturbances can lead to serious adverse events including cardiac arrhythmias, seizures, and renal impairment.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment. Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered. Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing. Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68819/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Diovan (valsartan).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Cozaar (losartan).\" Merck & Co, Inc, West Point, PA.[5] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[6] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Simeprevir, Rosuvastatin, Lactic acid, Mitapivat, Amphotericin B, Ciclopirox, Darunavir, Probenecid, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 68733, "ingredient1": "Ponatinib", "ingredient2": "Magnesium oxide", "severity": "Minor", "effect": "Coadministration with drugs that elevate the gastric pH such as proton pump inhibitors, H2-receptor antagonists, and antacids may decrease the oral bioavailability of ponatinib and reduce its concentrations in plasma. The aqueous solubility of ponatinib has been shown to be pH-dependent, with higher pH resulting in decreased solubility.", "source": "DDInter", "management_text": "-", "mechanism_text": "Absorption", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68820/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] \"Product Information. Iclusig (ponatinib).\" Ariad Pharmaceuticals Inc, Cambridge, MA.[3] \"Product Information. Iclusig (ponatinib).\" Ariad Pharmaceuticals Inc, Cambridge, MA.", "alternatives_a": "Magnesium gluconate, Sodium sulfate, Zinc sulfate, Magnesium sulfate, Magnesium aspartate, Magnesium lactate, Magnesium citrate, Sodium chloride, Zinc gluconate, Magnesium chloride, Alvimopan, More", "alternatives_b": "Entrectinib, Imatinib, Pralsetinib, Asciminib, Dacomitinib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Vemurafenib, More", "updated_at": 1767369485}, {"id": 68734, "ingredient1": "Posaconazole", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia are known risk factors for torsade de pointes associated with QT interval prolongation.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68821/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[5] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[8] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[9] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[10] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[11] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Caspofungin, Micafungin, Amphotericin B, Itraconazole, Miconazole, Oteseconazole, Flucytosine, Anidulafungin", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Prucalopride, More", "updated_at": 1767369485}, {"id": 68735, "ingredient1": "Prednisolone", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The overuse or abuse of laxatives can cause significant loss of electrolytes and potentiate the risk of hypokalemia associated with corticosteroid therapy. Corticosteroids promote the retention of sodium and water and the excretion of potassium. Although these effects are primarily associated with mineralocorticoids like fludrocortisone, they may also occur with higher dosages of glucocorticoids or adrenocorticotropic agents, particularly if given systemically for longer than brief periods.", "source": "DDInter", "management_text": "In general, laxatives should only be used on a short-term, intermittent basis in recommended dosages. During concomitant therapy with corticosteroids, particularly if fludrocortisone or large doses of a glucocorticoid or adrenocorticotropic agent is given, patients should be counseled to recognize potential signs and symptoms of hypokalemia such as fatigue, myalgia, and muscle weakness. If maintenance of bowel regularity is required, patients should be advised to exercise and increase fiber in the diet and/or consider the use of bulk-forming laxatives.", "mechanism_text": "Antagonism", "recommendation": "In general, laxatives should only be used on a short-term, intermittent basis in recommended dosages.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68822/", "reference_text": "[1] Chin RL \"Laxative-induced hypokalemia.\" Ann Emerg Med 32 (1998): 517-8[2] Blumenthal M, Goldberg A, Brinckmann J, eds. \"Herbal Medicine: Expanded Commission E Monographs.\" Newton, MA: Integrative Medicine Communications (2000):[3] Muller-Lissner SA \"Adverse effects of laxatives: fact and fiction.\" Pharmacology 47 (1993): 138-45[4] Seale JP, Compton MR \"Side-effects of corticosteroid agents.\" Med J Aust 144 (1986): 139-42[5] Swartz SL, Dluhy RG \"Corticosteroids: clinical pharmacology and therapeutic use.\" Drugs 16 (1978): 238-55[6] Lieberman P, Patterson R, Kunske R \"Complications of long-term steroid therapy for asthma.\" J Allergy Clin Immunol 49 (1972): 329-36[7] Ramsahoye BH, Davies SV, el-Gaylani N, Sandeman D, Scanlon MF \"The mineralocorticoid effects of high dose hydrocortisone.\" BMJ 310 (1995): 656-7", "alternatives_a": "Mometasone furoate, Amcinonide, Budesonide, Fluocinolone acetonide, Hydrocortisone butyrate, Fluticasone, Fluocinonide, Fluorometholone, Clobetasol, Beclomethasone dipropionate, Fluocinolone acetonide, More", "alternatives_b": "Alvimopan, Sodium sulfate, Sorbitol, Methylnaltrexone, Tegaserod, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Naldemedine, Prucalopride, More", "updated_at": 1767369485}, {"id": 68736, "ingredient1": "Prednisone", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The overuse or abuse of laxatives can cause significant loss of electrolytes and potentiate the risk of hypokalemia associated with corticosteroid therapy. Corticosteroids promote the retention of sodium and water and the excretion of potassium. Although these effects are primarily associated with mineralocorticoids like fludrocortisone, they may also occur with higher dosages of glucocorticoids or adrenocorticotropic agents, particularly if given systemically for longer than brief periods.", "source": "DDInter", "management_text": "In general, laxatives should only be used on a short-term, intermittent basis in recommended dosages. During concomitant therapy with corticosteroids, particularly if fludrocortisone or large doses of a glucocorticoid or adrenocorticotropic agent is given, patients should be counseled to recognize potential signs and symptoms of hypokalemia such as fatigue, myalgia, and muscle weakness. If maintenance of bowel regularity is required, patients should be advised to exercise and increase fiber in the diet and/or consider the use of bulk-forming laxatives.", "mechanism_text": "Antagonism", "recommendation": "In general, laxatives should only be used on a short-term, intermittent basis in recommended dosages.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68823/", "reference_text": "[1] Chin RL \"Laxative-induced hypokalemia.\" Ann Emerg Med 32 (1998): 517-8[2] Blumenthal M, Goldberg A, Brinckmann J, eds. \"Herbal Medicine: Expanded Commission E Monographs.\" Newton, MA: Integrative Medicine Communications (2000):[3] Muller-Lissner SA \"Adverse effects of laxatives: fact and fiction.\" Pharmacology 47 (1993): 138-45[4] Seale JP, Compton MR \"Side-effects of corticosteroid agents.\" Med J Aust 144 (1986): 139-42[5] Swartz SL, Dluhy RG \"Corticosteroids: clinical pharmacology and therapeutic use.\" Drugs 16 (1978): 238-55[6] Lieberman P, Patterson R, Kunske R \"Complications of long-term steroid therapy for asthma.\" J Allergy Clin Immunol 49 (1972): 329-36[7] Ramsahoye BH, Davies SV, el-Gaylani N, Sandeman D, Scanlon MF \"The mineralocorticoid effects of high dose hydrocortisone.\" BMJ 310 (1995): 656-7", "alternatives_a": "Budesonide, Cromoglicic acid, Olsalazine, Sulfasalazine, Balsalazide, Beclomethasone dipropionate, Mesalazine", "alternatives_b": "Alvimopan, Sodium sulfate, Sorbitol, Methylnaltrexone, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Naldemedine, Prucalopride, Linaclotide, More", "updated_at": 1767369485}, {"id": 68737, "ingredient1": "Primaquine", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia are known risk factors for torsade de pointes associated with QT interval prolongation.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68824/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[5] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[8] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[9] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[10] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[11] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Artesunate, Lumefantrine, Artemether, Pyrimethamine, Tafenoquine, Proguanil", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 68738, "ingredient1": "Probucol", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia are known risk factors for torsade de pointes associated with QT interval prolongation.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68825/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[5] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[8] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[9] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[10] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[11] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Cholestyramine, Rosuvastatin, Fenofibrate, Mipomersen, Evinacumab, Dextrothyroxine, Simvastatin, Cerivastatin, Lomitapide, Ezetimibe, Niacin, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 68739, "ingredient1": "Procainamide", "ingredient2": "Picosulfuric acid", "severity": "Major", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval. Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly. Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68826/", "reference_text": "[1] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[2] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[9] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[10] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[11] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[12] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[13] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Tocainide, Moricizine, Bretylium", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 68740, "ingredient1": "Prochlorperazine", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; hydroxychloroquine; mefloquine), and some narcotic analgesics. The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that can prolong the QT interval, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; mefloquine; halofantrine; lumefantrine), and some narcotic analgesics (methadone; propoxyphene).", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68827/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[6] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[9] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[10] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[11] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[12] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[13] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[14] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[15] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Naldemedine, Prucalopride, Linaclotide", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68741, "ingredient1": "Promazine", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; hydroxychloroquine; mefloquine), and some narcotic analgesics. The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that can prolong the QT interval, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; mefloquine; halofantrine; lumefantrine), and some narcotic analgesics (methadone; propoxyphene).", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68828/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[6] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[9] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[10] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[11] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[12] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[13] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[14] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[15] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Phenolphthalein, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68742, "ingredient1": "Promethazine", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; hydroxychloroquine; mefloquine), and some narcotic analgesics. The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that can prolong the QT interval, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; mefloquine; halofantrine; lumefantrine), and some narcotic analgesics (methadone; propoxyphene).", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68829/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[6] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[9] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[10] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[11] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[12] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[13] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[14] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[15] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Ketotifen, Mepyramine, Levocetirizine, Chlorcyclizine, Cetirizine, Acrivastine, Triprolidine, Tripelennamine, Azelastine, Dexbrompheniramine, Clemastine, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Phenolphthalein, Naloxegol, Plecanatide, Magnesium citrate, Bisacodyl, Lactitol, Lubiprostone, More", "updated_at": 1767369485}, {"id": 68743, "ingredient1": "Propafenone", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia are known risk factors for torsade de pointes associated with QT interval prolongation.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68830/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[5] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[8] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[9] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[10] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[11] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Tocainide, Moricizine, Bretylium", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 68744, "ingredient1": "Propiomazine", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline. Rare cases of generalized tonic-clonic seizures and/or loss of consciousness in association with low serum osmolality and electrolyte abnormalities (e.g., hyponatremia, hypokalemia, hypocalcemia, hypomagnesemia) have been reported with the use of bowel cleansing products in patients with no prior history of seizures. The condition resolved with correction of fluid and electrolyte abnormalities.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68831/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.[9] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.", "alternatives_a": "Suvorexant, Triazolam, Flurazepam, Methohexital, Methylphenobarbital, Zolpidem, Pentobarbital, Zaleplon, Dichloralphenazone, Valerian, Temazepam, More", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Prucalopride, Linaclotide, More", "updated_at": 1767369485}, {"id": 68745, "ingredient1": "Propofol", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia are known risk factors for torsade de pointes associated with QT interval prolongation.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68832/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[5] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[8] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[9] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[10] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[11] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Thiopental, Sodium oxybate, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Enflurane, Esketamine, Etomidate, Ketamine", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Naldemedine, More", "updated_at": 1767369485}, {"id": 68746, "ingredient1": "Dextropropoxyphene", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; hydroxychloroquine; mefloquine), and some narcotic analgesics. The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that can prolong the QT interval, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; mefloquine; halofantrine; lumefantrine), and some narcotic analgesics (methadone; propoxyphene).", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68833/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[6] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[9] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[10] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[11] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[12] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[13] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[14] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[15] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Dihydrocodeine, Acetaminophen, Naloxone, Naltrexone", "alternatives_b": "Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Naldemedine, More", "updated_at": 1767369485}, {"id": 68747, "ingredient1": "Propranolol", "ingredient2": "Magnesium oxide", "severity": "Minor", "effect": "Concurrent administration with aluminum and magnesium antacids has been shown to decrease the oral bioavailability of certain beta-blockers, although data are conflicting. The exact mechanism of interaction is unknown but may involve cation binding of beta-blockers or a reduction in the dissolution rate due to increased gastric pH. Based on available data, the clinical significance of this potential interaction is difficult to determine. As a precaution, patients may want to consider separating the administration times of beta-blockers and antacids or other aluminum- or magnesium-containing products by at least 2 hours.", "source": "DDInter", "management_text": "-", "mechanism_text": "Absorption", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68834/", "reference_text": "[1] D'Arcy PF, McElnay JC \"Drug-antacid interactions: assessment of clinical importance.\" Drug Intell Clin Pharm 21 (1987): 607-17[2] Regardh CG, Lundborg P, Persson BA \"The effect of antacid, metoclopramide, and propantheline on the bioavailability of metoprolol and atenolol.\" Biopharm Drug Dispos 2 (1981): 79-87[3] Hong CY, Hu SC, Lin SJ, Chiang BN \"Lack of influence of aluminum hydroxide on the bioavailability and beta-adrenoceptor blocking activity of propranolol.\" Int J Clin Pharmacol Ther Toxicol 23 (1985): 244-6[4] Kirch W, Schafer-Korting M, Axthelm T, Kohler H, Mutschler E \"Interaction of atenolol with furosemide and calcium and aluminum salts.\" Clin Pharmacol Ther 30 (1981): 429-35[5] Laer S, Neumann J, Scholz H \"Interaction between sotalol and an antacid preparation.\" Br J Clin Pharmacol 43 (1997): 269-72[6] Gugler R, Allgayer H \"Effects of antacids on the clinical pharmacokinetics of drugs. An update.\" Clin Pharmacokinet 18 (1990): 210-9[7] Dobbs JH, Skoutakis VA, Acchiardo SR, Dobbs BR \"Effects of aluminum hydroxide on the absorption of propranolol.\" Curr Ther Res Clin Exp 21 (1977): 887-92", "alternatives_a": "Felodipine, Amlodipine, Nifedipine, Ivabradine, Esmolol", "alternatives_b": "Magnesium gluconate, Sodium sulfate, Zinc sulfate, Magnesium sulfate, Magnesium aspartate, Magnesium lactate, Magnesium citrate, Sodium chloride, Zinc gluconate, Magnesium chloride, Alvimopan, More", "updated_at": 1767369485}, {"id": 68748, "ingredient1": "Protriptyline", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; hydroxychloroquine; mefloquine), and some narcotic analgesics. The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that can prolong the QT interval, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; mefloquine; halofantrine; lumefantrine), and some narcotic analgesics (methadone; propoxyphene).", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68835/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[6] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[9] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[10] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[11] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[12] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[13] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[14] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[15] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "St. John's Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 68749, "ingredient1": "Plantago seed", "ingredient2": "Picosulfuric acid", "severity": "Minor", "effect": "According to some manufacturers, bulk-forming laxatives may reduce the efficacy of bowel cleansing products containing sodium picosulfate, magnesium oxide, and citric acid anhydrous. The mechanism of interaction has not been described, and clinical significance is unknown.", "source": "DDInter", "management_text": "-", "mechanism_text": "Others", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68836/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Metamucil (psyllium).\" Procter and Gamble Pharmaceutic, Cincinnati, OH.[3] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[4] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, Prucalopride, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68750, "ingredient1": "Pyrazinamide", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate. The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis. The clinical significance of this effect remains unknown.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic. If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Others", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68837/", "reference_text": "[1] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[3] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference) Available from: URL: http://www.mhra.gov.uk/spc-pil/index.htm.\"[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[6] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[7] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Pyridoxine, Pretomanid", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, More", "updated_at": 1767369485}, {"id": 68751, "ingredient1": "Quazepam", "ingredient2": "Magnesium oxide", "severity": "Minor", "effect": "number of studies have reported that antacids can delay the gastrointestinal absorption and reduce the peak plasma concentration (Cmax) of some benzodiazepines, including clorazepate, chlordiazepoxide and diazepam, although the overall extent of absorption is generally not affected. The exact mechanism of interaction is unknown, but may involve delayed gastric emptying or cation binding of the benzodiazepine.", "source": "DDInter", "management_text": "-", "mechanism_text": "Absorption", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68838/", "reference_text": "[1] Greenblatt DJ, Allen MD, MacLaughlin DS, Harmatz JS, Shader RI \"Diazepam absorption: effect of antacids and food.\" Clin Pharmacol Ther 24 (1978): 600-9[2] Kroboth PD, Smith RB, Silver MR, Rault R, Sorkin MI, Puschett JB, Juhl RP \"Effects of end stage renal disease and aluminium hydroxide on triazolam pharmacokinetics.\" Br J Clin Pharmacol 19 (1985): 839-42[3] Greenblatt DJ, Shader RI, Harmatz JS, Franke K, Koch-Weser J \"Absorption rate, blood concentrations, and early response to oral chlordiazepoxide.\" Am J Psychiatry 134 (1977): 559-62[4] Shader RI, Ciraulo DA, Greenblatt DJ, Harmatz JS \"Steady-state plasma desmethyldiazepam during long-term clorazepate use: effects of antacids.\" Clin Pharmacol Ther 31 (1982): 180-3[5] Greenblatt DJ, Shader RI, Harmatz JS, Franke K, Koch-Weser J \"Influence of magnesium and aluminum hydroxide mixture on chlordiazepoxide absorption.\" Clin Pharmacol Ther 19 (1976): 234-9[6] Kroboth PD, Smith RB, Rault R, Silver MR, Sorkin MI, Puschett JB, Juhl RP \"Effects of end-stage renal disease and aluminum hydroxide on temazepam kinetics.\" Clin Pharmacol Ther 37 (1985): 453-9[7] Chun AH, Carrigan PJ, Hoffman DJ, Kershner RP, Stuart JD \"Effect of antacids on absorption of clorazepate.\" Clin Pharmacol Ther 22 (1977): 329-35[8] Nair SG, Gamble JA, Dundee JW, Howard PJ \"The influence of three antacids on the absorption and clinical action of oral diazepam.\" Br J Anaesth 48 (1976): 1175-80[9] Shader RI, Georgotas A, Greenblatt DJ, Harmatz JS, Allen MD \"Impaired absorption of desmethyldiazepam from clorazepate by magnesium aluminum hydroxide.\" Clin Pharmacol Ther 24 (1978): 308-15[10] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[11] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[12] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[13] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Magnesium gluconate, Sodium sulfate, Zinc sulfate, Magnesium sulfate, Magnesium aspartate, Magnesium lactate, Magnesium citrate, Sodium chloride, Zinc gluconate, Magnesium chloride, Alvimopan, More", "alternatives_b": "Suvorexant, Methohexital, Methylphenobarbital, Zolpidem, Pentobarbital, Zaleplon, Dichloralphenazone, Valerian, Butabarbital, Secobarbital, Chloral hydrate, More", "updated_at": 1767369485}, {"id": 68752, "ingredient1": "Quetiapine", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; hydroxychloroquine; mefloquine), and some narcotic analgesics. The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that can prolong the QT interval, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; mefloquine; halofantrine; lumefantrine), and some narcotic analgesics (methadone; propoxyphene).", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68839/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[6] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[9] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[10] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[11] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[12] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[13] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[14] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[15] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Naldemedine, Prucalopride, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68753, "ingredient1": "Quinapril", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations. Fluid and electrolyte disturbances can lead to serious adverse events including cardiac arrhythmias, seizures, and renal impairment.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment. Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered. Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing. Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68840/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Diovan (valsartan).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Cozaar (losartan).\" Merck & Co, Inc, West Point, PA.[5] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[6] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Felodipine, Amlodipine, Verapamil, Bisoprolol", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Phenolphthalein, Naloxegol, Plecanatide, Magnesium citrate, Lactitol, Lubiprostone, Methylcellulose, More", "updated_at": 1767369485}, {"id": 68754, "ingredient1": "Quinidine", "ingredient2": "Picosulfuric acid", "severity": "Major", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval. Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly. Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68841/", "reference_text": "[1] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[2] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[9] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[10] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[11] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[12] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[13] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Tocainide, Moricizine, Bretylium", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Linaclotide, Naloxone", "updated_at": 1767369485}, {"id": 68755, "ingredient1": "Quinine", "ingredient2": "Picosulfuric acid", "severity": "Major", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval. Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly. Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68842/", "reference_text": "[1] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[2] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[9] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[10] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[11] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[12] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[13] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Risdiplam, Collagenase clostridium histolyticum, Onasemnogene abeparvovec, Hyaluronic acid, Artesunate, Lumefantrine, Artemether, Pyrimethamine, Tafenoquine, Proguanil", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Prucalopride, More", "updated_at": 1767369485}, {"id": 68756, "ingredient1": "Quinupristin", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate. The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis. The clinical significance of this effect remains unknown.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic. If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Others", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68843/", "reference_text": "[1] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[3] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference) Available from: URL: http://www.mhra.gov.uk/spc-pil/index.htm.\"[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[6] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[7] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Alvimopan, Sorbitol, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Magnesium citrate, Bisacodyl, Lubiprostone, Methylcellulose, Naldemedine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68757, "ingredient1": "Raltegravir", "ingredient2": "Magnesium oxide", "severity": "Moderate", "effect": "Coadministration with aluminum- and magnesium-containing antacids has been shown to reduce the oral bioavailability of raltegravir. The proposed mechanism is chelation of raltegravir by polyvalent cations, but changes in solubility and lipophilicity of raltegravir related to pH increases may also contribute.", "source": "DDInter", "management_text": "It is not known to what extent non-antacid aluminum and magnesium salts may interact with raltegravir. Until more information is available, it may be advisable to avoid taking raltegravir with any aluminum- and/or magnesium-containing product. According to the manufacturer, antacids containing calcium carbonate may be used without dose adjustment for raltegravir.", "mechanism_text": "Absorption", "recommendation": "It is not known to what extent non-antacid aluminum and magnesium salts may interact with raltegravir.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68844/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[4] Kiser JJ, Bumpass JB, Meditz AL, et al. \"Effect of antacids on the pharmacokinetics of raltegravir in human immunodeficiency virus seronegative volunteers.\" Antimicrob Agents Chemother 54 (2010): 4999-5003[5] \"Product Information. Isentress (raltegravir).\" Merck & Company Inc, West Point, PA.[6] Moss DM, Siccardi M, Murphy M, et al. \"Divalent metals and pH alter raltegravir disposition in vitro.\" Antimicrob Agents Chemother 56 (2012): 3020-6", "alternatives_a": "Sodium chloride, Sodium sulfate, Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, More", "alternatives_b": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Valaciclovir, Zanamivir, Lenacapavir, Telaprevir, Etravirine, More", "updated_at": 1767369485}, {"id": 68758, "ingredient1": "Ramipril", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations. Fluid and electrolyte disturbances can lead to serious adverse events including cardiac arrhythmias, seizures, and renal impairment.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment. Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered. Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing. Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68845/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Diovan (valsartan).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Cozaar (losartan).\" Merck & Co, Inc, West Point, PA.[5] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[6] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Felodipine, Amlodipine, Verapamil, Bisoprolol, Amlodipine, Atorvastatin, Simvastatin, Lovastatin, Rosuvastatin, Niacin, Pravastatin, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Phenolphthalein, Naloxegol, Plecanatide, Magnesium citrate, Bisacodyl, Lactitol, Lubiprostone, More", "updated_at": 1767369485}, {"id": 68759, "ingredient1": "Ranitidine (bismuth citrate)", "ingredient2": "Magnesium oxide", "severity": "Minor", "effect": "Antacids and some aluminum, calcium, and magnesium salts may decrease the plasma concentrations of H2-receptor antagonists during oral coadministration. The mechanism of interaction is unknown, but may involve reduced oral absorption due to increased gastric pH. The clinical significance has not been established. As a precaution, patients may consider taking H2-receptor antagonists one to two hours before antacids.", "source": "DDInter", "management_text": "-", "mechanism_text": "Absorption", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68846/", "reference_text": "[1] Barzaghi N, Gatti G, Crema F, Perucca E \"Impaired bioavailability of famotidine given concurrently with a potent antacid.\" J Clin Pharmacol 29 (1989): 670-2[2] Albin H, Vincon G, Begaud B, Bistue C, Perez P \"Effect of aluminum phosphate on the bioavailability of ranitidine.\" Eur J Clin Pharmacol 32 (1987): 97-9[3] Covington TR, Lawson LC, Young LL, eds. \"Handbook of Nonprescription Drugs. 10th ed.\" Washington, DC: American Pharmaceutical Association (1993):[4] Donn KH, Eshelman FN, Plachetka JR, et al \"The effects of antacid and propantheline on the absorption of oral ranitidine.\" Pharmacotherapy 4 (1984): 89-92[5] Bachmann KA, Sullivan TJ, Jauregui L, Reese J, Miller K, Levine L \"Drug interactions of h-2-receptor antagonists.\" Scand J Gastroenterol 29 (1994): 14-9[6] Bodemar G, Norlander B, Walan A \"Diminished absorption of cimetidine caused by antacids.\" Lancet 02/24/79 (1979): 444-5[7] Russell WL, Lopez LM, Normann SA, et al \"Effect of antacids on predicted steady-state cimetidine concentrations.\" Dig Dis Sci 29 (1984): 385-9[8] Shelly DW, Doering PL, Russell WL, Guild RT, Lopez LM, Perrin J \"Effect of concomitant antacid administration on plasma cimetidine concentrations during repetitive dosing.\" Drug Intell Clin Pharm 20 (1986): 792-5[9] Steinberg WM, Lewis JH, Katz DM \"Antacids inhibit absorption of cimetidine.\" N Engl J Med 307 (1982): 400-4[10] Lin JH, Chremos AN, Kanovsky SM, Schwartz S, Yeh KC, Kann J \"Effects of antacids and food on absorption of famotidine.\" Br J Clin Pharmacol 24 (1987): 551-3[11] Mihaly GW, Marino AT, Webster LK, Jones DB, Louis WJ, Smallwood RA \"High dose of antacid (Mylanta II) reduces bioavailability of ranitidine.\" Br Med J 285 (1982): 998-9[12] Albin H, Vincon G, Demotes-Mainard F, et al \"Effect of aluminium phosphate on the bioavailability of cimetidine and prednisolone.\" Eur J Clin Pharmacol 26 (1984): 271-3", "alternatives_a": "Magaldrate, Magnesium gluconate, Sodium sulfate, Zinc sulfate, Magnesium sulfate, Magnesium aspartate, Magnesium lactate, Magnesium citrate, Sodium chloride, Zinc gluconate, Magnesium chloride, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68760, "ingredient1": "Ranolazine", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia are known risk factors for torsade de pointes associated with QT interval prolongation.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68847/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[5] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[8] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[9] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[10] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[11] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Alprostadil, Ubidecarenone, Ivabradine, Adenosine, Regadenoson", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Prucalopride, More", "updated_at": 1767369485}, {"id": 68761, "ingredient1": "Relugolix", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia are known risk factors for torsade de pointes associated with QT interval prolongation.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68848/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[5] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[8] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[9] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[10] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[11] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "alternatives_b": "Norethisterone, Nafarelin, Octreotide, Elagolix, Cetrorelix, Estradiol, Ganirelix, Lanreotide, Gonadorelin, Darolutamide, Anastrozole, More", "updated_at": 1767369485}, {"id": 68762, "ingredient1": "Remifentanil", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline. Rare cases of generalized tonic-clonic seizures and/or loss of consciousness in association with low serum osmolality and electrolyte abnormalities (e.g., hyponatremia, hypokalemia, hypocalcemia, hypomagnesemia) have been reported with the use of bowel cleansing products in patients with no prior history of seizures. The condition resolved with correction of fluid and electrolyte abnormalities.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68849/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.[9] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.", "alternatives_a": "Thiopental, Sodium oxybate, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Enflurane, Esketamine, Etomidate, Ketamine", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 68763, "ingredient1": "Ribociclib", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia are known risk factors for torsade de pointes associated with QT interval prolongation.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68850/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[5] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[8] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[9] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[10] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[11] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Prucalopride, More", "alternatives_b": "Imatinib, Dabrafenib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Selumetinib, Cobimetinib, More", "updated_at": 1767369485}, {"id": 68764, "ingredient1": "Rifabutin", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate. The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis. The clinical significance of this effect remains unknown.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic. If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Others", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68851/", "reference_text": "[1] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[3] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference) Available from: URL: http://www.mhra.gov.uk/spc-pil/index.htm.\"[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[6] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[7] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Pyridoxine, Pretomanid, Tinidazole, Pantoprazole, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Famotidine, Cimetidine, More", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Bisacodyl, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, Sodium sulfate, Prucalopride, More", "updated_at": 1767369485}, {"id": 68765, "ingredient1": "Rifampicin", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate. The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis. The clinical significance of this effect remains unknown.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic. If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Others", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68852/", "reference_text": "[1] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[3] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference) Available from: URL: http://www.mhra.gov.uk/spc-pil/index.htm.\"[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[6] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[7] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Pyridoxine, Pretomanid", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Bisacodyl, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, Sodium sulfate, Prucalopride, Linaclotide, More", "updated_at": 1767369485}, {"id": 68766, "ingredient1": "Rifamycin", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate. The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis. The clinical significance of this effect remains unknown.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic. If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Others", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68853/", "reference_text": "[1] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[3] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference) Available from: URL: http://www.mhra.gov.uk/spc-pil/index.htm.\"[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[6] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[7] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Alvimopan, Sorbitol, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Magnesium citrate, Bisacodyl, Lubiprostone, Methylcellulose, Naldemedine, More", "alternatives_b": "Ganciclovir, Acyclovir, Famciclovir, Trifluridine, Chlorhexidine, Povidone-iodine, Chlorhexidine, Miconazole, Mupirocin, Nystatin, Amphotericin B, More", "updated_at": 1767369485}, {"id": 68767, "ingredient1": "Rifapentine", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate. The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis. The clinical significance of this effect remains unknown.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic. If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Others", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68854/", "reference_text": "[1] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[3] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference) Available from: URL: http://www.mhra.gov.uk/spc-pil/index.htm.\"[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[6] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[7] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Pyridoxine, Pretomanid", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Bisacodyl, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, Sodium sulfate, Prucalopride, More", "updated_at": 1767369485}, {"id": 68768, "ingredient1": "Rifaximin", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate. The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis. The clinical significance of this effect remains unknown.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic. If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Others", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68855/", "reference_text": "[1] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[3] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference) Available from: URL: http://www.mhra.gov.uk/spc-pil/index.htm.\"[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[6] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[7] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Nystatin, Amphotericin B, Miconazole, Mupirocin", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, Sodium sulfate, More", "updated_at": 1767369485}, {"id": 68769, "ingredient1": "Rilpivirine", "ingredient2": "Magnesium oxide", "severity": "Moderate", "effect": "INTERVAL: Coadministration with antacids may decrease the oral bioavailability of rilpivirine. The proposed mechanism involves a pH-dependent reduction in dissolution and absorption of rilpivirine, which is poorly soluble over a wide pH range.", "source": "DDInter", "management_text": "To minimize the risk of reduced viral susceptibility and resistance development associated with subtherapeutic levels of rilpivirine, antacids or other medications that contain antacids (e.g., didanosine buffered tablets or pediatric oral solution) should be administered at least 2 hours before or 4 hours after the rilpivirine dose.", "mechanism_text": "Absorption", "recommendation": "To minimize the risk of reduced viral susceptibility and resistance development associated with subtherapeutic levels of rilpivirine, antacids or other medications that contain antacids (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68856/", "reference_text": "[1] \"Product Information. Edurant (rilpivirine).\" Tibotec Pharmaceuticals, Titusville, NJ.[2] \"Product Information. Edurant (rilpivirine).\" Tibotec Pharmaceuticals, Titusville, NJ.[3] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[4] \"Product Information. Viread (tenofovir).\" Gilead Sciences, Foster City, CA.", "alternatives_a": "Magnesium gluconate, Zinc sulfate, Magnesium aspartate, Magnesium lactate, Sodium chloride, Zinc gluconate, Magnesium chloride, Alvimopan, Sorbitol, Methylnaltrexone, Tegaserod, More", "alternatives_b": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Valaciclovir, Zanamivir, Lenacapavir, Telaprevir, Etravirine, More", "updated_at": 1767369485}, {"id": 68770, "ingredient1": "Rimantadine", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline. Rare cases of generalized tonic-clonic seizures and/or loss of consciousness in association with low serum osmolality and electrolyte abnormalities (e.g., hyponatremia, hypokalemia, hypocalcemia, hypomagnesemia) have been reported with the use of bowel cleansing products in patients with no prior history of seizures. The condition resolved with correction of fluid and electrolyte abnormalities.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68857/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.[9] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, More", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 68771, "ingredient1": "Riociguat", "ingredient2": "Magnesium oxide", "severity": "Moderate", "effect": "INTERVAL: Concurrent administration of riociguat with antacids may reduce its gastrointestinal absorption. Riociguat exhibits pH-dependent solubility, with increased solubility at lower pH.", "source": "DDInter", "management_text": "Antacids should not be taken within 1 hour of riociguat administration.", "mechanism_text": "Absorption", "recommendation": "Antacids should not be taken within 1 hour of riociguat administration.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68858/", "reference_text": "[1] \"Product Information. Adempas (riociguat).\" Bayer Pharmaceutical Inc, West Haven, CT.[2] \"Product Information. Adempas (riociguat).\" Bayer Pharmaceutical Inc, West Haven, CT.", "alternatives_a": "Magnesium gluconate, Sodium sulfate, Zinc sulfate, Magnesium sulfate, Magnesium aspartate, Magnesium lactate, Magnesium citrate, Sodium chloride, Zinc gluconate, Magnesium chloride, Alvimopan, More", "alternatives_b": "Macitentan, Metyrosine, Tadalafil, Bosentan, Ambrisentan", "updated_at": 1767369485}, {"id": 68772, "ingredient1": "Risperidone", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; hydroxychloroquine; mefloquine), and some narcotic analgesics. The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that can prolong the QT interval, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; mefloquine; halofantrine; lumefantrine), and some narcotic analgesics (methadone; propoxyphene).", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68859/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[6] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[9] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[10] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[11] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[12] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[13] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[14] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[15] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Naldemedine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68773, "ingredient1": "Rivastigmine", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline. Rare cases of generalized tonic-clonic seizures and/or loss of consciousness in association with low serum osmolality and electrolyte abnormalities (e.g., hyponatremia, hypokalemia, hypocalcemia, hypomagnesemia) have been reported with the use of bowel cleansing products in patients with no prior history of seizures. The condition resolved with correction of fluid and electrolyte abnormalities.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68860/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.[9] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.", "alternatives_a": "Memantine, Ginkgo biloba, Aducanumab", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, More", "updated_at": 1767369485}, {"id": 68774, "ingredient1": "Rofecoxib", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations. Fluid and electrolyte disturbances can lead to serious adverse events including cardiac arrhythmias, seizures, and renal impairment.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment. Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered. Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing. Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68861/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Diovan (valsartan).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Cozaar (losartan).\" Merck & Co, Inc, West Point, PA.[5] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[6] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole", "alternatives_b": "Alvimopan, Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, Magnesium carbonate, More", "updated_at": 1767369485}, {"id": 68775, "ingredient1": "Romidepsin", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia are known risk factors for torsade de pointes associated with QT interval prolongation.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68862/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[5] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[8] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[9] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[10] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[11] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Pertuzumab, Olaparib, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 68776, "ingredient1": "Rosuvastatin", "ingredient2": "Magnesium oxide", "severity": "Moderate", "effect": "INTERVAL: Coadministration with antacids or agents with acid-neutralizing effects may reduce the oral bioavailability of rosuvastatin. The mechanism of interaction has not been established but may involve a pH-dependent reduction in drug dissolution and absorption.", "source": "DDInter", "management_text": "Until further data are available, patients treated with rosuvastatin should probably avoid taking antacids or oral medications that contain antacids (e.g., didanosine buffered tablets or pediatric oral solution) for at least two hours before and after administration of rosuvastatin.", "mechanism_text": "Absorption", "recommendation": "Until further data are available, patients treated with rosuvastatin should probably avoid taking antacids or oral medications that contain antacids (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68863/", "reference_text": "[1] \"Product Information. Crestor (rosuvastatin).\" AstraZeneca Pharma Inc, Mississauga, ON.", "alternatives_a": "Amlodipine, Valsartan, Simvastatin, Atorvastatin, Lovastatin, Niacin, Pravastatin, Ezetimibe, Bempedoic acid, Indapamide, Fenofibrate, More", "alternatives_b": "Magnesium gluconate, Sodium sulfate, Zinc sulfate, Magnesium sulfate, Magnesium aspartate, Magnesium lactate, Magnesium citrate, Sodium chloride, Zinc gluconate, Magnesium chloride, Alvimopan, More", "updated_at": 1767369485}, {"id": 68777, "ingredient1": "Rucaparib", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia are known risk factors for torsade de pointes associated with QT interval prolongation.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68864/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[5] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[8] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[9] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[10] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[11] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Alvimopan, Sorbitol, Tegaserod, Bisacodyl, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, Prucalopride, Linaclotide, More", "alternatives_b": "Pertuzumab, Olaparib, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, More", "updated_at": 1767369485}, {"id": 68778, "ingredient1": "Salsalate", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations. Fluid and electrolyte disturbances can lead to serious adverse events including cardiac arrhythmias, seizures, and renal impairment.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment. Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered. Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing. Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68865/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Diovan (valsartan).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Cozaar (losartan).\" Merck & Co, Inc, West Point, PA.[5] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[6] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Acetaminophen, Ziconotide, Methoxyflurane", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Prucalopride, Linaclotide, More", "updated_at": 1767369485}, {"id": 68779, "ingredient1": "Saquinavir", "ingredient2": "Picosulfuric acid", "severity": "Major", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval. Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly. Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68866/", "reference_text": "[1] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[2] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[9] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[10] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[11] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[12] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[13] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Magnesium oxide, Linaclotide, More", "updated_at": 1767369485}, {"id": 68780, "ingredient1": "Sarecycline", "ingredient2": "Magnesium oxide", "severity": "Moderate", "effect": "INTERVAL: Administration of a tetracycline with aluminum, calcium, or magnesium salts significantly decreases tetracycline serum concentrations. The proposed mechanism is chelation of tetracycline by the cation, forming an insoluble complex that is poorly absorbed from the gastrointestinal tract. The interaction has also been reported with parenteral doxycycline and oral antacids.", "source": "DDInter", "management_text": "The administration of tetracyclines and preparations containing aluminum, magnesium, or calcium should be separated by two to four hours.", "mechanism_text": "Absorption", "recommendation": "The administration of tetracyclines and preparations containing aluminum, magnesium, or calcium should be separated by two to four hours.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68867/", "reference_text": "[1] Nguyen VX, Nix DE, Gillikin S, Schentag JJ \"Effect of oral antacid administration on the pharmacokinetics of intravenous doxycycline.\" Antimicrob Agents Chemother 33 (1989): 434-6[2] Gotz VP, Ryerson GG \"Evaluation of tetracycline on theophylline disposition in patients with chronic obstructive airways disease.\" Drug Intell Clin Pharm 20 (1986): 694-6[3] Upton RA \"Pharmacokinetic interactions between theophylline and other medication (Part I).\" Clin Pharmacokinet 20 (1991): 66-80[4] \"Product Information. Nuzyra (omadacycline).\" Paratek Pharmaceuticals, Inc., Boston, MA.[5] \"Product Information. Seysara (sarecycline).\" Allergan Inc, Irvine, CA.[6] McCormack JP, Reid SE, Lawson LM \"Theophylline toxicity induced by tetracycline.\" Clin Pharm 9 (1990): 546-9[7] Neuvonen PJ \"Interactions with the absorption of tetracyclines.\" Drugs 11 (1976): 45-54[8] D'Arcy PF, McElnay JC \"Drug-antacid interactions: assessment of clinical importance.\" Drug Intell Clin Pharm 21 (1987): 607-17[9] \"Product Information. Declomycin (demeclocycline).\" Lederle Laboratories, Wayne, NJ.[10] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[11] Garty M, Hurwitz A \"Effect of cimetidine and antacids on gastrointestinal absorption of tetracycline.\" Clin Pharmacol Ther 28 (1980): 203-7[12] Deppermann KM, Lode H, Hoffken G, Tschink G, Kalz C, Koeppe P \"Influence of ranitidine, pirenzepine, and aluminum magnesium hydroxide on the bioavailability of various antibiotics, including amoxicillin, cephalexin, doxycycline, and amoxicillin-clavulanic acid.\" Antimicrob Agents Chemother 33 (1989): 1901-7[13] Covington TR, Lawson LC, Young LL, eds. \"Handbook of Nonprescription Drugs. 10th ed.\" Washington, DC: American Pharmaceutical Association (1993):[14] \"Product Information. Achromycin (tetracycline).\" Lederle Laboratories, Wayne, NJ.[15] \"Product Information. Declomycin (demeclocycline).\" Lederle Laboratories, Wayne, NJ.", "alternatives_a": "Sodium chloride, Sodium sulfate, Alvimopan, Sorbitol, Tegaserod, Bisacodyl, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Sodium sulfate, More", "alternatives_b": "Tigecycline, Eravacycline", "updated_at": 1767369485}, {"id": 68781, "ingredient1": "Secnidazole", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate. The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis. The clinical significance of this effect remains unknown.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic. If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Others", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68868/", "reference_text": "[1] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[3] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference) Available from: URL: http://www.mhra.gov.uk/spc-pil/index.htm.\"[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[6] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[7] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, More", "alternatives_b": "Tinidazole, Quinacrine, Nitazoxanide, Tinidazole", "updated_at": 1767369485}, {"id": 68782, "ingredient1": "Selpercatinib", "ingredient2": "Magnesium oxide", "severity": "Major", "effect": "Coadministration with drugs that increase gastric pH may significantly decrease the oral bioavailability of selpercatinib and reduce its concentrations in plasma.", "source": "DDInter", "management_text": "Concomitant use of selpercatinib with locally-acting antacids or other agents with acid neutralizing or reducing effects should generally be avoided. If coadministration is required, the manufacturer recommends taking selpercatinib 2 hours before or 2 hours after the antacid.", "mechanism_text": "Absorption", "recommendation": "Concomitant use of selpercatinib with locally-acting antacids or other agents with acid neutralizing or reducing effects should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68869/", "reference_text": "[1] \"Product Information. Retevmo (selpercatinib).\" Lilly, Eli and Company, Indianapolis, IN.[2] \"Product Information. Retevmo (selpercatinib).\" Lilly, Eli and Company, Indianapolis, IN.", "alternatives_a": "Magnesium gluconate, Zinc sulfate, Magnesium sulfate, Magnesium aspartate, Magnesium lactate, Sodium chloride, Zinc gluconate, Magnesium chloride, Alvimopan, Sorbitol, Magnesium sulfate, More", "alternatives_b": "Entrectinib, Imatinib, Pralsetinib, Asciminib, Dacomitinib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Vemurafenib, More", "updated_at": 1767369485}, {"id": 68783, "ingredient1": "Sertraline", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; hydroxychloroquine; mefloquine), and some narcotic analgesics. The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that can prolong the QT interval, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; mefloquine; halofantrine; lumefantrine), and some narcotic analgesics (methadone; propoxyphene).", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68870/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[6] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[9] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[10] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[11] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[12] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[13] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[14] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[15] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "St. John's Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Naldemedine, Prucalopride, More", "updated_at": 1767369485}, {"id": 68784, "ingredient1": "Sevoflurane", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia are known risk factors for torsade de pointes associated with QT interval prolongation.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68871/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[5] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[8] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[9] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[10] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[11] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Thiopental, Sodium oxybate, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Enflurane, Esketamine, Etomidate, Ketamine", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Naldemedine, More", "updated_at": 1767369485}, {"id": 68785, "ingredient1": "Sibutramine", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline. Rare cases of generalized tonic-clonic seizures and/or loss of consciousness in association with low serum osmolality and electrolyte abnormalities (e.g., hyponatremia, hypokalemia, hypocalcemia, hypomagnesemia) have been reported with the use of bowel cleansing products in patients with no prior history of seizures. The condition resolved with correction of fluid and electrolyte abnormalities.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68872/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.[9] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.", "alternatives_a": "Lorcaserin, Orlistat, Naltrexone", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 68786, "ingredient1": "Siponimod", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia are known risk factors for torsade de pointes associated with QT interval prolongation.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68873/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[5] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[8] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[9] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[10] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[11] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "alternatives_b": "Golimumab, Cyclosporine, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, More", "updated_at": 1767369485}, {"id": 68787, "ingredient1": "Tolevamer", "ingredient2": "Magnesium oxide", "severity": "Major", "effect": "Systemic alkalosis has been reported when cation-exchange resins were administered orally in combination with nonabsorbable cation-donating preparations such as antacids or laxatives. The mechanism involves binding of the cation to the resin, which prevents the cation from neutralizing bicarbonate ions in the intestine and also interferes with the resin's potassium exchange capability.", "source": "DDInter", "management_text": "Nonabsorbable calcium, magnesium, or aluminum preparations such as antacids or laxatives should not be used in patients receiving oral cation-exchange resins. Alternatively, the interaction may be avoided by administering the resin as an enema.", "mechanism_text": "Others", "recommendation": "Nonabsorbable calcium, magnesium, or aluminum preparations such as antacids or laxatives should not be used in patients receiving oral cation-exchange resins.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68874/", "reference_text": "[1] Ziessman HA \"Alkalosis and seizure due to a cation-exchange resin and magnesium hydroxide.\" South Med J 69 (1976): 497-9[2] Madias NE, Levey AS \"Metabolic alkalosis due to absorption of \"nonabsorbable\" antacids.\" Am J Med 74 (1983): 155-8[3] \"Product Information. Resonium Calcium (calcium polystyrene sulfonate).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[4] \"Product Information. Kayexalate (sodium polystyrene sulfonate).\" Sanofi Winthrop Pharmaceuticals, New York, NY.[5] Baluarte HJ, Prebis J, Goldberg M, Gruskin AB \"Metabolic alkalosis in an anephric child caused by the combined use of Kayexalate and Basaljel.\" J Pediatr 92 (1978): 237-9[6] Foresti V \"Intestinal obstruction due to kayexalate in a patient concurrently treated with aluminum hydroxide and morphine sulfate.\" Clin Nephrol 41 (1994): 252[7] \"Product Information. Kayexalate (sodium polystyrene sulfonate).\" Sanofi Winthrop Pharmaceuticals, New York, NY.[8] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Hydroxocobalamin, Fomepizole, Ipecac, Nitrous acid, Dexrazoxane, Oxygen, Lanthanum carbonate, Difelikefalin, Cobicistat, Deferoxamine, Levoleucovorin, More", "alternatives_b": "Sodium chloride, Sodium sulfate, Alvimopan, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, More", "updated_at": 1767369485}, {"id": 68788, "ingredient1": "Salicylic acid (sodium)", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations. Fluid and electrolyte disturbances can lead to serious adverse events including cardiac arrhythmias, seizures, and renal impairment.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment. Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered. Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing. Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68875/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Diovan (valsartan).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Cozaar (losartan).\" Merck & Co, Inc, West Point, PA.[5] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[6] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Prucalopride, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68789, "ingredient1": "Solifenacin", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia are known risk factors for torsade de pointes associated with QT interval prolongation.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68876/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[5] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[8] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[9] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[10] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[11] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Darifenacin, Tadalafil, Ammonium chloride, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, Trospium, Flavoxate, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Naldemedine, More", "updated_at": 1767369485}, {"id": 68790, "ingredient1": "Sorafenib", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia are known risk factors for torsade de pointes associated with QT interval prolongation.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68877/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[5] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[8] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[9] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[10] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[11] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Imatinib, Dabrafenib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Selumetinib, Cobimetinib, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Prucalopride, More", "updated_at": 1767369485}, {"id": 68791, "ingredient1": "Sotalol", "ingredient2": "Picosulfuric acid", "severity": "Major", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval. Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly. Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68878/", "reference_text": "[1] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[2] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[9] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[10] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[11] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[12] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[13] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Acebutolol, Labetalol, Nadolol, Propranolol, Metoprolol, Carvedilol, Esmolol, Betaxolol, Nebivolol, Penbutolol, Bisoprolol, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Naldemedine, Prucalopride, More", "updated_at": 1767369485}, {"id": 68792, "ingredient1": "Sparfloxacin", "ingredient2": "Picosulfuric acid", "severity": "Major", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval. Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly. Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68879/", "reference_text": "[1] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[2] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[9] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[10] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[11] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[12] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[13] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Alvimopan, Sorbitol, Methylnaltrexone, Tegaserod, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Naldemedine, Prucalopride, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68793, "ingredient1": "Spectinomycin", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate. The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis. The clinical significance of this effect remains unknown.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic. If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Others", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68880/", "reference_text": "[1] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[3] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference) Available from: URL: http://www.mhra.gov.uk/spc-pil/index.htm.\"[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[6] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[7] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Tinidazole", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, More", "updated_at": 1767369485}, {"id": 68794, "ingredient1": "Spironolactone", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations. Fluid and electrolyte disturbances can lead to serious adverse events including cardiac arrhythmias, seizures, and renal impairment.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment. Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered. Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing. Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68881/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Diovan (valsartan).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Cozaar (losartan).\" Merck & Co, Inc, West Point, PA.[5] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[6] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Eplerenone, Finerenone", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Magnesium oxide, Linaclotide, Naloxone, Magnesium carbonate", "updated_at": 1767369485}, {"id": 68795, "ingredient1": "Streptomycin", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate. The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis. The clinical significance of this effect remains unknown.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic. If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Others", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68882/", "reference_text": "[1] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[3] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference) Available from: URL: http://www.mhra.gov.uk/spc-pil/index.htm.\"[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[6] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[7] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Pyridoxine, Pretomanid, Nystatin, Amphotericin B, Miconazole", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, More", "updated_at": 1767369485}, {"id": 68796, "ingredient1": "Sufentanil", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline. Rare cases of generalized tonic-clonic seizures and/or loss of consciousness in association with low serum osmolality and electrolyte abnormalities (e.g., hyponatremia, hypokalemia, hypocalcemia, hypomagnesemia) have been reported with the use of bowel cleansing products in patients with no prior history of seizures. The condition resolved with correction of fluid and electrolyte abnormalities.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68883/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.[9] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.", "alternatives_a": "Thiopental, Sodium oxybate, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Enflurane, Esketamine, Etomidate, Ketamine", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 68797, "ingredient1": "Sulfadiazine", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate. The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis. The clinical significance of this effect remains unknown.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic. If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Others", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68884/", "reference_text": "[1] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[3] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference) Available from: URL: http://www.mhra.gov.uk/spc-pil/index.htm.\"[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[6] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[7] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Simeprevir, Rosuvastatin, Lactic acid, Mitapivat, Amphotericin B, Ciclopirox, Darunavir, Probenecid, More", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, More", "updated_at": 1767369485}, {"id": 68798, "ingredient1": "Sulfadoxine", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate. The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis. The clinical significance of this effect remains unknown.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic. If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Others", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68885/", "reference_text": "[1] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[3] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference) Available from: URL: http://www.mhra.gov.uk/spc-pil/index.htm.\"[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[6] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[7] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Artesunate, Lumefantrine, Artemether, Pyrimethamine, Tafenoquine, Proguanil, Tamsulosin, Tinidazole, Ascorbic acid, Simeprevir, Rosuvastatin, More", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, More", "updated_at": 1767369485}, {"id": 68799, "ingredient1": "Sulfamethizole", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate. The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis. The clinical significance of this effect remains unknown.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic. If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Others", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68886/", "reference_text": "[1] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[3] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference) Available from: URL: http://www.mhra.gov.uk/spc-pil/index.htm.\"[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[6] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[7] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Sorbitol, Sodium citrate, Magnesium citrate, Sodium bicarbonate, Sodium chloride, Chlorhexidine, Tamsulosin, Tinidazole, Ascorbic acid, Simeprevir, Rosuvastatin, More", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, More", "updated_at": 1767369485}, {"id": 68800, "ingredient1": "Sulfamethoxazole", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate. The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis. The clinical significance of this effect remains unknown.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic. If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Others", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68887/", "reference_text": "[1] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[3] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference) Available from: URL: http://www.mhra.gov.uk/spc-pil/index.htm.\"[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[6] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[7] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Pyridoxine, Pretomanid, Tamsulosin, Tinidazole, Ascorbic acid, Simeprevir, Rosuvastatin, Lactic acid, Mitapivat, Amphotericin B, Ciclopirox, More", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, More", "updated_at": 1767369485}, {"id": 68801, "ingredient1": "Sulfisoxazole", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate. The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis. The clinical significance of this effect remains unknown.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic. If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Others", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68888/", "reference_text": "[1] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[3] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference) Available from: URL: http://www.mhra.gov.uk/spc-pil/index.htm.\"[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[6] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[7] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Simeprevir, Rosuvastatin, Lactic acid, Mitapivat, Amphotericin B, Ciclopirox, Darunavir, Probenecid, More", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, More", "updated_at": 1767369485}, {"id": 68802, "ingredient1": "Sulindac", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations. Fluid and electrolyte disturbances can lead to serious adverse events including cardiac arrhythmias, seizures, and renal impairment.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment. Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered. Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing. Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68889/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Diovan (valsartan).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Cozaar (losartan).\" Merck & Co, Inc, West Point, PA.[5] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[6] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 68803, "ingredient1": "Sunitinib", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia are known risk factors for torsade de pointes associated with QT interval prolongation.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68890/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[5] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[8] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[9] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[10] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[11] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Imatinib, Dabrafenib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Selumetinib, Cobimetinib, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 68804, "ingredient1": "Tacrine", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline. Rare cases of generalized tonic-clonic seizures and/or loss of consciousness in association with low serum osmolality and electrolyte abnormalities (e.g., hyponatremia, hypokalemia, hypocalcemia, hypomagnesemia) have been reported with the use of bowel cleansing products in patients with no prior history of seizures. The condition resolved with correction of fluid and electrolyte abnormalities.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68891/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.[9] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.", "alternatives_a": "Memantine, Ginkgo biloba, Aducanumab", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 68805, "ingredient1": "Tacrolimus", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia are known risk factors for torsade de pointes associated with QT interval prolongation.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68892/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[5] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[8] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[9] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[10] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[11] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Minoxidil, Deoxycholic acid, Calcium gluconate, Magnesium sulfate, Glycopyrronium, Pimecrolimus, Aminobenzoic acid, Finasteride, Ivermectin, Caffeine, Cromoglicic acid, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Phenolphthalein, Plecanatide, Magnesium citrate, Bisacodyl, Lactitol, Lubiprostone, Methylcellulose, More", "updated_at": 1767369485}, {"id": 68806, "ingredient1": "Tamoxifen", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia are known risk factors for torsade de pointes associated with QT interval prolongation.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68893/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[5] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[8] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[9] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[10] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[11] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Darolutamide, Anastrozole, Fulvestrant, Letrozole, Aminoglutethimide, Exemestane", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, Magnesium carbonate, More", "updated_at": 1767369485}, {"id": 68807, "ingredient1": "Tapentadol", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline. Rare cases of generalized tonic-clonic seizures and/or loss of consciousness in association with low serum osmolality and electrolyte abnormalities (e.g., hyponatremia, hypokalemia, hypocalcemia, hypomagnesemia) have been reported with the use of bowel cleansing products in patients with no prior history of seizures. The condition resolved with correction of fluid and electrolyte abnormalities.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68894/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.[9] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.", "alternatives_a": "Dihydrocodeine, Acetaminophen, Naloxone, Naltrexone", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 68808, "ingredient1": "Tedizolid", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate. The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis. The clinical significance of this effect remains unknown.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic. If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Others", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68895/", "reference_text": "[1] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[3] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference) Available from: URL: http://www.mhra.gov.uk/spc-pil/index.htm.\"[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[6] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[7] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, More", "alternatives_b": "Tinidazole", "updated_at": 1767369485}, {"id": 68809, "ingredient1": "Telavancin", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate. The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis. Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic. If concomitant use is required, additional bowel cleansing and colonoscopy may be required. The recommended dosage and duration of treatment with sodium picosulfate should not be exceeded. In addition, patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68896/", "reference_text": "[1] Muller-Lissner SA \"Adverse effects of laxatives: fact and fiction.\" Pharmacology 47 (1993): 138-45[2] Schaefer DC, Cheskin LJ \"Constipation in the elderly.\" Am Fam Physician 58 (1998): 907-14[3] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[4] Chin RL \"Laxative-induced hypokalemia.\" Ann Emerg Med 32 (1998): 517-8[5] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference) Available from: URL: http://www.mhra.gov.uk/spc-pil/index.htm.\"[9] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[10] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[11] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[12] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Tinidazole", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 68810, "ingredient1": "Telithromycin", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate. The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis. Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic. If concomitant use is required, additional bowel cleansing and colonoscopy may be required. The recommended dosage and duration of treatment with sodium picosulfate should not be exceeded. In addition, patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68897/", "reference_text": "[1] Muller-Lissner SA \"Adverse effects of laxatives: fact and fiction.\" Pharmacology 47 (1993): 138-45[2] Schaefer DC, Cheskin LJ \"Constipation in the elderly.\" Am Fam Physician 58 (1998): 907-14[3] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[4] Chin RL \"Laxative-induced hypokalemia.\" Ann Emerg Med 32 (1998): 517-8[5] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference) Available from: URL: http://www.mhra.gov.uk/spc-pil/index.htm.\"[9] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[10] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[11] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[12] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Magnesium oxide, Linaclotide, Naloxone, Magnesium carbonate", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68811, "ingredient1": "Telmisartan", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations. Fluid and electrolyte disturbances can lead to serious adverse events including cardiac arrhythmias, seizures, and renal impairment.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment. Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered. Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing. Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68898/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Diovan (valsartan).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Cozaar (losartan).\" Merck & Co, Inc, West Point, PA.[5] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[6] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Amlodipine, Sacubitril, Aliskiren, Nebivolol", "alternatives_b": "Alvimopan, Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, Magnesium carbonate, More", "updated_at": 1767369485}, {"id": 68812, "ingredient1": "Temazepam", "ingredient2": "Magnesium oxide", "severity": "Minor", "effect": "number of studies have reported that antacids can delay the gastrointestinal absorption and reduce the peak plasma concentration (Cmax) of some benzodiazepines, including clorazepate, chlordiazepoxide and diazepam, although the overall extent of absorption is generally not affected. The exact mechanism of interaction is unknown, but may involve delayed gastric emptying or cation binding of the benzodiazepine.", "source": "DDInter", "management_text": "-", "mechanism_text": "Absorption", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68899/", "reference_text": "[1] Greenblatt DJ, Allen MD, MacLaughlin DS, Harmatz JS, Shader RI \"Diazepam absorption: effect of antacids and food.\" Clin Pharmacol Ther 24 (1978): 600-9[2] Kroboth PD, Smith RB, Silver MR, Rault R, Sorkin MI, Puschett JB, Juhl RP \"Effects of end stage renal disease and aluminium hydroxide on triazolam pharmacokinetics.\" Br J Clin Pharmacol 19 (1985): 839-42[3] Greenblatt DJ, Shader RI, Harmatz JS, Franke K, Koch-Weser J \"Absorption rate, blood concentrations, and early response to oral chlordiazepoxide.\" Am J Psychiatry 134 (1977): 559-62[4] Shader RI, Ciraulo DA, Greenblatt DJ, Harmatz JS \"Steady-state plasma desmethyldiazepam during long-term clorazepate use: effects of antacids.\" Clin Pharmacol Ther 31 (1982): 180-3[5] Greenblatt DJ, Shader RI, Harmatz JS, Franke K, Koch-Weser J \"Influence of magnesium and aluminum hydroxide mixture on chlordiazepoxide absorption.\" Clin Pharmacol Ther 19 (1976): 234-9[6] Kroboth PD, Smith RB, Rault R, Silver MR, Sorkin MI, Puschett JB, Juhl RP \"Effects of end-stage renal disease and aluminum hydroxide on temazepam kinetics.\" Clin Pharmacol Ther 37 (1985): 453-9[7] Chun AH, Carrigan PJ, Hoffman DJ, Kershner RP, Stuart JD \"Effect of antacids on absorption of clorazepate.\" Clin Pharmacol Ther 22 (1977): 329-35[8] Nair SG, Gamble JA, Dundee JW, Howard PJ \"The influence of three antacids on the absorption and clinical action of oral diazepam.\" Br J Anaesth 48 (1976): 1175-80[9] Shader RI, Georgotas A, Greenblatt DJ, Harmatz JS, Allen MD \"Impaired absorption of desmethyldiazepam from clorazepate by magnesium aluminum hydroxide.\" Clin Pharmacol Ther 24 (1978): 308-15[10] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[11] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[12] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[13] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Suvorexant, Methohexital, Methylphenobarbital, Zolpidem, Pentobarbital, Zaleplon, Dichloralphenazone, Valerian, Butabarbital, Secobarbital, Chloral hydrate, More", "alternatives_b": "Magnesium gluconate, Sodium sulfate, Zinc sulfate, Magnesium sulfate, Magnesium aspartate, Magnesium lactate, Magnesium citrate, Sodium chloride, Zinc gluconate, Magnesium chloride, Alvimopan, More", "updated_at": 1767369485}, {"id": 68813, "ingredient1": "Terbutaline", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia are known risk factors for torsade de pointes associated with QT interval prolongation.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68900/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[5] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[8] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[9] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[10] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[11] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Formoterol, Orciprenaline, Pirbuterol, Isoprenaline, Formoterol, Cromoglicic acid, Ipratropium, Isoprenaline, Tiotropium, Beclomethasone dipropionate, Budesonide, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Naldemedine, More", "updated_at": 1767369485}, {"id": 68814, "ingredient1": "Terfenadine", "ingredient2": "Picosulfuric acid", "severity": "Major", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval. Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly. Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68901/", "reference_text": "[1] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[2] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[9] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[10] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[11] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[12] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[13] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Ketotifen, Mepyramine, Levocetirizine, Chlorcyclizine, Cetirizine, Acrivastine, Triprolidine, Tripelennamine, Azelastine, Dexbrompheniramine, Clemastine, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 68815, "ingredient1": "Tetrabenazine", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia are known risk factors for torsade de pointes associated with QT interval prolongation.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68902/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[5] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[8] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[9] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[10] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[11] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Dextromethorphan, Sodium oxybate, Riluzole, Inotersen, Tafamidis", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 68816, "ingredient1": "Thalidomide", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate. The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis. The clinical significance of this effect remains unknown.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic. If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Others", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68903/", "reference_text": "[1] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[3] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference) Available from: URL: http://www.mhra.gov.uk/spc-pil/index.htm.\"[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[6] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[7] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Golimumab, Cyclosporine, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, More", "alternatives_b": "Alvimopan, Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, Sodium sulfate, Prucalopride, More", "updated_at": 1767369485}, {"id": 68817, "ingredient1": "Theophylline", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline. Rare cases of generalized tonic-clonic seizures and/or loss of consciousness in association with low serum osmolality and electrolyte abnormalities (e.g., hyponatremia, hypokalemia, hypocalcemia, hypomagnesemia) have been reported with the use of bowel cleansing products in patients with no prior history of seizures. The condition resolved with correction of fluid and electrolyte abnormalities.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68904/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.[9] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.", "alternatives_a": "Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Montelukast, Dyphylline, Mepolizumab, Roflumilast, Pentoxifylline, More", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, More", "updated_at": 1767369485}, {"id": 68818, "ingredient1": "Thiethylperazine", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline. Rare cases of generalized tonic-clonic seizures and/or loss of consciousness in association with low serum osmolality and electrolyte abnormalities (e.g., hyponatremia, hypokalemia, hypocalcemia, hypomagnesemia) have been reported with the use of bowel cleansing products in patients with no prior history of seizures. The condition resolved with correction of fluid and electrolyte abnormalities.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68905/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.[9] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.", "alternatives_a": "Ketotifen, Mepyramine, Levocetirizine, Chlorcyclizine, Cetirizine, Acrivastine, Triprolidine, Tripelennamine, Azelastine, Dexbrompheniramine, Clemastine, More", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Prucalopride, Linaclotide, More", "updated_at": 1767369485}, {"id": 68819, "ingredient1": "Thioridazine", "ingredient2": "Picosulfuric acid", "severity": "Major", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval. Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly. Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68906/", "reference_text": "[1] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[2] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[9] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[10] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[11] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[12] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[13] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Naldemedine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68820, "ingredient1": "Thiothixene", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline. Rare cases of generalized tonic-clonic seizures and/or loss of consciousness in association with low serum osmolality and electrolyte abnormalities (e.g., hyponatremia, hypokalemia, hypocalcemia, hypomagnesemia) have been reported with the use of bowel cleansing products in patients with no prior history of seizures. The condition resolved with correction of fluid and electrolyte abnormalities.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68907/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.[9] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.", "alternatives_a": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68821, "ingredient1": "Thyroid, porcine", "ingredient2": "Magnesium oxide", "severity": "Moderate", "effect": "INTERVAL: Concurrent administration of simethicone and/or antacid preparations may decrease the oral bioavailability of levothyroxine. Pharmacologic effects of levothyroxine may be reduced. The exact mechanism of interaction is unknown but may involve nonspecific adsorption of levothyroxine to polyvalent cations, resulting in an insoluble complex that is poorly absorbed from the gastrointestinal tract. Additionally, because gastric acidity is required for adequate levothyroxine absorption, agents that effect intragastric pH may reduce levothyroxine absorption.", "source": "DDInter", "management_text": "It is recommended to separate the times of administration of levothyroxine and simethicone and antacids or other antacid-containing preparations (e.g., didanosine buffered tablets or pediatric oral solution) by at least 4 hours. Monitoring of serum TSH levels is recommended. Patients with gastrointestinal or malabsorption disorders may be at a greater risk of developing clinical or subclinical hypothyroidism due to this interaction.", "mechanism_text": "Absorption", "recommendation": "It is recommended to separate the times of administration of levothyroxine and simethicone and antacids or other antacid-containing preparations (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68908/", "reference_text": "[1] Schneyer CR \"Calcium carbonate and reduction of levothyroxine efficacy.\" JAMA 279 (1998): 750[2] \"Product Information. Synthroid (levothyroxine).\" Abbott Pharmaceutical, Abbott Park, IL.[3] Neafsey PJ \"Levothyroxine and calcium interaction: timing is everything.\" Home Healthc Nurse 22 (2004): 338-9[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Campbell NR, Hasinoff BB, Stalts H, Rao B, Wong NC \"Ferrous sulfate reduces thyroxine efficacy in patients with hypothyroidism.\" Ann Intern Med 117 (1992): 1010-3[6] Singh N, Singh PN, Hershman JM \"Effect of calcium carbonate on the absorption of levothyroxine.\" JAMA 283 (2000): 2822-5[7] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[8] Sperber AD, Liel Y \"Evidence for interference with the intestinal absorption of levothyroxine sodium by aluminum hydroxide.\" Arch Intern Med 152 (1992): 183-4[9] Csako G, McGriff NJ, Rotman-Pikielny P, Sarlis NJ, Pucino F \"Exaggerated levothyroxine malabsorption due to calcium carbonate supplementation in gastrointestinal disorders.\" Ann Pharmacother 35 (2001): 1578-83[10] Cerner Multum, Inc. \"Australian Product Information.\" O 0[11] Liel Y, Sperber AD, Shany S \"Nonspecific intestinal adsorption of levothyroxine by aluminum hydroxide.\" Am J Med 97 (1994): 363-5[12] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[13] \"Product Information. Armour thyroid (thyroid desiccated).\" Forest Pharmaceuticals, St. Louis, MO.[14] \"Product Information. Synthroid (levothyroxine).\" Abbott Pharmaceutical, Abbott Park, IL.", "alternatives_a": "Magnesium gluconate, Sodium sulfate, Zinc sulfate, Magnesium sulfate, Magnesium aspartate, Magnesium lactate, Magnesium citrate, Sodium chloride, Zinc gluconate, Magnesium chloride, Alvimopan, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68822, "ingredient1": "Ticarcillin", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate. The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis. The clinical significance of this effect remains unknown.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic. If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Others", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68909/", "reference_text": "[1] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[3] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference) Available from: URL: http://www.mhra.gov.uk/spc-pil/index.htm.\"[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[6] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[7] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Tazobactam, Sulbactam", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, More", "updated_at": 1767369485}, {"id": 68823, "ingredient1": "Ticlopidine", "ingredient2": "Magnesium oxide", "severity": "Minor", "effect": "Coadministration of oral medications that contain magnesium, aluminum, calcium, or sodium (i.e., antacids) has decreased ticlopidine serum concentrations by 18%. Administration of these drugs should be separated by at least three hours.", "source": "DDInter", "management_text": "-", "mechanism_text": "Absorption", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68910/", "reference_text": "[1] \"Product Information. Ticlid (ticlopidine).\" Syntex Laboratories Inc, Palo Alto, CA.[2] \"Product Information. Ticlid (ticlopidine).\" Syntex Laboratories Inc, Palo Alto, CA.", "alternatives_a": "Ticagrelor, Betrixaban, Apixaban, Cilostazol, Rivaroxaban, Clopidogrel, Iloprost, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, More", "alternatives_b": "Magnesium gluconate, Sodium sulfate, Zinc sulfate, Magnesium sulfate, Magnesium aspartate, Magnesium lactate, Magnesium citrate, Sodium chloride, Zinc gluconate, Magnesium chloride, Alvimopan, More", "updated_at": 1767369485}, {"id": 68824, "ingredient1": "Tigecycline", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate. The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis. The clinical significance of this effect remains unknown.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic. If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Others", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68911/", "reference_text": "[1] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[3] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference) Available from: URL: http://www.mhra.gov.uk/spc-pil/index.htm.\"[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[6] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[7] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68825, "ingredient1": "Tiludronic acid", "ingredient2": "Magnesium oxide", "severity": "Moderate", "effect": "INTERVAL: Products containing aluminum, calcium, magnesium and other polyvalent cations such as antacids or vitamin with mineral supplements are likely to interfere with the gastrointestinal absorption of oral bisphosphonates.", "source": "DDInter", "management_text": "Antacids or other oral medications containing aluminum, calcium, magnesium and other polyvalent cations should be administered at least 2 hours before or 2 hours after the bisphosphonate dose.", "mechanism_text": "Absorption", "recommendation": "Antacids or other oral medications containing aluminum, calcium, magnesium and other polyvalent cations should be administered at least 2 hours before or 2 hours after the bisphosphonate dose.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68912/", "reference_text": "[1] \"Product Information. Boniva (ibandronate).\" Roche Laboratories, Nutley, NJ.[2] \"Product Information. Fosamax (alendronate).\" Merck & Co, Inc, West Point, PA.[3] \"Product Information. Skelid (tilundronate).\" Sanofi Winthrop Pharmaceuticals, New York, NY.[4] Darcy PF \"Nutrient-drug interactions.\" Adverse Drug React Toxicol Rev 14 (1995): 233-54[5] \"Product Information. Bonefos (clodronate).\" Rhone-Poulenc Rorer Canada Inc, Laval, QC.[6] \"Product Information. Actonel (risedronate).\" Procter and Gamble Pharmaceuticals, Cincinnati, OH.[7] \"Product Information. Skelid (tilundronate).\" Sanofi Winthrop Pharmaceuticals, New York, NY.", "alternatives_a": "Vosoritide, Denosumab, Burosumab, Romosozumab, Zoledronic acid, Pamidronic acid", "alternatives_b": "Sodium chloride, Sodium sulfate, Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, More", "updated_at": 1767369485}, {"id": 68826, "ingredient1": "Timolol", "ingredient2": "Magnesium oxide", "severity": "Minor", "effect": "Concurrent administration with aluminum and magnesium antacids has been shown to decrease the oral bioavailability of certain beta-blockers, although data are conflicting. The exact mechanism of interaction is unknown but may involve cation binding of beta-blockers or a reduction in the dissolution rate due to increased gastric pH. Based on available data, the clinical significance of this potential interaction is difficult to determine. As a precaution, patients may want to consider separating the administration times of beta-blockers and antacids or other aluminum- or magnesium-containing products by at least 2 hours.", "source": "DDInter", "management_text": "-", "mechanism_text": "Absorption", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68913/", "reference_text": "[1] D'Arcy PF, McElnay JC \"Drug-antacid interactions: assessment of clinical importance.\" Drug Intell Clin Pharm 21 (1987): 607-17[2] Regardh CG, Lundborg P, Persson BA \"The effect of antacid, metoclopramide, and propantheline on the bioavailability of metoprolol and atenolol.\" Biopharm Drug Dispos 2 (1981): 79-87[3] Hong CY, Hu SC, Lin SJ, Chiang BN \"Lack of influence of aluminum hydroxide on the bioavailability and beta-adrenoceptor blocking activity of propranolol.\" Int J Clin Pharmacol Ther Toxicol 23 (1985): 244-6[4] Kirch W, Schafer-Korting M, Axthelm T, Kohler H, Mutschler E \"Interaction of atenolol with furosemide and calcium and aluminum salts.\" Clin Pharmacol Ther 30 (1981): 429-35[5] Laer S, Neumann J, Scholz H \"Interaction between sotalol and an antacid preparation.\" Br J Clin Pharmacol 43 (1997): 269-72[6] Gugler R, Allgayer H \"Effects of antacids on the clinical pharmacokinetics of drugs. An update.\" Clin Pharmacokinet 18 (1990): 210-9[7] Dobbs JH, Skoutakis VA, Acchiardo SR, Dobbs BR \"Effects of aluminum hydroxide on the absorption of propranolol.\" Curr Ther Res Clin Exp 21 (1977): 887-92", "alternatives_a": "Esmolol, Latanoprost, Apraclonidine, Methazolamide, Neostigmine, Pilocarpine, Clonidine, Physostigmine, Acetylcholine, Diclofenamide, Bimatoprost, More", "alternatives_b": "Magnesium gluconate, Sodium sulfate, Zinc sulfate, Magnesium sulfate, Magnesium aspartate, Magnesium lactate, Magnesium citrate, Sodium chloride, Zinc gluconate, Magnesium chloride, Alvimopan, More", "updated_at": 1767369485}, {"id": 68827, "ingredient1": "Tipranavir", "ingredient2": "Magnesium oxide", "severity": "Moderate", "effect": "INTERVAL: Concurrent administration of antacids or other agents with acid-neutralizing effects may decrease the oral bioavailability of tipranavir and reduce its concentrations in plasma. The mechanism of interaction has not been described. The clinical significance of these changes is unknown. However, subtherapeutic antiretroviral drug levels may lead to reduced viral susceptibility and development of resistance.", "source": "DDInter", "management_text": "Consideration should be given to separating tipranavir/ritonavir dosing from antacid administration to prevent reduced absorption of tipranavir.", "mechanism_text": "Absorption", "recommendation": "Consideration should be given to separating tipranavir/ritonavir dosing from antacid administration to prevent reduced absorption of tipranavir.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68914/", "reference_text": "[1] \"Product Information. Aptivus (tipranavir).\" Boehringer-Ingelheim, Ridgefield, CT.[2] Durant J, Clevenbergh P, Garraffo R, Halfon P, Icard S, DelGiudice P, Montagne N, Schapiro JM, Dellamonica P \"Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: pharmacological data from the Viradapt Study.\" Aids 14 (2000): 1333-9[3] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[4] \"Product Information. Aptivus (tipranavir).\" Boehringer-Ingelheim, Ridgefield, CT.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Valaciclovir, Zanamivir, Lenacapavir, Telaprevir, Etravirine, More", "alternatives_b": "Magnesium gluconate, Sodium sulfate, Zinc sulfate, Magnesium sulfate, Magnesium aspartate, Magnesium lactate, Magnesium citrate, Sodium chloride, Zinc gluconate, Magnesium chloride, Alvimopan, More", "updated_at": 1767369485}, {"id": 68828, "ingredient1": "Tizanidine", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia are known risk factors for torsade de pointes associated with QT interval prolongation.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68915/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[5] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[8] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[9] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[10] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[11] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Carisoprodol, Orphenadrine, Chlorzoxazone, Baclofen, Methocarbamol, Chlormezanone", "alternatives_b": "Alvimopan, Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, Magnesium carbonate, More", "updated_at": 1767369485}, {"id": 68829, "ingredient1": "Tobramycin", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate. The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis. The clinical significance of this effect remains unknown.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic. If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Others", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68916/", "reference_text": "[1] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[3] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference) Available from: URL: http://www.mhra.gov.uk/spc-pil/index.htm.\"[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[6] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[7] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Ganciclovir, Acyclovir, Famciclovir, Trifluridine, Chlorhexidine, Povidone-iodine", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, Sodium sulfate, More", "updated_at": 1767369485}, {"id": 68830, "ingredient1": "Tolazamide", "ingredient2": "Magnesium oxide", "severity": "Moderate", "effect": "INTERVAL: Some antacids have been reported to increase the rate of absorption and, rarely, the extent of absorption of oral sulfonylureas. The hypoglycemic effects of these agents may be altered.", "source": "DDInter", "management_text": "Sulfonylureas should be administered at least two hours before or after antacids when possible. Regular monitoring of blood sugar is advisable. In addition, patients should be apprised of the signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nausea, hunger, tremor, weakness, sweating, palpitations), how to treat it, and to contact their physician if it occurs.", "mechanism_text": "Absorption", "recommendation": "Sulfonylureas should be administered at least two hours before or after antacids when possible.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68917/", "reference_text": "[1] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[2] Prendergast BD \"Glyburide and glipizide, second-generation oral sulfonylurea hypoglycemic agents.\" Clin Pharm 3 (1984): 473-85[3] \"Product Information. Micronase (glyburide).\" Pharmacia and Upjohn, Kalamazoo, MI.[4] Kivisto KT, Neuvonen PJ \"Effect of magnesium hydroxide on the absorption and efficacy of tolbutamide and chlorpropamide.\" Eur J Clin Pharmacol 42 (1992): 675-80[5] Kolterman OG \"Glyburide in non-insulin-dependent diabetes: an update.\" Clin Ther 14 (1992): 196-213[6] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[7] Kivisto KT, Neuvonen PJ \"Enhancement of absorption and effect of glipizide by magnesium hydroxide.\" Clin Pharmacol Ther 49 (1991): 39-43[8] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[9] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[10] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[11] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[12] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[13] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[14] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[15] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[16] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[17] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Guar gum, Pramlintide, Alogliptin, Empagliflozin, Dulaglutide, Exenatide, Miglitol, Albiglutide, Rosiglitazone, Ertugliflozin, Semaglutide, More", "alternatives_b": "Magnesium gluconate, Sodium sulfate, Zinc sulfate, Magnesium sulfate, Magnesium aspartate, Magnesium lactate, Magnesium citrate, Sodium chloride, Zinc gluconate, Magnesium chloride, Alvimopan, More", "updated_at": 1767369485}, {"id": 68831, "ingredient1": "Tolbutamide", "ingredient2": "Magnesium oxide", "severity": "Moderate", "effect": "INTERVAL: Some antacids have been reported to increase the rate of absorption and, rarely, the extent of absorption of oral sulfonylureas. The hypoglycemic effects of these agents may be altered.", "source": "DDInter", "management_text": "Sulfonylureas should be administered at least two hours before or after antacids when possible. Regular monitoring of blood sugar is advisable. In addition, patients should be apprised of the signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nausea, hunger, tremor, weakness, sweating, palpitations), how to treat it, and to contact their physician if it occurs.", "mechanism_text": "Absorption", "recommendation": "Sulfonylureas should be administered at least two hours before or after antacids when possible.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68918/", "reference_text": "[1] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[2] Prendergast BD \"Glyburide and glipizide, second-generation oral sulfonylurea hypoglycemic agents.\" Clin Pharm 3 (1984): 473-85[3] \"Product Information. Micronase (glyburide).\" Pharmacia and Upjohn, Kalamazoo, MI.[4] Kivisto KT, Neuvonen PJ \"Effect of magnesium hydroxide on the absorption and efficacy of tolbutamide and chlorpropamide.\" Eur J Clin Pharmacol 42 (1992): 675-80[5] Kolterman OG \"Glyburide in non-insulin-dependent diabetes: an update.\" Clin Ther 14 (1992): 196-213[6] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[7] Kivisto KT, Neuvonen PJ \"Enhancement of absorption and effect of glipizide by magnesium hydroxide.\" Clin Pharmacol Ther 49 (1991): 39-43[8] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[9] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[10] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[11] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[12] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[13] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[14] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[15] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[16] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[17] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Sorbitol, Caffeine, Edrophonium, Indocyanine green, Inulin, Hexaminolevulinate, Secretin human, Galactose, Corticorelin, Macimorelin, Methacholine, More", "alternatives_b": "Magnesium gluconate, Sodium sulfate, Zinc sulfate, Magnesium sulfate, Magnesium aspartate, Magnesium lactate, Magnesium citrate, Sodium chloride, Zinc gluconate, Magnesium chloride, Alvimopan, More", "updated_at": 1767369485}, {"id": 68832, "ingredient1": "Tolmetin", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations. Fluid and electrolyte disturbances can lead to serious adverse events including cardiac arrhythmias, seizures, and renal impairment.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment. Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered. Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing. Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68919/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Diovan (valsartan).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Cozaar (losartan).\" Merck & Co, Inc, West Point, PA.[5] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[6] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole, Tolazoline, Rabeprazole, Dimethyl sulfoxide", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 68833, "ingredient1": "Toremifene", "ingredient2": "Picosulfuric acid", "severity": "Major", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval. Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly. Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68920/", "reference_text": "[1] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[2] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[9] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[10] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[11] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[12] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[13] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Darolutamide, Anastrozole, Fulvestrant, Letrozole, Aminoglutethimide, Exemestane", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 68834, "ingredient1": "Torasemide", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations. Fluid and electrolyte disturbances can lead to serious adverse events including cardiac arrhythmias, seizures, and renal impairment.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment. Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered. Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing. Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68921/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Diovan (valsartan).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Cozaar (losartan).\" Merck & Co, Inc, West Point, PA.[5] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[6] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Simeprevir, Rosuvastatin, Lactic acid, Mitapivat, Amphotericin B, Ciclopirox, Darunavir, Probenecid, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Naldemedine, More", "updated_at": 1767369485}, {"id": 68835, "ingredient1": "Tramadol", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; hydroxychloroquine; mefloquine), and some narcotic analgesics. The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that can prolong the QT interval, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; mefloquine; halofantrine; lumefantrine), and some narcotic analgesics (methadone; propoxyphene).", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68922/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[6] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[9] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[10] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[11] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[12] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[13] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[14] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[15] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Dihydrocodeine, Acetaminophen, Naloxone, Naltrexone", "alternatives_b": "Sorbitol, Magnesium sulfate, Methylnaltrexone, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Naldemedine, Prucalopride, More", "updated_at": 1767369485}, {"id": 68836, "ingredient1": "Trandolapril", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations. Fluid and electrolyte disturbances can lead to serious adverse events including cardiac arrhythmias, seizures, and renal impairment.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment. Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered. Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing. Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68923/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Diovan (valsartan).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Cozaar (losartan).\" Merck & Co, Inc, West Point, PA.[5] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[6] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Felodipine, Amlodipine, Verapamil, Bisoprolol", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Prucalopride, Linaclotide, More", "updated_at": 1767369485}, {"id": 68837, "ingredient1": "Tranylcypromine", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline. Rare cases of generalized tonic-clonic seizures and/or loss of consciousness in association with low serum osmolality and electrolyte abnormalities (e.g., hyponatremia, hypokalemia, hypocalcemia, hypomagnesemia) have been reported with the use of bowel cleansing products in patients with no prior history of seizures. The condition resolved with correction of fluid and electrolyte abnormalities.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68924/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.[9] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.", "alternatives_a": "St. John's Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 68838, "ingredient1": "Trazodone", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; hydroxychloroquine; mefloquine), and some narcotic analgesics. The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that can prolong the QT interval, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; mefloquine; halofantrine; lumefantrine), and some narcotic analgesics (methadone; propoxyphene).", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68925/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[6] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[9] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[10] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[11] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[12] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[13] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[14] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[15] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "St. John's Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Naldemedine, More", "updated_at": 1767369485}, {"id": 68839, "ingredient1": "Triamcinolone", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The overuse or abuse of laxatives can cause significant loss of electrolytes and potentiate the risk of hypokalemia associated with corticosteroid therapy. Corticosteroids promote the retention of sodium and water and the excretion of potassium. Although these effects are primarily associated with mineralocorticoids like fludrocortisone, they may also occur with higher dosages of glucocorticoids or adrenocorticotropic agents, particularly if given systemically for longer than brief periods.", "source": "DDInter", "management_text": "In general, laxatives should only be used on a short-term, intermittent basis in recommended dosages. During concomitant therapy with corticosteroids, particularly if fludrocortisone or large doses of a glucocorticoid or adrenocorticotropic agent is given, patients should be counseled to recognize potential signs and symptoms of hypokalemia such as fatigue, myalgia, and muscle weakness. If maintenance of bowel regularity is required, patients should be advised to exercise and increase fiber in the diet and/or consider the use of bulk-forming laxatives.", "mechanism_text": "Antagonism", "recommendation": "In general, laxatives should only be used on a short-term, intermittent basis in recommended dosages.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68926/", "reference_text": "[1] Chin RL \"Laxative-induced hypokalemia.\" Ann Emerg Med 32 (1998): 517-8[2] Blumenthal M, Goldberg A, Brinckmann J, eds. \"Herbal Medicine: Expanded Commission E Monographs.\" Newton, MA: Integrative Medicine Communications (2000):[3] Muller-Lissner SA \"Adverse effects of laxatives: fact and fiction.\" Pharmacology 47 (1993): 138-45[4] Seale JP, Compton MR \"Side-effects of corticosteroid agents.\" Med J Aust 144 (1986): 139-42[5] Swartz SL, Dluhy RG \"Corticosteroids: clinical pharmacology and therapeutic use.\" Drugs 16 (1978): 238-55[6] Lieberman P, Patterson R, Kunske R \"Complications of long-term steroid therapy for asthma.\" J Allergy Clin Immunol 49 (1972): 329-36[7] Ramsahoye BH, Davies SV, el-Gaylani N, Sandeman D, Scanlon MF \"The mineralocorticoid effects of high dose hydrocortisone.\" BMJ 310 (1995): 656-7", "alternatives_a": "Mometasone furoate, Amcinonide, Budesonide, Fluocinolone acetonide, Hydrocortisone butyrate, Fluticasone, Fluocinonide, Fluorometholone, Clobetasol, Beclomethasone dipropionate, Ciclesonide, More", "alternatives_b": "Alvimopan, Sodium sulfate, Sorbitol, Methylnaltrexone, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Naldemedine, Prucalopride, More", "updated_at": 1767369485}, {"id": 68840, "ingredient1": "Triamcinolone (ophthalmic)", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The overuse or abuse of laxatives can cause significant loss of electrolytes and potentiate the risk of hypokalemia associated with corticosteroid therapy. Corticosteroids promote the retention of sodium and water and the excretion of potassium. Although these effects are primarily associated with mineralocorticoids like fludrocortisone, they may also occur with higher dosages of glucocorticoids or adrenocorticotropic agents, particularly if given systemically for longer than brief periods.", "source": "DDInter", "management_text": "In general, laxatives should only be used on a short-term, intermittent basis in recommended dosages. During concomitant therapy with corticosteroids, particularly if fludrocortisone or large doses of a glucocorticoid or adrenocorticotropic agent is given, patients should be counseled to recognize potential signs and symptoms of hypokalemia such as fatigue, myalgia, and muscle weakness. If maintenance of bowel regularity is required, patients should be advised to exercise and increase fiber in the diet and/or consider the use of bulk-forming laxatives.", "mechanism_text": "Antagonism", "recommendation": "In general, laxatives should only be used on a short-term, intermittent basis in recommended dosages.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68927/", "reference_text": "[1] Chin RL \"Laxative-induced hypokalemia.\" Ann Emerg Med 32 (1998): 517-8[2] Blumenthal M, Goldberg A, Brinckmann J, eds. \"Herbal Medicine: Expanded Commission E Monographs.\" Newton, MA: Integrative Medicine Communications (2000):[3] Muller-Lissner SA \"Adverse effects of laxatives: fact and fiction.\" Pharmacology 47 (1993): 138-45[4] Seale JP, Compton MR \"Side-effects of corticosteroid agents.\" Med J Aust 144 (1986): 139-42[5] Swartz SL, Dluhy RG \"Corticosteroids: clinical pharmacology and therapeutic use.\" Drugs 16 (1978): 238-55[6] Lieberman P, Patterson R, Kunske R \"Complications of long-term steroid therapy for asthma.\" J Allergy Clin Immunol 49 (1972): 329-36[7] Ramsahoye BH, Davies SV, el-Gaylani N, Sandeman D, Scanlon MF \"The mineralocorticoid effects of high dose hydrocortisone.\" BMJ 310 (1995): 656-7", "alternatives_a": "Mometasone furoate, Amcinonide, Budesonide, Fluocinolone acetonide, Hydrocortisone butyrate, Fluticasone, Fluocinonide, Fluorometholone, Clobetasol, Beclomethasone dipropionate, Ciclesonide, More", "alternatives_b": "Alvimopan, Sodium sulfate, Sorbitol, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 68841, "ingredient1": "Triamterene", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations. Fluid and electrolyte disturbances can lead to serious adverse events including cardiac arrhythmias, seizures, and renal impairment.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment. Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered. Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing. Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68928/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Diovan (valsartan).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Cozaar (losartan).\" Merck & Co, Inc, West Point, PA.[5] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[6] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Eplerenone, Finerenone", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 68842, "ingredient1": "Triazolam", "ingredient2": "Magnesium oxide", "severity": "Minor", "effect": "number of studies have reported that antacids can delay the gastrointestinal absorption and reduce the peak plasma concentration (Cmax) of some benzodiazepines, including clorazepate, chlordiazepoxide and diazepam, although the overall extent of absorption is generally not affected. The exact mechanism of interaction is unknown, but may involve delayed gastric emptying or cation binding of the benzodiazepine.", "source": "DDInter", "management_text": "-", "mechanism_text": "Absorption", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68929/", "reference_text": "[1] Greenblatt DJ, Allen MD, MacLaughlin DS, Harmatz JS, Shader RI \"Diazepam absorption: effect of antacids and food.\" Clin Pharmacol Ther 24 (1978): 600-9[2] Kroboth PD, Smith RB, Silver MR, Rault R, Sorkin MI, Puschett JB, Juhl RP \"Effects of end stage renal disease and aluminium hydroxide on triazolam pharmacokinetics.\" Br J Clin Pharmacol 19 (1985): 839-42[3] Greenblatt DJ, Shader RI, Harmatz JS, Franke K, Koch-Weser J \"Absorption rate, blood concentrations, and early response to oral chlordiazepoxide.\" Am J Psychiatry 134 (1977): 559-62[4] Shader RI, Ciraulo DA, Greenblatt DJ, Harmatz JS \"Steady-state plasma desmethyldiazepam during long-term clorazepate use: effects of antacids.\" Clin Pharmacol Ther 31 (1982): 180-3[5] Greenblatt DJ, Shader RI, Harmatz JS, Franke K, Koch-Weser J \"Influence of magnesium and aluminum hydroxide mixture on chlordiazepoxide absorption.\" Clin Pharmacol Ther 19 (1976): 234-9[6] Kroboth PD, Smith RB, Rault R, Silver MR, Sorkin MI, Puschett JB, Juhl RP \"Effects of end-stage renal disease and aluminum hydroxide on temazepam kinetics.\" Clin Pharmacol Ther 37 (1985): 453-9[7] Chun AH, Carrigan PJ, Hoffman DJ, Kershner RP, Stuart JD \"Effect of antacids on absorption of clorazepate.\" Clin Pharmacol Ther 22 (1977): 329-35[8] Nair SG, Gamble JA, Dundee JW, Howard PJ \"The influence of three antacids on the absorption and clinical action of oral diazepam.\" Br J Anaesth 48 (1976): 1175-80[9] Shader RI, Georgotas A, Greenblatt DJ, Harmatz JS, Allen MD \"Impaired absorption of desmethyldiazepam from clorazepate by magnesium aluminum hydroxide.\" Clin Pharmacol Ther 24 (1978): 308-15[10] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[11] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[12] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[13] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Suvorexant, Methohexital, Methylphenobarbital, Zolpidem, Pentobarbital, Zaleplon, Dichloralphenazone, Valerian, Butabarbital, Secobarbital, Chloral hydrate, More", "alternatives_b": "Magnesium gluconate, Sodium sulfate, Zinc sulfate, Magnesium sulfate, Magnesium aspartate, Magnesium lactate, Magnesium citrate, Sodium chloride, Zinc gluconate, Magnesium chloride, Alvimopan, More", "updated_at": 1767369485}, {"id": 68843, "ingredient1": "Trichlormethiazide", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations. Fluid and electrolyte disturbances can lead to serious adverse events including cardiac arrhythmias, seizures, and renal impairment.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment. Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered. Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing. Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68930/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Diovan (valsartan).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Cozaar (losartan).\" Merck & Co, Inc, West Point, PA.[5] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[6] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Simeprevir, Rosuvastatin, Lactic acid, Mitapivat, Amphotericin B, Ciclopirox, Darunavir, Probenecid, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Phenolphthalein, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, More", "updated_at": 1767369485}, {"id": 68844, "ingredient1": "Triclabendazole", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia are known risk factors for torsade de pointes associated with QT interval prolongation.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68931/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[5] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[8] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[9] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[10] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[11] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "alternatives_b": "Praziquantel", "updated_at": 1767369485}, {"id": 68845, "ingredient1": "Triethylenetetramine", "ingredient2": "Magnesium oxide", "severity": "Moderate", "effect": "Concurrent oral administration of mineral supplements or mineral-containing products may block the absorption of trientine, and vice versa. The mechanism is trientine chelation of polyvalent metal ions resulting in a nonabsorbable complex.", "source": "DDInter", "management_text": "In general, mineral supplements or mineral-containing products (e.g., antacids) should not be used in patients treated with trientine.", "mechanism_text": "Absorption", "recommendation": "In general, mineral supplements or mineral-containing products (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68932/", "reference_text": "[1] \"Product Information. Syprine (trientine).\" Aton Pharma, Lawrenceville, NJ.[2] \"Product Information. Syprine (trientine).\" Aton Pharma, Lawrenceville, NJ.", "alternatives_a": "Magaldrate, Aluminum hydroxide, Sodium chloride, Sodium sulfate, Magnesium sulfate, Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, More", "alternatives_b": "Teduglutide, Lonafarnib, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "updated_at": 1767369485}, {"id": 68846, "ingredient1": "Trifluoperazine", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; hydroxychloroquine; mefloquine), and some narcotic analgesics. The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that can prolong the QT interval, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; mefloquine; halofantrine; lumefantrine), and some narcotic analgesics (methadone; propoxyphene).", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68933/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[6] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[9] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[10] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[11] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[12] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[13] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[14] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[15] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Naldemedine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68847, "ingredient1": "Triflupromazine", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; hydroxychloroquine; mefloquine), and some narcotic analgesics. The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that can prolong the QT interval, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; mefloquine; halofantrine; lumefantrine), and some narcotic analgesics (methadone; propoxyphene).", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68934/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[6] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[9] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[10] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[11] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[12] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[13] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[14] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[15] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Phenolphthalein, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68848, "ingredient1": "Alimemazine", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; hydroxychloroquine; mefloquine), and some narcotic analgesics. The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that can prolong the QT interval, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; mefloquine; halofantrine; lumefantrine), and some narcotic analgesics (methadone; propoxyphene).", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68935/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[6] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[9] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[10] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[11] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[12] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[13] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[14] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[15] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Ketotifen, Mepyramine, Levocetirizine, Chlorcyclizine, Cetirizine, Acrivastine, Triprolidine, Tripelennamine, Azelastine, Dexbrompheniramine, Clemastine, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Phenolphthalein, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 68849, "ingredient1": "Trimethoprim", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate. The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis. The clinical significance of this effect remains unknown.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic. If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Others", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68936/", "reference_text": "[1] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[3] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference) Available from: URL: http://www.mhra.gov.uk/spc-pil/index.htm.\"[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[6] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[7] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Pyridoxine, Pretomanid", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, Sodium sulfate, More", "updated_at": 1767369485}, {"id": 68850, "ingredient1": "Trimetrexate", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate. The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis. The clinical significance of this effect remains unknown.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic. If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Others", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68937/", "reference_text": "[1] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[3] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference) Available from: URL: http://www.mhra.gov.uk/spc-pil/index.htm.\"[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[6] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[7] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Tinidazole, Quinacrine, Nitazoxanide", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, More", "updated_at": 1767369485}, {"id": 68851, "ingredient1": "Trimipramine", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; hydroxychloroquine; mefloquine), and some narcotic analgesics. The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that can prolong the QT interval, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; mefloquine; halofantrine; lumefantrine), and some narcotic analgesics (methadone; propoxyphene).", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68938/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[6] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[9] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[10] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[11] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[12] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[13] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[14] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[15] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "St. John's Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 68852, "ingredient1": "Triptorelin", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia are known risk factors for torsade de pointes associated with QT interval prolongation.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68939/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[5] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[8] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[9] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[10] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[11] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Megestrol acetate, Ethinylestradiol, Diethylstilbestrol, Medroxyprogesterone acetate", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 68853, "ingredient1": "Troleandomycin", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate. The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis. The clinical significance of this effect remains unknown.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic. If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Others", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68940/", "reference_text": "[1] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[3] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference) Available from: URL: http://www.mhra.gov.uk/spc-pil/index.htm.\"[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[6] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[7] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Alvimopan, Sorbitol, Tegaserod, Bisacodyl, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, Sodium sulfate, Prucalopride, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68854, "ingredient1": "Citric acid", "ingredient2": "Trovafloxacin", "severity": "Moderate", "effect": "Urinary alkalinizers such as citrates may decrease the solubility of fluoroquinolones in the urine and increase the risk of crystalluria.", "source": "DDInter", "management_text": "Concomitant use should generally be avoided. Patients receiving this combination should be monitored for signs of renal toxicity and crystalluria.", "mechanism_text": "Excretion", "recommendation": "Concomitant use should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68941/", "reference_text": "[1] \"Multum Information Services, Inc. Expert Review Panel\"[2] \"Product Information. Cipro (ciprofloxacin).\" Bayer, West Haven, CT.", "alternatives_a": "Delafloxacin", "alternatives_b": "Glutamic acid, Pancrelipase", "updated_at": 1767369485}, {"id": 68855, "ingredient1": "Urea", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations. Fluid and electrolyte disturbances can lead to serious adverse events including cardiac arrhythmias, seizures, and renal impairment.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment. Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered. Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing. Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68942/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Diovan (valsartan).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Cozaar (losartan).\" Merck & Co, Inc, West Point, PA.[5] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[6] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Tromethamine", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 68856, "ingredient1": "Valbenazine", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia are known risk factors for torsade de pointes associated with QT interval prolongation.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68943/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[5] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[8] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[9] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[10] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[11] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Magnesium oxide, More", "alternatives_b": "Dextromethorphan, Sodium oxybate, Riluzole, Inotersen, Tafamidis", "updated_at": 1767369485}, {"id": 68857, "ingredient1": "Valdecoxib", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations. Fluid and electrolyte disturbances can lead to serious adverse events including cardiac arrhythmias, seizures, and renal impairment.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment. Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered. Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing. Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68944/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Diovan (valsartan).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Cozaar (losartan).\" Merck & Co, Inc, West Point, PA.[5] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[6] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole", "alternatives_b": "Alvimopan, Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, Magnesium carbonate, More", "updated_at": 1767369485}, {"id": 68858, "ingredient1": "Valsartan", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations. Fluid and electrolyte disturbances can lead to serious adverse events including cardiac arrhythmias, seizures, and renal impairment.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment. Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered. Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing. Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68945/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Diovan (valsartan).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Cozaar (losartan).\" Merck & Co, Inc, West Point, PA.[5] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[6] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Amlodipine, Sacubitril, Aliskiren, Nebivolol, Amlodipine, Atorvastatin, Simvastatin, Lovastatin, Rosuvastatin, Niacin, Pravastatin, More", "alternatives_b": "Alvimopan, Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, Magnesium carbonate, More", "updated_at": 1767369485}, {"id": 68859, "ingredient1": "Vancomycin", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate. The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis. The clinical significance of this effect remains unknown.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic. If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Others", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68946/", "reference_text": "[1] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[3] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference) Available from: URL: http://www.mhra.gov.uk/spc-pil/index.htm.\"[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[6] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[7] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Tinidazole, Nystatin, Amphotericin B, Miconazole, Ganciclovir, Acyclovir, Famciclovir, Trifluridine, Chlorhexidine, Povidone-iodine", "alternatives_b": "Alvimopan, Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, Sodium sulfate, Prucalopride, More", "updated_at": 1767369485}, {"id": 68860, "ingredient1": "Vandetanib", "ingredient2": "Picosulfuric acid", "severity": "Major", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval. Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly. Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68947/", "reference_text": "[1] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[2] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[9] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[10] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[11] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[12] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[13] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Imatinib, Dabrafenib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Selumetinib, Cobimetinib, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Naldemedine, More", "updated_at": 1767369485}, {"id": 68861, "ingredient1": "Vardenafil", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia are known risk factors for torsade de pointes associated with QT interval prolongation.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68948/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[5] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[8] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[9] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[10] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[11] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Darifenacin, Tadalafil, Ammonium chloride, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, Trospium, Flavoxate, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 68862, "ingredient1": "Vasopressin", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia are known risk factors for torsade de pointes associated with QT interval prolongation.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68949/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[5] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[8] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[9] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[10] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[11] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68863, "ingredient1": "Vemurafenib", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia are known risk factors for torsade de pointes associated with QT interval prolongation.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68950/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[5] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[8] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[9] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[10] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[11] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Simeprevir, Rosuvastatin, Lactic acid, Mitapivat, Amphotericin B, Ciclopirox, Darunavir, Probenecid, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Prucalopride, More", "updated_at": 1767369485}, {"id": 68864, "ingredient1": "Venlafaxine", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; hydroxychloroquine; mefloquine), and some narcotic analgesics. The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that can prolong the QT interval, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; mefloquine; halofantrine; lumefantrine), and some narcotic analgesics (methadone; propoxyphene).", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68951/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[6] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[9] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[10] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[11] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[12] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[13] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[14] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[15] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "St. John's Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Naldemedine, Prucalopride, More", "updated_at": 1767369485}, {"id": 68865, "ingredient1": "Vilazodone", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline. Rare cases of generalized tonic-clonic seizures and/or loss of consciousness in association with low serum osmolality and electrolyte abnormalities (e.g., hyponatremia, hypokalemia, hypocalcemia, hypomagnesemia) have been reported with the use of bowel cleansing products in patients with no prior history of seizures. The condition resolved with correction of fluid and electrolyte abnormalities.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68952/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.[9] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.", "alternatives_a": "St. John's Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 68866, "ingredient1": "Vismodegib", "ingredient2": "Magnesium oxide", "severity": "Minor", "effect": "The solubility of vismodegib is known to be pH-dependent (0.1 mcg/mL at pH 7 and 0.99 mg/mL at pH 1) and drugs that alter the pH of the upper gastrointestinal tract may affects its solubility and reduce its bioavailability.", "source": "DDInter", "management_text": "-", "mechanism_text": "Absorption", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68953/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Erivedge (vismodegib).\" Genentech, South San Francisco, CA.", "alternatives_a": "Magnesium gluconate, Sodium sulfate, Zinc sulfate, Magnesium sulfate, Magnesium aspartate, Magnesium lactate, Magnesium citrate, Sodium chloride, Zinc gluconate, Magnesium chloride, Alvimopan, More", "alternatives_b": "Pertuzumab, Olaparib, Oxaliplatin, Rucaparib, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, More", "updated_at": 1767369485}, {"id": 68867, "ingredient1": "Voriconazole", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia are known risk factors for torsade de pointes associated with QT interval prolongation.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68954/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[5] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[8] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[9] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[10] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[11] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Caspofungin, Micafungin, Amphotericin B, Itraconazole, Miconazole, Oteseconazole, Flucytosine, Anidulafungin", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Prucalopride, More", "updated_at": 1767369485}, {"id": 68868, "ingredient1": "Vortioxetine", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline. Rare cases of generalized tonic-clonic seizures and/or loss of consciousness in association with low serum osmolality and electrolyte abnormalities (e.g., hyponatremia, hypokalemia, hypocalcemia, hypomagnesemia) have been reported with the use of bowel cleansing products in patients with no prior history of seizures. The condition resolved with correction of fluid and electrolyte abnormalities.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68955/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.[9] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.", "alternatives_a": "St. John's Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 68869, "ingredient1": "Zalcitabine", "ingredient2": "Magnesium oxide", "severity": "Minor", "effect": "Magnesium and aluminum antacids have been shown to reduce the area under the curve of zalcitabine. The mechanism has not been described but may be due to chelation or alteration in gastrointestinal pH. Zalcitabine should be administered 2 hours prior to a magnesium and/or aluminum-containing antacid. The clinical significance of this interaction is unknown.", "source": "DDInter", "management_text": "-", "mechanism_text": "Absorption", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68956/", "reference_text": "[1] \"Product Information. HIVID (zalcitabine).\" Roche Laboratories, Nutley, NJ.[2] \"Product Information. Hivid (zalcitabine).\" Roche Laboratories, Nutley, NJ.", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Valaciclovir, Zanamivir, Lenacapavir, Telaprevir, Etravirine, More", "alternatives_b": "Calcium carbonate, Magnesium gluconate, Sodium sulfate, Zinc sulfate, Magnesium sulfate, Magnesium aspartate, Magnesium lactate, Magnesium citrate, Sodium chloride, Zinc gluconate, Magnesium chloride, More", "updated_at": 1767369485}, {"id": 68870, "ingredient1": "Ziprasidone", "ingredient2": "Picosulfuric acid", "severity": "Major", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval. Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly. Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68957/", "reference_text": "[1] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[2] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[9] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[10] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[11] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[12] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[13] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Naldemedine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68871, "ingredient1": "Abarelix", "ingredient2": "Polyethylene glycol (3350 with electrolytes)", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia are known risk factors for torsade de pointes associated with QT interval prolongation.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68958/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[5] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[8] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[9] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[10] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[11] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Darolutamide, Anastrozole, Fulvestrant, Letrozole, Aminoglutethimide, Exemestane", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68872, "ingredient1": "Aminophylline", "ingredient2": "Polyethylene glycol (3350 with electrolytes)", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline. Rare cases of generalized tonic-clonic seizures and/or loss of consciousness in association with low serum osmolality and electrolyte abnormalities (e.g., hyponatremia, hypokalemia, hypocalcemia, hypomagnesemia) have been reported with the use of bowel cleansing products in patients with no prior history of seizures. The condition resolved with correction of fluid and electrolyte abnormalities.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68959/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.[9] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.", "alternatives_a": "Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Montelukast, Dyphylline, Mepolizumab, Roflumilast, Pentoxifylline, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68873, "ingredient1": "Amoxapine", "ingredient2": "Polyethylene glycol (3350 with electrolytes)", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; hydroxychloroquine; mefloquine), and some narcotic analgesics. The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that can prolong the QT interval, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; mefloquine; halofantrine; lumefantrine), and some narcotic analgesics (methadone; propoxyphene).", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68960/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[6] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[9] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[10] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[11] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[12] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[13] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[14] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[15] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "St. John's Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68874, "ingredient1": "Polyethylene glycol (3350 with electrolytes)", "ingredient2": "Astemizole", "severity": "Major", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval. Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly. Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68961/", "reference_text": "[1] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[2] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[9] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[10] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[11] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[12] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[13] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Ketotifen, Levocetirizine, Cetirizine, Fexofenadine, Loratadine, Trimethobenzamide, Desloratadine, Azelastine, Pheniramine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68875, "ingredient1": "Bedaquiline", "ingredient2": "Polyethylene glycol (3350 with electrolytes)", "severity": "Major", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval. Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly. Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68962/", "reference_text": "[1] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[2] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[9] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[10] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[11] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[12] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[13] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Capreomycin, Pyrazinamide, Rifamycin, Sulfamethoxazole, Rifapentine, Streptomycin, Rifabutin, Isoniazid, Ethambutol, Ethionamide, Pyridoxine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68876, "ingredient1": "Bendroflumethiazide", "ingredient2": "Polyethylene glycol (3350 with electrolytes)", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations. Fluid and electrolyte disturbances can lead to serious adverse events including cardiac arrhythmias, seizures, and renal impairment.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment. Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered. Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing. Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68963/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Diovan (valsartan).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Cozaar (losartan).\" Merck & Co, Inc, West Point, PA.[5] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[6] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Sulfadiazine, Lactic acid, Mitapivat, Amphotericin B, Clindamycin, Ciclopirox, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68877, "ingredient1": "Benzthiazide", "ingredient2": "Polyethylene glycol (3350 with electrolytes)", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations. Fluid and electrolyte disturbances can lead to serious adverse events including cardiac arrhythmias, seizures, and renal impairment.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment. Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered. Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing. Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68964/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Diovan (valsartan).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Cozaar (losartan).\" Merck & Co, Inc, West Point, PA.[5] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[6] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Sulfadiazine, Lactic acid, Mitapivat, Amphotericin B, Clindamycin, Ciclopirox, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68878, "ingredient1": "Bepridil", "ingredient2": "Polyethylene glycol (3350 with electrolytes)", "severity": "Major", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval. Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly. Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68965/", "reference_text": "[1] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[2] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[9] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[10] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[11] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[12] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[13] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68879, "ingredient1": "Bromfenac", "ingredient2": "Polyethylene glycol (3350 with electrolytes)", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations. Fluid and electrolyte disturbances can lead to serious adverse events including cardiac arrhythmias, seizures, and renal impairment.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment. Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered. Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing. Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68966/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Diovan (valsartan).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Cozaar (losartan).\" Merck & Co, Inc, West Point, PA.[5] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[6] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Fluocinolone acetonide, Fluorometholone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68880, "ingredient1": "Frangula purshiana bark", "ingredient2": "Polyethylene glycol (3350 with electrolytes)", "severity": "Moderate", "effect": "Concomitant use of stimulant laxatives (e.g., bisacodyl, sodium picosulfate) may increase the risk of serious gastrointestinal adverse effects associated with certain osmotic laxatives (e.g., polyethylene glycol (PEG), oral sulfate solution), such as colonic mucosal ulcerations or ischemic colitis. When administered in conjunction with an osmotic laxative such as PEG, increased intramural pressure secondary to increased peristalsis may lead to ischemic colitis and perforation.", "source": "DDInter", "management_text": "The manufacturers for some osmotic bowel cleansing products recommend avoiding the concurrent use of stimulant laxatives. However, stimulant laxatives, in particular bisacodyl and sodium picosulfate, are sometimes used with PEG in certain bowel cleansing regimens to help reduce dose volume and improve patient tolerability and acceptance. Please consult individual product labeling for specific recommendations and guidance. Patients using osmotic bowel cleansing products and stimulant laxatives who present with sudden abdominal pain, rectal bleeding, or other symptoms of ischemic colitis should be evaluated promptly.", "mechanism_text": "Synergism", "recommendation": "The manufacturers for some osmotic bowel cleansing products recommend avoiding the concurrent use of stimulant laxatives.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68967/", "reference_text": "[1] Vaizman K, Li J, Iswara K, Tenner S \"Ischemic colitis induced by the combination of Bisacodyl and polyethylene glycol in preparation for colonoscopy.\" Am J Gastroenterol 102 (2007): S267[2] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. MoviPrep (polyethylene glycol 3350 with electrolytes).\" Physicians Total Care, Tulsa, OK.[4] Adamcewicz M, Bearelly D, Porat G, Friedenberg FK \"Mechanism of action and toxicities of purgatives used for colonoscopy preparation.\" Expert Opin Drug Metab Toxicol 7 (2011): 89-101[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Baudet JS, Castro V, Redondo I \"Recurrent ischemic colitis induced by colonoscopy bowel lavage.\" Am J Gastroenterol 105 (2010): 700-1[7] \"Product Information. GaviLyte-H and Bisacodyl with Flavor Packs (bisacodyl-PEG 3350 with electrolytes).\" Gavis Pharmaceuticals, Somerset, NJ.[8] Anastassopoulos K, Farraye FA, Knight T, Colman S, Cleveland MvB, Pelham RW \"A comparative study of treatment-emergent adverse events following use of common bowel preparations among a colonoscopy screening population: results from a post-marketing observational study.\" Dig Dis Sci 61 (2016): 2993-3006[9] Belsey J, Epstein O, heresbach D \"Systematic review: adverse event reports for oral sodium phosphate and polyethylene glycol.\" Aliment Pharmacol Ther 29 (2009): 15-28[10] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[11] \"Product Information. Bi-Peglyte (bisacodyl-PEG 3350 with electrolytes).\" Pendopharm, Montreal, QC.[12] Hung SY, Chen HC, Chen WT \"A randomized trial comparing the bowel cleansing efficacy of sodium picosulfate/magnesium citrate and polyethylene glycol/Bisacodyl (The Bowklean Study)\" Sci Rep 10 (2020): 5604[13] Barbeau P, Wolfe D, Yazdi F, et.al \"Comparative safety of bowel cleansers: protocol for a systematic review and network meta-analysis.\" BMJ Open 8 (2018): e021892[14] \"Product Information. Plenvu (polyethylene glycol 3350 with electrolytes).\" Bausch Health US (formerly Valeant Pharmaceuticals), Bridgewater, NJ.[15] Ajani S, Hurt RT, Teeters DA, Bellmore LR \"Ischaemic colitis associated with oral contraceptive and bisacodyl use.\" BMJ Case Rep 2012 (2012):", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68881, "ingredient1": "Castor oil", "ingredient2": "Polyethylene glycol (3350 with electrolytes)", "severity": "Moderate", "effect": "Concomitant use of stimulant laxatives (e.g., bisacodyl, sodium picosulfate) may increase the risk of serious gastrointestinal adverse effects associated with certain osmotic laxatives (e.g., polyethylene glycol (PEG), oral sulfate solution), such as colonic mucosal ulcerations or ischemic colitis. When administered in conjunction with an osmotic laxative such as PEG, increased intramural pressure secondary to increased peristalsis may lead to ischemic colitis and perforation.", "source": "DDInter", "management_text": "The manufacturers for some osmotic bowel cleansing products recommend avoiding the concurrent use of stimulant laxatives. However, stimulant laxatives, in particular bisacodyl and sodium picosulfate, are sometimes used with PEG in certain bowel cleansing regimens to help reduce dose volume and improve patient tolerability and acceptance. Please consult individual product labeling for specific recommendations and guidance. Patients using osmotic bowel cleansing products and stimulant laxatives who present with sudden abdominal pain, rectal bleeding, or other symptoms of ischemic colitis should be evaluated promptly.", "mechanism_text": "Synergism", "recommendation": "The manufacturers for some osmotic bowel cleansing products recommend avoiding the concurrent use of stimulant laxatives.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68968/", "reference_text": "[1] Vaizman K, Li J, Iswara K, Tenner S \"Ischemic colitis induced by the combination of Bisacodyl and polyethylene glycol in preparation for colonoscopy.\" Am J Gastroenterol 102 (2007): S267[2] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. MoviPrep (polyethylene glycol 3350 with electrolytes).\" Physicians Total Care, Tulsa, OK.[4] Adamcewicz M, Bearelly D, Porat G, Friedenberg FK \"Mechanism of action and toxicities of purgatives used for colonoscopy preparation.\" Expert Opin Drug Metab Toxicol 7 (2011): 89-101[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Baudet JS, Castro V, Redondo I \"Recurrent ischemic colitis induced by colonoscopy bowel lavage.\" Am J Gastroenterol 105 (2010): 700-1[7] \"Product Information. GaviLyte-H and Bisacodyl with Flavor Packs (bisacodyl-PEG 3350 with electrolytes).\" Gavis Pharmaceuticals, Somerset, NJ.[8] Anastassopoulos K, Farraye FA, Knight T, Colman S, Cleveland MvB, Pelham RW \"A comparative study of treatment-emergent adverse events following use of common bowel preparations among a colonoscopy screening population: results from a post-marketing observational study.\" Dig Dis Sci 61 (2016): 2993-3006[9] Belsey J, Epstein O, heresbach D \"Systematic review: adverse event reports for oral sodium phosphate and polyethylene glycol.\" Aliment Pharmacol Ther 29 (2009): 15-28[10] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[11] \"Product Information. Bi-Peglyte (bisacodyl-PEG 3350 with electrolytes).\" Pendopharm, Montreal, QC.[12] Hung SY, Chen HC, Chen WT \"A randomized trial comparing the bowel cleansing efficacy of sodium picosulfate/magnesium citrate and polyethylene glycol/Bisacodyl (The Bowklean Study)\" Sci Rep 10 (2020): 5604[13] Barbeau P, Wolfe D, Yazdi F, et.al \"Comparative safety of bowel cleansers: protocol for a systematic review and network meta-analysis.\" BMJ Open 8 (2018): e021892[14] \"Product Information. Plenvu (polyethylene glycol 3350 with electrolytes).\" Bausch Health US (formerly Valeant Pharmaceuticals), Bridgewater, NJ.[15] Ajani S, Hurt RT, Teeters DA, Bellmore LR \"Ischaemic colitis associated with oral contraceptive and bisacodyl use.\" BMJ Case Rep 2012 (2012):", "alternatives_a": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Naldemedine, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, Prucalopride, Sodium sulfate, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68882, "ingredient1": "Chlorpromazine", "ingredient2": "Polyethylene glycol (3350 with electrolytes)", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; hydroxychloroquine; mefloquine), and some narcotic analgesics. The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that can prolong the QT interval, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; mefloquine; halofantrine; lumefantrine), and some narcotic analgesics (methadone; propoxyphene).", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68969/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[6] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[9] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[10] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[11] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[12] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[13] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[14] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[15] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68883, "ingredient1": "Choline salicylate", "ingredient2": "Polyethylene glycol (3350 with electrolytes)", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations. Fluid and electrolyte disturbances can lead to serious adverse events including cardiac arrhythmias, seizures, and renal impairment.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment. Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered. Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing. Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68970/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Diovan (valsartan).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Cozaar (losartan).\" Merck & Co, Inc, West Point, PA.[5] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[6] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Acetaminophen, Ziconotide, Methoxyflurane", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68884, "ingredient1": "Cinoxacin", "ingredient2": "Polyethylene glycol (3350 with electrolytes)", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline. Rare cases of generalized tonic-clonic seizures and/or loss of consciousness in association with low serum osmolality and electrolyte abnormalities (e.g., hyponatremia, hypokalemia, hypocalcemia, hypomagnesemia) have been reported with the use of bowel cleansing products in patients with no prior history of seizures. The condition resolved with correction of fluid and electrolyte abnormalities.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68971/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.[9] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68885, "ingredient1": "Cisapride", "ingredient2": "Polyethylene glycol (3350 with electrolytes)", "severity": "Major", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval. Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly. Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68972/", "reference_text": "[1] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[2] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[9] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[10] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[11] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[12] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[13] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68886, "ingredient1": "Clofazimine", "ingredient2": "Polyethylene glycol (3350 with electrolytes)", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia are known risk factors for torsade de pointes associated with QT interval prolongation.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68973/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[5] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[8] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[9] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[10] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[11] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Dapsone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68887, "ingredient1": "Clomipramine", "ingredient2": "Polyethylene glycol (3350 with electrolytes)", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; hydroxychloroquine; mefloquine), and some narcotic analgesics. The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that can prolong the QT interval, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; mefloquine; halofantrine; lumefantrine), and some narcotic analgesics (methadone; propoxyphene).", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68974/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[6] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[9] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[10] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[11] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[12] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[13] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[14] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[15] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "St. John's Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68888, "ingredient1": "Clozapine", "ingredient2": "Polyethylene glycol (3350 with electrolytes)", "severity": "Major", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval. Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly. Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68975/", "reference_text": "[1] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[2] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[9] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[10] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[11] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[12] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[13] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68889, "ingredient1": "Cocaine (nasal)", "ingredient2": "Polyethylene glycol (3350 with electrolytes)", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline. Rare cases of generalized tonic-clonic seizures and/or loss of consciousness in association with low serum osmolality and electrolyte abnormalities (e.g., hyponatremia, hypokalemia, hypocalcemia, hypomagnesemia) have been reported with the use of bowel cleansing products in patients with no prior history of seizures. The condition resolved with correction of fluid and electrolyte abnormalities.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68976/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.[9] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68890, "ingredient1": "Crizotinib", "ingredient2": "Polyethylene glycol (3350 with electrolytes)", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia are known risk factors for torsade de pointes associated with QT interval prolongation.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68977/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[5] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[8] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[9] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[10] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[11] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Imatinib, Dacomitinib, Tepotinib, Avapritinib, Fedratinib, Larotrectinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68891, "ingredient1": "Cyclobenzaprine", "ingredient2": "Polyethylene glycol (3350 with electrolytes)", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline. Rare cases of generalized tonic-clonic seizures and/or loss of consciousness in association with low serum osmolality and electrolyte abnormalities (e.g., hyponatremia, hypokalemia, hypocalcemia, hypomagnesemia) have been reported with the use of bowel cleansing products in patients with no prior history of seizures. The condition resolved with correction of fluid and electrolyte abnormalities.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68978/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.[9] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.", "alternatives_a": "Carisoprodol, Chlorzoxazone, Baclofen, Methocarbamol, Chlormezanone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68892, "ingredient1": "Cycloserine", "ingredient2": "Polyethylene glycol (3350 with electrolytes)", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline. Rare cases of generalized tonic-clonic seizures and/or loss of consciousness in association with low serum osmolality and electrolyte abnormalities (e.g., hyponatremia, hypokalemia, hypocalcemia, hypomagnesemia) have been reported with the use of bowel cleansing products in patients with no prior history of seizures. The condition resolved with correction of fluid and electrolyte abnormalities.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68979/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.[9] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.", "alternatives_a": "Capreomycin, Pyrazinamide, Rifamycin, Sulfamethoxazole, Rifapentine, Streptomycin, Rifabutin, Isoniazid, Ethambutol, Ethionamide, Pyridoxine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68893, "ingredient1": "Dalfampridine", "ingredient2": "Polyethylene glycol (3350 with electrolytes)", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline. Rare cases of generalized tonic-clonic seizures and/or loss of consciousness in association with low serum osmolality and electrolyte abnormalities (e.g., hyponatremia, hypokalemia, hypocalcemia, hypomagnesemia) have been reported with the use of bowel cleansing products in patients with no prior history of seizures. The condition resolved with correction of fluid and electrolyte abnormalities.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68980/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.[9] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.", "alternatives_a": "Dextromethorphan, Sodium oxybate, Riluzole, Inotersen, Tafamidis", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68894, "ingredient1": "Dasatinib", "ingredient2": "Polyethylene glycol (3350 with electrolytes)", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia are known risk factors for torsade de pointes associated with QT interval prolongation.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68981/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[5] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[8] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[9] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[10] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[11] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Imatinib, Dacomitinib, Tepotinib, Avapritinib, Fedratinib, Larotrectinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68895, "ingredient1": "Daunorubicin", "ingredient2": "Polyethylene glycol (3350 with electrolytes)", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia are known risk factors for torsade de pointes associated with QT interval prolongation.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68982/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[5] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[8] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[9] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[10] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[11] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Valrubicin, Plicamycin, Ixabepilone, Mitoxantrone, Bleomycin, Mitomycin, Dactinomycin, Pertuzumab, Olaparib, Bortezomib, Tisagenlecleucel, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68896, "ingredient1": "Daunorubicin (liposomal)", "ingredient2": "Polyethylene glycol (3350 with electrolytes)", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia are known risk factors for torsade de pointes associated with QT interval prolongation.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68983/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[5] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[8] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[9] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[10] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[11] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Valrubicin, Plicamycin, Ixabepilone, Mitoxantrone, Bleomycin, Mitomycin, Dactinomycin, Pertuzumab, Olaparib, Bortezomib, Tisagenlecleucel, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68897, "ingredient1": "Degarelix", "ingredient2": "Polyethylene glycol (3350 with electrolytes)", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia are known risk factors for torsade de pointes associated with QT interval prolongation.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68984/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[5] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[8] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[9] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[10] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[11] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Darolutamide, Anastrozole, Fulvestrant, Letrozole, Aminoglutethimide, Exemestane", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68898, "ingredient1": "Delafloxacin", "ingredient2": "Polyethylene glycol (3350 with electrolytes)", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline. Rare cases of generalized tonic-clonic seizures and/or loss of consciousness in association with low serum osmolality and electrolyte abnormalities (e.g., hyponatremia, hypokalemia, hypocalcemia, hypomagnesemia) have been reported with the use of bowel cleansing products in patients with no prior history of seizures. The condition resolved with correction of fluid and electrolyte abnormalities.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68985/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.[9] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68899, "ingredient1": "Desipramine", "ingredient2": "Polyethylene glycol (3350 with electrolytes)", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; hydroxychloroquine; mefloquine), and some narcotic analgesics. The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that can prolong the QT interval, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; mefloquine; halofantrine; lumefantrine), and some narcotic analgesics (methadone; propoxyphene).", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68986/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[6] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[9] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[10] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[11] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[12] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[13] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[14] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[15] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "St. John's Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68900, "ingredient1": "Desvenlafaxine", "ingredient2": "Polyethylene glycol (3350 with electrolytes)", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline. Rare cases of generalized tonic-clonic seizures and/or loss of consciousness in association with low serum osmolality and electrolyte abnormalities (e.g., hyponatremia, hypokalemia, hypocalcemia, hypomagnesemia) have been reported with the use of bowel cleansing products in patients with no prior history of seizures. The condition resolved with correction of fluid and electrolyte abnormalities.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68987/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.[9] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.", "alternatives_a": "St. John's Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68901, "ingredient1": "Deutetrabenazine", "ingredient2": "Polyethylene glycol (3350 with electrolytes)", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia are known risk factors for torsade de pointes associated with QT interval prolongation.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68988/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[5] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[8] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[9] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[10] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[11] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Dextromethorphan, Sodium oxybate, Riluzole, Inotersen, Tafamidis", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68902, "ingredient1": "Dexfenfluramine", "ingredient2": "Polyethylene glycol (3350 with electrolytes)", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline. Rare cases of generalized tonic-clonic seizures and/or loss of consciousness in association with low serum osmolality and electrolyte abnormalities (e.g., hyponatremia, hypokalemia, hypocalcemia, hypomagnesemia) have been reported with the use of bowel cleansing products in patients with no prior history of seizures. The condition resolved with correction of fluid and electrolyte abnormalities.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68989/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.[9] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.", "alternatives_a": "Lorcaserin, Orlistat, Naltrexone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68903, "ingredient1": "Dexmethylphenidate", "ingredient2": "Polyethylene glycol (3350 with electrolytes)", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline. Rare cases of generalized tonic-clonic seizures and/or loss of consciousness in association with low serum osmolality and electrolyte abnormalities (e.g., hyponatremia, hypokalemia, hypocalcemia, hypomagnesemia) have been reported with the use of bowel cleansing products in patients with no prior history of seizures. The condition resolved with correction of fluid and electrolyte abnormalities.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68990/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.[9] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.", "alternatives_a": "Solriamfetol, Caffeine, Armodafinil, Citicoline, Modafinil", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68904, "ingredient1": "Dextroamphetamine", "ingredient2": "Polyethylene glycol (3350 with electrolytes)", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline. Rare cases of generalized tonic-clonic seizures and/or loss of consciousness in association with low serum osmolality and electrolyte abnormalities (e.g., hyponatremia, hypokalemia, hypocalcemia, hypomagnesemia) have been reported with the use of bowel cleansing products in patients with no prior history of seizures. The condition resolved with correction of fluid and electrolyte abnormalities.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68991/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.[9] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.", "alternatives_a": "Solriamfetol, Caffeine, Armodafinil, Citicoline, Modafinil", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68905, "ingredient1": "Dezocine", "ingredient2": "Polyethylene glycol (3350 with electrolytes)", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline. Rare cases of generalized tonic-clonic seizures and/or loss of consciousness in association with low serum osmolality and electrolyte abnormalities (e.g., hyponatremia, hypokalemia, hypocalcemia, hypomagnesemia) have been reported with the use of bowel cleansing products in patients with no prior history of seizures. The condition resolved with correction of fluid and electrolyte abnormalities.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68992/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.[9] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.", "alternatives_a": "Acetaminophen, Naloxone, Naltrexone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68906, "ingredient1": "Diclofenamide", "ingredient2": "Polyethylene glycol (3350 with electrolytes)", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations. Fluid and electrolyte disturbances can lead to serious adverse events including cardiac arrhythmias, seizures, and renal impairment.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment. Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered. Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing. Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68993/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Diovan (valsartan).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Cozaar (losartan).\" Merck & Co, Inc, West Point, PA.[5] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[6] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Sulfadiazine, Lactic acid, Mitapivat, Amphotericin B, Clindamycin, Ciclopirox, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68907, "ingredient1": "Diethylpropion", "ingredient2": "Polyethylene glycol (3350 with electrolytes)", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline. Rare cases of generalized tonic-clonic seizures and/or loss of consciousness in association with low serum osmolality and electrolyte abnormalities (e.g., hyponatremia, hypokalemia, hypocalcemia, hypomagnesemia) have been reported with the use of bowel cleansing products in patients with no prior history of seizures. The condition resolved with correction of fluid and electrolyte abnormalities.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68994/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.[9] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.", "alternatives_a": "Lorcaserin, Orlistat, Naltrexone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68908, "ingredient1": "Diflunisal", "ingredient2": "Polyethylene glycol (3350 with electrolytes)", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations. Fluid and electrolyte disturbances can lead to serious adverse events including cardiac arrhythmias, seizures, and renal impairment.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment. Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered. Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing. Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68995/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Diovan (valsartan).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Cozaar (losartan).\" Merck & Co, Inc, West Point, PA.[5] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[6] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Acetaminophen, Ziconotide, Methoxyflurane", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68909, "ingredient1": "Disopyramide", "ingredient2": "Polyethylene glycol (3350 with electrolytes)", "severity": "Major", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval. Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly. Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68996/", "reference_text": "[1] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[2] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[9] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[10] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[11] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[12] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[13] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Tocainide, Moricizine, Bretylium", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68910, "ingredient1": "Dofetilide", "ingredient2": "Polyethylene glycol (3350 with electrolytes)", "severity": "Major", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval. Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly. Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68997/", "reference_text": "[1] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[2] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[9] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[10] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[11] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[12] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[13] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Tocainide, Moricizine, Bretylium", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68911, "ingredient1": "Dolasetron", "ingredient2": "Polyethylene glycol (3350 with electrolytes)", "severity": "Major", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval. Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly. Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68998/", "reference_text": "[1] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[2] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[9] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[10] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[11] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[12] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[13] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Rolapitant, Nabilone, Aprepitant", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68912, "ingredient1": "Donepezil", "ingredient2": "Polyethylene glycol (3350 with electrolytes)", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline. Rare cases of generalized tonic-clonic seizures and/or loss of consciousness in association with low serum osmolality and electrolyte abnormalities (e.g., hyponatremia, hypokalemia, hypocalcemia, hypomagnesemia) have been reported with the use of bowel cleansing products in patients with no prior history of seizures. The condition resolved with correction of fluid and electrolyte abnormalities.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68999/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.[9] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.", "alternatives_a": "Ginkgo biloba, Aducanumab", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68913, "ingredient1": "Doxapram", "ingredient2": "Polyethylene glycol (3350 with electrolytes)", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline. Rare cases of generalized tonic-clonic seizures and/or loss of consciousness in association with low serum osmolality and electrolyte abnormalities (e.g., hyponatremia, hypokalemia, hypocalcemia, hypomagnesemia) have been reported with the use of bowel cleansing products in patients with no prior history of seizures. The condition resolved with correction of fluid and electrolyte abnormalities.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/69000/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.[9] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.", "alternatives_a": "Nitric Oxide, Ivacaftor, Elexacaftor, Lumacaftor", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68914, "ingredient1": "Doxepin", "ingredient2": "Polyethylene glycol (3350 with electrolytes)", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; hydroxychloroquine; mefloquine), and some narcotic analgesics. The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that can prolong the QT interval, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; mefloquine; halofantrine; lumefantrine), and some narcotic analgesics (methadone; propoxyphene).", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/69001/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[6] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[9] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[10] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[11] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[12] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[13] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[14] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[15] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "St. John's Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine, Tetracaine, Pheniramine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68915, "ingredient1": "Doxepin (topical)", "ingredient2": "Polyethylene glycol (3350 with electrolytes)", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; hydroxychloroquine; mefloquine), and some narcotic analgesics. The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that can prolong the QT interval, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; mefloquine; halofantrine; lumefantrine), and some narcotic analgesics (methadone; propoxyphene).", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/69002/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[6] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[9] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[10] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[11] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[12] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[13] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[14] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[15] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "St. John's Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine, Tetracaine, Pheniramine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68916, "ingredient1": "Doxorubicin", "ingredient2": "Polyethylene glycol (3350 with electrolytes)", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia are known risk factors for torsade de pointes associated with QT interval prolongation.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/69003/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[5] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[8] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[9] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[10] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[11] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Valrubicin, Plicamycin, Ixabepilone, Mitoxantrone, Bleomycin, Mitomycin, Dactinomycin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68917, "ingredient1": "Doxorubicin (liposomal)", "ingredient2": "Polyethylene glycol (3350 with electrolytes)", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia are known risk factors for torsade de pointes associated with QT interval prolongation.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/69004/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[5] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[8] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[9] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[10] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[11] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Valrubicin, Plicamycin, Ixabepilone, Mitoxantrone, Bleomycin, Mitomycin, Dactinomycin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68918, "ingredient1": "Dronabinol", "ingredient2": "Polyethylene glycol (3350 with electrolytes)", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline. Rare cases of generalized tonic-clonic seizures and/or loss of consciousness in association with low serum osmolality and electrolyte abnormalities (e.g., hyponatremia, hypokalemia, hypocalcemia, hypomagnesemia) have been reported with the use of bowel cleansing products in patients with no prior history of seizures. The condition resolved with correction of fluid and electrolyte abnormalities.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/69005/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.[9] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.", "alternatives_a": "Rolapitant, Nabilone, Aprepitant", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68919, "ingredient1": "Dronedarone", "ingredient2": "Polyethylene glycol (3350 with electrolytes)", "severity": "Major", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval. Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly. Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/69006/", "reference_text": "[1] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[2] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[9] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[10] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[11] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[12] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[13] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Tocainide, Moricizine, Bretylium", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68920, "ingredient1": "Droperidol", "ingredient2": "Polyethylene glycol (3350 with electrolytes)", "severity": "Major", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval. Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly. Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/69007/", "reference_text": "[1] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[2] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[9] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[10] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[11] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[12] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[13] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68921, "ingredient1": "Duloxetine", "ingredient2": "Polyethylene glycol (3350 with electrolytes)", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline. Rare cases of generalized tonic-clonic seizures and/or loss of consciousness in association with low serum osmolality and electrolyte abnormalities (e.g., hyponatremia, hypokalemia, hypocalcemia, hypomagnesemia) have been reported with the use of bowel cleansing products in patients with no prior history of seizures. The condition resolved with correction of fluid and electrolyte abnormalities.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/69008/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.[9] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.", "alternatives_a": "St. John's Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68922, "ingredient1": "Efavirenz", "ingredient2": "Polyethylene glycol (3350 with electrolytes)", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; hydroxychloroquine; mefloquine), and some narcotic analgesics. The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that can prolong the QT interval, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; mefloquine; halofantrine; lumefantrine), and some narcotic analgesics (methadone; propoxyphene).", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/69009/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[6] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[9] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[10] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[11] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[12] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[13] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[14] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[15] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Lenacapavir, Telaprevir, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68923, "ingredient1": "Enalapril", "ingredient2": "Polyethylene glycol (3350 with electrolytes)", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations. Fluid and electrolyte disturbances can lead to serious adverse events including cardiac arrhythmias, seizures, and renal impairment.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment. Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered. Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing. Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/69010/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Diovan (valsartan).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Cozaar (losartan).\" Merck & Co, Inc, West Point, PA.[5] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[6] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Felodipine, Amlodipine, Verapamil, Bisoprolol", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68924, "ingredient1": "Encorafenib", "ingredient2": "Polyethylene glycol (3350 with electrolytes)", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia are known risk factors for torsade de pointes associated with QT interval prolongation.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/69011/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[5] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[8] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[9] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[10] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[11] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Imatinib, Dacomitinib, Tepotinib, Avapritinib, Fedratinib, Larotrectinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68925, "ingredient1": "Enoxacin", "ingredient2": "Polyethylene glycol (3350 with electrolytes)", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline. Rare cases of generalized tonic-clonic seizures and/or loss of consciousness in association with low serum osmolality and electrolyte abnormalities (e.g., hyponatremia, hypokalemia, hypocalcemia, hypomagnesemia) have been reported with the use of bowel cleansing products in patients with no prior history of seizures. The condition resolved with correction of fluid and electrolyte abnormalities.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/69012/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.[9] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68926, "ingredient1": "Entrectinib", "ingredient2": "Polyethylene glycol (3350 with electrolytes)", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia are known risk factors for torsade de pointes associated with QT interval prolongation.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/69013/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[5] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[8] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[9] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[10] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[11] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Imatinib, Dacomitinib, Tepotinib, Avapritinib, Fedratinib, Larotrectinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68927, "ingredient1": "Enzalutamide", "ingredient2": "Polyethylene glycol (3350 with electrolytes)", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; hydroxychloroquine; mefloquine), and some narcotic analgesics. The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that can prolong the QT interval, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; mefloquine; halofantrine; lumefantrine), and some narcotic analgesics (methadone; propoxyphene).", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/69014/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[6] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[9] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[10] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[11] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[12] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[13] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[14] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[15] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Darolutamide, Anastrozole, Fulvestrant, Letrozole, Aminoglutethimide, Exemestane", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68928, "ingredient1": "Ephedrine", "ingredient2": "Polyethylene glycol (3350 with electrolytes)", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline. Rare cases of generalized tonic-clonic seizures and/or loss of consciousness in association with low serum osmolality and electrolyte abnormalities (e.g., hyponatremia, hypokalemia, hypocalcemia, hypomagnesemia) have been reported with the use of bowel cleansing products in patients with no prior history of seizures. The condition resolved with correction of fluid and electrolyte abnormalities.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/69015/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.[9] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.", "alternatives_a": "Homatropine, Tropicamide, Phenylephrine, Ciclesonide, Mupirocin, Mometasone furoate, Budesonide, Mometasone, Epinephrine, Flunisolide, Olopatadine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68929, "ingredient1": "Epirubicin", "ingredient2": "Polyethylene glycol (3350 with electrolytes)", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia are known risk factors for torsade de pointes associated with QT interval prolongation.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/69016/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[5] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[8] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[9] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[10] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[11] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Valrubicin, Plicamycin, Ixabepilone, Mitoxantrone, Bleomycin, Mitomycin, Dactinomycin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68930, "ingredient1": "Eprosartan", "ingredient2": "Polyethylene glycol (3350 with electrolytes)", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations. Fluid and electrolyte disturbances can lead to serious adverse events including cardiac arrhythmias, seizures, and renal impairment.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment. Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered. Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing. Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/69017/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Diovan (valsartan).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Cozaar (losartan).\" Merck & Co, Inc, West Point, PA.[5] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[6] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Amlodipine, Sacubitril, Nebivolol", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68931, "ingredient1": "Eribulin", "ingredient2": "Polyethylene glycol (3350 with electrolytes)", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia are known risk factors for torsade de pointes associated with QT interval prolongation.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/69018/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[5] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[8] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[9] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[10] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[11] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Pertuzumab, Olaparib, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68932, "ingredient1": "Ertapenem", "ingredient2": "Polyethylene glycol (3350 with electrolytes)", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline. Rare cases of generalized tonic-clonic seizures and/or loss of consciousness in association with low serum osmolality and electrolyte abnormalities (e.g., hyponatremia, hypokalemia, hypocalcemia, hypomagnesemia) have been reported with the use of bowel cleansing products in patients with no prior history of seizures. The condition resolved with correction of fluid and electrolyte abnormalities.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/69019/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.[9] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.", "alternatives_a": "Cefepime, Aztreonam, Ceftazidime, Cefapirin, Cefoxitin, Cefprozil, Cefonicid, Cefoperazone, Cefdinir, Cefalotin, Cefmetazole, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68933, "ingredient1": "Erythromycin", "ingredient2": "Polyethylene glycol (3350 with electrolytes)", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia are known risk factors for torsade de pointes associated with QT interval prolongation.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/69020/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[5] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[8] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[9] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[10] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[11] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Dirithromycin, Lincomycin, Troleandomycin, Clindamycin, Clindamycin, Vitamin A, Isotretinoin, Chloramphenicol, Fluorometholone, Tretinoin, Dapsone, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68934, "ingredient1": "Escitalopram", "ingredient2": "Polyethylene glycol (3350 with electrolytes)", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; hydroxychloroquine; mefloquine), and some narcotic analgesics. The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that can prolong the QT interval, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; mefloquine; halofantrine; lumefantrine), and some narcotic analgesics (methadone; propoxyphene).", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/69021/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[6] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[9] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[10] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[11] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[12] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[13] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[14] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[15] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "St. John's Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68935, "ingredient1": "Etacrynic acid", "ingredient2": "Polyethylene glycol (3350 with electrolytes)", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations. Fluid and electrolyte disturbances can lead to serious adverse events including cardiac arrhythmias, seizures, and renal impairment.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment. Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered. Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing. Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/69022/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Diovan (valsartan).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Cozaar (losartan).\" Merck & Co, Inc, West Point, PA.[5] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[6] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68936, "ingredient1": "Etodolac", "ingredient2": "Polyethylene glycol (3350 with electrolytes)", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations. Fluid and electrolyte disturbances can lead to serious adverse events including cardiac arrhythmias, seizures, and renal impairment.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment. Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered. Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing. Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/69023/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Diovan (valsartan).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Cozaar (losartan).\" Merck & Co, Inc, West Point, PA.[5] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[6] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Chondroitin sulfate, Rabeprazole, Esomeprazole, Glucosamine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68937, "ingredient1": "Ezogabine", "ingredient2": "Polyethylene glycol (3350 with electrolytes)", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia are known risk factors for torsade de pointes associated with QT interval prolongation.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/69024/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[5] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[8] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[9] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[10] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[11] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Brivaracetam, Topiramate, Cenobamate, Lamotrigine, Methylphenobarbital, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Oxcarbazepine, Ethotoin, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68938, "ingredient1": "Fenfluramine", "ingredient2": "Polyethylene glycol (3350 with electrolytes)", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline. Rare cases of generalized tonic-clonic seizures and/or loss of consciousness in association with low serum osmolality and electrolyte abnormalities (e.g., hyponatremia, hypokalemia, hypocalcemia, hypomagnesemia) have been reported with the use of bowel cleansing products in patients with no prior history of seizures. The condition resolved with correction of fluid and electrolyte abnormalities.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/69025/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.[9] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.", "alternatives_a": "Lorcaserin, Orlistat, Naltrexone, Brivaracetam, Topiramate, Cenobamate, Lamotrigine, Methylphenobarbital, Ethosuximide, Lacosamide, Levetiracetam, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68939, "ingredient1": "Fenoprofen", "ingredient2": "Polyethylene glycol (3350 with electrolytes)", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations. Fluid and electrolyte disturbances can lead to serious adverse events including cardiac arrhythmias, seizures, and renal impairment.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment. Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered. Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing. Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/69026/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Diovan (valsartan).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Cozaar (losartan).\" Merck & Co, Inc, West Point, PA.[5] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[6] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Chondroitin sulfate, Rabeprazole, Esomeprazole, Glucosamine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68940, "ingredient1": "Flecainide", "ingredient2": "Polyethylene glycol (3350 with electrolytes)", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia are known risk factors for torsade de pointes associated with QT interval prolongation.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/69027/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[5] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[8] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[9] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[10] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[11] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Tocainide, Moricizine, Bretylium", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68941, "ingredient1": "Fluconazole", "ingredient2": "Polyethylene glycol (3350 with electrolytes)", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia are known risk factors for torsade de pointes associated with QT interval prolongation.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/69028/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[5] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[8] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[9] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[10] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[11] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Tinidazole, Cefepime, Metronidazole, Secnidazole, Cefixime, Amikacin, Caspofungin, Micafungin, Amphotericin B, Miconazole, Oteseconazole, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68942, "ingredient1": "Fludeoxyglucose (18F)", "ingredient2": "Polyethylene glycol (3350 with electrolytes)", "severity": "Moderate", "effect": "Certain medications may interfere with the results of diagnostic studies using fludeoxyglucose F18 by increasing or decreasing uptake of the agent into tissues.", "source": "DDInter", "management_text": "Clinicians should be aware of possible diagnostic interference associated with the following medications: colony-stimulating factors may increase uptake in spleen and bone marrow; glucose-induced hyperglycemia may interfere with uptake; dopamine and insulin may decrease myocardial and tumor cell uptake; laxative-induced intestinal muscle activity and/or irritation may increase intestinal uptake.", "mechanism_text": "Absorption", "recommendation": "Clinicians should be aware of possible diagnostic interference associated with the following medications: colony-stimulating factors may increase uptake in spleen and bone marrow; glucose-induced hyperglycemia may interfere with uptake; dopamine and insulin may decrease myocardial and tumor cell uptake; laxative-induced intestinal muscle activity and/or irritation may increase intestinal uptake.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/69029/", "reference_text": "[1] \"Multum Information Services, Inc. Expert Review Panel\"[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Metamucil (psyllium).\" Procter and Gamble Pharmaceutic, Cincinnati, OH.", "alternatives_a": "Capromab pendetide, Gallium Ga-68 gozetotide, Indium In-111 pentetreotide", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68943, "ingredient1": "Fluoxetine", "ingredient2": "Polyethylene glycol (3350 with electrolytes)", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; hydroxychloroquine; mefloquine), and some narcotic analgesics. The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that can prolong the QT interval, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; mefloquine; halofantrine; lumefantrine), and some narcotic analgesics (methadone; propoxyphene).", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/69030/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[6] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[9] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[10] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[11] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[12] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[13] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[14] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[15] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "St. John's Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68944, "ingredient1": "Fluphenazine", "ingredient2": "Polyethylene glycol (3350 with electrolytes)", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; hydroxychloroquine; mefloquine), and some narcotic analgesics. The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that can prolong the QT interval, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; mefloquine; halofantrine; lumefantrine), and some narcotic analgesics (methadone; propoxyphene).", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/69031/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[6] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[9] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[10] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[11] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[12] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[13] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[14] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[15] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68945, "ingredient1": "Flurbiprofen", "ingredient2": "Polyethylene glycol (3350 with electrolytes)", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations. Fluid and electrolyte disturbances can lead to serious adverse events including cardiac arrhythmias, seizures, and renal impairment.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment. Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered. Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing. Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/69032/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Diovan (valsartan).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Cozaar (losartan).\" Merck & Co, Inc, West Point, PA.[5] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[6] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Tolazoline, Rabeprazole, Dimethyl sulfoxide, Chondroitin sulfate, Rabeprazole, Esomeprazole, Glucosamine, Neomycin, Chlorhexidine, Povidone-iodine, Bacitracin, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68946, "ingredient1": "Flutamide", "ingredient2": "Polyethylene glycol (3350 with electrolytes)", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia are known risk factors for torsade de pointes associated with QT interval prolongation.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/69033/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[5] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[8] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[9] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[10] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[11] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Darolutamide, Anastrozole, Fulvestrant, Letrozole, Aminoglutethimide, Exemestane", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68947, "ingredient1": "Fluvoxamine", "ingredient2": "Polyethylene glycol (3350 with electrolytes)", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline. Rare cases of generalized tonic-clonic seizures and/or loss of consciousness in association with low serum osmolality and electrolyte abnormalities (e.g., hyponatremia, hypokalemia, hypocalcemia, hypomagnesemia) have been reported with the use of bowel cleansing products in patients with no prior history of seizures. The condition resolved with correction of fluid and electrolyte abnormalities.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/69034/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.[9] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.", "alternatives_a": "St. John's Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68948, "ingredient1": "Foscarnet", "ingredient2": "Polyethylene glycol (3350 with electrolytes)", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; hydroxychloroquine; mefloquine), and some narcotic analgesics. The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that can prolong the QT interval, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; mefloquine; halofantrine; lumefantrine), and some narcotic analgesics (methadone; propoxyphene).", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/69035/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[6] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[9] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[10] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[11] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[12] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[13] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[14] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[15] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Lenacapavir, Telaprevir, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68949, "ingredient1": "Fosinopril", "ingredient2": "Polyethylene glycol (3350 with electrolytes)", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations. Fluid and electrolyte disturbances can lead to serious adverse events including cardiac arrhythmias, seizures, and renal impairment.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment. Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered. Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing. Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/69036/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Diovan (valsartan).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Cozaar (losartan).\" Merck & Co, Inc, West Point, PA.[5] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[6] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Felodipine, Amlodipine, Verapamil, Bisoprolol", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68950, "ingredient1": "Fostemsavir", "ingredient2": "Polyethylene glycol (3350 with electrolytes)", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia are known risk factors for torsade de pointes associated with QT interval prolongation.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/69037/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[5] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[8] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[9] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[10] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[11] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Lenacapavir, Telaprevir, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68951, "ingredient1": "Furosemide", "ingredient2": "Polyethylene glycol (3350 with electrolytes)", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations. Fluid and electrolyte disturbances can lead to serious adverse events including cardiac arrhythmias, seizures, and renal impairment.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment. Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered. Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing. Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/69038/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Diovan (valsartan).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Cozaar (losartan).\" Merck & Co, Inc, West Point, PA.[5] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[6] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Sulfadiazine, Lactic acid, Mitapivat, Amphotericin B, Clindamycin, Ciclopirox, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68952, "ingredient1": "Galantamine", "ingredient2": "Polyethylene glycol (3350 with electrolytes)", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline. Rare cases of generalized tonic-clonic seizures and/or loss of consciousness in association with low serum osmolality and electrolyte abnormalities (e.g., hyponatremia, hypokalemia, hypocalcemia, hypomagnesemia) have been reported with the use of bowel cleansing products in patients with no prior history of seizures. The condition resolved with correction of fluid and electrolyte abnormalities.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/69039/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.[9] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.", "alternatives_a": "Ginkgo biloba, Aducanumab", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68953, "ingredient1": "Gatifloxacin", "ingredient2": "Polyethylene glycol (3350 with electrolytes)", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; hydroxychloroquine; mefloquine), and some narcotic analgesics. The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that can prolong the QT interval, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; mefloquine; halofantrine; lumefantrine), and some narcotic analgesics (methadone; propoxyphene).", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/69040/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[6] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[9] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[10] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[11] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[12] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[13] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[14] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[15] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Rifamycin, Kanamycin, Ampicillin, Acyclovir, Netilmicin, Polymyxin B, Famciclovir, Trifluridine, Tobramycin, Benzylpenicillin, Gentamicin, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68954, "ingredient1": "Gemifloxacin", "ingredient2": "Polyethylene glycol (3350 with electrolytes)", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; hydroxychloroquine; mefloquine), and some narcotic analgesics. The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that can prolong the QT interval, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; mefloquine; halofantrine; lumefantrine), and some narcotic analgesics (methadone; propoxyphene).", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/69041/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[6] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[9] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[10] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[11] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[12] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[13] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[14] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[15] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68955, "ingredient1": "Gilteritinib", "ingredient2": "Polyethylene glycol (3350 with electrolytes)", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia are known risk factors for torsade de pointes associated with QT interval prolongation.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/69042/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[5] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[8] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[9] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[10] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[11] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Imatinib, Dacomitinib, Tepotinib, Avapritinib, Fedratinib, Larotrectinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68956, "ingredient1": "Glasdegib", "ingredient2": "Polyethylene glycol (3350 with electrolytes)", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia are known risk factors for torsade de pointes associated with QT interval prolongation.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/69043/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[5] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[8] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[9] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[10] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[11] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Pertuzumab, Olaparib, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68957, "ingredient1": "Goserelin", "ingredient2": "Polyethylene glycol (3350 with electrolytes)", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia are known risk factors for torsade de pointes associated with QT interval prolongation.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/69044/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[5] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[8] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[9] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[10] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[11] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Megestrol acetate, Ethinylestradiol, Diethylstilbestrol, Medroxyprogesterone acetate", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68958, "ingredient1": "Granisetron", "ingredient2": "Polyethylene glycol (3350 with electrolytes)", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia are known risk factors for torsade de pointes associated with QT interval prolongation.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/69045/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[5] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[8] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[9] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[10] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[11] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Rolapitant, Nabilone, Aprepitant", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68959, "ingredient1": "Grepafloxacin", "ingredient2": "Polyethylene glycol (3350 with electrolytes)", "severity": "Major", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval. Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly. Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/69046/", "reference_text": "[1] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[2] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[9] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[10] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[11] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[12] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[13] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68960, "ingredient1": "Halofantrine", "ingredient2": "Polyethylene glycol (3350 with electrolytes)", "severity": "Major", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval. Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly. Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/69047/", "reference_text": "[1] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[2] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[9] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[10] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[11] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[12] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[13] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Artesunate, Artemether, Tafenoquine, Atovaquone, Sulfadoxine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68961, "ingredient1": "Haloperidol", "ingredient2": "Polyethylene glycol (3350 with electrolytes)", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; hydroxychloroquine; mefloquine), and some narcotic analgesics. The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that can prolong the QT interval, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; mefloquine; halofantrine; lumefantrine), and some narcotic analgesics (methadone; propoxyphene).", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/69048/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[6] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[9] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[10] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[11] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[12] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[13] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[14] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[15] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68962, "ingredient1": "Halothane", "ingredient2": "Polyethylene glycol (3350 with electrolytes)", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia are known risk factors for torsade de pointes associated with QT interval prolongation.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/69049/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[5] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[8] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[9] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[10] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[11] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Thiopental, Sodium oxybate, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Enflurane, Esketamine, Etomidate, Ketamine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68963, "ingredient1": "Diamorphine", "ingredient2": "Polyethylene glycol (3350 with electrolytes)", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline. Rare cases of generalized tonic-clonic seizures and/or loss of consciousness in association with low serum osmolality and electrolyte abnormalities (e.g., hyponatremia, hypokalemia, hypocalcemia, hypomagnesemia) have been reported with the use of bowel cleansing products in patients with no prior history of seizures. The condition resolved with correction of fluid and electrolyte abnormalities.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/69050/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.[9] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.", "alternatives_a": "Acamprosate, Naltrexone, Varenicline, Disulfiram, Nalmefene, Nicotine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68964, "ingredient1": "Histrelin", "ingredient2": "Polyethylene glycol (3350 with electrolytes)", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia are known risk factors for torsade de pointes associated with QT interval prolongation.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/69051/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[5] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[8] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[9] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[10] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[11] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Megestrol acetate, Ethinylestradiol, Diethylstilbestrol, Medroxyprogesterone acetate", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68965, "ingredient1": "Hydroflumethiazide", "ingredient2": "Polyethylene glycol (3350 with electrolytes)", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations. Fluid and electrolyte disturbances can lead to serious adverse events including cardiac arrhythmias, seizures, and renal impairment.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment. Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered. Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing. Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/69052/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Diovan (valsartan).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Cozaar (losartan).\" Merck & Co, Inc, West Point, PA.[5] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[6] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Sulfadiazine, Lactic acid, Mitapivat, Amphotericin B, Clindamycin, Ciclopirox, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68966, "ingredient1": "Hydromorphone", "ingredient2": "Polyethylene glycol (3350 with electrolytes)", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline. Rare cases of generalized tonic-clonic seizures and/or loss of consciousness in association with low serum osmolality and electrolyte abnormalities (e.g., hyponatremia, hypokalemia, hypocalcemia, hypomagnesemia) have been reported with the use of bowel cleansing products in patients with no prior history of seizures. The condition resolved with correction of fluid and electrolyte abnormalities.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/69053/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.[9] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.", "alternatives_a": "Acetaminophen, Naloxone, Naltrexone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68967, "ingredient1": "Hydroxychloroquine", "ingredient2": "Polyethylene glycol (3350 with electrolytes)", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; hydroxychloroquine; mefloquine), and some narcotic analgesics. The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that can prolong the QT interval, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; mefloquine; halofantrine; lumefantrine), and some narcotic analgesics (methadone; propoxyphene).", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/69054/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[6] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[9] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[10] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[11] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[12] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[13] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[14] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[15] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Artesunate, Artemether, Tafenoquine, Atovaquone, Sulfadoxine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68968, "ingredient1": "Hydroxyzine", "ingredient2": "Polyethylene glycol (3350 with electrolytes)", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia are known risk factors for torsade de pointes associated with QT interval prolongation.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/69055/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[5] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[8] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[9] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[10] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[11] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Meprobamate, Buspirone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68969, "ingredient1": "Ibutilide", "ingredient2": "Polyethylene glycol (3350 with electrolytes)", "severity": "Major", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval. Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly. Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/69056/", "reference_text": "[1] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[2] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[9] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[10] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[11] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[12] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[13] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Tocainide, Moricizine, Bretylium", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68970, "ingredient1": "Idarubicin", "ingredient2": "Polyethylene glycol (3350 with electrolytes)", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia are known risk factors for torsade de pointes associated with QT interval prolongation.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/69057/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[5] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[8] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[9] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[10] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[11] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Valrubicin, Plicamycin, Ixabepilone, Mitoxantrone, Bleomycin, Mitomycin, Dactinomycin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68971, "ingredient1": "Iloperidone", "ingredient2": "Polyethylene glycol (3350 with electrolytes)", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; hydroxychloroquine; mefloquine), and some narcotic analgesics. The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that can prolong the QT interval, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; mefloquine; halofantrine; lumefantrine), and some narcotic analgesics (methadone; propoxyphene).", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/69058/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[6] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[9] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[10] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[11] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[12] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[13] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[14] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[15] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68972, "ingredient1": "Imipramine", "ingredient2": "Polyethylene glycol (3350 with electrolytes)", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; hydroxychloroquine; mefloquine), and some narcotic analgesics. The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that can prolong the QT interval, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; mefloquine; halofantrine; lumefantrine), and some narcotic analgesics (methadone; propoxyphene).", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/69059/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[6] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[9] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[10] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[11] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[12] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[13] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[14] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[15] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "St. John's Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68973, "ingredient1": "Indapamide", "ingredient2": "Polyethylene glycol (3350 with electrolytes)", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations. Fluid and electrolyte disturbances can lead to serious adverse events including cardiac arrhythmias, seizures, and renal impairment.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment. Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered. Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing. Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/69060/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Diovan (valsartan).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Cozaar (losartan).\" Merck & Co, Inc, West Point, PA.[5] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[6] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Felodipine, Amlodipine, Verapamil, Bisoprolol, Tamsulosin, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Sulfadiazine, Lactic acid, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68974, "ingredient1": "Indomethacin", "ingredient2": "Polyethylene glycol (3350 with electrolytes)", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations. Fluid and electrolyte disturbances can lead to serious adverse events including cardiac arrhythmias, seizures, and renal impairment.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment. Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered. Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing. Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/69061/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Diovan (valsartan).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Cozaar (losartan).\" Merck & Co, Inc, West Point, PA.[5] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[6] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Fluocinolone acetonide, Fluorometholone, Chondroitin sulfate, Rabeprazole, Esomeprazole, Glucosamine, Fluocinolone acetonide, Fluorometholone, Tolazoline, Rabeprazole, Dimethyl sulfoxide, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68975, "ingredient1": "Inotuzumab ozogamicin", "ingredient2": "Polyethylene glycol (3350 with electrolytes)", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia are known risk factors for torsade de pointes associated with QT interval prolongation.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/69062/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[5] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[8] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[9] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[10] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[11] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68976, "ingredient1": "Interferon alfa-2a, Recombinant", "ingredient2": "Polyethylene glycol (3350 with electrolytes)", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline. Rare cases of generalized tonic-clonic seizures and/or loss of consciousness in association with low serum osmolality and electrolyte abnormalities (e.g., hyponatremia, hypokalemia, hypocalcemia, hypomagnesemia) have been reported with the use of bowel cleansing products in patients with no prior history of seizures. The condition resolved with correction of fluid and electrolyte abnormalities.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/69063/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.[9] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68977, "ingredient1": "Interferon alfa-2b", "ingredient2": "Polyethylene glycol (3350 with electrolytes)", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline. Rare cases of generalized tonic-clonic seizures and/or loss of consciousness in association with low serum osmolality and electrolyte abnormalities (e.g., hyponatremia, hypokalemia, hypocalcemia, hypomagnesemia) have been reported with the use of bowel cleansing products in patients with no prior history of seizures. The condition resolved with correction of fluid and electrolyte abnormalities.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/69064/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.[9] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.", "alternatives_a": "Oprelvekin, Sipuleucel-T, Elapegademase, Ropeginterferon alfa-2b, Sargramostim, Histamine, Pegademase, Pegfilgrastim, Filgrastim, Glatiramer", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68978, "ingredient1": "Interferon alfa-n1", "ingredient2": "Polyethylene glycol (3350 with electrolytes)", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline. Rare cases of generalized tonic-clonic seizures and/or loss of consciousness in association with low serum osmolality and electrolyte abnormalities (e.g., hyponatremia, hypokalemia, hypocalcemia, hypomagnesemia) have been reported with the use of bowel cleansing products in patients with no prior history of seizures. The condition resolved with correction of fluid and electrolyte abnormalities.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/69065/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.[9] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.", "alternatives_a": "Oprelvekin, Sipuleucel-T, Elapegademase, Ropeginterferon alfa-2b, Sargramostim, Histamine, Pegademase, Pegfilgrastim, Filgrastim, Glatiramer", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68979, "ingredient1": "Interferon alfa-n3", "ingredient2": "Polyethylene glycol (3350 with electrolytes)", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline. Rare cases of generalized tonic-clonic seizures and/or loss of consciousness in association with low serum osmolality and electrolyte abnormalities (e.g., hyponatremia, hypokalemia, hypocalcemia, hypomagnesemia) have been reported with the use of bowel cleansing products in patients with no prior history of seizures. The condition resolved with correction of fluid and electrolyte abnormalities.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/69066/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.[9] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68980, "ingredient1": "Interferon alfacon-1", "ingredient2": "Polyethylene glycol (3350 with electrolytes)", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline. Rare cases of generalized tonic-clonic seizures and/or loss of consciousness in association with low serum osmolality and electrolyte abnormalities (e.g., hyponatremia, hypokalemia, hypocalcemia, hypomagnesemia) have been reported with the use of bowel cleansing products in patients with no prior history of seizures. The condition resolved with correction of fluid and electrolyte abnormalities.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/69067/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.[9] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.", "alternatives_a": "Oprelvekin, Sipuleucel-T, Elapegademase, Ropeginterferon alfa-2b, Sargramostim, Histamine, Pegademase, Pegfilgrastim, Filgrastim, Glatiramer", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68981, "ingredient1": "Interferon beta-1a", "ingredient2": "Polyethylene glycol (3350 with electrolytes)", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline. Rare cases of generalized tonic-clonic seizures and/or loss of consciousness in association with low serum osmolality and electrolyte abnormalities (e.g., hyponatremia, hypokalemia, hypocalcemia, hypomagnesemia) have been reported with the use of bowel cleansing products in patients with no prior history of seizures. The condition resolved with correction of fluid and electrolyte abnormalities.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/69068/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.[9] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.", "alternatives_a": "Oprelvekin, Sipuleucel-T, Elapegademase, Ropeginterferon alfa-2b, Sargramostim, Histamine, Pegademase, Pegfilgrastim, Filgrastim, Glatiramer", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68982, "ingredient1": "Interferon beta-1b", "ingredient2": "Polyethylene glycol (3350 with electrolytes)", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline. Rare cases of generalized tonic-clonic seizures and/or loss of consciousness in association with low serum osmolality and electrolyte abnormalities (e.g., hyponatremia, hypokalemia, hypocalcemia, hypomagnesemia) have been reported with the use of bowel cleansing products in patients with no prior history of seizures. The condition resolved with correction of fluid and electrolyte abnormalities.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/69069/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.[9] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.", "alternatives_a": "Oprelvekin, Sipuleucel-T, Elapegademase, Ropeginterferon alfa-2b, Sargramostim, Histamine, Pegademase, Pegfilgrastim, Filgrastim, Glatiramer", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68983, "ingredient1": "Interferon gamma-1b", "ingredient2": "Polyethylene glycol (3350 with electrolytes)", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline. Rare cases of generalized tonic-clonic seizures and/or loss of consciousness in association with low serum osmolality and electrolyte abnormalities (e.g., hyponatremia, hypokalemia, hypocalcemia, hypomagnesemia) have been reported with the use of bowel cleansing products in patients with no prior history of seizures. The condition resolved with correction of fluid and electrolyte abnormalities.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/69070/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.[9] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68984, "ingredient1": "Irbesartan", "ingredient2": "Polyethylene glycol (3350 with electrolytes)", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations. Fluid and electrolyte disturbances can lead to serious adverse events including cardiac arrhythmias, seizures, and renal impairment.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment. Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered. Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing. Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/69071/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Diovan (valsartan).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Cozaar (losartan).\" Merck & Co, Inc, West Point, PA.[5] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[6] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Amlodipine, Sacubitril, Nebivolol", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68985, "ingredient1": "Isocarboxazid", "ingredient2": "Polyethylene glycol (3350 with electrolytes)", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline. Rare cases of generalized tonic-clonic seizures and/or loss of consciousness in association with low serum osmolality and electrolyte abnormalities (e.g., hyponatremia, hypokalemia, hypocalcemia, hypomagnesemia) have been reported with the use of bowel cleansing products in patients with no prior history of seizures. The condition resolved with correction of fluid and electrolyte abnormalities.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/69072/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.[9] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.", "alternatives_a": "St. John's Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68986, "ingredient1": "Polyethylene glycol (3350 with electrolytes)", "ingredient2": "Ivosidenib", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia are known risk factors for torsade de pointes associated with QT interval prolongation.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/69073/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[5] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[8] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[9] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[10] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[11] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Pertuzumab, Olaparib, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68987, "ingredient1": "Polyethylene glycol (3350 with electrolytes)", "ingredient2": "Ketoconazole", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia are known risk factors for torsade de pointes associated with QT interval prolongation.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/69074/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[5] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[8] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[9] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[10] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[11] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Sulfadiazine, Lactic acid, Mitapivat, Amphotericin B, Clindamycin, Ciclopirox, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68988, "ingredient1": "Polyethylene glycol (3350 with electrolytes)", "ingredient2": "Ketoprofen", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations. Fluid and electrolyte disturbances can lead to serious adverse events including cardiac arrhythmias, seizures, and renal impairment.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment. Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered. Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing. Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/69075/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Diovan (valsartan).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Cozaar (losartan).\" Merck & Co, Inc, West Point, PA.[5] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[6] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Chondroitin sulfate, Rabeprazole, Esomeprazole, Glucosamine, Tolazoline, Rabeprazole, Dimethyl sulfoxide", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68989, "ingredient1": "Polyethylene glycol (3350 with electrolytes)", "ingredient2": "Lactulose", "severity": "Moderate", "effect": "In the treatment of portal-systemic encephalopathy, the loose stools produced by concomitant use of other laxatives may falsely suggest that adequate lactulose dosage has been achieved.", "source": "DDInter", "management_text": "The use of other laxatives should generally be avoided when lactulose is prescribed for portal-systemic encephalopathy, especially during the initial phase of therapy.", "mechanism_text": "Others", "recommendation": "The use of other laxatives should generally be avoided when lactulose is prescribed for portal-systemic encephalopathy, especially during the initial phase of therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/69076/", "reference_text": "[1] \"Product Information. Cephulac (lactulose).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[2] \"Product Information. Generlac (lactulose).\" Morton Grove Pharmaceuticals Inc, Morton Grove, IL.[3] \"Product Information. Enulose (lactulose).\" United Research Laboratories/Mutual Pharmaceutical Company, Philadelphia, PA.[4] \"Product Information. Chronulac (lactulose).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[5] \"Product Information. Metamucil (psyllium).\" Procter and Gamble Pharmaceutic, Cincinnati, OH.", "alternatives_a": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Naldemedine, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, Prucalopride, Sodium sulfate, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68990, "ingredient1": "Polyethylene glycol (3350 with electrolytes)", "ingredient2": "Lapatinib", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia are known risk factors for torsade de pointes associated with QT interval prolongation.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/69077/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[5] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[8] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[9] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[10] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[11] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Imatinib, Dacomitinib, Tepotinib, Avapritinib, Fedratinib, Larotrectinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68991, "ingredient1": "Polyethylene glycol (3350 with electrolytes)", "ingredient2": "Lefamulin", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia are known risk factors for torsade de pointes associated with QT interval prolongation.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/69078/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[5] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[8] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[9] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[10] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[11] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Tinidazole, Linezolid, Bacitracin, Oritavancin, Polymyxin B, Daptomycin, Vancomycin, Metronidazole, Spectinomycin, Nitrofurantoin, Fosfomycin, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68992, "ingredient1": "Polyethylene glycol (3350 with electrolytes)", "ingredient2": "Lenvatinib", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia are known risk factors for torsade de pointes associated with QT interval prolongation.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/69079/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[5] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[8] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[9] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[10] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[11] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Imatinib, Dacomitinib, Tepotinib, Avapritinib, Fedratinib, Larotrectinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68993, "ingredient1": "Polyethylene glycol (3350 with electrolytes)", "ingredient2": "Leuprolide", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia are known risk factors for torsade de pointes associated with QT interval prolongation.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/69080/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[5] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[8] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[9] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[10] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[11] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Megestrol acetate, Ethinylestradiol, Diethylstilbestrol, Medroxyprogesterone acetate", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68994, "ingredient1": "Polyethylene glycol (3350 with electrolytes)", "ingredient2": "Levofloxacin", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; hydroxychloroquine; mefloquine), and some narcotic analgesics. The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that can prolong the QT interval, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; mefloquine; halofantrine; lumefantrine), and some narcotic analgesics (methadone; propoxyphene).", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/69081/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[6] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[9] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[10] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[11] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[12] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[13] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[14] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[15] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Tinidazole, Pantoprazole, Dexlansoprazole, Rabeprazole, Bismuth subcitrate potassium, Metronidazole, Rifabutin, Esomeprazole, Vonoprazan, Amoxicillin, Lansoprazole, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68995, "ingredient1": "Polyethylene glycol (3350 with electrolytes)", "ingredient2": "Levacetylmethadol", "severity": "Major", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval. Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly. Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/69082/", "reference_text": "[1] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[2] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[9] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[10] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[11] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[12] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[13] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Acamprosate, Naltrexone, Varenicline, Disulfiram, Nalmefene, Nicotine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68996, "ingredient1": "Polyethylene glycol (3350 with electrolytes)", "ingredient2": "Levomilnacipran", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline. Rare cases of generalized tonic-clonic seizures and/or loss of consciousness in association with low serum osmolality and electrolyte abnormalities (e.g., hyponatremia, hypokalemia, hypocalcemia, hypomagnesemia) have been reported with the use of bowel cleansing products in patients with no prior history of seizures. The condition resolved with correction of fluid and electrolyte abnormalities.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/69083/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.[9] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.", "alternatives_a": "St. John's Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68997, "ingredient1": "Polyethylene glycol (3350 with electrolytes)", "ingredient2": "Levorphanol", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline. Rare cases of generalized tonic-clonic seizures and/or loss of consciousness in association with low serum osmolality and electrolyte abnormalities (e.g., hyponatremia, hypokalemia, hypocalcemia, hypomagnesemia) have been reported with the use of bowel cleansing products in patients with no prior history of seizures. The condition resolved with correction of fluid and electrolyte abnormalities.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/69084/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.[9] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68998, "ingredient1": "Polyethylene glycol (3350 with electrolytes)", "ingredient2": "Linaclotide", "severity": "Minor", "effect": "The concomitant use of linaclotide with proton pump inhibitors, laxatives, or nonsteroidal anti-inflammatory drugs may increase the risk of diarrhea.", "source": "DDInter", "management_text": "-", "mechanism_text": "Others", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/69085/", "reference_text": "[1] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[2] \"Product Information. Linzess (linaclotide).\" Forest Pharmaceuticals, St. Louis, MO.[3] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"", "alternatives_a": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Naldemedine, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, Prucalopride, Sodium sulfate, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 68999, "ingredient1": "Polyethylene glycol (3350 with electrolytes)", "ingredient2": "Lindane", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline. Rare cases of generalized tonic-clonic seizures and/or loss of consciousness in association with low serum osmolality and electrolyte abnormalities (e.g., hyponatremia, hypokalemia, hypocalcemia, hypomagnesemia) have been reported with the use of bowel cleansing products in patients with no prior history of seizures. The condition resolved with correction of fluid and electrolyte abnormalities.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/69086/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.[9] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.", "alternatives_a": "Disulfiram", "alternatives_b": "", "updated_at": 1767369485}, {"id": 69000, "ingredient1": "Polyethylene glycol (3350 with electrolytes)", "ingredient2": "Lisdexamfetamine", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; hydroxychloroquine; mefloquine), and some narcotic analgesics. The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that can prolong the QT interval, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; mefloquine; halofantrine; lumefantrine), and some narcotic analgesics (methadone; propoxyphene).", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/69087/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[6] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[9] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[10] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[11] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[12] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[13] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[14] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[15] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Solriamfetol, Caffeine, Armodafinil, Citicoline, Modafinil", "alternatives_b": "", "updated_at": 1767369485}]